$T1$ may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.It also causes neurologic depression, $T2$
Lithium carbonate
cyanosis
1
$T1$ may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.It also causes neurologic depression, cyanosis, and $T2$
Lithium carbonate
cardiac arrhythmia
1
$T1$ may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.It also causes $T2$
Lithium carbonate
neurologic depression
1
$T1$ and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
tricuspid regurgitation
Lithium carbonate
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
tricuspid regurgitation
0
$T1$ and $T2$
tricuspid regurgitation
atrial flutter
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest $T2$
congestive heart failure
tricuspid regurgitation
0
$T1$ and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to $T2$
tricuspid regurgitation
lithium
0
$T1$ and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
tricuspid regurgitation
congenital heart disease
0
$T1$ and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
tricuspid regurgitation
neurologic depression
0
$T1$ and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
tricuspid regurgitation
cyanosis
0
$T1$ and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
tricuspid regurgitation
cardiac arrhythmia
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
Lithium carbonate
0
$T1$, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
atrial flutter
Lithium carbonate
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
congestive heart failure
Lithium carbonate
0
$T1$ compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
lithium
Lithium carbonate
0
$T1$ may be a factor in the increasing incidence of $T2$
Lithium carbonate
congenital heart disease
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
atrial flutter
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, $T2$
toxicity
congestive heart failure
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
lithium
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
congenital heart disease
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
neurologic depression
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
cyanosis
0
$T1$ in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
toxicity
cardiac arrhythmia
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and $T2$
congestive heart failure
atrial flutter
0
$T1$, and the 11th described patient with cardiac disease among infants exposed to $T2$
atrial flutter
lithium
0
$T1$, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
atrial flutter
congenital heart disease
0
$T1$, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
atrial flutter
neurologic depression
0
$T1$, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
atrial flutter
cyanosis
0
$T1$, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
atrial flutter
cardiac arrhythmia
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to $T2$
congestive heart failure
lithium
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
congestive heart failure
congenital heart disease
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
congestive heart failure
neurologic depression
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
congestive heart failure
cyanosis
0
$T1$, and a high serum lithium level is described.This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
congestive heart failure
cardiac arrhythmia
0
$T1$ compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
lithium
congenital heart disease
0
$T1$ compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
lithium
neurologic depression
0
$T1$ compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
lithium
cyanosis
0
$T1$ compounds in the first trimester of pregnancy.Sixty-three percent of these infants had tricuspid valve involvement.
lithium
cardiac arrhythmia
0
$T1$ when taken during early pregnancy.It also causes $T2$
congenital heart disease
neurologic depression
0
$T1$ when taken during early pregnancy.It also causes neurologic depression, $T2$
congenital heart disease
cyanosis
0
$T1$ when taken during early pregnancy.It also causes neurologic depression, cyanosis, and $T2$
congenital heart disease
cardiac arrhythmia
0
$T1$, $T2$
neurologic depression
cyanosis
0
$T1$, cyanosis, and $T2$
neurologic depression
cardiac arrhythmia
0
$T1$, and $T2$
cyanosis
cardiac arrhythmia
0
$T1$ recurred.$T2$
dyskinesia
Phenobarbital
1
$T1$ developed a dyskinesia soon after starting phenobarbital therapy for seizures.Known causes of movement disorders were eliminated after evaluation.
neurologic impairment
Phenobarbital
0
$T1$.Known causes of movement disorders were eliminated after evaluation.
seizures
Phenobarbital
0
$T1$ should be added to the list of anticonvulsant drugs that can cause $T2$
Phenobarbital
movement disorders
0
$T1$ developed a dyskinesia soon after starting phenobarbital therapy for seizures.Known causes of movement disorders were eliminated after evaluation.
neurologic impairment
dyskinesia
0
$T1$.Known causes of movement disorders were eliminated after evaluation.
seizures
dyskinesia
0
$T1$ recurred.Phenobarbital should be added to the list of anticonvulsant drugs that can cause $T2$
dyskinesia
movement disorders
0
$T1$ developed a dyskinesia soon after starting phenobarbital therapy for $T2$
neurologic impairment
seizures
0
$T1$ developed a dyskinesia soon after starting phenobarbital therapy for seizures.Known causes of movement disorders were eliminated after evaluation.
neurologic impairment
movement disorders
0
$T1$.Known causes of movement disorders were eliminated after evaluation.
seizures
movement disorders
0
$T1$ (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when $T2$
drowsiness
VPA
1
$T1$ (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.By measuring VPA-induced changes of blood $T2$
drowsiness
NH3
1
$T1$ content, it may be possible to identify patients at higher risk of obtundation when $T2$
NH3
VPA
0
$T1$ patients who were already being treated with other antiepileptic drugs.A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.
epileptic
NH3
0
$T1$ patients who were already being treated with other antiepileptic drugs.A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.
epileptic
VPA
0
$T1$ patients who were already being treated with other antiepileptic drugs.A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.
epileptic
drowsiness
0
$T1$-induced $T2$
haloperidol
catalepsy
1
$T1$-induced $T2$
apomorphine
hyperactivity
1
$T1$-induced catalepsy and a partial prevention of $T2$
haloperidol
apomorphine
0
$T1$-induced catalepsy and a partial prevention of apomorphine-induced $T2$
haloperidol
hyperactivity
0
$T1$-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.
haloperidol
DA
0
$T1$-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and $T2$
haloperidol
DOPAC
0
$T1$ and a partial prevention of $T2$
catalepsy
apomorphine
0
$T1$ and a partial prevention of apomorphine-induced $T2$
catalepsy
hyperactivity
0
$T1$ and a partial prevention of apomorphine-induced hyperactivity.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.
catalepsy
DA
0
$T1$ and a partial prevention of apomorphine-induced hyperactivity.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and $T2$
catalepsy
DOPAC
0
$T1$-induced hyperactivity.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.
apomorphine
DA
0
$T1$-induced hyperactivity.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and $T2$
apomorphine
DOPAC
0
$T1$.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.
hyperactivity
DA
0
$T1$.Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and $T2$
hyperactivity
DOPAC
0
$T1$ concentration or GAD activity.The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the $T2$
DOPAC
DA
0
$T1$ was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.
cardiac hypertrophy
ISO
1
$T1$ shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and $T2$
ISO
hyperplasia
1
$T1$ remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.
hydroxyproline
ISO
0
$T1$ shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular $T2$
ISO
hypertrophy
0
$T1$ was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.
cardiac hypertrophy
hydroxyproline
0
$T1$ was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.
cardiac hypertrophy
hypertrophy
0
$T1$ was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content.
cardiac hypertrophy
hyperplasia
0
$T1$ remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.
hydroxyproline
hypertrophy
0
$T1$ remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy.Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.
hydroxyproline
hyperplasia
0
$T1$ and $T2$
hypertrophy
hyperplasia
0
$T1$ $T2$
BHA
forestomach carcinogenesis
1
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
RA
0
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
forestomach carcinogenesis
0
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
BHA
0
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
papillomas
0
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
carcinoma
0
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
epithelial hyperplasia
0
$T1$ effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.
carcinogenic
Tumors
0
$T1$ acted as a co-carcinogen in the BHA $T2$
RA
forestomach carcinogenesis
0
$T1$ acted as a co-carcinogen in the $T2$
RA
BHA
0
$T1$, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.RA alone did not induce hyperplastic changes in the forestomach.
papillomas
RA
0
$T1$) in the group given RA-free water.In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
carcinoma
RA
0
$T1$.Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.
epithelial hyperplasia
RA
0
$T1$, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.RA alone did not induce hyperplastic changes in the forestomach.
Tumors
RA
0
$T1$, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.RA alone did not induce hyperplastic changes in the forestomach.
papillomas
forestomach carcinogenesis
0
$T1$) in the group given RA-free water.In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
carcinoma
forestomach carcinogenesis
0
$T1$.Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.
epithelial hyperplasia
forestomach carcinogenesis
0
$T1$, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.RA alone did not induce hyperplastic changes in the forestomach.
Tumors
forestomach carcinogenesis
0
$T1$, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.RA alone did not induce hyperplastic changes in the forestomach.
papillomas
BHA
0
$T1$) in the group given RA-free water.In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
carcinoma
BHA
0
$T1$.Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.
epithelial hyperplasia
BHA
0
$T1$, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.RA alone did not induce hyperplastic changes in the forestomach.
Tumors
BHA
0
$T1$) in the group given RA-free water.In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
carcinoma
papillomas
0
$T1$.Tumors, all $T2$
epithelial hyperplasia
papillomas
0
$T1$, all $T2$
Tumors
papillomas
0
$T1$) in the group given RA-free water.In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced $T2$
carcinoma
epithelial hyperplasia
0
$T1$) in the group given RA-free water.In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.
carcinoma
Tumors
0
$T1$.$T2$
epithelial hyperplasia
Tumors
0
$T1$ exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.
alfentanil
rigidity
1
$T1$ exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received $T2$
alfentanil
ketanserin
0
$T1$ alone.These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.
ketanserin
rigidity
0
$T1$ alone.These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.
ketanserin
serotonin
0
$T1$ at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.)
Chlordiazepoxide
ketanserin
0
$T1$ alone.These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.
ketanserin
cardiovascular, and respiratory depression
0
$T1$ exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.
alfentanil
serotonin
0
$T1$ at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.)
Chlordiazepoxide
alfentanil
0
$T1$ exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.
alfentanil
cardiovascular, and respiratory depression
0
$T1$ antagonists may be clinically useful in attenuating opiate-induced $T2$
serotonin
rigidity
0
$T1$ at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.)
Chlordiazepoxide
rigidity
0
$T1$, although further studies will be necessary to assess the interaction of possibly enhanced CNS, $T2$
rigidity
cardiovascular, and respiratory depression
0
$T1$ at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.)
Chlordiazepoxide
serotonin
0
$T1$ antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, $T2$
serotonin
cardiovascular, and respiratory depression
0
$T1$ at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.)
Chlordiazepoxide
cardiovascular, and respiratory depression
0
$T1$-induced $T2$
edrophonium
bradycardias
1
$T1$-induced bradycardias.This low dose of $T2$
edrophonium
glycopyrronium
0
$T1$.This low dose of $T2$
bradycardias
glycopyrronium
0
$T1$ by $T2$
muscular rigidity
fentanyl
1
$T1$.Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.
ketamine
fentanyl
0
$T1$, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.
CO2
fentanyl
0
$T1$.Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.
prazosin
fentanyl
0
$T1$.Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.
ketamine
muscular rigidity
0
$T1$, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.
CO2
muscular rigidity
0
$T1$.Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.
prazosin
muscular rigidity
0
$T1$.Under proper control of respiration, body temperature and end-tidal $T2$
ketamine
CO2
0
$T1$.Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.
ketamine
prazosin
0
$T1$, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, $T2$
CO2
prazosin
0
$T1$ associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.
sagittal and left transverse sinus thrombosis
epsilon-aminocaproic acid
1
$T1$ to promote clotting and reduce blood loss.Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, $T2$
menorrhagia
cerebral sinus thrombosis
0
$T1$ associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.
sagittal and left transverse sinus thrombosis
cerebral sinus thrombosis
0
$T1$ has not been previously described.Careful use of $T2$
cerebral sinus thrombosis
epsilon-aminocaproic acid
0
$T1$.Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, $T2$
blood loss
cerebral sinus thrombosis
0
$T1$ has been reported during treatment with epsilon-aminocaproic acid, $T2$
thromboembolic disease
cerebral sinus thrombosis
0
$T1$ associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.This antifibrinolytic agent has been used in women with $T2$
sagittal and left transverse sinus thrombosis
menorrhagia
0
$T1$ to promote clotting and reduce blood loss.Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.
menorrhagia
epsilon-aminocaproic acid
0
$T1$ to promote clotting and reduce $T2$
menorrhagia
blood loss
0
$T1$ to promote clotting and reduce blood loss.Although increased risk of $T2$
menorrhagia
thromboembolic disease
0
$T1$ associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce $T2$
sagittal and left transverse sinus thrombosis
blood loss
0
$T1$ associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.
sagittal and left transverse sinus thrombosis
thromboembolic disease
0
$T1$.Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.
blood loss
epsilon-aminocaproic acid
0
$T1$ has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.Careful use of $T2$
thromboembolic disease
epsilon-aminocaproic acid
0
$T1$.Although increased risk of $T2$
blood loss
thromboembolic disease
0
$T1$ that causes hemorrhagic cystitis.Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.
cyclophosphamide
hemorrhagic cystitis
1
$T1$ uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of $T2$
mesna
hemorrhagic cystitis
0
$T1$ that causes hemorrhagic cystitis.Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.
cyclophosphamide
mesna
0
$T1$ and injection-site pain in the placebo group.$T2$
nausea
Flumazenil
1
$T1$ in the flumazenil group and nausea and injection-site pain in the placebo group.$T2$
vomiting
Flumazenil
1
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.
benzodiazepine
Flumazenil
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.
benzodiazepine
diazepam
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid ($T2$
benzodiazepine
fentanyl
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, $T2$
benzodiazepine
meperidine
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or $T2$
benzodiazepine
morphine
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.
benzodiazepine
nausea
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.
benzodiazepine
vomiting
0
$T1$ antagonist, flumazenil, were assessed in a double-blind multicenter study.Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.
benzodiazepine
pain
0
$T1$ was found to promptly reverse sedation induced by $T2$
Flumazenil
diazepam
0
$T1$, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
fentanyl
Flumazenil
0
$T1$, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
meperidine
Flumazenil
0
$T1$) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
morphine
Flumazenil
0
$T1$ in the placebo group.$T2$
pain
Flumazenil
0
$T1$, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
fentanyl
diazepam
0
$T1$, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
meperidine
diazepam
0
$T1$) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
morphine
diazepam
0
$T1$ and injection-site pain in the placebo group.Flumazenil was found to promptly reverse sedation induced by $T2$
nausea
diazepam
0
$T1$ in the flumazenil group and nausea and injection-site pain in the placebo group.Flumazenil was found to promptly reverse sedation induced by $T2$
vomiting
diazepam
0
$T1$ in the placebo group.Flumazenil was found to promptly reverse sedation induced by $T2$
pain
diazepam
0
$T1$, $T2$
fentanyl
meperidine
0
$T1$, meperidine, or $T2$
fentanyl
morphine
0
$T1$, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
fentanyl
nausea
0
$T1$, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
fentanyl
vomiting
0
$T1$, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
fentanyl
pain
0
$T1$, or $T2$
meperidine
morphine
0
$T1$, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
meperidine
nausea
0
$T1$, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
meperidine
vomiting
0
$T1$, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
meperidine
pain
0
$T1$) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
morphine
nausea
0
$T1$) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
morphine
vomiting
0
$T1$) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.
morphine
pain
0
$T1$ in the flumazenil group and $T2$
vomiting
nausea
0
$T1$ and injection-site $T2$
nausea
pain
0
$T1$ in the flumazenil group and nausea and injection-site $T2$
vomiting
pain
0
$T1$, are reported.Special reference is made to their clinical presentation, which may be totally asymptomatic.
oral contraceptives
focal nodular hyperplasia
1
$T1$, are reported.Special reference is made to their clinical presentation, which may be totally asymptomatic.
oral contraceptives
adenoma
1
$T1$ and $T2$
adenoma
focal nodular hyperplasia
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
arterial occlusion
heparin
1
$T1$ is heparin-induced platelet aggregation.Appropriate treatment consists of discontinuation of $T2$
thrombocytopenia
heparin
1
$T1$ and thrombocytopenia is heparin-induced platelet aggregation.Appropriate treatment consists of discontinuation of $T2$
thromboembolism
heparin
0
$T1$ and $T2$
thromboembolism
thrombocytopenia
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
arterial occlusion
thromboembolism
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
thrombi
thromboembolism
0
$T1$ in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
ischemic
thromboembolism
0
$T1$ that appear to be ischemic in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
gastrointestinal and musculoskeletal symptoms
thromboembolism
0
$T1$ and thrombocytopenia is heparin-induced $T2$
thromboembolism
platelet aggregation
0
$T1$ and thrombocytopenia is heparin-induced platelet aggregation.Appropriate treatment consists of discontinuation of heparin, and anticoagulation with $T2$
thromboembolism
sodium warfarin
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
thrombi
heparin
0
$T1$ in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
ischemic
heparin
0
$T1$ that appear to be ischemic in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
gastrointestinal and musculoskeletal symptoms
heparin
0
$T1$.Appropriate treatment consists of discontinuation of $T2$
platelet aggregation
heparin
0
$T1$, and anticoagulation with $T2$
heparin
sodium warfarin
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
arterial occlusion
thrombocytopenia
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
thrombi
thrombocytopenia
0
$T1$ in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
ischemic
thrombocytopenia
0
$T1$ that appear to be ischemic in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
gastrointestinal and musculoskeletal symptoms
thrombocytopenia
0
$T1$ is heparin-induced $T2$
thrombocytopenia
platelet aggregation
0
$T1$ is heparin-induced platelet aggregation.Appropriate treatment consists of discontinuation of heparin, and anticoagulation with $T2$
thrombocytopenia
sodium warfarin
0
$T1$ by platelet-fibrin $T2$
arterial occlusion
thrombi
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be $T2$
arterial occlusion
ischemic
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by $T2$
arterial occlusion
gastrointestinal and musculoskeletal symptoms
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
arterial occlusion
platelet aggregation
0
$T1$ by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
arterial occlusion
sodium warfarin
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be $T2$
thrombi
ischemic
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by $T2$
thrombi
gastrointestinal and musculoskeletal symptoms
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
thrombi
platelet aggregation
0
$T1$ with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.
thrombi
sodium warfarin
0
$T1$ that appear to be $T2$
gastrointestinal and musculoskeletal symptoms
ischemic
0
$T1$ in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
ischemic
platelet aggregation
0
$T1$ in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
ischemic
sodium warfarin
0
$T1$ that appear to be ischemic in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
gastrointestinal and musculoskeletal symptoms
platelet aggregation
0
$T1$ that appear to be ischemic in origin, and might serve to warn the clinician of these complications.Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed.
gastrointestinal and musculoskeletal symptoms
sodium warfarin
0
$T1$.Appropriate treatment consists of discontinuation of heparin, and anticoagulation with $T2$
platelet aggregation
sodium warfarin
0
$T1$-induced $T2$
Paracetamol
acute liver failure
1
$T1$ had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver injury
Paracetamol
0
$T1$, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver disease
Paracetamol
0
$T1$ among survivors of acute liver failure.CONCLUSIONS: $T2$
substance abuse
Paracetamol
0
$T1$-induced acute liver failure did not affect long-term mortality.Clinical follow-up may be justified by the cause of the liver failure, but not by the $T2$
Paracetamol
liver failure
0
$T1$ had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver injury
acute liver failure
0
$T1$, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver disease
acute liver failure
0
$T1$ among survivors of acute liver failure.CONCLUSIONS: Paracetamol-induced $T2$
substance abuse
acute liver failure
0
$T1$ did not affect long-term mortality.Clinical follow-up may be justified by the cause of the liver failure, but not by the $T2$
acute liver failure
liver failure
0
$T1$ had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of $T2$
liver injury
liver disease
0
$T1$ had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver injury
substance abuse
0
$T1$ had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver injury
liver failure
0
$T1$, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver disease
substance abuse
0
$T1$, whereas suicides were frequent in both groups.These observations speak against long-term effects of acute liver failure.
liver disease
liver failure
0
$T1$ among survivors of acute liver failure.CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.
substance abuse
liver failure
0
$T1$-induced $T2$
METH
psychosis
1
$T1$6 gene (HTR6) with METH-induced psychosis.METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.
5-HT
METH
0
$T1$6 gene (HTR6) with METH-induced psychosis.METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.
5-HT
psychosis
0
$T1$, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.
schizophrenia
5-HT
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
clozapine
5-HT
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
olanzapine
5-HT
0
$T1$ or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
d-amphetamine
5-HT
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
hyperactivity
5-HT
0
$T1$ was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
phencyclidine
5-HT
0
$T1$.Therefore, we conducted an analysis of the association of the $T2$
paranoid type schizophrenia
5-HT
0
$T1$, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.
schizophrenia
METH
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
clozapine
METH
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
olanzapine
METH
0
$T1$ or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
d-amphetamine
METH
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
hyperactivity
METH
0
$T1$ was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
phencyclidine
METH
0
$T1$.Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.
paranoid type schizophrenia
METH
0
$T1$, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia.
schizophrenia
psychosis
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
clozapine
psychosis
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
olanzapine
psychosis
0
$T1$ or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
d-amphetamine
psychosis
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
hyperactivity
psychosis
0
$T1$ was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
phencyclidine
psychosis
0
$T1$.Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis.
paranoid type schizophrenia
psychosis
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
clozapine
schizophrenia
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
olanzapine
schizophrenia
0
$T1$ or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of $T2$
d-amphetamine
schizophrenia
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
hyperactivity
schizophrenia
0
$T1$ was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of $T2$
phencyclidine
schizophrenia
0
$T1$, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.The symptoms of methamphetamine (METH)-induced psychosis are similar to those of $T2$
schizophrenia
paranoid type schizophrenia
0
$T1$ and $T2$
clozapine
olanzapine
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by $T2$
clozapine
d-amphetamine
0
$T1$ and olanzapine, and d-amphetamine-induced $T2$
clozapine
hyperactivity
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or $T2$
clozapine
phencyclidine
0
$T1$ and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
clozapine
paranoid type schizophrenia
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by $T2$
olanzapine
d-amphetamine
0
$T1$, and d-amphetamine-induced $T2$
olanzapine
hyperactivity
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or $T2$
olanzapine
phencyclidine
0
$T1$, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
olanzapine
paranoid type schizophrenia
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by $T2$
hyperactivity
d-amphetamine
0
$T1$ or $T2$
d-amphetamine
phencyclidine
0
$T1$ or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
d-amphetamine
paranoid type schizophrenia
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or $T2$
hyperactivity
phencyclidine
0
$T1$ in rats is corrected with the use of a selective 5-HT6 receptor antagonist.In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.
hyperactivity
paranoid type schizophrenia
0
$T1$ was restored by 5-HT6 receptor antagonist in an animal study using rats.These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
phencyclidine
paranoid type schizophrenia
0
$T1$ and the risk of $T2$
bupropion
convulsions
1
$T1$ into the left lateral ventricle while the cortical activity was continuously recorded.Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.
penicillin-G potassium
epilepsies
1
$T1$-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.
penicillin
epilepsies
0
$T1$ and connected to an electrocorticogram setup.After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.
urethane
penicillin
0
$T1$ into the left lateral ventricle while the cortical activity was continuously recorded.Basal activity, latent period and the $T2$
penicillin-G potassium
penicillin
0
$T1$ and connected to an electrocorticogram setup.After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.
urethane
epilepsies
0
$T1$ and connected to an electrocorticogram setup.After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl $T2$
urethane
penicillin-G potassium
0
$T1$, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.
bradycardia
Dexmedetomidine
1
$T1$ in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.
pentobarbital
Dexmedetomidine
0
$T1$ saturations were 95% or higher.CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.
oxygen
Dexmedetomidine
0
$T1$ in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).Although dexmedetomidine sedation was associated with a 16% incidence of $T2$
pentobarbital
bradycardia
0
$T1$ in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and $T2$
pentobarbital
oxygen
0
$T1$, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and $T2$
bradycardia
oxygen
0
$T1$.These findings suggest that alterations in MAP kinase-related pathways in the prefronto-striatal circuitries might be involved in the manifestation of $T2$
METH
aggressive behaviors
1
$T1$.Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.
hyperactivity
METH
0
$T1$.Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.
hyperactivity
aggressive behaviors
0
$T1$ that only ceased after $T2$
myoclonic status
LTG
1
$T1$) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.
IGE
LTG
0
$T1$) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.
IGE
myoclonic status
0
$T1$-induced dyskinesia are unclear.Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.
levodopa
drug-induced dyskinesias
1
$T1$, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.rTMS at 1 Hz was observed to markedly reduce $T2$
Parkinson disease
drug-induced dyskinesias
0
$T1$ infusion.rTMS at 1 Hz was observed to markedly reduce $T2$
apomorphine
drug-induced dyskinesias
0
$T1$-induced dyskinesia are unclear.Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced $T2$
levodopa
Parkinson disease
0
$T1$, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous $T2$
Parkinson disease
apomorphine
0
$T1$-induced dyskinesia are unclear.Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous $T2$
levodopa
apomorphine
0
$T1$ between December 28, 2002, and October 31, 2003.BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status.
propofol
inability to repeat words
1
$T1$ was 81.5 (95% CI = 78.1 to 84.8).The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96.7 (+/-2.4; range 84 to 98).
inability to repeat words
retrograde amnesia
0
$T1$ between December 28, 2002, and October 31, 2003.BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status.
propofol
retrograde amnesia
0
$T1$-positive mothers also received hepatitis B immune globulin.Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.
hepatitis B surface antigen
hepatitis B
1
$T1$ and $T2$
hepatitis B
rubella
0
$T1$-positive mothers also received hepatitis B immune globulin.Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.
hepatitis B surface antigen
rubella
0
$T1$-induced apoptosis and reduces the extent of acute $T2$
doxorubicin
heart failure
1
$T1$ agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.
tumor
doxorubicin
0
$T1$ agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.
tumor
heart failure
0
$T1$.BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.
nephrosis
doxorubicin
1
$T1$-induced $T2$
doxorubicin
renal lesions
0
$T1$ in the onset of these lesions.METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.
mitochondrial injury
doxorubicin
0
$T1$ in $T2$
superoxide
doxorubicin
0
$T1$ synthase activity.In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased.
citrate
doxorubicin
0
$T1$.BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.
nephrosis
renal lesions
0
$T1$.BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.
nephrosis
mitochondrial injury
0
$T1$.BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.
nephrosis
superoxide
0
$T1$.BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.
nephrosis
citrate
0
$T1$ in the onset of these lesions.METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.
mitochondrial injury
renal lesions
0
$T1$ in doxorubicin-induced $T2$
superoxide
renal lesions
0
$T1$ synthase activity.In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased.
citrate
renal lesions
0
$T1$ in the onset of these lesions.METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.
mitochondrial injury
superoxide
0
$T1$ in the onset of these lesions.METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.
mitochondrial injury
citrate
0
$T1$ synthase activity.In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased.
citrate
superoxide
0
$T1$ associated with $T2$
seizures
amphotericin B
1
$T1$ patient.CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.
AIDS
amphotericin B
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
amphotericin B
0
$T1$ also has a potential for inducing seizures.However, these other potential causes of seizure were ruled out.
Didanosine
amphotericin B
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
amphotericin B
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
amphotericin B
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
amphotericin B
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
amphotericin B
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
phenytoin
amphotericin B
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
lorazepam
amphotericin B
0
$T1$, both of which the patient had, can potentially cause seizures.The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
cryptococcal meningitis
amphotericin B
0
$T1$; alcohol intake as well as withdrawal can also cause seizures.Didanosine also has a potential for inducing seizures.
alcohol abuse
amphotericin B
0
$T1$ intake as well as withdrawal can also cause seizures.Didanosine also has a potential for inducing seizures.
alcohol
amphotericin B
0
$T1$ patient.CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.
AIDS
seizures
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
seizures
0
$T1$ also has a potential for inducing seizures.However, these other potential causes of seizure were ruled out.
Didanosine
seizures
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
seizures
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
seizures
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
seizures
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
seizures
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
phenytoin
seizures
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
lorazepam
seizures
0
$T1$, both of which the patient had, can potentially cause seizures.The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
cryptococcal meningitis
seizures
0
$T1$; alcohol intake as well as withdrawal can also cause seizures.Didanosine also has a potential for inducing seizures.
alcohol abuse
seizures
0
$T1$ intake as well as withdrawal can also cause seizures.Didanosine also has a potential for inducing seizures.
alcohol
seizures
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
AIDS
0
$T1$ also has a potential for inducing seizures.However, these other potential causes of seizure were ruled out.
Didanosine
AIDS
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
AIDS
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
AIDS
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
AIDS
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
AIDS
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
phenytoin
AIDS
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
lorazepam
AIDS
0
$T1$, both of which the patient had, can potentially cause seizures.The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
cryptococcal meningitis
AIDS
0
$T1$; alcohol intake as well as withdrawal can also cause seizures.Didanosine also has a potential for inducing seizures.
alcohol abuse
AIDS
0
$T1$ intake as well as withdrawal can also cause seizures.Didanosine also has a potential for inducing seizures.
alcohol
AIDS
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
Didanosine
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, $T2$
grand mal seizures
hydroxyzine
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, $T2$
grand mal seizures
promethazine
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, $T2$
grand mal seizures
hydrocortisone
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and $T2$
grand mal seizures
prochlorperazine
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
phenytoin
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
lorazepam
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
cryptococcal meningitis
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
alcohol abuse
0
$T1$ during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine.
grand mal seizures
alcohol
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
Didanosine
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
Didanosine
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
Didanosine
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
Didanosine
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
phenytoin
Didanosine
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
lorazepam
Didanosine
0
$T1$, both of which the patient had, can potentially cause seizures.The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
cryptococcal meningitis
Didanosine
0
$T1$; alcohol intake as well as withdrawal can also cause seizures.$T2$
alcohol abuse
Didanosine
0
$T1$ intake as well as withdrawal can also cause seizures.$T2$
alcohol
Didanosine
0
$T1$, $T2$
hydroxyzine
promethazine
0
$T1$, promethazine, $T2$
hydroxyzine
hydrocortisone
0
$T1$, promethazine, hydrocortisone, and $T2$
hydroxyzine
prochlorperazine
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of $T2$
hydroxyzine
phenytoin
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and $T2$
hydroxyzine
lorazepam
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
cryptococcal meningitis
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
alcohol abuse
0
$T1$, promethazine, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydroxyzine
alcohol
0
$T1$, $T2$
promethazine
hydrocortisone
0
$T1$, hydrocortisone, and $T2$
promethazine
prochlorperazine
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of $T2$
promethazine
phenytoin
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and $T2$
promethazine
lorazepam
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
cryptococcal meningitis
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
alcohol abuse
0
$T1$, hydrocortisone, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
promethazine
alcohol
0
$T1$, and $T2$
hydrocortisone
prochlorperazine
0
$T1$, and prochlorperazine.Despite administration of $T2$
hydrocortisone
phenytoin
0
$T1$, and prochlorperazine.Despite administration of phenytoin and $T2$
hydrocortisone
lorazepam
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
cryptococcal meningitis
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
alcohol abuse
0
$T1$, and prochlorperazine.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
hydrocortisone
alcohol
0
$T1$.Despite administration of $T2$
prochlorperazine
phenytoin
0
$T1$.Despite administration of phenytoin and $T2$
prochlorperazine
lorazepam
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
cryptococcal meningitis
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
alcohol abuse
0
$T1$.Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
prochlorperazine
alcohol
0
$T1$ and $T2$
phenytoin
lorazepam
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and $T2$
phenytoin
cryptococcal meningitis
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
phenytoin
alcohol abuse
0
$T1$ and lorazepam, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
phenytoin
alcohol
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and $T2$
lorazepam
cryptococcal meningitis
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
lorazepam
alcohol abuse
0
$T1$, the seizures persisted and occurred only during amphotercin B administration.DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.
lorazepam
alcohol
0
$T1$, both of which the patient had, can potentially cause seizures.The patient had a history of $T2$
cryptococcal meningitis
alcohol abuse
0
$T1$, both of which the patient had, can potentially cause seizures.The patient had a history of alcohol abuse; $T2$
cryptococcal meningitis
alcohol
0
$T1$; $T2$
alcohol abuse
alcohol
0
$T1$.CONCLUSION: This small study suggests that a once-daily dosing regimen of $T2$
decreased auditory function
tobramycin
1
$T1$.MATERIALS AND METHODS: Patients undergoing treatment with i.v.
toxicity
tobramycin
0
$T1$ was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.
creatinine
tobramycin
0
$T1$.In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.
nephrotoxicity
tobramycin
0
$T1$.MATERIALS AND METHODS: Patients undergoing treatment with i.v.
toxicity
creatinine
0
$T1$.MATERIALS AND METHODS: Patients undergoing treatment with i.v.
toxicity
nephrotoxicity
0
$T1$.MATERIALS AND METHODS: Patients undergoing treatment with i.v.
toxicity
decreased auditory function
0
$T1$ was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of $T2$
creatinine
nephrotoxicity
0
$T1$ was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented $T2$
creatinine
decreased auditory function
0
$T1$.In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented $T2$
nephrotoxicity
decreased auditory function
0
$T1$.In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on $T2$
cardiomyopathy
doxorubicin
1
$T1$ derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.
anthracycline
SM-5887
0
$T1$ derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.
anthracycline
doxorubicin
0
$T1$ derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.
anthracycline
cardiomyopathy
0
$T1$ derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.
anthracycline
cardiotoxicity
0
$T1$ does not have any potential of chronic cardiotoxicity and deteriorating effect on $T2$
SM-5887
doxorubicin
0
$T1$.In conclusion, $T2$
cardiomyopathy
SM-5887
0
$T1$ does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced $T2$
SM-5887
cardiotoxicity
0
$T1$-induced $T2$
doxorubicin
cardiotoxicity
0
$T1$.In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced $T2$
cardiomyopathy
cardiotoxicity
0
$T1$-induced $T2$
levodopa
dyskinesias
1
$T1$, pallidotomy significantly reduces levodopa-induced $T2$
Parkinson's disease
dyskinesias
0
$T1$, and rigidity were sustained in the 11 patients examined at two years.The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.
bradykinesia
Parkinson's disease
0
$T1$ were sustained in the 11 patients examined at two years.The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.
rigidity
Parkinson's disease
0
$T1$, pallidotomy significantly reduces $T2$
Parkinson's disease
levodopa
0
$T1$, and rigidity were sustained in the 11 patients examined at two years.The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.
bradykinesia
dyskinesias
0
$T1$ were sustained in the 11 patients examined at two years.The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.
rigidity
dyskinesias
0
$T1$, and $T2$
bradykinesia
rigidity
0
$T1$, and rigidity were sustained in the 11 patients examined at two years.The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.
bradykinesia
levodopa
0
$T1$ were sustained in the 11 patients examined at two years.The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.
rigidity
levodopa
0
$T1$ model of $T2$
PILO
TLE
1
$T1$ and related brain damage.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
seizures
PILO
0
$T1$ is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
epilepsy
PILO
0
$T1$ followed by spontaneous recurrent seizures and related brain damage.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
status epilepticus
PILO
0
$T1$.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
brain damage
PILO
0
$T1$ and related brain damage.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
seizures
TLE
0
$T1$ is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
epilepsy
TLE
0
$T1$ followed by spontaneous recurrent seizures and related brain damage.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
status epilepticus
TLE
0
$T1$.We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.
brain damage
TLE
0
$T1$ is characterized by an acute period of status epilepticus followed by spontaneous recurrent $T2$
epilepsy
seizures
0
$T1$ followed by spontaneous recurrent $T2$
status epilepticus
seizures
0
$T1$ and related $T2$
seizures
brain damage
0
$T1$ is characterized by an acute period of $T2$
epilepsy
status epilepticus
0
$T1$ is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related $T2$
epilepsy
brain damage
0
$T1$ followed by spontaneous recurrent seizures and related $T2$
status epilepticus
brain damage
0
$T1$ therapy was discontinued.RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively.
corticosteroid
IOP rise
1
$T1$-induced $T2$
steroid
IOP rise
0
$T1$ therapy was discontinued.RESULTS: No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively.
corticosteroid
steroid
0
$T1$ (neutrophil count < 0.5 x 10(9)/l).There was no evidence of cardiotoxicity.
neutropenia
daunorubicin
1
$T1$ was an effective and well tolerated agent in the treatment of $T2$
daunorubicin
Kaposi's sarcoma
0
$T1$ related Kaposi's sarcoma.Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.
AIDS
daunorubicin
0
$T1$ of selected 'target' lesions were measured.Clinical, biochemical and haematological toxicities were assessed.
oedema
daunorubicin
0
$T1$, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).There was no evidence of cardiotoxicity.
toxicity
daunorubicin
0
$T1$.In this small patient sample, liposomal $T2$
cardiotoxicity
daunorubicin
0
$T1$ related Kaposi's sarcoma.Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.
AIDS
Kaposi's sarcoma
0
$T1$ of selected 'target' lesions were measured.Clinical, biochemical and haematological toxicities were assessed.
oedema
Kaposi's sarcoma
0
$T1$, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).There was no evidence of cardiotoxicity.
toxicity
Kaposi's sarcoma
0
$T1$ (neutrophil count < 0.5 x 10(9)/l).There was no evidence of cardiotoxicity.
neutropenia
Kaposi's sarcoma
0
$T1$.In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of $T2$
cardiotoxicity
Kaposi's sarcoma
0
$T1$ related Kaposi's sarcoma.Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.
AIDS
oedema
0
$T1$ related Kaposi's sarcoma.Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.
AIDS
toxicity
0
$T1$ related Kaposi's sarcoma.Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.
AIDS
neutropenia
0
$T1$ related Kaposi's sarcoma.Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.
AIDS
cardiotoxicity
0
$T1$ of selected 'target' lesions were measured.Clinical, biochemical and haematological toxicities were assessed.
oedema
toxicity
0
$T1$ of selected 'target' lesions were measured.Clinical, biochemical and haematological toxicities were assessed.
oedema
neutropenia
0
$T1$ of selected 'target' lesions were measured.Clinical, biochemical and haematological toxicities were assessed.
oedema
cardiotoxicity
0
$T1$, with three subjects experiencing severe $T2$
toxicity
neutropenia
0
$T1$, with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l).There was no evidence of $T2$
toxicity
cardiotoxicity
0
$T1$ (neutrophil count < 0.5 x 10(9)/l).There was no evidence of $T2$
neutropenia
cardiotoxicity
0
$T1$-induced $T2$
heparin
thrombosis
1
$T1$ who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.The authors present a case of failure of ancrod treatment in a patient with $T2$
platelet aggregation
heparin
0
$T1$ who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.The authors present a case of failure of ancrod treatment in a patient with heparin-induced $T2$
platelet aggregation
thrombosis
0
$T1$ in a pediatric patient following the administration of $T2$
tonic-clonic seizure
flumazenil
1
$T1$.Seizures and cardiac arrhythmias have complicated its use in adult patients.
benzodiazepines
tonic-clonic seizure
0
$T1$ induced by benzodiazepines.Seizures and cardiac arrhythmias have complicated its use in adult patients.
respiratory depression
tonic-clonic seizure
0
$T1$ have complicated its use in adult patients.Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.
cardiac arrhythmias
tonic-clonic seizure
0
$T1$ patients who have coingested tricyclic antidepressants have a higher risk of these complications.Little information exists concerning adverse effects of flumazenil in children.
Overdose
tonic-clonic seizure
0
$T1$.Seizures and cardiac arrhythmias have complicated its use in adult patients.
benzodiazepines
flumazenil
0
$T1$ induced by benzodiazepines.Seizures and cardiac arrhythmias have complicated its use in adult patients.
respiratory depression
flumazenil
0
$T1$ have complicated its use in adult patients.Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.
cardiac arrhythmias
flumazenil
0
$T1$ patients who have coingested tricyclic antidepressants have a higher risk of these complications.Little information exists concerning adverse effects of flumazenil in children.
Overdose
flumazenil
0
$T1$ induced by $T2$
respiratory depression
benzodiazepines
0
$T1$.Seizures and $T2$
benzodiazepines
cardiac arrhythmias
0
$T1$.Seizures and cardiac arrhythmias have complicated its use in adult patients.
benzodiazepines
Overdose
0
$T1$ induced by benzodiazepines.Seizures and $T2$
respiratory depression
cardiac arrhythmias
0
$T1$ induced by benzodiazepines.Seizures and cardiac arrhythmias have complicated its use in adult patients.
respiratory depression
Overdose
0
$T1$ have complicated its use in adult patients.$T2$
cardiac arrhythmias
Overdose
0
$T1$ caused by a single dose of $T2$
neuropathy
isoniazid
1
$T1$ were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than $T2$
ventricular fibrillation
metrizoate
1
$T1$ and $T2$
Iopentol
iohexol
0
$T1$ and iohexol also produced significantly less decrease in aortic blood pressure than $T2$
Iopentol
metrizoate
0
$T1$ were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).$T2$
ventricular fibrillation
Iopentol
0
$T1$ also produced significantly less decrease in aortic blood pressure than $T2$
iohexol
metrizoate
0
$T1$ were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).Iopentol and $T2$
ventricular fibrillation
iohexol
0
$T1$ in a 21-year-old white woman are presented.This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes.
deep venous thrombosis
oral contraceptive
1
$T1$-induced $T2$
dipyridamole
hyperemia
1
$T1$.The results obtained show a correlation with the anatomic area at risk similar to that obtained with $T2$
coronary stenosis
thallium
0
$T1$, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).
coronary occlusion
coronary stenosis
0
$T1$; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of $T2$
hyperemia
coronary stenosis
0
$T1$-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of $T2$
dipyridamole
coronary stenosis
0
$T1$, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).
coronary occlusion
thallium
0
$T1$; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.
hyperemia
thallium
0
$T1$-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.
dipyridamole
thallium
0
$T1$, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).
coronary occlusion
hyperemia
0
$T1$, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).
coronary occlusion
dipyridamole
0
$T1$ in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).Renal failure was associated with weight loss in the furosemide-treated group.
Renal function significantly deteriorated
Furosemide
1
$T1$ may be deleterious in the prevention of radiocontrast $T2$
Furosemide
nephropathy
0
$T1$ was associated with weight loss in the furosemide-treated group.$T2$
Renal failure
Furosemide
0
$T1$ from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).Renal failure was associated with weight loss in the furosemide-treated group.
creatinine
Furosemide
0
$T1$ in the furosemide-treated group.$T2$
weight loss
Furosemide
0
$T1$ was associated with weight loss in the furosemide-treated group.Furosemide may be deleterious in the prevention of radiocontrast $T2$
Renal failure
nephropathy
0
$T1$ in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).Renal failure was associated with weight loss in the furosemide-treated group.
Renal function significantly deteriorated
nephropathy
0
$T1$ from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).Renal failure was associated with weight loss in the furosemide-treated group.
creatinine
nephropathy
0
$T1$ in the furosemide-treated group.Furosemide may be deleterious in the prevention of radiocontrast $T2$
weight loss
nephropathy
0
$T1$ in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).$T2$
Renal function significantly deteriorated
Renal failure
0
$T1$ from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).$T2$
creatinine
Renal failure
0
$T1$ was associated with $T2$
Renal failure
weight loss
0
$T1$ in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum $T2$
Renal function significantly deteriorated
creatinine
0
$T1$ in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).Renal failure was associated with $T2$
Renal function significantly deteriorated
weight loss
0
$T1$ from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).Renal failure was associated with $T2$
creatinine
weight loss
0
$T1$ is reported.At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron.
diabetes insipidus
lithium
1
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
oral contraceptive
1
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
steroids
0
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
focal nodular hyperplasia
0
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
adenoma
0
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
hamartoma
0
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
hepatoma
0
$T1$ Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.The recent literature contains 44 case reports.
Liver Tumors
rupture
0
$T1$ $T2$
oral contraceptive
steroids
0
$T1$, adenoma, hamartoma, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of $T2$
focal nodular hyperplasia
oral contraceptive
0
$T1$, hamartoma, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of $T2$
adenoma
oral contraceptive
0
$T1$, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of $T2$
hamartoma
oral contraceptive
0
$T1$.Significant statistical etiologic factors include prolonged uninterrupted usage of $T2$
hepatoma
oral contraceptive
0
$T1$ steroids.Eight deaths and liver $T2$
oral contraceptive
rupture
0
$T1$, adenoma, hamartoma, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive $T2$
focal nodular hyperplasia
steroids
0
$T1$, hamartoma, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive $T2$
adenoma
steroids
0
$T1$, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive $T2$
hamartoma
steroids
0
$T1$.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive $T2$
hepatoma
steroids
0
$T1$.Eight deaths and liver $T2$
steroids
rupture
0
$T1$, $T2$
focal nodular hyperplasia
adenoma
0
$T1$, adenoma, $T2$
focal nodular hyperplasia
hamartoma
0
$T1$, adenoma, hamartoma, and $T2$
focal nodular hyperplasia
hepatoma
0
$T1$, adenoma, hamartoma, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.
focal nodular hyperplasia
rupture
0
$T1$, $T2$
adenoma
hamartoma
0
$T1$, hamartoma, and $T2$
adenoma
hepatoma
0
$T1$, hamartoma, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.
adenoma
rupture
0
$T1$, and $T2$
hamartoma
hepatoma
0
$T1$, and hepatoma.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.
hamartoma
rupture
0
$T1$.Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.
hepatoma
rupture
0
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
tacrolimus
SOS
1
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
tacrolimus
TMA
1
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
everolimus
SOS
1
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
everolimus
acute renal failure
1
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
tacrolimus
acute renal failure
1
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
everolimus
TMA
1
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
everolimus
GVHD
0
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
tacrolimus
GVHD
0
$T1$, the incidence of TMA and $T2$
GVHD
SOS
0
$T1$, the incidence of $T2$
GVHD
TMA
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
GVHD
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
sirolimus
GVHD
0
$T1$; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
MDS
GVHD
0
$T1$; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
AML
GVHD
0
$T1$.Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.
mucositis
GVHD
0
$T1$.The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.
acute renal failure
GVHD
0
$T1$ and $T2$
everolimus
tacrolimus
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
everolimus
0
$T1$, seems to mediate antileukemia effects.We report on a combination of $T2$
sirolimus
everolimus
0
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome ($T2$
everolimus
MDS
0
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia ($T2$
everolimus
AML
0
$T1$ and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV $T2$
everolimus
mucositis
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
tacrolimus
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and $T2$
sirolimus
tacrolimus
0
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome ($T2$
tacrolimus
MDS
0
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia ($T2$
tacrolimus
AML
0
$T1$ in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV $T2$
tacrolimus
mucositis
0
$T1$ and $T2$
TMA
SOS
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
SOS
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
sirolimus
SOS
0
$T1$; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
MDS
SOS
0
$T1$; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
AML
SOS
0
$T1$.Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.
mucositis
SOS
0
$T1$.The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.
acute renal failure
SOS
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
TMA
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
sirolimus
TMA
0
$T1$; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
MDS
TMA
0
$T1$; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
AML
TMA
0
$T1$.Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.
mucositis
TMA
0
$T1$.The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.
acute renal failure
TMA
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of $T2$
methotrexate
sirolimus
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
MDS
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
AML
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
mucositis
0
$T1$ is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.
methotrexate
acute renal failure
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome ($T2$
sirolimus
MDS
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia ($T2$
sirolimus
AML
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
sirolimus
mucositis
0
$T1$, seems to mediate antileukemia effects.We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
sirolimus
acute renal failure
0
$T1$; n = 17) or acute myeloid leukemia ($T2$
MDS
AML
0
$T1$; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV $T2$
MDS
mucositis
0
$T1$; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
MDS
acute renal failure
0
$T1$; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV $T2$
AML
mucositis
0
$T1$; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.All patients engrafted, and only 1 patient experienced grade IV mucositis.
AML
acute renal failure
0
$T1$.Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD.
mucositis
acute renal failure
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
bicuculline
1
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
aminophylline
1
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
BAY k-8644
1
$T1$.On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.
valproate
loreclezole
0
$T1$.The results support the hypothesis that the protective activity of $T2$
clonazepam
loreclezole
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
loreclezole
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
loreclezole
0
$T1$, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.The results support the hypothesis that the protective activity of $T2$
bicuculline
loreclezole
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.
N-methyl-D-aspartic acid
loreclezole
0
$T1$ inhibited the anticonvulsive action of loreclezole combined with clonazepam.The results support the hypothesis that the protective activity of $T2$
BAY k-8644
loreclezole
0
$T1$ and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of $T2$
loreclezole
calcium
0
$T1$ and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.The results support the hypothesis that the protective activity of $T2$
aminophylline
loreclezole
0
$T1$.On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with $T2$
valproate
clonazepam
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
valproate
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
valproate
0
$T1$.On the other hand, $T2$
valproate
bicuculline
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with $T2$
N-methyl-D-aspartic acid
valproate
0
$T1$.On the other hand, bicuculline, aminophylline and $T2$
valproate
BAY k-8644
0
$T1$.On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.
valproate
calcium
0
$T1$.On the other hand, bicuculline, $T2$
valproate
aminophylline
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
clonazepam
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
clonazepam
0
$T1$, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with $T2$
bicuculline
clonazepam
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with $T2$
N-methyl-D-aspartic acid
clonazepam
0
$T1$ inhibited the anticonvulsive action of loreclezole combined with $T2$
BAY k-8644
clonazepam
0
$T1$.The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of $T2$
clonazepam
calcium
0
$T1$ and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with $T2$
aminophylline
clonazepam
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or $T2$
seizure
carbamazepine
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
N-methyl-D-aspartic acid
0
$T1$ and afterdischarge durations.The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.
seizure
calcium
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
bicuculline
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
N-methyl-D-aspartic acid
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
BAY k-8644
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
calcium
0
$T1$ (applied at their subprotective doses) also exhibited antiseizure effect in this test.However, only two first combinations occurred to be of pharmacodynamic nature.
carbamazepine
aminophylline
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.On the other hand, $T2$
N-methyl-D-aspartic acid
bicuculline
0
$T1$, aminophylline and $T2$
bicuculline
BAY k-8644
0
$T1$, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of $T2$
bicuculline
calcium
0
$T1$, $T2$
bicuculline
aminophylline
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.On the other hand, bicuculline, aminophylline and $T2$
N-methyl-D-aspartic acid
BAY k-8644
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.
N-methyl-D-aspartic acid
calcium
0
$T1$ and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.On the other hand, bicuculline, $T2$
N-methyl-D-aspartic acid
aminophylline
0
$T1$ inhibited the anticonvulsive action of loreclezole combined with clonazepam.The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of $T2$
BAY k-8644
calcium
0
$T1$ and $T2$
aminophylline
BAY k-8644
0
$T1$ and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of $T2$
aminophylline
calcium
0
$T1$ given concurrently with other $T2$
bupropion
hepatotoxic
1
$T1$.CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other $T2$
carbimazole
hepatotoxic
1
$T1$.CONCLUSIONS: Clinicians should be aware of the possibility of $T2$
carbimazole
acute liver insult
1
$T1$ induced by $T2$
acute liver insult
bupropion
1
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
liver failure
acute liver insult
0
$T1$ had been treated with carbimazole and propranolol for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
hyperthyroidism
acute liver insult
0
$T1$ for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
propranolol
acute liver insult
0
$T1$ induced by bupropion given concurrently with other $T2$
acute liver insult
hepatotoxic
0
$T1$ and coagulopathy.Death resulted 19 days after the onset of symptoms.
sepsis
acute liver insult
0
$T1$.Death resulted 19 days after the onset of symptoms.
coagulopathy
acute liver insult
0
$T1$.CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by $T2$
carbimazole
bupropion
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
liver failure
bupropion
0
$T1$ had been treated with carbimazole and propranolol for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
hyperthyroidism
bupropion
0
$T1$ for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
propranolol
bupropion
0
$T1$ and coagulopathy.Death resulted 19 days after the onset of symptoms.
sepsis
bupropion
0
$T1$.Death resulted 19 days after the onset of symptoms.
coagulopathy
bupropion
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
liver failure
carbimazole
0
$T1$ had been treated with carbimazole and propranolol for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
hyperthyroidism
carbimazole
0
$T1$ for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
propranolol
carbimazole
0
$T1$ and coagulopathy.Death resulted 19 days after the onset of symptoms.
sepsis
carbimazole
0
$T1$.Death resulted 19 days after the onset of symptoms.
coagulopathy
carbimazole
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of $T2$
liver failure
hyperthyroidism
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and $T2$
liver failure
propranolol
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
liver failure
hepatotoxic
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
liver failure
sepsis
0
$T1$ possibly associated with concurrent use of bupropion and carbimazole.CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
liver failure
coagulopathy
0
$T1$ had been treated with carbimazole and $T2$
hyperthyroidism
propranolol
0
$T1$ had been treated with carbimazole and propranolol for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
hyperthyroidism
hepatotoxic
0
$T1$ had been treated with carbimazole and propranolol for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
hyperthyroidism
sepsis
0
$T1$ had been treated with carbimazole and propranolol for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
hyperthyroidism
coagulopathy
0
$T1$ for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
propranolol
hepatotoxic
0
$T1$ for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
propranolol
sepsis
0
$T1$ for the past 5 years.He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.
propranolol
coagulopathy
0
$T1$ and coagulopathy.Death resulted 19 days after the onset of symptoms.
sepsis
hepatotoxic
0
$T1$.Death resulted 19 days after the onset of symptoms.
coagulopathy
hepatotoxic
0
$T1$ and $T2$
sepsis
coagulopathy
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
venous thrombo-embolism
1
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
gallbladder disease
oestrogen
1
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
stroke
oestrogen
1
$T1$-only HT, versus similar-sized placebo groups.The only significantly increased risk reported was for $T2$
oestrogen
venous thrombo-embolism
1
$T1$.Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking $T2$
dementia
oestrogen
1
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
dementia
1
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
cardiovascular disease
0
$T1$.Among women with $T2$
dementia
cardiovascular disease
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
cardiovascular disease
0
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
gallbladder disease
cardiovascular disease
0
$T1$ and (for combined HT) colon cancer, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
fractures
cardiovascular disease
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
cardiovascular disease
0
$T1$, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking $T2$
cardiovascular disease
oestrogen
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
cardiovascular disease
0
$T1$, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.The only significantly increased risk reported was for $T2$
cardiovascular disease
venous thrombo-embolism
0
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
stroke
cardiovascular disease
0
$T1$.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
breast cancer
cardiovascular disease
0
$T1$, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
colon cancer
cardiovascular disease
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
dementia
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
cancer
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
gallbladder disease
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
fractures
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
Menstrual Disorders
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
oestrogen
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
progestogens
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
venous thrombo-embolism
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
stroke
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
breast cancer
0
$T1$ and dementia in older women.This is an updated version of the original Cochrane review first published in 2005.
osteoporosis
colon cancer
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
dementia
0
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
gallbladder disease
dementia
0
$T1$ and (for combined HT) colon cancer, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
fractures
dementia
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
dementia
0
$T1$.Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.
dementia
venous thrombo-embolism
0
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
stroke
dementia
0
$T1$.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
breast cancer
dementia
0
$T1$, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
colon cancer
dementia
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
gallbladder disease
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
fractures
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane $T2$
cancer
Menstrual Disorders
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
oestrogen
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
progestogens
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
venous thrombo-embolism
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
stroke
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
breast cancer
0
$T1$, gallbladder disease, cognition, fractures and quality of life.SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.
cancer
colon cancer
0
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of $T2$
gallbladder disease
fractures
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
gallbladder disease
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
gallbladder disease
0
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
gallbladder disease
venous thrombo-embolism
0
$T1$ and $T2$
stroke
gallbladder disease
0
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of $T2$
gallbladder disease
breast cancer
0
$T1$ (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) $T2$
gallbladder disease
colon cancer
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
fractures
0
$T1$ and (for combined HT) colon cancer, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
fractures
oestrogen
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
fractures
0
$T1$ and (for combined HT) colon cancer, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
fractures
venous thrombo-embolism
0
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of $T2$
stroke
fractures
0
$T1$.The only statistically significant benefits of HT were a decreased incidence of $T2$
breast cancer
fractures
0
$T1$ and (for combined HT) $T2$
fractures
colon cancer
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
oestrogen
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
progestogens
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
venous thrombo-embolism
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
stroke
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
breast cancer
0
$T1$ and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.Also relevant non-indexed journals and conference abstracts.
Menstrual Disorders
colon cancer
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
oestrogen
0
$T1$.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
breast cancer
oestrogen
0
$T1$, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
colon cancer
oestrogen
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
stroke
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
breast cancer
0
$T1$, via oral, transdermal, subcutaneous or transnasal routes.DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data.
progestogens
colon cancer
0
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
stroke
venous thrombo-embolism
0
$T1$.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.
breast cancer
venous thrombo-embolism
0
$T1$, with long-term use.Among women aged over 65 who were relatively healthy (i.e.
colon cancer
venous thrombo-embolism
0
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of $T2$
stroke
breast cancer
0
$T1$ and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) $T2$
stroke
colon cancer
0
$T1$.The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) $T2$
breast cancer
colon cancer
0
$T1$ in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
elevated ICP
mannitol
1
$T1$ may leak through the altered BBB near $T2$
mannitol
gliomas
0
$T1$ and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
brain edema
mannitol
0
$T1$ patients.METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.
brain tumor
mannitol
0
$T1$ patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.CONCLUSIONS: The results of our study show that even after a single bolus, $T2$
metastases
mannitol
0
$T1$ and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.CONCLUSIONS: The results of our study show that even after a single bolus, $T2$
meningioma
mannitol
0
$T1$ may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral $T2$
mannitol
edema
0
$T1$ and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
brain edema
gliomas
0
$T1$ in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
elevated ICP
gliomas
0
$T1$ patients.METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.
brain tumor
gliomas
0
$T1$ patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near $T2$
metastases
gliomas
0
$T1$ and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near $T2$
meningioma
gliomas
0
$T1$, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral $T2$
gliomas
edema
0
$T1$ and lower $T2$
brain edema
elevated ICP
0
$T1$ and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
brain edema
brain tumor
0
$T1$ and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
brain edema
metastases
0
$T1$ and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
brain edema
meningioma
0
$T1$ and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
brain edema
edema
0
$T1$ in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
elevated ICP
brain tumor
0
$T1$ in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
elevated ICP
metastases
0
$T1$ in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
elevated ICP
meningioma
0
$T1$ in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
elevated ICP
edema
0
$T1$ patients.METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.
brain tumor
metastases
0
$T1$ patients.METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.
brain tumor
meningioma
0
$T1$ patients.METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.
brain tumor
edema
0
$T1$ and $T2$
meningioma
metastases
0
$T1$ patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral $T2$
metastases
edema
0
$T1$ and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral $T2$
meningioma
edema
0
$T1$.The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.
muscle fasciculation
succinylcholine
1
$T1$ is used, lidocaine is proven to be the useful pretreatment agent for the reduction of $T2$
succinylcholine
postoperative myalgia
1
$T1$ is used, $T2$
succinylcholine
lidocaine
0
$T1$ is proven to be the useful pretreatment agent for the reduction of $T2$
lidocaine
postoperative myalgia
0
$T1$ and the occurrence of muscle fasciculation.The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.
myalgia
lidocaine
0
$T1$ (Group PR) for tracheal intubation.Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.
rocuronium
lidocaine
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) thiopental iv.
Morphine
lidocaine
0
$T1$ iv.followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.
thiopental
lidocaine
0
$T1$.The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.
muscle fasciculation
lidocaine
0
$T1$ and the occurrence of muscle fasciculation.The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.
myalgia
succinylcholine
0
$T1$ (Group PR) for tracheal intubation.Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.
rocuronium
succinylcholine
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) thiopental iv.
Morphine
succinylcholine
0
$T1$ iv.followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.
thiopental
succinylcholine
0
$T1$ and the occurrence of muscle fasciculation.The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.
myalgia
postoperative myalgia
0
$T1$ (Group PR) for tracheal intubation.Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.
rocuronium
postoperative myalgia
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) thiopental iv.
Morphine
postoperative myalgia
0
$T1$ iv.followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.
thiopental
postoperative myalgia
0
$T1$.The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.
muscle fasciculation
postoperative myalgia
0
$T1$ (Group PR) for tracheal intubation.Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.
rocuronium
myalgia
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) thiopental iv.
Morphine
myalgia
0
$T1$ iv.followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.
thiopental
myalgia
0
$T1$ and the occurrence of $T2$
myalgia
muscle fasciculation
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) thiopental iv.
Morphine
rocuronium
0
$T1$ iv.followed by succinylcholine (Group PS, LS) or $T2$
thiopental
rocuronium
0
$T1$ (Group PR) for tracheal intubation.Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.
rocuronium
muscle fasciculation
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) $T2$
Morphine
thiopental
0
$T1$ 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.Anesthesia was induced with 5 mg.kg(-1) thiopental iv.
Morphine
muscle fasciculation
0
$T1$ iv.followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.
thiopental
muscle fasciculation
0
$T1$, and nausea; most adverse events were mild to moderate in severity.CONCLUSION: The results of this study indicate that $T2$
flatulence
levofloxacin
1
$T1$, flatulence, and nausea; most adverse events were mild to moderate in severity.CONCLUSION: The results of this study indicate that $T2$
diarrhea
levofloxacin
1
$T1$; most adverse events were mild to moderate in severity.CONCLUSION: The results of this study indicate that $T2$
nausea
levofloxacin
1
$T1$ 500 mg once daily is an effective and safe treatment for acute bacterial $T2$
levofloxacin
sinusitis
0
$T1$, flatulence, and nausea; most adverse events were mild to moderate in severity.CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial $T2$
diarrhea
sinusitis
0
$T1$, and nausea; most adverse events were mild to moderate in severity.CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial $T2$
flatulence
sinusitis
0
$T1$; most adverse events were mild to moderate in severity.CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial $T2$
nausea
sinusitis
0
$T1$, $T2$
diarrhea
flatulence
0
$T1$, flatulence, and $T2$
diarrhea
nausea
0
$T1$, and $T2$
flatulence
nausea
0
$T1$ in one and nausea in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
facial flush
CLZ
1
$T1$ in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
nausea
CLZ
1
$T1$ of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
headache
BPT
1
$T1$ in one and nausea in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
facial flush
BPT
1
$T1$ of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
headache
CLZ
1
$T1$ in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
nausea
BPT
1
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
BPT
0
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
CLZ
0
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
cAMP
0
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
platelet aggregation
0
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
headache
0
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
facial flush
0
$T1$ analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).Thereby, a clinical study of the combined administration of the two agents was attempted.
prostacyclin
nausea
0
$T1$/$T2$
BPT
CLZ
0
$T1$ content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted.
cAMP
BPT
0
$T1$ and determination of intraplatelet cAMP were performed.Throughout the observation period, no significant alteration in vital signs was observed.
platelet aggregation
BPT
0
$T1$ content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted.
cAMP
CLZ
0
$T1$ and determination of intraplatelet cAMP were performed.Throughout the observation period, no significant alteration in vital signs was observed.
platelet aggregation
CLZ
0
$T1$ and determination of intraplatelet cAMP were performed.Throughout the observation period, no significant alteration in vital signs was observed.
platelet aggregation
cAMP
0
$T1$ of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
headache
cAMP
0
$T1$ in one and nausea in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
facial flush
cAMP
0
$T1$ in one, especially after ingestion of CLZ.All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.
nausea
cAMP
0
$T1$ and determination of intraplatelet cAMP were performed.Throughout the observation period, no significant alteration in vital signs was observed.
platelet aggregation
headache
0
$T1$ and determination of intraplatelet cAMP were performed.Throughout the observation period, no significant alteration in vital signs was observed.
platelet aggregation
facial flush
0
$T1$ and determination of intraplatelet cAMP were performed.Throughout the observation period, no significant alteration in vital signs was observed.
platelet aggregation
nausea
0
$T1$ of a short duration accompanying $T2$
headache
facial flush
0
$T1$ of a short duration accompanying facial flush in one and $T2$
headache
nausea
0
$T1$ in one and $T2$
facial flush
nausea
0
$T1$).Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
oedema
etoricoxib
1
$T1$ 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from $T2$
diclofenac
GI AEs
1
$T1$ and p<0.01 for oedema).Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
hypertension
etoricoxib
1
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose aspirin was allowed.
RA
etoricoxib
0
$T1$ 150 mg. Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with $T2$
diclofenac
etoricoxib
0
$T1$ was allowed.The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
aspirin
etoricoxib
0
$T1$ event data.Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
thrombotic cardiovascular
etoricoxib
0
$T1$, were significantly higher with $T2$
GI AEs
etoricoxib
0
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose aspirin was allowed.
RA
diclofenac
0
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose $T2$
RA
aspirin
0
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose aspirin was allowed.
RA
thrombotic cardiovascular
0
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose aspirin was allowed.
RA
GI AEs
0
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose aspirin was allowed.
RA
hypertension
0
$T1$ were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).Use of gastroprotective agents and low-dose aspirin was allowed.
RA
oedema
0
$T1$ was allowed.The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
aspirin
diclofenac
0
$T1$ event data.Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
thrombotic cardiovascular
diclofenac
0
$T1$ and p<0.01 for oedema).Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
hypertension
diclofenac
0
$T1$).Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
oedema
diclofenac
0
$T1$ was allowed.The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
aspirin
thrombotic cardiovascular
0
$T1$ was allowed.The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
aspirin
GI AEs
0
$T1$ was allowed.The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
aspirin
hypertension
0
$T1$ was allowed.The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).
aspirin
oedema
0
$T1$ event data.Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
thrombotic cardiovascular
GI AEs
0
$T1$ event data.Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
thrombotic cardiovascular
hypertension
0
$T1$ event data.Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).
thrombotic cardiovascular
oedema
0
$T1$ and p<0.01 for oedema).Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
hypertension
GI AEs
0
$T1$).Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).
oedema
GI AEs
0
$T1$ and p<0.01 for $T2$
hypertension
oedema
0
$T1$ induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
Haloperidol
EPS
1
$T1$ induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), $T2$
Haloperidol
tremor
1
$T1$ therapy.Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
lithium
EPS
1
$T1$ therapy.Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), $T2$
lithium
tremor
1
$T1$ induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
Haloperidol
akathisia
1
$T1$, including akathisia, with $T2$
EPS
quetiapine
0
$T1$, the incidence of $T2$
bipolar mania
EPS
0
$T1$, including $T2$
EPS
akathisia
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
DVP
EPS
0
$T1$ (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
tremor
EPS
0
$T1$, the incidence of EPS, including akathisia, with $T2$
bipolar mania
quetiapine
0
$T1$, with $T2$
akathisia
quetiapine
0
$T1$ therapy.Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
lithium
quetiapine
0
$T1$ induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
Haloperidol
quetiapine
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
DVP
quetiapine
0
$T1$ (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
tremor
quetiapine
0
$T1$, the incidence of EPS, including $T2$
bipolar mania
akathisia
0
$T1$ therapy.Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
lithium
bipolar mania
0
$T1$ induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
Haloperidol
bipolar mania
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
DVP
bipolar mania
0
$T1$ (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
tremor
bipolar mania
0
$T1$ therapy.Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
lithium
akathisia
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
DVP
akathisia
0
$T1$ (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.No significant differences were observed between quetiapine and placebo on SAS and BARS scores.
tremor
akathisia
0
$T1$ therapy.$T2$
lithium
Haloperidol
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving $T2$
DVP
lithium
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
DVP
Haloperidol
0
$T1$ (4.9%).Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
DVP
tremor
0
$T1$-induced $T2$
dietary sodium chloride
increase in MAP
1
$T1$ in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.
increase in MAP
captopril
0
$T1$-induced increase in MAP in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.
dietary sodium chloride
captopril
0
$T1$-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high $T2$
captopril
sodium chloride
0
$T1$ also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.CONCLUSIONS: In both lifetime $T2$
clonidine
captopril
0
$T1$ resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.
hexamethonium
captopril
0
$T1$ clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.CONCLUSIONS: In both lifetime $T2$
alpha2-adrenergic receptor agonist
captopril
0
$T1$ in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.
increase in MAP
sodium chloride
0
$T1$ in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist $T2$
increase in MAP
clonidine
0
$T1$ resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced $T2$
hexamethonium
increase in MAP
0
$T1$ in both groups.Infusion of the central nervous system $T2$
increase in MAP
alpha2-adrenergic receptor agonist
0
$T1$-induced increase in MAP in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.
dietary sodium chloride
sodium chloride
0
$T1$-induced increase in MAP in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist $T2$
dietary sodium chloride
clonidine
0
$T1$ resulted in a rapid decline in MAP that eliminated the $T2$
hexamethonium
dietary sodium chloride
0
$T1$-induced increase in MAP in both groups.Infusion of the central nervous system $T2$
dietary sodium chloride
alpha2-adrenergic receptor agonist
0
$T1$ also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high $T2$
clonidine
sodium chloride
0
$T1$ resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.
hexamethonium
sodium chloride
0
$T1$ clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high $T2$
alpha2-adrenergic receptor agonist
sodium chloride
0
$T1$ resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.Infusion of the central nervous system alpha2-adrenergic receptor agonist $T2$
hexamethonium
clonidine
0
$T1$ $T2$
alpha2-adrenergic receptor agonist
clonidine
0
$T1$ resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.Infusion of the central nervous system $T2$
hexamethonium
alpha2-adrenergic receptor agonist
0
$T1$ were also evident in distal levels of the peripheral nerves of chickens given TOTP or $T2$
Degenerating myelinated fibers
DFP
1
$T1$, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
neuropathy
DFP
1
$T1$ were also evident in distal levels of the peripheral nerves of chickens given $T2$
Degenerating myelinated fibers
TOTP
1
$T1$, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
neuropathy
TOTP
1
$T1$ compounds.Chickens given 200 ppm $T2$
organophosphorous
corticosterone
0
$T1$, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
neuropathy
corticosterone
0
$T1$ without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given $T2$
corticosterone
TOTP
0
$T1$ without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or $T2$
corticosterone
DFP
0
$T1$ esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.Chickens given 200 ppm $T2$
Neurotoxic
corticosterone
0
$T1$ without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.$T2$
corticosterone
Degenerating myelinated fibers
0
$T1$, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given $T2$
neuropathy
organophosphorous
0
$T1$ compounds.Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.
organophosphorous
TOTP
0
$T1$ compounds.Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.
organophosphorous
DFP
0
$T1$ esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given $T2$
Neurotoxic
organophosphorous
0
$T1$ compounds.Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.
organophosphorous
Degenerating myelinated fibers
0
$T1$, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.$T2$
neuropathy
Neurotoxic
0
$T1$, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
neuropathy
Degenerating myelinated fibers
0
$T1$ or $T2$
TOTP
DFP
0
$T1$ esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.
Neurotoxic
TOTP
0
$T1$ esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.
Neurotoxic
DFP
0
$T1$ esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.
Neurotoxic
Degenerating myelinated fibers
0
$T1$-induced $T2$
reserpine
akinesia
1
$T1$-induced $T2$
haloperidol
catalepsy
1
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
Parkinson's disease
0
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
haloperidol
0
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
catalepsy
0
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
reserpine
0
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
akinesia
0
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
6-OHDA
0
$T1$ in several animal models of Parkinson's disease is described.Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.
adenosine A(2A)/A(1) receptor antagonist
MPTP
0
$T1$ including mouse and rat models of $T2$
Parkinson's disease
haloperidol
0
$T1$ including mouse and rat models of haloperidol-induced $T2$
Parkinson's disease
catalepsy
0
$T1$ including mouse and rat models of haloperidol-induced catalepsy, mouse model of $T2$
Parkinson's disease
reserpine
0
$T1$ including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced $T2$
Parkinson's disease
akinesia
0
$T1$ including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine ($T2$
Parkinson's disease
6-OHDA
0
$T1$ including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and $T2$
Parkinson's disease
MPTP
0
$T1$-induced catalepsy, mouse model of $T2$
haloperidol
reserpine
0
$T1$-induced catalepsy, mouse model of reserpine-induced $T2$
haloperidol
akinesia
0
$T1$-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine ($T2$
haloperidol
6-OHDA
0
$T1$-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and $T2$
haloperidol
MPTP
0
$T1$, mouse model of $T2$
catalepsy
reserpine
0
$T1$, mouse model of reserpine-induced $T2$
catalepsy
akinesia
0
$T1$, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine ($T2$
catalepsy
6-OHDA
0
$T1$, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and $T2$
catalepsy
MPTP
0
$T1$-induced akinesia, rat 6-hydroxydopamine ($T2$
reserpine
6-OHDA
0
$T1$-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and $T2$
reserpine
MPTP
0
$T1$, rat 6-hydroxydopamine ($T2$
akinesia
6-OHDA
0
$T1$, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and $T2$
akinesia
MPTP
0
$T1$) lesion model of drug-induced rotation, and $T2$
6-OHDA
MPTP
0
$T1$ during treatment with pegylated interferon alpha-2b weekly and ribavirin.She complained of seeing parasites and the larvae of fleas in her stools.
delusional parasitosis
pegylated interferon alpha-2b
1
$T1$ during treatment with pegylated interferon alpha-2b weekly and $T2$
delusional parasitosis
ribavirin
1
$T1$ patients with interferon and ribavirin, a lot of side effects are described.Twenty-three percent to 44% of patients develop depression.
chronic hepatitis C
delusional parasitosis
0
$T1$.A minority of patients evolve to psychosis.
depression
delusional parasitosis
0
$T1$.To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.
psychosis
delusional parasitosis
0
$T1$ patients with interferon and ribavirin, a lot of side effects are described.Twenty-three percent to 44% of patients develop depression.
chronic hepatitis C
pegylated interferon alpha-2b
0
$T1$ patients with interferon and ribavirin, a lot of side effects are described.Twenty-three percent to 44% of patients develop depression.
chronic hepatitis C
ribavirin
0
$T1$ patients with interferon and ribavirin, a lot of side effects are described.Twenty-three percent to 44% of patients develop $T2$
chronic hepatitis C
depression
0
$T1$ patients with interferon and ribavirin, a lot of side effects are described.Twenty-three percent to 44% of patients develop depression.
chronic hepatitis C
psychosis
0
$T1$.She complained of seeing parasites and the larvae of fleas in her stools.
ribavirin
pegylated interferon alpha-2b
0
$T1$.A minority of patients evolve to psychosis.
depression
pegylated interferon alpha-2b
0
$T1$.To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.
psychosis
pegylated interferon alpha-2b
0
$T1$.A minority of patients evolve to psychosis.
depression
ribavirin
0
$T1$.To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.
psychosis
ribavirin
0
$T1$.A minority of patients evolve to $T2$
depression
psychosis
0
$T1$ treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
alprazolam
NMS
1
$T1$ and alprazolam treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
paroxetine
NMS
1
$T1$ should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion.Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from $T2$
NMS
depression
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
NMS
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
NMS
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
NMS
0
$T1$ should be noted in elderly depressive patients whose symptoms often include dehydration, $T2$
NMS
agitation
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
NMS
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
NMS
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
NMS
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
fever
NMS
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
NMS
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
NMS
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
NMS
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
NMS
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
NMS
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
NMS
0
$T1$ should be noted in elderly depressive patients whose symptoms often include $T2$
NMS
dehydration
0
$T1$ should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, $T2$
NMS
malnutrition
0
$T1$ and $T2$
paroxetine
alprazolam
0
$T1$ and alprazolam treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
paroxetine
depression
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
paroxetine
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
paroxetine
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
paroxetine
0
$T1$ and alprazolam treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
paroxetine
agitation
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
paroxetine
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
paroxetine
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
paroxetine
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined $T2$
fever
paroxetine
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
paroxetine
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
paroxetine
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
paroxetine
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
paroxetine
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
paroxetine
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
paroxetine
0
$T1$ and alprazolam treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
paroxetine
dehydration
0
$T1$ and alprazolam treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
paroxetine
malnutrition
0
$T1$ treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
alprazolam
depression
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
alprazolam
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
alprazolam
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
alprazolam
0
$T1$ treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
alprazolam
agitation
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
alprazolam
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
alprazolam
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
alprazolam
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and $T2$
fever
alprazolam
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
alprazolam
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
alprazolam
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
alprazolam
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
alprazolam
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
alprazolam
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
alprazolam
0
$T1$ treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
alprazolam
dehydration
0
$T1$ treatment.The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.
alprazolam
malnutrition
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
depression
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
depression
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
depression
0
$T1$, malnutrition, and exhaustion.Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from $T2$
agitation
depression
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
depression
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
depression
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
depression
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
fever
depression
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
depression
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
depression
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
depression
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
depression
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
depression
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
depression
0
$T1$, agitation, malnutrition, and exhaustion.Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from $T2$
dehydration
depression
0
$T1$, and exhaustion.Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from $T2$
malnutrition
depression
0
$T1$ hospital due to $T2$
psychiatric
insomnia
0
$T1$ hospital due to insomnia, $T2$
psychiatric
loss of appetite
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
agitation
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
psychomotor retardation
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
muscle rigidity
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
tremors
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
fever
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
extrapyramidal symptoms
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
creatine
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
aspartate
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
alanine
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
bromocriptine
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
diazepam
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
dehydration
0
$T1$ hospital due to insomnia, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
psychiatric
malnutrition
0
$T1$, $T2$
insomnia
loss of appetite
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
agitation
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
psychomotor retardation
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
muscle rigidity
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
tremors
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
fever
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
extrapyramidal symptoms
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
creatine
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
aspartate
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
alanine
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
bromocriptine
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
diazepam
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
dehydration
0
$T1$, loss of appetite, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
insomnia
malnutrition
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
agitation
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
psychomotor retardation
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
muscle rigidity
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
tremors
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
fever
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
extrapyramidal symptoms
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
creatine
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
aspartate
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
alanine
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
bromocriptine
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
diazepam
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
dehydration
0
$T1$, exhaustion, and agitation.Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.
loss of appetite
malnutrition
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
agitation
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
agitation
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
agitation
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
fever
agitation
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
agitation
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
agitation
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
agitation
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
agitation
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
agitation
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
agitation
0
$T1$, $T2$
dehydration
agitation
0
$T1$, $T2$
agitation
malnutrition
0
$T1$, disorientation, and severe $T2$
psychomotor retardation
muscle rigidity
0
$T1$, disorientation, and severe muscle rigidity with $T2$
psychomotor retardation
tremors
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
fever
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe $T2$
psychomotor retardation
extrapyramidal symptoms
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
creatine
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
aspartate
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
alanine
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
bromocriptine
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
diazepam
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
dehydration
0
$T1$, disorientation, and severe muscle rigidity with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
psychomotor retardation
malnutrition
0
$T1$ with $T2$
muscle rigidity
tremors
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
fever
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe $T2$
muscle rigidity
extrapyramidal symptoms
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
creatine
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
aspartate
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
alanine
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
bromocriptine
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
diazepam
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
dehydration
0
$T1$ with tremors.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
muscle rigidity
malnutrition
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
fever
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe $T2$
tremors
extrapyramidal symptoms
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
creatine
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
aspartate
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
alanine
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
bromocriptine
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
diazepam
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
dehydration
0
$T1$.The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.
tremors
malnutrition
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
fever
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
fever
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
fever
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
fever
0
$T1$ and diazepam to treat his symptoms.7 days later, the $T2$
bromocriptine
fever
0
$T1$ to treat his symptoms.7 days later, the $T2$
diazepam
fever
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
fever
dehydration
0
$T1$ disappeared and the patient's serum CPK levels were normalized (175 IU/L).This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
fever
malnutrition
0
$T1$.Laboratory tests showed an elevation of $T2$
extrapyramidal symptoms
creatine
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), $T2$
extrapyramidal symptoms
aspartate
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), $T2$
extrapyramidal symptoms
alanine
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
bromocriptine
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
diazepam
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
dehydration
0
$T1$.Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.
extrapyramidal symptoms
malnutrition
0
$T1$ phosphokinase (2218 IU/L), $T2$
creatine
aspartate
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), $T2$
creatine
alanine
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received $T2$
creatine
bromocriptine
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and $T2$
creatine
diazepam
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
dehydration
0
$T1$ phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
creatine
malnutrition
0
$T1$ aminotransferase (134 IU/L), $T2$
aspartate
alanine
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received $T2$
aspartate
bromocriptine
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and $T2$
aspartate
diazepam
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
dehydration
0
$T1$ aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
aspartate
malnutrition
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received $T2$
alanine
bromocriptine
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and $T2$
alanine
diazepam
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
dehydration
0
$T1$ aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.The patient received bromocriptine and diazepam to treat his symptoms.
alanine
malnutrition
0
$T1$ and $T2$
bromocriptine
diazepam
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
dehydration
0
$T1$ and diazepam to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
bromocriptine
malnutrition
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
dehydration
0
$T1$ to treat his symptoms.7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
diazepam
malnutrition
0
$T1$, agitation, $T2$
dehydration
malnutrition
0
$T1$ on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.Mature rats were trained with sound-source location and sound-silence discriminations.
Pilocarpine
Status epilepticus
1
$T1$ on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.Mature rats were trained with sound-source location and sound-silence discriminations.
Pilocarpine
impaired auditory location discrimination
1
$T1$ on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous $T2$
Pilocarpine
seizures
0
$T1$.Mature rats were trained with sound-source location and sound-silence discriminations.
seizures
impaired auditory location discrimination
0
$T1$.Mature rats were trained with sound-source location and sound-silence discriminations.
seizures
Status epilepticus
0
$T1$ in rat causes an age-dependent, long-term impairment in auditory discrimination.This impairment may explain one cause of $T2$
Status epilepticus
impaired auditory location discrimination
0
$T1$ and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
hypertension
cyclooxygenase inhibitors
1
$T1$, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
stroke
cyclooxygenase inhibitors
1
$T1$, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
myocardial infarction
cyclooxygenase inhibitors
1
$T1$ during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
heart failure
cyclooxygenase inhibitors
1
$T1$ suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by $T2$
cyclooxygenase inhibitors
prostaglandin
0
$T1$ suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.Diagnostic markers such as N-terminal pro brain natriuretic peptide ($T2$
cyclooxygenase inhibitors
NT-proBNP
0
$T1$ suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious $T2$
cyclooxygenase inhibitors
cardiovascular toxicity
0
$T1$, $T2$
myocardial infarction
stroke
0
$T1$, stroke, $T2$
myocardial infarction
hypertension
0
$T1$, stroke, hypertension and $T2$
myocardial infarction
heart failure
0
$T1$, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
myocardial infarction
prostaglandin
0
$T1$, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
myocardial infarction
NT-proBNP
0
$T1$, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
myocardial infarction
cardiovascular toxicity
0
$T1$, $T2$
stroke
hypertension
0
$T1$, hypertension and $T2$
stroke
heart failure
0
$T1$, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
stroke
prostaglandin
0
$T1$, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
stroke
NT-proBNP
0
$T1$, hypertension and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
stroke
cardiovascular toxicity
0
$T1$ and $T2$
hypertension
heart failure
0
$T1$ and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
hypertension
prostaglandin
0
$T1$ and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
hypertension
NT-proBNP
0
$T1$ and heart failure during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
hypertension
cardiovascular toxicity
0
$T1$ during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
heart failure
prostaglandin
0
$T1$ during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
heart failure
NT-proBNP
0
$T1$ during treatment with cyclooxygenase inhibitors.Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.
heart failure
cardiovascular toxicity
0
$T1$-independent effects.Diagnostic markers such as N-terminal pro brain natriuretic peptide ($T2$
prostaglandin
NT-proBNP
0
$T1$-independent effects.Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious $T2$
prostaglandin
cardiovascular toxicity
0
$T1$) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious $T2$
NT-proBNP
cardiovascular toxicity
0
$T1$ in all patients with CHF, but this risk was reduced in the $T2$
renal impairment
enalapril
1
$T1$ use and advanced age increased this risk.Diabetes was associated with an increased risk of $T2$
Diuretic
renal impairment
1
$T1$ in all patients with $T2$
renal impairment
CHF
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
renal impairment
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
renal impairment
0
$T1$, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
creatinine
renal impairment
0
$T1$, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
hypertension
renal impairment
0
$T1$ was associated with an increased risk of $T2$
Diabetes
renal impairment
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
CHF
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
CHF
0
$T1$, but this risk was reduced in the $T2$
CHF
enalapril
0
$T1$, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
creatinine
CHF
0
$T1$, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
hypertension
CHF
0
$T1$ was associated with an increased risk of renal impairment in all patients with $T2$
Diabetes
CHF
0
$T1$ use and advanced age increased this risk.Diabetes was associated with an increased risk of renal impairment in all patients with $T2$
Diuretic
CHF
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of $T2$
angiotensin
Left Ventricular Dysfunction
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
enalapril
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
creatinine
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
hypertension
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
Diabetes
0
$T1$-converting enzyme inhibitor therapy.METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
angiotensin
Diuretic
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
enalapril
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
creatinine
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
hypertension
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
Diabetes
0
$T1$ (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days.
Left Ventricular Dysfunction
Diuretic
0
$T1$, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
creatinine
enalapril
0
$T1$, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
hypertension
enalapril
0
$T1$ was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the $T2$
Diabetes
enalapril
0
$T1$ use and advanced age increased this risk.Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the $T2$
Diuretic
enalapril
0
$T1$, low systolic blood pressure (<100 mm Hg), history of $T2$
creatinine
hypertension
0
$T1$, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
creatinine
Diabetes
0
$T1$, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
creatinine
Diuretic
0
$T1$, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
hypertension
Diabetes
0
$T1$, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
hypertension
Diuretic
0
$T1$ use and advanced age increased this risk.$T2$
Diuretic
Diabetes
0
$T1$ $T2$
pemoline
overdose
1
$T1$ movements should be considered in patients presenting after $T2$
choreoathetoid
pemoline
1
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
pemoline
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
pemoline
0
$T1$ previously treated with methylphenidate without success.This was their first day of pemoline therapy.
attention deficit disorder
pemoline
0
$T1$ has been rarely reported in the acute toxicology literature.The possibility of choreoathetoid movements should be considered in patients presenting after $T2$
movement disorder
pemoline
0
$T1$ without success.This was their first day of pemoline therapy.
methylphenidate
pemoline
0
$T1$ in an attempt to control the choreoathetoid movements.Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.
benzodiazepines
pemoline
0
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
choreoathetoid
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
choreoathetoid
0
$T1$ previously treated with methylphenidate without success.This was their first day of pemoline therapy.
attention deficit disorder
choreoathetoid
0
$T1$ has been rarely reported in the acute toxicology literature.The possibility of $T2$
movement disorder
choreoathetoid
0
$T1$ without success.This was their first day of pemoline therapy.
methylphenidate
choreoathetoid
0
$T1$ in an attempt to control the choreoathetoid movements.Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.
benzodiazepines
choreoathetoid
0
$T1$ movements should be considered in patients presenting after pemoline $T2$
choreoathetoid
overdose
0
$T1$ derivative that is structurally different from $T2$
oxazolidine
amphetamines
0
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
attention deficit disorder
0
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
movement disorder
0
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
methylphenidate
0
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
benzodiazepines
0
$T1$ derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
oxazolidine
overdose
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
attention deficit disorder
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
movement disorder
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
methylphenidate
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
benzodiazepines
0
$T1$ and used in the treatment of attention deficit disorder.Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
amphetamines
overdose
0
$T1$ previously treated with methylphenidate without success.This was their first day of pemoline therapy.
attention deficit disorder
movement disorder
0
$T1$ previously treated with $T2$
attention deficit disorder
methylphenidate
0
$T1$ previously treated with methylphenidate without success.This was their first day of pemoline therapy.
attention deficit disorder
benzodiazepines
0
$T1$ previously treated with methylphenidate without success.This was their first day of pemoline therapy.
attention deficit disorder
overdose
0
$T1$ without success.This was their first day of pemoline therapy.
methylphenidate
movement disorder
0
$T1$ in an attempt to control the choreoathetoid movements.Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.
benzodiazepines
movement disorder
0
$T1$ has been rarely reported in the acute toxicology literature.The possibility of choreoathetoid movements should be considered in patients presenting after pemoline $T2$
movement disorder
overdose
0
$T1$ without success.This was their first day of pemoline therapy.
methylphenidate
benzodiazepines
0
$T1$ without success.This was their first day of pemoline therapy.
methylphenidate
overdose
0
$T1$ in an attempt to control the choreoathetoid movements.Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.
benzodiazepines
overdose
0
$T1$ is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.
Hemorrhagic cystitis
mesna
1
$T1$ is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.
Hemorrhagic cystitis
ifosfamide
1
$T1$ administration suggests it is a safe, practical, and economic method of drug delivery that permits $T2$
mesna
ifosfamide
0
$T1$ of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.
toxicity
mesna
0
$T1$ and is unable to absorb the drug.Limited clinical experience with continuous subcutaneous $T2$
emesis
mesna
0
$T1$ of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.
toxicity
ifosfamide
0
$T1$ and is unable to absorb the drug.Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits $T2$
emesis
ifosfamide
0
$T1$ is a major potential $T2$
Hemorrhagic cystitis
toxicity
0
$T1$ is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.
Hemorrhagic cystitis
emesis
0
$T1$ of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.
toxicity
emesis
0
$T1$-induced muscular $T2$
diazepam
incoordination
1
$T1$ and antagonized amphetamine-induced motor activity, and neither verapamil nor $T2$
incoordination
NH4Ac
1
$T1$ affected the convulsant action of metrazol.The data suggest that $T2$
NH4Ac
hyperammonemia
0
$T1$ analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that $T2$
morphine
hyperammonemia
0
$T1$ and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that $T2$
incoordination
hyperammonemia
0
$T1$-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that $T2$
diazepam
hyperammonemia
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
hyperammonemia
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
hyperammonemia
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
hyperammonemia
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
hyperammonemia
0
$T1$ exerts a $T2$
hyperammonemia
calcium
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
hyperammonemia
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
hyperammonemia
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
hyperammonemia
0
$T1$ nor NH4Ac affected the convulsant action of metrazol.The data suggest that $T2$
verapamil
hyperammonemia
0
$T1$- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that $T2$
analgesia
hyperammonemia
0
$T1$-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that $T2$
amphetamine
hyperammonemia
0
$T1$.The data suggest that $T2$
metrazol
hyperammonemia
0
$T1$ analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor $T2$
morphine
NH4Ac
0
$T1$-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor $T2$
diazepam
NH4Ac
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
NH4Ac
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
NH4Ac
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
NH4Ac
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
NH4Ac
0
$T1$ affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
NH4Ac
calcium
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
NH4Ac
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
NH4Ac
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
NH4Ac
0
$T1$ nor $T2$
verapamil
NH4Ac
0
$T1$- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor $T2$
analgesia
NH4Ac
0
$T1$-induced motor activity, and neither verapamil nor $T2$
amphetamine
NH4Ac
0
$T1$ affected the convulsant action of $T2$
NH4Ac
metrazol
0
$T1$ analgesia- and diazepam-induced muscular $T2$
morphine
incoordination
0
$T1$ analgesia- and $T2$
morphine
diazepam
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
morphine
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
morphine
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
morphine
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
morphine
0
$T1$ analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
morphine
calcium
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
morphine
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
morphine
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
morphine
0
$T1$ analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither $T2$
morphine
verapamil
0
$T1$ $T2$
morphine
analgesia
0
$T1$ analgesia- and diazepam-induced muscular incoordination and antagonized $T2$
morphine
amphetamine
0
$T1$ analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of $T2$
morphine
metrazol
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
incoordination
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
incoordination
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
incoordination
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
incoordination
0
$T1$ and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
incoordination
calcium
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
incoordination
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
incoordination
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
incoordination
0
$T1$ and antagonized amphetamine-induced motor activity, and neither $T2$
incoordination
verapamil
0
$T1$- and diazepam-induced muscular $T2$
analgesia
incoordination
0
$T1$ and antagonized $T2$
incoordination
amphetamine
0
$T1$ and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of $T2$
incoordination
metrazol
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
diazepam
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
diazepam
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
diazepam
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
diazepam
0
$T1$-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
diazepam
calcium
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
diazepam
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
diazepam
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
diazepam
0
$T1$-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither $T2$
diazepam
verapamil
0
$T1$- and $T2$
analgesia
diazepam
0
$T1$-induced muscular incoordination and antagonized $T2$
diazepam
amphetamine
0
$T1$-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of $T2$
diazepam
metrazol
0
$T1$.Experiments in vitro showed that $T2$
liver disease
acetylcholine
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
catecholamine
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and $T2$
liver disease
KCl
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
calcium
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
depression
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
acetaldehyde
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
ammonia
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
verapamil
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
analgesia
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
amphetamine
0
$T1$.Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.
liver disease
metrazol
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent $T2$
acetylcholine
catecholamine
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and $T2$
acetylcholine
KCl
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
calcium
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the $T2$
acetylcholine
depression
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by $T2$
acetylcholine
acetaldehyde
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
ammonia
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
verapamil
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
analgesia
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
amphetamine
0
$T1$-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
acetylcholine
metrazol
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent $T2$
KCl
catecholamine
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
calcium
0
$T1$ in both tissues, but calcium-independent $T2$
depression
catecholamine
0
$T1$ release by $T2$
catecholamine
acetaldehyde
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that $T2$
catecholamine
ammonia
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
verapamil
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
analgesia
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
amphetamine
0
$T1$ release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
catecholamine
metrazol
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
calcium
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the $T2$
KCl
depression
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by $T2$
KCl
acetaldehyde
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
ammonia
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
verapamil
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
analgesia
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
amphetamine
0
$T1$-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
KCl
metrazol
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
calcium
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
calcium
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
calcium
0
$T1$ nor NH4Ac affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
verapamil
calcium
0
$T1$- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
analgesia
calcium
0
$T1$-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.The data suggest that hyperammonemia exerts a $T2$
amphetamine
calcium
0
$T1$.The data suggest that hyperammonemia exerts a $T2$
metrazol
calcium
0
$T1$ in both tissues, but calcium-independent catecholamine release by $T2$
depression
acetaldehyde
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that $T2$
depression
ammonia
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
verapamil
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
analgesia
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
amphetamine
0
$T1$ in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
depression
metrazol
0
$T1$ was not blocked by NH4Ac.These results suggested that $T2$
acetaldehyde
ammonia
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
verapamil
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
analgesia
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
amphetamine
0
$T1$ was not blocked by NH4Ac.These results suggested that ammonia blocks calcium channels.
acetaldehyde
metrazol
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
verapamil
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
analgesia
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
amphetamine
0
$T1$ blocks calcium channels.Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.
ammonia
metrazol
0
$T1$- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither $T2$
analgesia
verapamil
0
$T1$-induced motor activity, and neither $T2$
amphetamine
verapamil
0
$T1$ nor NH4Ac affected the convulsant action of $T2$
verapamil
metrazol
0
$T1$- and diazepam-induced muscular incoordination and antagonized $T2$
analgesia
amphetamine
0
$T1$- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of $T2$
analgesia
metrazol
0
$T1$-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of $T2$
amphetamine
metrazol
0
$T1$, nor on the presence of cyanosis, and although $T2$
CM
CIN
1
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
CIN
1
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
CIN
1
$T1$, and although $T2$
cyanosis
CIN
0
$T1$ and Cr also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Na
CIN
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and Cr also were checked at the same intervals.
K
CIN
0
$T1$ also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Cr
CIN
0
$T1$, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
Loss of kidney function
CIN
0
$T1$.Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
renal injury
CIN
0
$T1$, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).Although clinically silent, CIN is not rare in pediatrics.
congenital heart diseases
CIN
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
CM
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
CM
0
$T1$, nor on the presence of $T2$
CM
cyanosis
0
$T1$ and Cr also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Na
CM
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and Cr also were checked at the same intervals.
K
CM
0
$T1$ also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Cr
CM
0
$T1$, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
Loss of kidney function
CM
0
$T1$.Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
renal injury
CM
0
$T1$, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).Although clinically silent, CIN is not rare in pediatrics.
congenital heart diseases
CM
0
$T1$ (group A, n = 40) or $T2$
iopromide
iohexol
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
cyanosis
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
Na
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium ($T2$
iopromide
K
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
Cr
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
Loss of kidney function
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
renal injury
0
$T1$ (group A, n = 40) or iohexol (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iopromide
congenital heart diseases
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
cyanosis
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
Na
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium ($T2$
iohexol
K
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
Cr
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
Loss of kidney function
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
renal injury
0
$T1$ (group B, n = 40).Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.
iohexol
congenital heart diseases
0
$T1$ and Cr also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Na
cyanosis
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and Cr also were checked at the same intervals.
K
cyanosis
0
$T1$ also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Cr
cyanosis
0
$T1$, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
Loss of kidney function
cyanosis
0
$T1$.Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
renal injury
cyanosis
0
$T1$, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).Although clinically silent, CIN is not rare in pediatrics.
congenital heart diseases
cyanosis
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for $T2$
K
Na
0
$T1$ and $T2$
Na
Cr
0
$T1$ and Cr also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, $T2$
Na
Loss of kidney function
0
$T1$ and Cr also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Na
renal injury
0
$T1$ and Cr also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Na
congenital heart diseases
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and $T2$
K
Cr
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and Cr also were checked at the same intervals.
K
Loss of kidney function
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and Cr also were checked at the same intervals.
K
renal injury
0
$T1$), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.Urine samples for Na and Cr also were checked at the same intervals.
K
congenital heart diseases
0
$T1$ also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, $T2$
Cr
Loss of kidney function
0
$T1$ also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Cr
renal injury
0
$T1$ also were checked at the same intervals.Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.
Cr
congenital heart diseases
0
$T1$, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had $T2$
Loss of kidney function
renal injury
0
$T1$, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.
Loss of kidney function
congenital heart diseases
0
$T1$.Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
renal injury
congenital heart diseases
0
$T1$ duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.
seizure
caffeine
1
$T1$ after caffeine administration.Although intravenous $T2$
ventricular tachycardia
caffeine
1
$T1$.We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.
ventricular ectopy
caffeine
1
$T1$ duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of $T2$
seizure
ventricular tachycardia
0
$T1$.We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of $T2$
ventricular ectopy
ventricular tachycardia
0
$T1$ or arrhythmia who developed sustained bigeminy and 2 brief runs of $T2$
cardiac disease
ventricular tachycardia
0
$T1$ after caffeine administration.Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious $T2$
ventricular tachycardia
ventricular arrhythmias
0
$T1$ or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.Although intravenous $T2$
cardiac disease
caffeine
0
$T1$ is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious $T2$
caffeine
ventricular arrhythmias
0
$T1$ duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign $T2$
seizure
ventricular ectopy
0
$T1$ duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.We describe a patient with no previous history of $T2$
seizure
cardiac disease
0
$T1$ duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.
seizure
ventricular arrhythmias
0
$T1$.We describe a patient with no previous history of $T2$
ventricular ectopy
cardiac disease
0
$T1$.We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.
ventricular ectopy
ventricular arrhythmias
0
$T1$ or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious $T2$
cardiac disease
ventricular arrhythmias
0
$T1$ (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.
visual deficits
ethambutol
1
$T1$, it is important to properly manage $T2$
optic neuropathy
ethambutol
1
$T1$ in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).Ethambutol is an antimycobacterial agent often used to treat tuberculosis.
axonal degeneration
ethambutol
0
$T1$.A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.
tuberculosis
ethambutol
0
$T1$ dosing in patients with $T2$
ethambutol
renal impairment
0
$T1$ in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).Ethambutol is an antimycobacterial agent often used to treat tuberculosis.
axonal degeneration
optic neuropathy
0
$T1$.A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.
tuberculosis
optic neuropathy
0
$T1$ (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.
visual deficits
optic neuropathy
0
$T1$, it is important to properly manage ethambutol dosing in patients with $T2$
optic neuropathy
renal impairment
0
$T1$ in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).Ethambutol is an antimycobacterial agent often used to treat $T2$
axonal degeneration
tuberculosis
0
$T1$ in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).Ethambutol is an antimycobacterial agent often used to treat tuberculosis.
axonal degeneration
visual deficits
0
$T1$ in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).Ethambutol is an antimycobacterial agent often used to treat tuberculosis.
axonal degeneration
renal impairment
0
$T1$.A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.
tuberculosis
visual deficits
0
$T1$.A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.
tuberculosis
renal impairment
0
$T1$ (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.
visual deficits
renal impairment
0
$T1$ were similar for all 3 treatment groups and across valdecoxib doses.Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of $T2$
aspirin
thrombotic
1
$T1$ doses was not associated with an increased incidence of $T2$
valdecoxib
thrombotic
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
valdecoxib
0
$T1$ doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in $T2$
valdecoxib
osteoarthritis
0
$T1$ doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and $T2$
valdecoxib
rheumatoid arthritis
0
$T1$ 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
diclofenac
valdecoxib
0
$T1$ 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
ibuprofen
valdecoxib
0
$T1$ 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
naproxen
valdecoxib
0
$T1$ were similar for all 3 treatment groups and across valdecoxib doses.Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) $T2$
aspirin
valdecoxib
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
thrombotic
0
$T1$ events relative to nonselective NSAIDs or placebo in $T2$
thrombotic
osteoarthritis
0
$T1$ events relative to nonselective NSAIDs or placebo in osteoarthritis and $T2$
thrombotic
rheumatoid arthritis
0
$T1$ 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
diclofenac
thrombotic
0
$T1$ 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
ibuprofen
thrombotic
0
$T1$ 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
naproxen
thrombotic
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
osteoarthritis
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
rheumatoid arthritis
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
diclofenac
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
ibuprofen
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
naproxen
0
$T1$.There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).
arthritis
aspirin
0
$T1$ and $T2$
osteoarthritis
rheumatoid arthritis
0
$T1$ 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
diclofenac
osteoarthritis
0
$T1$ 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
ibuprofen
osteoarthritis
0
$T1$ 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
naproxen
osteoarthritis
0
$T1$ were similar for all 3 treatment groups and across valdecoxib doses.Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in $T2$
aspirin
osteoarthritis
0
$T1$ 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
diclofenac
rheumatoid arthritis
0
$T1$ 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
ibuprofen
rheumatoid arthritis
0
$T1$ 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
naproxen
rheumatoid arthritis
0
$T1$ were similar for all 3 treatment groups and across valdecoxib doses.Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and $T2$
aspirin
rheumatoid arthritis
0
$T1$ 75 mg bid, $T2$
diclofenac
ibuprofen
0
$T1$ 75 mg bid, ibuprofen 800 mg tid, or $T2$
diclofenac
naproxen
0
$T1$ 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
diclofenac
aspirin
0
$T1$ 800 mg tid, or $T2$
ibuprofen
naproxen
0
$T1$ 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
ibuprofen
aspirin
0
$T1$ 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).
naproxen
aspirin
0
$T1$ women receiving either $T2$
sexually dysfunctional
fluoxetine
1
$T1$ women receiving either fluoxetine, sertraline, or $T2$
sexually dysfunctional
paroxetine
1
$T1$ women receiving either fluoxetine, $T2$
sexually dysfunctional
sertraline
1
$T1$ women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg $T2$
sexually dysfunctional
ephedrine
0
$T1$, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg $T2$
fluoxetine
ephedrine
0
$T1$, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg $T2$
sertraline
ephedrine
0
$T1$ participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg $T2$
paroxetine
ephedrine
0
$T1$, $T2$
fluoxetine
sertraline
0
$T1$, sertraline, or $T2$
fluoxetine
paroxetine
0
$T1$, or $T2$
sertraline
paroxetine
0
$T1$ in the substantia nigra nucleus of the brain.Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.
6-hydroxydopamine
erectile dysfunction
1
$T1$-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.
apomorphine
erectile dysfunction
0
$T1$ and its metabolites were decreased in the striatum of substantia nigra lesioned rats.Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study $T2$
dopamine
erectile dysfunction
0
$T1$ in $T2$
erectile dysfunction
Parkinson's disease
0
$T1$ in the substantia nigra nucleus of the brain.Behavioral $T2$
6-hydroxydopamine
apomorphine
0
$T1$ in the substantia nigra nucleus of the brain.Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.
6-hydroxydopamine
dopamine
0
$T1$ in the substantia nigra nucleus of the brain.Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.
6-hydroxydopamine
Parkinson's disease
0
$T1$-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.
apomorphine
dopamine
0
$T1$-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals.Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.
apomorphine
Parkinson's disease
0
$T1$ and its metabolites were decreased in the striatum of substantia nigra lesioned rats.Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in $T2$
dopamine
Parkinson's disease
0
$T1$ in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with $T2$
dyskinesias
levodopa
1
$T1$-induced $T2$
MPTP
parkinsonism
1
$T1$ D1 receptor agents with an intermediate duration of efficacy such as $T2$
DA
A-86929
0
$T1$ as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
parkinsonism
DA
0
$T1$ and selective DA D2 receptor agonist.Potent $T2$
levodopa
DA
0
$T1$ D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in $T2$
DA
PD
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
DA
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
DA
0
$T1$-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
MPTP
DA
0
$T1$ in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
dyskinesias
DA
0
$T1$ or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
LY-171555
DA
0
$T1$ as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
parkinsonism
A-86929
0
$T1$ and selective DA D2 receptor agonist.Potent DA D1 receptor agents with an intermediate duration of efficacy such as $T2$
levodopa
A-86929
0
$T1$ (approximately 4 hr at higher doses tested) are potential therapeutic tools in $T2$
A-86929
PD
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
A-86929
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
A-86929
0
$T1$-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
MPTP
A-86929
0
$T1$ in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
dyskinesias
A-86929
0
$T1$ or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
LY-171555
A-86929
0
$T1$ as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with $T2$
parkinsonism
levodopa
0
$T1$ as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
parkinsonism
PD
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
parkinsonism
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
parkinsonism
0
$T1$ as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced $T2$
parkinsonism
dyskinesias
0
$T1$ as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either $T2$
parkinsonism
LY-171555
0
$T1$ and selective DA D2 receptor agonist.Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in $T2$
levodopa
PD
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
levodopa
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
levodopa
0
$T1$-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with $T2$
MPTP
levodopa
0
$T1$ or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with $T2$
LY-171555
levodopa
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
PD
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
PD
0
$T1$-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
MPTP
PD
0
$T1$ in these animals than with either LY-171555 or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
dyskinesias
PD
0
$T1$ or subsequent challenge of levodopa.Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.
LY-171555
PD
0
$T1$ (< 1 hr) and too long for $T2$
SKF-82958
A-77636
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
MPTP
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
dyskinesias
0
$T1$ (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
SKF-82958
LY-171555
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
MPTP
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
dyskinesias
0
$T1$ (> 20 hr, leading to behavioral tolerance).We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
A-77636
LY-171555
0
$T1$-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced $T2$
MPTP
dyskinesias
0
$T1$-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either $T2$
MPTP
LY-171555
0
$T1$ in these animals than with either $T2$
dyskinesias
LY-171555
0
$T1$ group.The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated $T2$
lidocaine
convulsions
1
$T1$ group, and in 6% of the lidocaine group.The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated $T2$
chloroprocaine
convulsions
1
$T1$-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated $T2$
bupivacaine
convulsions
1
$T1$ from extreme doses.A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.
cardiopulmonary arrest
convulsions
0
$T1$-induced seizures, in 57% of the chloroprocaine group, and in 6% of the $T2$
bupivacaine
lidocaine
0
$T1$-induced seizures, in 57% of the $T2$
bupivacaine
chloroprocaine
0
$T1$ from extreme doses.A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of $T2$
cardiopulmonary arrest
bupivacaine
0
$T1$ group, and in 6% of the $T2$
chloroprocaine
lidocaine
0
$T1$ from extreme doses.A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the $T2$
cardiopulmonary arrest
lidocaine
0
$T1$ from extreme doses.A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the $T2$
cardiopulmonary arrest
chloroprocaine
0
$T1$ within a few days.When the $T2$
myoclonic, atypical absence and/or atonic (minor motor) seizures
carbamazepine
1
$T1$, had an acute aberrant reaction characterized by the onset of $T2$
epilepsy
myoclonic, atypical absence and/or atonic (minor motor) seizures
0
$T1$ within a few days.When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.
myoclonic, atypical absence and/or atonic (minor motor) seizures
seizures
0
$T1$ within a few days.When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.
myoclonic, atypical absence and/or atonic (minor motor) seizures
ceroid lipofuscinosis
0
$T1$, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.When the $T2$
epilepsy
carbamazepine
0
$T1$ was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.The child in whom the $T2$
carbamazepine
seizures
0
$T1$ was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.The child in whom the seizures persisted was later found to have $T2$
carbamazepine
ceroid lipofuscinosis
0
$T1$, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.
epilepsy
seizures
0
$T1$, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.
epilepsy
ceroid lipofuscinosis
0
$T1$ persisted was later found to have $T2$
seizures
ceroid lipofuscinosis
0
$T1$ may be mediated by the endogenous opioid system.The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
angiotensin-converting enzyme inhibitors
hypotension
1
$T1$ may be mediated by the endogenous opioid system.The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
angiotensin-converting enzyme inhibitors
overdose
1
$T1$ in the reversal of $T2$
naloxone
hypotension
0
$T1$ in the reversal of hypotension resulting from $T2$
naloxone
captopril
0
$T1$, manifested by marked hypotension, that resolved promptly with the administration of naloxone.To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.
overdose
naloxone
0
$T1$ may be mediated by the endogenous opioid system.The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
angiotensin-converting enzyme inhibitors
naloxone
0
$T1$ resulting from $T2$
hypotension
captopril
0
$T1$, manifested by marked hypotension, that resolved promptly with the administration of naloxone.To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.
overdose
hypotension
0
$T1$, manifested by marked hypotension, that resolved promptly with the administration of naloxone.To our knowledge, this is the first reported case of captopril-induced hypotension treated with naloxone.
overdose
captopril
0
$T1$ may be mediated by the endogenous opioid system.The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
angiotensin-converting enzyme inhibitors
captopril
0
$T1$, associated with either therapeutic or modestly elevated carbamazepine serum levels.Because $T2$
atrioventricular conduction delay
carbamazepine
1
$T1$ or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.Because $T2$
bradyarrhythmias
carbamazepine
1
$T1$ in the setting of a massive carbamazepine overdose.The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.
sinus tachycardias
carbamazepine
1
$T1$ emerged.One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
cardiac dysfunction
carbamazepine
0
$T1$.The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.
overdose
carbamazepine
0
$T1$ is widely used in the treatment of many neurologic and $T2$
carbamazepine
psychiatric
0
$T1$ emerged.One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
cardiac dysfunction
bradyarrhythmias
0
$T1$ emerged.One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
cardiac dysfunction
atrioventricular conduction delay
0
$T1$ emerged.One patient group developed $T2$
cardiac dysfunction
sinus tachycardias
0
$T1$ emerged.One patient group developed sinus tachycardias in the setting of a massive carbamazepine $T2$
cardiac dysfunction
overdose
0
$T1$ emerged.One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
cardiac dysfunction
psychiatric
0
$T1$ or $T2$
bradyarrhythmias
atrioventricular conduction delay
0
$T1$ in the setting of a massive carbamazepine overdose.The second group consisted almost exclusively of elderly women who developed potentially life-threatening $T2$
sinus tachycardias
bradyarrhythmias
0
$T1$.The second group consisted almost exclusively of elderly women who developed potentially life-threatening $T2$
overdose
bradyarrhythmias
0
$T1$ or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.Because carbamazepine is widely used in the treatment of many neurologic and $T2$
bradyarrhythmias
psychiatric
0
$T1$ in the setting of a massive carbamazepine overdose.The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or $T2$
sinus tachycardias
atrioventricular conduction delay
0
$T1$.The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or $T2$
overdose
atrioventricular conduction delay
0
$T1$, associated with either therapeutic or modestly elevated carbamazepine serum levels.Because carbamazepine is widely used in the treatment of many neurologic and $T2$
atrioventricular conduction delay
psychiatric
0
$T1$ in the setting of a massive carbamazepine $T2$
sinus tachycardias
overdose
0
$T1$ in the setting of a massive carbamazepine overdose.The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.
sinus tachycardias
psychiatric
0
$T1$.The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.
overdose
psychiatric
0
$T1$-induced $T2$
haloperidol
catalepsy
1
$T1$ increased the latency to step down the bar.These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence $T2$
NMDA
haloperidol
0
$T1$ increased the latency to step down the bar.These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced $T2$
NMDA
catalepsy
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
amino acid
NMDA
0
$T1$ receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
dopamine
NMDA
0
$T1$ increased the latency to step down the bar.These findings suggest that $T2$
NMDA
glutamate
0
$T1$ and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of $T2$
MK-801
NMDA
0
$T1$ previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of $T2$
AP7
NMDA
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
amino acid
haloperidol
0
$T1$ receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
dopamine
haloperidol
0
$T1$-mediated mechanisms in the neural circuits at the IC level influence $T2$
glutamate
haloperidol
0
$T1$ and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
MK-801
haloperidol
0
$T1$ previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
AP7
haloperidol
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
amino acid
catalepsy
0
$T1$ receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
dopamine
catalepsy
0
$T1$-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced $T2$
glutamate
catalepsy
0
$T1$ and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
MK-801
catalepsy
0
$T1$ previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
AP7
catalepsy
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the $T2$
amino acid
dopamine
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
amino acid
glutamate
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
amino acid
MK-801
0
$T1$-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
amino acid
AP7
0
$T1$ receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
dopamine
glutamate
0
$T1$ receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
dopamine
MK-801
0
$T1$ receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
dopamine
AP7
0
$T1$ and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
MK-801
glutamate
0
$T1$ previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.
AP7
glutamate
0
$T1$ and $T2$
MK-801
AP7
0
$T1$-induced $T2$
haloperidol
catalepsy
1
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
PD
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
AMN082
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
haloperidol
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
catalepsy
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
apomorphine
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
6-OHDA
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
akinetic
0
$T1$ (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.
glutamate
dopamine
0
$T1$ (10 and 20 mg/kg p.o.)have no effect on the same models of $T2$
AMN082
PD
0
$T1$-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.Higher doses of AMN082 (10 and 20 mg/kg p.o.)
haloperidol
PD
0
$T1$ in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.Higher doses of AMN082 (10 and 20 mg/kg p.o.)
catalepsy
PD
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
apomorphine
PD
0
$T1$-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
6-OHDA
PD
0
$T1$ symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
akinetic
PD
0
$T1$.Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced $T2$
PD
dopamine
0
$T1$-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.Higher doses of $T2$
haloperidol
AMN082
0
$T1$ in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.Higher doses of $T2$
catalepsy
AMN082
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
apomorphine
AMN082
0
$T1$-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
6-OHDA
AMN082
0
$T1$ symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
akinetic
AMN082
0
$T1$ (10 and 20 mg/kg p.o.)have no effect on the same models of PD.
AMN082
dopamine
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
apomorphine
haloperidol
0
$T1$-lesioned rats.In addition, AMN082 reduces the duration of $T2$
6-OHDA
haloperidol
0
$T1$ symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.In addition, AMN082 reduces the duration of $T2$
akinetic
haloperidol
0
$T1$-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.Higher doses of AMN082 (10 and 20 mg/kg p.o.)
haloperidol
dopamine
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
apomorphine
catalepsy
0
$T1$-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced $T2$
6-OHDA
catalepsy
0
$T1$ symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced $T2$
akinetic
catalepsy
0
$T1$ in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.Higher doses of AMN082 (10 and 20 mg/kg p.o.)
catalepsy
dopamine
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral $T2$
apomorphine
6-OHDA
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major $T2$
apomorphine
akinetic
0
$T1$-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
apomorphine
dopamine
0
$T1$ symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral $T2$
akinetic
6-OHDA
0
$T1$-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
6-OHDA
dopamine
0
$T1$ symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
akinetic
dopamine
0
$T1$ caused by nitroglycerin-induced hypotension in adult mice.BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.
memory impairment
NTG
1
$T1$ but did not improve latency in the absence of hypotension.The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during $T2$
NTG
hypotension
1
$T1$ caused by nitroglycerin-induced hypotension in adult mice.BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.
memory impairment
NIMO
0
$T1$ but did not improve latency in the absence of hypotension.The observed effect of $T2$
NTG
NIMO
0
$T1$ may have been attributable to the preservation of calcium homeostasis during $T2$
NIMO
hypotension
0
$T1$.We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
cognitive dysfunction
NIMO
0
$T1$ may have been attributable to the preservation of $T2$
NIMO
calcium
0
$T1$ caused by nitroglycerin-induced hypotension in adult mice.BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.
memory impairment
hypotension
0
$T1$ caused by nitroglycerin-induced hypotension in adult mice.BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of $T2$
memory impairment
cognitive dysfunction
0
$T1$ caused by nitroglycerin-induced hypotension in adult mice.BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.
memory impairment
calcium
0
$T1$.We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
cognitive dysfunction
NTG
0
$T1$ but did not improve latency in the absence of hypotension.The observed effect of NIMO may have been attributable to the preservation of $T2$
NTG
calcium
0
$T1$.We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
cognitive dysfunction
hypotension
0
$T1$ homeostasis during $T2$
calcium
hypotension
0
$T1$.We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.
cognitive dysfunction
calcium
0
$T1$ due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.
gastrointestinal haemorrhage
flavonoids
1
$T1$ due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.
gastrointestinal haemorrhage
warfarin
1
$T1$ and $T2$
haemopericardium
gastrointestinal haemorrhage
0
$T1$ and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.
haemopericardium
warfarin
0
$T1$ and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal $T2$
haemopericardium
haemorrhage
0
$T1$ and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.
haemopericardium
flavonoids
0
$T1$ due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal $T2$
gastrointestinal haemorrhage
haemorrhage
0
$T1$ in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate $T2$
haemorrhage
warfarin
0
$T1$, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate $T2$
flavonoids
warfarin
0
$T1$ in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.We propose that naturally occurring compounds such as $T2$
haemorrhage
flavonoids
0
$T1$ is the best explanation for the complex morphological alterations observed.Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
myocardial hyperactivity
isoproterenol
1
$T1$, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by $T2$
ischaemic injury
isoproterenol
1
$T1$ supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
oxygen
isoproterenol
0
$T1$ and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
hypotension
isoproterenol
0
$T1$ supply vs. demand following coronary hypotension and $T2$
oxygen
myocardial hyperactivity
0
$T1$ and $T2$
hypotension
myocardial hyperactivity
0
$T1$ is the best explanation for the complex morphological alterations observed.Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
myocardial hyperactivity
ischaemic injury
0
$T1$ supply vs. demand following coronary $T2$
oxygen
hypotension
0
$T1$ supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
oxygen
ischaemic injury
0
$T1$ and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol.
hypotension
ischaemic injury
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
obese
1
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
cardiac dysfunction
doxorubicin
1
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
doxorubicin
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
cardiotoxicity
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high $T2$
triglycerides
fat
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
ATP
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, $T2$
fat
cardiac dysfunction
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant $T2$
fat
renal or hepatic toxicity
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
doxorubicinol
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
AMP
0
$T1$ diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
fat
ADP
0
$T1$ rats are highly sensitized to $T2$
obese
doxorubicin
0
$T1$ rats are highly sensitized to doxorubicin-induced $T2$
obese
cardiotoxicity
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
obese
0
$T1$ rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial $T2$
obese
ATP
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
cardiac dysfunction
obese
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
renal or hepatic toxicity
obese
0
$T1$ (toxic metabolite) in the normal diet-fed (ND) and OB hearts.Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
doxorubicinol
obese
0
$T1$-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
AMP
obese
0
$T1$ ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
ADP
obese
0
$T1$-induced $T2$
doxorubicin
cardiotoxicity
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
doxorubicin
0
$T1$-induced cardiotoxicity by substantially downregulating cardiac mitochondrial $T2$
doxorubicin
ATP
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
renal or hepatic toxicity
doxorubicin
0
$T1$ (toxic metabolite) in the normal diet-fed (ND) and OB hearts.Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
doxorubicinol
doxorubicin
0
$T1$-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
AMP
doxorubicin
0
$T1$ ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
ADP
doxorubicin
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
cardiotoxicity
0
$T1$ by substantially downregulating cardiac mitochondrial $T2$
cardiotoxicity
ATP
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
cardiac dysfunction
cardiotoxicity
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
renal or hepatic toxicity
cardiotoxicity
0
$T1$ (toxic metabolite) in the normal diet-fed (ND) and OB hearts.Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
doxorubicinol
cardiotoxicity
0
$T1$-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
AMP
cardiotoxicity
0
$T1$ ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
ADP
cardiotoxicity
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
ATP
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
cardiac dysfunction
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
renal or hepatic toxicity
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
doxorubicinol
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
AMP
0
$T1$ and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.
triglycerides
ADP
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
cardiac dysfunction
ATP
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
renal or hepatic toxicity
ATP
0
$T1$ (toxic metabolite) in the normal diet-fed (ND) and OB hearts.Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
doxorubicinol
ATP
0
$T1$-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
AMP
ATP
0
$T1$ ratio after doxorubicin administration.Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.
ADP
ATP
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant $T2$
cardiac dysfunction
renal or hepatic toxicity
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and $T2$
cardiac dysfunction
doxorubicinol
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
cardiac dysfunction
AMP
0
$T1$, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
cardiac dysfunction
ADP
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and $T2$
renal or hepatic toxicity
doxorubicinol
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
renal or hepatic toxicity
AMP
0
$T1$.Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
renal or hepatic toxicity
ADP
0
$T1$ (toxic metabolite) in the normal diet-fed (ND) and OB hearts.Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial $T2$
doxorubicinol
AMP
0
$T1$ (toxic metabolite) in the normal diet-fed (ND) and OB hearts.Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/$T2$
doxorubicinol
ADP
0
$T1$-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/$T2$
AMP
ADP
0
$T1$ has been reported most frequently among the adverse cardiovascular effects of lithium.In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.
Sinus node dysfunction
Lithium
1
$T1$ with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.
atrioventricular (AV) block
Lithium
1
$T1$ has been reported most frequently among the adverse cardiovascular effects of lithium.In the present case, complete $T2$
Sinus node dysfunction
atrioventricular (AV) block
0
$T1$ with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.Serum lithium levels remained under or within the therapeutic range during the $T2$
atrioventricular (AV) block
syncopal attacks
0
$T1$.$T2$
syncopal attacks
Lithium
0
$T1$ has been reported most frequently among the adverse cardiovascular effects of lithium.In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.
Sinus node dysfunction
syncopal attacks
0
$T1$ due to $T2$
NMS
ziprasidone
1
$T1$.We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.
movement disorders
NMS
0
$T1$ who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.This case is the earliest (second day of treatment) $T2$
schizophrenia
NMS
0
$T1$.We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.
movement disorders
ziprasidone
0
$T1$ who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.This case is the earliest (second day of treatment) NMS due to $T2$
schizophrenia
ziprasidone
0
$T1$.We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.
movement disorders
schizophrenia
0
$T1$-induced $T2$
ISPH
MI
1
$T1$ exerts a beneficial effect against $T2$
mangiferin
ISPH
0
$T1$ exerts a beneficial effect against ISPH-induced $T2$
mangiferin
MI
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
mangiferin
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
mangiferin
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
mangiferin
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
mangiferin
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
mangiferin
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
mangiferin
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
TTC
mangiferin
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
ischemic myocardium
mangiferin
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
superoxide
mangiferin
0
$T1$ levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
glutathione
mangiferin
0
$T1$, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin C
mangiferin
0
$T1$ and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin E
mangiferin
0
$T1$) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
dimethyl sulphoxide
mangiferin
0
$T1$ exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against $T2$
mangiferin
cardiac damage
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
ISPH
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
ISPH
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
ISPH
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
ISPH
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
ISPH
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
ISPH
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
TTC
ISPH
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
ischemic myocardium
ISPH
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
superoxide
ISPH
0
$T1$ levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
glutathione
ISPH
0
$T1$, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin C
ISPH
0
$T1$ and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin E
ISPH
0
$T1$) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
dimethyl sulphoxide
ISPH
0
$T1$-induced MI due to its antioxidant potential, which regulated the tissues defense system against $T2$
ISPH
cardiac damage
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
MI
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
MI
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
MI
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
MI
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
MI
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
MI
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
TTC
MI
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
ischemic myocardium
MI
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
superoxide
MI
0
$T1$ levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
glutathione
MI
0
$T1$, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin C
MI
0
$T1$ and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin E
MI
0
$T1$) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
dimethyl sulphoxide
MI
0
$T1$ due to its antioxidant potential, which regulated the tissues defense system against $T2$
MI
cardiac damage
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
myocardial damage
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
lactate
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
creatine
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
uric acid
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
iron
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
TTC
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
ischemic myocardium
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
superoxide
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
glutathione
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
Vitamin C
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
Vitamin E
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
dimethyl sulphoxide
0
$T1$ from Mangifera indica Linn.(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.
polyphenol
cardiac damage
0
$T1$ in rat heart, which was determined by the increased activity of serum $T2$
myocardial damage
lactate
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and $T2$
myocardial damage
creatine
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased $T2$
myocardial damage
uric acid
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma $T2$
myocardial damage
iron
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ($T2$
myocardial damage
TTC
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the $T2$
myocardial damage
ischemic myocardium
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
superoxide
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
glutathione
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
Vitamin C
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
Vitamin E
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
dimethyl sulphoxide
0
$T1$ in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
myocardial damage
cardiac damage
0
$T1$ dehydrogenase (LDH) and $T2$
lactate
creatine
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased $T2$
lactate
uric acid
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma $T2$
lactate
iron
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ($T2$
lactate
TTC
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the $T2$
lactate
ischemic myocardium
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
superoxide
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
glutathione
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
Vitamin C
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
Vitamin E
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
dimethyl sulphoxide
0
$T1$ dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
lactate
cardiac damage
0
$T1$ phosphokinase isoenzymes (CK-MB), increased $T2$
creatine
uric acid
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma $T2$
creatine
iron
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ($T2$
creatine
TTC
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the $T2$
creatine
ischemic myocardium
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
superoxide
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
glutathione
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
Vitamin C
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
Vitamin E
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
dimethyl sulphoxide
0
$T1$ phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
creatine
cardiac damage
0
$T1$ level and reduced plasma $T2$
uric acid
iron
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ($T2$
uric acid
TTC
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the $T2$
uric acid
ischemic myocardium
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
superoxide
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
glutathione
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
Vitamin C
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
Vitamin E
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
dimethyl sulphoxide
0
$T1$ level and reduced plasma iron binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
uric acid
cardiac damage
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ($T2$
iron
TTC
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the $T2$
iron
ischemic myocardium
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
superoxide
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
glutathione
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
Vitamin C
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
Vitamin E
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
dimethyl sulphoxide
0
$T1$ binding capacity.The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
iron
cardiac damage
0
$T1$) test used for macroscopic enzyme mapping assay of the $T2$
TTC
ischemic myocardium
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as $T2$
TTC
superoxide
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and $T2$
TTC
glutathione
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, $T2$
TTC
Vitamin C
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, $T2$
TTC
Vitamin E
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
TTC
dimethyl sulphoxide
0
$T1$) test used for macroscopic enzyme mapping assay of the ischemic myocardium.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
TTC
cardiac damage
0
$T1$.The heart tissue antioxidant enzymes such as $T2$
ischemic myocardium
superoxide
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and $T2$
ischemic myocardium
glutathione
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, $T2$
ischemic myocardium
Vitamin C
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, $T2$
ischemic myocardium
Vitamin E
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
ischemic myocardium
dimethyl sulphoxide
0
$T1$.The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
ischemic myocardium
cardiac damage
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and $T2$
superoxide
glutathione
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, $T2$
superoxide
Vitamin C
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, $T2$
superoxide
Vitamin E
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of $T2$
superoxide
dimethyl sulphoxide
0
$T1$ dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
superoxide
cardiac damage
0
$T1$, Vitamin E and $T2$
Vitamin C
glutathione
0
$T1$ and $T2$
Vitamin E
glutathione
0
$T1$ levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of $T2$
glutathione
dimethyl sulphoxide
0
$T1$ levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
glutathione
cardiac damage
0
$T1$, $T2$
Vitamin C
Vitamin E
0
$T1$, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of $T2$
Vitamin C
dimethyl sulphoxide
0
$T1$, Vitamin E and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin C
cardiac damage
0
$T1$ and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of $T2$
Vitamin E
dimethyl sulphoxide
0
$T1$ and glutathione levels were altered in MI rats.Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Vitamin E
cardiac damage
0
$T1$) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.
dimethyl sulphoxide
cardiac damage
0
$T1$ than women after $T2$
myoclonus
etomidate
1
$T1$ 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.Men experience increased incidence of $T2$
remifentanil
myoclonus
0
$T1$ 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.Men experience increased incidence of myoclonus than women after $T2$
remifentanil
etomidate
0
$T1$ 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, $T2$
remifentanil
nausea
0
$T1$ 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or $T2$
remifentanil
pruritus
0
$T1$ 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, $T2$
remifentanil
apnea
0
$T1$, or pruritus.Men experience increased incidence of $T2$
nausea
myoclonus
0
$T1$.Men experience increased incidence of $T2$
pruritus
myoclonus
0
$T1$, nausea, or pruritus.Men experience increased incidence of $T2$
apnea
myoclonus
0
$T1$, or pruritus.Men experience increased incidence of myoclonus than women after $T2$
nausea
etomidate
0
$T1$.Men experience increased incidence of myoclonus than women after $T2$
pruritus
etomidate
0
$T1$, nausea, or pruritus.Men experience increased incidence of myoclonus than women after $T2$
apnea
etomidate
0
$T1$, or $T2$
nausea
pruritus
0
$T1$, $T2$
apnea
nausea
0
$T1$, nausea, or $T2$
apnea
pruritus
0
$T1$-induced $T2$
scopolamine
amnesia
1
$T1$ acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
choline
daidzein
0
$T1$ might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced $T2$
daidzein
amnesia
0
$T1$ might play a role in $T2$
daidzein
acetylcholine
0
$T1$).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
AD
daidzein
0
$T1$ might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates $T2$
daidzein
scopolamine
0
$T1$, we conducted a series of in vivo tests.Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.
impairments of learning and memory
daidzein
0
$T1$ acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
choline
amnesia
0
$T1$ acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
choline
acetylcholine
0
$T1$ acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease ($T2$
choline
AD
0
$T1$ acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
choline
scopolamine
0
$T1$ acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
choline
impairments of learning and memory
0
$T1$ biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced $T2$
acetylcholine
amnesia
0
$T1$).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
AD
amnesia
0
$T1$, we conducted a series of in vivo tests.Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.
impairments of learning and memory
amnesia
0
$T1$).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
AD
acetylcholine
0
$T1$ biosynthesis as a ChAT activator, and that it also ameliorates $T2$
acetylcholine
scopolamine
0
$T1$, we conducted a series of in vivo tests.Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.
impairments of learning and memory
acetylcholine
0
$T1$).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
AD
scopolamine
0
$T1$).Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro.
AD
impairments of learning and memory
0
$T1$, we conducted a series of in vivo tests.Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.
impairments of learning and memory
scopolamine
0
$T1$ could be the pathogenesis of hiccups in our patient.CONCLUSIONS: Diagnosis of drug-induced hiccups is difficult and often achieved only by a process of elimination.
azithromycin
hiccups
1
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
hiccups
1
$T1$.Hiccups were persistent and exhausting.
pharyngitis
azithromycin
0
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
azithromycin
0
$T1$ and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
dexamethasone
azithromycin
0
$T1$), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
methylprednisolone
azithromycin
0
$T1$ (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
benzodiazepines
azithromycin
0
$T1$) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
midazolam
azithromycin
0
$T1$ could be the pathogenesis of hiccups in our patient.CONCLUSIONS: Diagnosis of drug-induced hiccups is difficult and often achieved only by a process of elimination.
azithromycin
macrolide
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
hiccups
0
$T1$ and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
dexamethasone
hiccups
0
$T1$), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
methylprednisolone
hiccups
0
$T1$ (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
benzodiazepines
hiccups
0
$T1$) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
midazolam
hiccups
0
$T1$ antimicrobials have been reported to be associated with $T2$
macrolide
hiccups
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
baclofen
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
dexamethasone
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
methylprednisolone
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
benzodiazepines
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
midazolam
0
$T1$.Hiccups were persistent and exhausting.
pharyngitis
macrolide
0
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
dexamethasone
0
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
methylprednisolone
0
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
benzodiazepines
0
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
midazolam
0
$T1$ finally resolved hiccups.No organic cause of hiccups was identified despite extensive investigation.
baclofen
macrolide
0
$T1$ and $T2$
dexamethasone
methylprednisolone
0
$T1$ and methylprednisolone), $T2$
dexamethasone
benzodiazepines
0
$T1$ and methylprednisolone), benzodiazepines ($T2$
dexamethasone
midazolam
0
$T1$ and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
dexamethasone
macrolide
0
$T1$), $T2$
methylprednisolone
benzodiazepines
0
$T1$), benzodiazepines ($T2$
methylprednisolone
midazolam
0
$T1$), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
methylprednisolone
macrolide
0
$T1$ ($T2$
benzodiazepines
midazolam
0
$T1$ (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
benzodiazepines
macrolide
0
$T1$) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.
midazolam
macrolide
0
$T1$-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.The proportion of patients with major and $T2$
warfarin
intracranial bleeding
1
$T1$-related $T2$
warfarin
bleeding
1
$T1$ at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.The proportion of patients with major and $T2$
bleeding
intracranial bleeding
0
$T1$ is a rare but important complication of $T2$
Haemorrhagic myocarditis
cyclophosphamide
1
$T1$ of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraine without aura
NO
1
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for $T2$
GTN
migraine without aura
1
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.
GTN
migraine with aura
0
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.
GTN
pain
0
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.
GTN
NO
0
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.
GTN
headache
0
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 $T2$
GTN
migraineurs
0
$T1$-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.
GTN
depression
0
$T1$ of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraine without aura
migraine with aura
0
$T1$ of the International Headache Society.The results therefore suggest that NO is involved in the $T2$
migraine without aura
pain
0
$T1$ of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraine without aura
headache
0
$T1$ fulfilled the diagnostic criteria for $T2$
migraineurs
migraine without aura
0
$T1$ of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraine without aura
depression
0
$T1$ mechanisms of migraine with aura.Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in $T2$
pain
migraine with aura
0
$T1$ in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in $T2$
NO
migraine with aura
0
$T1$ in $T2$
headache
migraine with aura
0
$T1$ fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraineurs
migraine with aura
0
$T1$ and headache in $T2$
depression
migraine with aura
0
$T1$ mechanisms of migraine with aura.Since cortical spreading depression has been shown to liberate $T2$
pain
NO
0
$T1$ mechanisms of migraine with aura.Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and $T2$
pain
headache
0
$T1$ fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.The results therefore suggest that NO is involved in the $T2$
migraineurs
pain
0
$T1$ mechanisms of migraine with aura.Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading $T2$
pain
depression
0
$T1$ in animals, this finding may help our understanding of the coupling between cortical spreading depression and $T2$
NO
headache
0
$T1$ fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraineurs
NO
0
$T1$ in animals, this finding may help our understanding of the coupling between cortical spreading $T2$
NO
depression
0
$T1$ fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraineurs
headache
0
$T1$ and $T2$
depression
headache
0
$T1$ fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
migraineurs
depression
0
$T1$ and/or amphetamine is a strong risk factor for $T2$
cocaine
stroke
1
$T1$ is a strong risk factor for $T2$
amphetamine
stroke
1
$T1$ stroke is based almost solely on data from case series.The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.
ischemic
stroke
0
$T1$ and/or $T2$
cocaine
amphetamine
0
$T1$ stroke is based almost solely on data from case series.The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.
ischemic
cocaine
0
$T1$ stroke is based almost solely on data from case series.The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.
ischemic
amphetamine
0
$T1$ and hypertriglyceridaemia among women on tamoxifen.INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.
vascular events
tamoxifen
1
$T1$ among women on tamoxifen.INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.
hypertriglyceridaemia
tamoxifen
1
$T1$ recorded in women in the study.It is essential to continue follow-up to quantify the long-term risks and benefits of $T2$
breast cancer
tamoxifen
0
$T1$.Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.
endometrial cancer
breast cancer
0
$T1$ and hypertriglyceridaemia among women on tamoxifen.INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.
vascular events
breast cancer
0
$T1$ among women on tamoxifen.INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.
hypertriglyceridaemia
breast cancer
0
$T1$.Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.
endometrial cancer
tamoxifen
0
$T1$.Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.
endometrial cancer
vascular events
0
$T1$.Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.
endometrial cancer
hypertriglyceridaemia
0
$T1$ and $T2$
vascular events
hypertriglyceridaemia
0
$T1$-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.Measures of $T2$
Cocaine
pupillary oscillation
1
$T1$-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past $T2$
Cocaine
CIP
1
$T1$ were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past $T2$
pupillary oscillation
CIP
0
$T1$ were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of $T2$
pupillary oscillation
crack
0
$T1$-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of $T2$
Cocaine
crack
0
$T1$ addicts who denied past $T2$
crack
CIP
0
$T1$.It seems that combined treatment of $T2$
seizures
fluvoxamine
1
$T1$-fluvoxamine treatment-induced $T2$
levomepromazine
seizures
1
$T1$.It seems that combined treatment of fluvoxamine with $T2$
seizures
phenothiazines
0
$T1$-fluvoxamine treatment-induced seizures.It seems that combined treatment of $T2$
levomepromazine
fluvoxamine
0
$T1$-fluvoxamine treatment-induced seizures.It seems that combined treatment of fluvoxamine with $T2$
levomepromazine
phenothiazines
0
$T1$ with $T2$
fluvoxamine
phenothiazines
0
$T1$ due to a short epsilon-aminocaproic acid ($T2$
necrotizing myopathy
EACA
1
$T1$ in man?Report of a case and literature review.
myopathy
EACA
1
$T1$) treatment in a 72 year-old patient with subarachnoid haemorrhage ($T2$
EACA
SAH
0
$T1$ in man?Report of a case and literature review.
myopathy
necrotizing myopathy
0
$T1$ in man?Report of a case and literature review.
myopathy
SAH
0
$T1$ due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage ($T2$
necrotizing myopathy
SAH
0
$T1$ while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
impotence
cimetidine
1
$T1$ is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of $T2$
ranitidine
cimetidine
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.
histamine
ranitidine
0
$T1$, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
Zollinger-Ellison syndrome
ranitidine
0
$T1$, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
systemic mastocytosis
ranitidine
0
$T1$ while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
impotence
ranitidine
0
$T1$ or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states.
hepatic or hematologic toxicity
ranitidine
0
$T1$ level than seen with cimetidine therapy.The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states.
creatinine
ranitidine
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.
histamine
cimetidine
0
$T1$, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
Zollinger-Ellison syndrome
cimetidine
0
$T1$, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
systemic mastocytosis
cimetidine
0
$T1$ or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states.
hepatic or hematologic toxicity
cimetidine
0
$T1$ level than seen with cimetidine therapy.The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states.
creatinine
cimetidine
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had $T2$
histamine
Zollinger-Ellison syndrome
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had Zollinger-Ellison syndrome, one patient had $T2$
histamine
systemic mastocytosis
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.
histamine
impotence
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.
histamine
hepatic or hematologic toxicity
0
$T1$ receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.
histamine
creatinine
0
$T1$, one patient had $T2$
Zollinger-Ellison syndrome
systemic mastocytosis
0
$T1$, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
Zollinger-Ellison syndrome
impotence
0
$T1$, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
Zollinger-Ellison syndrome
hepatic or hematologic toxicity
0
$T1$, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
Zollinger-Ellison syndrome
creatinine
0
$T1$, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
systemic mastocytosis
impotence
0
$T1$, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
systemic mastocytosis
hepatic or hematologic toxicity
0
$T1$, and two patients had idiopathic hypersecretion.The rates of onset of the action of cimetidine and ranitidine were the same.
systemic mastocytosis
creatinine
0
$T1$ while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with $T2$
impotence
hepatic or hematologic toxicity
0
$T1$ while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum $T2$
impotence
creatinine
0
$T1$ or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum $T2$
hepatic or hematologic toxicity
creatinine
0
$T1$ may be disappearing from Australia despite a total lack of association with salicylates or $T2$
Reye syndrome
aspirin
1
$T1$ may be disappearing from Australia despite a total lack of association with $T2$
Reye syndrome
salicylates
0
$T1$) dominating the pediatric analgesic and antipyretic market.$T2$
acetaminophen
Reye syndrome
0
$T1$ or $T2$
salicylates
aspirin
0
$T1$) dominating the pediatric analgesic and antipyretic market.Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or $T2$
acetaminophen
aspirin
0
$T1$) dominating the pediatric analgesic and antipyretic market.Reye syndrome may be disappearing from Australia despite a total lack of association with $T2$
acetaminophen
salicylates
0
$T1$ preparations continue to play a major role in $T2$
ergot
migraine
1
$T1$, together with striking angiographic findings, is described secondary to the ingestion of $T2$
vasospasm
methysergide
1
$T1$, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.A brief review of the literature on similar cases is presented.
vasospasm
St. Anthony's fire
0
$T1$ by a 48-year-old woman.A brief review of the literature on similar cases is presented.
methysergide
St. Anthony's fire
0
$T1$ preparations continue to play a major role in migraine therapy, so that the danger of $T2$
ergot
St. Anthony's fire
0
$T1$ that it has caused through the ages and its past and present role in the management of migraine headache.Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of $T2$
gangrene
St. Anthony's fire
0
$T1$ therapy, so that the danger of $T2$
migraine
St. Anthony's fire
0
$T1$ channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of $T2$
calcium
St. Anthony's fire
0
$T1$, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.A brief review of the literature on similar cases is presented.
vasospasm
ergot
0
$T1$, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.A brief review of the literature on similar cases is presented.
vasospasm
gangrene
0
$T1$, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.A brief review of the literature on similar cases is presented.
vasospasm
migraine
0
$T1$, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.A brief review of the literature on similar cases is presented.
vasospasm
calcium
0
$T1$ by a 48-year-old woman.A brief review of the literature on similar cases is presented.
methysergide
ergot
0
$T1$ by a 48-year-old woman.A brief review of the literature on similar cases is presented.
methysergide
gangrene
0
$T1$ by a 48-year-old woman.A brief review of the literature on similar cases is presented.
methysergide
migraine
0
$T1$ by a 48-year-old woman.A brief review of the literature on similar cases is presented.
methysergide
calcium
0
$T1$ that it has caused through the ages and its past and present role in the management of migraine headache.Despite the advent of calcium channel blockers and beta-adrenergic antagonists, $T2$
gangrene
ergot
0
$T1$ channel blockers and beta-adrenergic antagonists, $T2$
calcium
ergot
0
$T1$ that it has caused through the ages and its past and present role in the management of migraine headache.Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in $T2$
gangrene
migraine
0
$T1$ that it has caused through the ages and its past and present role in the management of migraine headache.Despite the advent of $T2$
gangrene
calcium
0
$T1$ channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in $T2$
calcium
migraine
0
$T1$ concentrations after oxprenolol pretreatment, the $T2$
terbutaline
hypokalemia
1
$T1$ pretreatment, the $T2$
oxprenolol
hypokalemia
0
$T1$ effects.Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.
potassium
hypokalemia
0
$T1$ concentrations after $T2$
terbutaline
oxprenolol
0
$T1$ effects.Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.
potassium
oxprenolol
0
$T1$ effects.Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.
potassium
terbutaline
0
$T1$ action of $T2$
hypotensive
methyldopa
1
$T1$ B3 cells in the medulla contribute to the $T2$
serotonin
hypotensive
0
$T1$ B3 cells in the medulla contribute to the hypotensive action of $T2$
serotonin
methyldopa
0
$T1$, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
hypertensive
serotonin
0
$T1$-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
stroke
serotonin
0
$T1$ lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline $T2$
5,7-DHT
serotonin
0
$T1$, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
hypertensive
hypotensive
0
$T1$-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
stroke
hypotensive
0
$T1$ lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the $T2$
5,7-DHT
hypotensive
0
$T1$, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
hypertensive
methyldopa
0
$T1$-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
stroke
methyldopa
0
$T1$ lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of $T2$
5,7-DHT
methyldopa
0
$T1$, $T2$
hypertensive
stroke
0
$T1$, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
hypertensive
5,7-DHT
0
$T1$-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
stroke
5,7-DHT
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
sexual side effects
1
$T1$ caused by serotonin reuptake blockers.Future controlled studies are needed to further investigate the effectiveness and safety of $T2$
sexual side effects
yohimbine
0
$T1$ reuptake blockers.Future controlled studies are needed to further investigate the effectiveness and safety of $T2$
serotonin
yohimbine
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
yohimbine
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
yohimbine
0
$T1$, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
obsessive compulsive disorder
yohimbine
0
$T1$, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
trichotillomania
yohimbine
0
$T1$, and a wound-up feeling in some patients.CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.
anxiety
yohimbine
0
$T1$ who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
affective disorders
yohimbine
0
$T1$ caused by $T2$
sexual side effects
serotonin
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
sexual side effects
0
$T1$, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
obsessive compulsive disorder
sexual side effects
0
$T1$, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
trichotillomania
sexual side effects
0
$T1$, and a wound-up feeling in some patients.CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the $T2$
anxiety
sexual side effects
0
$T1$ who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
affective disorders
sexual side effects
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
serotonin
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
serotonin
0
$T1$, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
obsessive compulsive disorder
serotonin
0
$T1$, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
trichotillomania
serotonin
0
$T1$, and a wound-up feeling in some patients.CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by $T2$
anxiety
serotonin
0
$T1$ who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
affective disorders
serotonin
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of $T2$
male impotence
clomipramine
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
obsessive compulsive disorder
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
trichotillomania
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
anxiety
0
$T1$.A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
male impotence
affective disorders
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
obsessive compulsive disorder
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
trichotillomania
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
anxiety
0
$T1$.This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
clomipramine
affective disorders
0
$T1$, $T2$
obsessive compulsive disorder
trichotillomania
0
$T1$, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
obsessive compulsive disorder
anxiety
0
$T1$, trichotillomania, anxiety, or $T2$
obsessive compulsive disorder
affective disorders
0
$T1$, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
trichotillomania
anxiety
0
$T1$, anxiety, or $T2$
trichotillomania
affective disorders
0
$T1$ who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.basis in an open clinical trial.
affective disorders
anxiety
0
$T1$-induced $T2$
dilevalol
liver injury
1
$T1$ immune reaction as a mechanism for dilevalol-associated hepatitis.OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.
Hypersensitivity
dilevalol
1
$T1$ immune reaction as a mechanism for dilevalol-associated hepatitis.OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.
Hypersensitivity
liver injury
0
$T1$.In patients receiving $T2$
myocardial hypertrophy
tacrolimus
1
$T1$.Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.
cardiac toxicity
myocardial hypertrophy
0
$T1$ caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.
hypertrophy
myocardial hypertrophy
0
$T1$ and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.
edema
myocardial hypertrophy
0
$T1$.Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.
cardiac toxicity
tacrolimus
0
$T1$ caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.
hypertrophy
tacrolimus
0
$T1$ and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.
edema
tacrolimus
0
$T1$.Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.
cardiac toxicity
hypertrophy
0
$T1$.Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.
cardiac toxicity
edema
0
$T1$ caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial $T2$
hypertrophy
edema
0
$T1$ were selected.All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.
dyskinesias
Levodopa
1
$T1$ equivalent daily intake was significantly reduced in the STN group.Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.
Levodopa
PD
0
$T1$ were selected.All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.
dyskinesias
PD
0
$T1$ after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced $T2$
homonymous hemianopsia
PD
0
$T1$ 1000 mg/day.The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced $T2$
Valproate
PD
0
$T1$ equivalent daily intake was significantly reduced in the STN group.Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.
Levodopa
homonymous hemianopsia
0
$T1$ equivalent daily intake was significantly reduced in the STN group.Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.
Levodopa
Valproate
0
$T1$ were selected.All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.
dyskinesias
homonymous hemianopsia
0
$T1$ were selected.All patients had bilateral symptoms and their levodopa equivalent dosing were analysed.
dyskinesias
Valproate
0
$T1$ after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with $T2$
homonymous hemianopsia
Valproate
0
$T1$, which is an experimental model of human nephrotic syndrome.Antithrombin (50 or 500 IU/kg/i.v.)
nephrosis
puromycin aminonucleoside
1
$T1$-induced nephrotic syndrome.Treatment with antithrombin may be clinically effective in patients with $T2$
puromycin aminonucleoside
nephrotic syndrome
0
$T1$.Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
hematological abnormalities
puromycin aminonucleoside
0
$T1$ such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.
renal damage
puromycin aminonucleoside
0
$T1$ were also suppressed.Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.
hyperlipidemia
puromycin aminonucleoside
0
$T1$, which is an experimental model of human nephrotic syndrome.Antithrombin (50 or 500 IU/kg/i.v.)
nephrosis
nephrotic syndrome
0
$T1$, which is an experimental model of human nephrotic syndrome.Antithrombin (50 or 500 IU/kg/i.v.)
nephrosis
hematological abnormalities
0
$T1$, which is an experimental model of human nephrotic syndrome.Antithrombin (50 or 500 IU/kg/i.v.)
nephrosis
renal damage
0
$T1$, which is an experimental model of human nephrotic syndrome.Antithrombin (50 or 500 IU/kg/i.v.)
nephrosis
hyperlipidemia
0
$T1$.Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
hematological abnormalities
nephrotic syndrome
0
$T1$ such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.
renal damage
nephrotic syndrome
0
$T1$ were also suppressed.Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.
hyperlipidemia
nephrotic syndrome
0
$T1$.Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.
hematological abnormalities
renal damage
0
$T1$.Puromycin aminonucleoside-induced renal dysfunction and $T2$
hematological abnormalities
hyperlipidemia
0
$T1$ were also suppressed.Histopathological examination revealed severe $T2$
hyperlipidemia
renal damage
0
$T1$ occurring after $T2$
apical ballooning syndrome
amphetamine
1
$T1$ of the base (as opposed to the classic apical ballooning).In this article, we report an interesting case of a young woman who presented with this rare type of reverse $T2$
akinesia
apical ballooning syndrome
0
$T1$ of the base (as opposed to the classic apical ballooning).In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after $T2$
akinesia
amphetamine
0
$T1$ was similar in all groups.These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.
locomotor hyperactivity
amphetamine
1
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
corticosterone
0
$T1$ treatment, on dopaminergic regulation of PPI.The altered effects of $T2$
corticosterone
apomorphine
0
$T1$ treatment, on dopaminergic regulation of PPI.The altered effects of apomorphine and $T2$
corticosterone
amphetamine
0
$T1$-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
serotonin
corticosterone
0
$T1$, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
8-OH-DPAT
corticosterone
0
$T1$ was similar in all groups.These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by $T2$
locomotor hyperactivity
corticosterone
0
$T1$ treatment, on dopaminergic regulation of PPI.The altered effects of apomorphine and amphetamine could indicate differential changes in $T2$
corticosterone
dopamine
0
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
apomorphine
0
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
amphetamine
0
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
serotonin
0
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
8-OH-DPAT
0
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
locomotor hyperactivity
0
$T1$ may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.
schizophrenia
dopamine
0
$T1$ and $T2$
apomorphine
amphetamine
0
$T1$-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
serotonin
apomorphine
0
$T1$, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
8-OH-DPAT
apomorphine
0
$T1$ was similar in all groups.These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.
locomotor hyperactivity
apomorphine
0
$T1$ and amphetamine could indicate differential changes in $T2$
apomorphine
dopamine
0
$T1$-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
serotonin
amphetamine
0
$T1$, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
8-OH-DPAT
amphetamine
0
$T1$ could indicate differential changes in $T2$
amphetamine
dopamine
0
$T1$-1A receptor agonist, $T2$
serotonin
8-OH-DPAT
0
$T1$-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.Amphetamine-induced $T2$
serotonin
locomotor hyperactivity
0
$T1$-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
serotonin
dopamine
0
$T1$, induced a significant disruption of PPI in all groups.Amphetamine-induced $T2$
8-OH-DPAT
locomotor hyperactivity
0
$T1$, induced a significant disruption of PPI in all groups.Amphetamine-induced locomotor hyperactivity was similar in all groups.
8-OH-DPAT
dopamine
0
$T1$ was similar in all groups.These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.
locomotor hyperactivity
dopamine
0
$T1$ can increase the iron level in the SN, where excessive iron causes the $T2$
iron dextran
degeneration of dopaminergic neurons
1
$T1$ can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.The chronic iron overload may be more destructive to dopaminergic neurons than the acute $T2$
iron dextran
iron
0
$T1$.To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
Parkinson's disease
iron dextran
0
$T1$ hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.
tyrosine
iron dextran
0
$T1$ release and content, as well as its metabolites contents were decreased in caudate putamen.Even more dramatic changes were found in chronic overload group.
dopamine
iron dextran
0
$T1$.The chronic iron overload may be more destructive to dopaminergic neurons than the acute $T2$
degeneration of dopaminergic neurons
iron
0
$T1$.To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
Parkinson's disease
degeneration of dopaminergic neurons
0
$T1$ hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.
tyrosine
degeneration of dopaminergic neurons
0
$T1$ release and content, as well as its metabolites contents were decreased in caudate putamen.Even more dramatic changes were found in chronic overload group.
dopamine
degeneration of dopaminergic neurons
0
$T1$.To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
Parkinson's disease
iron
0
$T1$ hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.
tyrosine
iron
0
$T1$ release and content, as well as its metabolites contents were decreased in caudate putamen.Even more dramatic changes were found in chronic overload group.
dopamine
iron
0
$T1$.To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, $T2$
Parkinson's disease
tyrosine
0
$T1$.To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
Parkinson's disease
dopamine
0
$T1$ hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.
tyrosine
dopamine
0
$T1$ resolved in all patients after warfarin was discontinued.In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.
LV Cutaneous lesions
warfarin
1
$T1$ may be a late-onset adverse reaction associated with $T2$
LV
warfarin
0
$T1$-derived anticoagulants are an uncommon occurrence.Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.
coumarin
warfarin
0
$T1$, though systemic involvement may be encountered.We report 4 patients with late-onset LV probably due to warfarin.
cutaneous small vessel vasculitis
warfarin
0
$T1$ biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.
skin lesion
warfarin
0
$T1$-derived anticoagulants are an uncommon occurrence.Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.
coumarin
LV
0
$T1$, though systemic involvement may be encountered.We report 4 patients with late-onset LV probably due to warfarin.
cutaneous small vessel vasculitis
LV
0
$T1$ biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.
skin lesion
LV
0
$T1$ resolved in all patients after warfarin was discontinued.In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.
LV Cutaneous lesions
LV
0
$T1$-derived anticoagulants are an uncommon occurrence.Leukocytoclastic vasculitis (LV) is primarily a $T2$
coumarin
cutaneous small vessel vasculitis
0
$T1$-derived anticoagulants are an uncommon occurrence.Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.
coumarin
skin lesion
0
$T1$-derived anticoagulants are an uncommon occurrence.Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.
coumarin
LV Cutaneous lesions
0
$T1$, though systemic involvement may be encountered.We report 4 patients with late-onset LV probably due to warfarin.
cutaneous small vessel vasculitis
skin lesion
0
$T1$, though systemic involvement may be encountered.We report 4 patients with late-onset LV probably due to warfarin.
cutaneous small vessel vasculitis
LV Cutaneous lesions
0
$T1$ biopsies were available in 3 patients, confirming $T2$
skin lesion
LV Cutaneous lesions
0
$T1$ induces $T2$
morphine
spastic paraparesis
1
$T1$ induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via $T2$
morphine
NMDA
0
$T1$ via $T2$
spinal cord ischemia
NMDA
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
NMDA
0
$T1$ significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
MK-801
NMDA
0
$T1$ with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via $T2$
spastic paraparesis
NMDA
0
$T1$, which is involved in NMDA receptor activation.We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via $T2$
glutamate
NMDA
0
$T1$ in the setting of spinal cord ischemia via $T2$
neurotoxic
NMDA
0
$T1$ induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.We suggest that opioids may be neurotoxic in the setting of $T2$
morphine
spinal cord ischemia
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
morphine
0
$T1$ significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.These data indicate that IT $T2$
MK-801
morphine
0
$T1$ induces spastic paraparesis with a concomitant increase in CSF $T2$
morphine
glutamate
0
$T1$ induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.We suggest that opioids may be $T2$
morphine
neurotoxic
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
spinal cord ischemia
0
$T1$ significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
MK-801
spinal cord ischemia
0
$T1$ with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.We suggest that opioids may be neurotoxic in the setting of $T2$
spastic paraparesis
spinal cord ischemia
0
$T1$, which is involved in NMDA receptor activation.We suggest that opioids may be neurotoxic in the setting of $T2$
glutamate
spinal cord ischemia
0
$T1$ in the setting of $T2$
neurotoxic
spinal cord ischemia
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
MK-801
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
spastic paraparesis
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
glutamate
0
$T1$ for 6 min with a balloon catheter.In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.
aortic occlusion
neurotoxic
0
$T1$ significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.These data indicate that IT morphine induces $T2$
MK-801
spastic paraparesis
0
$T1$ significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF $T2$
MK-801
glutamate
0
$T1$ significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
MK-801
neurotoxic
0
$T1$ with a concomitant increase in CSF $T2$
spastic paraparesis
glutamate
0
$T1$ with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.We suggest that opioids may be $T2$
spastic paraparesis
neurotoxic
0
$T1$, which is involved in NMDA receptor activation.We suggest that opioids may be $T2$
glutamate
neurotoxic
0
$T1$-induced $T2$
pilocarpine
seizures
1
$T1$, but seemed normal in other neurological tests.Our observations show that beta2-subunits play an important role in the regulation of $T2$
seizures
sodium
0
$T1$) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.
STX
sodium
0
$T1$-induced seizures, but seemed normal in other neurological tests.Our observations show that beta2-subunits play an important role in the regulation of $T2$
pilocarpine
sodium
0
$T1$) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.
STX
seizures
0
$T1$) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.
STX
pilocarpine
0
$T1$ and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
benzoylecgonine
seizure
1
$T1$ and amphetamines in adult $T2$
cocaine
seizure
0
$T1$.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
amphetamine
seizure
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.
alcohol
seizure
0
$T1$ (p < 0.0005).CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult $T2$
cocaine or amphetamine abuse
seizure
0
$T1$ in adult $T2$
amphetamines
seizure
0
$T1$ patients had a low yield.As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of $T2$
seizure
drug abuse
0
$T1$.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
amphetamine
cocaine
0
$T1$ and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
benzoylecgonine
cocaine
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.
alcohol
cocaine
0
$T1$ (p < 0.0005).CONCLUSIONS: During this study period, routine plasma screening for $T2$
cocaine or amphetamine abuse
cocaine
0
$T1$ and $T2$
cocaine
amphetamines
0
$T1$ and amphetamines in adult seizure patients had a low yield.As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of $T2$
cocaine
drug abuse
0
$T1$ and no samples (0%, 95% CI 0-1.2%) were positive for $T2$
benzoylecgonine
amphetamine
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for $T2$
alcohol
amphetamine
0
$T1$.Positive test results were more common in patient visits where there was a history or suspicion of $T2$
amphetamine
cocaine or amphetamine abuse
0
$T1$.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
amphetamine
amphetamines
0
$T1$.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
amphetamine
drug abuse
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for $T2$
alcohol
benzoylecgonine
0
$T1$ and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.Positive test results were more common in patient visits where there was a history or suspicion of $T2$
benzoylecgonine
cocaine or amphetamine abuse
0
$T1$ and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
benzoylecgonine
amphetamines
0
$T1$ and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).
benzoylecgonine
drug abuse
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.
alcohol
cocaine or amphetamine abuse
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.
alcohol
amphetamines
0
$T1$-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.
alcohol
drug abuse
0
$T1$ (p < 0.0005).CONCLUSIONS: During this study period, routine plasma screening for cocaine and $T2$
cocaine or amphetamine abuse
amphetamines
0
$T1$ (p < 0.0005).CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.
cocaine or amphetamine abuse
drug abuse
0
$T1$ in adult seizure patients had a low yield.As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of $T2$
amphetamines
drug abuse
0
$T1$ responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.
levodopa
dyskinesias
1
$T1$ responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.
levodopa
parkinsonism
0
$T1$ and $T2$
parkinsonism
dyskinesias
0
$T1$-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
methadone
pain-intolerant
1
$T1$-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
methadone
pain
0
$T1$ stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
opioid addicts
pain
0
$T1$ 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.
hydromorphone
pain
0
$T1$ 10 mg) analgesic agents.Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.
ketorolac
pain
0
$T1$ subset of clinical patients.Their complaints of $T2$
pain-intolerant
pain
0
$T1$ stabilized in $T2$
opioid addicts
methadone
0
$T1$-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid ($T2$
methadone
hydromorphone
0
$T1$-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory ($T2$
methadone
ketorolac
0
$T1$ stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid ($T2$
opioid addicts
hydromorphone
0
$T1$ stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory ($T2$
opioid addicts
ketorolac
0
$T1$ stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
opioid addicts
pain-intolerant
0
$T1$ 2 mg) and nonsteroidal anti-inflammatory ($T2$
hydromorphone
ketorolac
0
$T1$ 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.
hydromorphone
pain-intolerant
0
$T1$ 10 mg) analgesic agents.Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.
ketorolac
pain-intolerant
0
$T1$ urine volume and urine NAG activity increased significantly by day two, but returned to normal by day four.After day four all treated animals exhibited a marked rise in urine albumin, total protein excretion and NAG activity.
PAN
proteinuria
1
$T1$, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.
renal tubular dysfunction
PAN
0
$T1$, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.
renal tubular dysfunction
proteinuria
0
$T1$ may mediate estrogen-initiated tumor angiogenesis.Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.
pituitary tumors
E2
1
$T1$ may mediate estrogen-initiated tumor angiogenesis.Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.
pituitary tumors
estrogen
0
$T1$ induced $T2$
estrogen
tumor
0
$T1$, are still unknown.To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.
carcinogenesis
estrogen
0
$T1$ exposure.These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of $T2$
E2
estrogen
0
$T1$ may mediate estrogen-initiated tumor angiogenesis.Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.
pituitary tumors
tumor
0
$T1$ may mediate estrogen-initiated tumor angiogenesis.Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.
pituitary tumors
carcinogenesis
0
$T1$, are still unknown.To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.
carcinogenesis
tumor
0
$T1$ exposure.These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced $T2$
E2
tumor
0
$T1$, are still unknown.To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.
carcinogenesis
E2
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
pravastatin
1
$T1$-associated $T2$
pravastatin
myopathy
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
non-insulin-dependent diabetes mellitus
pravastatin
0
$T1$.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
hypertension
pravastatin
0
$T1$.He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
hypercholesterolemia
pravastatin
0
$T1$, probably due to chronic autoimmune thyroiditis, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
hypothyroidism
pravastatin
0
$T1$, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
autoimmune thyroiditis
pravastatin
0
$T1$ and simvastatin have been associated with toxic myopathy, $T2$
lovastatin
pravastatin
0
$T1$ have been associated with toxic myopathy, $T2$
simvastatin
pravastatin
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
myopathy
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
non-insulin-dependent diabetes mellitus
myopathy
0
$T1$.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
hypertension
myopathy
0
$T1$.He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
hypercholesterolemia
myopathy
0
$T1$, probably due to chronic autoimmune thyroiditis, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
hypothyroidism
myopathy
0
$T1$, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
autoimmune thyroiditis
myopathy
0
$T1$ and simvastatin have been associated with toxic myopathy, pravastatin-associated $T2$
lovastatin
myopathy
0
$T1$ have been associated with toxic myopathy, pravastatin-associated $T2$
simvastatin
myopathy
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by $T2$
inflammatory myopathy
non-insulin-dependent diabetes mellitus
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and $T2$
inflammatory myopathy
hypertension
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
hypercholesterolemia
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
hypothyroidism
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
autoimmune thyroiditis
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
lovastatin
0
$T1$ associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.
inflammatory myopathy
simvastatin
0
$T1$ and $T2$
non-insulin-dependent diabetes mellitus
hypertension
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of $T2$
non-insulin-dependent diabetes mellitus
hypercholesterolemia
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
non-insulin-dependent diabetes mellitus
hypothyroidism
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
non-insulin-dependent diabetes mellitus
autoimmune thyroiditis
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
non-insulin-dependent diabetes mellitus
lovastatin
0
$T1$ and hypertension.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
non-insulin-dependent diabetes mellitus
simvastatin
0
$T1$.He assumed pravastatin (20 mg/day) because of $T2$
hypertension
hypercholesterolemia
0
$T1$.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
hypertension
hypothyroidism
0
$T1$.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
hypertension
autoimmune thyroiditis
0
$T1$.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
hypertension
lovastatin
0
$T1$.He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
hypertension
simvastatin
0
$T1$.He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
hypercholesterolemia
hypothyroidism
0
$T1$.He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
hypercholesterolemia
autoimmune thyroiditis
0
$T1$.He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
hypercholesterolemia
lovastatin
0
$T1$.He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
hypercholesterolemia
simvastatin
0
$T1$, probably due to chronic $T2$
hypothyroidism
autoimmune thyroiditis
0
$T1$, probably due to chronic autoimmune thyroiditis, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
hypothyroidism
lovastatin
0
$T1$, probably due to chronic autoimmune thyroiditis, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
hypothyroidism
simvastatin
0
$T1$, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
autoimmune thyroiditis
lovastatin
0
$T1$, was evidenced.Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.
autoimmune thyroiditis
simvastatin
0
$T1$ and $T2$
lovastatin
simvastatin
0
$T1$ is proportional to the degree of cytotoxic insult ($T2$
myocardial damage
DXR
1
$T1$ after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.Any other suspected cases of ocular toxicity associated with topically applied $T2$
aplastic anemia
chloramphenicol
1
$T1$ extraction and beginning topical therapy with chloramphenicol.The first signs of pancytopenia began within one month of the surgery.
cataract
aplastic anemia
0
$T1$ began within one month of the surgery.The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.
pancytopenia
aplastic anemia
0
$T1$ after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible $T2$
aplastic anemia
bone marrow hypoplasia
0
$T1$ after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.Any other suspected cases of $T2$
aplastic anemia
ocular toxicity
0
$T1$ extraction and beginning topical therapy with chloramphenicol.The first signs of pancytopenia began within one month of the surgery.
cataract
chloramphenicol
0
$T1$ began within one month of the surgery.The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.
pancytopenia
chloramphenicol
0
$T1$ have also been reported.Any other suspected cases of ocular toxicity associated with topically applied $T2$
bone marrow hypoplasia
chloramphenicol
0
$T1$ associated with topically applied $T2$
ocular toxicity
chloramphenicol
0
$T1$ extraction and beginning topical therapy with chloramphenicol.The first signs of $T2$
cataract
pancytopenia
0
$T1$ extraction and beginning topical therapy with chloramphenicol.The first signs of pancytopenia began within one month of the surgery.
cataract
bone marrow hypoplasia
0
$T1$ extraction and beginning topical therapy with chloramphenicol.The first signs of pancytopenia began within one month of the surgery.
cataract
ocular toxicity
0
$T1$ began within one month of the surgery.The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.
pancytopenia
bone marrow hypoplasia
0
$T1$ began within one month of the surgery.The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.
pancytopenia
ocular toxicity
0
$T1$ have also been reported.Any other suspected cases of $T2$
bone marrow hypoplasia
ocular toxicity
0
$T1$.The reaction was specific to $T2$
bradycardia
trihexyphenidyl
1
$T1$ patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.The patient developed, paradoxically, sinus $T2$
schizophrenic
bradycardia
0
$T1$.The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.
bradycardia
psychiatric
0
$T1$ patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.The patient developed, paradoxically, sinus bradycardia.
schizophrenic
trihexyphenidyl
0
$T1$ and not to other anticholinergic drugs.This antidyskinetic drug is widely used in clinical $T2$
trihexyphenidyl
psychiatric
0
$T1$ patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.The patient developed, paradoxically, sinus bradycardia.
schizophrenic
psychiatric
0
$T1$ induced by $T2$
nephrotoxicity
CSA
1
$T1$ at toxic doses, however, increased CSA nephrotoxicity.Thus, the nephrotoxicity induced by $T2$
Gentamicin
CSA
0
$T1$ and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
amphothericin B
CSA
0
$T1$, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
ketoconazole
CSA
0
$T1$ in the rat model.Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
toxicity
CSA
0
$T1$ at toxic doses, however, increased CSA nephrotoxicity.Thus, the $T2$
Gentamicin
nephrotoxicity
0
$T1$ and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
amphothericin B
nephrotoxicity
0
$T1$, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
ketoconazole
nephrotoxicity
0
$T1$ in the rat model.Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
toxicity
nephrotoxicity
0
$T1$ and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.$T2$
amphothericin B
Gentamicin
0
$T1$, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.$T2$
ketoconazole
Gentamicin
0
$T1$ in the rat model.$T2$
toxicity
Gentamicin
0
$T1$ and $T2$
amphothericin B
ketoconazole
0
$T1$ and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced $T2$
amphothericin B
toxicity
0
$T1$, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced $T2$
ketoconazole
toxicity
0
$T1$ in response to $T2$
locomotor hyperactivity
nicotine
1
$T1$ binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to $T2$
spiperone
nicotine
0
$T1$ initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing $T2$
nicotine
DA
0
$T1$ binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.These results suggest that chronic nicotine-treated rats develop $T2$
spiperone
locomotor hyperactivity
0
$T1$ in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing $T2$
locomotor hyperactivity
DA
0
$T1$ binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing $T2$
spiperone
DA
0
$T1$ with $T2$
rise in resting blood pressure
hydrocortisone
1
$T1$ uptake indicated that overall resting sympathetic nervous system activity was not increased.The rise in resting blood pressure with $T2$
norepinephrine
hydrocortisone
0
$T1$ is associated with an $T2$
hydrocortisone
increased cardiac output
0
$T1$ uptake indicated that overall resting sympathetic nervous system activity was not increased.The $T2$
norepinephrine
rise in resting blood pressure
0
$T1$ with hydrocortisone is associated with an $T2$
rise in resting blood pressure
increased cardiac output
0
$T1$ uptake indicated that overall resting sympathetic nervous system activity was not increased.The rise in resting blood pressure with hydrocortisone is associated with an $T2$
norepinephrine
increased cardiac output
0
$T1$ causes $T2$
suprofen
acute declines in renal function
1
$T1$ effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.
nephrotoxic
suprofen
0
$T1$ causes acute declines in renal function, most likely by directly altering the intrarenal distribution of $T2$
suprofen
uric acid
0
$T1$ excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.
sodium
suprofen
0
$T1$ consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.
oxygen
suprofen
0
$T1$ effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.
nephrotoxic
acute declines in renal function
0
$T1$, most likely by directly altering the intrarenal distribution of $T2$
acute declines in renal function
uric acid
0
$T1$ excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.
sodium
acute declines in renal function
0
$T1$ consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.
oxygen
acute declines in renal function
0
$T1$ effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.
nephrotoxic
uric acid
0
$T1$ effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.There were no significant differences in renal $T2$
nephrotoxic
sodium
0
$T1$ effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.There were no significant differences in renal sodium excretion, $T2$
nephrotoxic
oxygen
0
$T1$ excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.
sodium
uric acid
0
$T1$ consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.
oxygen
uric acid
0
$T1$ excretion, $T2$
sodium
oxygen
0
$T1$ and behavior.A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.
seizures
Cocaine
1
$T1$, hypersensitivity, "beating drum" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching.Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states.
hyperactivity
Cocaine
0
$T1$ to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation.These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation.
Hypersensitivity
Cocaine
0
$T1$ and behavior.A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.
seizures
hyperactivity
0
$T1$ and behavior.A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.
seizures
Hypersensitivity
0
$T1$, hypersensitivity, "beating drum" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching.Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states.
hyperactivity
Hypersensitivity
0
$T1$ in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.
cholestasis
ethinyl estradiol
1
$T1$, a poor choleretic, to taurocholic acid, a good choleretic.When this conversion is impaired with $T2$
deoxycholic acid
ethinyl estradiol
0
$T1$ in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.
cholestasis
deoxycholic acid
0
$T1$ from 1.5% in controls to nearly 4.0% (P less than 0.01).These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.
taurodeoxycholic acid
deoxycholic acid
0
$T1$, a poor choleretic, to taurocholic acid, a good choleretic.When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful $T2$
deoxycholic acid
bile acid
0
$T1$, a poor choleretic, to $T2$
deoxycholic acid
taurocholic acid
0
$T1$ from 1.5% in controls to nearly 4.0% (P less than 0.01).These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.
taurodeoxycholic acid
ethinyl estradiol
0
$T1$ treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful $T2$
ethinyl estradiol
bile acid
0
$T1$, a good choleretic.When this conversion is impaired with $T2$
taurocholic acid
ethinyl estradiol
0
$T1$ in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.
cholestasis
taurodeoxycholic acid
0
$T1$ in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.
cholestasis
bile acid
0
$T1$ in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.
cholestasis
taurocholic acid
0
$T1$ from 1.5% in controls to nearly 4.0% (P less than 0.01).These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.
taurodeoxycholic acid
bile acid
0
$T1$ from 1.5% in controls to nearly 4.0% (P less than 0.01).These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.
taurodeoxycholic acid
taurocholic acid
0
$T1$, a good choleretic.When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful $T2$
taurocholic acid
bile acid
0
$T1$ after $T2$
left ventricular end-diastolic volume falls
ouabain
1
$T1$ administration even when it is initially normal.Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial $T2$
ouabain
oxygen
0
$T1$ who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after $T2$
coronary artery disease
ouabain
0
$T1$ left ventricular end-diastolic volume falls after $T2$
congestive heart failure
ouabain
0
$T1$ on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
digitalis glycosides
ouabain
0
$T1$ who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial $T2$
coronary artery disease
oxygen
0
$T1$ left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial $T2$
congestive heart failure
oxygen
0
$T1$ on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
digitalis glycosides
oxygen
0
$T1$ after ouabain administration even when it is initially normal.Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial oxygen consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial $T2$
left ventricular end-diastolic volume falls
oxygen
0
$T1$ who are not in clinical $T2$
coronary artery disease
congestive heart failure
0
$T1$ on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
digitalis glycosides
coronary artery disease
0
$T1$ who are not in clinical congestive heart failure $T2$
coronary artery disease
left ventricular end-diastolic volume falls
0
$T1$ on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
digitalis glycosides
congestive heart failure
0
$T1$ $T2$
congestive heart failure
left ventricular end-diastolic volume falls
0
$T1$ on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
digitalis glycosides
left ventricular end-diastolic volume falls
0
$T1$ have been reported after concomitant administration with erythromycin or $T2$
sudden cardiac death
azole
1
$T1$ antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
azole
QT-interval prolongation
1
$T1$.After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.
QT-interval prolongation
diltiazem
1
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or $T2$
torsades de pointes
azole
1
$T1$ have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
sudden cardiac death
cisapride
1
$T1$, and sudden cardiac death have been reported after concomitant administration with $T2$
torsades de pointes
erythromycin
1
$T1$ or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
erythromycin
QT-interval prolongation
1
$T1$.After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.
QT-interval prolongation
cisapride
1
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
torsades de pointes
cisapride
1
$T1$ have been reported after concomitant administration with $T2$
sudden cardiac death
erythromycin
1
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
gastrointestinal motility disorders
QT-interval prolongation
0
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
torsades de pointes
QT-interval prolongation
0
$T1$ have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
sudden cardiac death
QT-interval prolongation
0
$T1$ and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.The patient was in near syncope and had $T2$
gastroesophageal reflux disorder
QT-interval prolongation
0
$T1$.The patient was in near syncope and had $T2$
hypertension
QT-interval prolongation
0
$T1$ and had $T2$
syncope
QT-interval prolongation
0
$T1$ is prescribed with any potent inhibitor of CYP3A4, including $T2$
cisapride
diltiazem
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
gastrointestinal motility disorders
cisapride
0
$T1$ or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
erythromycin
cisapride
0
$T1$ antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
azole
cisapride
0
$T1$ and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.The patient was in near syncope and had QT-interval prolongation.
gastroesophageal reflux disorder
cisapride
0
$T1$.The patient was in near syncope and had QT-interval prolongation.
hypertension
cisapride
0
$T1$ and had QT-interval prolongation.After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.
syncope
cisapride
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
gastrointestinal motility disorders
diltiazem
0
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
torsades de pointes
diltiazem
0
$T1$ have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
sudden cardiac death
diltiazem
0
$T1$ or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
erythromycin
diltiazem
0
$T1$ antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
azole
diltiazem
0
$T1$ and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.The patient was in near syncope and had QT-interval prolongation.
gastroesophageal reflux disorder
diltiazem
0
$T1$.The patient was in near syncope and had QT-interval prolongation.
hypertension
diltiazem
0
$T1$ and had QT-interval prolongation.After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.
syncope
diltiazem
0
$T1$.Prolongation of QT interval, $T2$
gastrointestinal motility disorders
torsades de pointes
0
$T1$.Prolongation of QT interval, torsades de pointes, and $T2$
gastrointestinal motility disorders
sudden cardiac death
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with $T2$
gastrointestinal motility disorders
erythromycin
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or $T2$
gastrointestinal motility disorders
azole
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
gastrointestinal motility disorders
gastroesophageal reflux disorder
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
gastrointestinal motility disorders
hypertension
0
$T1$.Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
gastrointestinal motility disorders
syncope
0
$T1$, and $T2$
torsades de pointes
sudden cardiac death
0
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for $T2$
torsades de pointes
gastroesophageal reflux disorder
0
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for $T2$
torsades de pointes
hypertension
0
$T1$, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
torsades de pointes
syncope
0
$T1$ have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for $T2$
sudden cardiac death
gastroesophageal reflux disorder
0
$T1$ have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for $T2$
sudden cardiac death
hypertension
0
$T1$ have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
sudden cardiac death
syncope
0
$T1$ or $T2$
erythromycin
azole
0
$T1$ or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for $T2$
erythromycin
gastroesophageal reflux disorder
0
$T1$ or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for $T2$
erythromycin
hypertension
0
$T1$ or azole antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
erythromycin
syncope
0
$T1$ antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for $T2$
azole
gastroesophageal reflux disorder
0
$T1$ antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for $T2$
azole
hypertension
0
$T1$ antifungal agents, but not with other CYP3A4 inhibitors.A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
azole
syncope
0
$T1$ and diltiazem, an agent that has inhibitory effect on CYP3A4, for $T2$
gastroesophageal reflux disorder
hypertension
0
$T1$ and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.The patient was in near $T2$
gastroesophageal reflux disorder
syncope
0
$T1$.The patient was in near $T2$
hypertension
syncope
0
$T1$).Neurotoxicity was largely moderate.
thrombocytopenia
paclitaxel
1
$T1$, and thrombocytopenia).Neurotoxicity was largely moderate.
granulocytopenia
paclitaxel
1
$T1$, and thrombocytopenia).Neurotoxicity was largely moderate.
granulocytopenia
carboplatin
1
$T1$, granulocytopenia, and thrombocytopenia).Neurotoxicity was largely moderate.
leukopenia
paclitaxel
1
$T1$, granulocytopenia, and thrombocytopenia).Neurotoxicity was largely moderate.
leukopenia
carboplatin
1
$T1$).Neurotoxicity was largely moderate.
thrombocytopenia
carboplatin
1
$T1$ was largely moderate.So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients.
Neurotoxicity
carboplatin
1
$T1$ was largely moderate.So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients.
Neurotoxicity
paclitaxel
1
$T1$ 185 mg/m2 and $T2$
paclitaxel
carboplatin
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
paclitaxel
0
$T1$ of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).Neurotoxicity was largely moderate.
toxicity
paclitaxel
0
$T1$ (leukopenia, granulocytopenia, and thrombocytopenia).Neurotoxicity was largely moderate.
myelosuppression
paclitaxel
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
carboplatin
0
$T1$ of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).Neurotoxicity was largely moderate.
toxicity
carboplatin
0
$T1$ (leukopenia, granulocytopenia, and thrombocytopenia).Neurotoxicity was largely moderate.
myelosuppression
carboplatin
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
toxicity
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
myelosuppression
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
leukopenia
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
granulocytopenia
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
thrombocytopenia
0
$T1$, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.
ovarian cancer
Neurotoxicity
0
$T1$ of the combination was $T2$
toxicity
myelosuppression
0
$T1$ of the combination was myelosuppression ($T2$
toxicity
leukopenia
0
$T1$ of the combination was myelosuppression (leukopenia, $T2$
toxicity
granulocytopenia
0
$T1$ of the combination was myelosuppression (leukopenia, granulocytopenia, and $T2$
toxicity
thrombocytopenia
0
$T1$ of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).$T2$
toxicity
Neurotoxicity
0
$T1$ ($T2$
myelosuppression
leukopenia
0
$T1$ (leukopenia, $T2$
myelosuppression
granulocytopenia
0
$T1$ (leukopenia, granulocytopenia, and $T2$
myelosuppression
thrombocytopenia
0
$T1$ (leukopenia, granulocytopenia, and thrombocytopenia).$T2$
myelosuppression
Neurotoxicity
0
$T1$, $T2$
leukopenia
granulocytopenia
0
$T1$, granulocytopenia, and $T2$
leukopenia
thrombocytopenia
0
$T1$, granulocytopenia, and thrombocytopenia).$T2$
leukopenia
Neurotoxicity
0
$T1$, and $T2$
granulocytopenia
thrombocytopenia
0
$T1$, and thrombocytopenia).$T2$
granulocytopenia
Neurotoxicity
0
$T1$).$T2$
thrombocytopenia
Neurotoxicity
0
$T1$ (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
hemolytic anemia
tacrolimus
1
$T1$ (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
IDDM
tacrolimus
1
$T1$ (1).All early-conversion patients showed improvement/resolution of symptoms.
pruritus
tacrolimus
1
$T1$) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
PTLD
tacrolimus
1
$T1$ (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
cardiomyopathy
tacrolimus
1
$T1$ (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
neurotoxicity
tacrolimus
1
$T1$ (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
GI toxicity
tacrolimus
1
$T1$ (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
hepatotoxicity
tacrolimus
1
$T1$ (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).All early-conversion patients showed improvement/resolution of symptoms.
nephrotoxicity
tacrolimus
1
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
tacrolimus
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
neurotoxicity
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
IDDM
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
nephrotoxicity
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
GI toxicity
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
cardiomyopathy
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
hepatotoxicity
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
PTLD
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
hemolytic anemia
0
$T1$-based immunosuppression (CyA) is necessary.We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion.
cyclosporine
pruritus
0
$T1$ (15), $T2$
neurotoxicity
IDDM
0
$T1$ (15), IDDM (12), $T2$
neurotoxicity
nephrotoxicity
0
$T1$ (15), IDDM (12), nephrotoxicity (3), $T2$
neurotoxicity
GI toxicity
0
$T1$ (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), $T2$
neurotoxicity
cardiomyopathy
0
$T1$ (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), $T2$
neurotoxicity
hepatotoxicity
0
$T1$ (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease ($T2$
neurotoxicity
PTLD
0
$T1$ (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), $T2$
neurotoxicity
hemolytic anemia
0
$T1$ (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and $T2$
neurotoxicity
pruritus
0
$T1$ (12), $T2$
IDDM
nephrotoxicity
0
$T1$ (12), nephrotoxicity (3), $T2$
IDDM
GI toxicity
0
$T1$ (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), $T2$
IDDM
cardiomyopathy
0
$T1$ (12), nephrotoxicity (3), GI toxicity (5), $T2$
IDDM
hepatotoxicity
0
$T1$ (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease ($T2$
IDDM
PTLD
0
$T1$ (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), $T2$
IDDM
hemolytic anemia
0
$T1$ (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and $T2$
IDDM
pruritus
0
$T1$ (3), $T2$
nephrotoxicity
GI toxicity
0
$T1$ (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), $T2$
nephrotoxicity
cardiomyopathy
0
$T1$ (3), GI toxicity (5), $T2$
nephrotoxicity
hepatotoxicity
0
$T1$ (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease ($T2$
nephrotoxicity
PTLD
0
$T1$ (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), $T2$
nephrotoxicity
hemolytic anemia
0
$T1$ (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and $T2$
nephrotoxicity
pruritus
0
$T1$ (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), $T2$
GI toxicity
cardiomyopathy
0
$T1$ (5), $T2$
GI toxicity
hepatotoxicity
0
$T1$ (5), hepatotoxicity (6), post-transplant lmphoproliferate disease ($T2$
GI toxicity
PTLD
0
$T1$ (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), $T2$
GI toxicity
hemolytic anemia
0
$T1$ (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and $T2$
GI toxicity
pruritus
0
$T1$ (6), post-transplant lmphoproliferate disease (PTLD) (2), $T2$
hepatotoxicity
cardiomyopathy
0
$T1$) (2), $T2$
PTLD
cardiomyopathy
0
$T1$ (1), $T2$
cardiomyopathy
hemolytic anemia
0
$T1$ (1), hemolytic anemia (1), and $T2$
cardiomyopathy
pruritus
0
$T1$ (6), post-transplant lmphoproliferate disease ($T2$
hepatotoxicity
PTLD
0
$T1$ (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), $T2$
hepatotoxicity
hemolytic anemia
0
$T1$ (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and $T2$
hepatotoxicity
pruritus
0
$T1$) (2), cardiomyopathy (1), $T2$
PTLD
hemolytic anemia
0
$T1$) (2), cardiomyopathy (1), hemolytic anemia (1), and $T2$
PTLD
pruritus
0
$T1$ (1), and $T2$
hemolytic anemia
pruritus
0
$T1$ was less severe and more often reversible with netilmicin than with $T2$
ototoxicity
tobramycin
1
$T1$ was less severe and more often reversible with $T2$
ototoxicity
netilmicin
1
$T1$ occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
Nephrotoxicity
netilmicin
1
$T1$-treated patients (18 of 78 vs 67 of 115).We conclude that aminoglycoside-associated $T2$
piperacillin
ototoxicity
1
$T1$ occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
Nephrotoxicity
piperacillin
1
$T1$ occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
Nephrotoxicity
tobramycin
1
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
toxicity
netilmicin
0
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
toxicity
tobramycin
0
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
toxicity
piperacillin
0
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe $T2$
toxicity
infections
0
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
toxicity
Nephrotoxicity
0
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
toxicity
ototoxicity
0
$T1$ of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
toxicity
aminoglycoside
0
$T1$ than with $T2$
netilmicin
tobramycin
0
$T1$-treated patients (18 of 78 vs 67 of 115).We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with $T2$
piperacillin
netilmicin
0
$T1$.The two treatment regimens were equally efficacious.
infections
netilmicin
0
$T1$-associated ototoxicity was less severe and more often reversible with $T2$
aminoglycoside
netilmicin
0
$T1$-treated patients (18 of 78 vs 67 of 115).We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with $T2$
piperacillin
tobramycin
0
$T1$.The two treatment regimens were equally efficacious.
infections
tobramycin
0
$T1$-associated ototoxicity was less severe and more often reversible with netilmicin than with $T2$
aminoglycoside
tobramycin
0
$T1$.The two treatment regimens were equally efficacious.
infections
piperacillin
0
$T1$-treated patients (18 of 78 vs 67 of 115).We conclude that $T2$
piperacillin
aminoglycoside
0
$T1$.The two treatment regimens were equally efficacious.
infections
Nephrotoxicity
0
$T1$.The two treatment regimens were equally efficacious.
infections
ototoxicity
0
$T1$.The two treatment regimens were equally efficacious.
infections
aminoglycoside
0
$T1$ occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
Nephrotoxicity
ototoxicity
0
$T1$ occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
Nephrotoxicity
aminoglycoside
0
$T1$-associated $T2$
aminoglycoside
ototoxicity
0
$T1$- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
fluorthyl
convulsions
1
$T1$-induced $T2$
bicuculline
convulsions
1
$T1$-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
PTZ
convulsions
1
$T1$-, electroshock-, or bicuculline-induced $T2$
picrotoxin
convulsions
1
$T1$ are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
PGs
convulsions
0
$T1$ are involved in the mechanism(s) underlying $T2$
PGs
fluorthyl
0
$T1$ are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not $T2$
PGs
picrotoxin
0
$T1$ are involved in the mechanism(s) underlying fluorthyl- and $T2$
PGs
PTZ
0
$T1$ are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
PGs
bicuculline
0
$T1$, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that $T2$
Ibuprofen
PGs
0
$T1$, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that $T2$
sulindac
PGs
0
$T1$, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that $T2$
mefenamic acid
PGs
0
$T1$ increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that $T2$
meclofenamic acid
PGs
0
$T1$, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
Ibuprofen
convulsions
0
$T1$, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
sulindac
convulsions
0
$T1$, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
mefenamic acid
convulsions
0
$T1$ increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced $T2$
meclofenamic acid
convulsions
0
$T1$- and PTZ-induced convulsions, but not $T2$
fluorthyl
picrotoxin
0
$T1$- and $T2$
fluorthyl
PTZ
0
$T1$- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
fluorthyl
bicuculline
0
$T1$, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying $T2$
Ibuprofen
fluorthyl
0
$T1$, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying $T2$
sulindac
fluorthyl
0
$T1$, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying $T2$
mefenamic acid
fluorthyl
0
$T1$ increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying $T2$
meclofenamic acid
fluorthyl
0
$T1$-induced convulsions, but not $T2$
PTZ
picrotoxin
0
$T1$-, electroshock-, or $T2$
picrotoxin
bicuculline
0
$T1$, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not $T2$
Ibuprofen
picrotoxin
0
$T1$, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not $T2$
sulindac
picrotoxin
0
$T1$, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not $T2$
mefenamic acid
picrotoxin
0
$T1$ increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not $T2$
meclofenamic acid
picrotoxin
0
$T1$-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
PTZ
bicuculline
0
$T1$, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and $T2$
Ibuprofen
PTZ
0
$T1$, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and $T2$
sulindac
PTZ
0
$T1$, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and $T2$
mefenamic acid
PTZ
0
$T1$ increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and $T2$
meclofenamic acid
PTZ
0
$T1$, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
Ibuprofen
bicuculline
0
$T1$, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
sulindac
bicuculline
0
$T1$, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
mefenamic acid
bicuculline
0
$T1$ increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or $T2$
meclofenamic acid
bicuculline
0
$T1$, $T2$
Ibuprofen
sulindac
0
$T1$, sulindac, $T2$
Ibuprofen
mefenamic acid
0
$T1$, sulindac, mefenamic acid, and low dose $T2$
Ibuprofen
meclofenamic acid
0
$T1$, $T2$
sulindac
mefenamic acid
0
$T1$, mefenamic acid, and low dose $T2$
sulindac
meclofenamic acid
0
$T1$, and low dose $T2$
mefenamic acid
meclofenamic acid
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
benazapril
angioedema
1
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
amlodipine
angioedema
1
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
benazapril
intestinal angioedema
1
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
amlodipine
intestinal angioedema
1
$T1$ was suspected, and anti-$T2$
angioedema
hypertensive
0
$T1$, nausea and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
abdominal pain
angioedema
0
$T1$ and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
nausea
angioedema
0
$T1$.Physical exam, complete metabolic panel, and hemogram were in the normal range.
vomiting
angioedema
0
$T1$ was suspected, and anti-hypertensive medications were discontinued.Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of $T2$
angioedema
ascites
0
$T1$ was suspected, and anti-hypertensive medications were discontinued.Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.
angioedema
angiotensin
0
$T1$ was suspected, and anti-hypertensive medications were discontinued.Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.
angioedema
intestinal angioedema
0
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
amlodipine
hypertensive
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
benazapril
hypertensive
0
$T1$, nausea and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
abdominal pain
hypertensive
0
$T1$ and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
nausea
hypertensive
0
$T1$.Physical exam, complete metabolic panel, and hemogram were in the normal range.
vomiting
hypertensive
0
$T1$ medications were discontinued.Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of $T2$
hypertensive
ascites
0
$T1$ medications were discontinued.Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.
hypertensive
angiotensin
0
$T1$ medications were discontinued.Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.
hypertensive
intestinal angioedema
0
$T1$/$T2$
amlodipine
benazapril
0
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with $T2$
amlodipine
abdominal pain
0
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, $T2$
amlodipine
nausea
0
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and $T2$
amlodipine
vomiting
0
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
amlodipine
ascites
0
$T1$/benazapril 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
amlodipine
angiotensin
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with $T2$
benazapril
abdominal pain
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, $T2$
benazapril
nausea
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and $T2$
benazapril
vomiting
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
benazapril
ascites
0
$T1$ 10/5 mg.The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.
benazapril
angiotensin
0
$T1$, $T2$
abdominal pain
nausea
0
$T1$, nausea and $T2$
abdominal pain
vomiting
0
$T1$, nausea and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
abdominal pain
ascites
0
$T1$, nausea and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
abdominal pain
angiotensin
0
$T1$, nausea and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
abdominal pain
intestinal angioedema
0
$T1$ and $T2$
nausea
vomiting
0
$T1$ and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
nausea
ascites
0
$T1$ and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
nausea
angiotensin
0
$T1$ and vomiting.Physical exam, complete metabolic panel, and hemogram were in the normal range.
nausea
intestinal angioedema
0
$T1$.Physical exam, complete metabolic panel, and hemogram were in the normal range.
vomiting
ascites
0
$T1$.Physical exam, complete metabolic panel, and hemogram were in the normal range.
vomiting
angiotensin
0
$T1$.Physical exam, complete metabolic panel, and hemogram were in the normal range.
vomiting
intestinal angioedema
0
$T1$.The recognition of angiotensin-converting enzyme (ACE) and $T2$
ascites
angiotensin
0
$T1$.The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) $T2$
ascites
intestinal angioedema
0
$T1$ receptor blocker (ARB) $T2$
angiotensin
intestinal angioedema
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
hepatotoxicity
1
$T1$ treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, $T2$
VPA
steatosis
1
$T1$ treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of $T2$
VPA
necrosis
1
$T1$ as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
hepatotoxicity
15-F(2t)-IsoP
1
$T1$ as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
hepatotoxicity
VPA
1
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
hepatotoxicity
1
$T1$ treatment results in oxidative stress, as measured by levels of $T2$
VPA
15-F(2t)-IsoP
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
VPA
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
VPA
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
glutathione
VPA
0
$T1$ of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
inflammation
VPA
0
$T1$ and (E)-2,4-diene-VPA were not elevated throughout the study.Overall, these findings indicate that $T2$
4-ene-VPA
VPA
0
$T1$ were not elevated throughout the study.Overall, these findings indicate that $T2$
2,4-diene-VPA
VPA
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to $T2$
glutathione
hepatotoxicity
0
$T1$ as shown by the increasing incidence of $T2$
hepatotoxicity
inflammation
0
$T1$ as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
hepatotoxicity
necrosis
0
$T1$ as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
hepatotoxicity
steatosis
0
$T1$ as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of $T2$
hepatotoxicity
4-ene-VPA
0
$T1$ as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-$T2$
hepatotoxicity
2,4-diene-VPA
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
15-F(2t)-IsoP
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
15-F(2t)-IsoP
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
glutathione
15-F(2t)-IsoP
0
$T1$ of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
inflammation
15-F(2t)-IsoP
0
$T1$, which precedes the onset of $T2$
15-F(2t)-IsoP
necrosis
0
$T1$, which precedes the onset of necrosis, $T2$
15-F(2t)-IsoP
steatosis
0
$T1$ and (E)-2,4-diene-VPA were not elevated throughout the study.Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of $T2$
4-ene-VPA
15-F(2t)-IsoP
0
$T1$ were not elevated throughout the study.Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of $T2$
2,4-diene-VPA
15-F(2t)-IsoP
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma $T2$
LPO
TBARs
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
glutathione
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
inflammation
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
necrosis
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
steatosis
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
4-ene-VPA
0
$T1$ levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05).Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).
LPO
2,4-diene-VPA
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-$T2$
TBARs
glutathione
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
inflammation
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
necrosis
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
steatosis
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
4-ene-VPA
0
$T1$ were not increased until 14 days (2-fold vs. control, p < 0.05).Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
TBARs
2,4-diene-VPA
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of $T2$
glutathione
inflammation
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
glutathione
necrosis
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
glutathione
steatosis
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
glutathione
4-ene-VPA
0
$T1$ S-transferase (alpha-GST) and by histology.Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.
glutathione
2,4-diene-VPA
0
$T1$ of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
inflammation
necrosis
0
$T1$ of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.
inflammation
steatosis
0
$T1$ of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of $T2$
inflammation
4-ene-VPA
0
$T1$ of the liver capsule, necrosis, and steatosis throughout the study.The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-$T2$
inflammation
2,4-diene-VPA
0
$T1$, $T2$
necrosis
steatosis
0
$T1$ and (E)-2,4-diene-VPA were not elevated throughout the study.Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of $T2$
4-ene-VPA
necrosis
0
$T1$ were not elevated throughout the study.Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of $T2$
2,4-diene-VPA
necrosis
0
$T1$ and (E)-2,4-diene-VPA were not elevated throughout the study.Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, $T2$
4-ene-VPA
steatosis
0
$T1$ were not elevated throughout the study.Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, $T2$
2,4-diene-VPA
steatosis
0
$T1$ and (E)-$T2$
4-ene-VPA
2,4-diene-VPA
0
$T1$ crisis in a patient with pheochromocytoma.Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and $T2$
hypertensive
amisulpride
1
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
vomiting
amisulpride
1
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
headache
amisulpride
1
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
vomiting
tiapride
1
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
headache
tiapride
1
$T1$ crisis in a patient with pheochromocytoma.Physicians and other healthcare professionals should be aware of this potential adverse effect of $T2$
hypertensive
tiapride
1
$T1$.Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and $T2$
pheochromocytoma
amisulpride
0
$T1$.Physicians and other healthcare professionals should be aware of this potential adverse effect of $T2$
pheochromocytoma
tiapride
0
$T1$ crisis in a patient with $T2$
hypertensive
pheochromocytoma
0
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
headache
pheochromocytoma
0
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
vomiting
pheochromocytoma
0
$T1$ and verapamil treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
nicardipine
pheochromocytoma
0
$T1$ treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
verapamil
pheochromocytoma
0
$T1$ drugs, but the underlying mechanism is unknown.In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
benzamide
pheochromocytoma
0
$T1$ and $T2$
tiapride
amisulpride
0
$T1$ and verapamil treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
nicardipine
amisulpride
0
$T1$ treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
verapamil
amisulpride
0
$T1$ drugs, but the underlying mechanism is unknown.In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
benzamide
amisulpride
0
$T1$ and verapamil treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
nicardipine
tiapride
0
$T1$ treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
verapamil
tiapride
0
$T1$ drugs, but the underlying mechanism is unknown.In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
benzamide
tiapride
0
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
headache
hypertensive
0
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
vomiting
hypertensive
0
$T1$ and verapamil treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
nicardipine
hypertensive
0
$T1$ treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
verapamil
hypertensive
0
$T1$ drugs, but the underlying mechanism is unknown.In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
benzamide
hypertensive
0
$T1$ and $T2$
headache
vomiting
0
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent $T2$
headache
nicardipine
0
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and $T2$
headache
verapamil
0
$T1$ and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
headache
benzamide
0
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent $T2$
vomiting
nicardipine
0
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and $T2$
vomiting
verapamil
0
$T1$ 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.
vomiting
benzamide
0
$T1$ and $T2$
nicardipine
verapamil
0
$T1$ and verapamil treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
nicardipine
benzamide
0
$T1$ treatment.Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.
verapamil
benzamide
0
$T1$ levels were related to several psychopathology scores and the global hyperkinesia rating.HVA levels were related to global $T2$
amphetamine
hyperkinesia
1
$T1$-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
cocaine
hyperkinesia
1
$T1$ or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.HVA levels were related to global hyperkinesia but not to psychopathology ratings.
Methamphetamine
psychotic symptoms
1
$T1$-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
cocaine
psychotic symptoms
1
$T1$ or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.HVA levels were related to global $T2$
Methamphetamine
hyperkinesia
1
$T1$ levels were related to several psychopathology scores and the global hyperkinesia rating.HVA levels were related to global hyperkinesia but not to psychopathology ratings.
amphetamine
psychotic symptoms
1
$T1$ metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
catecholamine
psychotic symptoms
0
$T1$ but not to psychopathology ratings.Although many other factors such as sensitization may play a role, intensity of stimulant-induced $T2$
hyperkinesia
psychotic symptoms
0
$T1$ emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
psychiatric
psychotic symptoms
0
$T1$ and $T2$
psychotic symptoms
stereotypies
0
$T1$ metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
catecholamine
hyperkinesia
0
$T1$ emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and $T2$
psychiatric
catecholamine
0
$T1$ metabolite levels.Methamphetamine or $T2$
catecholamine
amphetamine
0
$T1$-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and $T2$
cocaine
catecholamine
0
$T1$ metabolite levels.$T2$
catecholamine
Methamphetamine
0
$T1$ metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
catecholamine
stereotypies
0
$T1$ emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
psychiatric
hyperkinesia
0
$T1$ but not to psychopathology ratings.Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and $T2$
hyperkinesia
stereotypies
0
$T1$ emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or $T2$
psychiatric
amphetamine
0
$T1$ emergency service with a diagnosis of amphetamine- or $T2$
psychiatric
cocaine
0
$T1$ emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.$T2$
psychiatric
Methamphetamine
0
$T1$ emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
psychiatric
stereotypies
0
$T1$-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or $T2$
cocaine
amphetamine
0
$T1$ or $T2$
Methamphetamine
amphetamine
0
$T1$ levels were related to several psychopathology scores and the global hyperkinesia rating.HVA levels were related to global hyperkinesia but not to psychopathology ratings.
amphetamine
stereotypies
0
$T1$-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.$T2$
cocaine
Methamphetamine
0
$T1$-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
cocaine
stereotypies
0
$T1$ or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.HVA levels were related to global hyperkinesia but not to psychopathology ratings.
Methamphetamine
stereotypies
0
$T1$ $T2$
diltiazem
overdose
1
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
diltiazem
1
$T1$ after $T2$
cardiac arrest
diltiazem
1
$T1$, unrecordable blood pressure, and then became asystolic.He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).
bradycardia
diltiazem
1
$T1$ after diltiazem $T2$
cardiac arrest
overdose
0
$T1$ therapy in severe diltiazem overdose, particularly with the onset of asystole.It should be considered early in cases of $T2$
calcium
cardiac arrest
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
cardiac arrest
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
cardiac arrest
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
cardiac arrest
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
cardiac arrest
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
cardiac arrest
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
cardiac arrest
0
$T1$.The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.
tonic-clonic seizures
cardiac arrest
0
$T1$, unrecordable blood pressure, and then became asystolic.He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).
bradycardia
cardiac arrest
0
$T1$).He required inotropic support and temporary pacing over the next 48 hours.
epinephrine
cardiac arrest
0
$T1$ after diltiazem overdose.The case also highlights the problems with delayed $T2$
cardiac arrest
toxicity
0
$T1$ therapy in severe diltiazem overdose, particularly with the onset of asystole.It should be considered early in cases of cardiac arrest after $T2$
calcium
diltiazem
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
diltiazem
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
diltiazem
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
diltiazem
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
diltiazem
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
diltiazem
0
$T1$.The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.
tonic-clonic seizures
diltiazem
0
$T1$).He required inotropic support and temporary pacing over the next 48 hours.
epinephrine
diltiazem
0
$T1$ overdose.The case also highlights the problems with delayed $T2$
diltiazem
toxicity
0
$T1$ therapy in severe diltiazem overdose, particularly with the onset of asystole.It should be considered early in cases of cardiac arrest after diltiazem $T2$
calcium
overdose
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
overdose
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
overdose
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
overdose
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
overdose
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
overdose
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
overdose
0
$T1$.The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.
tonic-clonic seizures
overdose
0
$T1$, unrecordable blood pressure, and then became asystolic.He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).
bradycardia
overdose
0
$T1$).He required inotropic support and temporary pacing over the next 48 hours.
epinephrine
overdose
0
$T1$.The case also highlights the problems with delayed $T2$
overdose
toxicity
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
calcium
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
calcium
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
calcium
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
calcium
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
calcium
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
calcium
0
$T1$.The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.
tonic-clonic seizures
calcium
0
$T1$, unrecordable blood pressure, and then became asystolic.He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).
bradycardia
calcium
0
$T1$).He required inotropic support and temporary pacing over the next 48 hours.
epinephrine
calcium
0
$T1$ therapy in severe diltiazem overdose, particularly with the onset of asystole.It should be considered early in cases of cardiac arrest after diltiazem overdose.
calcium
toxicity
0
$T1$, $T2$
paracetamol
aspirin
0
$T1$, aspirin, $T2$
paracetamol
isosorbide
0
$T1$, aspirin, isosorbide $T2$
paracetamol
nitrate
0
$T1$, aspirin, isosorbide nitrate, and $T2$
paracetamol
alcohol
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild $T2$
paracetamol
hypotension
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
tonic-clonic seizures
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
bradycardia
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
epinephrine
0
$T1$, aspirin, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
paracetamol
toxicity
0
$T1$, $T2$
aspirin
isosorbide
0
$T1$, isosorbide $T2$
aspirin
nitrate
0
$T1$, isosorbide nitrate, and $T2$
aspirin
alcohol
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild $T2$
aspirin
hypotension
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
tonic-clonic seizures
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
bradycardia
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
epinephrine
0
$T1$, isosorbide nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
aspirin
toxicity
0
$T1$ $T2$
isosorbide
nitrate
0
$T1$ nitrate, and $T2$
isosorbide
alcohol
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild $T2$
isosorbide
hypotension
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
tonic-clonic seizures
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
bradycardia
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
epinephrine
0
$T1$ nitrate, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
isosorbide
toxicity
0
$T1$, and $T2$
nitrate
alcohol
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild $T2$
nitrate
hypotension
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
tonic-clonic seizures
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
bradycardia
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
epinephrine
0
$T1$, and alcohol.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
nitrate
toxicity
0
$T1$.He initially presented to hospital after six hours with mild $T2$
alcohol
hypotension
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
tonic-clonic seizures
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
bradycardia
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
epinephrine
0
$T1$.He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.
alcohol
toxicity
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised $T2$
hypotension
tonic-clonic seizures
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
bradycardia
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
epinephrine
0
$T1$ and was treated with activated charcoal and intravenous fluids.Eighteen hours after the overdose he had two generalised tonic-clonic seizures.
hypotension
toxicity
0
$T1$.The patient remained unresponsive with junctional $T2$
tonic-clonic seizures
bradycardia
0
$T1$.The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.
tonic-clonic seizures
epinephrine
0
$T1$.The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.
tonic-clonic seizures
toxicity
0
$T1$, unrecordable blood pressure, and then became asystolic.He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline ($T2$
bradycardia
epinephrine
0
$T1$, unrecordable blood pressure, and then became asystolic.He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).
bradycardia
toxicity
0
$T1$).He required inotropic support and temporary pacing over the next 48 hours.
epinephrine
toxicity
0
$T1$ and no further adverse renal effects occurred over the next 12 months.We review previous reports linking $T2$
naproxen
RPN
1
$T1$, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
rheumatoid arthritis
RPN
0
$T1$ to antiinflammatory drug use and discuss possible advantages of $T2$
RPN
sulindac
0
$T1$, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
fenoprofen calcium
RPN
0
$T1$ and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
salicylates
RPN
0
$T1$ salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
gold
RPN
0
$T1$ to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced $T2$
RPN
renal toxicity
0
$T1$, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
rheumatoid arthritis
naproxen
0
$T1$ and no further adverse renal effects occurred over the next 12 months.We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of $T2$
naproxen
sulindac
0
$T1$, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
fenoprofen calcium
naproxen
0
$T1$ and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
salicylates
naproxen
0
$T1$ salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
gold
naproxen
0
$T1$ and no further adverse renal effects occurred over the next 12 months.We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced $T2$
naproxen
renal toxicity
0
$T1$, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
rheumatoid arthritis
sulindac
0
$T1$, who had previously been treated with sulindac, $T2$
rheumatoid arthritis
fenoprofen calcium
0
$T1$, who had previously been treated with sulindac, fenoprofen calcium, high dose $T2$
rheumatoid arthritis
salicylates
0
$T1$, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and $T2$
rheumatoid arthritis
gold
0
$T1$, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
rheumatoid arthritis
renal toxicity
0
$T1$, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
fenoprofen calcium
sulindac
0
$T1$ and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
salicylates
sulindac
0
$T1$ salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
gold
sulindac
0
$T1$ in patients who have experienced $T2$
sulindac
renal toxicity
0
$T1$, high dose $T2$
fenoprofen calcium
salicylates
0
$T1$, high dose salicylates and $T2$
fenoprofen calcium
gold
0
$T1$, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
fenoprofen calcium
renal toxicity
0
$T1$ and $T2$
salicylates
gold
0
$T1$ and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
salicylates
renal toxicity
0
$T1$ salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.No other factor predisposing to RPN could be discovered.
gold
renal toxicity
0
$T1$ and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
hypotension
verapamil
1
$T1$, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
cardiac failure
beta-adrenergic blocking drugs
1
$T1$ during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
bradycardia
verapamil
1
$T1$, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
cardiac failure
verapamil
1
$T1$ and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
hypotension
beta-adrenergic blocking drugs
1
$T1$ during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
bradycardia
beta-adrenergic blocking drugs
1
$T1$ and $T2$
beta-adrenergic blocking drugs
verapamil
0
$T1$ developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
ischaemic heart disease
beta-adrenergic blocking drugs
0
$T1$ developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.This clinical picture resolved completely with cessation of the combined therapy.
ischaemic heart disease
verapamil
0
$T1$ developed profound $T2$
ischaemic heart disease
cardiac failure
0
$T1$ developed profound cardiac failure, $T2$
ischaemic heart disease
hypotension
0
$T1$ developed profound cardiac failure, hypotension and $T2$
ischaemic heart disease
bradycardia
0
$T1$, $T2$
cardiac failure
hypotension
0
$T1$, hypotension and $T2$
cardiac failure
bradycardia
0
$T1$ and $T2$
hypotension
bradycardia
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
impotence
bendrofluazide
1
$T1$ and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
Raynaud's phenomenon
propranolol
1
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
impaired glucose tolerance
bendrofluazide
1
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
gout
bendrofluazide
1
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
impotence
propranolol
1
$T1$ in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
dyspnoea
propranolol
1
$T1$.In the $T2$
bendrofluazide
propranolol
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
bendrofluazide
0
$T1$ and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
Raynaud's phenomenon
bendrofluazide
0
$T1$ in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
dyspnoea
bendrofluazide
0
$T1$ is known to have occurred in the propranolol group.Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking $T2$
corneal disease
bendrofluazide
0
$T1$.In the propranolol group, serum $T2$
bendrofluazide
potassium
0
$T1$.In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the $T2$
bendrofluazide
urea
0
$T1$.In the propranolol group, serum potassium and $T2$
bendrofluazide
uric acid
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
propranolol
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
impaired glucose tolerance
propranolol
0
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
gout
propranolol
0
$T1$ is known to have occurred in the propranolol group.Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.
corneal disease
propranolol
0
$T1$ group, serum $T2$
propranolol
potassium
0
$T1$ group, serum potassium and uric acid levels rose in both sexes, but the $T2$
propranolol
urea
0
$T1$ group, serum potassium and $T2$
propranolol
uric acid
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
impotence
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
impaired glucose tolerance
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
gout
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
Raynaud's phenomenon
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
dyspnoea
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
corneal disease
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
potassium
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
urea
0
$T1$ are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.The trial is single-blind.
hypertension
uric acid
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include $T2$
impotence
impaired glucose tolerance
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and $T2$
impotence
gout
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and $T2$
impotence
Raynaud's phenomenon
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and $T2$
impotence
dyspnoea
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
impotence
corneal disease
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
impotence
potassium
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
impotence
urea
0
$T1$ also occurred more frequently in patients taking propranolol than in those taking placebos.Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
impotence
uric acid
0
$T1$ in men and women and $T2$
impaired glucose tolerance
gout
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and $T2$
impaired glucose tolerance
Raynaud's phenomenon
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and $T2$
impaired glucose tolerance
dyspnoea
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No $T2$
impaired glucose tolerance
corneal disease
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
impaired glucose tolerance
potassium
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
impaired glucose tolerance
urea
0
$T1$ in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
impaired glucose tolerance
uric acid
0
$T1$ in men, associated with bendrofluazide treatment, and $T2$
gout
Raynaud's phenomenon
0
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and $T2$
gout
dyspnoea
0
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No $T2$
gout
corneal disease
0
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
gout
potassium
0
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
gout
urea
0
$T1$ in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
gout
uric acid
0
$T1$ and $T2$
Raynaud's phenomenon
dyspnoea
0
$T1$ and dyspnoea in men and women taking propranolol.No $T2$
Raynaud's phenomenon
corneal disease
0
$T1$ and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
Raynaud's phenomenon
potassium
0
$T1$ and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
Raynaud's phenomenon
urea
0
$T1$ and dyspnoea in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
Raynaud's phenomenon
uric acid
0
$T1$ in men and women taking propranolol.No $T2$
dyspnoea
corneal disease
0
$T1$ in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
dyspnoea
potassium
0
$T1$ in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
dyspnoea
urea
0
$T1$ in men and women taking propranolol.No corneal disease is known to have occurred in the propranolol group.
dyspnoea
uric acid
0
$T1$ is known to have occurred in the propranolol group.Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.
corneal disease
potassium
0
$T1$ is known to have occurred in the propranolol group.Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.
corneal disease
urea
0
$T1$ is known to have occurred in the propranolol group.Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.
corneal disease
uric acid
0
$T1$ and uric acid levels rose in both sexes, but the $T2$
potassium
urea
0
$T1$ and $T2$
potassium
uric acid
0
$T1$ levels rose in both sexes, but the $T2$
uric acid
urea
0
$T1$ (p = 0.43).A randomised placebo-controlled trial of $T2$
bradycardia
dexmedetomidine
1
$T1$ (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.An anticholinergic did not reduce the incidence of bradycardia (p = 0.43).
hypotension
dexmedetomidine
1
$T1$ (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.
myocardial infarction
dexmedetomidine
0
$T1$ (OR 0.65, 95% CI 0.26-1.63, p = 0.36).Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.
myocardial ischaemia
dexmedetomidine
0
$T1$ (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and $T2$
myocardial infarction
myocardial ischaemia
0
$T1$ (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).Peri-operative $T2$
myocardial infarction
hypotension
0
$T1$ (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.
myocardial infarction
bradycardia
0
$T1$ (OR 0.65, 95% CI 0.26-1.63, p = 0.36).Peri-operative $T2$
myocardial ischaemia
hypotension
0
$T1$ (OR 0.65, 95% CI 0.26-1.63, p = 0.36).Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.
myocardial ischaemia
bradycardia
0
$T1$ (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.An anticholinergic did not reduce the incidence of $T2$
hypotension
bradycardia
0
$T1$ and muscular atrophy.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular weakness
chloroquine
1
$T1$.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular atrophy
chloroquine
1
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
SLE
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
chloroquine
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
myopathy
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
creatine
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
creatine
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
creatine
0
$T1$.At the same time, slightly increased $T2$
arthralgia
creatine
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
myositis
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with $T2$
creatine
steroids
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
muscular weakness
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
muscular atrophy
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
polymyositis
0
$T1$ kinase (CK) levels were noted.Myositis was suspected, and the patient was treated with steroids.
creatine
affection of the musculoskeletal system
0
$T1$-induced myopathy, medication was stopped.Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of $T2$
chloroquine
SLE
0
$T1$, medication was stopped.Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of $T2$
myopathy
SLE
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
SLE
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
SLE
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
SLE
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
SLE
0
$T1$.Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.
myositis
SLE
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.
steroids
SLE
0
$T1$ and muscular atrophy.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular weakness
SLE
0
$T1$.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular atrophy
SLE
0
$T1$ or toxic myopathy.As it revealed chloroquine-induced myopathy, medication was stopped.
polymyositis
SLE
0
$T1$ and drug-induced side effects is important for appropriate treatment of $T2$
affection of the musculoskeletal system
SLE
0
$T1$-induced $T2$
chloroquine
myopathy
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
chloroquine
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
chloroquine
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
chloroquine
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
chloroquine
0
$T1$.Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.
myositis
chloroquine
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.
steroids
chloroquine
0
$T1$ or toxic myopathy.As it revealed $T2$
polymyositis
chloroquine
0
$T1$-induced myopathy, medication was stopped.Discriminating between primary SLE-induced $T2$
chloroquine
affection of the musculoskeletal system
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
myopathy
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
myopathy
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
myopathy
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
myopathy
0
$T1$.Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.
myositis
myopathy
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.
steroids
myopathy
0
$T1$ and muscular atrophy.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular weakness
myopathy
0
$T1$.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular atrophy
myopathy
0
$T1$ or toxic myopathy.As it revealed chloroquine-induced $T2$
polymyositis
myopathy
0
$T1$, medication was stopped.Discriminating between primary SLE-induced $T2$
myopathy
affection of the musculoskeletal system
0
$T1$ and undergone periods of treatment with $T2$
renal involvement
azathioprine
0
$T1$ and undergone periods of treatment with azathioprine and $T2$
renal involvement
cyclophosphamide
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of $T2$
renal involvement
arthralgia
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
myositis
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
steroids
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
muscular weakness
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
muscular atrophy
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
polymyositis
0
$T1$ and undergone periods of treatment with azathioprine and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
renal involvement
affection of the musculoskeletal system
0
$T1$ and $T2$
azathioprine
cyclophosphamide
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of $T2$
azathioprine
arthralgia
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
myositis
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
steroids
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
muscular weakness
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
muscular atrophy
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
polymyositis
0
$T1$ and cyclophosphamide.Additional therapy with chloroquine (CQ) was started because of arthralgia.
azathioprine
affection of the musculoskeletal system
0
$T1$.Additional therapy with chloroquine (CQ) was started because of $T2$
cyclophosphamide
arthralgia
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
myositis
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
steroids
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
muscular weakness
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
muscular atrophy
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
polymyositis
0
$T1$.Additional therapy with chloroquine (CQ) was started because of arthralgia.
cyclophosphamide
affection of the musculoskeletal system
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
myositis
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
steroids
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
muscular weakness
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
muscular atrophy
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
polymyositis
0
$T1$.At the same time, slightly increased creatine kinase (CK) levels were noted.
arthralgia
affection of the musculoskeletal system
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.
steroids
myositis
0
$T1$ and muscular atrophy.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular weakness
myositis
0
$T1$.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular atrophy
myositis
0
$T1$.Thus, muscle biopsy of the deltoid muscle was performed in order to exclude $T2$
myositis
polymyositis
0
$T1$.Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.
myositis
affection of the musculoskeletal system
0
$T1$.The CK increase persisted, however, and she developed progressive $T2$
steroids
muscular weakness
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and $T2$
steroids
muscular atrophy
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.
steroids
polymyositis
0
$T1$.The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.
steroids
affection of the musculoskeletal system
0
$T1$ and $T2$
muscular weakness
muscular atrophy
0
$T1$ and muscular atrophy.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular weakness
polymyositis
0
$T1$ and muscular atrophy.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular weakness
affection of the musculoskeletal system
0
$T1$.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular atrophy
polymyositis
0
$T1$.Routine controls revealed markedly elevated CK levels of 1,700 U/l.
muscular atrophy
affection of the musculoskeletal system
0
$T1$ or toxic myopathy.As it revealed chloroquine-induced myopathy, medication was stopped.
polymyositis
affection of the musculoskeletal system
0
$T1$ in 1 child was associated with $T2$
cidofovir
progressive renal failure
1
$T1$ in 1 child was associated with progressive renal failure and $T2$
cidofovir
neutropenia
1
$T1$ in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous $T2$
adenovirus disease
ribavirin
0
$T1$ in 1 child was associated with progressive renal failure and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
cidofovir
ribavirin
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
ribavirin
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
ribavirin
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
ribavirin
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
ribavirin
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
ribavirin
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
ribavirin
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
ribavirin
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
ribavirin
0
$T1$ and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
progressive renal failure
ribavirin
0
$T1$.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
neutropenia
ribavirin
0
$T1$.Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.
immunodeficiency
ribavirin
0
$T1$.Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.
infection
ribavirin
0
$T1$ in 1 child was associated with progressive renal failure and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
cidofovir
adenovirus disease
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
adenovirus disease
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
adenovirus disease
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
adenovirus disease
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
adenovirus disease
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
adenovirus disease
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
adenovirus disease
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
adenovirus disease
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
adenovirus disease
0
$T1$ and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
progressive renal failure
adenovirus disease
0
$T1$.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
neutropenia
adenovirus disease
0
$T1$.Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.
immunodeficiency
adenovirus disease
0
$T1$.Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.
infection
adenovirus disease
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
cidofovir
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
cidofovir
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
cidofovir
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
cidofovir
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
cidofovir
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
cidofovir
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
cidofovir
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
cidofovir
0
$T1$ in 1 child was associated with progressive renal failure and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with $T2$
cidofovir
immunodeficiency
0
$T1$ in 1 child was associated with progressive renal failure and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
cidofovir
infection
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of $T2$
guanosine
respiratory syncytial virus infection
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat $T2$
guanosine
hepatitis C
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for $T2$
guanosine
infection with hemorrhagic fever viruses
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
anemia
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
nephrotoxicity
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
hemorrhagic cystitis
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
DiGeorge syndrome
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
progressive renal failure
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
neutropenia
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
immunodeficiency
0
$T1$ analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
guanosine
infection
0
$T1$, and orally in combination with interferon to treat $T2$
respiratory syncytial virus infection
hepatitis C
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for $T2$
respiratory syncytial virus infection
infection with hemorrhagic fever viruses
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild $T2$
respiratory syncytial virus infection
anemia
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
nephrotoxicity
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
hemorrhagic cystitis
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
DiGeorge syndrome
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
progressive renal failure
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
neutropenia
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
immunodeficiency
0
$T1$, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
respiratory syncytial virus infection
infection
0
$T1$.Intravenous ribavirin is the treatment of choice for $T2$
hepatitis C
infection with hemorrhagic fever viruses
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
anemia
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
nephrotoxicity
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
hemorrhagic cystitis
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
DiGeorge syndrome
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
progressive renal failure
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
neutropenia
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
immunodeficiency
0
$T1$.Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
hepatitis C
infection
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild $T2$
infection with hemorrhagic fever viruses
anemia
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
nephrotoxicity
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
hemorrhagic cystitis
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
DiGeorge syndrome
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
progressive renal failure
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
neutropenia
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
immunodeficiency
0
$T1$.The most common adverse effect of intravenous ribavirin is reversible mild anemia.
infection with hemorrhagic fever viruses
infection
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is $T2$
anemia
nephrotoxicity
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
hemorrhagic cystitis
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
DiGeorge syndrome
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
progressive renal failure
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
neutropenia
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
immunodeficiency
0
$T1$.The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
anemia
infection
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
hemorrhagic cystitis
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
DiGeorge syndrome
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
progressive renal failure
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
neutropenia
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
immunodeficiency
0
$T1$.OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
nephrotoxicity
infection
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
hemorrhagic cystitis
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
progressive renal failure
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
neutropenia
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
immunodeficiency
0
$T1$ and the immunocompetent neonate with adenovirus pneumonia.The remaining 3 children died of adenovirus disease.
hemorrhagic cystitis
infection
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
progressive renal failure
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
neutropenia
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
immunodeficiency
0
$T1$.The remaining infant had recently undergone a cardiac transplant.
DiGeorge syndrome
infection
0
$T1$ and $T2$
progressive renal failure
neutropenia
0
$T1$ and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with $T2$
progressive renal failure
immunodeficiency
0
$T1$ and neutropenia.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
progressive renal failure
infection
0
$T1$.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with $T2$
neutropenia
immunodeficiency
0
$T1$.DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.
neutropenia
infection
0
$T1$.Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the $T2$
immunodeficiency
infection
0
$T1$ should be regularly screened with respect to hepatic enzyme levels.Therapy should be discontinued on the suspicion of $T2$
amiodarone
cholestatic injury
1
$T1$ due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving $T2$
hepatic injury
amiodarone
1
$T1$.Patients receiving $T2$
cirrhosis of the liver
amiodarone
1
$T1$, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving $T2$
steatosis
amiodarone
1
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
hepatic injury
0
$T1$ due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
hepatic injury
cholestatic injury
0
$T1$ due to amiodarone treatment, including $T2$
hepatic injury
steatosis
0
$T1$ due to amiodarone treatment, including steatosis, alterations resembling $T2$
hepatic injury
alcoholic hepatitis
0
$T1$ due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular $T2$
hepatic injury
cirrhosis of the liver
0
$T1$ due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
hepatic injury
hepatomegaly
0
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
amiodarone
0
$T1$, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving $T2$
alcoholic hepatitis
amiodarone
0
$T1$ should be regularly screened with respect to hepatic enzyme levels.Therapy should be discontinued on the suspicion of cholestatic injury or $T2$
amiodarone
hepatomegaly
0
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
cholestatic injury
0
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
steatosis
0
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
alcoholic hepatitis
0
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
cirrhosis of the liver
0
$T1$.The use of amiodarone has, however, been limited due to its serious side-effects.
tachyarrhythmias
hepatomegaly
0
$T1$, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
steatosis
cholestatic injury
0
$T1$, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
alcoholic hepatitis
cholestatic injury
0
$T1$.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
cirrhosis of the liver
cholestatic injury
0
$T1$ or $T2$
cholestatic injury
hepatomegaly
0
$T1$, alterations resembling $T2$
steatosis
alcoholic hepatitis
0
$T1$, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular $T2$
steatosis
cirrhosis of the liver
0
$T1$, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
steatosis
hepatomegaly
0
$T1$, cholestatic hepatitis and micronodular $T2$
alcoholic hepatitis
cirrhosis of the liver
0
$T1$, cholestatic hepatitis and micronodular cirrhosis of the liver.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
alcoholic hepatitis
hepatomegaly
0
$T1$.Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels.
cirrhosis of the liver
hepatomegaly
0
$T1$ but showed either no cross-tolerance or an augmented response to ketamine.While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced $T2$
morphine
catalepsy
1
$T1$.While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced $T2$
ketamine
catalepsy
1
$T1$ and catalepsy in the rat.Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
analgesia
catalepsy
0
$T1$, differences in latency, $T2$
catalepsy
rigidity
0
$T1$, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for $T2$
catalepsy
naloxone
0
$T1$ but showed either no cross-tolerance or an augmented response to $T2$
morphine
ketamine
0
$T1$ and catalepsy in the rat.Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
analgesia
ketamine
0
$T1$.While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, $T2$
ketamine
rigidity
0
$T1$.While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for $T2$
ketamine
naloxone
0
$T1$ and catalepsy in the rat.Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
analgesia
morphine
0
$T1$ but showed either no cross-tolerance or an augmented response to ketamine.While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, $T2$
morphine
rigidity
0
$T1$ but showed either no cross-tolerance or an augmented response to ketamine.While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for $T2$
morphine
naloxone
0
$T1$ and catalepsy in the rat.Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
analgesia
rigidity
0
$T1$ and catalepsy in the rat.Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
analgesia
naloxone
0
$T1$ and behavior, asymmetry of cross-tolerance and a widely-different ID50 for $T2$
rigidity
naloxone
0
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
Acute renal failure
vancomycin
1
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving $T2$
Acute renal failure
tenofovir disoproxil fumarate
1
$T1$ in patients with $T2$
Acute renal failure
AIDS
0
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
Acute renal failure
tenofovir
0
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for $T2$
Acute renal failure
osteomyelitis
0
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
Acute renal failure
renal failure
0
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
Acute renal failure
Fanconi syndrome
0
$T1$ in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
Acute renal failure
nephrotoxic
0
$T1$ on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
AIDS
tenofovir
0
$T1$ on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
AIDS
vancomycin
0
$T1$ on tenofovir while receiving prolonged vancomycin course for $T2$
AIDS
osteomyelitis
0
$T1$ on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
AIDS
renal failure
0
$T1$ on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving $T2$
AIDS
tenofovir disoproxil fumarate
0
$T1$ on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
AIDS
Fanconi syndrome
0
$T1$ on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
AIDS
nephrotoxic
0
$T1$ may raise the risk of renal failure during prolonged administration of $T2$
tenofovir
vancomycin
0
$T1$.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
osteomyelitis
tenofovir
0
$T1$ may raise the risk of $T2$
tenofovir
renal failure
0
$T1$ as part of an antiretroviral regimen.Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
tenofovir disoproxil fumarate
tenofovir
0
$T1$ and renal insufficiency because of its effects on the proximal renal tubule.Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
Fanconi syndrome
tenofovir
0
$T1$ agent.Clinicians should be aware that $T2$
nephrotoxic
tenofovir
0
$T1$.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
osteomyelitis
vancomycin
0
$T1$ during prolonged administration of $T2$
renal failure
vancomycin
0
$T1$ as part of an antiretroviral regimen.Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
tenofovir disoproxil fumarate
vancomycin
0
$T1$ and renal insufficiency because of its effects on the proximal renal tubule.Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
Fanconi syndrome
vancomycin
0
$T1$ agent.Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of $T2$
nephrotoxic
vancomycin
0
$T1$.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
osteomyelitis
renal failure
0
$T1$.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving $T2$
osteomyelitis
tenofovir disoproxil fumarate
0
$T1$.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
osteomyelitis
Fanconi syndrome
0
$T1$.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
osteomyelitis
nephrotoxic
0
$T1$ as part of an antiretroviral regimen.Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
tenofovir disoproxil fumarate
renal failure
0
$T1$ and renal insufficiency because of its effects on the proximal renal tubule.Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
Fanconi syndrome
renal failure
0
$T1$ agent.Clinicians should be aware that tenofovir may raise the risk of $T2$
nephrotoxic
renal failure
0
$T1$ as part of an antiretroviral regimen.Tenofovir has been implicated in the development of $T2$
tenofovir disoproxil fumarate
Fanconi syndrome
0
$T1$ as part of an antiretroviral regimen.Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
tenofovir disoproxil fumarate
nephrotoxic
0
$T1$ and renal insufficiency because of its effects on the proximal renal tubule.Vancomycin nephrotoxicity is infrequent but may result from coadministration with a $T2$
Fanconi syndrome
nephrotoxic
0
$T1$ (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
methotrexate
leukoencephalopathy
1
$T1$, and capecitabine.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
carmofur
leukoencephalopathy
1
$T1$ and its derivative carmofur, and capecitabine.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
5-fluorouracil
leukoencephalopathy
1
$T1$.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
capecitabine
leukoencephalopathy
1
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
leukoencephalopathy
0
$T1$ were excluded.RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
cerebrovascular accidents
leukoencephalopathy
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
leukoencephalopathy
0
$T1$ after exposure to intrathecal or systemic chemotherapy have been proposed.DWI findings in this cohort are indicative of $T2$
leukoencephalopathy
cytotoxic oedema within cerebral white matter
0
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
cerebrovascular accidents
0
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
methotrexate
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
stroke
0
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
5-fluorouracil
0
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
carmofur
0
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
capecitabine
0
$T1$-like episodes while receiving systemic or intrathecal chemotherapy.We only included studies providing detailed neuroimaging data.
stroke
cytotoxic oedema within cerebral white matter
0
$T1$ were excluded.RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with $T2$
cerebrovascular accidents
methotrexate
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
cerebrovascular accidents
0
$T1$ were excluded.RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), $T2$
cerebrovascular accidents
5-fluorouracil
0
$T1$ were excluded.RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative $T2$
cerebrovascular accidents
carmofur
0
$T1$ were excluded.RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and $T2$
cerebrovascular accidents
capecitabine
0
$T1$ were excluded.RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
cerebrovascular accidents
cytotoxic oedema within cerebral white matter
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
methotrexate
0
$T1$ (intrathecal, systemic), $T2$
methotrexate
5-fluorouracil
0
$T1$ (intrathecal, systemic), 5-fluorouracil and its derivative $T2$
methotrexate
carmofur
0
$T1$ (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and $T2$
methotrexate
capecitabine
0
$T1$ (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
methotrexate
cytotoxic oedema within cerebral white matter
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
5-fluorouracil
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
carmofur
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
capecitabine
0
$T1$.Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.
leukaemia
cytotoxic oedema within cerebral white matter
0
$T1$ and its derivative $T2$
5-fluorouracil
carmofur
0
$T1$ and its derivative carmofur, and $T2$
5-fluorouracil
capecitabine
0
$T1$ and its derivative carmofur, and capecitabine.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
5-fluorouracil
cytotoxic oedema within cerebral white matter
0
$T1$, and $T2$
carmofur
capecitabine
0
$T1$, and capecitabine.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
carmofur
cytotoxic oedema within cerebral white matter
0
$T1$.Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).
capecitabine
cytotoxic oedema within cerebral white matter
0
$T1$ may have a mechanism distinct from kindling resulting from repeated administration of $T2$
seizures
cocaine
1
$T1$ $T2$
lidocaine
seizures
1
$T1$ uptake into the hippocampus.Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
norepinephrine
Desipramine
0
$T1$ uptake into the hippocampus.Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
norepinephrine
seizures
0
$T1$ uptake into the hippocampus.Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
norepinephrine
cocaine
0
$T1$ uptake into the hippocampus.Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
norepinephrine
lidocaine
0
$T1$ or tricaine with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]$T2$
bupivacaine
norepinephrine
0
$T1$ with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]$T2$
tricaine
norepinephrine
0
$T1$ uptake into the hippocampus.Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.
norepinephrine
Na
0
$T1$-induced sensitization of lidocaine $T2$
Desipramine
seizures
0
$T1$-induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of $T2$
Desipramine
cocaine
0
$T1$-induced sensitization of $T2$
Desipramine
lidocaine
0
$T1$ or tricaine with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
bupivacaine
Desipramine
0
$T1$ with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
tricaine
Desipramine
0
$T1$(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.Repeated administration of cocaine induces up-regulation of hippocampal NET function.
Na
Desipramine
0
$T1$ or tricaine with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
bupivacaine
seizures
0
$T1$ with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
tricaine
seizures
0
$T1$(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.Repeated administration of cocaine induces up-regulation of hippocampal NET function.
Na
seizures
0
$T1$ seizures may have a mechanism distinct from kindling resulting from repeated administration of $T2$
lidocaine
cocaine
0
$T1$ or tricaine with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
bupivacaine
cocaine
0
$T1$ with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
tricaine
cocaine
0
$T1$(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.Repeated administration of cocaine induces up-regulation of hippocampal NET function.
Na
cocaine
0
$T1$ or tricaine with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
bupivacaine
lidocaine
0
$T1$ with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
tricaine
lidocaine
0
$T1$(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.Repeated administration of cocaine induces up-regulation of hippocampal NET function.
Na
lidocaine
0
$T1$ or $T2$
bupivacaine
tricaine
0
$T1$ or tricaine with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
bupivacaine
Na
0
$T1$ with desipramine reversed this effect.Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.
tricaine
Na
0
$T1$ while decreasing the risk of $T2$
ribavirin
hemolytic anemia
1
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
hemolytic anemia
1
$T1$, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
HCV infection
anemia
0
$T1$ but has other potential disadvantages.Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with $T2$
anemia
chronic hepatitis C
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
anemia
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
anemia
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
anemia
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
anemia
0
$T1$ but has other potential disadvantages.Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of $T2$
anemia
ribavirin
0
$T1$ but has other potential disadvantages.Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of $T2$
anemia
hemolytic anemia
0
$T1$, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
hemolysis
anemia
0
$T1$.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
renal or cardiovascular disorders
anemia
0
$T1$ but has other potential disadvantages.$T2$
anemia
Viramidine
0
$T1$, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
HCV infection
chronic hepatitis C
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
HCV infection
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
HCV infection
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
HCV infection
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
HCV infection
0
$T1$, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
HCV infection
ribavirin
0
$T1$, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
HCV infection
hemolytic anemia
0
$T1$, and this anemia can be problematic in patients with $T2$
hemolysis
HCV infection
0
$T1$, especially those who have comorbid $T2$
HCV infection
renal or cardiovascular disorders
0
$T1$, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
HCV infection
Viramidine
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
chronic hepatitis C
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
chronic hepatitis C
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
chronic hepatitis C
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
chronic hepatitis C
0
$T1$ while decreasing the risk of hemolytic anemia in patients with $T2$
ribavirin
chronic hepatitis C
0
$T1$ in patients with $T2$
hemolytic anemia
chronic hepatitis C
0
$T1$, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
hemolysis
chronic hepatitis C
0
$T1$.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
renal or cardiovascular disorders
chronic hepatitis C
0
$T1$, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with $T2$
Viramidine
chronic hepatitis C
0
$T1$, $T2$
cirrhosis
hepatocellular carcinoma
0
$T1$, hepatocellular carcinoma, and $T2$
cirrhosis
end-stage liver disease
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated $T2$
cirrhosis
interferon
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
ribavirin
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
hemolytic anemia
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
hemolysis
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
renal or cardiovascular disorders
0
$T1$, hepatocellular carcinoma, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
cirrhosis
Viramidine
0
$T1$, and $T2$
hepatocellular carcinoma
end-stage liver disease
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated $T2$
hepatocellular carcinoma
interferon
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
ribavirin
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
hemolytic anemia
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
hemolysis
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
renal or cardiovascular disorders
0
$T1$, and end-stage liver disease.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
hepatocellular carcinoma
Viramidine
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated $T2$
end-stage liver disease
interferon
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
ribavirin
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
hemolytic anemia
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
hemolysis
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
renal or cardiovascular disorders
0
$T1$.The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
end-stage liver disease
Viramidine
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
ribavirin
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
hemolysis
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
renal or cardiovascular disorders
0
$T1$ and ribavirin.Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.
interferon
Viramidine
0
$T1$, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
hemolysis
ribavirin
0
$T1$.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
renal or cardiovascular disorders
ribavirin
0
$T1$, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of $T2$
Viramidine
ribavirin
0
$T1$, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
hemolysis
hemolytic anemia
0
$T1$.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
renal or cardiovascular disorders
hemolytic anemia
0
$T1$, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of $T2$
Viramidine
hemolytic anemia
0
$T1$, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid $T2$
hemolysis
renal or cardiovascular disorders
0
$T1$, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
hemolysis
Viramidine
0
$T1$.In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.
renal or cardiovascular disorders
Viramidine
0
$T1$ treatment is associated with considerable risk for $T2$
Pamidronate
hypocalcemia
1
$T1$ in susceptible persons.Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.
calcium carbonate
hypercalcemia
1
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
calcium carbonate
0
$T1$ in susceptible persons.Treatment with hydration, furosemide, and discontinuation of the $T2$
calcium carbonate
calcium
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
calcium carbonate
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
calcium carbonate
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
calcium carbonate
0
$T1$ in susceptible persons.Treatment with hydration, $T2$
calcium carbonate
furosemide
0
$T1$ in susceptible persons.Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.
calcium carbonate
Pamidronate
0
$T1$ in susceptible persons.Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.
calcium carbonate
hypocalcemia
0
$T1$ in susceptible persons.Treatment with hydration, furosemide, and discontinuation of the calcium and $T2$
calcium carbonate
vitamin D
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
hypercalcemia
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
calcium
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
acute renal insufficiency
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
metabolic alkalosis
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
1,25-dihydroxyvitamin D
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
furosemide
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
Pamidronate
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
hypocalcemia
0
$T1$: the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
toxicity
vitamin D
0
$T1$ and vitamin D source is adequate.Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe $T2$
calcium
hypercalcemia
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
hypercalcemia
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
hypercalcemia
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
hypercalcemia
0
$T1$, and discontinuation of the calcium and vitamin D source is adequate.Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe $T2$
furosemide
hypercalcemia
0
$T1$ treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe $T2$
Pamidronate
hypercalcemia
0
$T1$, even in cases of initially severe $T2$
hypocalcemia
hypercalcemia
0
$T1$ source is adequate.Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe $T2$
vitamin D
hypercalcemia
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
calcium
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
calcium
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
calcium
0
$T1$, and discontinuation of the $T2$
furosemide
calcium
0
$T1$ and vitamin D source is adequate.$T2$
calcium
Pamidronate
0
$T1$ and vitamin D source is adequate.Pamidronate treatment is associated with considerable risk for $T2$
calcium
hypocalcemia
0
$T1$ and $T2$
calcium
vitamin D
0
$T1$, relative $T2$
acute renal insufficiency
metabolic alkalosis
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and $T2$
acute renal insufficiency
1,25-dihydroxyvitamin D
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
furosemide
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
Pamidronate
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
hypocalcemia
0
$T1$, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
acute renal insufficiency
vitamin D
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and $T2$
metabolic alkalosis
1,25-dihydroxyvitamin D
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
furosemide
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
Pamidronate
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
hypocalcemia
0
$T1$, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.No malignant lesion was found.
metabolic alkalosis
vitamin D
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
furosemide
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
Pamidronate
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
hypocalcemia
0
$T1$ concentrations.No malignant lesion was found.
1,25-dihydroxyvitamin D
vitamin D
0
$T1$, and discontinuation of the calcium and vitamin D source is adequate.$T2$
furosemide
Pamidronate
0
$T1$, and discontinuation of the calcium and vitamin D source is adequate.Pamidronate treatment is associated with considerable risk for $T2$
furosemide
hypocalcemia
0
$T1$, and discontinuation of the calcium and $T2$
furosemide
vitamin D
0
$T1$ source is adequate.$T2$
vitamin D
Pamidronate
0
$T1$ source is adequate.Pamidronate treatment is associated with considerable risk for $T2$
vitamin D
hypocalcemia
0
$T1$ and the incidence of RIHA in a real-world population.Despite these uncertainties, this initial evaluation of the direct cost of treating $T2$
ribavirin
RIHA
1
$T1$ monotherapy in the treatment of chronic hepatitis C (CHC).Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).
interferon-alpha
RIHA
1
$T1$: clinical and economic implications.OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).
hepatitis C
ribavirin
0
$T1$ monotherapy in the treatment of chronic hepatitis C (CHC).Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).
interferon-alpha
ribavirin
0
$T1$ in a clinical trial setting.METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.
CHC
ribavirin
0
$T1$: clinical and economic implications.OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).
hepatitis C
RIHA
0
$T1$ in a clinical trial setting.METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.
CHC
RIHA
0
$T1$: clinical and economic implications.OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with $T2$
hepatitis C
interferon-alpha
0
$T1$: clinical and economic implications.OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).
hepatitis C
CHC
0
$T1$ monotherapy in the treatment of chronic hepatitis C (CHC).Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).
interferon-alpha
CHC
0
$T1$.Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine $T2$
melatonin
catatonia
1
$T1$ and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
Serotonin
catatonia
1
$T1$ appeared to act on systems more closely involved with the induction of ketamine $T2$
dopamine
catatonia
1
$T1$ $T2$
ketamine
catatonia
1
$T1$ on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.
amines
ketamine
0
$T1$ on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.
amines
catatonia
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
amines
0
$T1$ on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin.
amines
dopamine
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
amines
0
$T1$ and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
Serotonin
amines
0
$T1$ which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
N-acetyl serotonin
amines
0
$T1$ on the pineal in spite of the immature blood-brain barrier in the young chick and the intact barrier in the rat.In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by $T2$
amines
melatonin
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
ketamine
0
$T1$ appeared to act on systems more closely involved with the induction of $T2$
dopamine
ketamine
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
ketamine
0
$T1$ and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
Serotonin
ketamine
0
$T1$ which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
N-acetyl serotonin
ketamine
0
$T1$.Furthermore, dopamine appeared to act on systems more closely involved with the induction of $T2$
melatonin
ketamine
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
catatonia
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
catatonia
0
$T1$ which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
N-acetyl serotonin
catatonia
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
dopamine
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with $T2$
catecholamines
norepinephrine
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
Serotonin
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
N-acetyl serotonin
0
$T1$ and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
catecholamines
melatonin
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
dopamine
0
$T1$ and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
Serotonin
dopamine
0
$T1$ which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
N-acetyl serotonin
dopamine
0
$T1$.Furthermore, $T2$
melatonin
dopamine
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
Serotonin
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
N-acetyl serotonin
0
$T1$ did not.The pineal indolamines exhibited mixed actions.
norepinephrine
melatonin
0
$T1$ and $T2$
Serotonin
N-acetyl serotonin
0
$T1$ and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
Serotonin
melatonin
0
$T1$ which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.
N-acetyl serotonin
melatonin
0
$T1$ and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.$T2$
Drowsiness
Azelastine
1
$T1$ were increased significantly over placebo only in the high-dose azelastine group.$T2$
altered taste perception
Azelastine
1
$T1$ group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.There were no serious side effects in any of the treatment groups.
chlorpheniramine
Azelastine
0
$T1$ appears to be a safe, efficacious medication for $T2$
Azelastine
seasonal allergic rhinitis
0
$T1$ group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.There were no serious side effects in any of the treatment groups.
chlorpheniramine
seasonal allergic rhinitis
0
$T1$ group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.There were no serious side effects in any of the treatment groups.
chlorpheniramine
Drowsiness
0
$T1$ group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.There were no serious side effects in any of the treatment groups.
chlorpheniramine
altered taste perception
0
$T1$ and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.Azelastine appears to be a safe, efficacious medication for $T2$
Drowsiness
seasonal allergic rhinitis
0
$T1$ were increased significantly over placebo only in the high-dose azelastine group.Azelastine appears to be a safe, efficacious medication for $T2$
altered taste perception
seasonal allergic rhinitis
0
$T1$ and $T2$
Drowsiness
altered taste perception
0
$T1$ and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of $T2$
hypercalcaemia
calcium carbon-ate
1
$T1$ are reported in patients who had regularly consumed large amounts of calcium carbon-ate-$T2$
nephrolithiasis
sodium bicarbonate
1
$T1$ and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-$T2$
hypercalcaemia
sodium bicarbonate
1
$T1$ are reported in patients who had regularly consumed large amounts of $T2$
nephrolithiasis
calcium carbon-ate
1
$T1$ and two of recurrent $T2$
hypercalcaemia
nephrolithiasis
0
$T1$-$T2$
calcium carbon-ate
sodium bicarbonate
0
$T1$ in these patients is due to pathology at both the neuromuscular junction (most likely due to $T2$
weakness
ND-NMBA
1
$T1$.The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to $T2$
loss of thick, myosin filaments
corticosteroids
1
$T1$ (most likely due to $T2$
pathology at both the neuromuscular junction
ND-NMBA
1
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
ND-NMBA
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
corticosteroids
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
weakness
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
respiratory insufficiency
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
acidosis
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
vecuronium
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
loss of thick, myosin filaments
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
pathology at both the neuromuscular junction
0
$T1$ due to nondepolarizing neuromuscular blocking agents and corticosteroids.The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
paralysis
Hepatic dysfunction
0
$T1$) and muscle (most likely due to $T2$
ND-NMBA
corticosteroids
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
ND-NMBA
0
$T1$) and muscle (most likely due to corticosteroids).Hepatic dysfunction and $T2$
ND-NMBA
acidosis
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed loss of thick, myosin filaments.
vecuronium
ND-NMBA
0
$T1$.The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to $T2$
loss of thick, myosin filaments
ND-NMBA
0
$T1$) and muscle (most likely due to corticosteroids).$T2$
ND-NMBA
Hepatic dysfunction
0
$T1$ in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to $T2$
weakness
corticosteroids
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
corticosteroids
0
$T1$).Hepatic dysfunction and $T2$
corticosteroids
acidosis
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed loss of thick, myosin filaments.
vecuronium
corticosteroids
0
$T1$ (most likely due to ND-NMBA) and muscle (most likely due to $T2$
pathology at both the neuromuscular junction
corticosteroids
0
$T1$).$T2$
corticosteroids
Hepatic dysfunction
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
weakness
0
$T1$ in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).Hepatic dysfunction and $T2$
weakness
acidosis
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed loss of thick, myosin filaments.
vecuronium
weakness
0
$T1$.The $T2$
loss of thick, myosin filaments
weakness
0
$T1$ in these patients is due to $T2$
weakness
pathology at both the neuromuscular junction
0
$T1$ in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).$T2$
weakness
Hepatic dysfunction
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
acidosis
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
vecuronium
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
loss of thick, myosin filaments
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
pathology at both the neuromuscular junction
0
$T1$ who developed prolonged weakness following the discontinuation of ND-NMBAs.Two patients also received intravenous corticosteroids.
respiratory insufficiency
Hepatic dysfunction
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed loss of thick, myosin filaments.
vecuronium
acidosis
0
$T1$.The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).
loss of thick, myosin filaments
acidosis
0
$T1$ (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).Hepatic dysfunction and $T2$
pathology at both the neuromuscular junction
acidosis
0
$T1$ and $T2$
Hepatic dysfunction
acidosis
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed $T2$
vecuronium
loss of thick, myosin filaments
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed loss of thick, myosin filaments.
vecuronium
pathology at both the neuromuscular junction
0
$T1$ level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL.A muscle biopsy in this patient showed loss of thick, myosin filaments.
vecuronium
Hepatic dysfunction
0
$T1$.The weakness in these patients is due to $T2$
loss of thick, myosin filaments
pathology at both the neuromuscular junction
0
$T1$.The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).
loss of thick, myosin filaments
Hepatic dysfunction
0
$T1$ (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).$T2$
pathology at both the neuromuscular junction
Hepatic dysfunction
0
$T1$ may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.
PGE2
bladder hyperactivity
1
$T1$ may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.
PGE2
tachykinins
0
$T1$ or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
RP 67,580
PGE2
0
$T1$, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
SR 48,968
PGE2
0
$T1$ may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.
PGE2
Prostanoids
0
$T1$, contribute to both urge and $T2$
tachykinins
bladder hyperactivity
0
$T1$ or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
RP 67,580
bladder hyperactivity
0
$T1$, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
SR 48,968
bladder hyperactivity
0
$T1$ may, via release of tachykinins, contribute to both urge and $T2$
Prostanoids
bladder hyperactivity
0
$T1$ or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
RP 67,580
tachykinins
0
$T1$, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
SR 48,968
tachykinins
0
$T1$ may, via release of $T2$
Prostanoids
tachykinins
0
$T1$ or $T2$
RP 67,580
SR 48,968
0
$T1$ or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
RP 67,580
Prostanoids
0
$T1$, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.
SR 48,968
Prostanoids
0
$T1$ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.
HCTZ
hypokalemia
1
$T1$.Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.
cardiac arrhythmias
HCTZ
1
$T1$ diuretics cause hypokalemia and depletion of body potassium.The more profound $T2$
thiazide
hypokalemia
0
$T1$.Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.
cardiac arrhythmias
thiazide
0
$T1$ with hydrochlorothiazide (HCTC) administered on a twice daily schedule.Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.
diastolic hypertension
thiazide
0
$T1$ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.
HCTZ
thiazide
0
$T1$ diuretics cause hypokalemia and depletion of body $T2$
thiazide
potassium
0
$T1$.Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.
cardiac arrhythmias
hypokalemia
0
$T1$ with hydrochlorothiazide (HCTC) administered on a twice daily schedule.Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.
diastolic hypertension
hypokalemia
0
$T1$.The more profound $T2$
potassium
hypokalemia
0
$T1$.Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.
cardiac arrhythmias
diastolic hypertension
0
$T1$.Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.
cardiac arrhythmias
potassium
0
$T1$ with hydrochlorothiazide (HCTC) administered on a twice daily schedule.Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.
diastolic hypertension
HCTZ
0
$T1$ with hydrochlorothiazide (HCTC) administered on a twice daily schedule.Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.
diastolic hypertension
potassium
0
$T1$ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.
HCTZ
potassium
0
$T1$ phase was associated with an increased frequency of $T2$
chlorthalidone
ventricular ectopic beats
1
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
potassium
0
$T1$ and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
hypertension
potassium
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
potassium
0
$T1$ after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
coronary artery disease
potassium
0
$T1$ treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma $T2$
amiloride
potassium
0
$T1$ phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma $T2$
chlorthalidone
potassium
0
$T1$) concentrations were similar on the 2 regimens.Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.
norepinephrine
potassium
0
$T1$ (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma $T2$
ventricular ectopic beats
potassium
0
$T1$, even minor falls in plasma $T2$
ischaemic heart disease
potassium
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
hypertension
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards $T2$
coronary disease
cardiac arrhythmias
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
coronary artery disease
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
amiloride
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
chlorthalidone
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
norepinephrine
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
ventricular ectopic beats
0
$T1$.If this were so, patients with coronary artery disease might be especially susceptible.
cardiac arrhythmias
ischaemic heart disease
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
hypertension
0
$T1$ and known $T2$
hypertension
coronary artery disease
0
$T1$ and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
hypertension
amiloride
0
$T1$ and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
hypertension
chlorthalidone
0
$T1$ and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
hypertension
norepinephrine
0
$T1$ and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
hypertension
ventricular ectopic beats
0
$T1$ and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
hypertension
ischaemic heart disease
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
coronary artery disease
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
amiloride
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
chlorthalidone
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
norepinephrine
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
ventricular ectopic beats
0
$T1$.It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
coronary disease
ischaemic heart disease
0
$T1$ after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
coronary artery disease
amiloride
0
$T1$ after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
coronary artery disease
chlorthalidone
0
$T1$ after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
coronary artery disease
norepinephrine
0
$T1$ after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
coronary artery disease
ventricular ectopic beats
0
$T1$ after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.
coronary artery disease
ischaemic heart disease
0
$T1$ treatment, the $T2$
amiloride
chlorthalidone
0
$T1$) concentrations were similar on the 2 regimens.Compared to $T2$
norepinephrine
amiloride
0
$T1$ treatment, the chlorthalidone phase was associated with an increased frequency of $T2$
amiloride
ventricular ectopic beats
0
$T1$ treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with $T2$
amiloride
ischaemic heart disease
0
$T1$) concentrations were similar on the 2 regimens.Compared to amiloride treatment, the $T2$
norepinephrine
chlorthalidone
0
$T1$ phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with $T2$
chlorthalidone
ischaemic heart disease
0
$T1$) concentrations were similar on the 2 regimens.Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of $T2$
norepinephrine
ventricular ectopic beats
0
$T1$) concentrations were similar on the 2 regimens.Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.
norepinephrine
ischaemic heart disease
0
$T1$ (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with $T2$
ventricular ectopic beats
ischaemic heart disease
0
$T1$ produced by $T2$
respiratory paralysis
thiopental
1
$T1$ reverses respiratory paralysis produced by thiopental and involves $T2$
naloxone
GABA
0
$T1$ produced by thiopental and involves $T2$
respiratory paralysis
GABA
0
$T1$ and involves $T2$
thiopental
GABA
0
$T1$ and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves $T2$
glutamate
GABA
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
GABA
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
GABA
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
GABA
0
$T1$ with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
respiratory arrest
GABA
0
$T1$ studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
amino acids
GABA
0
$T1$ reverses $T2$
naloxone
respiratory paralysis
0
$T1$ reverses respiratory paralysis produced by $T2$
naloxone
thiopental
0
$T1$ and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.These data suggest $T2$
glutamate
naloxone
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
naloxone
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
naloxone
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
naloxone
0
$T1$ with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
respiratory arrest
naloxone
0
$T1$ studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
amino acids
naloxone
0
$T1$ and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.These data suggest naloxone reverses $T2$
glutamate
respiratory paralysis
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
respiratory paralysis
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
respiratory paralysis
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
respiratory paralysis
0
$T1$ with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
respiratory arrest
respiratory paralysis
0
$T1$ studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
amino acids
respiratory paralysis
0
$T1$ and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.These data suggest naloxone reverses respiratory paralysis produced by $T2$
glutamate
thiopental
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
thiopental
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
thiopental
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
thiopental
0
$T1$ with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
respiratory arrest
thiopental
0
$T1$ studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
amino acids
thiopental
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
glutamate
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
glutamate
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
glutamate
0
$T1$ with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
respiratory arrest
glutamate
0
$T1$ studied in four regions of rat brain.Naloxone (2.5 mg/kg, i.v.)
amino acids
glutamate
0
$T1$ or $T2$
aspartate
glycine
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with $T2$
aspartate
thiosemicarbazide
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
respiratory arrest
0
$T1$ or glycine levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
aspartate
amino acids
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with $T2$
glycine
thiosemicarbazide
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
respiratory arrest
0
$T1$ levels compared to controls in rat cortex and brain stem.Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.
glycine
amino acids
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
respiratory arrest
0
$T1$ for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.50 mg/kg, i.v.
thiosemicarbazide
amino acids
0
$T1$ with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the $T2$
respiratory arrest
amino acids
0
$T1$ immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987.
hepatitis B
HBeAg
1
$T1$ immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987.
hepatitis B
HBsAg
1
$T1$ immune globulin (HBIG) and at least three injections of plasma derived $T2$
hepatitis B
hepatitis B vaccine
0
$T1$ positive rate in HBsAg positive was 23 to 26%.The $T2$
HBeAg
HBsAg
0
$T1$.We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987.
hepatitis B vaccine
HBsAg
0
$T1$.We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987.
hepatitis B vaccine
HBeAg
0
$T1$ exert $T2$
prostaglandin E2
hyperalgesia
1
$T1$ and prostaglandin E2 exert $T2$
prostaglandin D2
hyperalgesia
1
$T1$ and $T2$
prostaglandin D2
prostaglandin E2
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by acetic acid writhing tests.
pg
prostaglandin D2
0
$T1$ responses.These results demonstrate that both $T2$
pain
prostaglandin D2
0
$T1$ writhing tests.The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
acetic acid
prostaglandin D2
0
$T1$ (greater than or equal to 500 ng) but not by the substance P antagonist.Prostaglandin F2 alpha had little effect on pain responses.
AH6809
prostaglandin D2
0
$T1$ had little effect on pain responses.These results demonstrate that both $T2$
Prostaglandin F2 alpha
prostaglandin D2
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by acetic acid writhing tests.
pg
prostaglandin E2
0
$T1$ responses.These results demonstrate that both prostaglandin D2 and $T2$
pain
prostaglandin E2
0
$T1$ writhing tests.The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
acetic acid
prostaglandin E2
0
$T1$ (greater than or equal to 500 ng) but not by the substance P antagonist.Prostaglandin F2 alpha had little effect on pain responses.
AH6809
prostaglandin E2
0
$T1$ had little effect on pain responses.These results demonstrate that both prostaglandin D2 and $T2$
Prostaglandin F2 alpha
prostaglandin E2
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by acetic acid writhing tests.
pg
pain
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by $T2$
pg
acetic acid
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by acetic acid writhing tests.
pg
hyperalgesia
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by acetic acid writhing tests.
pg
AH6809
0
$T1$ to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.Similar results were obtained by acetic acid writhing tests.
pg
Prostaglandin F2 alpha
0
$T1$ writhing tests.The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
acetic acid
pain
0
$T1$ responses.These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert $T2$
pain
hyperalgesia
0
$T1$ (greater than or equal to 500 ng) but not by the substance P antagonist.Prostaglandin F2 alpha had little effect on $T2$
AH6809
pain
0
$T1$ had little effect on $T2$
Prostaglandin F2 alpha
pain
0
$T1$ writhing tests.The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
acetic acid
hyperalgesia
0
$T1$ writhing tests.The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
acetic acid
AH6809
0
$T1$ writhing tests.The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
acetic acid
Prostaglandin F2 alpha
0
$T1$ (greater than or equal to 500 ng) but not by the substance P antagonist.Prostaglandin F2 alpha had little effect on pain responses.
AH6809
hyperalgesia
0
$T1$ had little effect on pain responses.These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert $T2$
Prostaglandin F2 alpha
hyperalgesia
0
$T1$ (greater than or equal to 500 ng) but not by the substance P antagonist.$T2$
AH6809
Prostaglandin F2 alpha
0
$T1$.Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like $T2$
SIAT
salbutamol
1
$T1$, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).CONCLUSION: Salbutamol is presented here as a possible trigger for $T2$
arrhythmia
SIAT
0
$T1$.Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as $T2$
SIAT
atenolol
0
$T1$.Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce $T2$
SIAT
tachycardia
0
$T1$, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.
arrhythmia
salbutamol
0
$T1$ (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as $T2$
salbutamol
atenolol
0
$T1$ (known to induce $T2$
salbutamol
tachycardia
0
$T1$, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.
arrhythmia
atenolol
0
$T1$, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.
arrhythmia
tachycardia
0
$T1$) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as $T2$
tachycardia
atenolol
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
cisplatin
1
$T1$ represents a potential therapeutic option to protect against acute $T2$
coenzyme Q10
cisplatin
0
$T1$ represents a potential therapeutic option to protect against acute cisplatin $T2$
coenzyme Q10
nephrotoxicity
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
coenzyme Q10
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
blood urea nitrogen
coenzyme Q10
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
creatinine
coenzyme Q10
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
reduced glutathione
coenzyme Q10
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
superoxide
coenzyme Q10
0
$T1$ necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
tumor
coenzyme Q10
0
$T1$ factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
necrosis
coenzyme Q10
0
$T1$ synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.It was concluded that $T2$
nitric oxide
coenzyme Q10
0
$T1$ ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
platinum
coenzyme Q10
0
$T1$ and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
selenium
coenzyme Q10
0
$T1$ ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
zinc
coenzyme Q10
0
$T1$ $T2$
cisplatin
nephrotoxicity
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
blood urea nitrogen
cisplatin
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
creatinine
cisplatin
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
reduced glutathione
cisplatin
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
superoxide
cisplatin
0
$T1$ necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
tumor
cisplatin
0
$T1$ factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
necrosis
cisplatin
0
$T1$ synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute $T2$
nitric oxide
cisplatin
0
$T1$ ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
platinum
cisplatin
0
$T1$ and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
selenium
cisplatin
0
$T1$ ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
zinc
cisplatin
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
nephrotoxicity
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
blood urea nitrogen
nephrotoxicity
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
creatinine
nephrotoxicity
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
reduced glutathione
nephrotoxicity
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
superoxide
nephrotoxicity
0
$T1$ necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
tumor
nephrotoxicity
0
$T1$ factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
necrosis
nephrotoxicity
0
$T1$ synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin $T2$
nitric oxide
nephrotoxicity
0
$T1$ ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
platinum
nephrotoxicity
0
$T1$ and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
selenium
nephrotoxicity
0
$T1$ ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
zinc
nephrotoxicity
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
blood urea nitrogen
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
creatinine
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
reduced glutathione
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
superoxide
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
tumor
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
necrosis
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
nitric oxide
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
platinum
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
selenium
0
$T1$ induced by a single i.p.injection of cisplatin (5 mg/kg).
acute renal injury
zinc
0
$T1$ and serum $T2$
blood urea nitrogen
creatinine
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ($T2$
blood urea nitrogen
reduced glutathione
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and $T2$
blood urea nitrogen
superoxide
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of $T2$
blood urea nitrogen
tumor
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor $T2$
blood urea nitrogen
necrosis
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
blood urea nitrogen
nitric oxide
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and $T2$
blood urea nitrogen
platinum
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of $T2$
blood urea nitrogen
selenium
0
$T1$ and serum creatinine levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and $T2$
blood urea nitrogen
zinc
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ($T2$
creatinine
reduced glutathione
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and $T2$
creatinine
superoxide
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of $T2$
creatinine
tumor
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor $T2$
creatinine
necrosis
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
creatinine
nitric oxide
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and $T2$
creatinine
platinum
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of $T2$
creatinine
selenium
0
$T1$ levels which were increased by cisplatin.Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and $T2$
creatinine
zinc
0
$T1$ level and $T2$
reduced glutathione
superoxide
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of $T2$
reduced glutathione
tumor
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor $T2$
reduced glutathione
necrosis
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
reduced glutathione
nitric oxide
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and $T2$
reduced glutathione
platinum
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of $T2$
reduced glutathione
selenium
0
$T1$ level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and $T2$
reduced glutathione
zinc
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of $T2$
superoxide
tumor
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor $T2$
superoxide
necrosis
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
superoxide
nitric oxide
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and $T2$
superoxide
platinum
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of $T2$
superoxide
selenium
0
$T1$ dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and $T2$
superoxide
zinc
0
$T1$ $T2$
tumor
necrosis
0
$T1$ necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
tumor
nitric oxide
0
$T1$ necrosis factor-alpha, nitric oxide and $T2$
tumor
platinum
0
$T1$ necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of $T2$
tumor
selenium
0
$T1$ necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and $T2$
tumor
zinc
0
$T1$ factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
necrosis
nitric oxide
0
$T1$ factor-alpha, nitric oxide and $T2$
necrosis
platinum
0
$T1$ factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of $T2$
necrosis
selenium
0
$T1$ factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and $T2$
necrosis
zinc
0
$T1$ ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
platinum
nitric oxide
0
$T1$ and zinc ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
selenium
nitric oxide
0
$T1$ ions in renal tissue resulted from cisplatin administration.Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
zinc
nitric oxide
0
$T1$ ion concentration, and attenuated the reductions of $T2$
platinum
selenium
0
$T1$ ion concentration, and attenuated the reductions of selenium and $T2$
platinum
zinc
0
$T1$ and $T2$
selenium
zinc
0
$T1$.This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.
acute renal failure
gentamicin
1
$T1$ can lessen $T2$
metformin
gentamicin
0
$T1$ can lessen gentamicin $T2$
metformin
nephrotoxicity
0
$T1$ even in nondiabetic patients.Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.
vascular dysfunction
metformin
0
$T1$.Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.
toxicity
metformin
0
$T1$ species from the electron transfer chain, were significantly decreased by metformin.Thus, our study suggests that pleiotropic effects of $T2$
oxygen
metformin
0
$T1$.This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.
acute renal failure
metformin
0
$T1$ $T2$
gentamicin
nephrotoxicity
0
$T1$ even in nondiabetic patients.Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.
vascular dysfunction
gentamicin
0
$T1$.Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.
toxicity
gentamicin
0
$T1$ species from the electron transfer chain, were significantly decreased by metformin.Thus, our study suggests that pleiotropic effects of metformin can lessen $T2$
oxygen
gentamicin
0
$T1$ even in nondiabetic patients.Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.
vascular dysfunction
nephrotoxicity
0
$T1$.Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.
toxicity
nephrotoxicity
0
$T1$ species from the electron transfer chain, were significantly decreased by metformin.Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin $T2$
oxygen
nephrotoxicity
0
$T1$.This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.
acute renal failure
nephrotoxicity
0
$T1$ even in nondiabetic patients.Here we tested whether it has a beneficial effect in a rat model of gentamicin $T2$
vascular dysfunction
toxicity
0
$T1$ even in nondiabetic patients.Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.
vascular dysfunction
oxygen
0
$T1$ even in nondiabetic patients.Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.
vascular dysfunction
acute renal failure
0
$T1$.Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.
toxicity
oxygen
0
$T1$.Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.
toxicity
acute renal failure
0
$T1$.This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.
acute renal failure
oxygen
0
$T1$ during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).CONCLUSION: The use of light $T2$
delirium
propofol
1
$T1$ sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing $T2$
propofol
postoperative delirium
1
$T1$ repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
hip fracture
postoperative delirium
0
$T1$ during hospitalization was lower in the light sedation group than in the deep sedation group (0.5+/-1.5 days vs 1.4+/-4.0 days; P=.01).CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.
delirium
postoperative delirium
0
$T1$ who underwent hip fracture repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
dementia
postoperative delirium
0
$T1$ (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.RESULTS: From April 2, 2005, through October 30, 2008, a total of 114 patients were randomized.
Mental Disorders
postoperative delirium
0
$T1$ repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
hip fracture
delirium
0
$T1$ who underwent $T2$
dementia
hip fracture
0
$T1$ repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
hip fracture
propofol
0
$T1$ repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
hip fracture
Mental Disorders
0
$T1$ who underwent hip fracture repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
dementia
delirium
0
$T1$ (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.RESULTS: From April 2, 2005, through October 30, 2008, a total of 114 patients were randomized.
Mental Disorders
delirium
0
$T1$ who underwent hip fracture repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
dementia
propofol
0
$T1$ who underwent hip fracture repair under spinal anesthesia with propofol sedation.Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation.
dementia
Mental Disorders
0
$T1$ (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.RESULTS: From April 2, 2005, through October 30, 2008, a total of 114 patients were randomized.
Mental Disorders
propofol
0
$T1$.Our report may show an adverse effect on the Rho/ROCK pathway by $T2$
coronary artery spasm
sorafenib
1
$T1$.However, there was no stenosis in coronary arteries on angiography.
subendocardial infarction
sorafenib
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
sorafenib
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
sorafenib
0
$T1$-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral nicorandil reduced his symptoms and maintained stable angina status.
Ca
sorafenib
0
$T1$ ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral nicorandil reduced his symptoms and maintained stable angina status.
nitrates
sorafenib
0
$T1$ reduced his symptoms and maintained stable angina status.We report the first case of sorafenib-induced coronary artery spasm.
nicorandil
sorafenib
0
$T1$ status.We report the first case of sorafenib-induced coronary artery spasm.
stable angina
sorafenib
0
$T1$.However, there was no stenosis in coronary arteries on angiography.
subendocardial infarction
coronary artery spasm
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
subendocardial infarction
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
subendocardial infarction
0
$T1$.However, there was no stenosis in coronary arteries on angiography.
subendocardial infarction
Ca
0
$T1$.However, there was no stenosis in coronary arteries on angiography.
subendocardial infarction
nitrates
0
$T1$.However, there was no stenosis in coronary arteries on angiography.
subendocardial infarction
nicorandil
0
$T1$.However, there was no stenosis in coronary arteries on angiography.
subendocardial infarction
stable angina
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
coronary artery spasm
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
coronary artery spasm
0
$T1$-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral nicorandil reduced his symptoms and maintained stable angina status.
Ca
coronary artery spasm
0
$T1$ ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral nicorandil reduced his symptoms and maintained stable angina status.
nitrates
coronary artery spasm
0
$T1$ reduced his symptoms and maintained stable angina status.We report the first case of sorafenib-induced coronary artery spasm.
nicorandil
coronary artery spasm
0
$T1$ status.We report the first case of sorafenib-induced coronary artery spasm.
stable angina
coronary artery spasm
0
$T1$ was admitted due to continuing $T2$
renal cell carcinoma
chest pain
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
Ca
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
nitrates
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
nicorandil
0
$T1$ was admitted due to continuing chest pain at rest.Two weeks before his admission, sorafenib had been started.
renal cell carcinoma
stable angina
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
Ca
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
nitrates
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
nicorandil
0
$T1$ at rest.Two weeks before his admission, sorafenib had been started.
chest pain
stable angina
0
$T1$-channel blocker and $T2$
Ca
nitrates
0
$T1$-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral $T2$
Ca
nicorandil
0
$T1$-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral nicorandil reduced his symptoms and maintained $T2$
Ca
stable angina
0
$T1$ ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral $T2$
nitrates
nicorandil
0
$T1$ ameliorated his symptoms, but relapse occurred after resumption of sorafenib.Addition of oral nicorandil reduced his symptoms and maintained $T2$
nitrates
stable angina
0
$T1$ reduced his symptoms and maintained $T2$
nicorandil
stable angina
0
$T1$ in comparison to control rats in all the parameters studied.However, ciprofloxacin- and norfloxacin-treated rats did not differ significantly from each other in various behavioural parameters.
anxious behaviour
norfloxacin
1
$T1$ in comparison to control rats in all the parameters studied.However, ciprofloxacin- and norfloxacin-treated rats did not differ significantly from each other in various behavioural parameters.
anxious behaviour
ciprofloxacin
1
$T1$ and $T2$
ciprofloxacin
norfloxacin
0
$T1$, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.The tests included open-field exploratory behaviour, elevated plus maze and elevated zero maze, social interaction and novelty-suppressed feeding latency behaviour.
fluoroquinolones
ciprofloxacin
0
$T1$, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.The tests included open-field exploratory behaviour, elevated plus maze and elevated zero maze, social interaction and novelty-suppressed feeding latency behaviour.
fluoroquinolones
norfloxacin
0
$T1$, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.The tests included open-field exploratory behaviour, elevated plus maze and elevated zero maze, social interaction and novelty-suppressed feeding latency behaviour.
fluoroquinolones
anxious behaviour
0
$T1$-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.
AZT
cardiac dilation and dysfunction
1
$T1$-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.
AZT
cardiomyopathy
1
$T1$ occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
myocarditis
AZT
0
$T1$ individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
HIV-infected
AZT
0
$T1$ in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
heart failure
AZT
0
$T1$), but has resulted in an increase in cardiac and skeletal myopathies.METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
AIDS
AZT
0
$T1$.METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
cardiac and skeletal myopathies
AZT
0
$T1$ due to activation of apoptotic pathways, resulting in $T2$
cardiomyopathy
cardiac dilation and dysfunction
0
$T1$ occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
myocarditis
cardiomyopathy
0
$T1$ individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
HIV-infected
cardiomyopathy
0
$T1$ in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
heart failure
cardiomyopathy
0
$T1$), but has resulted in an increase in cardiac and skeletal myopathies.METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
AIDS
cardiomyopathy
0
$T1$.METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
cardiac and skeletal myopathies
cardiomyopathy
0
$T1$ occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
myocarditis
cardiac dilation and dysfunction
0
$T1$ individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
HIV-infected
cardiac dilation and dysfunction
0
$T1$ in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.
heart failure
cardiac dilation and dysfunction
0
$T1$), but has resulted in an increase in cardiac and skeletal myopathies.METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
AIDS
cardiac dilation and dysfunction
0
$T1$.METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
cardiac and skeletal myopathies
cardiac dilation and dysfunction
0
$T1$ occur in many $T2$
myocarditis
HIV-infected
0
$T1$ occur in many HIV-infected individuals, resulting in symptomatic $T2$
myocarditis
heart failure
0
$T1$ occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ($T2$
myocarditis
AIDS
0
$T1$ occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in $T2$
myocarditis
cardiac and skeletal myopathies
0
$T1$ individuals, resulting in symptomatic $T2$
HIV-infected
heart failure
0
$T1$ individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ($T2$
HIV-infected
AIDS
0
$T1$ individuals, resulting in symptomatic heart failure in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in $T2$
HIV-infected
cardiac and skeletal myopathies
0
$T1$ in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ($T2$
heart failure
AIDS
0
$T1$ in up to 5% of patients.Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in $T2$
heart failure
cardiac and skeletal myopathies
0
$T1$), but has resulted in an increase in $T2$
AIDS
cardiac and skeletal myopathies
0
$T1$ shortly after initiation of $T2$
chorea
valproate
1
$T1$ and chorea shortly after initiation of $T2$
encephalopathy
valproate
1
$T1$ following her presentation with acute encephalopathy and chorea shortly after initiation of $T2$
nonketotic hyperglycinemia
valproate
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
disorder of amino acid metabolism
valproate
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
glycine
valproate
0
$T1$, intractable seizures, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
apnea
valproate
0
$T1$, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
seizures
valproate
0
$T1$, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
hypotonia
valproate
0
$T1$.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
psychomotor retardation
valproate
0
$T1$ and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of $T2$
language delay
valproate
0
$T1$, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of $T2$
mental retardation
valproate
0
$T1$ and $T2$
encephalopathy
chorea
0
$T1$ following her presentation with acute encephalopathy and $T2$
nonketotic hyperglycinemia
chorea
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
disorder of amino acid metabolism
chorea
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
glycine
chorea
0
$T1$, intractable seizures, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
apnea
chorea
0
$T1$, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
seizures
chorea
0
$T1$, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
hypotonia
chorea
0
$T1$.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
psychomotor retardation
chorea
0
$T1$ and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and $T2$
language delay
chorea
0
$T1$, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and $T2$
mental retardation
chorea
0
$T1$ following her presentation with acute $T2$
nonketotic hyperglycinemia
encephalopathy
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
disorder of amino acid metabolism
encephalopathy
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
glycine
encephalopathy
0
$T1$, intractable seizures, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
apnea
encephalopathy
0
$T1$, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
seizures
encephalopathy
0
$T1$, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
hypotonia
encephalopathy
0
$T1$.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
psychomotor retardation
encephalopathy
0
$T1$ and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute $T2$
language delay
encephalopathy
0
$T1$, who was found to have nonketotic hyperglycinemia following her presentation with acute $T2$
mental retardation
encephalopathy
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
disorder of amino acid metabolism
nonketotic hyperglycinemia
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
glycine
nonketotic hyperglycinemia
0
$T1$, intractable seizures, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
apnea
nonketotic hyperglycinemia
0
$T1$, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
seizures
nonketotic hyperglycinemia
0
$T1$, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
hypotonia
nonketotic hyperglycinemia
0
$T1$.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
psychomotor retardation
nonketotic hyperglycinemia
0
$T1$ and mental retardation, who was found to have $T2$
language delay
nonketotic hyperglycinemia
0
$T1$, who was found to have $T2$
mental retardation
nonketotic hyperglycinemia
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of $T2$
disorder of amino acid metabolism
glycine
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal $T2$
disorder of amino acid metabolism
apnea
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable $T2$
disorder of amino acid metabolism
seizures
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and $T2$
disorder of amino acid metabolism
hypotonia
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant $T2$
disorder of amino acid metabolism
psychomotor retardation
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
disorder of amino acid metabolism
language delay
0
$T1$ in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
disorder of amino acid metabolism
mental retardation
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal $T2$
glycine
apnea
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable $T2$
glycine
seizures
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and $T2$
glycine
hypotonia
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant $T2$
glycine
psychomotor retardation
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
glycine
language delay
0
$T1$ in the brain and other body compartments.In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.
glycine
mental retardation
0
$T1$, intractable $T2$
apnea
seizures
0
$T1$, intractable seizures, and $T2$
apnea
hypotonia
0
$T1$, intractable seizures, and hypotonia, followed by significant $T2$
apnea
psychomotor retardation
0
$T1$, intractable seizures, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
apnea
language delay
0
$T1$, intractable seizures, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
apnea
mental retardation
0
$T1$, and $T2$
seizures
hypotonia
0
$T1$, and hypotonia, followed by significant $T2$
seizures
psychomotor retardation
0
$T1$, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
seizures
language delay
0
$T1$, and hypotonia, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
seizures
mental retardation
0
$T1$, followed by significant $T2$
hypotonia
psychomotor retardation
0
$T1$, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
hypotonia
language delay
0
$T1$, followed by significant psychomotor retardation.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
hypotonia
mental retardation
0
$T1$.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
psychomotor retardation
language delay
0
$T1$.An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.
psychomotor retardation
mental retardation
0
$T1$ and $T2$
language delay
mental retardation
0
$T1$-induced $T2$
scopolamine
amnesia
1
$T1$ into the CA1 region of the hippocampus improves the $T2$
ritanserin
scopolamine
0
$T1$ into the CA1 region of the hippocampus improves the scopolamine-induced $T2$
ritanserin
amnesia
0
$T1$-treated group.However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
DMSO
ritanserin
0
$T1$-treated group.However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
DMSO
scopolamine
0
$T1$-treated group.However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.
DMSO
amnesia
0
$T1$ model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.
puromycin aminonucleoside
hypoxia
1
$T1$ and focal and segmental hypoxia in the remnant kidney model.Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the $T2$
nephrotic syndrome
puromycin aminonucleoside
1
$T1$ and progressive $T2$
hypoxia
glomerular diseases
0
$T1$ and/or glomerular hypertension.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
proteinuria
hypoxia
0
$T1$.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
hypertension
hypoxia
0
$T1$ and focal and segmental hypoxia in the remnant kidney model.Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
nephrotic syndrome
hypoxia
0
$T1$ in both models.Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.
tubulointerstitial injury
hypoxia
0
$T1$ and/or glomerular hypertension.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
proteinuria
glomerular diseases
0
$T1$.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
hypertension
glomerular diseases
0
$T1$ model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.
puromycin aminonucleoside
glomerular diseases
0
$T1$ and focal and segmental hypoxia in the remnant kidney model.Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
nephrotic syndrome
glomerular diseases
0
$T1$ in both models.Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.
tubulointerstitial injury
glomerular diseases
0
$T1$ and/or glomerular $T2$
proteinuria
hypertension
0
$T1$ and/or glomerular hypertension.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
proteinuria
puromycin aminonucleoside
0
$T1$ and/or glomerular hypertension.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
proteinuria
nephrotic syndrome
0
$T1$ and/or glomerular hypertension.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
proteinuria
tubulointerstitial injury
0
$T1$.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
hypertension
puromycin aminonucleoside
0
$T1$.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
hypertension
nephrotic syndrome
0
$T1$.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available.
hypertension
tubulointerstitial injury
0
$T1$ model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.The degree of hypoxia showed a positive correlation with microscopic $T2$
puromycin aminonucleoside
tubulointerstitial injury
0
$T1$ and focal and segmental hypoxia in the remnant kidney model.Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
nephrotic syndrome
tubulointerstitial injury
0
$T1$ are used in patients with a possible underlying $T2$
mitoxantrone
heart damage
1
$T1$ or anthracyclines such as mitoxantrone are used in patients with a possible underlying $T2$
cyclophosphamide
heart damage
1
$T1$ is low.However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
cardiac toxicity
autoimmune disease
0
$T1$ is low.However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, $T2$
cardiac toxicity
systemic sclerosis
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
cardiac toxicity
0
$T1$.The number of deaths related to $T2$
infections
cardiac toxicity
0
$T1$ is low.However, caution is required when $T2$
cardiac toxicity
cyclophosphamide
0
$T1$ is low.However, caution is required when cyclophosphamide or $T2$
cardiac toxicity
anthracyclines
0
$T1$ is low.However, caution is required when cyclophosphamide or anthracyclines such as $T2$
cardiac toxicity
mitoxantrone
0
$T1$ is low.However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying $T2$
cardiac toxicity
heart damage
0
$T1$ patients.In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine.
systemic sclerosis
autoimmune disease
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
autoimmune disease
0
$T1$.The number of deaths related to cardiac toxicity is low.
infections
autoimmune disease
0
$T1$ or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine.
cyclophosphamide
autoimmune disease
0
$T1$ such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine.
anthracyclines
autoimmune disease
0
$T1$ are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine.
mitoxantrone
autoimmune disease
0
$T1$, for example, systemic sclerosis patients.In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine.
heart damage
autoimmune disease
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
systemic sclerosis
0
$T1$.The number of deaths related to cardiac toxicity is low.
infections
systemic sclerosis
0
$T1$ or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, $T2$
cyclophosphamide
systemic sclerosis
0
$T1$ such as mitoxantrone are used in patients with a possible underlying heart damage, for example, $T2$
anthracyclines
systemic sclerosis
0
$T1$ are used in patients with a possible underlying heart damage, for example, $T2$
mitoxantrone
systemic sclerosis
0
$T1$, for example, $T2$
heart damage
systemic sclerosis
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
infections
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
cyclophosphamide
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
anthracyclines
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
mitoxantrone
0
$T1$.Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.
multiple sclerosis
heart damage
0
$T1$.The number of deaths related to cardiac toxicity is low.
infections
cyclophosphamide
0
$T1$.The number of deaths related to cardiac toxicity is low.
infections
anthracyclines
0
$T1$.The number of deaths related to cardiac toxicity is low.
infections
mitoxantrone
0
$T1$.The number of deaths related to cardiac toxicity is low.
infections
heart damage
0
$T1$ or $T2$
cyclophosphamide
anthracyclines
0
$T1$ or anthracyclines such as $T2$
cyclophosphamide
mitoxantrone
0
$T1$ such as $T2$
anthracyclines
mitoxantrone
0
$T1$ such as mitoxantrone are used in patients with a possible underlying $T2$
anthracyclines
heart damage
0
$T1$-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat $T2$
fenoldopam
arteritis
1
$T1$ administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat $T2$
theophylline
arteritis
1
$T1$ synthase (iNOS), basic fibroblast growth factor (bFGF) and $T2$
nitric oxide
tumor
0
$T1$ synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.
nitric oxide
arteritis
0
$T1$ synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.
nitric oxide
fenoldopam
0
$T1$ synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.
nitric oxide
theophylline
0
$T1$ growth factor-beta1 (TGF-beta1).Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.
tumor
arteritis
0
$T1$ growth factor-beta1 (TGF-beta1).Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.
tumor
fenoldopam
0
$T1$ growth factor-beta1 (TGF-beta1).Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.
tumor
theophylline
0
$T1$ administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-$T2$
theophylline
fenoldopam
0
$T1$, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.
hemorrhage
LMWH
1
$T1$ was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.
thromboembolism
LMWH
1
$T1$.Data on mid- and long-term LMWH administration in these patients are sparse.
UH
LMWH
0
$T1$ was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with $T2$
thromboembolism
UH
0
$T1$, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups).CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with $T2$
hemorrhage
UH
0
$T1$ was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for $T2$
thromboembolism
hemorrhage
0
$T1$-induced $T2$
topiramate
nephrolithiasis
1
$T1$.Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.
refractory seizures
topiramate
0
$T1$ in patients secondary to inhibition of carbonic anhydrase.In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH.
metabolic acidosis
topiramate
0
$T1$ nephrolithiasis.We report the first two cases of $T2$
calcium phosphate
topiramate
0
$T1$.Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.
refractory seizures
nephrolithiasis
0
$T1$ in patients secondary to inhibition of carbonic anhydrase.In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH.
metabolic acidosis
nephrolithiasis
0
$T1$ nephrolithiasis.We report the first two cases of topiramate-induced $T2$
calcium phosphate
nephrolithiasis
0
$T1$.Urologists should be aware that this medication can cause $T2$
refractory seizures
metabolic acidosis
0
$T1$.Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.
refractory seizures
calcium phosphate
0
$T1$ in patients secondary to inhibition of carbonic anhydrase.In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH.
metabolic acidosis
calcium phosphate
0
$T1$ by reducing urinary potassium loss in neutropenic patients on $T2$
hypokalemia
AmB
1
$T1$ can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on $T2$
spironolactone
AmB
0
$T1$ can reduce potassium requirements and prevent $T2$
spironolactone
hypokalemia
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
spironolactone
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
spironolactone
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
spironolactone
0
$T1$ can reduce potassium requirements and prevent hypokalemia by reducing urinary $T2$
spironolactone
potassium
0
$T1$ can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in $T2$
spironolactone
neutropenic
0
$T1$ were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
hematological disorders
spironolactone
0
$T1$.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
fungal infection
spironolactone
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
AmB
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
AmB
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
AmB
0
$T1$ loss in neutropenic patients on $T2$
potassium
AmB
0
$T1$ patients on $T2$
neutropenic
AmB
0
$T1$ were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
hematological disorders
AmB
0
$T1$.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
fungal infection
AmB
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
hypokalemia
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
hypokalemia
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
hypokalemia
0
$T1$ by reducing urinary $T2$
hypokalemia
potassium
0
$T1$ by reducing urinary potassium loss in $T2$
hypokalemia
neutropenic
0
$T1$ were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
hematological disorders
hypokalemia
0
$T1$.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
fungal infection
hypokalemia
0
$T1$ patients?OBJECTIVE: $T2$
cancer
Nephrotoxicity
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
toxicity
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
potassium
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
neutropenic
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
hematological disorders
0
$T1$ patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
cancer
fungal infection
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
toxicity
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
potassium
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
neutropenic
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
hematological disorders
0
$T1$ is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Nephrotoxicity
fungal infection
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
potassium
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
neutropenic
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
hematological disorders
0
$T1$ of AmB.This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
toxicity
fungal infection
0
$T1$ loss in $T2$
potassium
neutropenic
0
$T1$ were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
hematological disorders
potassium
0
$T1$.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
fungal infection
potassium
0
$T1$ were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
hematological disorders
neutropenic
0
$T1$.RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).
fungal infection
neutropenic
0
$T1$ were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected $T2$
hematological disorders
fungal infection
0
$T1$-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.Thus, the absence of D2R lowers the threshold for $T2$
pilocarpine
seizures
1
$T1$.Thus, the absence of D2R lowers the threshold for $T2$
KA
seizures
1
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
epilepsy
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of $T2$
Excitotoxicity
DA
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
seizures
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
neurotoxicity
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
pilocarpine
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
KA
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
glutamate
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
acetylcholine
0
$T1$ receptors in the occurrence of epilepsy-induced neuronal cell death.Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
DA
neurodegeneration
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
epilepsy
0
$T1$ induced by both glutamate and acetylcholine.Moreover, the dopaminergic control of $T2$
seizures
epilepsy
0
$T1$.However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
neurotoxicity
epilepsy
0
$T1$-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
pilocarpine
epilepsy
0
$T1$.Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
KA
epilepsy
0
$T1$ and acetylcholine.Moreover, the dopaminergic control of $T2$
glutamate
epilepsy
0
$T1$.Moreover, the dopaminergic control of $T2$
acetylcholine
epilepsy
0
$T1$-induced $T2$
epilepsy
neurodegeneration
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
seizures
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
neurotoxicity
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
pilocarpine
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
KA
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
glutamate
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
acetylcholine
0
$T1$ leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.
Excitotoxicity
neurodegeneration
0
$T1$.However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
neurotoxicity
seizures
0
$T1$ induced by both $T2$
seizures
glutamate
0
$T1$ induced by both glutamate and $T2$
seizures
acetylcholine
0
$T1$ induced by both glutamate and acetylcholine.Moreover, the dopaminergic control of epilepsy-induced $T2$
seizures
neurodegeneration
0
$T1$.However, $T2$
neurotoxicity
pilocarpine
0
$T1$.However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to $T2$
neurotoxicity
KA
0
$T1$.However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
neurotoxicity
glutamate
0
$T1$.However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
neurotoxicity
acetylcholine
0
$T1$.However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
neurotoxicity
neurodegeneration
0
$T1$-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to $T2$
pilocarpine
KA
0
$T1$-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.Thus, the absence of D2R lowers the threshold for seizures induced by both $T2$
pilocarpine
glutamate
0
$T1$-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and $T2$
pilocarpine
acetylcholine
0
$T1$-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
pilocarpine
neurodegeneration
0
$T1$.Thus, the absence of D2R lowers the threshold for seizures induced by both $T2$
KA
glutamate
0
$T1$.Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and $T2$
KA
acetylcholine
0
$T1$.Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
KA
neurodegeneration
0
$T1$ and $T2$
glutamate
acetylcholine
0
$T1$ and acetylcholine.Moreover, the dopaminergic control of epilepsy-induced $T2$
glutamate
neurodegeneration
0
$T1$.Moreover, the dopaminergic control of epilepsy-induced $T2$
acetylcholine
neurodegeneration
0
$T1$-induced $T2$
risperidone
hyperprolactinemia
1
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
risperidone
0
$T1$ may be associated with arrested growth and development resulting in either delayed puberty or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
prolactinomas
risperidone
0
$T1$ or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
delayed puberty
risperidone
0
$T1$ may be useful for the treatment of $T2$
Cabergoline
risperidone
0
$T1$ (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
Mental Disorders
risperidone
0
$T1$ or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
bipolar disorder
risperidone
0
$T1$, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
psychoses
risperidone
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
hyperprolactinemia
0
$T1$ may be associated with arrested growth and development resulting in either delayed puberty or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
prolactinomas
hyperprolactinemia
0
$T1$ or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
delayed puberty
hyperprolactinemia
0
$T1$ may be useful for the treatment of risperidone-induced $T2$
Cabergoline
hyperprolactinemia
0
$T1$ (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
Mental Disorders
hyperprolactinemia
0
$T1$ or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
bipolar disorder
hyperprolactinemia
0
$T1$, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
psychoses
hyperprolactinemia
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
prolactinomas
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
delayed puberty
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
Cabergoline
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
Mental Disorders
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
bipolar disorder
0
$T1$ agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
dopamine
psychoses
0
$T1$ may be associated with arrested growth and development resulting in either $T2$
prolactinomas
delayed puberty
0
$T1$ may be associated with arrested growth and development resulting in either delayed puberty or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
prolactinomas
Cabergoline
0
$T1$ may be associated with arrested growth and development resulting in either delayed puberty or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
prolactinomas
Mental Disorders
0
$T1$ may be associated with arrested growth and development resulting in either delayed puberty or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
prolactinomas
bipolar disorder
0
$T1$ may be associated with arrested growth and development resulting in either delayed puberty or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
prolactinomas
psychoses
0
$T1$ or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
delayed puberty
Cabergoline
0
$T1$ or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
delayed puberty
Mental Disorders
0
$T1$ or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
delayed puberty
bipolar disorder
0
$T1$ or short stature.These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.
delayed puberty
psychoses
0
$T1$ (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
Mental Disorders
Cabergoline
0
$T1$ or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
bipolar disorder
Cabergoline
0
$T1$, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.
psychoses
Cabergoline
0
$T1$ (fourth edition) $T2$
Mental Disorders
bipolar disorder
0
$T1$ (fourth edition) bipolar disorder or $T2$
Mental Disorders
psychoses
0
$T1$ or $T2$
bipolar disorder
psychoses
0
$T1$ shortly after initiation of treatment with metformin hydrochloride.Ultrasound of the liver and abdominal CT were normal.
cholestatic jaundice
metformin
1
$T1$, with portal edema, ductular proliferation, and acute inflammation.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
cholestasis
metformin
1
$T1$ shortly after initiation of treatment with metformin hydrochloride.Ultrasound of the liver and abdominal CT were normal.
cholestatic jaundice
cholestasis
0
$T1$ shortly after initiation of treatment with metformin hydrochloride.Ultrasound of the liver and abdominal CT were normal.
cholestatic jaundice
edema
0
$T1$ shortly after initiation of treatment with metformin hydrochloride.Ultrasound of the liver and abdominal CT were normal.
cholestatic jaundice
inflammation
0
$T1$ shortly after initiation of treatment with metformin hydrochloride.Ultrasound of the liver and abdominal CT were normal.
cholestatic jaundice
jaundice
0
$T1$ shortly after initiation of treatment with metformin hydrochloride.Ultrasound of the liver and abdominal CT were normal.
cholestatic jaundice
hepatotoxicity
0
$T1$, ductular proliferation, and acute inflammation.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
edema
metformin
0
$T1$.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
inflammation
metformin
0
$T1$ 2 wk after the initiation of metformin, we believe that this case represents an example of $T2$
jaundice
metformin
0
$T1$-associated $T2$
metformin
hepatotoxicity
0
$T1$, with portal $T2$
cholestasis
edema
0
$T1$, with portal edema, ductular proliferation, and acute $T2$
cholestasis
inflammation
0
$T1$, with portal edema, ductular proliferation, and acute inflammation.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
cholestasis
jaundice
0
$T1$, with portal edema, ductular proliferation, and acute inflammation.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
cholestasis
hepatotoxicity
0
$T1$, ductular proliferation, and acute $T2$
edema
inflammation
0
$T1$, ductular proliferation, and acute inflammation.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
edema
jaundice
0
$T1$, ductular proliferation, and acute inflammation.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
edema
hepatotoxicity
0
$T1$.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
inflammation
jaundice
0
$T1$.Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
inflammation
hepatotoxicity
0
$T1$ 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated $T2$
jaundice
hepatotoxicity
0
$T1$ appears to be associated with vigabatrin therapy.The field defects and some electrophysiological abnormalities persist when $T2$
visual field constriction
vigabatrin
1
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
nephrotoxicity
1
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
CsA
1
$T1$ withdrawal.However, when converting patients to $T2$
CsA
RAPA
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
RAPA
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
RAPA
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
RAPA
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
RAPA
0
$T1$ in one, and oral aphtous ulcers in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
PTLD
RAPA
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
RAPA
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
RAPA
0
$T1$ in two, PTLD in one, and oral aphtous ulcers in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
pneumonia
RAPA
0
$T1$ drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and $T2$
RAPA
Pneumocystis carinii pneumonia
0
$T1$ with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.There were no deaths.
infectious mononucleosis
RAPA
0
$T1$.There were no deaths.
bronchiolitis obliterans
RAPA
0
$T1$ in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
aphtous ulcers
RAPA
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
CsA
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
CsA
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
CsA
0
$T1$ in one, and oral aphtous ulcers in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
PTLD
CsA
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
CsA
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
CsA
0
$T1$ in two, PTLD in one, and oral aphtous ulcers in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
pneumonia
CsA
0
$T1$ withdrawal.However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and $T2$
CsA
Pneumocystis carinii pneumonia
0
$T1$ with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.There were no deaths.
infectious mononucleosis
CsA
0
$T1$.There were no deaths.
bronchiolitis obliterans
CsA
0
$T1$ in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
aphtous ulcers
CsA
0
$T1$ $T2$
Tac
toxicity
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
Facial dysmorphism
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
PTLD
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and $T2$
Tac
hepatotoxicity
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
creatinine
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
pneumonia
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
Pneumocystis carinii pneumonia
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
infectious mononucleosis
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
bronchiolitis obliterans
0
$T1$ toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
Tac
aphtous ulcers
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
nephrotoxicity
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
Facial dysmorphism
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
PTLD
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and $T2$
toxicity
hepatotoxicity
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
creatinine
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
pneumonia
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
Pneumocystis carinii pneumonia
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
infectious mononucleosis
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
bronchiolitis obliterans
0
$T1$ (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.Follow-up is 7 to 24 months.
toxicity
aphtous ulcers
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].$T2$
nephrotoxicity
Facial dysmorphism
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
PTLD
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
nephrotoxicity
0
$T1$ there was a significant decrease in serum $T2$
nephrotoxicity
creatinine
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
pneumonia
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
Pneumocystis carinii pneumonia
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
infectious mononucleosis
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
bronchiolitis obliterans
0
$T1$ there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
nephrotoxicity
aphtous ulcers
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
PTLD
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
Facial dysmorphism
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].$T2$
creatinine
Facial dysmorphism
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
pneumonia
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
Pneumocystis carinii pneumonia
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
infectious mononucleosis
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
bronchiolitis obliterans
0
$T1$ improved in two patients.No relapse of PTLD was observed.
Facial dysmorphism
aphtous ulcers
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
PTLD
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
PTLD
0
$T1$ in two, $T2$
pneumonia
PTLD
0
$T1$ in one, and oral aphtous ulcers in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
PTLD
Pneumocystis carinii pneumonia
0
$T1$ with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.There were no deaths.
infectious mononucleosis
PTLD
0
$T1$.There were no deaths.
bronchiolitis obliterans
PTLD
0
$T1$ in one, and oral $T2$
PTLD
aphtous ulcers
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
creatinine
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
pneumonia
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
Pneumocystis carinii pneumonia
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
infectious mononucleosis
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
bronchiolitis obliterans
0
$T1$ in 1.Follow-up is 7 to 24 months.
hepatotoxicity
aphtous ulcers
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
pneumonia
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
Pneumocystis carinii pneumonia
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
infectious mononucleosis
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
bronchiolitis obliterans
0
$T1$ [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].Facial dysmorphism improved in two patients.
creatinine
aphtous ulcers
0
$T1$ in two, PTLD in one, and oral aphtous ulcers in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
pneumonia
Pneumocystis carinii pneumonia
0
$T1$ with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.There were no deaths.
infectious mononucleosis
pneumonia
0
$T1$.There were no deaths.
bronchiolitis obliterans
pneumonia
0
$T1$ in two, PTLD in one, and oral $T2$
pneumonia
aphtous ulcers
0
$T1$ with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.There were no deaths.
infectious mononucleosis
Pneumocystis carinii pneumonia
0
$T1$.There were no deaths.
bronchiolitis obliterans
Pneumocystis carinii pneumonia
0
$T1$ in one.RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.
aphtous ulcers
Pneumocystis carinii pneumonia
0
$T1$ with polyclonal PTLD lung infiltrate) and two had $T2$
infectious mononucleosis
bronchiolitis obliterans
0
$T1$ with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.There were no deaths.
infectious mononucleosis
aphtous ulcers
0
$T1$.There were no deaths.
bronchiolitis obliterans
aphtous ulcers
0
$T1$.Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).
apomorphine
dyskinesia
1
$T1$-induced dyskinesias by motor and mental tasks.Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.
levodopa
dyskinesia
1
$T1$-induced dyskinesias by motor and mental tasks.Ten patients who had $T2$
levodopa
Parkinson's disease
0
$T1$-induced dyskinesias by motor and mental tasks.Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of $T2$
levodopa
apomorphine
0
$T1$ with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).
Parkinson's disease
dyskinesia
0
$T1$ with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of $T2$
Parkinson's disease
apomorphine
0
$T1$ on cardiovascular function involve $T2$
ADR
mitochondrial structural and functional impairment
1
$T1$, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.
bradycardia
ADR
1
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
cardiomyopathy
mitochondrial structural and functional impairment
0
$T1$ chemotherapy has been limited due to its cumulative cardiovascular toxicity.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cancer
mitochondrial structural and functional impairment
0
$T1$.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cardiovascular toxicity
mitochondrial structural and functional impairment
0
$T1$ characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.
cardiovascular arrhythmias
mitochondrial structural and functional impairment
0
$T1$, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.
bradycardia
mitochondrial structural and functional impairment
0
$T1$, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.
swelling
mitochondrial structural and functional impairment
0
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
cardiomyopathy
ADR
0
$T1$ chemotherapy has been limited due to its cumulative cardiovascular toxicity.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cancer
ADR
0
$T1$.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cardiovascular toxicity
ADR
0
$T1$ characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.
cardiovascular arrhythmias
ADR
0
$T1$, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.
swelling
ADR
0
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in $T2$
cardiomyopathy
cancer
0
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative $T2$
cardiomyopathy
cardiovascular toxicity
0
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
cardiomyopathy
cardiovascular arrhythmias
0
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
cardiomyopathy
bradycardia
0
$T1$ in mice: suppression of cytochrome c oxidase II gene expression.The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
cardiomyopathy
swelling
0
$T1$ chemotherapy has been limited due to its cumulative $T2$
cancer
cardiovascular toxicity
0
$T1$ chemotherapy has been limited due to its cumulative cardiovascular toxicity.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cancer
cardiovascular arrhythmias
0
$T1$ chemotherapy has been limited due to its cumulative cardiovascular toxicity.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cancer
bradycardia
0
$T1$ chemotherapy has been limited due to its cumulative cardiovascular toxicity.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cancer
swelling
0
$T1$.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cardiovascular toxicity
cardiovascular arrhythmias
0
$T1$.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cardiovascular toxicity
bradycardia
0
$T1$.Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p.
cardiovascular toxicity
swelling
0
$T1$ characterized by $T2$
cardiovascular arrhythmias
bradycardia
0
$T1$ characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent $T2$
cardiovascular arrhythmias
swelling
0
$T1$, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent $T2$
bradycardia
swelling
0
$T1$ after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
bradycardia
isoniazid
1
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
isoniazid
1
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
bradycardia
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
bradycardia
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
bradycardia
0
$T1$-urethane.Isoniazid significantly increased $T2$
chloralose
bradycardia
0
$T1$.Isoniazid significantly increased $T2$
urethane
bradycardia
0
$T1$ after $T2$
bradycardia
propranolol
0
$T1$ after propranolol, $T2$
bradycardia
pindolol
0
$T1$ after propranolol, pindolol, $T2$
bradycardia
labetalol
0
$T1$ after propranolol, pindolol, labetalol and $T2$
bradycardia
atenolol
0
$T1$ after propranolol, pindolol, labetalol and atenolol, as well as after $T2$
bradycardia
clonidine
0
$T1$ after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after $T2$
bradycardia
hexamethonium
0
$T1$ after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or $T2$
bradycardia
carbachol
0
$T1$ after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with $T2$
bradycardia
methylatropine
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
isoniazid
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
isoniazid
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
chloralose
isoniazid
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
urethane
isoniazid
0
$T1$, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
propranolol
isoniazid
0
$T1$, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
pindolol
isoniazid
0
$T1$ and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
labetalol
isoniazid
0
$T1$, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
atenolol
isoniazid
0
$T1$, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
clonidine
isoniazid
0
$T1$ or carbachol.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
hexamethonium
isoniazid
0
$T1$.Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.
carbachol
isoniazid
0
$T1$ or previously vagotomised.These results are compatible with interference by $T2$
methylatropine
isoniazid
0
$T1$ induced by vasodilators and change the accompanying reflex $T2$
hypotension
tachycardia
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid ($T2$
hypotension
GABA
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with $T2$
hypotension
chloralose
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-$T2$
hypotension
urethane
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
propranolol
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
pindolol
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
labetalol
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
atenolol
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
clonidine
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
hexamethonium
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
carbachol
0
$T1$ induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
hypotension
methylatropine
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid ($T2$
tachycardia
GABA
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with $T2$
tachycardia
chloralose
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-$T2$
tachycardia
urethane
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
propranolol
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
pindolol
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
labetalol
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
atenolol
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
clonidine
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
hexamethonium
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
carbachol
0
$T1$ to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
tachycardia
methylatropine
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with $T2$
GABA
chloralose
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-$T2$
GABA
urethane
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
propranolol
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
pindolol
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
labetalol
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
atenolol
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
clonidine
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
hexamethonium
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
carbachol
0
$T1$).In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
GABA
methylatropine
0
$T1$-$T2$
chloralose
urethane
0
$T1$-urethane.Isoniazid significantly increased bradycardia after $T2$
chloralose
propranolol
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, $T2$
chloralose
pindolol
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, $T2$
chloralose
labetalol
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and $T2$
chloralose
atenolol
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after $T2$
chloralose
clonidine
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after $T2$
chloralose
hexamethonium
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or $T2$
chloralose
carbachol
0
$T1$-urethane.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
chloralose
methylatropine
0
$T1$.Isoniazid significantly increased bradycardia after $T2$
urethane
propranolol
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, $T2$
urethane
pindolol
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, $T2$
urethane
labetalol
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and $T2$
urethane
atenolol
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after $T2$
urethane
clonidine
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after $T2$
urethane
hexamethonium
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or $T2$
urethane
carbachol
0
$T1$.Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
urethane
methylatropine
0
$T1$, $T2$
propranolol
pindolol
0
$T1$, pindolol, $T2$
propranolol
labetalol
0
$T1$, pindolol, labetalol and $T2$
propranolol
atenolol
0
$T1$, pindolol, labetalol and atenolol, as well as after $T2$
propranolol
clonidine
0
$T1$, pindolol, labetalol and atenolol, as well as after clonidine, but not after $T2$
propranolol
hexamethonium
0
$T1$, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or $T2$
propranolol
carbachol
0
$T1$, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with $T2$
propranolol
methylatropine
0
$T1$, $T2$
pindolol
labetalol
0
$T1$, labetalol and $T2$
pindolol
atenolol
0
$T1$, labetalol and atenolol, as well as after $T2$
pindolol
clonidine
0
$T1$, labetalol and atenolol, as well as after clonidine, but not after $T2$
pindolol
hexamethonium
0
$T1$, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or $T2$
pindolol
carbachol
0
$T1$, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with $T2$
pindolol
methylatropine
0
$T1$ and $T2$
labetalol
atenolol
0
$T1$ and atenolol, as well as after $T2$
labetalol
clonidine
0
$T1$ and atenolol, as well as after clonidine, but not after $T2$
labetalol
hexamethonium
0
$T1$ and atenolol, as well as after clonidine, but not after hexamethonium or $T2$
labetalol
carbachol
0
$T1$ and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with $T2$
labetalol
methylatropine
0
$T1$, as well as after $T2$
atenolol
clonidine
0
$T1$, as well as after clonidine, but not after $T2$
atenolol
hexamethonium
0
$T1$, as well as after clonidine, but not after hexamethonium or $T2$
atenolol
carbachol
0
$T1$, as well as after clonidine, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with $T2$
atenolol
methylatropine
0
$T1$, but not after $T2$
clonidine
hexamethonium
0
$T1$, but not after hexamethonium or $T2$
clonidine
carbachol
0
$T1$, but not after hexamethonium or carbachol.Enhancement was not observed in rats pretreated with $T2$
clonidine
methylatropine
0
$T1$ or $T2$
hexamethonium
carbachol
0
$T1$ or carbachol.Enhancement was not observed in rats pretreated with $T2$
hexamethonium
methylatropine
0
$T1$.Enhancement was not observed in rats pretreated with $T2$
carbachol
methylatropine
0
$T1$.Physiological dose (<1 mg) of $T2$
seizures
folic acid
1
$T1$) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.Physiological dose (<1 mg) of $T2$
lupus
folic acid
1
$T1$ both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for $T2$
folic acid
epileptic seizures
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
folic acid
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
folic acid
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed status epilepticus and later symptoms of systemic lupus erythematodes.
carbamazepine
folic acid
0
$T1$ and later symptoms of systemic lupus erythematodes.Her pregnancy ended with stillbirth.
status epilepticus
folic acid
0
$T1$.CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.
stillbirth
folic acid
0
$T1$ both in healthy and 60 epileptic women, all without any $T2$
folic acid
autoimmune disease
0
$T1$) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for $T2$
lupus
epileptic seizures
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
lupus
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
lupus
0
$T1$) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of $T2$
lupus
seizures
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed status epilepticus and later symptoms of systemic lupus erythematodes.
carbamazepine
lupus
0
$T1$ and later symptoms of systemic lupus erythematodes.Her pregnancy ended with stillbirth.
status epilepticus
lupus
0
$T1$.CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced $T2$
stillbirth
lupus
0
$T1$) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any $T2$
lupus
autoimmune disease
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
epileptic seizures
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
epileptic seizures
0
$T1$.Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for $T2$
seizures
epileptic seizures
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed status epilepticus and later symptoms of systemic lupus erythematodes.
carbamazepine
epileptic seizures
0
$T1$ and later symptoms of systemic lupus erythematodes.Her pregnancy ended with stillbirth.
status epilepticus
epileptic seizures
0
$T1$.CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.
stillbirth
epileptic seizures
0
$T1$, did not increase the risk for $T2$
autoimmune disease
epileptic seizures
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
cleft lip and palate
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
seizures
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
carbamazepine
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
status epilepticus
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
stillbirth
0
$T1$ and epilepsy-related side effects.STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females.
birth defects
autoimmune disease
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
seizures
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
carbamazepine
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
status epilepticus
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
stillbirth
0
$T1$.Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.
cleft lip and palate
autoimmune disease
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed status epilepticus and later symptoms of systemic lupus erythematodes.
carbamazepine
seizures
0
$T1$ and later symptoms of systemic lupus erythematodes.Her pregnancy ended with stillbirth.
status epilepticus
seizures
0
$T1$.CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of $T2$
stillbirth
seizures
0
$T1$.Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any $T2$
seizures
autoimmune disease
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed $T2$
carbamazepine
status epilepticus
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed status epilepticus and later symptoms of systemic lupus erythematodes.
carbamazepine
stillbirth
0
$T1$ and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.She developed status epilepticus and later symptoms of systemic lupus erythematodes.
carbamazepine
autoimmune disease
0
$T1$ and later symptoms of systemic lupus erythematodes.Her pregnancy ended with $T2$
status epilepticus
stillbirth
0
$T1$ and later symptoms of systemic lupus erythematodes.Her pregnancy ended with stillbirth.
status epilepticus
autoimmune disease
0
$T1$.CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.
stillbirth
autoimmune disease
0
$T1$ and discomfort and may be related to disordered gastrointestinal motility.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
abdominal pain
Cisapride
1
$T1$ affects jejunal contraction characteristics and some symptoms in $T2$
Cisapride
IBS
0
$T1$.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
disordered gastrointestinal motility
Cisapride
0
$T1$-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].
constipation
Cisapride
0
$T1$-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].CONCLUSION: $T2$
Diarrhoea
Cisapride
0
$T1$ score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].CONCLUSION: $T2$
pain
Cisapride
0
$T1$ and discomfort and may be related to disordered gastrointestinal motility.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
abdominal pain
IBS
0
$T1$.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
disordered gastrointestinal motility
IBS
0
$T1$-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].
constipation
IBS
0
$T1$-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in $T2$
Diarrhoea
IBS
0
$T1$ score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in $T2$
pain
IBS
0
$T1$ and discomfort and may be related to $T2$
abdominal pain
disordered gastrointestinal motility
0
$T1$ and discomfort and may be related to disordered gastrointestinal motility.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
abdominal pain
constipation
0
$T1$ and discomfort and may be related to disordered gastrointestinal motility.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
abdominal pain
Diarrhoea
0
$T1$ and discomfort and may be related to disordered gastrointestinal motility.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
abdominal pain
pain
0
$T1$.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
disordered gastrointestinal motility
constipation
0
$T1$.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
disordered gastrointestinal motility
Diarrhoea
0
$T1$.Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
disordered gastrointestinal motility
pain
0
$T1$-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].$T2$
constipation
Diarrhoea
0
$T1$-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].Diarrhoea-predominant IBS patients had a higher $T2$
constipation
pain
0
$T1$-predominant IBS patients had a higher $T2$
Diarrhoea
pain
0
$T1$ and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.Cardiotoxicity has been demonstrated after both intravenous and oral administration of $T2$
gastroenteritis
erythromycin
1
$T1$.Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.
ventricular tachycardia
clarithromycin
1
$T1$.We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of $T2$
macrolides
clarithromycin
0
$T1$ but has never been reported with the newer macrolides.We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of $T2$
erythromycin
clarithromycin
0
$T1$ and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.
gastroenteritis
clarithromycin
0
$T1$ has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of $T2$
Cardiotoxicity
clarithromycin
0
$T1$.The $T2$
clarithromycin
dysrhythmias
0
$T1$.Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.
ventricular tachycardia
macrolides
0
$T1$.Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.
ventricular tachycardia
erythromycin
0
$T1$.Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.
ventricular tachycardia
gastroenteritis
0
$T1$.Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.
ventricular tachycardia
Cardiotoxicity
0
$T1$.Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.
ventricular tachycardia
dysrhythmias
0
$T1$ but has never been reported with the newer $T2$
erythromycin
macrolides
0
$T1$ and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer $T2$
gastroenteritis
macrolides
0
$T1$ has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer $T2$
Cardiotoxicity
macrolides
0
$T1$.We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.
macrolides
dysrhythmias
0
$T1$ has been demonstrated after both intravenous and oral administration of $T2$
Cardiotoxicity
erythromycin
0
$T1$ but has never been reported with the newer macrolides.We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.
erythromycin
dysrhythmias
0
$T1$ and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.$T2$
gastroenteritis
Cardiotoxicity
0
$T1$ and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.
gastroenteritis
dysrhythmias
0
$T1$ has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.
Cardiotoxicity
dysrhythmias
0
$T1$-induced $T2$
lithium
nephrogenic diabetes insipidus
1
$T1$ persisted in this patient for ten years after lithium was stopped.We discuss the possible renal mechanisms and the implications for management of patients with $T2$
polyuria
lithium
1
$T1$ following a head injury.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
dehydration
nephrogenic diabetes insipidus
0
$T1$.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
head injury
nephrogenic diabetes insipidus
0
$T1$ persisted in this patient for ten years after lithium was stopped.We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced $T2$
polyuria
nephrogenic diabetes insipidus
0
$T1$ secretion, with clear evidence of nephrogenic diabetes insipidus.Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.
vasopressin
nephrogenic diabetes insipidus
0
$T1$ following a head injury.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
dehydration
lithium
0
$T1$.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
head injury
lithium
0
$T1$ secretion, with clear evidence of nephrogenic diabetes insipidus.Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.
vasopressin
lithium
0
$T1$ following a $T2$
dehydration
head injury
0
$T1$ following a head injury.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
dehydration
polyuria
0
$T1$ following a head injury.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
dehydration
vasopressin
0
$T1$.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
head injury
polyuria
0
$T1$.Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
head injury
vasopressin
0
$T1$ secretion, with clear evidence of nephrogenic diabetes insipidus.Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but $T2$
vasopressin
polyuria
0
$T1$ increased with length of follow-up (P< or = .05).No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status, except for heart rate variability.
cardiac abnormalities
doxorubicin
1
$T1$ who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
bone tumors
cardiotoxicity
0
$T1$, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
Rosen's T5 or T10 protocol
cardiotoxicity
0
$T1$-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.Life-long cardiac follow-up in these patients is warranted.
doxorubicin
cardiotoxicity
0
$T1$, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).
ventricular arrhythmias
cardiotoxicity
0
$T1$, decreased shortening fraction, or decreased ejection fraction.The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).
ventricular dilation
cardiotoxicity
0
$T1$ increased with length of follow-up (P< or = .05).No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status, except for heart rate variability.
cardiac abnormalities
cardiotoxicity
0
$T1$ who were treated according to $T2$
bone tumors
Rosen's T5 or T10 protocol
0
$T1$ who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
bone tumors
doxorubicin
0
$T1$ who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
bone tumors
ventricular arrhythmias
0
$T1$ who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
bone tumors
ventricular dilation
0
$T1$ who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
bone tumors
cardiac abnormalities
0
$T1$, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
Rosen's T5 or T10 protocol
doxorubicin
0
$T1$, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
Rosen's T5 or T10 protocol
ventricular arrhythmias
0
$T1$, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
Rosen's T5 or T10 protocol
ventricular dilation
0
$T1$, both including doxorubicin.Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment.
Rosen's T5 or T10 protocol
cardiac abnormalities
0
$T1$, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).
ventricular arrhythmias
doxorubicin
0
$T1$, decreased shortening fraction, or decreased ejection fraction.The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).
ventricular dilation
doxorubicin
0
$T1$, left $T2$
ventricular arrhythmias
ventricular dilation
0
$T1$, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.The incidence of $T2$
ventricular arrhythmias
cardiac abnormalities
0
$T1$, decreased shortening fraction, or decreased ejection fraction.The incidence of $T2$
ventricular dilation
cardiac abnormalities
0
$T1$ group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).Swelling and warmth at the injection site were not significantly different between the two groups.
diazepam
venous complications
1
$T1$ group (p < 0.001).Swelling and warmth at the injection site were not significantly different between the two groups.
midazolam
venous complications
1
$T1$ during the injection had no effect on the incidence of $T2$
pain
venous complications
0
$T1$ and warmth at the injection site were not significantly different between the two groups.Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of $T2$
Swelling
venous complications
0
$T1$ use, and pain during the injection had no effect on the incidence of $T2$
alcohol
venous complications
0
$T1$ group compared with 7% (4 of 60 patients) in the $T2$
diazepam
midazolam
0
$T1$ group (p < 0.001).Swelling and warmth at the injection site were not significantly different between the two groups.
midazolam
pain
0
$T1$ group (p < 0.001).$T2$
midazolam
Swelling
0
$T1$ group (p < 0.001).Swelling and warmth at the injection site were not significantly different between the two groups.
midazolam
alcohol
0
$T1$ group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).Swelling and warmth at the injection site were not significantly different between the two groups.
diazepam
pain
0
$T1$ group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).$T2$
diazepam
Swelling
0
$T1$ group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).Swelling and warmth at the injection site were not significantly different between the two groups.
diazepam
alcohol
0
$T1$ and warmth at the injection site were not significantly different between the two groups.Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and $T2$
Swelling
pain
0
$T1$ use, and $T2$
alcohol
pain
0
$T1$ and warmth at the injection site were not significantly different between the two groups.Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, $T2$
Swelling
alcohol
0
$T1$ due to surreptitious $T2$
rhabdomyolysis
furosemide
1
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
tetany
1
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
tetany
0
$T1$ which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
tetany
magnesium
0
$T1$ which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
tetany
hypokalemia
0
$T1$ which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
tetany
hypocalcemia
0
$T1$ is associated with muscle spasms and $T2$
hypomagnesemia
tetany
0
$T1$, severe hypomagnesemia is associated with muscle spasms and $T2$
muscle weakness
tetany
0
$T1$ and $T2$
muscle spasms
tetany
0
$T1$ which cannot be corrected by $T2$
tetany
potassium
0
$T1$ which cannot be corrected by potassium and $T2$
tetany
calcium
0
$T1$ which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are $T2$
tetany
obese
0
$T1$ which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or $T2$
tetany
edematous
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
magnesium
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
hypokalemia
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
hypocalcemia
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
hypomagnesemia
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
muscle weakness
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
muscle spasms
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
potassium
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
calcium
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
obese
0
$T1$ due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
rhabdomyolysis
edematous
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
magnesium
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
hypokalemia
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
hypocalcemia
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
hypomagnesemia
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
muscle weakness
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
muscle spasms
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
potassium
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
calcium
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
obese
0
$T1$--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.
furosemide
edematous
0
$T1$ has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of $T2$
hypokalemia
magnesium
0
$T1$ was observed (8), but the effects of $T2$
hypocalcemia
magnesium
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
hypomagnesemia
magnesium
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
muscle weakness
magnesium
0
$T1$ and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
muscle spasms
magnesium
0
$T1$ and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
potassium
magnesium
0
$T1$ supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
calcium
magnesium
0
$T1$ or edematous.Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of $T2$
obese
magnesium
0
$T1$.Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of $T2$
edematous
magnesium
0
$T1$ has been reported in such patients (3-7) and in one case $T2$
hypokalemia
hypocalcemia
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
hypomagnesemia
hypokalemia
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
muscle weakness
hypokalemia
0
$T1$ and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
muscle spasms
hypokalemia
0
$T1$ and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
potassium
hypokalemia
0
$T1$ supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
calcium
hypokalemia
0
$T1$ or edematous.Symptomatic $T2$
obese
hypokalemia
0
$T1$.Symptomatic $T2$
edematous
hypokalemia
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
hypomagnesemia
hypocalcemia
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
muscle weakness
hypocalcemia
0
$T1$ and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
muscle spasms
hypocalcemia
0
$T1$ and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
potassium
hypocalcemia
0
$T1$ supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or edematous.
calcium
hypocalcemia
0
$T1$ or edematous.Symptomatic hypokalemia has been reported in such patients (3-7) and in one case $T2$
obese
hypocalcemia
0
$T1$.Symptomatic hypokalemia has been reported in such patients (3-7) and in one case $T2$
edematous
hypocalcemia
0
$T1$, severe $T2$
muscle weakness
hypomagnesemia
0
$T1$ is associated with $T2$
hypomagnesemia
muscle spasms
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by $T2$
hypomagnesemia
potassium
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by potassium and $T2$
hypomagnesemia
calcium
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are $T2$
hypomagnesemia
obese
0
$T1$ is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or $T2$
hypomagnesemia
edematous
0
$T1$, severe hypomagnesemia is associated with $T2$
muscle weakness
muscle spasms
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by $T2$
muscle weakness
potassium
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and $T2$
muscle weakness
calcium
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are $T2$
muscle weakness
obese
0
$T1$, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or $T2$
muscle weakness
edematous
0
$T1$ and tetany which cannot be corrected by $T2$
muscle spasms
potassium
0
$T1$ and tetany which cannot be corrected by potassium and $T2$
muscle spasms
calcium
0
$T1$ and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are $T2$
muscle spasms
obese
0
$T1$ and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or $T2$
muscle spasms
edematous
0
$T1$ and $T2$
potassium
calcium
0
$T1$ and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are $T2$
potassium
obese
0
$T1$ and calcium supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or $T2$
potassium
edematous
0
$T1$ supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are $T2$
calcium
obese
0
$T1$ supplementation alone (1,2).Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or $T2$
calcium
edematous
0
$T1$ or $T2$
obese
edematous
0
$T1$-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.
pilocarpine
seizure
1
$T1$-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to $T2$
pilocarpine
neuronal loss
1
$T1$ decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
glutamic acid
pilocarpine
0
$T1$ decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
glutamic acid
seizure
0
$T1$ decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
glutamic acid
digoxigenin
0
$T1$ decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
glutamic acid
cresyl violet
0
$T1$ decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
glutamic acid
neuronal loss
0
$T1$ decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.
glutamic acid
GABA
0
$T1$-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the $T2$
digoxigenin
pilocarpine
0
$T1$-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including $T2$
pilocarpine
cresyl violet
0
$T1$-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.
pilocarpine
GABA
0
$T1$-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.
digoxigenin
seizure
0
$T1$ staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.
cresyl violet
seizure
0
$T1$ rather than to a decrease in GAD mRNA levels.The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.
neuronal loss
seizure
0
$T1$-induced damage.Such differential vulnerability appears to be another indication of the heterogeneity of $T2$
seizure
GABA
0
$T1$-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including $T2$
digoxigenin
cresyl violet
0
$T1$-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to $T2$
digoxigenin
neuronal loss
0
$T1$-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.
digoxigenin
GABA
0
$T1$ staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to $T2$
cresyl violet
neuronal loss
0
$T1$ staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.
cresyl violet
GABA
0
$T1$ rather than to a decrease in GAD mRNA levels.The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.
neuronal loss
GABA
0
$T1$ related renal dysfunction.Addition of misoprostol can minimize this $T2$
indomethacin
renal impairment
1
$T1$ related renal dysfunction.Addition of $T2$
indomethacin
misoprostol
0
$T1$ can minimize this $T2$
misoprostol
renal impairment
0
$T1$, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
creatinine
misoprostol
0
$T1$, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
BUN
misoprostol
0
$T1$ can minimize this renal impairment without affecting $T2$
misoprostol
pain
0
$T1$ were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
K
misoprostol
0
$T1$, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
creatinine
indomethacin
0
$T1$, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
BUN
indomethacin
0
$T1$ related renal dysfunction.Addition of misoprostol can minimize this renal impairment without affecting $T2$
indomethacin
pain
0
$T1$ were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
K
indomethacin
0
$T1$, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
creatinine
renal impairment
0
$T1$, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
BUN
renal impairment
0
$T1$ without affecting $T2$
renal impairment
pain
0
$T1$ were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
K
renal impairment
0
$T1$, $T2$
BUN
creatinine
0
$T1$, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
creatinine
pain
0
$T1$, and $T2$
creatinine
K
0
$T1$, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
BUN
pain
0
$T1$, creatinine, and $T2$
BUN
K
0
$T1$ were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A.Response to treatment did not differ significantly between the 2 groups.
K
pain
0
$T1$ and gentamicin.Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing $T2$
kanamycin
impairment of renal reabsorption
1
$T1$.Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing $T2$
gentamicin
impairment of renal reabsorption
1
$T1$ may act as nephrotoxicants at glomerular and/or tubular level inducing $T2$
aminoglycosides
impairment of renal reabsorption
0
$T1$ had no effect.Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin.
netilmicin
impairment of renal reabsorption
0
$T1$ and potassium.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
sodium
impairment of renal reabsorption
0
$T1$.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
potassium
impairment of renal reabsorption
0
$T1$.Thus, $T2$
gentamicin
aminoglycosides
0
$T1$ and gentamicin.Thus, $T2$
kanamycin
aminoglycosides
0
$T1$ had no effect.Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin.
netilmicin
aminoglycosides
0
$T1$ and potassium.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
sodium
aminoglycosides
0
$T1$.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
potassium
aminoglycosides
0
$T1$ and $T2$
kanamycin
gentamicin
0
$T1$ had no effect.Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and $T2$
netilmicin
gentamicin
0
$T1$ and potassium.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
sodium
gentamicin
0
$T1$.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
potassium
gentamicin
0
$T1$ had no effect.Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with $T2$
netilmicin
kanamycin
0
$T1$ and potassium.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
sodium
kanamycin
0
$T1$.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
potassium
kanamycin
0
$T1$ and potassium.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
sodium
netilmicin
0
$T1$.While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i.v.
potassium
netilmicin
0
$T1$ and $T2$
sodium
potassium
0
$T1$ $T2$
ouabain
arrhythmia
1
$T1$, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.Its antiarrhythmic effectiveness surpasses that of $T2$
GYKI-41 099
propranolol
0
$T1$, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.Its antiarrhythmic effectiveness surpasses that of propranolol and $T2$
GYKI-41 099
pindolol
0
$T1$, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the $T2$
GYKI-41 099
ouabain
0
$T1$, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain $T2$
GYKI-41 099
arrhythmia
0
$T1$, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.
GYKI-41 099
14C-41 099
0
$T1$ and $T2$
propranolol
pindolol
0
$T1$ and pindolol inhibiting the $T2$
propranolol
ouabain
0
$T1$ and pindolol inhibiting the ouabain $T2$
propranolol
arrhythmia
0
$T1$ and pindolol inhibiting the ouabain arrhythmia in dogs and cats.GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.
propranolol
14C-41 099
0
$T1$ inhibiting the $T2$
pindolol
ouabain
0
$T1$ inhibiting the ouabain $T2$
pindolol
arrhythmia
0
$T1$ inhibiting the ouabain arrhythmia in dogs and cats.GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.
pindolol
14C-41 099
0
$T1$ arrhythmia in dogs and cats.GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.
ouabain
14C-41 099
0
$T1$ in dogs and cats.GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.
arrhythmia
14C-41 099
0
$T1$.Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had $T2$
oral contraception
chorea
1
$T1$-induced chorea after prolonged oral contraception.Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had $T2$
amphetamine
chorea
1
$T1$ or $T2$
chorea
rheumatic fever
0
$T1$-induced chorea after prolonged $T2$
amphetamine
oral contraception
0
$T1$.Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or $T2$
oral contraception
rheumatic fever
0
$T1$-induced chorea after prolonged oral contraception.Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or $T2$
amphetamine
rheumatic fever
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
NH4CL
coma
1
$T1$ $T2$
ammonia
coma
0
$T1$ coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving $T2$
ammonia
L-dopa
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
NH4CL
ammonia
0
$T1$ injection.The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.
ammonium salt
ammonia
0
$T1$ coma after L-dopa, can be accounted for by the peripheral effect of $T2$
ammonia
dopamine
0
$T1$.Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
urea
ammonia
0
$T1$ coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.These results provide a reasonable explanation for the beneficial effects observed in some $T2$
ammonia
encephalopathic
0
$T1$ after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving $T2$
coma
L-dopa
0
$T1$ injection.The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.
ammonium salt
coma
0
$T1$ after L-dopa, can be accounted for by the peripheral effect of $T2$
coma
dopamine
0
$T1$.Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
urea
coma
0
$T1$ after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.These results provide a reasonable explanation for the beneficial effects observed in some $T2$
coma
encephalopathic
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
NH4CL
L-dopa
0
$T1$ injection.The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.
ammonium salt
L-dopa
0
$T1$ on renal function rather than its central action.These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving $T2$
dopamine
L-dopa
0
$T1$.Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
urea
L-dopa
0
$T1$ patients receiving $T2$
encephalopathic
L-dopa
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the $T2$
NH4CL
ammonium salt
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
NH4CL
dopamine
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
NH4CL
urea
0
$T1$.This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
NH4CL
encephalopathic
0
$T1$ injection.The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.
ammonium salt
dopamine
0
$T1$ injection.The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and $T2$
ammonium salt
urea
0
$T1$ injection.The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea.
ammonium salt
encephalopathic
0
$T1$.Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
urea
dopamine
0
$T1$ on renal function rather than its central action.These results provide a reasonable explanation for the beneficial effects observed in some $T2$
dopamine
encephalopathic
0
$T1$.Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
urea
encephalopathic
0
$T1$-related HIT.CONCLUSIONS: In our series, the occurrence of $T2$
UFH
HIT
1
$T1$ (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.
low-molecular weight heparin
UFH
0
$T1$ on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.In 2 other patients, the platelet count decreased suddenly from 107 x 10(9)/L on POD 4 to 65 x 10(9)/L on POD 6 and from 76 x 10(9)/L on POD 7 to 33 x 10(9)/L on POD 9, respectively.
thrombosis
UFH
0
$T1$ test was negative in these patients.The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.
platelet aggregation
UFH
0
$T1$ (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.
low-molecular weight heparin
HIT
0
$T1$ on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.In 2 other patients, the platelet count decreased suddenly from 107 x 10(9)/L on POD 4 to 65 x 10(9)/L on POD 6 and from 76 x 10(9)/L on POD 7 to 33 x 10(9)/L on POD 9, respectively.
thrombosis
HIT
0
$T1$ test was negative in these patients.The percentage of HIT antibody-positive patients was 0.5% preoperatively, 5.6% on POD 7, and 5.6% on POD 14.
platelet aggregation
HIT
0
$T1$ (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.
low-molecular weight heparin
thrombosis
0
$T1$ (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.
low-molecular weight heparin
platelet aggregation
0
$T1$ on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.In 2 other patients, the platelet count decreased suddenly from 107 x 10(9)/L on POD 4 to 65 x 10(9)/L on POD 6 and from 76 x 10(9)/L on POD 7 to 33 x 10(9)/L on POD 9, respectively.
thrombosis
platelet aggregation
0
$T1$.Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the $T2$
PTU
vasculitis
1
$T1$ and Graves' disease who presented with palpable purpuric lesions.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of $T2$
Turner syndrome
PTU
0
$T1$ who presented with palpable purpuric lesions.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of $T2$
Graves' disease
PTU
0
$T1$.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of $T2$
purpuric lesions
PTU
0
$T1$.Subsequent treatment of persistent $T2$
PTU
hyperthyroidism
0
$T1$ and Graves' disease who presented with palpable purpuric lesions.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
Turner syndrome
vasculitis
0
$T1$ who presented with palpable purpuric lesions.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
Graves' disease
vasculitis
0
$T1$.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
purpuric lesions
vasculitis
0
$T1$ with radioablation did not result in an exacerbation of the $T2$
hyperthyroidism
vasculitis
0
$T1$ and $T2$
Turner syndrome
Graves' disease
0
$T1$ and Graves' disease who presented with palpable $T2$
Turner syndrome
purpuric lesions
0
$T1$ and Graves' disease who presented with palpable purpuric lesions.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
Turner syndrome
hyperthyroidism
0
$T1$ who presented with palpable $T2$
Graves' disease
purpuric lesions
0
$T1$ who presented with palpable purpuric lesions.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
Graves' disease
hyperthyroidism
0
$T1$.The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
purpuric lesions
hyperthyroidism
0
$T1$) after succinylcholine ($T2$
jaw of steel
Sch
1
$T1$) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat $T2$
Sch
malignant hyperthermia
0
$T1$) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.Anesthesia was continued uneventfully with $T2$
Sch
propofol
0
$T1$) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat $T2$
jaw of steel
malignant hyperthermia
0
$T1$) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.Anesthesia was continued uneventfully with $T2$
jaw of steel
propofol
0
$T1$ infusion while all facilities were available to detect and treat $T2$
propofol
malignant hyperthermia
0
$T1$.Neurological development was affected even without neurological diagnosis.
neurological dysfunctions
dexamethasone
1
$T1$, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
asphyxia
neurological dysfunctions
0
$T1$, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
malformations
neurological dysfunctions
0
$T1$ grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
haemorrhage
neurological dysfunctions
0
$T1$, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
periventricular leukomalacia
neurological dysfunctions
0
$T1$.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
psychomotor retardation
neurological dysfunctions
0
$T1$, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
asphyxia
dexamethasone
0
$T1$, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
malformations
dexamethasone
0
$T1$ grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
haemorrhage
dexamethasone
0
$T1$, and severe psychomotor retardation.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
periventricular leukomalacia
dexamethasone
0
$T1$.Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.
psychomotor retardation
dexamethasone
0
$T1$, $T2$
asphyxia
malformations
0
$T1$, malformations, major surgical interventions, small for gestational age, intraventricular $T2$
asphyxia
haemorrhage
0
$T1$, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, $T2$
asphyxia
periventricular leukomalacia
0
$T1$, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe $T2$
asphyxia
psychomotor retardation
0
$T1$, major surgical interventions, small for gestational age, intraventricular $T2$
malformations
haemorrhage
0
$T1$, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, $T2$
malformations
periventricular leukomalacia
0
$T1$, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe $T2$
malformations
psychomotor retardation
0
$T1$ grades III and IV, $T2$
haemorrhage
periventricular leukomalacia
0
$T1$ grades III and IV, periventricular leukomalacia, and severe $T2$
haemorrhage
psychomotor retardation
0
$T1$, and severe $T2$
periventricular leukomalacia
psychomotor retardation
0
$T1$ (by 61%, P < 0.05).An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.
levodopa
LID
1
$T1$ (by 61%, P < 0.05).An overshooting of peak grip force by 51% (P < 0.05) and of static grip force by 45% (P < 0.01) was observed in the ON- compared with the OFF-drug condition.
levodopa
Parkinson's disease
0
$T1$ - LID, while static grip force was increased by 138% (P < 0.01) between groups.Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).
Parkinson's disease
LID
0
$T1$ therapy and subsequent postinfarction $T2$
steroid
septal rupture
1
$T1$ with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of $T2$
angioedema
droperidol
1
$T1$ involving the subcutaneous tissues that may cause upper-airway obstruction.We report the case of a previously healthy 19-year-old man with no known drug allergies in whom $T2$
edema
angioedema
0
$T1$.We report the case of a previously healthy 19-year-old man with no known drug allergies in whom $T2$
upper-airway obstruction
angioedema
0
$T1$ in whom $T2$
drug allergies
angioedema
0
$T1$ with significant $T2$
angioedema
tongue swelling
0
$T1$ involving the subcutaneous tissues that may cause upper-airway obstruction.We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of $T2$
edema
droperidol
0
$T1$.We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of $T2$
upper-airway obstruction
droperidol
0
$T1$ in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of $T2$
drug allergies
droperidol
0
$T1$ and protrusion developed within 10 minutes of the administration of a single IV dose of $T2$
tongue swelling
droperidol
0
$T1$ involving the subcutaneous tissues that may cause $T2$
edema
upper-airway obstruction
0
$T1$ involving the subcutaneous tissues that may cause upper-airway obstruction.We report the case of a previously healthy 19-year-old man with no known $T2$
edema
drug allergies
0
$T1$ involving the subcutaneous tissues that may cause upper-airway obstruction.We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant $T2$
edema
tongue swelling
0
$T1$.We report the case of a previously healthy 19-year-old man with no known $T2$
upper-airway obstruction
drug allergies
0
$T1$.We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant $T2$
upper-airway obstruction
tongue swelling
0
$T1$ in whom angioedema with significant $T2$
drug allergies
tongue swelling
0
$T1$ occurring in association with the new macrolide antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
visual hallucinations
clarithromycin
1
$T1$ in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the $T2$
clarithromycin
ESRD
0
$T1$ per se.Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.
uremia
clarithromycin
0
$T1$ antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
macrolide
clarithromycin
0
$T1$ in face of chronic renal failure in a functionally anephric patient, with underlying $T2$
clarithromycin
aluminum
0
$T1$ in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this $T2$
clarithromycin
neurotoxic
0
$T1$ occurring in association with the new macrolide antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
visual hallucinations
ESRD
0
$T1$ per se.Unreported in the literature is $T2$
uremia
visual hallucinations
0
$T1$ occurring in association with the new $T2$
visual hallucinations
macrolide
0
$T1$ occurring in association with the new macrolide antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
visual hallucinations
aluminum
0
$T1$ occurring in association with the new macrolide antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
visual hallucinations
neurotoxic
0
$T1$ per se.Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.
uremia
ESRD
0
$T1$ antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
macrolide
ESRD
0
$T1$ intoxication, may have facilitated the appearance of this neurotoxic side effect.It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the $T2$
aluminum
ESRD
0
$T1$ side effect.It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the $T2$
neurotoxic
ESRD
0
$T1$ per se.Unreported in the literature is visual hallucinations occurring in association with the new $T2$
uremia
macrolide
0
$T1$ per se.Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.
uremia
aluminum
0
$T1$ per se.Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.
uremia
neurotoxic
0
$T1$ antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
macrolide
aluminum
0
$T1$ antibiotic, clarithromycin.We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).
macrolide
neurotoxic
0
$T1$ intoxication, may have facilitated the appearance of this $T2$
aluminum
neurotoxic
0
$T1$ appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.Rats treated by unloaded NP behaved as controls.
Proteinuria
DX
1
$T1$, despite of an enhanced $T2$
DX
renal toxicity
0
$T1$ nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
cyanoacrylate
renal toxicity
0
$T1$, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.
glomerulonephritis
renal toxicity
0
$T1$ appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.Rats treated by unloaded NP behaved as controls.
Proteinuria
renal toxicity
0
$T1$ of the former.Both effects (better survival and $T2$
renal toxicity
nephrosis
0
$T1$ nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
cyanoacrylate
DX
0
$T1$, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.
glomerulonephritis
DX
0
$T1$, despite of an enhanced renal toxicity of the former.Both effects (better survival and $T2$
DX
nephrosis
0
$T1$ nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
cyanoacrylate
glomerulonephritis
0
$T1$ nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
cyanoacrylate
Proteinuria
0
$T1$ nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
cyanoacrylate
nephrosis
0
$T1$, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.$T2$
glomerulonephritis
Proteinuria
0
$T1$, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.
glomerulonephritis
nephrosis
0
$T1$ appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.Rats treated by unloaded NP behaved as controls.
Proteinuria
nephrosis
0
$T1$ is reported after chemotherapy containing $T2$
myocardial infarction
etoposide
1
$T1$, in a man with no risk factors for $T2$
etoposide
coronary heart disease
0
$T1$ is reported after chemotherapy containing etoposide, in a man with no risk factors for $T2$
myocardial infarction
coronary heart disease
0
$T1$ effect on plasma estradiol, testosterone, and LH.The differences in the means were significant.
digoxin
decrease in sexual desire
1
$T1$ and decreased levels of plasma testosterone and luteinizing hormone (LH).This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.
estrogen
decrease in sexual desire
0
$T1$, and LH.The differences in the means were significant.
testosterone
decrease in sexual desire
0
$T1$, testosterone, and LH.The differences in the means were significant.
estradiol
decrease in sexual desire
0
$T1$ patients.A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.
rheumatic heart disease
decrease in sexual desire
0
$T1$ and decreased levels of plasma testosterone and luteinizing hormone (LH).This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.
estrogen
digoxin
0
$T1$ effect on plasma estradiol, $T2$
digoxin
testosterone
0
$T1$ effect on plasma $T2$
digoxin
estradiol
0
$T1$ patients.A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.
rheumatic heart disease
digoxin
0
$T1$ and decreased levels of plasma testosterone and luteinizing hormone (LH).This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.
estrogen
testosterone
0
$T1$ and decreased levels of plasma testosterone and luteinizing hormone (LH).This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.
estrogen
estradiol
0
$T1$ and decreased levels of plasma testosterone and luteinizing hormone (LH).This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH.
estrogen
rheumatic heart disease
0
$T1$, $T2$
estradiol
testosterone
0
$T1$ patients.A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.
rheumatic heart disease
testosterone
0
$T1$ patients.A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.
rheumatic heart disease
estradiol
0
$T1$ in vitro further substantiates the potential role of this drug in causing $T2$
indomethacin
aplastic anemia
1
$T1$ and indomethacin were given.Indomethacin was first given four weeks prior to the onset of symptoms.
allopurinol
aplastic anemia
0
$T1$ and indomethacin were given.Indomethacin was first given four weeks prior to the onset of symptoms.
allopurinol
indomethacin
0
$T1$ alters plasma lipoproteins by lowering VLDL and increasing HDL.It is likely that the early and striking increase of plasma HDL found in $T2$
puromycin aminonucleoside
nephrotic
1
$T1$ occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.
albuminuria
nephrotic
0
$T1$, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.Plasma apolipoprotein A-I tended to increase (40% increase at day 5).
fatty acids
nephrotic
0
$T1$ and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.Plasma apolipoprotein A-I tended to increase (40% increase at day 5).
triacylglycerol
nephrotic
0
$T1$ and HDL remained constant.Plasma apolipoprotein A-I tended to increase (40% increase at day 5).
cholesteryl esters
nephrotic
0
$T1$ occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.
albuminuria
puromycin aminonucleoside
0
$T1$, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.Plasma apolipoprotein A-I tended to increase (40% increase at day 5).
fatty acids
puromycin aminonucleoside
0
$T1$ and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.Plasma apolipoprotein A-I tended to increase (40% increase at day 5).
triacylglycerol
puromycin aminonucleoside
0
$T1$ and HDL remained constant.Plasma apolipoprotein A-I tended to increase (40% increase at day 5).
cholesteryl esters
puromycin aminonucleoside
0
$T1$ occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).In pre-nephrotic stage the plasma level of $T2$
albuminuria
fatty acids
0
$T1$ occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).In pre-nephrotic stage the plasma level of fatty acids, $T2$
albuminuria
triacylglycerol
0
$T1$ occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, $T2$
albuminuria
cholesteryl esters
0
$T1$, $T2$
fatty acids
triacylglycerol
0
$T1$, triacylglycerol and VLDL decreased while that of phospholipid, $T2$
fatty acids
cholesteryl esters
0
$T1$ and VLDL decreased while that of phospholipid, $T2$
triacylglycerol
cholesteryl esters
0
$T1$ overdose, whereas activities were increased equally in patients with $T2$
paracetamol
fulminant hepatic failure
1
$T1$, whereas activities were increased equally in patients with $T2$
overdose
fulminant hepatic failure
0
$T1$ due to $T2$
fulminant hepatic failure
viral hepatitis
0
$T1$ due to viral hepatitis whether or not they survived.A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with $T2$
fulminant hepatic failure
aspartate
0
$T1$ $T2$
paracetamol
overdose
0
$T1$ overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to $T2$
paracetamol
viral hepatitis
0
$T1$ overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with $T2$
paracetamol
aspartate
0
$T1$, whereas activities were increased equally in patients with fulminant hepatic failure due to $T2$
overdose
viral hepatitis
0
$T1$, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with $T2$
overdose
aspartate
0
$T1$ whether or not they survived.A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with $T2$
viral hepatitis
aspartate
0
$T1$-induced $T2$
tolazamide
Wernicke's encephalopathy
1
$T1$-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.
thiamine
tolazamide
0
$T1$ kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with $T2$
diabetic
tolazamide
0
$T1$.These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with $T2$
TPP
tolazamide
0
$T1$ and the patient with $T2$
Wernicke-Korsakoff syndrome
tolazamide
0
$T1$-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.
thiamine
Wernicke's encephalopathy
0
$T1$ kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced $T2$
diabetic
Wernicke's encephalopathy
0
$T1$.These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced $T2$
TPP
Wernicke's encephalopathy
0
$T1$ and the patient with tolazamide-induced $T2$
Wernicke-Korsakoff syndrome
Wernicke's encephalopathy
0
$T1$-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.
thiamine
diabetic
0
$T1$-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.
thiamine
TPP
0
$T1$-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.
thiamine
Wernicke-Korsakoff syndrome
0
$T1$ kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for $T2$
diabetic
TPP
0
$T1$ kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.These data suggest a similarity between postalcoholic $T2$
diabetic
Wernicke-Korsakoff syndrome
0
$T1$.These data suggest a similarity between postalcoholic $T2$
TPP
Wernicke-Korsakoff syndrome
0
$T1$ was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.These findings indicate that ischemia produced by $T2$
myocardial ischemia
epinephrine
1
$T1$ was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.These findings indicate that $T2$
myocardial ischemia
ischemia
0
$T1$.Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
coronary artery disease
myocardial ischemia
0
$T1$ consumption were compared during epinephrine infusion and supine bicycle exercise.Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
oxygen
myocardial ischemia
0
$T1$ and angina.However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
depression
myocardial ischemia
0
$T1$.However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
angina
myocardial ischemia
0
$T1$ produced by $T2$
ischemia
epinephrine
0
$T1$.Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
coronary artery disease
epinephrine
0
$T1$ consumption were compared during epinephrine infusion and supine bicycle exercise.Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
oxygen
epinephrine
0
$T1$ and angina.However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
depression
epinephrine
0
$T1$.However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
angina
epinephrine
0
$T1$.Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
coronary artery disease
ischemia
0
$T1$ consumption were compared during epinephrine infusion and supine bicycle exercise.Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
oxygen
ischemia
0
$T1$ and angina.However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
depression
ischemia
0
$T1$.However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
angina
ischemia
0
$T1$.Objective signs of ischemia and factors increasing myocardial $T2$
coronary artery disease
oxygen
0
$T1$.Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
coronary artery disease
depression
0
$T1$.Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
coronary artery disease
angina
0
$T1$ consumption were compared during epinephrine infusion and supine bicycle exercise.Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment $T2$
oxygen
depression
0
$T1$ consumption were compared during epinephrine infusion and supine bicycle exercise.Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and $T2$
oxygen
angina
0
$T1$ and $T2$
depression
angina
0
$T1$ has an irreversible effect on the post-lesion DA pool contributing to $T2$
amphetamine
contralateral rotation
1
$T1$, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.
SN lesion
contralateral rotation
0
$T1$ induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.
6-OHDA
contralateral rotation
0
$T1$, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.
SN lesion
amphetamine
0
$T1$ induced $T2$
6-OHDA
SN lesion
0
$T1$ induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine-induced rotational behavior.
6-OHDA
amphetamine
0
$T1$ patients concentrated their urine well.It is concluded that the dominant mechanisms by which $T2$
hypothyroid
lithium
1
$T1$ and hypothyroidism during lithium treatment.We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.
nephrogenic diabetes insipidus
lithium
0
$T1$ and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.Hypothyroidism developed in eight patients while they were taking lithium.
thyroxine
lithium
0
$T1$ and hypothyroidism during lithium treatment.We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.
nephrogenic diabetes insipidus
hypothyroid
0
$T1$ and hypothyroidism during lithium treatment.We measured serum $T2$
nephrogenic diabetes insipidus
thyroxine
0
$T1$ and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.Hypothyroidism developed in eight patients while they were taking lithium.
thyroxine
hypothyroid
0
$T1$-induced peripheral $T2$
AZT
anaemia
1
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
AZT
0
$T1$, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
AIDS
AZT
0
$T1$ of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
infection
AZT
0
$T1$ (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
leukaemia
AZT
0
$T1$ treated mice with similar degrees of anaemia.However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.
PHZ
AZT
0
$T1$ was inappropriate for the degree of anaemia observed in AZT treated infected mice.$T2$
reticulocytosis
AZT
0
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
anaemia
0
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
AIDS
0
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
infection
0
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
leukaemia
0
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
PHZ
0
$T1$ mice.The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
immunodeficient
reticulocytosis
0
$T1$, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
AIDS
anaemia
0
$T1$ of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
infection
anaemia
0
$T1$ (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
leukaemia
anaemia
0
$T1$ treated mice with similar degrees of anaemia.However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.
PHZ
anaemia
0
$T1$ was inappropriate for the degree of anaemia observed in AZT treated infected mice.AZT-induced peripheral $T2$
reticulocytosis
anaemia
0
$T1$, $T2$
AIDS
infection
0
$T1$, infection of female C57BL/6 mice with LP-BM5 murine $T2$
AIDS
leukaemia
0
$T1$, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
AIDS
PHZ
0
$T1$, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
AIDS
reticulocytosis
0
$T1$ of female C57BL/6 mice with LP-BM5 murine $T2$
infection
leukaemia
0
$T1$ of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
infection
PHZ
0
$T1$ of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
infection
reticulocytosis
0
$T1$ (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
leukaemia
PHZ
0
$T1$ (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.
leukaemia
reticulocytosis
0
$T1$ treated mice with similar degrees of anaemia.However, $T2$
PHZ
reticulocytosis
0
$T1$-induced $T2$
adriamycin
cardiomyopathy
1
$T1$ scintigraphy may be a useful method for detection of $T2$
MIBG
adriamycin
0
$T1$), serves as an index of adrenergic neuron integrity and function.Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.
NE
adriamycin
0
$T1$) indicates that MIBG scintigraphy may be a useful method for detection of $T2$
vacuolar degeneration
adriamycin
0
$T1$ scintigraphy may be a useful method for detection of adriamycin-induced $T2$
MIBG
cardiomyopathy
0
$T1$), serves as an index of adrenergic neuron integrity and function.Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.
NE
cardiomyopathy
0
$T1$) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced $T2$
vacuolar degeneration
cardiomyopathy
0
$T1$), serves as an index of adrenergic neuron integrity and function.Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.
NE
MIBG
0
$T1$) indicates that $T2$
vacuolar degeneration
MIBG
0
$T1$), serves as an index of adrenergic neuron integrity and function.Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.
NE
vacuolar degeneration
0
$T1$ associated with propranolol toxicity: a case report.An elderly woman developed an Alzheimer-like subacute dementia as a result of $T2$
Amnestic syndrome
propranolol
1
$T1$ associated with propranolol toxicity: a case report.An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.
Amnestic syndrome
toxicity
0
$T1$ associated with propranolol toxicity: a case report.An elderly woman developed an $T2$
Amnestic syndrome
Alzheimer
0
$T1$ associated with propranolol toxicity: a case report.An elderly woman developed an Alzheimer-like subacute $T2$
Amnestic syndrome
dementia
0
$T1$ toxicity.Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.
propranolol
toxicity
0
$T1$-like subacute dementia as a result of $T2$
Alzheimer
propranolol
0
$T1$ as a result of $T2$
dementia
propranolol
0
$T1$-like subacute dementia as a result of propranolol toxicity.Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.
Alzheimer
toxicity
0
$T1$ as a result of propranolol toxicity.Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities.
dementia
toxicity
0
$T1$-like subacute $T2$
Alzheimer
dementia
0
$T1$, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of $T2$
tachycardia
ketamine
1
$T1$ was followed by the sudden appearance of a stimulatory phase.Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.
depression
ketamine
0
$T1$ was followed by the sudden appearance of a stimulatory phase.Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced $T2$
depression
tachycardia
0
$T1$ $T2$
succinylcholine
apnoea
1
$T1$ that accompanied the $T2$
bradycardia
noradrenaline
1
$T1$ when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).Conversely, administration of rauwolscine (3 mg kg-1 i.v.)
orthostatic hypotension
prazosin
1
$T1$ were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.
cirazoline
bradycardia
1
$T1$ rats (SHR).2.
hypertensive
Abbott-53693
1
$T1$ rats (SHR).2.
hypertensive
noradrenaline
1
$T1$ were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.Furthermore, the $T2$
Abbott-53693
bradycardia
1
$T1$ rats (SHR).2.
hypertensive
cirazoline
1
$T1$ rats (SHR).2.
hypertensive
orthostatic hypotension
0
$T1$ when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).Conversely, administration of $T2$
orthostatic hypotension
rauwolscine
0
$T1$ when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).Conversely, administration of rauwolscine (3 mg kg-1 i.v.)
orthostatic hypotension
bradycardia
0
$T1$ when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).Conversely, administration of rauwolscine (3 mg kg-1 i.v.)
orthostatic hypotension
cirazoline
0
$T1$ when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).Conversely, administration of rauwolscine (3 mg kg-1 i.v.)
orthostatic hypotension
Abbott-53693
0
$T1$ when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).Conversely, administration of rauwolscine (3 mg kg-1 i.v.)
orthostatic hypotension
noradrenaline
0
$T1$ rats (SHR).2.
hypertensive
prazosin
0
$T1$ (3 mg kg-1 i.v.)in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.
rauwolscine
prazosin
0
$T1$ that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic $T2$
bradycardia
prazosin
0
$T1$ were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.
cirazoline
prazosin
0
$T1$ were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic $T2$
Abbott-53693
prazosin
0
$T1$-induced pressor effect in SHR was similar with and without chronic $T2$
noradrenaline
prazosin
0
$T1$ rats (SHR).2.
hypertensive
rauwolscine
0
$T1$ rats (SHR).2.
hypertensive
bradycardia
0
$T1$ (3 mg kg-1 i.v.)in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.
rauwolscine
bradycardia
0
$T1$ (3 mg kg-1 i.v.)in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.
rauwolscine
cirazoline
0
$T1$ (3 mg kg-1 i.v.)in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.
rauwolscine
Abbott-53693
0
$T1$ (3 mg kg-1 i.v.)in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.
rauwolscine
noradrenaline
0
$T1$ were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).On the other hand, the pressor effects of $T2$
cirazoline
Abbott-53693
0
$T1$ were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.
cirazoline
noradrenaline
0
$T1$ were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.Furthermore, the bradycardia that accompanied the $T2$
Abbott-53693
noradrenaline
0
$T1$ and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for $T2$
estradiol
thrombosis of both the ICA and the venous sinus
1
$T1$ has been described infrequently.In this case, the authors postulate that the use of $T2$
cerebral artery and the venous sinus occlusion
estradiol
1
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found occlusion of the left internal carotid artery (ICA).
hemorrhagic infarct
progesterone
1
$T1$.Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.
venous sinus thrombosis
progesterone
1
$T1$.Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.
venous sinus thrombosis
estradiol
1
$T1$ has been described infrequently.In this case, the authors postulate that the use of estradiol and $T2$
cerebral artery and the venous sinus occlusion
progesterone
1
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found occlusion of the left internal carotid artery (ICA).
hemorrhagic infarct
estradiol
1
$T1$ and the underlying DM increased vascular thrombogenicity, which provided a common denominator for $T2$
progesterone
thrombosis of both the ICA and the venous sinus
1
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
venous sinus thrombosis
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
venous sinus thrombosis
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
venous sinus thrombosis
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
venous sinus thrombosis
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
venous sinus thrombosis
0
$T1$.Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.
venous sinus thrombosis
DM
0
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found occlusion of the left internal carotid artery (ICA).
hemorrhagic infarct
venous sinus thrombosis
0
$T1$ (ICA).Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of $T2$
occlusion of the left internal carotid artery
venous sinus thrombosis
0
$T1$.Coexistence of the $T2$
venous sinus thrombosis
cerebral artery and the venous sinus occlusion
0
$T1$.Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.
venous sinus thrombosis
thrombosis of both the ICA and the venous sinus
0
$T1$, $T2$
headache
nausea
0
$T1$, nausea and $T2$
headache
vomiting
0
$T1$, nausea and vomiting, left $T2$
headache
hemiparesis
0
$T1$, nausea and vomiting, left hemiparesis and $T2$
headache
seizure
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
progesterone
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
estradiol
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
DM
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
hemorrhagic infarct
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
occlusion of the left internal carotid artery
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
cerebral artery and the venous sinus occlusion
0
$T1$, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
headache
thrombosis of both the ICA and the venous sinus
0
$T1$ and $T2$
nausea
vomiting
0
$T1$ and vomiting, left $T2$
nausea
hemiparesis
0
$T1$ and vomiting, left hemiparesis and $T2$
nausea
seizure
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
progesterone
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
estradiol
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
DM
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
hemorrhagic infarct
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
occlusion of the left internal carotid artery
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
cerebral artery and the venous sinus occlusion
0
$T1$ and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
nausea
thrombosis of both the ICA and the venous sinus
0
$T1$, left $T2$
vomiting
hemiparesis
0
$T1$, left hemiparesis and $T2$
vomiting
seizure
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
progesterone
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
estradiol
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
DM
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
hemorrhagic infarct
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
occlusion of the left internal carotid artery
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
cerebral artery and the venous sinus occlusion
0
$T1$, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
vomiting
thrombosis of both the ICA and the venous sinus
0
$T1$ and $T2$
hemiparesis
seizure
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
progesterone
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
estradiol
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
DM
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
hemorrhagic infarct
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
occlusion of the left internal carotid artery
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
cerebral artery and the venous sinus occlusion
0
$T1$ and seizure two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
hemiparesis
thrombosis of both the ICA and the venous sinus
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
progesterone
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
estradiol
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
DM
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
hemorrhagic infarct
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
occlusion of the left internal carotid artery
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
cerebral artery and the venous sinus occlusion
0
$T1$ two days after parenteral use of progesterone and estradiol.Diabetes mellitus (DM) was found during admission.
seizure
thrombosis of both the ICA and the venous sinus
0
$T1$ and $T2$
estradiol
progesterone
0
$T1$ and the underlying $T2$
progesterone
DM
0
$T1$ (ICA).Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.
occlusion of the left internal carotid artery
progesterone
0
$T1$ and progesterone and the underlying $T2$
estradiol
DM
0
$T1$ (ICA).Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.
occlusion of the left internal carotid artery
estradiol
0
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found occlusion of the left internal carotid artery (ICA).
hemorrhagic infarct
DM
0
$T1$ (ICA).Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.
occlusion of the left internal carotid artery
DM
0
$T1$ has been described infrequently.In this case, the authors postulate that the use of estradiol and progesterone and the underlying $T2$
cerebral artery and the venous sinus occlusion
DM
0
$T1$ increased vascular thrombogenicity, which provided a common denominator for $T2$
DM
thrombosis of both the ICA and the venous sinus
0
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found $T2$
hemorrhagic infarct
occlusion of the left internal carotid artery
0
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found occlusion of the left internal carotid artery (ICA).
hemorrhagic infarct
cerebral artery and the venous sinus occlusion
0
$T1$ in the right frontal lobe and increased density in the superior sagittal sinus (SSS).Left carotid angiography found occlusion of the left internal carotid artery (ICA).
hemorrhagic infarct
thrombosis of both the ICA and the venous sinus
0
$T1$ (ICA).Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.
occlusion of the left internal carotid artery
cerebral artery and the venous sinus occlusion
0
$T1$ (ICA).Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.
occlusion of the left internal carotid artery
thrombosis of both the ICA and the venous sinus
0
$T1$ has been described infrequently.In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for $T2$
cerebral artery and the venous sinus occlusion
thrombosis of both the ICA and the venous sinus
0
$T1$, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
fatiguability
chloroquine
1
$T1$ resolved spontaneously following $T2$
heart failure
chloroquine
1
$T1$, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dyspnoea
chloroquine
1
$T1$.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
syncopal attacks
chloroquine
1
$T1$ pattern.The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following $T2$
right bundle branch block
chloroquine
1
$T1$ discontinuation.She however remains $T2$
chloroquine
blind
1
$T1$, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following $T2$
retinopathy
chloroquine
1
$T1$ progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dizziness
chloroquine
1
$T1$ was treated by pacemaker insertion and the heart failure resolved spontaneously following $T2$
heart block
chloroquine
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
deterioration of vision
chloroquine
0
$T1$ was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.She however remains $T2$
heart block
blind
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
deterioration of vision
heart block
0
$T1$, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
fatiguability
heart block
0
$T1$, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dyspnoea
heart block
0
$T1$ progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dizziness
heart block
0
$T1$.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
syncopal attacks
heart block
0
$T1$, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.The $T2$
retinopathy
heart block
0
$T1$ was treated by pacemaker insertion and the $T2$
heart block
heart failure
0
$T1$ pattern.The $T2$
right bundle branch block
heart block
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
deterioration of vision
blind
0
$T1$, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
fatiguability
blind
0
$T1$, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dyspnoea
blind
0
$T1$ progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dizziness
blind
0
$T1$.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
syncopal attacks
blind
0
$T1$, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.
retinopathy
blind
0
$T1$ resolved spontaneously following chloroquine discontinuation.She however remains $T2$
heart failure
blind
0
$T1$ pattern.The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.
right bundle branch block
blind
0
$T1$, easy $T2$
deterioration of vision
fatiguability
0
$T1$, easy fatiguability, $T2$
deterioration of vision
dyspnoea
0
$T1$, easy fatiguability, dyspnoea, $T2$
deterioration of vision
dizziness
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to $T2$
deterioration of vision
syncopal attacks
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine $T2$
deterioration of vision
retinopathy
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
deterioration of vision
heart failure
0
$T1$, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with $T2$
deterioration of vision
right bundle branch block
0
$T1$, $T2$
fatiguability
dyspnoea
0
$T1$, dyspnoea, $T2$
fatiguability
dizziness
0
$T1$, dyspnoea, dizziness progressing to $T2$
fatiguability
syncopal attacks
0
$T1$, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine $T2$
fatiguability
retinopathy
0
$T1$, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
fatiguability
heart failure
0
$T1$, dyspnoea, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with $T2$
fatiguability
right bundle branch block
0
$T1$, $T2$
dyspnoea
dizziness
0
$T1$, dizziness progressing to $T2$
dyspnoea
syncopal attacks
0
$T1$, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine $T2$
dyspnoea
retinopathy
0
$T1$, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dyspnoea
heart failure
0
$T1$, dizziness progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with $T2$
dyspnoea
right bundle branch block
0
$T1$ progressing to $T2$
dizziness
syncopal attacks
0
$T1$ progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine $T2$
dizziness
retinopathy
0
$T1$ progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
dizziness
heart failure
0
$T1$ progressing to syncopal attacks.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with $T2$
dizziness
right bundle branch block
0
$T1$.Ophthalmological assessment revealed features of chloroquine $T2$
syncopal attacks
retinopathy
0
$T1$.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
syncopal attacks
heart failure
0
$T1$.Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with $T2$
syncopal attacks
right bundle branch block
0
$T1$, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.The heart block was treated by pacemaker insertion and the $T2$
retinopathy
heart failure
0
$T1$, cardiac assessment revealed features of heart failure and a complete heart block with $T2$
retinopathy
right bundle branch block
0
$T1$ pattern.The heart block was treated by pacemaker insertion and the $T2$
right bundle branch block
heart failure
0
$T1$ and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.The number of successful resuscitations did not differ among groups.
dysrhythmias
levobupivacaine
1
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
seizures
ropivacaine
1
$T1$-induced $T2$
ropivacaine
cardiac arrest
1
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
seizures
levobupivacaine
1
$T1$ and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.The number of successful resuscitations did not differ among groups.
dysrhythmias
ropivacaine
1
$T1$ appears to be more susceptible to treatment than that induced by bupivacaine or $T2$
cardiac arrest
levobupivacaine
1
$T1$ of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by $T2$
toxicity
bupivacaine
0
$T1$ of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or $T2$
toxicity
levobupivacaine
0
$T1$ of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that $T2$
toxicity
ropivacaine
0
$T1$ of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced $T2$
toxicity
cardiac arrest
0
$T1$ was required in the Ropivacaine group than in the other groups.We conclude that the systemic $T2$
epinephrine
toxicity
0
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
seizures
toxicity
0
$T1$ and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.The number of successful resuscitations did not differ among groups.
dysrhythmias
toxicity
0
$T1$ or $T2$
bupivacaine
levobupivacaine
0
$T1$-induced cardiac arrest appears to be more susceptible to treatment than that induced by $T2$
ropivacaine
bupivacaine
0
$T1$ appears to be more susceptible to treatment than that induced by $T2$
cardiac arrest
bupivacaine
0
$T1$ was required in the Ropivacaine group than in the other groups.We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by $T2$
epinephrine
bupivacaine
0
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
seizures
bupivacaine
0
$T1$ and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.The number of successful resuscitations did not differ among groups.
dysrhythmias
bupivacaine
0
$T1$-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or $T2$
ropivacaine
levobupivacaine
0
$T1$ was required in the Ropivacaine group than in the other groups.We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or $T2$
epinephrine
levobupivacaine
0
$T1$ was required in the Ropivacaine group than in the other groups.We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that $T2$
epinephrine
ropivacaine
0
$T1$ was required in the Ropivacaine group than in the other groups.We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced $T2$
epinephrine
cardiac arrest
0
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
seizures
cardiac arrest
0
$T1$ and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.The number of successful resuscitations did not differ among groups.
dysrhythmias
cardiac arrest
0
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
seizures
epinephrine
0
$T1$ and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.The number of successful resuscitations did not differ among groups.
dysrhythmias
epinephrine
0
$T1$ were similar and were larger than those of bupivacaine.The cumulative doses of levobupivacaine that produced $T2$
seizures
dysrhythmias
0
$T1$ does not completely prevent the occurrence of $T2$
OCT
hypercalcemia
1
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
OCT
1
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
adynamic bone disease
1
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
hypercalcemia
1
$T1$ does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of $T2$
OCT
secondary hyperparathyroidism
0
$T1$ does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of $T2$
OCT
adynamic bone disease
0
$T1$ does not completely prevent the occurrence of hypercalcemia in experimental dogs with $T2$
OCT
renal insufficiency
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
OCT
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
OCT
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
OCT
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
OCT
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
OCT
0
$T1$ and fibrosis, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
woven osteoid
OCT
0
$T1$, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
fibrosis
OCT
0
$T1$ because it does not induce low bone turnover and, therefore, does not increase the risk of $T2$
secondary hyperparathyroidism
adynamic bone disease
0
$T1$, it may be of use in the management of $T2$
renal insufficiency
secondary hyperparathyroidism
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
secondary hyperparathyroidism
0
$T1$ in experimental dogs with renal insufficiency, it may be of use in the management of $T2$
hypercalcemia
secondary hyperparathyroidism
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
secondary hyperparathyroidism
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
secondary hyperparathyroidism
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
secondary hyperparathyroidism
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
secondary hyperparathyroidism
0
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
secondary hyperparathyroidism
0
$T1$ and fibrosis, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
woven osteoid
secondary hyperparathyroidism
0
$T1$, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
fibrosis
secondary hyperparathyroidism
0
$T1$, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of $T2$
renal insufficiency
adynamic bone disease
0
$T1$ in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of $T2$
hypercalcemia
adynamic bone disease
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
adynamic bone disease
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
adynamic bone disease
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
adynamic bone disease
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
adynamic bone disease
0
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
adynamic bone disease
0
$T1$ and fibrosis, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
woven osteoid
adynamic bone disease
0
$T1$, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
fibrosis
adynamic bone disease
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
renal insufficiency
0
$T1$ in experimental dogs with $T2$
hypercalcemia
renal insufficiency
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
renal insufficiency
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
renal insufficiency
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
renal insufficiency
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
renal insufficiency
0
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
renal insufficiency
0
$T1$ and fibrosis, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
woven osteoid
renal insufficiency
0
$T1$, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
fibrosis
renal insufficiency
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new $T2$
Calcitriol
vitamin D
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
impaired renal function
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
phosphate
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
calcium
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
hyperphosphatemia
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
woven osteoid
0
$T1$ therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.
Calcitriol
fibrosis
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
hypercalcemia
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
hypercalcemia
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
hypercalcemia
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
hypercalcemia
0
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
hypercalcemia
0
$T1$ and fibrosis, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
woven osteoid
hypercalcemia
0
$T1$, but did not significantly alter the level of bone turnover.In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.
fibrosis
hypercalcemia
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or $T2$
vitamin D
impaired renal function
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
phosphate
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
calcium
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
hyperphosphatemia
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
woven osteoid
0
$T1$ analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
vitamin D
fibrosis
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
phosphate
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
calcium
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
hyperphosphatemia
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
woven osteoid
0
$T1$.METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22).
impaired renal function
fibrosis
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
calcium
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
hyperphosphatemia
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
woven osteoid
0
$T1$ supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks.Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months.
phosphate
fibrosis
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
hyperphosphatemia
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
woven osteoid
0
$T1$ and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period.RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
calcium
fibrosis
0
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
woven osteoid
0
$T1$.In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.
hyperphosphatemia
fibrosis
0
$T1$ and $T2$
woven osteoid
fibrosis
0
$T1$ and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.
Nausea
paclitaxel
1
$T1$ were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.
vomiting
paclitaxel
1
$T1$ was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.
arthralgia
paclitaxel
1
$T1$.Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.
polyneuropathy
paclitaxel
1
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
paclitaxel
1
$T1$/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.
myalgia
paclitaxel
1
$T1$ are indicated, and phase III studies comparing $T2$
NSCLC
paclitaxel
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
NSCLC
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
NSCLC
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
NSCLC
0
$T1$.Further phase II studies with paclitaxel combined with other drugs active against $T2$
toxicity
NSCLC
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
NSCLC
0
$T1$.Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.
polyneuropathy
NSCLC
0
$T1$/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.
myalgia
NSCLC
0
$T1$ was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.
arthralgia
NSCLC
0
$T1$ and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.
Nausea
NSCLC
0
$T1$ were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.
vomiting
NSCLC
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
paclitaxel
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
paclitaxel
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
paclitaxel
0
$T1$.Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing $T2$
toxicity
paclitaxel
0
$T1$ types, notably $T2$
tumor
ovarian and breast carcinoma
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
leukopenia
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
toxicity
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
neutropenia
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
polyneuropathy
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
myalgia
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
arthralgia
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
Nausea
0
$T1$ types, notably ovarian and breast carcinoma.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
tumor
vomiting
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
leukopenia
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
toxicity
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
neutropenia
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
polyneuropathy
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
myalgia
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
arthralgia
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
Nausea
0
$T1$.Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
ovarian and breast carcinoma
vomiting
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
toxicity
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
neutropenia
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
polyneuropathy
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
myalgia
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
arthralgia
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
Nausea
0
$T1$.We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
leukopenia
vomiting
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
toxicity
0
$T1$.Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.
polyneuropathy
toxicity
0
$T1$/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.
myalgia
toxicity
0
$T1$ was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.
arthralgia
toxicity
0
$T1$ and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic $T2$
Nausea
toxicity
0
$T1$ were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic $T2$
vomiting
toxicity
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe $T2$
neutropenia
polyneuropathy
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
myalgia
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
arthralgia
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
Nausea
0
$T1$, while 29% had grade 1 or 2.Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.
neutropenia
vomiting
0
$T1$.Similarly, grade 1 or 2 $T2$
polyneuropathy
myalgia
0
$T1$.Similarly, grade 1 or 2 myalgia/$T2$
polyneuropathy
arthralgia
0
$T1$.Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.
polyneuropathy
Nausea
0
$T1$.Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.
polyneuropathy
vomiting
0
$T1$/$T2$
myalgia
arthralgia
0
$T1$/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.$T2$
myalgia
Nausea
0
$T1$/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and $T2$
myalgia
vomiting
0
$T1$ was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.$T2$
arthralgia
Nausea
0
$T1$ was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.Nausea and $T2$
arthralgia
vomiting
0
$T1$ and $T2$
Nausea
vomiting
0
$T1$ can lead to cerebral hemorrhage in previously $T2$
caffeine
hypertensive
1
$T1$ was noted in 18% of the hypertensive rats.A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.
Subarachnoid and cerebral hemorrhage
caffeine
1
$T1$ was noted in 18% of the hypertensive rats.A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.
Subarachnoid and cerebral hemorrhage
PPA
1
$T1$ can lead to $T2$
caffeine
cerebral hemorrhage
1
$T1$/caffeine can lead to cerebral hemorrhage in previously $T2$
PPA
hypertensive
1
$T1$/caffeine can lead to $T2$
PPA
cerebral hemorrhage
1
$T1$ in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.
stroke
PPA
1
$T1$ in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.
stroke
cerebral hemorrhage
0
$T1$ in previously $T2$
cerebral hemorrhage
hypertensive
0
$T1$ was noted in 18% of the hypertensive rats.A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.
Subarachnoid and cerebral hemorrhage
cerebral hemorrhage
0
$T1$/$T2$
PPA
caffeine
0
$T1$ in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.
stroke
caffeine
0
$T1$ in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.
stroke
hypertensive
0
$T1$ in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.$T2$
stroke
Subarachnoid and cerebral hemorrhage
0
$T1$ was noted in 18% of the hypertensive rats.A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.
Subarachnoid and cerebral hemorrhage
hypertensive
0
$T1$ (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
ataxia
amiodarone
1
$T1$ (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
anorexia
amiodarone
1
$T1$ and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
nausea
amiodarone
1
$T1$ (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
thyroid function abnormalities
amiodarone
1
$T1$ (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
visual halos or blurring
amiodarone
1
$T1$ in approximately 50% of patients.However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with $T2$
toxicity
amiodarone
0
$T1$ in approximately 50% of patients.However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with $T2$
toxicity
VT
0
$T1$ in approximately 50% of patients.However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or $T2$
toxicity
VF
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
toxicity
0
$T1$ or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
tremor
toxicity
0
$T1$ (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
ataxia
toxicity
0
$T1$ and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
nausea
toxicity
0
$T1$ (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
anorexia
toxicity
0
$T1$ (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
visual halos or blurring
toxicity
0
$T1$ (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
thyroid function abnormalities
toxicity
0
$T1$ (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant $T2$
pulmonary interstitial infiltrates
toxicity
0
$T1$ or VF can be successfully managed with $T2$
VT
amiodarone
0
$T1$ can be successfully managed with $T2$
VF
amiodarone
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
amiodarone
0
$T1$ or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
tremor
amiodarone
0
$T1$ (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
pulmonary interstitial infiltrates
amiodarone
0
$T1$ or $T2$
VT
VF
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
VT
0
$T1$ or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
tremor
VT
0
$T1$ (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
ataxia
VT
0
$T1$ and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
nausea
VT
0
$T1$ (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
anorexia
VT
0
$T1$ (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
visual halos or blurring
VT
0
$T1$ (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
thyroid function abnormalities
VT
0
$T1$ (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
pulmonary interstitial infiltrates
VT
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
VF
0
$T1$ or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
tremor
VF
0
$T1$ (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
ataxia
VF
0
$T1$ and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
nausea
VF
0
$T1$ (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
anorexia
VF
0
$T1$ (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
visual halos or blurring
VF
0
$T1$ (6%) and pulmonary interstitial infiltrates (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
thyroid function abnormalities
VF
0
$T1$ (5%).Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
pulmonary interstitial infiltrates
VF
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
tremor
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
ataxia
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
nausea
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
anorexia
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
visual halos or blurring
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
thyroid function abnormalities
0
$T1$ (n = 36) and who were refractory to conventional antiarrhythmic drugs.The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.
cardiac arrest
pulmonary interstitial infiltrates
0
$T1$ or $T2$
tremor
ataxia
0
$T1$ or ataxia (35%), $T2$
tremor
nausea
0
$T1$ or ataxia (35%), nausea and $T2$
tremor
anorexia
0
$T1$ or ataxia (35%), nausea and anorexia (8%), $T2$
tremor
visual halos or blurring
0
$T1$ or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), $T2$
tremor
thyroid function abnormalities
0
$T1$ or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and $T2$
tremor
pulmonary interstitial infiltrates
0
$T1$ (35%), $T2$
ataxia
nausea
0
$T1$ (35%), nausea and $T2$
ataxia
anorexia
0
$T1$ (35%), nausea and anorexia (8%), $T2$
ataxia
visual halos or blurring
0
$T1$ (35%), nausea and anorexia (8%), visual halos or blurring (6%), $T2$
ataxia
thyroid function abnormalities
0
$T1$ (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and $T2$
ataxia
pulmonary interstitial infiltrates
0
$T1$ and $T2$
nausea
anorexia
0
$T1$ and anorexia (8%), $T2$
nausea
visual halos or blurring
0
$T1$ and anorexia (8%), visual halos or blurring (6%), $T2$
nausea
thyroid function abnormalities
0
$T1$ and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and $T2$
nausea
pulmonary interstitial infiltrates
0
$T1$ (8%), $T2$
anorexia
visual halos or blurring
0
$T1$ (8%), visual halos or blurring (6%), $T2$
anorexia
thyroid function abnormalities
0
$T1$ (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and $T2$
anorexia
pulmonary interstitial infiltrates
0
$T1$ (6%), $T2$
visual halos or blurring
thyroid function abnormalities
0
$T1$ (6%), thyroid function abnormalities (6%) and $T2$
visual halos or blurring
pulmonary interstitial infiltrates
0
$T1$ (6%) and $T2$
thyroid function abnormalities
pulmonary interstitial infiltrates
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
hypotension
1
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
ventricular arrhythmias
1
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
desipramine
1
$T1$ (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
ventricular arrhythmias
CaCl2
1
$T1$ did not reverse tricyclic antidepressant-induced hypotension in rats.$T2$
4-aminopyridine
CaCl2
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
CaCl2
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
CaCl2
0
$T1$ therapy may possibly worsen both cardiovascular and central nervous system toxicity.These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced $T2$
CaCl2
hypotension
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
CaCl2
0
$T1$ therapy may possibly worsen both cardiovascular and central nervous system toxicity.These findings do not support a role for $T2$
CaCl2
calcium
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
CaCl2
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
CaCl2
0
$T1$ (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
seizures
CaCl2
0
$T1$ therapy may possibly worsen both $T2$
CaCl2
cardiovascular and central nervous system toxicity
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
4-aminopyridine
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
4-aminopyridine
0
$T1$ did not reverse tricyclic antidepressant-induced hypotension in rats.CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.
4-aminopyridine
hypotension
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
4-aminopyridine
0
$T1$ did not reverse tricyclic antidepressant-induced hypotension in rats.CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.
4-aminopyridine
calcium
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
4-aminopyridine
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
4-aminopyridine
0
$T1$ (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or $T2$
ventricular arrhythmias
4-aminopyridine
0
$T1$ (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or $T2$
seizures
4-aminopyridine
0
$T1$ did not reverse tricyclic antidepressant-induced hypotension in rats.CaCl2 therapy may possibly worsen both $T2$
4-aminopyridine
cardiovascular and central nervous system toxicity
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
desipramine
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
desipramine
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
calcium
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: $T2$
desipramine
NaHCO3
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
seizures
0
$T1$ IP followed in 15 min by 4-aminopyridine or saline.RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
desipramine
cardiovascular and central nervous system toxicity
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
hypotension
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
overdose
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
calcium
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
bradycardia
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
NaHCO3
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
ventricular arrhythmias
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
seizures
0
$T1$ in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.
toxicity
cardiovascular and central nervous system toxicity
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
hypotension
0
$T1$ channel inhibition in the pathogenesis of tricyclic antidepressant-induced $T2$
calcium
hypotension
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
hypotension
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
hypotension
0
$T1$ (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
ventricular arrhythmias
hypotension
0
$T1$ (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
seizures
hypotension
0
$T1$.These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced $T2$
cardiovascular and central nervous system toxicity
hypotension
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
calcium
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
bradycardia
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
NaHCO3
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
ventricular arrhythmias
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
seizures
0
$T1$.CaCl2 and 4-aminopyridine.
overdose
cardiovascular and central nervous system toxicity
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
calcium
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
calcium
0
$T1$ (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
ventricular arrhythmias
calcium
0
$T1$ (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
seizures
calcium
0
$T1$.These findings do not support a role for $T2$
cardiovascular and central nervous system toxicity
calcium
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
NaHCO3
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
ventricular arrhythmias
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
seizures
0
$T1$.Fifteen min later, animals received CaCl2, NaHCO3, or saline.
bradycardia
cardiovascular and central nervous system toxicity
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
ventricular arrhythmias
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
seizures
0
$T1$ briefly (5 min) reversed hypotension and QRS prolongation.CaCl2 and 4-aminopyridine failed to improve blood pressure.
NaHCO3
cardiovascular and central nervous system toxicity
0
$T1$ (p = 0.004) and $T2$
ventricular arrhythmias
seizures
0
$T1$ (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
ventricular arrhythmias
cardiovascular and central nervous system toxicity
0
$T1$ (p = 0.03) in the CaCl2 group was higher than the other groups.CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.
seizures
cardiovascular and central nervous system toxicity
0
$T1$/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
thrombocytopenia
cis-RA
1
$T1$ (n = 1).All toxicities resolved after cis-RA was discontinued.
rash
cis-RA
1
$T1$/thrombocytopenia/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
anemia
cis-RA
1
$T1$, and may be predicted by serum cis-RA levels.Monitoring of serum calcium and $T2$
hypercalcemia
cis-RA
1
$T1$/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
emesis
cis-RA
1
$T1$ in vitro were achieved at this dose.The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.
neuroblastoma
cis-RA
0
$T1$ resolved after cis-RA was discontinued.Three complete responses were observed in marrow metastases.
toxicities
cis-RA
0
$T1$.Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.
metastases
cis-RA
0
$T1$ and $T2$
calcium
cis-RA
0
$T1$ resolved after cis-RA was discontinued.Three complete responses were observed in marrow metastases.
toxicities
neuroblastoma
0
$T1$ in vitro were achieved at this dose.The DLT included $T2$
neuroblastoma
hypercalcemia
0
$T1$ (n = 1).All toxicities resolved after cis-RA was discontinued.
rash
neuroblastoma
0
$T1$/thrombocytopenia/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
anemia
neuroblastoma
0
$T1$/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
thrombocytopenia
neuroblastoma
0
$T1$/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
emesis
neuroblastoma
0
$T1$.Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.
metastases
neuroblastoma
0
$T1$ in vitro were achieved at this dose.The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.
neuroblastoma
calcium
0
$T1$ resolved after cis-RA was discontinued.Three complete responses were observed in marrow metastases.
toxicities
hypercalcemia
0
$T1$ (n = 1).All $T2$
rash
toxicities
0
$T1$/thrombocytopenia/emesis/rash (n = 1).All $T2$
anemia
toxicities
0
$T1$/emesis/rash (n = 1).All $T2$
thrombocytopenia
toxicities
0
$T1$/rash (n = 1).All $T2$
emesis
toxicities
0
$T1$ resolved after cis-RA was discontinued.Three complete responses were observed in marrow $T2$
toxicities
metastases
0
$T1$ resolved after cis-RA was discontinued.Three complete responses were observed in marrow metastases.
toxicities
calcium
0
$T1$ (n = 1).All toxicities resolved after cis-RA was discontinued.
rash
hypercalcemia
0
$T1$/thrombocytopenia/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
anemia
hypercalcemia
0
$T1$/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
thrombocytopenia
hypercalcemia
0
$T1$/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
emesis
hypercalcemia
0
$T1$.Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.
metastases
hypercalcemia
0
$T1$, and may be predicted by serum cis-RA levels.Monitoring of serum $T2$
hypercalcemia
calcium
0
$T1$/thrombocytopenia/emesis/$T2$
anemia
rash
0
$T1$/emesis/$T2$
thrombocytopenia
rash
0
$T1$/$T2$
emesis
rash
0
$T1$ (n = 1).All toxicities resolved after cis-RA was discontinued.
rash
metastases
0
$T1$ (n = 1).All toxicities resolved after cis-RA was discontinued.
rash
calcium
0
$T1$/$T2$
anemia
thrombocytopenia
0
$T1$/thrombocytopenia/$T2$
anemia
emesis
0
$T1$/thrombocytopenia/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
anemia
metastases
0
$T1$/thrombocytopenia/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
anemia
calcium
0
$T1$/$T2$
thrombocytopenia
emesis
0
$T1$/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
thrombocytopenia
metastases
0
$T1$/emesis/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
thrombocytopenia
calcium
0
$T1$/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
emesis
metastases
0
$T1$/rash (n = 1).All toxicities resolved after cis-RA was discontinued.
emesis
calcium
0
$T1$.Serum levels of 7.4 +/- 3.0 mumol/L (peak) and 4.0 +/- 2.8 mumol/L (trough) at the MTD were maintained during 14 days of therapy.
metastases
calcium
0
$T1$, tremor and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by $T2$
mydriasis
carbachol
1
$T1$, tremor and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and $T2$
mydriasis
eserine
1
$T1$ and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and $T2$
tremor
eserine
1
$T1$ and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by $T2$
tremor
carbachol
1
$T1$ caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and $T2$
clonic-tonic convulsions
eserine
1
$T1$ caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by $T2$
clonic-tonic convulsions
carbachol
1
$T1$ inhibited the vocalization and fighting produced by $T2$
Calcium chloride
carbachol
0
$T1$ inhibited the vocalization and fighting produced by carbachol and $T2$
Calcium chloride
eserine
0
$T1$, tremor and clonic-tonic convulsions caused by carbachol and eserine.$T2$
mydriasis
Calcium chloride
0
$T1$ and clonic-tonic convulsions caused by carbachol and eserine.$T2$
tremor
Calcium chloride
0
$T1$ caused by carbachol and eserine.$T2$
clonic-tonic convulsions
Calcium chloride
0
$T1$ inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.These results further support the view that $T2$
Calcium chloride
calcium
0
$T1$ inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.These results further support the view that calcium ions in excess have an $T2$
Calcium chloride
atropine
0
$T1$ and $T2$
carbachol
eserine
0
$T1$ and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.These results further support the view that $T2$
carbachol
calcium
0
$T1$ and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.These results further support the view that calcium ions in excess have an $T2$
carbachol
atropine
0
$T1$ most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.These results further support the view that $T2$
eserine
calcium
0
$T1$ most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.These results further support the view that calcium ions in excess have an $T2$
eserine
atropine
0
$T1$, $T2$
mydriasis
tremor
0
$T1$, tremor and $T2$
mydriasis
clonic-tonic convulsions
0
$T1$, tremor and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.
mydriasis
calcium
0
$T1$, tremor and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.
mydriasis
atropine
0
$T1$ and $T2$
tremor
clonic-tonic convulsions
0
$T1$ and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.
tremor
calcium
0
$T1$ and clonic-tonic convulsions caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.
tremor
atropine
0
$T1$ caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.
clonic-tonic convulsions
calcium
0
$T1$ caused by carbachol and eserine.Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.
clonic-tonic convulsions
atropine
0
$T1$ ions in excess have an $T2$
calcium
atropine
0
$T1$ have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
myasthenia gravis
penicillamine
1
$T1$, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
proteinuria
penicillamine
1
$T1$, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
Skin rashes
penicillamine
1
$T1$ and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
polymyositis
penicillamine
1
$T1$, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
systemic lupus erythematosus
penicillamine
1
$T1$ treated with $T2$
rheumatoid arthritis
penicillamine
0
$T1$ resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with $T2$
skin lesion
penicillamine
0
$T1$, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with $T2$
elastosis perforans serpiginosa
penicillamine
0
$T1$ but not in patients with rheumatoid arthritis treated with $T2$
Wilson's disease
penicillamine
0
$T1$, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
Skin rashes
rheumatoid arthritis
0
$T1$, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
proteinuria
rheumatoid arthritis
0
$T1$, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
systemic lupus erythematosus
rheumatoid arthritis
0
$T1$ and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
polymyositis
rheumatoid arthritis
0
$T1$ have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
myasthenia gravis
rheumatoid arthritis
0
$T1$ resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with $T2$
skin lesion
rheumatoid arthritis
0
$T1$, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with $T2$
elastosis perforans serpiginosa
rheumatoid arthritis
0
$T1$ but not in patients with $T2$
Wilson's disease
rheumatoid arthritis
0
$T1$, $T2$
Skin rashes
proteinuria
0
$T1$, proteinuria, $T2$
Skin rashes
systemic lupus erythematosus
0
$T1$, proteinuria, systemic lupus erythematosus, $T2$
Skin rashes
polymyositis
0
$T1$, proteinuria, systemic lupus erythematosus, polymyositis and $T2$
Skin rashes
myasthenia gravis
0
$T1$, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
Skin rashes
skin lesion
0
$T1$, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
Skin rashes
elastosis perforans serpiginosa
0
$T1$, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
Skin rashes
Wilson's disease
0
$T1$, $T2$
proteinuria
systemic lupus erythematosus
0
$T1$, systemic lupus erythematosus, $T2$
proteinuria
polymyositis
0
$T1$, systemic lupus erythematosus, polymyositis and $T2$
proteinuria
myasthenia gravis
0
$T1$, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
proteinuria
skin lesion
0
$T1$, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
proteinuria
elastosis perforans serpiginosa
0
$T1$, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
proteinuria
Wilson's disease
0
$T1$, $T2$
systemic lupus erythematosus
polymyositis
0
$T1$, polymyositis and $T2$
systemic lupus erythematosus
myasthenia gravis
0
$T1$, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
systemic lupus erythematosus
skin lesion
0
$T1$, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
systemic lupus erythematosus
elastosis perforans serpiginosa
0
$T1$, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
systemic lupus erythematosus
Wilson's disease
0
$T1$ and $T2$
polymyositis
myasthenia gravis
0
$T1$ and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
polymyositis
skin lesion
0
$T1$ and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
polymyositis
elastosis perforans serpiginosa
0
$T1$ and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
polymyositis
Wilson's disease
0
$T1$ have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
myasthenia gravis
skin lesion
0
$T1$ have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
myasthenia gravis
elastosis perforans serpiginosa
0
$T1$ have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.A patient who had developed all 5 is now described.
myasthenia gravis
Wilson's disease
0
$T1$ resembled $T2$
skin lesion
elastosis perforans serpiginosa
0
$T1$ resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with $T2$
skin lesion
Wilson's disease
0
$T1$, which has been reported as a rare side effect in patients with $T2$
elastosis perforans serpiginosa
Wilson's disease
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.$T2$
thioridazine
Supraventricular tachycardia
1
$T1$) and Elavil (amitriptyline) each produced $T2$
nortriptyline
left bundle branch block
1
$T1$) appeared to be responsible for five cases of $T2$
thioridazine
ventricular tachycardia
1
$T1$) each produced $T2$
amitriptyline
left bundle branch block
1
$T1$ are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving $T2$
cardiac arrhythmias
phenothiazines
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
cardiac arrhythmias
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
cardiac arrhythmias
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
cardiac arrhythmias
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
cardiac arrhythmias
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
cardiac arrhythmias
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
cardiac arrhythmias
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
cardiac arrhythmias
0
$T1$ and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
lidocaine
cardiac arrhythmias
0
$T1$ combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
propranolol
cardiac arrhythmias
0
$T1$ generally subsided within 48 hours after administration of the drugs was stopped.Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.
tachyarrhythmias
cardiac arrhythmias
0
$T1$ are a potential hazard in patients without $T2$
cardiac arrhythmias
heart disease
0
$T1$ are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.A prospective clinical trial is suggested to quantify the risk of $T2$
cardiac arrhythmias
cardiac complications
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
phenothiazines
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
phenothiazines
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
phenothiazines
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
phenothiazines
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
phenothiazines
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
phenothiazines
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
phenothiazines
0
$T1$ and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
lidocaine
phenothiazines
0
$T1$ combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
propranolol
phenothiazines
0
$T1$ generally subsided within 48 hours after administration of the drugs was stopped.Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.
tachyarrhythmias
phenothiazines
0
$T1$ who are receiving customary therapeutic doses of psychotropic drugs.A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving $T2$
heart disease
phenothiazines
0
$T1$ to patients receiving $T2$
cardiac complications
phenothiazines
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine ($T2$
thioridazine
chlorpromazine
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
nortriptyline
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
amitriptyline
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
left bundle branch block
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
lidocaine
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
propranolol
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
tachyarrhythmias
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
heart disease
0
$T1$) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
thioridazine
cardiac complications
0
$T1$, one of which was fatal in a 35 year old woman.$T2$
ventricular tachycardia
Supraventricular tachycardia
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine ($T2$
ventricular tachycardia
chlorpromazine
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
nortriptyline
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
amitriptyline
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
left bundle branch block
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
lidocaine
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
propranolol
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
tachyarrhythmias
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
heart disease
0
$T1$, one of which was fatal in a 35 year old woman.Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
ventricular tachycardia
cardiac complications
0
$T1$ developed in one patient receiving Thorazine ($T2$
Supraventricular tachycardia
chlorpromazine
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl ($T2$
Supraventricular tachycardia
nortriptyline
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil ($T2$
Supraventricular tachycardia
amitriptyline
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced $T2$
Supraventricular tachycardia
left bundle branch block
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
lidocaine
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
propranolol
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
tachyarrhythmias
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
heart disease
0
$T1$ developed in one patient receiving Thorazine (chlorpromazine).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Supraventricular tachycardia
cardiac complications
0
$T1$).Aventyl ($T2$
chlorpromazine
nortriptyline
0
$T1$).Aventyl (nortriptyline) and Elavil ($T2$
chlorpromazine
amitriptyline
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced $T2$
chlorpromazine
left bundle branch block
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
lidocaine
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
propranolol
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
tachyarrhythmias
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
heart disease
0
$T1$).Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
chlorpromazine
cardiac complications
0
$T1$) and Elavil ($T2$
nortriptyline
amitriptyline
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
lidocaine
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
propranolol
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
tachyarrhythmias
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
heart disease
0
$T1$) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
nortriptyline
cardiac complications
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
lidocaine
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
propranolol
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
tachyarrhythmias
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
heart disease
0
$T1$) each produced left bundle branch block in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
amitriptyline
cardiac complications
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
lidocaine
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
propranolol
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
tachyarrhythmias
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
heart disease
0
$T1$ in a 73 year old woman.Electrocardiographic T and U wave abnormalities were present in most patients.
left bundle branch block
cardiac complications
0
$T1$ and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of $T2$
lidocaine
propranolol
0
$T1$ and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.The $T2$
lidocaine
tachyarrhythmias
0
$T1$ and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
lidocaine
heart disease
0
$T1$ and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
lidocaine
cardiac complications
0
$T1$ combined with ventricular pacing in one.The $T2$
propranolol
tachyarrhythmias
0
$T1$ combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
propranolol
heart disease
0
$T1$ combined with ventricular pacing in one.The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.
propranolol
cardiac complications
0
$T1$ generally subsided within 48 hours after administration of the drugs was stopped.Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.
tachyarrhythmias
heart disease
0
$T1$ generally subsided within 48 hours after administration of the drugs was stopped.Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.
tachyarrhythmias
cardiac complications
0
$T1$ who are receiving customary therapeutic doses of psychotropic drugs.A prospective clinical trial is suggested to quantify the risk of $T2$
heart disease
cardiac complications
0
$T1$-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical $T2$
muscimol
myoclonus
1
$T1$ have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of MK-212 and (-)-$T2$
benzodiazepines
baclofen
0
$T1$ have been found to be beneficial in the management of clinical myoclonus, the $T2$
benzodiazepines
muscimol
0
$T1$ have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical $T2$
benzodiazepines
myoclonus
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
serotonin
benzodiazepines
0
$T1$ and the $T2$
5-HTP
benzodiazepines
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
benzodiazepines
0
$T1$ have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of $T2$
benzodiazepines
MK-212
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
clonazepam
benzodiazepines
0
$T1$ (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
diazepam
benzodiazepines
0
$T1$-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of MK-212 and (-)-$T2$
muscimol
baclofen
0
$T1$ in the management of clinical $T2$
baclofen
myoclonus
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
serotonin
baclofen
0
$T1$ and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of MK-212 and (-)-$T2$
5-HTP
baclofen
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
baclofen
0
$T1$ and (-)-$T2$
MK-212
baclofen
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
clonazepam
baclofen
0
$T1$ (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
diazepam
baclofen
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
serotonin
muscimol
0
$T1$ and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the $T2$
5-HTP
muscimol
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
muscimol
0
$T1$-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of $T2$
muscimol
MK-212
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
clonazepam
muscimol
0
$T1$ (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
diazepam
muscimol
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
serotonin
myoclonus
0
$T1$ and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical $T2$
5-HTP
myoclonus
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
myoclonus
0
$T1$ and (-)-baclofen in the management of clinical $T2$
MK-212
myoclonus
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
clonazepam
myoclonus
0
$T1$ (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
diazepam
myoclonus
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
serotonin
5-HTP
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the $T2$
l-dopa
serotonin
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
serotonin
MK-212
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, $T2$
serotonin
clonazepam
0
$T1$ receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than $T2$
serotonin
diazepam
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
5-HTP
0
$T1$ and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.Our present study indicated the possible value of $T2$
5-HTP
MK-212
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
clonazepam
5-HTP
0
$T1$ (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
diazepam
5-HTP
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
MK-212
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
clonazepam
0
$T1$ (80-160 mg/kg) was without effect.In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.
l-dopa
diazepam
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
clonazepam
MK-212
0
$T1$ (0.3-3 mg/kg) in blocking the myoclonic jerks.While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.
diazepam
MK-212
0
$T1$ (0.1-0.3 mg/kg) was found to be several fold more potent than $T2$
clonazepam
diazepam
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
prednisone
ketosis
1
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, $T2$
prednisone
hypotension
1
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound $T2$
prednisone
coma
1
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
prednisone
lactic acidosis
1
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe $T2$
prednisone
hyperglycemia
1
$T1$, and acidosis.Nonketotic $T2$
hyperglycemia
lactic acidosis
0
$T1$, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
hyperglycemia
Kearns-Sayre syndrome
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe $T2$
lethargy
hyperglycemia
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe $T2$
somnolence
hyperglycemia
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe $T2$
polydipsia
hyperglycemia
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe $T2$
polyphagia
hyperglycemia
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe $T2$
polyuria
hyperglycemia
0
$T1$, hypotension, severe $T2$
coma
hyperglycemia
0
$T1$, severe $T2$
hypotension
hyperglycemia
0
$T1$, and $T2$
hyperglycemia
acidosis
0
$T1$, and acidosis.Nonketotic lactic acidosis was present in one and $T2$
hyperglycemia
ketosis
0
$T1$, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum $T2$
hyperglycemia
lactate
0
$T1$, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
hyperglycemia
Respiratory failure
0
$T1$, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
hyperglycemia
metabolic-endocrine failure
0
$T1$ was present in one and ketosis without a known serum lactate level was present in the other.Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.
lactic acidosis
Kearns-Sayre syndrome
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
lethargy
lactic acidosis
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
somnolence
lactic acidosis
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polydipsia
lactic acidosis
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyphagia
lactic acidosis
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyuria
lactic acidosis
0
$T1$, hypotension, severe hyperglycemia, and acidosis.Nonketotic $T2$
coma
lactic acidosis
0
$T1$, severe hyperglycemia, and acidosis.Nonketotic $T2$
hypotension
lactic acidosis
0
$T1$.Nonketotic $T2$
acidosis
lactic acidosis
0
$T1$ was present in one and $T2$
lactic acidosis
ketosis
0
$T1$ was present in one and ketosis without a known serum $T2$
lactic acidosis
lactate
0
$T1$ was present in one and ketosis without a known serum lactate level was present in the other.$T2$
lactic acidosis
Respiratory failure
0
$T1$ was present in one and ketosis without a known serum lactate level was present in the other.Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.
lactic acidosis
metabolic-endocrine failure
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
prednisone
Kearns-Sayre syndrome
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
lethargy
Kearns-Sayre syndrome
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
somnolence
Kearns-Sayre syndrome
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polydipsia
Kearns-Sayre syndrome
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyphagia
Kearns-Sayre syndrome
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyuria
Kearns-Sayre syndrome
0
$T1$, hypotension, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
coma
Kearns-Sayre syndrome
0
$T1$, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
hypotension
Kearns-Sayre syndrome
0
$T1$.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
acidosis
Kearns-Sayre syndrome
0
$T1$ without a known serum lactate level was present in the other.Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.
ketosis
Kearns-Sayre syndrome
0
$T1$ level was present in the other.Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.
lactate
Kearns-Sayre syndrome
0
$T1$ rapidly ensued and both patients expired in spite of efforts at resuscitation.We believe these two cases represent a newly described and catastrophic metabolic-endocrine failure in the $T2$
Respiratory failure
Kearns-Sayre syndrome
0
$T1$ in the $T2$
metabolic-endocrine failure
Kearns-Sayre syndrome
0
$T1$, both boys developed $T2$
prednisone
lethargy
0
$T1$, both boys developed lethargy, increasing $T2$
prednisone
somnolence
0
$T1$, both boys developed lethargy, increasing somnolence, $T2$
prednisone
polydipsia
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, $T2$
prednisone
polyphagia
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and $T2$
prednisone
polyuria
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and $T2$
prednisone
acidosis
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
prednisone
lactate
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
prednisone
Respiratory failure
0
$T1$, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
prednisone
metabolic-endocrine failure
0
$T1$, increasing $T2$
lethargy
somnolence
0
$T1$, increasing somnolence, $T2$
lethargy
polydipsia
0
$T1$, increasing somnolence, polydipsia, $T2$
lethargy
polyphagia
0
$T1$, increasing somnolence, polydipsia, polyphagia, and $T2$
lethargy
polyuria
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound $T2$
lethargy
coma
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, $T2$
lethargy
hypotension
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and $T2$
lethargy
acidosis
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
lethargy
ketosis
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
lethargy
lactate
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
lethargy
Respiratory failure
0
$T1$, increasing somnolence, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
lethargy
metabolic-endocrine failure
0
$T1$, $T2$
somnolence
polydipsia
0
$T1$, polydipsia, $T2$
somnolence
polyphagia
0
$T1$, polydipsia, polyphagia, and $T2$
somnolence
polyuria
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound $T2$
somnolence
coma
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, $T2$
somnolence
hypotension
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and $T2$
somnolence
acidosis
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
somnolence
ketosis
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
somnolence
lactate
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
somnolence
Respiratory failure
0
$T1$, polydipsia, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
somnolence
metabolic-endocrine failure
0
$T1$, $T2$
polydipsia
polyphagia
0
$T1$, polyphagia, and $T2$
polydipsia
polyuria
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound $T2$
polydipsia
coma
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, $T2$
polydipsia
hypotension
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and $T2$
polydipsia
acidosis
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polydipsia
ketosis
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polydipsia
lactate
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polydipsia
Respiratory failure
0
$T1$, polyphagia, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polydipsia
metabolic-endocrine failure
0
$T1$, and $T2$
polyphagia
polyuria
0
$T1$, and polyuria.Both presented in the emergency room with profound $T2$
polyphagia
coma
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, $T2$
polyphagia
hypotension
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and $T2$
polyphagia
acidosis
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyphagia
ketosis
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyphagia
lactate
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyphagia
Respiratory failure
0
$T1$, and polyuria.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyphagia
metabolic-endocrine failure
0
$T1$.Both presented in the emergency room with profound $T2$
polyuria
coma
0
$T1$.Both presented in the emergency room with profound coma, $T2$
polyuria
hypotension
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and $T2$
polyuria
acidosis
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyuria
ketosis
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyuria
lactate
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyuria
Respiratory failure
0
$T1$.Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis.
polyuria
metabolic-endocrine failure
0
$T1$, $T2$
coma
hypotension
0
$T1$, hypotension, severe hyperglycemia, and $T2$
coma
acidosis
0
$T1$, hypotension, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and $T2$
coma
ketosis
0
$T1$, hypotension, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum $T2$
coma
lactate
0
$T1$, hypotension, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
coma
Respiratory failure
0
$T1$, hypotension, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
coma
metabolic-endocrine failure
0
$T1$, severe hyperglycemia, and $T2$
hypotension
acidosis
0
$T1$, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and $T2$
hypotension
ketosis
0
$T1$, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum $T2$
hypotension
lactate
0
$T1$, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
hypotension
Respiratory failure
0
$T1$, severe hyperglycemia, and acidosis.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
hypotension
metabolic-endocrine failure
0
$T1$.Nonketotic lactic acidosis was present in one and $T2$
acidosis
ketosis
0
$T1$.Nonketotic lactic acidosis was present in one and ketosis without a known serum $T2$
acidosis
lactate
0
$T1$.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
acidosis
Respiratory failure
0
$T1$.Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
acidosis
metabolic-endocrine failure
0
$T1$ without a known serum $T2$
ketosis
lactate
0
$T1$ without a known serum lactate level was present in the other.$T2$
ketosis
Respiratory failure
0
$T1$ without a known serum lactate level was present in the other.Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.
ketosis
metabolic-endocrine failure
0
$T1$ level was present in the other.$T2$
lactate
Respiratory failure
0
$T1$ level was present in the other.Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.
lactate
metabolic-endocrine failure
0
$T1$ rapidly ensued and both patients expired in spite of efforts at resuscitation.We believe these two cases represent a newly described and catastrophic $T2$
Respiratory failure
metabolic-endocrine failure
0
$T1$ caused by $T2$
cognitive deficits
STZ
1
$T1$-icv in rats and its potential in the treatment of neurodegenerative diseases such as $T2$
STZ
Alzheimer's disease
1
$T1$ (30 mg/kg) in antagonizing the cognitive deficits caused by $T2$
crocin
STZ
0
$T1$ (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as $T2$
crocin
Alzheimer's disease
0
$T1$, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
carotenoids
crocin
0
$T1$ in treated STZ-injected group in passive avoidance test.CONCLUSION: Therefore, these results demonstrate the effectiveness of $T2$
learning and memory impairment
crocin
0
$T1$ (30 mg/kg) in antagonizing the $T2$
crocin
cognitive deficits
0
$T1$ (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of $T2$
crocin
neurodegenerative diseases
0
$T1$, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
carotenoids
STZ
0
$T1$ in treated STZ-injected group in passive avoidance test.CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by $T2$
learning and memory impairment
STZ
0
$T1$-icv in rats and its potential in the treatment of $T2$
STZ
neurodegenerative diseases
0
$T1$, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
carotenoids
Alzheimer's disease
0
$T1$ in treated STZ-injected group in passive avoidance test.CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as $T2$
learning and memory impairment
Alzheimer's disease
0
$T1$ caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as $T2$
cognitive deficits
Alzheimer's disease
0
$T1$ such as $T2$
neurodegenerative diseases
Alzheimer's disease
0
$T1$, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
carotenoids
learning and memory impairment
0
$T1$, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
carotenoids
cognitive deficits
0
$T1$, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
carotenoids
neurodegenerative diseases
0
$T1$ in treated STZ-injected group in passive avoidance test.CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the $T2$
learning and memory impairment
cognitive deficits
0
$T1$ in treated STZ-injected group in passive avoidance test.CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of $T2$
learning and memory impairment
neurodegenerative diseases
0
$T1$ caused by STZ-icv in rats and its potential in the treatment of $T2$
cognitive deficits
neurodegenerative diseases
0
$T1$ should be regarded as a potential cause of rosaceiform $T2$
pimecrolimus
dermatitis
1
$T1$ while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
eruptions
pimecrolimus
1
$T1$ and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.Continuous topical use of immunomodulators such as tacrolimus or $T2$
telangiectasia
pimecrolimus
1
$T1$ or pimecrolimus should be regarded as a potential cause of rosaceiform $T2$
tacrolimus
dermatitis
0
$T1$-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
rosacea
dermatitis
0
$T1$ while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
eruptions
dermatitis
0
$T1$.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
facial dermatitis
dermatitis
0
$T1$ and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform $T2$
telangiectasia
dermatitis
0
$T1$-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
rosacea
tacrolimus
0
$T1$ while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
eruptions
tacrolimus
0
$T1$.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
facial dermatitis
tacrolimus
0
$T1$ and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.Continuous topical use of immunomodulators such as $T2$
telangiectasia
tacrolimus
0
$T1$ or $T2$
tacrolimus
pimecrolimus
0
$T1$-like dermatitis $T2$
rosacea
eruptions
0
$T1$-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for $T2$
rosacea
facial dermatitis
0
$T1$-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed $T2$
rosacea
telangiectasia
0
$T1$-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
rosacea
pimecrolimus
0
$T1$ while using 0.03% or 0.1% tacrolimus ointment for $T2$
eruptions
facial dermatitis
0
$T1$ while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.Skin biopsy specimens showed $T2$
eruptions
telangiectasia
0
$T1$.Skin biopsy specimens showed $T2$
facial dermatitis
telangiectasia
0
$T1$.Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.
facial dermatitis
pimecrolimus
0
$T1$-pre-treated Wistar rats.All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e.
LiCl
damage of neuronal cells
1
$T1$ in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.Empty nanoparticles provided similar results to control (saline-treated) group of animals.
damage of neuronal cells
tacrine
1
$T1$ and delayed hippocampal damage.The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.
seizures
LiCl
1
$T1$ and delayed hippocampal damage.The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.
seizures
tacrine
1
$T1$ nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.administration in LiCl-pre-treated Wistar rats.
poly-L-lactid acid
tacrine
0
$T1$ nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.administration in $T2$
poly-L-lactid acid
LiCl
0
$T1$ and delayed hippocampal damage.The toxic effects of tacrine-loaded $T2$
seizures
poly-L-lactid acid
0
$T1$ nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.administration in LiCl-pre-treated Wistar rats.
poly-L-lactid acid
damage of neuronal cells
0
$T1$ nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.administration in LiCl-pre-treated Wistar rats.
poly-L-lactid acid
epilepsy
0
$T1$ nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.administration in LiCl-pre-treated Wistar rats.
poly-L-lactid acid
lithium
0
$T1$-pre-treated Wistar rats.All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e.
LiCl
tacrine
0
$T1$-lithium model of $T2$
tacrine
epilepsy
0
$T1$-$T2$
tacrine
lithium
0
$T1$-pre-treated Wistar rats.All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e.
LiCl
epilepsy
0
$T1$-pre-treated Wistar rats.All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e.
LiCl
lithium
0
$T1$ and delayed hippocampal damage.The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.
seizures
damage of neuronal cells
0
$T1$ and delayed hippocampal damage.The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.
seizures
epilepsy
0
$T1$ and delayed hippocampal damage.The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.
seizures
lithium
0
$T1$ in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.Empty nanoparticles provided similar results to control (saline-treated) group of animals.
damage of neuronal cells
epilepsy
0
$T1$ in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.Empty nanoparticles provided similar results to control (saline-treated) group of animals.
damage of neuronal cells
lithium
0
$T1$ model of $T2$
lithium
epilepsy
0
$T1$ rat and guinea pig models induced by aconitine or $T2$
arrhythmic
ouabain
1
$T1$ rat and guinea pig models induced by $T2$
arrhythmic
aconitine
1
$T1$ produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by $T2$
pilocarpine
aconitine
0
$T1$ produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or $T2$
pilocarpine
ouabain
0
$T1$ produced antiarrhythmic actions on $T2$
pilocarpine
arrhythmic
0
$T1$ produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.The mechanism may be related to the improvement of $T2$
pilocarpine
Ca
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
pilocarpine
0
$T1$ receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.These data suggest that $T2$
acetylcholine
pilocarpine
0
$T1$) partially abolished the beneficial effects of pilocarpine.These data suggest that $T2$
4-diphenylacetoxy-N-methylpiperidine-methiodide
pilocarpine
0
$T1$ or $T2$
aconitine
ouabain
0
$T1$ or ouabain via stimulating the cardiac M(3)-mAChR.The mechanism may be related to the improvement of $T2$
aconitine
Ca
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
aconitine
0
$T1$ receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by $T2$
acetylcholine
aconitine
0
$T1$) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by $T2$
4-diphenylacetoxy-N-methylpiperidine-methiodide
aconitine
0
$T1$ via stimulating the cardiac M(3)-mAChR.The mechanism may be related to the improvement of $T2$
ouabain
Ca
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
ouabain
0
$T1$ receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or $T2$
acetylcholine
ouabain
0
$T1$) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or $T2$
4-diphenylacetoxy-N-methylpiperidine-methiodide
ouabain
0
$T1$ rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.The mechanism may be related to the improvement of $T2$
arrhythmic
Ca
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
arrhythmic
0
$T1$ receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on $T2$
acetylcholine
arrhythmic
0
$T1$) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on $T2$
4-diphenylacetoxy-N-methylpiperidine-methiodide
arrhythmic
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
Ca
0
$T1$ receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
acetylcholine
Ca
0
$T1$) partially abolished the beneficial effects of pilocarpine.These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
4-diphenylacetoxy-N-methylpiperidine-methiodide
Ca
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
acetylcholine
0
$T1$, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
ventricular tachycardia and fibrillation
4-diphenylacetoxy-N-methylpiperidine-methiodide
0
$T1$ receptor (mAChR) antagonist 4-DAMP ($T2$
acetylcholine
4-diphenylacetoxy-N-methylpiperidine-methiodide
0
$T1$ with numbness in both feet.His vision was 6/15 and 2/60 in the right and left eyes, respectively.
paraesthesia
disulfiram
1
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
disulfiram
1
$T1$.He had been taking disulfiram for alcohol dependence for the preceding 3 years.
scotomata
disulfiram
1
$T1$ for the preceding 3 years.Disulfiram discontinuation lead to an immediate symptomatic improvement.
alcohol dependence
disulfiram
0
$T1$ in both eyes with intermittent headaches for 2 months.He also complained of paraesthesia with numbness in both feet.
loss of vision
disulfiram
0
$T1$ for 2 months.He also complained of paraesthesia with numbness in both feet.
headaches
disulfiram
0
$T1$ in both feet.His vision was 6/15 and 2/60 in the right and left eyes, respectively.
numbness
disulfiram
0
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
alcohol dependence
0
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
loss of vision
0
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
headaches
0
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
paraesthesia
0
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
numbness
0
$T1$ after chronic use of disulfiram for alcohol dependence management.MATERIALS AND METHODS: A case report.
optic and peripheral neuropathy
scotomata
0
$T1$ in both eyes with intermittent headaches for 2 months.He also complained of paraesthesia with numbness in both feet.
loss of vision
alcohol dependence
0
$T1$ for 2 months.He also complained of paraesthesia with numbness in both feet.
headaches
alcohol dependence
0
$T1$ with numbness in both feet.His vision was 6/15 and 2/60 in the right and left eyes, respectively.
paraesthesia
alcohol dependence
0
$T1$ in both feet.His vision was 6/15 and 2/60 in the right and left eyes, respectively.
numbness
alcohol dependence
0
$T1$.He had been taking disulfiram for $T2$
scotomata
alcohol dependence
0
$T1$ in both eyes with intermittent $T2$
loss of vision
headaches
0
$T1$ in both eyes with intermittent headaches for 2 months.He also complained of $T2$
loss of vision
paraesthesia
0
$T1$ in both eyes with intermittent headaches for 2 months.He also complained of paraesthesia with $T2$
loss of vision
numbness
0
$T1$ in both eyes with intermittent headaches for 2 months.He also complained of paraesthesia with numbness in both feet.
loss of vision
scotomata
0
$T1$ for 2 months.He also complained of $T2$
headaches
paraesthesia
0
$T1$ for 2 months.He also complained of paraesthesia with $T2$
headaches
numbness
0
$T1$ for 2 months.He also complained of paraesthesia with numbness in both feet.
headaches
scotomata
0
$T1$ with $T2$
paraesthesia
numbness
0
$T1$ with numbness in both feet.His vision was 6/15 and 2/60 in the right and left eyes, respectively.
paraesthesia
scotomata
0
$T1$ in both feet.His vision was 6/15 and 2/60 in the right and left eyes, respectively.
numbness
scotomata
0
$T1$, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
Hepatitis B virus (HBV) infection
hepatitis B surface antigen and e antigen
1
$T1$, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
Hepatitis B virus (HBV) infection
cirrhosis
0
$T1$, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
Hepatitis B virus (HBV) infection
lamivudine
0
$T1$, which causes $T2$
Hepatitis B virus (HBV) infection
liver cirrhosis
0
$T1$, which causes liver cirrhosis and $T2$
Hepatitis B virus (HBV) infection
hepatocellular carcinoma
0
$T1$ to patients with HBV-related $T2$
lamivudine
cirrhosis
0
$T1$ and hepatocellular carcinoma, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
liver cirrhosis
cirrhosis
0
$T1$, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
hepatocellular carcinoma
cirrhosis
0
$T1$ were observed to have disappeared in this patient.The administration of lamivudine to patients with HBV-related $T2$
hepatitis B surface antigen and e antigen
cirrhosis
0
$T1$ and hepatocellular carcinoma, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
liver cirrhosis
lamivudine
0
$T1$, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
hepatocellular carcinoma
lamivudine
0
$T1$ were observed to have disappeared in this patient.The administration of $T2$
hepatitis B surface antigen and e antigen
lamivudine
0
$T1$ and $T2$
liver cirrhosis
hepatocellular carcinoma
0
$T1$ and hepatocellular carcinoma, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
liver cirrhosis
hepatitis B surface antigen and e antigen
0
$T1$, remains a major health problem in Asian countries.Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.
hepatocellular carcinoma
hepatitis B surface antigen and e antigen
0
$T1$ was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
Sodium thiopenthal
narcosis
1
$T1$ on pharmacological $T2$
melatonin
narcosis
1
$T1$-induced narcosis.Thus, the dual action of melatonin on pharmacological $T2$
diazepam
narcosis
1
$T1$- or diazepam-induced narcosis.Thus, the dual action of melatonin on pharmacological $T2$
ketamine
narcosis
1
$T1$ on pharmacological narcosis seems to be specific for the $T2$
melatonin
barbiturate
0
$T1$ was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
Sodium thiopenthal
melatonin
0
$T1$- or diazepam-induced narcosis.Thus, the dual action of $T2$
ketamine
melatonin
0
$T1$-induced narcosis.Thus, the dual action of $T2$
diazepam
melatonin
0
$T1$ seems to be specific for the $T2$
narcosis
barbiturate
0
$T1$ was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
Sodium thiopenthal
barbiturate
0
$T1$- or diazepam-induced narcosis.Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the $T2$
ketamine
barbiturate
0
$T1$-induced narcosis.Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the $T2$
diazepam
barbiturate
0
$T1$ was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
Sodium thiopenthal
ketamine
0
$T1$ was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
Sodium thiopenthal
diazepam
0
$T1$- or $T2$
ketamine
diazepam
0
$T1$, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
E-2020
amnesia
1
$T1$ but does not affect spontaneous movement.The findings suggest that $T2$
amnesia
NIK-247
1
$T1$, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
tacrine
amnesia
1
$T1$-induced $T2$
scopolamine
amnesia
1
$T1$-induced amnesia but does not affect spontaneous movement.The findings suggest that $T2$
scopolamine
NIK-247
0
$T1$, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
tacrine
NIK-247
0
$T1$, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
E-2020
NIK-247
0
$T1$ may be a useful drug for the treatment of $T2$
NIK-247
Alzheimer's disease
0
$T1$, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
tacrine
scopolamine
0
$T1$, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
E-2020
scopolamine
0
$T1$-induced amnesia but does not affect spontaneous movement.The findings suggest that NIK-247 may be a useful drug for the treatment of $T2$
scopolamine
Alzheimer's disease
0
$T1$ but does not affect spontaneous movement.The findings suggest that NIK-247 may be a useful drug for the treatment of $T2$
amnesia
Alzheimer's disease
0
$T1$, but not $T2$
tacrine
E-2020
0
$T1$, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
tacrine
Alzheimer's disease
0
$T1$, strongly inhibited butyrylcholinestrase (BuChE) in human serum.All three drugs produced mixed inhibition of AChE activity.
E-2020
Alzheimer's disease
0
$T1$ and dosulepine hydrochloride in a tetraparetic patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented $T2$
paroxetine
hallucinations
1
$T1$ that only stopped after the withdrawal of psycho-active drugs and $T2$
hallucinations
tramadol
1
$T1$ in a tetraparetic patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented $T2$
dosulepine hydrochloride
hallucinations
1
$T1$ pain and chronic non malignant pain.This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.
cancer
hallucinations
0
$T1$ that only stopped after the withdrawal of psycho-active drugs and tramadol.The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if $T2$
hallucinations
pain
0
$T1$ patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented $T2$
tetraparetic
hallucinations
0
$T1$.Fifty-six days after initiation of the treatment the patient presented $T2$
chronic pain
hallucinations
0
$T1$ pain and chronic non malignant pain.This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.
cancer
tramadol
0
$T1$.The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if $T2$
tramadol
pain
0
$T1$ and dosulepine hydrochloride in a tetraparetic patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and $T2$
paroxetine
tramadol
0
$T1$ in a tetraparetic patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and $T2$
dosulepine hydrochloride
tramadol
0
$T1$ patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and $T2$
tetraparetic
tramadol
0
$T1$.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and $T2$
chronic pain
tramadol
0
$T1$ pain and chronic non malignant pain.This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.
cancer
pain
0
$T1$ pain and chronic non malignant pain.This drug was initiated in association with $T2$
cancer
paroxetine
0
$T1$ pain and chronic non malignant pain.This drug was initiated in association with paroxetine and $T2$
cancer
dosulepine hydrochloride
0
$T1$ pain and chronic non malignant pain.This drug was initiated in association with paroxetine and dosulepine hydrochloride in a $T2$
cancer
tetraparetic
0
$T1$ pain and chronic non malignant pain.This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with $T2$
cancer
chronic pain
0
$T1$ and dosulepine hydrochloride in a tetraparetic patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.
paroxetine
pain
0
$T1$ in a tetraparetic patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.
dosulepine hydrochloride
pain
0
$T1$ patient with chronic pain.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.
tetraparetic
pain
0
$T1$.Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.
chronic pain
pain
0
$T1$ and $T2$
paroxetine
dosulepine hydrochloride
0
$T1$ and dosulepine hydrochloride in a $T2$
paroxetine
tetraparetic
0
$T1$ and dosulepine hydrochloride in a tetraparetic patient with $T2$
paroxetine
chronic pain
0
$T1$ in a $T2$
dosulepine hydrochloride
tetraparetic
0
$T1$ in a tetraparetic patient with $T2$
dosulepine hydrochloride
chronic pain
0
$T1$ patient with $T2$
tetraparetic
chronic pain
0
$T1$ which was caused by $T2$
aplastic anemia
gold
1
$T1$ which was caused by gold in one case and $T2$
aplastic anemia
D-penicillamine
1
$T1$ which was caused by gold in one case and D-penicillamine in the other.In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.
aplastic anemia
RA
0
$T1$ in one case and D-penicillamine in the other.In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.
gold
RA
0
$T1$ in the other.In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.
D-penicillamine
RA
0
$T1$ following BMT has been reported, these are the first cases for which prolonged followup has been available.This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive $T2$
RA
synovitis
0
$T1$ which was caused by gold in one case and D-penicillamine in the other.In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.
aplastic anemia
synovitis
0
$T1$ in one case and $T2$
gold
D-penicillamine
0
$T1$ in one case and D-penicillamine in the other.In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.
gold
synovitis
0
$T1$ in the other.In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent.
D-penicillamine
synovitis
0
$T1$ to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.
Acute experimental models of renal damage
PAN
1
$T1$.The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.
PAN
excretion of proteins
1
$T1$ to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.
Acute experimental models of renal damage
BEA
1
$T1$ to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.
Acute experimental models of renal damage
HCBD
1
$T1$ to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.
Acute experimental models of renal damage
renal damage
0
$T1$ and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.
HCBD
renal damage
0
$T1$.The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.
PAN
renal damage
0
$T1$ were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.
BEA
renal damage
0
$T1$ of a wide range of molecular weights.Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.
excretion of proteins
renal damage
0
$T1$ were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of $T2$
glucose
renal damage
0
$T1$ to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.
Acute experimental models of renal damage
excretion of proteins
0
$T1$ to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.
Acute experimental models of renal damage
glucose
0
$T1$.The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.
PAN
HCBD
0
$T1$ and papillary damage caused by $T2$
HCBD
BEA
0
$T1$ of a wide range of molecular weights.Proximal tubular damage caused by $T2$
excretion of proteins
HCBD
0
$T1$ and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.Alkaline phosphatase and $T2$
HCBD
glucose
0
$T1$.The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.
PAN
BEA
0
$T1$.The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.
PAN
glucose
0
$T1$ of a wide range of molecular weights.Proximal tubular damage caused by HCBD and papillary damage caused by $T2$
excretion of proteins
BEA
0
$T1$ were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.Alkaline phosphatase and $T2$
BEA
glucose
0
$T1$ of a wide range of molecular weights.Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.
excretion of proteins
glucose
0
$T1$ after 500 mg of $T2$
neuromuscular blockade
magnesium sulfate
1
$T1$ after 500 mg of magnesium sulfate was administered.This reaction demonstrates that $T2$
neuromuscular blockade
nifedipine
1
$T1$ after 500 mg of magnesium sulfate was administered.This reaction demonstrates that nifedipine can seriously potentiate the $T2$
neuromuscular blockade
toxicity
0
$T1$ after 500 mg of magnesium sulfate was administered.This reaction demonstrates that nifedipine can seriously potentiate the toxicity of $T2$
neuromuscular blockade
magnesium
0
$T1$ was administered.This reaction demonstrates that $T2$
magnesium sulfate
nifedipine
0
$T1$ was administered.This reaction demonstrates that nifedipine can seriously potentiate the $T2$
magnesium sulfate
toxicity
0
$T1$ was administered.This reaction demonstrates that nifedipine can seriously potentiate the toxicity of $T2$
magnesium sulfate
magnesium
0
$T1$ can seriously potentiate the $T2$
nifedipine
toxicity
0
$T1$ can seriously potentiate the toxicity of $T2$
nifedipine
magnesium
0
$T1$ of $T2$
toxicity
magnesium
0
$T1$.The protracted infusion schedule for $T2$
hematuria
ifosfamide
1
$T1$ (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
leukopenia
ifosfamide
1
$T1$ (1), nausea (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
confusion
ifosfamide
1
$T1$ (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
nausea
ifosfamide
1
$T1$ permits convenient outpatient administration without $T2$
ifosfamide
Mesna
0
$T1$; confusion (1), nausea (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
toxicity
ifosfamide
0
$T1$.The protracted infusion schedule for ifosfamide permits convenient outpatient administration without $T2$
hematuria
Mesna
0
$T1$; confusion (1), nausea (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
toxicity
Mesna
0
$T1$ (1), nausea (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
confusion
Mesna
0
$T1$ (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
nausea
Mesna
0
$T1$ (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
leukopenia
Mesna
0
$T1$; confusion (1), nausea (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
toxicity
hematuria
0
$T1$ (1), nausea (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
confusion
hematuria
0
$T1$ (1), and Grade 2 leukopenia (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
nausea
hematuria
0
$T1$ (1).The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.
leukopenia
hematuria
0
$T1$; $T2$
toxicity
confusion
0
$T1$; confusion (1), $T2$
toxicity
nausea
0
$T1$; confusion (1), nausea (1), and Grade 2 $T2$
toxicity
leukopenia
0
$T1$ (1), $T2$
confusion
nausea
0
$T1$ (1), nausea (1), and Grade 2 $T2$
confusion
leukopenia
0
$T1$ (1), and Grade 2 $T2$
nausea
leukopenia
0
$T1$.Thrombosis might be a rare but hazardous complication of $T2$
myocardial infarction
CC
1
$T1$ with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
thromboembolism
CC
1
$T1$ with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
thromboembolism
myocardial infarction
0
$T1$ or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
coronary thrombosis
myocardial infarction
0
$T1$.An electrocardiogram showed a lateral and anterior wall myocardial infarction.
chest pain
myocardial infarction
0
$T1$ to the fetus, so a coronary angiogram was postponed until the second trimester.It showed normal coronary vessels.
radiation injury
myocardial infarction
0
$T1$.$T2$
myocardial infarction
Thrombosis
0
$T1$ or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
coronary thrombosis
CC
0
$T1$.An electrocardiogram showed a lateral and anterior wall myocardial infarction.
chest pain
CC
0
$T1$ to the fetus, so a coronary angiogram was postponed until the second trimester.It showed normal coronary vessels.
radiation injury
CC
0
$T1$ might be a rare but hazardous complication of $T2$
Thrombosis
CC
0
$T1$ or $T2$
coronary thrombosis
thromboembolism
0
$T1$ with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with $T2$
thromboembolism
chest pain
0
$T1$ with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
thromboembolism
radiation injury
0
$T1$ with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
thromboembolism
Thrombosis
0
$T1$ or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with $T2$
coronary thrombosis
chest pain
0
$T1$ or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
coronary thrombosis
radiation injury
0
$T1$ or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
coronary thrombosis
Thrombosis
0
$T1$.An electrocardiogram showed a lateral and anterior wall myocardial infarction.
chest pain
radiation injury
0
$T1$.An electrocardiogram showed a lateral and anterior wall myocardial infarction.
chest pain
Thrombosis
0
$T1$ to the fetus, so a coronary angiogram was postponed until the second trimester.It showed normal coronary vessels.
radiation injury
Thrombosis
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
PB
1
$T1$, which may lead to more serious and deleterious consequences.For this reason, each clinician should recognize this entity in the differential diagnosis of $T2$
liver damage
PB
1
$T1$ and $T2$
Hepatonecrosis
cholangitis
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
PB
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
liver damage
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
epilepsy
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
cardiac arrest
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
bronchopneumonia
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
necrosis
0
$T1$ and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Hepatonecrosis
chronic hepatic enzyme dysfunction
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
liver damage
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
epilepsy
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
cardiac arrest
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
bronchopneumonia
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
necrosis
0
$T1$ related to long-term phenobarbital therapy: an autopsy report of two patients.Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
cholangitis
chronic hepatic enzyme dysfunction
0
$T1$ treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
epilepsy
PB
0
$T1$, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
cardiac arrest
PB
0
$T1$.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
bronchopneumonia
PB
0
$T1$ surrounded by a hard ring of non-specific granulomatous tissue.Inflammatory reactions of internal and external hepatic biliary ducts were also seen.
necrosis
PB
0
$T1$-related asymptomatic $T2$
PB
chronic hepatic enzyme dysfunction
0
$T1$ treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
epilepsy
liver damage
0
$T1$, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
cardiac arrest
liver damage
0
$T1$.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
bronchopneumonia
liver damage
0
$T1$ surrounded by a hard ring of non-specific granulomatous tissue.Inflammatory reactions of internal and external hepatic biliary ducts were also seen.
necrosis
liver damage
0
$T1$, which may lead to more serious and deleterious consequences.For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic $T2$
liver damage
chronic hepatic enzyme dysfunction
0
$T1$ treated with PB who died suddenly: one as consequence of $T2$
epilepsy
cardiac arrest
0
$T1$ treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute $T2$
epilepsy
bronchopneumonia
0
$T1$ treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of $T2$
epilepsy
necrosis
0
$T1$ treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
epilepsy
chronic hepatic enzyme dysfunction
0
$T1$, the other of acute $T2$
cardiac arrest
bronchopneumonia
0
$T1$, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of $T2$
cardiac arrest
necrosis
0
$T1$, the other of acute bronchopneumonia.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
cardiac arrest
chronic hepatic enzyme dysfunction
0
$T1$.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of $T2$
bronchopneumonia
necrosis
0
$T1$.At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.
bronchopneumonia
chronic hepatic enzyme dysfunction
0
$T1$ surrounded by a hard ring of non-specific granulomatous tissue.Inflammatory reactions of internal and external hepatic biliary ducts were also seen.
necrosis
chronic hepatic enzyme dysfunction
0
$T1$ are described.All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.
optic neuropathy
ethambutol
1
$T1$ and should be avoided if possible or used with caution and proper ophthalmological follow-up.The author postulates that in cases of ethambutol associated chiasmopathy, $T2$
visual loss
ethambutol
1
$T1$, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.We report 3 cases which presented with bitemporal hemianopia.
tuberculosis
ethambutol
0
$T1$.CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.
bitemporal hemianopia
ethambutol
0
$T1$, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.We report 3 cases which presented with bitemporal hemianopia.
tuberculosis
optic neuropathy
0
$T1$ are described.All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.
optic neuropathy
visual loss
0
$T1$.CLINICAL PICTURE: Three patients with ethambutol-associated toxic $T2$
bitemporal hemianopia
optic neuropathy
0
$T1$, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.We report 3 cases which presented with bitemporal hemianopia.
tuberculosis
visual loss
0
$T1$, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.We report 3 cases which presented with $T2$
tuberculosis
bitemporal hemianopia
0
$T1$.CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.
bitemporal hemianopia
visual loss
0
$T1$ and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced $T2$
nimesulide
angioedema
1
$T1$ in patients who experienced urticaria/angioedema caused by NSAIDs.However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced $T2$
paracetamol
angioedema
1
$T1$-induced $T2$
NSAID
angioedema
1
$T1$ and $T2$
nimesulide
paracetamol
0
$T1$ and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of $T2$
nimesulide
NSAID
0
$T1$ and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic $T2$
nimesulide
urticaria
0
$T1$ in patients who experienced urticaria/angioedema caused by NSAIDs.However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of $T2$
paracetamol
NSAID
0
$T1$ in patients who experienced urticaria/angioedema caused by NSAIDs.However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic $T2$
paracetamol
urticaria
0
$T1$ and, above all, by a history of $T2$
urticaria
NSAID
0
$T1$ and, above all, by a history of NSAID-induced $T2$
urticaria
angioedema
0
$T1$ promotes $T2$
Verapamil
AF
1
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
Verapamil
0
$T1$(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
Ca
Verapamil
0
$T1$-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
morphine
Verapamil
0
$T1$ anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
chloralose
Verapamil
0
$T1$ promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by $T2$
Verapamil
diltiazem
0
$T1$ and nadolol was applied in some experiments.Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.
atropine
Verapamil
0
$T1$ was applied in some experiments.Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.
nadolol
Verapamil
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
AF
0
$T1$(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
Ca
AF
0
$T1$-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
morphine
AF
0
$T1$ anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
chloralose
AF
0
$T1$ in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by $T2$
AF
diltiazem
0
$T1$ and nadolol was applied in some experiments.Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.
atropine
AF
0
$T1$ was applied in some experiments.Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.
nadolol
AF
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
Ca
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
morphine
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
chloralose
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
diltiazem
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
atropine
0
$T1$-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Atrial tachycardia
nadolol
0
$T1$(2+) channel blockers, we administered verapamil to $T2$
Ca
morphine
0
$T1$(2+) channel blockers, we administered verapamil to morphine-$T2$
Ca
chloralose
0
$T1$(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
Ca
diltiazem
0
$T1$(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with $T2$
Ca
atropine
0
$T1$(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and $T2$
Ca
nadolol
0
$T1$-$T2$
morphine
chloralose
0
$T1$-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
morphine
diltiazem
0
$T1$-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with $T2$
morphine
atropine
0
$T1$-chloralose anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and $T2$
morphine
nadolol
0
$T1$ anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.
chloralose
diltiazem
0
$T1$ anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with $T2$
chloralose
atropine
0
$T1$ anesthetized dogs.Diltiazem was used as a comparison drug and autonomic blockade with atropine and $T2$
chloralose
nadolol
0
$T1$ and nadolol was applied in some experiments.Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.
atropine
diltiazem
0
$T1$ was applied in some experiments.Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.
nadolol
diltiazem
0
$T1$ and $T2$
atropine
nadolol
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
IVMP
1
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
IVMP
1
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
IVMP
1
$T1$, $T2$
hypotension
bradycardia
0
$T1$, bradycardia, and $T2$
hypotension
asystole
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of $T2$
hypotension
ischemic
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
cardiac disease
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
pulmonary-renal syndrome
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
hemoptysis
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
renal failure
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
hypoxemia
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
ventricular arrhythmia
0
$T1$, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
hypotension
sudden death
0
$T1$, and $T2$
bradycardia
asystole
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of $T2$
bradycardia
ischemic
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
cardiac disease
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
pulmonary-renal syndrome
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
hemoptysis
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
renal failure
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
hypoxemia
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
ventricular arrhythmia
0
$T1$, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
bradycardia
sudden death
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of $T2$
asystole
ischemic
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
cardiac disease
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
pulmonary-renal syndrome
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
hemoptysis
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
renal failure
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
hypoxemia
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
ventricular arrhythmia
0
$T1$ after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.There was a history of ischemic cardiac disease 9 years earlier.
asystole
sudden death
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.
ischemic
IVMP
0
$T1$).These mechanisms are not well understood because, in most cases, the patients were not monitored at the moment of the event.
IVMP
cardiac disease
0
$T1$ with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
pulmonary-renal syndrome
IVMP
0
$T1$, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hemoptysis
IVMP
0
$T1$, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
renal failure
IVMP
0
$T1$ that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hypoxemia
IVMP
0
$T1$).These mechanisms are not well understood because, in most cases, the patients were not monitored at the moment of the event.
IVMP
ventricular arrhythmia
0
$T1$ after a high dose of intravenous methylprednisolone ($T2$
sudden death
IVMP
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.
ischemic
cardiac disease
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a $T2$
ischemic
pulmonary-renal syndrome
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with $T2$
ischemic
hemoptysis
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive $T2$
ischemic
renal failure
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and $T2$
ischemic
hypoxemia
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.
ischemic
ventricular arrhythmia
0
$T1$ cardiac disease 9 years earlier.The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.
ischemic
sudden death
0
$T1$ with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
pulmonary-renal syndrome
cardiac disease
0
$T1$, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hemoptysis
cardiac disease
0
$T1$, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
renal failure
cardiac disease
0
$T1$ that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hypoxemia
cardiac disease
0
$T1$ were important risk factors in the case reported here, and the authors discount $T2$
cardiac disease
ventricular arrhythmia
0
$T1$ after a high dose of intravenous methylprednisolone (IVMP).These mechanisms are not well understood because, in most cases, the patients were not monitored at the moment of the event.
sudden death
cardiac disease
0
$T1$ with $T2$
pulmonary-renal syndrome
hemoptysis
0
$T1$ with hemoptysis, rapidly progressive $T2$
pulmonary-renal syndrome
renal failure
0
$T1$ with hemoptysis, rapidly progressive renal failure, and $T2$
pulmonary-renal syndrome
hypoxemia
0
$T1$ with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
pulmonary-renal syndrome
ventricular arrhythmia
0
$T1$ with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
pulmonary-renal syndrome
sudden death
0
$T1$, rapidly progressive $T2$
hemoptysis
renal failure
0
$T1$, rapidly progressive renal failure, and $T2$
hemoptysis
hypoxemia
0
$T1$, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hemoptysis
ventricular arrhythmia
0
$T1$, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hemoptysis
sudden death
0
$T1$, and $T2$
renal failure
hypoxemia
0
$T1$, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
renal failure
ventricular arrhythmia
0
$T1$, and hypoxemia that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
renal failure
sudden death
0
$T1$ that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hypoxemia
ventricular arrhythmia
0
$T1$ that required mechanical ventilation in the intensive care unit.After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.
hypoxemia
sudden death
0
$T1$ after a high dose of intravenous methylprednisolone (IVMP).These mechanisms are not well understood because, in most cases, the patients were not monitored at the moment of the event.
sudden death
ventricular arrhythmia
0
$T1$ showed changes compatible with myelodysplastic syndrome (MDS).A variety of histological patterns was observed.
thrombocytopenia
AZT
1
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
macrocytic anemia
AZT
1
$T1$ incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the $T2$
AZT
myelodysplastic syndrome
1
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
AIDS
AZT
0
$T1$ thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
thymidine
AZT
0
$T1$ hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
phosphate
AZT
0
$T1$.Above mentioned $T2$
hypocellular marrow
AZT
0
$T1$, hemosiderosis and a hypocellular marrow.Above mentioned $T2$
dyserythropoiesis
AZT
0
$T1$ and a hypocellular marrow.Above mentioned $T2$
hemosiderosis
AZT
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
macrocytic anemia
myelodysplastic syndrome
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
AIDS
myelodysplastic syndrome
0
$T1$ thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
thymidine
myelodysplastic syndrome
0
$T1$ hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
phosphate
myelodysplastic syndrome
0
$T1$ showed changes compatible with myelodysplastic syndrome (MDS).A variety of histological patterns was observed.
thrombocytopenia
myelodysplastic syndrome
0
$T1$.Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the $T2$
hypocellular marrow
myelodysplastic syndrome
0
$T1$, hemosiderosis and a hypocellular marrow.Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the $T2$
dyserythropoiesis
myelodysplastic syndrome
0
$T1$ and a hypocellular marrow.Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the $T2$
hemosiderosis
myelodysplastic syndrome
0
$T1$ in $T2$
macrocytic anemia
AIDS
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of $T2$
macrocytic anemia
thymidine
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the $T2$
macrocytic anemia
phosphate
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
macrocytic anemia
thrombocytopenia
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
macrocytic anemia
hypocellular marrow
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
macrocytic anemia
dyserythropoiesis
0
$T1$ in AIDS patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
macrocytic anemia
hemosiderosis
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of $T2$
AIDS
thymidine
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the $T2$
AIDS
phosphate
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
AIDS
thrombocytopenia
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
AIDS
hypocellular marrow
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
AIDS
dyserythropoiesis
0
$T1$ patients on long term AZT therapy.It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.
AIDS
hemosiderosis
0
$T1$ thus preventing the $T2$
thymidine
phosphate
0
$T1$ thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
thymidine
thrombocytopenia
0
$T1$ thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
thymidine
hypocellular marrow
0
$T1$ thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
thymidine
dyserythropoiesis
0
$T1$ thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
thymidine
hemosiderosis
0
$T1$ hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
phosphate
thrombocytopenia
0
$T1$ hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
phosphate
hypocellular marrow
0
$T1$ hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
phosphate
dyserythropoiesis
0
$T1$ hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).
phosphate
hemosiderosis
0
$T1$ showed changes compatible with myelodysplastic syndrome (MDS).A variety of histological patterns was observed.
thrombocytopenia
hypocellular marrow
0
$T1$ showed changes compatible with myelodysplastic syndrome (MDS).A variety of histological patterns was observed.
thrombocytopenia
dyserythropoiesis
0
$T1$ showed changes compatible with myelodysplastic syndrome (MDS).A variety of histological patterns was observed.
thrombocytopenia
hemosiderosis
0
$T1$, hemosiderosis and a $T2$
dyserythropoiesis
hypocellular marrow
0
$T1$ and a $T2$
hemosiderosis
hypocellular marrow
0
$T1$, $T2$
dyserythropoiesis
hemosiderosis
0
$T1$ in order to avoid $T2$
acetaminophen
hepatic damage
1
$T1$ can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid $T2$
ethanol
hepatic damage
1
$T1$.We see the main application of NAA as for the combinational use in pharmaceutical preparations of $T2$
NAD
acetaminophen
0
$T1$.We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid $T2$
NAD
hepatic damage
0
$T1$.We see the main application of $T2$
NAD
NAA
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
NAD
0
$T1$ can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate $T2$
ethanol
NAD
0
$T1$-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
glutamate
NAD
0
$T1$ transaminase (GOT) and glutamate-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
oxaloacetate
NAD
0
$T1$ transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
pyruvate
NAD
0
$T1$ as for the combinational use in pharmaceutical preparations of $T2$
NAA
acetaminophen
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
acetaminophen
0
$T1$ can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.We see the main application of NAA as for the combinational use in pharmaceutical preparations of $T2$
ethanol
acetaminophen
0
$T1$-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
glutamate
acetaminophen
0
$T1$ transaminase (GOT) and glutamate-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
oxaloacetate
acetaminophen
0
$T1$ transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
pyruvate
acetaminophen
0
$T1$ as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid $T2$
NAA
hepatic damage
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
hepatic damage
0
$T1$-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
glutamate
hepatic damage
0
$T1$ transaminase (GOT) and glutamate-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
oxaloacetate
hepatic damage
0
$T1$ transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
pyruvate
hepatic damage
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
NAA
0
$T1$ can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.We see the main application of $T2$
ethanol
NAA
0
$T1$-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
glutamate
NAA
0
$T1$ transaminase (GOT) and glutamate-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
oxaloacetate
NAA
0
$T1$ transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
pyruvate
NAA
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
ethanol
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
glutamate
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
oxaloacetate
0
$T1$ polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
poly(ADP-ribose)
pyruvate
0
$T1$-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
glutamate
ethanol
0
$T1$ transaminase (GOT) and glutamate-pyruvate transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
oxaloacetate
ethanol
0
$T1$ transaminase (GPT).While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.
pyruvate
ethanol
0
$T1$ transaminase (GOT) and $T2$
oxaloacetate
glutamate
0
$T1$-$T2$
glutamate
pyruvate
0
$T1$ transaminase (GOT) and glutamate-$T2$
oxaloacetate
pyruvate
0
$T1$-induced arrhythmia was significantly higher than those for the other types of arrhythmias.This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.
adrenaline
arrhythmia
1
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
arrhythmia
1
$T1$ had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation $T2$
cibenzoline
arrhythmia
0
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
cibenzoline
0
$T1$-induced arrhythmia was significantly higher than those for the other types of arrhythmias.This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.
adrenaline
cibenzoline
0
$T1$ and tocainide, and all three drugs have central nervous system (CNS) stimulant action.Because $T2$
mexiletine
cibenzoline
0
$T1$, and all three drugs have central nervous system (CNS) stimulant action.Because $T2$
tocainide
cibenzoline
0
$T1$ had only weak $T2$
cibenzoline
hypotensive
0
$T1$ had only weak hypotensive and sinus node $T2$
cibenzoline
depressive
0
$T1$ and tocainide, and all three drugs have central nervous system (CNS) stimulant action.Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation $T2$
mexiletine
arrhythmia
0
$T1$, and all three drugs have central nervous system (CNS) stimulant action.Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation $T2$
tocainide
arrhythmia
0
$T1$ and sinus node depressive effects and was found to be orally active when given to coronary ligation $T2$
hypotensive
arrhythmia
0
$T1$ effects and was found to be orally active when given to coronary ligation $T2$
depressive
arrhythmia
0
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
adrenaline
0
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
mexiletine
0
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
tocainide
0
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
hypotensive
0
$T1$, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.
digitalis
depressive
0
$T1$-induced arrhythmia was significantly higher than those for the other types of arrhythmias.This pharmacological profile is similar to those of $T2$
adrenaline
mexiletine
0
$T1$-induced arrhythmia was significantly higher than those for the other types of arrhythmias.This pharmacological profile is similar to those of mexiletine and $T2$
adrenaline
tocainide
0
$T1$-induced arrhythmia was significantly higher than those for the other types of arrhythmias.This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.
adrenaline
hypotensive
0
$T1$-induced arrhythmia was significantly higher than those for the other types of arrhythmias.This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.
adrenaline
depressive
0
$T1$ and $T2$
mexiletine
tocainide
0
$T1$ and tocainide, and all three drugs have central nervous system (CNS) stimulant action.Because cibenzoline had only weak $T2$
mexiletine
hypotensive
0
$T1$ and tocainide, and all three drugs have central nervous system (CNS) stimulant action.Because cibenzoline had only weak hypotensive and sinus node $T2$
mexiletine
depressive
0
$T1$, and all three drugs have central nervous system (CNS) stimulant action.Because cibenzoline had only weak $T2$
tocainide
hypotensive
0
$T1$, and all three drugs have central nervous system (CNS) stimulant action.Because cibenzoline had only weak hypotensive and sinus node $T2$
tocainide
depressive
0
$T1$ and sinus node $T2$
hypotensive
depressive
0
$T1$.Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with $T2$
glomerular disease
D-penicillamine
1
$T1$ after five to 12 months of treatment with $T2$
proteinuria
D-penicillamine
1
$T1$ developed heavy proteinuria after five to 12 months of treatment with $T2$
rheumatoid arthritis
D-penicillamine
0
$T1$.Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal.
D-penicillamine
membranous glomerulonephritis
0
$T1$.Four patients with $T2$
glomerular disease
rheumatoid arthritis
0
$T1$.Four patients with rheumatoid arthritis developed heavy $T2$
glomerular disease
proteinuria
0
$T1$.Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.
glomerular disease
membranous glomerulonephritis
0
$T1$ developed heavy $T2$
rheumatoid arthritis
proteinuria
0
$T1$ developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal.
rheumatoid arthritis
membranous glomerulonephritis
0
$T1$ after five to 12 months of treatment with D-penicillamine.Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal.
proteinuria
membranous glomerulonephritis
0
$T1$ by selective injection of each into the right coronary artery of dogs.Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.
Hypaque 76%
Ventricular fibrillation
1
$T1$.$T2$
sodium citrate
Ventricular fibrillation
1
$T1$ and no sodium citrate.$T2$
calcium disodium edetate
Ventricular fibrillation
1
$T1$ contains calcium disodium edetate and no sodium citrate.$T2$
Hypaque
Ventricular fibrillation
0
$T1$ occurred significantly more often with Renografin, suggesting that chelating agents contribute to $T2$
Ventricular fibrillation
toxicity
0
$T1$ occurred significantly more often with $T2$
Ventricular fibrillation
Renografin
0
$T1$ contains calcium disodium edetate and no sodium citrate.Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to $T2$
Hypaque
toxicity
0
$T1$ by selective injection of each into the right coronary artery of dogs.Renografin contains the chelating agents sodium citrate and disodium edetate, while $T2$
Hypaque 76%
Hypaque
0
$T1$ contains calcium disodium edetate and no sodium citrate.Ventricular fibrillation occurred significantly more often with $T2$
Hypaque
Renografin
0
$T1$ contains calcium disodium edetate and no $T2$
Hypaque
sodium citrate
0
$T1$ contains $T2$
Hypaque
calcium disodium edetate
0
$T1$ by selective injection of each into the right coronary artery of dogs.Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.
Hypaque 76%
toxicity
0
$T1$, suggesting that chelating agents contribute to $T2$
Renografin
toxicity
0
$T1$.Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to $T2$
sodium citrate
toxicity
0
$T1$ and no sodium citrate.Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to $T2$
calcium disodium edetate
toxicity
0
$T1$ by selective injection of each into the right coronary artery of dogs.Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.
Hypaque 76%
Renografin
0
$T1$ by selective injection of each into the right coronary artery of dogs.Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no $T2$
Hypaque 76%
sodium citrate
0
$T1$ by selective injection of each into the right coronary artery of dogs.Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains $T2$
Hypaque 76%
calcium disodium edetate
0
$T1$.Ventricular fibrillation occurred significantly more often with $T2$
sodium citrate
Renografin
0
$T1$ and no sodium citrate.Ventricular fibrillation occurred significantly more often with $T2$
calcium disodium edetate
Renografin
0
$T1$ and no $T2$
calcium disodium edetate
sodium citrate
0
$T1$ (2 mg/kg over 24 h), resulting in a mean (+/-s.d.)International Normalized Ratio of 3.5+/-0.9.
warfarin
ICH
1
$T1$ (2 mg/kg over 24 h), resulting in a mean (+/-s.d.)International Normalized Ratio of 3.5+/-0.9.
warfarin
hemorrhage
0
$T1$ induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).
hemorrhage
ICH
0
$T1$.There is no consensus on the optimal treatment for W-ICH.
stroke
hemorrhage
0
$T1$ induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).
hemorrhage
PCC
0
$T1$ induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.The mean hemorrhagic blood volume was reduced in PCC-treated animals (6.5+/-3.1 microL) compared with saline controls (15.3+/-11.2 microL, P=0.015).
hemorrhage
hematomas
0
$T1$.There is no consensus on the optimal treatment for W-ICH.
stroke
warfarin
0
$T1$ (2 mg/kg over 24 h), resulting in a mean (+/-s.d.)International Normalized Ratio of 3.5+/-0.9.
warfarin
PCC
0
$T1$ (2 mg/kg over 24 h), resulting in a mean (+/-s.d.)International Normalized Ratio of 3.5+/-0.9.
warfarin
hematomas
0
$T1$.There is no consensus on the optimal treatment for W-ICH.
stroke
ICH
0
$T1$ to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.Future studies are needed to assess the therapeutic potential emerging from our finding for human W-$T2$
PCC
ICH
0
$T1$ (i.e., >15 microL).In contrast, such extensive lesions were never found in the PCC group.
hematomas
ICH
0
$T1$.There is no consensus on the optimal treatment for W-ICH.
stroke
PCC
0
$T1$.There is no consensus on the optimal treatment for W-ICH.
stroke
hematomas
0
$T1$ (i.e., >15 microL).In contrast, such extensive lesions were never found in the PCC group.
hematomas
PCC
0
$T1$ in comparison with women who either quit drinking or who were nondrinkers.Amphetamine abuse was predictive of larger cranial to body growth ratios.
decreased cranial to body growth
alcohol
1
$T1$ in comparison with women who either quit drinking or who were nondrinkers.$T2$
decreased cranial to body growth
Amphetamine
1
$T1$.RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies.
drug abuse
alcohol
0
$T1$ abuse was predictive of larger cranial to body growth ratios.CONCLUSIONS: Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies.
Amphetamine
alcohol
0
$T1$.RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies.
drug abuse
decreased cranial to body growth
0
$T1$.RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies.
drug abuse
Amphetamine
0
$T1$.The SF-36 scores changed significantly in the domains of physical functioning, role function emotional, social function and mental heath.
dry mouth
Tolterodine
1
$T1$ was well tolerated and its effects improved the quality of life in Thai women with $T2$
Tolterodine
OAB
0
$T1$ episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.
nocturia
OAB
0
$T1$.The SF-36 scores changed significantly in the domains of physical functioning, role function emotional, social function and mental heath.
dry mouth
OAB
0
$T1$ episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.
nocturia
Tolterodine
0
$T1$ episodes decreased from 5.4 +/- 4.2 to 1.1 +/- 1.0 times per night.The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.
nocturia
dry mouth
0
$T1$ SAH associated with $T2$
aneurysmal
cocaine
1
$T1$ associated with $T2$
SAH
cocaine
1
$T1$, including arterial vasoconstriction and vasculitis.However, there are few studies of angiographic effects of cocaine on human cerebral arteries.
neurovascular complications
cocaine
0
$T1$ could be found in patients who underwent angiography after aneurysmal SAH associated with $T2$
vasculitis
cocaine
0
$T1$, including arterial vasoconstriction and vasculitis.However, there are few studies of angiographic effects of cocaine on human cerebral arteries.
neurovascular complications
SAH
0
$T1$ could be found in patients who underwent angiography after aneurysmal $T2$
vasculitis
SAH
0
$T1$ $T2$
aneurysmal
SAH
0
$T1$, including arterial vasoconstriction and vasculitis.However, there are few studies of angiographic effects of cocaine on human cerebral arteries.
neurovascular complications
vasculitis
0
$T1$, including arterial vasoconstriction and vasculitis.However, there are few studies of angiographic effects of cocaine on human cerebral arteries.
neurovascular complications
aneurysmal
0
$T1$ could be found in patients who underwent angiography after $T2$
vasculitis
aneurysmal
0
$T1$-based chemotherapy in the same patient.$T2$
doxorubicin
Atrial fibrillation
1
$T1$ and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.$T2$
gastric lymphoma
Atrial fibrillation
0
$T1$, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.$T2$
myotonic dystrophy
Atrial fibrillation
0
$T1$, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.$T2$
muscular dystrophy
Atrial fibrillation
0
$T1$ or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the $T2$
Atrial fibrillation
arrhythmia
0
$T1$ or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.The $T2$
Atrial fibrillation
cardiac toxicity
0
$T1$ and $T2$
gastric lymphoma
myotonic dystrophy
0
$T1$ and myotonic dystrophy, the most common form of adult $T2$
gastric lymphoma
muscular dystrophy
0
$T1$ and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of $T2$
gastric lymphoma
doxorubicin
0
$T1$ and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
gastric lymphoma
arrhythmia
0
$T1$ and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
gastric lymphoma
cardiac toxicity
0
$T1$, the most common form of adult $T2$
myotonic dystrophy
muscular dystrophy
0
$T1$, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of $T2$
myotonic dystrophy
doxorubicin
0
$T1$, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
myotonic dystrophy
arrhythmia
0
$T1$, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
myotonic dystrophy
cardiac toxicity
0
$T1$, and sudden atrial fibrillation following one cycle of $T2$
muscular dystrophy
doxorubicin
0
$T1$, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
muscular dystrophy
arrhythmia
0
$T1$, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
muscular dystrophy
cardiac toxicity
0
$T1$-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
doxorubicin
arrhythmia
0
$T1$-based chemotherapy in the same patient.Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.
doxorubicin
cardiac toxicity
0
$T1$ intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the $T2$
cardiac toxicity
arrhythmia
0
$T1$ were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.Systemic plasma VEGF165 levels did not change with therapy.
constipation
thalidomide
1
$T1$ and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.Systemic plasma VEGF165 levels did not change with therapy.
Somnolence
thalidomide
1
$T1$ for $T2$
thalidomide
renal cell carcinoma
0
$T1$ and most patients could not tolerate the 1200 mg/day dose level.Systemic plasma VEGF165 levels did not change with therapy.
toxicities
thalidomide
0
$T1$ (4%), one minor response, and 2 patients stable for over 6 months.Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.
metastases
thalidomide
0
$T1$ and most patients could not tolerate the 1200 mg/day dose level.Systemic plasma VEGF165 levels did not change with therapy.
toxicities
renal cell carcinoma
0
$T1$ (4%), one minor response, and 2 patients stable for over 6 months.Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.
metastases
renal cell carcinoma
0
$T1$ and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.Systemic plasma VEGF165 levels did not change with therapy.
Somnolence
renal cell carcinoma
0
$T1$ were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level.Systemic plasma VEGF165 levels did not change with therapy.
constipation
renal cell carcinoma
0
$T1$ (4%), one minor response, and 2 patients stable for over 6 months.Somnolence and constipation were prominent $T2$
metastases
toxicities
0
$T1$ and constipation were prominent $T2$
Somnolence
toxicities
0
$T1$ were prominent $T2$
constipation
toxicities
0
$T1$ (4%), one minor response, and 2 patients stable for over 6 months.$T2$
metastases
Somnolence
0
$T1$ (4%), one minor response, and 2 patients stable for over 6 months.Somnolence and $T2$
metastases
constipation
0
$T1$ and $T2$
Somnolence
constipation
0
$T1$-induced muscle rigidity.In contrast, 2R,4R-APDC injections were ineffective.
haloperidol
muscle rigidity
1
$T1$ receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.
glutamate
haloperidol
0
$T1$ receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.
glutamate
parkinsonian
0
$T1$ receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.
glutamate
muscle rigidity
0
$T1$ receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.
glutamate
AIDA
0
$T1$ receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.
glutamate
2R,4R-APDC
0
$T1$-induced muscle rigidity.In contrast, 2R,4R-APDC injections were ineffective.
haloperidol
parkinsonian
0
$T1$ in doses of 7.5-15 microg/0.5 microl diminished the $T2$
AIDA
haloperidol
0
$T1$-induced muscle rigidity.In contrast, $T2$
haloperidol
2R,4R-APDC
0
$T1$ $T2$
parkinsonian
muscle rigidity
0
$T1$ in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.In contrast, 2R,4R-APDC injections were ineffective.
AIDA
parkinsonian
0
$T1$ injections were ineffective.The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate $T2$
2R,4R-APDC
parkinsonian
0
$T1$ in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.In contrast, 2R,4R-APDC injections were ineffective.
AIDA
muscle rigidity
0
$T1$ injections were ineffective.The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian $T2$
2R,4R-APDC
muscle rigidity
0
$T1$ in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.In contrast, $T2$
AIDA
2R,4R-APDC
0
$T1$.No other medications were involved except for dipyrone for analgesia.
hepatitis
Isoflurane
1
$T1$, a common anesthetic agent, can cause severe $T2$
Isoflurane
cholestatic hepatitis
1
$T1$.No other medications were involved except for dipyrone for analgesia.
hepatitis
cholestatic hepatitis
0
$T1$ was uneventful.DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.
dipyrone
cholestatic hepatitis
0
$T1$.The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.
analgesia
cholestatic hepatitis
0
$T1$ aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
alanine
cholestatic hepatitis
0
$T1$ reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
bilirubin
cholestatic hepatitis
0
$T1$, which has a significant mortality rate.CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe $T2$
halothane hepatitis
cholestatic hepatitis
0
$T1$ was uneventful.DISCUSSION: The clinical and histologic picture of this case resembles halothane hepatitis, which has a significant mortality rate.
dipyrone
Isoflurane
0
$T1$.The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.
analgesia
Isoflurane
0
$T1$ aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
alanine
Isoflurane
0
$T1$ reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
bilirubin
Isoflurane
0
$T1$, which has a significant mortality rate.CONCLUSIONS: $T2$
halothane hepatitis
Isoflurane
0
$T1$.No other medications were involved except for dipyrone for analgesia.
hepatitis
dipyrone
0
$T1$.No other medications were involved except for dipyrone for $T2$
hepatitis
analgesia
0
$T1$.No other medications were involved except for dipyrone for analgesia.
hepatitis
alanine
0
$T1$.No other medications were involved except for dipyrone for analgesia.
hepatitis
bilirubin
0
$T1$.No other medications were involved except for dipyrone for analgesia.
hepatitis
halothane hepatitis
0
$T1$.The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.
analgesia
dipyrone
0
$T1$ aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
alanine
dipyrone
0
$T1$ reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
bilirubin
dipyrone
0
$T1$ was uneventful.DISCUSSION: The clinical and histologic picture of this case resembles $T2$
dipyrone
halothane hepatitis
0
$T1$.The $T2$
analgesia
alanine
0
$T1$.The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum $T2$
analgesia
bilirubin
0
$T1$.The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.
analgesia
halothane hepatitis
0
$T1$ aminotransferase was elevated to a peak concentration of 1533 U/L and the serum $T2$
alanine
bilirubin
0
$T1$ aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
alanine
halothane hepatitis
0
$T1$ reached a peak of 17.0 mg/dL.There was slow improvement over 4 months.
bilirubin
halothane hepatitis
0
$T1$ and placebo days (P < 0.05).The present study indicates that NO-induced immediate $T2$
GTN
headache
1
$T1$-induced immediate $T2$
NO
headache
1
$T1$ and 16 healthy controls.The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.
tension-type headache
NO
0
$T1$ may be associated with release of calcitonin gene-related peptide (CGRP).In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
primary headaches
NO
0
$T1$ and placebo days (P < 0.05).The present study indicates that $T2$
GTN
NO
0
$T1$ and 16 healthy controls.The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.
tension-type headache
headache
0
$T1$ may be associated with release of calcitonin gene-related peptide (CGRP).In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
primary headaches
headache
0
$T1$ may be associated with release of calcitonin gene-related peptide (CGRP).In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic $T2$
primary headaches
tension-type headache
0
$T1$ and 16 healthy controls.The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.
tension-type headache
GTN
0
$T1$ may be associated with release of calcitonin gene-related peptide (CGRP).In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
primary headaches
GTN
0
$T1$ can provoke coronary spasm in some patients with $T2$
dobutamine
coronary spastic angina
1
$T1$ can provoke coronary spasm in some patients with coronary spastic angina.When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also $T2$
dobutamine
coronary spasm
1
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
coronary spasm
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
dobutamine
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
coronary stenosis
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
coronary spastic angina
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
anginal
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
acetylcholine
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
chest pain
0
$T1$ due to coronary spasm is induced by dobutamine.We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.
myocardial ischemia
coronary artery disease
0
$T1$, but also $T2$
coronary stenosis
coronary spasm
0
$T1$.When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also $T2$
coronary spastic angina
coronary spasm
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
anginal
coronary spasm
0
$T1$, and no fixed coronary artery stenosis was documented on angiograms in all patients.DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.
acetylcholine
coronary spasm
0
$T1$ and electrocardiographic changes were preceded by asynergy.These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.
chest pain
coronary spasm
0
$T1$, not only fixed coronary stenosis, but also $T2$
coronary artery disease
coronary spasm
0
$T1$ can provoke coronary spasm in some patients with coronary spastic angina.When DSE is performed to evaluate coronary artery disease, not only fixed $T2$
dobutamine
coronary stenosis
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
anginal
dobutamine
0
$T1$, and no fixed coronary artery stenosis was documented on angiograms in all patients.DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.
acetylcholine
dobutamine
0
$T1$ and electrocardiographic changes were preceded by asynergy.These findings indicate that $T2$
chest pain
dobutamine
0
$T1$ can provoke coronary spasm in some patients with coronary spastic angina.When DSE is performed to evaluate $T2$
dobutamine
coronary artery disease
0
$T1$.When DSE is performed to evaluate coronary artery disease, not only fixed $T2$
coronary spastic angina
coronary stenosis
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
anginal
coronary stenosis
0
$T1$, and no fixed coronary artery stenosis was documented on angiograms in all patients.DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.
acetylcholine
coronary stenosis
0
$T1$ and electrocardiographic changes were preceded by asynergy.These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.
chest pain
coronary stenosis
0
$T1$, not only fixed $T2$
coronary artery disease
coronary stenosis
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
anginal
coronary spastic angina
0
$T1$, and no fixed coronary artery stenosis was documented on angiograms in all patients.DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.
acetylcholine
coronary spastic angina
0
$T1$ and electrocardiographic changes were preceded by asynergy.These findings indicate that dobutamine can provoke coronary spasm in some patients with $T2$
chest pain
coronary spastic angina
0
$T1$.When DSE is performed to evaluate $T2$
coronary spastic angina
coronary artery disease
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of $T2$
anginal
acetylcholine
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
anginal
chest pain
0
$T1$ attacks at rest with ST elevation on the electrocardiogram (variant angina).Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
anginal
coronary artery disease
0
$T1$, and no fixed coronary artery stenosis was documented on angiograms in all patients.DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.
acetylcholine
chest pain
0
$T1$, and no fixed coronary artery stenosis was documented on angiograms in all patients.DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.
acetylcholine
coronary artery disease
0
$T1$ and electrocardiographic changes were preceded by asynergy.These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.
chest pain
coronary artery disease
0
$T1$-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with $T2$
lead
hypertension
1
$T1$ inactivation, $T2$
NO
lead
0
$T1$ inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with $T2$
NO
hypertension
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
oxygen
NO
0
$T1$ in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
nitrotyrosine
NO
0
$T1$, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.
lead acetate
NO
0
$T1$ supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.
Vitamin E
NO
0
$T1$, or NOS expression in the control group.The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.
MDA
NO
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
oxygen
lead
0
$T1$ in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
nitrotyrosine
lead
0
$T1$, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.
lead acetate
lead
0
$T1$ supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.
Vitamin E
lead
0
$T1$, or NOS expression in the control group.The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.
MDA
lead
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
oxygen
hypertension
0
$T1$ in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
nitrotyrosine
hypertension
0
$T1$, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.
lead acetate
hypertension
0
$T1$ supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.
Vitamin E
hypertension
0
$T1$, or NOS expression in the control group.The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.
MDA
hypertension
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as $T2$
oxygen
nitrotyrosine
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
oxygen
lead acetate
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
oxygen
Vitamin E
0
$T1$ species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
oxygen
MDA
0
$T1$ in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
nitrotyrosine
lead acetate
0
$T1$ in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
nitrotyrosine
Vitamin E
0
$T1$ in various tissues in rats with lead-induced hypertension.This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
nitrotyrosine
MDA
0
$T1$, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.
lead acetate
Vitamin E
0
$T1$, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.
lead acetate
MDA
0
$T1$ supplementation had no effect on either blood pressure, plasma $T2$
Vitamin E
MDA
0
$T1$-phentermine developed valvular heart disease.One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.
fenfluramine
aortic insufficiency
1
$T1$ developed valvular heart disease.One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.
phentermine
aortic insufficiency
1
$T1$-phentermine developed valvular heart disease.One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.
fenfluramine
valvular heart disease
0
$T1$ for 14 days or more and had echocardiograms obtained before therapy.MEASUREMENTS: Follow-up echocardiography.
dexfenfluramine
valvular heart disease
0
$T1$.CONCLUSION: Users of diet medications are at risk for $T2$
aortic insufficiency
valvular heart disease
0
$T1$).RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.
mitral regurgitation
valvular heart disease
0
$T1$ developed valvular heart disease.One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.
phentermine
valvular heart disease
0
$T1$ and mild aortic regurgitation that progressed to moderate regurgitation.The second patient developed new moderate aortic insufficiency.
bicuspid aortic valve
valvular heart disease
0
$T1$ for 14 days or more and had echocardiograms obtained before therapy.MEASUREMENTS: Follow-up echocardiography.
dexfenfluramine
fenfluramine
0
$T1$).RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving $T2$
mitral regurgitation
fenfluramine
0
$T1$-$T2$
fenfluramine
phentermine
0
$T1$-phentermine developed valvular heart disease.One had baseline $T2$
fenfluramine
bicuspid aortic valve
0
$T1$ for 14 days or more and had echocardiograms obtained before therapy.MEASUREMENTS: Follow-up echocardiography.
dexfenfluramine
aortic insufficiency
0
$T1$ for 14 days or more and had echocardiograms obtained before therapy.MEASUREMENTS: Follow-up echocardiography.
dexfenfluramine
mitral regurgitation
0
$T1$ for 14 days or more and had echocardiograms obtained before therapy.MEASUREMENTS: Follow-up echocardiography.
dexfenfluramine
phentermine
0
$T1$ for 14 days or more and had echocardiograms obtained before therapy.MEASUREMENTS: Follow-up echocardiography.
dexfenfluramine
bicuspid aortic valve
0
$T1$).RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.
mitral regurgitation
aortic insufficiency
0
$T1$ and mild aortic regurgitation that progressed to moderate regurgitation.The second patient developed new moderate $T2$
bicuspid aortic valve
aortic insufficiency
0
$T1$).RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-$T2$
mitral regurgitation
phentermine
0
$T1$).RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.
mitral regurgitation
bicuspid aortic valve
0
$T1$ developed valvular heart disease.One had baseline $T2$
phentermine
bicuspid aortic valve
0
$T1$.Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.
peripheral neurotoxicity
CDDP
1
$T1$.Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.
peripheral neurotoxicity
CBDCA
1
$T1$ that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.This model can be used alone or in combination with other drugs to explore the effect of $T2$
CDDP
CBDCA
0
$T1$ is induced in the two drugs by the same mechanism.This model can be used alone or in combination with other drugs to explore the effect of $T2$
neurotoxicity
CBDCA
0
$T1$ perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.
Pain
CBDCA
0
$T1$ were detected in the dorsal root ganglia and kidney after CBDCA treatment.CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.
platinum
CBDCA
0
$T1$ that it is probable that $T2$
CDDP
neurotoxicity
0
$T1$ perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.
Pain
CDDP
0
$T1$ were detected in the dorsal root ganglia and kidney after CBDCA treatment.CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by $T2$
platinum
CDDP
0
$T1$.Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.
peripheral neurotoxicity
neurotoxicity
0
$T1$ perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.
Pain
neurotoxicity
0
$T1$ were detected in the dorsal root ganglia and kidney after CBDCA treatment.CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that $T2$
platinum
neurotoxicity
0
$T1$.$T2$
peripheral neurotoxicity
Pain
0
$T1$.Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.
peripheral neurotoxicity
platinum
0
$T1$ perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.
Pain
platinum
0
$T1$ diagnosed in women treated with tamoxifen have poorer prognosis.Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.
Endometrial cancers
tamoxifen
1
$T1$ diagnosed in women treated with tamoxifen have poorer prognosis.Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.
Endometrial cancers
breast cancer
0
$T1$ and poorer prognosis than those with endometrial cancer who had not received this treatment.Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.
advanced disease
Endometrial cancers
0
$T1$ as a preventive treatment for $T2$
tamoxifen
breast cancer
0
$T1$ and poorer prognosis than those with endometrial cancer who had not received this treatment.Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.
advanced disease
breast cancer
0
$T1$ and poorer prognosis than those with endometrial cancer who had not received this treatment.Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.
advanced disease
tamoxifen
0
$T1$ may be at increased risk for granulosa cell tumors because of alterations in $T2$
liver dysfunction
tamoxifen
1
$T1$.CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in $T2$
granulosa cell tumor of the ovary
tamoxifen
1
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
tumors
granulosa cell tumor of the ovary
0
$T1$ receptor-positive breast carcinoma.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
estrogen
granulosa cell tumor of the ovary
0
$T1$.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
breast carcinoma
granulosa cell tumor of the ovary
0
$T1$ transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic $T2$
aspartate
granulosa cell tumor of the ovary
0
$T1$ transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic $T2$
alanine
granulosa cell tumor of the ovary
0
$T1$.CONCLUSION: Patients with tamoxifen-induced $T2$
granulosa cell tumor of the ovary
liver dysfunction
0
$T1$.CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for $T2$
granulosa cell tumor of the ovary
granulosa cell tumors
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
tumors
tamoxifen
0
$T1$ receptor-positive breast carcinoma.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
estrogen
tamoxifen
0
$T1$.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
breast carcinoma
tamoxifen
0
$T1$ transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.
aspartate
tamoxifen
0
$T1$ transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.
alanine
tamoxifen
0
$T1$ because of alterations in $T2$
granulosa cell tumors
tamoxifen
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II $T2$
tumors
estrogen
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive $T2$
tumors
breast carcinoma
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
tumors
aspartate
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
tumors
alanine
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
tumors
liver dysfunction
0
$T1$.CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
tumors
granulosa cell tumors
0
$T1$ receptor-positive $T2$
estrogen
breast carcinoma
0
$T1$ receptor-positive breast carcinoma.Her $T2$
estrogen
aspartate
0
$T1$ receptor-positive breast carcinoma.Her aspartate transaminase and $T2$
estrogen
alanine
0
$T1$ receptor-positive breast carcinoma.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
estrogen
liver dysfunction
0
$T1$ receptor-positive breast carcinoma.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
estrogen
granulosa cell tumors
0
$T1$.Her $T2$
breast carcinoma
aspartate
0
$T1$.Her aspartate transaminase and $T2$
breast carcinoma
alanine
0
$T1$.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
breast carcinoma
liver dysfunction
0
$T1$.Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.
breast carcinoma
granulosa cell tumors
0
$T1$ transaminase and $T2$
aspartate
alanine
0
$T1$ transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.
aspartate
liver dysfunction
0
$T1$ transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.
aspartate
granulosa cell tumors
0
$T1$ transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.
alanine
liver dysfunction
0
$T1$ transaminase levels increase markedly after 6 months of tamoxifen use.After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.
alanine
granulosa cell tumors
0
$T1$ may be at increased risk for $T2$
liver dysfunction
granulosa cell tumors
0
$T1$.The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.
hyperprolactinemia
fluoxetine
1
$T1$.CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.
fluoxetine
adenomyosis
1
$T1$.The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.
hyperprolactinemia
adenomyosis
0
$T1$ reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.
serotonin
adenomyosis
0
$T1$ that results in a myometrial invasion by endometrial stroma.This invasion eventually progresses to $T2$
steroids
adenomyosis
0
$T1$ reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce $T2$
serotonin
hyperprolactinemia
0
$T1$.The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.
hyperprolactinemia
steroids
0
$T1$ reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.
serotonin
fluoxetine
0
$T1$.CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian $T2$
fluoxetine
steroids
0
$T1$ reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls.
serotonin
steroids
0
$T1$ induced by $T2$
hypotension
labetalol
1
$T1$ induced by labetalol with $T2$
hypotension
isoflurane
1
$T1$ scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.The tests were performed preoperatively and 2 days postoperatively.
anxiety
hypotension
0
$T1$ scale) and two-part memory test battery with immediate and delayed recall.The tests were performed preoperatively and 2 days postoperatively.
depression
hypotension
0
$T1$ with $T2$
labetalol
isoflurane
0
$T1$ scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.The tests were performed preoperatively and 2 days postoperatively.
anxiety
labetalol
0
$T1$ scale) and two-part memory test battery with immediate and delayed recall.The tests were performed preoperatively and 2 days postoperatively.
depression
labetalol
0
$T1$ scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall.The tests were performed preoperatively and 2 days postoperatively.
anxiety
isoflurane
0
$T1$ scale) and two-part memory test battery with immediate and delayed recall.The tests were performed preoperatively and 2 days postoperatively.
depression
isoflurane
0
$T1$ scale and self-rating $T2$
anxiety
depression
0
$T1$ on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.The frequencies at which the impairment occurred varied between patients; in one only low frequencies (0.25-0.5 kHz) were involved.
hearing impairment
bupivacaine
1
$T1$ was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.
adrenaline
hearing impairment
1
$T1$ was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.
adrenaline
bupivacaine
0
$T1$.This patient had hearing threshold changes (15-20 dB) at 6-10 kHz on the opposite side also.
bupivacaine
auditory dysfunction
0
$T1$ was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.
adrenaline
auditory dysfunction
0
$T1$ on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.The frequencies at which the impairment occurred varied between patients; in one only low frequencies (0.25-0.5 kHz) were involved.
hearing impairment
auditory dysfunction
0
$T1$ occurred less often in the midazolam group it lasted longer.On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.
apnoea
Midazolam
1
$T1$ occurred less often in the midazolam group it lasted longer.On the whole, the differences between midazolam and $T2$
apnoea
thiopentone
1
$T1$ had no apparent clinical consequences.$T2$
thiopentone
Midazolam
0
$T1$ + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
scopolamine
Midazolam
0
$T1$ (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
morphine
Midazolam
0
$T1$ the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
nitrazepam
Midazolam
0
$T1$ + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
scopolamine
thiopentone
0
$T1$ (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
morphine
thiopentone
0
$T1$ the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
nitrazepam
thiopentone
0
$T1$ + $T2$
scopolamine
morphine
0
$T1$ + morphine (+5 mg $T2$
scopolamine
nitrazepam
0
$T1$ + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
scopolamine
apnoea
0
$T1$ (+5 mg $T2$
morphine
nitrazepam
0
$T1$ (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
morphine
apnoea
0
$T1$ the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v.was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.
nitrazepam
apnoea
0
$T1$ at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.
congestive heart failure
adriamycin
1
$T1$ after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.Our results suggest that $T2$
acute myeloblastic leukemia
adriamycin
1
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
adriamycin
0
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
congestive heart failure
0
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
myocardial lesions
0
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
anthracycline
0
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
cardiomyopathy
0
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
acute myeloblastic leukemia
0
$T1$ and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).
Cardiotoxic
leukemia
0
$T1$ resembled those found in human anthracycline-induced cardiomyopathy.1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
myocardial lesions
adriamycin
0
$T1$-induced cardiomyopathy.1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
anthracycline
adriamycin
0
$T1$.1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
cardiomyopathy
adriamycin
0
$T1$ is a more potent cardiotoxin in monkeys than in man, and that $T2$
adriamycin
leukemia
0
$T1$ at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.Histologically, the $T2$
congestive heart failure
myocardial lesions
0
$T1$ at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.Histologically, the myocardial lesions resembled those found in human $T2$
congestive heart failure
anthracycline
0
$T1$ at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.Histologically, the myocardial lesions resembled those found in human anthracycline-induced $T2$
congestive heart failure
cardiomyopathy
0
$T1$ at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.
congestive heart failure
acute myeloblastic leukemia
0
$T1$ at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.
congestive heart failure
leukemia
0
$T1$ resembled those found in human $T2$
myocardial lesions
anthracycline
0
$T1$ resembled those found in human anthracycline-induced $T2$
myocardial lesions
cardiomyopathy
0
$T1$ resembled those found in human anthracycline-induced cardiomyopathy.1 of the 10 monkeys developed $T2$
myocardial lesions
acute myeloblastic leukemia
0
$T1$ resembled those found in human anthracycline-induced cardiomyopathy.1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
myocardial lesions
leukemia
0
$T1$-induced $T2$
anthracycline
cardiomyopathy
0
$T1$-induced cardiomyopathy.1 of the 10 monkeys developed $T2$
anthracycline
acute myeloblastic leukemia
0
$T1$-induced cardiomyopathy.1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
anthracycline
leukemia
0
$T1$.1 of the 10 monkeys developed $T2$
cardiomyopathy
acute myeloblastic leukemia
0
$T1$.1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
cardiomyopathy
leukemia
0
$T1$ after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that $T2$
acute myeloblastic leukemia
leukemia
0
$T1$ is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.It is recommended that $T2$
cardiomyopathy
doxorubicin
1
$T1$ dosage be sharply restricted in children with $T2$
doxorubicin
Wilms tumor
0
$T1$ cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.
anthracycline
doxorubicin
0
$T1$ bed and conventional dosage of doxorubicin.The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.
tumor
doxorubicin
0
$T1$ is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.It is recommended that doxorubicin dosage be sharply restricted in children with $T2$
cardiomyopathy
Wilms tumor
0
$T1$ cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.The $T2$
anthracycline
cardiomyopathy
0
$T1$ bed and conventional dosage of doxorubicin.The $T2$
tumor
cardiomyopathy
0
$T1$ cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.
anthracycline
Wilms tumor
0
$T1$ bed and conventional dosage of doxorubicin.The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.
tumor
Wilms tumor
0
$T1$ cardiomyopathy after irradiation to the $T2$
anthracycline
tumor
0
$T1$ developed only prostatitis.Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental $T2$
testosterone
prostate cancer
1
$T1$ developed only $T2$
testosterone
prostatitis
1
$T1$ in genetically susceptible rats.Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.
carcinogenesis
testosterone
0
$T1$.Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.
tumors
testosterone
0
$T1$ in genetically susceptible rats.Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.
carcinogenesis
prostate cancer
0
$T1$ in genetically susceptible rats.Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.
carcinogenesis
tumors
0
$T1$ in genetically susceptible rats.Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.
carcinogenesis
prostatitis
0
$T1$.Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.
tumors
prostate cancer
0
$T1$.Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental $T2$
prostatitis
prostate cancer
0
$T1$.Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.
tumors
prostatitis
0
$T1$ and thrombocytopenia while on treatment with $T2$
renal failure
mitomycin C
1
$T1$ and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
HUS
mitomycin C
1
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
mitomycin C
0
$T1$ while on treatment with $T2$
thrombocytopenia
mitomycin C
0
$T1$ and died in $T2$
mitomycin C
pulmonary edema
0
$T1$, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
thrombi
mitomycin C
0
$T1$ wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
ischemic
mitomycin C
0
$T1$ who developed renal failure and thrombocytopenia while on treatment with $T2$
gastric adenocarcinoma
mitomycin C
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
HUS
0
$T1$ and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
HUS
thrombocytopenia
0
$T1$ and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
HUS
renal failure
0
$T1$ and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
HUS
pulmonary edema
0
$T1$ and include arteriolar fibrin $T2$
HUS
thrombi
0
$T1$ and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, $T2$
HUS
ischemic
0
$T1$ and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
HUS
gastric adenocarcinoma
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
thrombocytopenia
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
renal failure
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
pulmonary edema
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
thrombi
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
ischemic
0
$T1$, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
hemolytic anemia
gastric adenocarcinoma
0
$T1$ and $T2$
renal failure
thrombocytopenia
0
$T1$ while on treatment with mitomycin C and died in $T2$
thrombocytopenia
pulmonary edema
0
$T1$, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
thrombi
thrombocytopenia
0
$T1$ wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
ischemic
thrombocytopenia
0
$T1$ who developed renal failure and $T2$
gastric adenocarcinoma
thrombocytopenia
0
$T1$ and thrombocytopenia while on treatment with mitomycin C and died in $T2$
renal failure
pulmonary edema
0
$T1$, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
thrombi
renal failure
0
$T1$ wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
ischemic
renal failure
0
$T1$ who developed $T2$
gastric adenocarcinoma
renal failure
0
$T1$, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
thrombi
pulmonary edema
0
$T1$ wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
ischemic
pulmonary edema
0
$T1$ who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in $T2$
gastric adenocarcinoma
pulmonary edema
0
$T1$, expanded subendothelial zones in glomerular capillary walls, $T2$
thrombi
ischemic
0
$T1$, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
thrombi
gastric adenocarcinoma
0
$T1$ wrinkling of glomerular basement membranes and mesangiolysis.The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.
ischemic
gastric adenocarcinoma
0
$T1$ (during 5-FU infusion).However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).
angina
5-FU
1
$T1$ infusion is associated with a significant increase in silent ST segment deviation suggestive of $T2$
5-FU
ischemia
1
$T1$ associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
cardiac toxicity
5-FU
0
$T1$ in order to assess the incidence of ischemic ST changes.Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.
tumors
5-FU
0
$T1$ infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with $T2$
5-FU
coronary artery disease
0
$T1$, both of which occurred at the end of the chemotherapy course.We conclude that $T2$
sudden death
5-FU
0
$T1$ associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid $T2$
cardiac toxicity
tumors
0
$T1$ associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
cardiac toxicity
ischemia
0
$T1$ associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
cardiac toxicity
angina
0
$T1$ associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
cardiac toxicity
coronary artery disease
0
$T1$ associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
cardiac toxicity
sudden death
0
$T1$ in order to assess the incidence of ischemic ST changes.Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.
tumors
ischemia
0
$T1$ in order to assess the incidence of ischemic ST changes.Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.
tumors
angina
0
$T1$ in order to assess the incidence of ischemic ST changes.Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.
tumors
coronary artery disease
0
$T1$ in order to assess the incidence of ischemic ST changes.Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.
tumors
sudden death
0
$T1$ (during 5-FU infusion).However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).
angina
ischemia
0
$T1$, particularly among patients with $T2$
ischemia
coronary artery disease
0
$T1$, both of which occurred at the end of the chemotherapy course.We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of $T2$
sudden death
ischemia
0
$T1$ (during 5-FU infusion).However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).
angina
coronary artery disease
0
$T1$ (during 5-FU infusion).However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).
angina
sudden death
0
$T1$, both of which occurred at the end of the chemotherapy course.We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with $T2$
sudden death
coronary artery disease
0
$T1$ in patients pretreated with $T2$
ifosfamide
nephrotoxic
1
$T1$ was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.We recommend careful use of $T2$
anuria
ifosfamide
1
$T1$, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.Postrenal failure was excluded by echography.
breast cancer
anuria
0
$T1$ was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.We recommend careful use of ifosfamide in patients pretreated with $T2$
anuria
nephrotoxic
0
$T1$ was mainly due to ifosfamide, occurring in a patient having received previous $T2$
anuria
cisplatin
0
$T1$ because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.However, correction of the hemodynamic parameters did not improve renal function.
renal failure
anuria
0
$T1$ was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient $T2$
anuria
hypotension
0
$T1$, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.Postrenal failure was excluded by echography.
breast cancer
ifosfamide
0
$T1$ chemotherapy and with poor kidney perfusion due to transient hypotension.We recommend careful use of $T2$
cisplatin
ifosfamide
0
$T1$ because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.However, correction of the hemodynamic parameters did not improve renal function.
renal failure
ifosfamide
0
$T1$.We recommend careful use of $T2$
hypotension
ifosfamide
0
$T1$, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.Postrenal failure was excluded by echography.
breast cancer
nephrotoxic
0
$T1$, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.Postrenal failure was excluded by echography.
breast cancer
cisplatin
0
$T1$, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.Postrenal failure was excluded by echography.
breast cancer
renal failure
0
$T1$, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.Postrenal failure was excluded by echography.
breast cancer
hypotension
0
$T1$ chemotherapy and with poor kidney perfusion due to transient hypotension.We recommend careful use of ifosfamide in patients pretreated with $T2$
cisplatin
nephrotoxic
0
$T1$ because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.However, correction of the hemodynamic parameters did not improve renal function.
renal failure
nephrotoxic
0
$T1$.We recommend careful use of ifosfamide in patients pretreated with $T2$
hypotension
nephrotoxic
0
$T1$ because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.However, correction of the hemodynamic parameters did not improve renal function.
renal failure
cisplatin
0
$T1$ chemotherapy and with poor kidney perfusion due to transient $T2$
cisplatin
hypotension
0
$T1$ because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.However, correction of the hemodynamic parameters did not improve renal function.
renal failure
hypotension
0
$T1$ in her seeing eye one day after having started topical medication with $T2$
vein thrombosis
dipivalyl epinephrine
1
$T1$ in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced $T2$
vein thrombosis
glaucoma
0
$T1$ for advanced $T2$
dipivalyl epinephrine
glaucoma
0
$T1$ of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following $T2$
hypokalemia
bendrofluazide
1
$T1$ also reduced the rise in plasma aldosterone and urine potassium excretion following $T2$
Timolol
bendrofluazide
0
$T1$ and urine potassium excretion following $T2$
aldosterone
bendrofluazide
0
$T1$ and increased the urine sodium/potassium ratio.There was no evidence of a shift of $T2$
bendrofluazide
potassium
0
$T1$ and increased the urine $T2$
bendrofluazide
sodium
0
$T1$ of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.$T2$
hypokalemia
Timolol
0
$T1$ of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.Timolol also reduced the rise in plasma $T2$
hypokalemia
aldosterone
0
$T1$ of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.
hypokalemia
potassium
0
$T1$ of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine $T2$
hypokalemia
sodium
0
$T1$ also reduced the rise in plasma $T2$
Timolol
aldosterone
0
$T1$ also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.There was no evidence of a shift of $T2$
Timolol
potassium
0
$T1$ also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine $T2$
Timolol
sodium
0
$T1$ and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.There was no evidence of a shift of $T2$
aldosterone
potassium
0
$T1$ and urine potassium excretion following bendrofluazide and increased the urine $T2$
aldosterone
sodium
0
$T1$/potassium ratio.There was no evidence of a shift of $T2$
sodium
potassium
0
$T1$-induced $T2$
risperidone
hyperprolactinemia
1
$T1$ reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).These findings became more marked when the analysis was restricted to non-Hispanic white patients.
serotonin
risperidone
0
$T1$ concentration increased with pubertal status but was not affected by hyperprolactinemia.As expected, bone mineral content and BMD increased with sexual maturity.
testosterone
risperidone
0
$T1$, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.CONCLUSIONS: This is the first study to link $T2$
fractures
risperidone
0
$T1$ reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).These findings became more marked when the analysis was restricted to non-Hispanic white patients.
serotonin
hyperprolactinemia
0
$T1$ concentration increased with pubertal status but was not affected by hyperprolactinemia.As expected, bone mineral content and BMD increased with sexual maturity.
testosterone
serotonin
0
$T1$ reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).These findings became more marked when the analysis was restricted to non-Hispanic white patients.
serotonin
fractures
0
$T1$ concentration increased with pubertal status but was not affected by hyperprolactinemia.As expected, bone mineral content and BMD increased with sexual maturity.
testosterone
hyperprolactinemia
0
$T1$, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.CONCLUSIONS: This is the first study to link risperidone-induced $T2$
fractures
hyperprolactinemia
0
$T1$ concentration increased with pubertal status but was not affected by hyperprolactinemia.As expected, bone mineral content and BMD increased with sexual maturity.
testosterone
fractures
0
$T1$ have been reported in the literature.Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.
seizures
levofloxacin
1
$T1$ (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
LiCl
polyuria
1
$T1$-induced $T2$
lithium
polyuria
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
lithium
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
prostaglandin E
lithium
0
$T1$ (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
LiCl
lithium
0
$T1$ mediates $T2$
PGE(2)
lithium
0
$T1$-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
Na
lithium
0
$T1$-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
K
lithium
0
$T1$ cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
Cl
lithium
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
polyuria
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
prostaglandin E
polyuria
0
$T1$ mediates lithium-induced $T2$
PGE(2)
polyuria
0
$T1$-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
Na
polyuria
0
$T1$-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
K
polyuria
0
$T1$ cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
Cl
polyuria
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal $T2$
PG
prostaglandin E
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
LiCl
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
PGE(2)
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
Na
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
K
0
$T1$) isomerase has not been evaluated.The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
PG
Cl
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of $T2$
prostaglandin E
LiCl
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
prostaglandin E
PGE(2)
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
prostaglandin E
Na
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
prostaglandin E
K
0
$T1$ synthase-1 (mPGES-1).A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
prostaglandin E
Cl
0
$T1$ (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
LiCl
PGE(2)
0
$T1$ (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
LiCl
Na
0
$T1$ (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
LiCl
K
0
$T1$ (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.
LiCl
Cl
0
$T1$-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
Na
PGE(2)
0
$T1$-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
K
PGE(2)
0
$T1$ cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.
Cl
PGE(2)
0
$T1$-$T2$
Na
K
0
$T1$-K-2$T2$
Na
Cl
0
$T1$-2$T2$
K
Cl
0
$T1$ (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent $T2$
chondroitin sulfate
hypotension
1
$T1$ (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs.
chondroitin sulfate
heparin
0
$T1$ in pigs.The no observed effect level (NOEL) for this contaminant appears to be approximately 1mg/kg, corresponding to a contamination level of approximately 3%.
hypotension
heparin
0
$T1$ $T2$
DOX
cardiomyopathy
1
$T1$ and apoptosis after induction of DOX-induced cardiomyopathy.DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.
inflammation
DOX
0
$T1$ doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
anthracycline
DOX
0
$T1$ effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
cardiotoxic
DOX
0
$T1$ was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.
cardiac dysfunction
DOX
0
$T1$ and apoptosis after induction of DOX-induced cardiomyopathy.DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.
inflammation
cardiomyopathy
0
$T1$ doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
anthracycline
cardiomyopathy
0
$T1$ effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
cardiotoxic
cardiomyopathy
0
$T1$ was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.
cardiac dysfunction
cardiomyopathy
0
$T1$ doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac $T2$
anthracycline
inflammation
0
$T1$ effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac $T2$
cardiotoxic
inflammation
0
$T1$ and apoptosis after induction of DOX-induced cardiomyopathy.DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.
inflammation
cardiac dysfunction
0
$T1$ doxorubicin (DOX) is limited by its $T2$
anthracycline
cardiotoxic
0
$T1$ doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
anthracycline
cardiac dysfunction
0
$T1$ effects, which are attributed to the induction of apoptosis.To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.
cardiotoxic
cardiac dysfunction
0
$T1$ associated with $T2$
hepatotoxicity
sulfasalazine
1
$T1$: A case series from a local surveillance of serious adverse events.BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.
arthritis
hepatotoxicity
0
$T1$ - one died after a liver transplant.All but one event occurred within 6 weeks of treatment.
hepatic failure
hepatotoxicity
0
$T1$, three eosinophilia and one interstitial nephritis.Five patients were of Black British of African or Caribbean descent.
skin rash
hepatotoxicity
0
$T1$ and one interstitial nephritis.Five patients were of Black British of African or Caribbean descent.
eosinophilia
hepatotoxicity
0
$T1$.Five patients were of Black British of African or Caribbean descent.
interstitial nephritis
hepatotoxicity
0
$T1$: A case series from a local surveillance of serious adverse events.BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.
arthritis
sulfasalazine
0
$T1$ - one died after a liver transplant.All but one event occurred within 6 weeks of treatment.
hepatic failure
sulfasalazine
0
$T1$, three eosinophilia and one interstitial nephritis.Five patients were of Black British of African or Caribbean descent.
skin rash
sulfasalazine
0
$T1$ and one interstitial nephritis.Five patients were of Black British of African or Caribbean descent.
eosinophilia
sulfasalazine
0
$T1$.Five patients were of Black British of African or Caribbean descent.
interstitial nephritis
sulfasalazine
0
$T1$: A case series from a local surveillance of serious adverse events.BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.
arthritis
hepatic failure
0
$T1$: A case series from a local surveillance of serious adverse events.BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.
arthritis
skin rash
0
$T1$: A case series from a local surveillance of serious adverse events.BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.
arthritis
eosinophilia
0
$T1$: A case series from a local surveillance of serious adverse events.BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.
arthritis
interstitial nephritis
0
$T1$ - one died after a liver transplant.All but one event occurred within 6 weeks of treatment.
hepatic failure
skin rash
0
$T1$ - one died after a liver transplant.All but one event occurred within 6 weeks of treatment.
hepatic failure
eosinophilia
0
$T1$ - one died after a liver transplant.All but one event occurred within 6 weeks of treatment.
hepatic failure
interstitial nephritis
0
$T1$, three $T2$
skin rash
eosinophilia
0
$T1$, three eosinophilia and one $T2$
skin rash
interstitial nephritis
0
$T1$ and one $T2$
eosinophilia
interstitial nephritis
0
$T1$ serum concentrations with respective pathogens were assessed.The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).
amikacin
nephrotoxicity
1
$T1$ were randomized to either conventional or extended-interval amikacin.The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via $T2$
aminoglycoside
amikacin
0
$T1$ and other suspected infections.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
febrile neutropenia
amikacin
0
$T1$.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
infections
amikacin
0
$T1$ that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via $T2$
hematologic/oncologic disorder
amikacin
0
$T1$ and evaluation of efficacy via $T2$
creatinine
amikacin
0
$T1$ were randomized to either conventional or extended-interval amikacin.The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.
aminoglycoside
nephrotoxicity
0
$T1$ and other suspected infections.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
febrile neutropenia
nephrotoxicity
0
$T1$.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
infections
nephrotoxicity
0
$T1$ that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.
hematologic/oncologic disorder
nephrotoxicity
0
$T1$ and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).
creatinine
nephrotoxicity
0
$T1$ and other suspected infections.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
febrile neutropenia
aminoglycoside
0
$T1$.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
infections
aminoglycoside
0
$T1$ that required treatment with an $T2$
hematologic/oncologic disorder
aminoglycoside
0
$T1$ were randomized to either conventional or extended-interval amikacin.The occurrence of nephrotoxicity by means of an increase in serum $T2$
aminoglycoside
creatinine
0
$T1$ and other suspected $T2$
febrile neutropenia
infections
0
$T1$ and other suspected infections.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
febrile neutropenia
hematologic/oncologic disorder
0
$T1$ and other suspected infections.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
febrile neutropenia
creatinine
0
$T1$.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
infections
hematologic/oncologic disorder
0
$T1$.Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population.
infections
creatinine
0
$T1$ that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.The occurrence of nephrotoxicity by means of an increase in serum $T2$
hematologic/oncologic disorder
creatinine
0
$T1$.No effect of 5-HTTLPR or gender on memory function or $T2$
memory impairments
MDMA
1
$T1$ transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.
5-HT
MDMA
0
$T1$ on functions in which 5-HT is involved, such as cognitive function.Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the $T2$
neurotoxic lesions
5-HT
0
$T1$ transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.
5-HT
memory impairments
0
$T1$ on functions in which 5-HT is involved, such as cognitive function.Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
neurotoxic lesions
MDMA
0
$T1$ on functions in which 5-HT is involved, such as cognitive function.Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.
neurotoxic lesions
memory impairments
0
$T1$, induced by haloperidol ($T2$
hyperprolactinemia
HAL
1
$T1$, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
hyperprolactinemia
PRL
0
$T1$, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
hyperprolactinemia
T
0
$T1$, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
hyperprolactinemia
hypertrophy
0
$T1$, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
hyperprolactinemia
hyperplasia
0
$T1$) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
HAL
PRL
0
$T1$) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
HAL
T
0
$T1$) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
HAL
hypertrophy
0
$T1$) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.The study was performed on sexually mature male rats.
HAL
hyperplasia
0
$T1$ was more than twice higher, whereas $T2$
PRL
T
0
$T1$ was more than twice higher, whereas T concentration was almost twice lower than that in the control group.Light microscopy visualized the following: $T2$
PRL
hypertrophy
0
$T1$ was more than twice higher, whereas T concentration was almost twice lower than that in the control group.Light microscopy visualized the following: hypertrophy and epithelium $T2$
PRL
hyperplasia
0
$T1$ concentration was almost twice lower than that in the control group.Light microscopy visualized the following: $T2$
T
hypertrophy
0
$T1$ concentration was almost twice lower than that in the control group.Light microscopy visualized the following: hypertrophy and epithelium $T2$
T
hyperplasia
0
$T1$ and epithelium $T2$
hypertrophy
hyperplasia
0
$T1$ intake from supplements is associated with an increased risk of $T2$
vitamin C
cardiovascular disease
1
$T1$ intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with $T2$
vitamin C
diabetes
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
vitamin C
0
$T1$ were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.
coronary artery disease
vitamin C
0
$T1$ were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.
stroke
vitamin C
0
$T1$, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
folate
vitamin C
0
$T1$, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
vitamin E
vitamin C
0
$T1$, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
beta-carotene
vitamin C
0
$T1$ mortality in postmenopausal women with $T2$
cardiovascular disease
diabetes
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
cardiovascular disease
0
$T1$ were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.
coronary artery disease
cardiovascular disease
0
$T1$ were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.
stroke
cardiovascular disease
0
$T1$, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
folate
cardiovascular disease
0
$T1$, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
vitamin E
cardiovascular disease
0
$T1$, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
beta-carotene
cardiovascular disease
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
diabetes
0
$T1$ were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.
coronary artery disease
diabetes
0
$T1$ were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.
stroke
diabetes
0
$T1$, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
folate
diabetes
0
$T1$, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
vitamin E
diabetes
0
$T1$, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).
beta-carotene
diabetes
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
coronary artery disease
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
stroke
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
folate
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
vitamin E
0
$T1$.OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
atherosclerosis
beta-carotene
0
$T1$ were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of $T2$
coronary artery disease
stroke
0
$T1$, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of $T2$
folate
coronary artery disease
0
$T1$, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of $T2$
vitamin E
coronary artery disease
0
$T1$, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of $T2$
beta-carotene
coronary artery disease
0
$T1$, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of $T2$
folate
stroke
0
$T1$, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of $T2$
vitamin E
stroke
0
$T1$, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of $T2$
beta-carotene
stroke
0
$T1$, $T2$
folate
vitamin E
0
$T1$, vitamin E, and $T2$
folate
beta-carotene
0
$T1$, and $T2$
vitamin E
beta-carotene
0
$T1$ among Danish women on $T2$
VTE
COCs
1
$T1$ among Danish women on COCs is similar to that among women taking $T2$
VTE
CPA
0
$T1$ among Danish women on COCs is similar to that among women taking CPA/$T2$
VTE
EE
0
$T1$-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.CONCLUSION: Our results suggest the absolute risk of $T2$
levonorgestrel
VTE
0
$T1$/$T2$
CPA
EE
0
$T1$ is similar to that among women taking $T2$
COCs
CPA
0
$T1$-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking $T2$
levonorgestrel
CPA
0
$T1$ is similar to that among women taking CPA/$T2$
COCs
EE
0
$T1$-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA/$T2$
levonorgestrel
EE
0
$T1$-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.CONCLUSION: Our results suggest the absolute risk of VTE among Danish women on $T2$
levonorgestrel
COCs
0
$T1$ was increased in animals treated with lindane indicating that $T2$
convulsions
lindane
1
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
lindane
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
NDMA
lindane
0
$T1$), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that $T2$
MC
lindane
0
$T1$ (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that $T2$
phenobarbital
lindane
0
$T1$ per se or its metabolites formed by PB or $T2$
lindane
ethanol
0
$T1$ incidence of convulsions was increased in animals treated with lindane indicating that $T2$
cobalt chloride
lindane
0
$T1$ per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral $T2$
lindane
toxicity
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
NDMA
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
MC
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
convulsions
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
phenobarbital
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
ethanol
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
cobalt chloride
0
$T1$.Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.
neurotoxicity
toxicity
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene ($T2$
NDMA
MC
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
NDMA
convulsions
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with $T2$
NDMA
phenobarbital
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
NDMA
ethanol
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
NDMA
cobalt chloride
0
$T1$-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
NDMA
toxicity
0
$T1$), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of $T2$
MC
convulsions
0
$T1$), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with $T2$
MC
phenobarbital
0
$T1$), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or $T2$
MC
ethanol
0
$T1$), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by $T2$
MC
cobalt chloride
0
$T1$), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral $T2$
MC
toxicity
0
$T1$ (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of $T2$
phenobarbital
convulsions
0
$T1$ was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or $T2$
convulsions
ethanol
0
$T1$ incidence of $T2$
cobalt chloride
convulsions
0
$T1$ was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral $T2$
convulsions
toxicity
0
$T1$ (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or $T2$
phenobarbital
ethanol
0
$T1$ (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by $T2$
phenobarbital
cobalt chloride
0
$T1$ (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral $T2$
phenobarbital
toxicity
0
$T1$ incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or $T2$
cobalt chloride
ethanol
0
$T1$ inducible P450 isoenzymes are involved in its neurobehavioral $T2$
ethanol
toxicity
0
$T1$ incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral $T2$
cobalt chloride
toxicity
0
$T1$-associated $T2$
bupropion
seizures
1
$T1$ may add to the risk of bupropion-associated $T2$
sleep deprivation
seizures
0
$T1$ may add to the risk of $T2$
sleep deprivation
bupropion
0
$T1$ group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).CONCLUSIONS: $T2$
iohexol
Nephropathy
1
$T1$ induced by contrast medium may be less likely to develop in high-risk patients when $T2$
Nephropathy
iodixanol
0
$T1$ with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.
diabetes
Nephropathy
0
$T1$ concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).CONCLUSIONS: $T2$
creatinine
Nephropathy
0
$T1$ group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when $T2$
iohexol
iodixanol
0
$T1$ with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.
diabetes
iodixanol
0
$T1$ concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when $T2$
creatinine
iodixanol
0
$T1$ with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.
diabetes
iohexol
0
$T1$ concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the $T2$
creatinine
iohexol
0
$T1$ with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.
diabetes
creatinine
0
$T1$ was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.
capsaicin
pain
1
$T1$ study no brain stem activation was found in the acute pain state compared to the pain free state.The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted $T2$
migraine
pain
0
$T1$ as such, rather than in a specific type of $T2$
pain
headache
0
$T1$ as such, rather than in a specific type of headache as was suggested for $T2$
pain
cluster headache
0
$T1$ was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.
capsaicin
migraine
0
$T1$ was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.
capsaicin
headache
0
$T1$ was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.
capsaicin
cluster headache
0
$T1$ study no brain stem activation was found in the acute pain state compared to the pain free state.The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of $T2$
migraine
headache
0
$T1$ study no brain stem activation was found in the acute pain state compared to the pain free state.The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for $T2$
migraine
cluster headache
0
$T1$ as was suggested for $T2$
headache
cluster headache
0
$T1$ does not ensure protection from $T2$
risperidone
neuroleptic malignant syndrome
1
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.
dopamine
neuroleptic malignant syndrome
0
$T1$ derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
benzisoxazole
neuroleptic malignant syndrome
0
$T1$ 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
serotonin
neuroleptic malignant syndrome
0
$T1$, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.
extrapyramidal symptoms
neuroleptic malignant syndrome
0
$T1$ and bromocriptine.It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from $T2$
dantrolene
neuroleptic malignant syndrome
0
$T1$.It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from $T2$
bromocriptine
neuroleptic malignant syndrome
0
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.
dopamine
risperidone
0
$T1$ derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
benzisoxazole
risperidone
0
$T1$ 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
serotonin
risperidone
0
$T1$, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.
extrapyramidal symptoms
risperidone
0
$T1$ and bromocriptine.It appears that the protection from extrapyramidal side effects observed with $T2$
dantrolene
risperidone
0
$T1$.It appears that the protection from extrapyramidal side effects observed with $T2$
bromocriptine
risperidone
0
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a $T2$
dopamine
benzisoxazole
0
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a benzisoxazole derivative antipsychotic, has high $T2$
dopamine
serotonin
0
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.
dopamine
extrapyramidal symptoms
0
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.
dopamine
dantrolene
0
$T1$ D2 receptor blockade in the striatum of the basal ganglia.Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.
dopamine
bromocriptine
0
$T1$ derivative antipsychotic, has high $T2$
benzisoxazole
serotonin
0
$T1$ derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
benzisoxazole
extrapyramidal symptoms
0
$T1$ derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
benzisoxazole
dantrolene
0
$T1$ derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
benzisoxazole
bromocriptine
0
$T1$ 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
serotonin
extrapyramidal symptoms
0
$T1$ 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
serotonin
dantrolene
0
$T1$ 5-HT2 receptor blockade and dose-related D2 receptor blockade.The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
serotonin
bromocriptine
0
$T1$, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.
extrapyramidal symptoms
dantrolene
0
$T1$, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.
extrapyramidal symptoms
bromocriptine
0
$T1$ and $T2$
dantrolene
bromocriptine
0
$T1$ induced by $T2$
NS
PAN
1
$T1$ system proteins are altered in rats with nephrotic syndrome (NS).In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.
angiotensin
NS
0
$T1$ system proteins are altered in rats with nephrotic syndrome (NS).In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.
angiotensin
PAN
0
$T1$ associated bladder tumor is an aggressive disease.However, long-term survival is possible when radical cystectomy is performed for $T2$
Cyclophosphamide
bladder tumors
1
$T1$.MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
urothelial cancer
Cyclophosphamide
0
$T1$ underwent partial cystectomy for palliation and died 3 months later.CONCLUSIONS: $T2$
cancer
Cyclophosphamide
0
$T1$.Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.
carcinoma
Cyclophosphamide
0
$T1$.MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
urothelial cancer
bladder tumors
0
$T1$ underwent partial cystectomy for palliation and died 3 months later.CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.
cancer
bladder tumors
0
$T1$.Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.
carcinoma
bladder tumors
0
$T1$.MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
urothelial cancer
cancer
0
$T1$.MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
urothelial cancer
carcinoma
0
$T1$.Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.
carcinoma
cancer
0
$T1$ is associated with the intrathecal use of hyperbaric 5% $T2$
Leg and/or back pain
lignocaine
1
$T1$ solution for spinal anaesthesia were studied.Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.
glucose
Leg and/or back pain
0
$T1$ admitted to a high alcohol intake, which might be a contributing factor.$T2$
pain
Leg and/or back pain
0
$T1$ intake, which might be a contributing factor.$T2$
alcohol
Leg and/or back pain
0
$T1$ solution for spinal anaesthesia were studied.Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.
glucose
lignocaine
0
$T1$ admitted to a high alcohol intake, which might be a contributing factor.Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% $T2$
pain
lignocaine
0
$T1$ intake, which might be a contributing factor.Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% $T2$
alcohol
lignocaine
0
$T1$ solution for spinal anaesthesia were studied.Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.
glucose
pain
0
$T1$ solution for spinal anaesthesia were studied.Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia.
glucose
alcohol
0
$T1$ admitted to a high $T2$
pain
alcohol
0
$T1$.We suspect that the potential for $T2$
hypertensives
caffeine
1
$T1$-induced hallucinations, which may occur without other signs of neurotoxicity."Eyes-closed" $T2$
ifosfamide
hallucinatory
1
$T1$."Eyes-closed" $T2$
neurotoxicity
hallucinatory
0
$T1$ experiences appear to be an unusual feature of this presentation.Patients anxious about this experience respond well to support and education about this occurrence.
hallucinatory
agitation
0
$T1$ experiences appear to be an unusual feature of this presentation.Patients anxious about this experience respond well to support and education about this occurrence.
hallucinatory
haloperidol
0
$T1$-induced hallucinations, which may occur without other signs of $T2$
ifosfamide
neurotoxicity
0
$T1$-induced hallucinations, which may occur without other signs of neurotoxicity."Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation.
ifosfamide
agitation
0
$T1$-induced hallucinations, which may occur without other signs of neurotoxicity."Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation.
ifosfamide
haloperidol
0
$T1$."Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation.
neurotoxicity
agitation
0
$T1$."Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation.
neurotoxicity
haloperidol
0
$T1$ becomes marked, high-potency neuroleptics (i.e., $T2$
agitation
haloperidol
0
$T1$ therapy.Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.
chlorpropamide
optic neuropathy
1
$T1$ treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of $T2$
adult-onset diabetes
chlorpropamide
0
$T1$ therapy.Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.
chlorpropamide
visual loss
0
$T1$ therapy.Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.
chlorpropamide
diabetics
0
$T1$ treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.
adult-onset diabetes
optic neuropathy
0
$T1$ should be considered in the differential diagnosis of $T2$
optic neuropathy
visual loss
0
$T1$ should be considered in the differential diagnosis of visual loss in $T2$
optic neuropathy
diabetics
0
$T1$ treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.
adult-onset diabetes
visual loss
0
$T1$ treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.
adult-onset diabetes
diabetics
0
$T1$ in $T2$
visual loss
diabetics
0
$T1$-induced $T2$
levodopa
dyskinesias
1
$T1$-induced dyskinesias by thalamic lesions in the course of routine treatment of $T2$
levodopa
Parkinsonism
0
$T1$ in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.Control of $T2$
dystonic
levodopa
0
$T1$-induced dyskinesias by $T2$
levodopa
thalamic lesions
0
$T1$ by thalamic lesions in the course of routine treatment of $T2$
dyskinesias
Parkinsonism
0
$T1$ in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.Control of levodopa-induced $T2$
dystonic
dyskinesias
0
$T1$ by $T2$
dyskinesias
thalamic lesions
0
$T1$ in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of $T2$
dystonic
Parkinsonism
0
$T1$ in the course of routine treatment of $T2$
thalamic lesions
Parkinsonism
0
$T1$ in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.Control of levodopa-induced dyskinesias by $T2$
dystonic
thalamic lesions
0
$T1$ were analyzed for factors associated with nephrotoxicity.In 42 of these patients, data were examined for factors associated with clinical outcome.
amikacin
nephrotoxic
1
$T1$ clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).Model-dependent pharmacokinetic parameters were calculated by computer based on a one-compartment model.
creatinine
nephrotoxic
0
$T1$ were analyzed for factors associated with nephrotoxicity.In 42 of these patients, data were examined for factors associated with clinical outcome.
amikacin
creatinine
0
$T1$ can cause chronic $T2$
cyclosporine
nephrotoxicity
1
$T1$, which was used for the first postoperative week.Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.
azathioprine
cyclosporine
0
$T1$ and serum creatinine levels.Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.
urea nitrogen
cyclosporine
0
$T1$.We think that even these lower dosages of $T2$
creatinine
cyclosporine
0
$T1$, which was used for the first postoperative week.Group II showed a better perioperative renal function as determined by serum blood $T2$
azathioprine
urea nitrogen
0
$T1$, which was used for the first postoperative week.Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.
azathioprine
creatinine
0
$T1$, which was used for the first postoperative week.Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.
azathioprine
nephrotoxicity
0
$T1$ and serum creatinine levels.Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.
urea nitrogen
creatinine
0
$T1$ and serum creatinine levels.Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.
urea nitrogen
nephrotoxicity
0
$T1$.We think that even these lower dosages of cyclosporine can cause chronic $T2$
creatinine
nephrotoxicity
0
$T1$-induced cholestasis associated with histological evidence of $T2$
azathioprine
bile duct injury
1
$T1$ and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.
polymyositis
bile duct injury
0
$T1$, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.
liver disease
bile duct injury
0
$T1$ and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.
polymyositis
azathioprine
0
$T1$, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.
liver disease
azathioprine
0
$T1$ and without previous evidence of $T2$
polymyositis
liver disease
0
$T1$-induced $T2$
isoflurane
hypotension
1
$T1$) clearance, respectively.Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.
PAH
isoflurane
0
$T1$, nitrous oxide, oxygen, and isoflurane.Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
fentanyl
isoflurane
0
$T1$, oxygen, and isoflurane.Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
nitrous oxide
isoflurane
0
$T1$, and isoflurane.Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
oxygen
isoflurane
0
$T1$) clearance, respectively.Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.
PAH
hypotension
0
$T1$, nitrous oxide, oxygen, and isoflurane.Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
fentanyl
hypotension
0
$T1$, oxygen, and isoflurane.Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
nitrous oxide
hypotension
0
$T1$, and isoflurane.Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
oxygen
hypotension
0
$T1$) clearance, respectively.Anesthesia was maintained with $T2$
PAH
fentanyl
0
$T1$) clearance, respectively.Anesthesia was maintained with fentanyl, $T2$
PAH
nitrous oxide
0
$T1$) clearance, respectively.Anesthesia was maintained with fentanyl, nitrous oxide, $T2$
PAH
oxygen
0
$T1$, $T2$
fentanyl
nitrous oxide
0
$T1$, nitrous oxide, $T2$
fentanyl
oxygen
0
$T1$, $T2$
nitrous oxide
oxygen
0
$T1$.By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.
hypokalemia
terbutaline
1
$T1$/sparteine type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
debrisoquine
metoprolol
0
$T1$/$T2$
debrisoquine
sparteine
0
$T1$/sparteine type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
debrisoquine
terbutaline
0
$T1$/sparteine type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
debrisoquine
hypokalemia
0
$T1$/sparteine type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
debrisoquine
potassium
0
$T1$/sparteine type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
debrisoquine
alpha-hydroxymetoprolol
0
$T1$ type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
sparteine
metoprolol
0
$T1$ area under the plasma concentration vs. time curve (+67%).Higher metoprolol/alpha-hydroxymetoprolol ratios in PMs were predictive for higher R-/S-isomer ratios of unchanged drug.
terbutaline
metoprolol
0
$T1$.By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.
hypokalemia
metoprolol
0
$T1$, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).
potassium
metoprolol
0
$T1$ ratios in PMs were predictive for higher R-/S-isomer ratios of unchanged drug.There was a difference in metoprolol potency with higher racemic $T2$
alpha-hydroxymetoprolol
metoprolol
0
$T1$ type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
sparteine
terbutaline
0
$T1$ type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
sparteine
hypokalemia
0
$T1$ type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
sparteine
potassium
0
$T1$ type.The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.
sparteine
alpha-hydroxymetoprolol
0
$T1$, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.In PMs, metoprolol increased the $T2$
potassium
terbutaline
0
$T1$ area under the plasma concentration vs. time curve (+67%).Higher metoprolol/$T2$
terbutaline
alpha-hydroxymetoprolol
0
$T1$.By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.
hypokalemia
potassium
0
$T1$.By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.
hypokalemia
alpha-hydroxymetoprolol
0
$T1$, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).
potassium
alpha-hydroxymetoprolol
0
$T1$, suggesting the concomitant formation of warm-reactive autoantibodies.These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced $T2$
cefotetan
hemolytic anemia
1
$T1$ and first-generation cephalosporins.We describe a patient who developed anemia while receiving intravenous cefotetan.
penicillins
cefotetan
0
$T1$, suggesting the concomitant formation of warm-reactive autoantibodies.These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.
cefotetan
cephalosporins
0
$T1$ while receiving intravenous cefotetan.Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.
anemia
cefotetan
0
$T1$, suggesting the concomitant formation of warm-reactive autoantibodies.These observations, in conjunction with clinical and laboratory evidence of extravascular $T2$
cefotetan
hemolysis
0
$T1$ and first-generation cephalosporins.We describe a patient who developed anemia while receiving intravenous cefotetan.
penicillins
hemolytic anemia
0
$T1$, possibly involving both drug-adsorption and autoantibody formation mechanisms.This case emphasizes the need for increased awareness of hemolytic reactions to all $T2$
hemolytic anemia
cephalosporins
0
$T1$ while receiving intravenous cefotetan.Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.
anemia
hemolytic anemia
0
$T1$, are consistent with drug-induced $T2$
hemolysis
hemolytic anemia
0
$T1$ and first-generation cephalosporins.We describe a patient who developed anemia while receiving intravenous cefotetan.
penicillins
cephalosporins
0
$T1$ and first-generation cephalosporins.We describe a patient who developed $T2$
penicillins
anemia
0
$T1$ and first-generation cephalosporins.We describe a patient who developed anemia while receiving intravenous cefotetan.
penicillins
hemolysis
0
$T1$ while receiving intravenous cefotetan.Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.
anemia
cephalosporins
0
$T1$, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.This case emphasizes the need for increased awareness of hemolytic reactions to all $T2$
hemolysis
cephalosporins
0
$T1$ while receiving intravenous cefotetan.Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.
anemia
hemolysis
0
$T1$ that have been reported earlier.The patients had developed transient renal failure after the intermittent administration of $T2$
acute renal failure
rifampicin
1
$T1$ that have been reported earlier.The patients had developed transient $T2$
acute renal failure
renal failure
0
$T1$ that have been reported earlier.The patients had developed transient renal failure after the intermittent administration of rifampicin.
acute renal failure
anuria
0
$T1$ that have been reported earlier.The patients had developed transient renal failure after the intermittent administration of rifampicin.
acute renal failure
renal lesions
0
$T1$ after the intermittent administration of $T2$
renal failure
rifampicin
0
$T1$.The stage of olig-$T2$
rifampicin
anuria
0
$T1$.The stage of olig-anuria lasted for 1-3 weeks, and five of the patients were treated by hemodialysis.
rifampicin
renal lesions
0
$T1$ after the intermittent administration of rifampicin.The stage of olig-$T2$
renal failure
anuria
0
$T1$ after the intermittent administration of rifampicin.The stage of olig-anuria lasted for 1-3 weeks, and five of the patients were treated by hemodialysis.
renal failure
renal lesions
0
$T1$ lasted for 1-3 weeks, and five of the patients were treated by hemodialysis.Two of the patients died due to unrelated causes during the follow-up period.
anuria
renal lesions
0
$T1$ showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.
HBeAg
type B hepatitis
1
$T1$-positive donors.Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.
HBsAg
type B hepatitis
0
$T1$ developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients.
hepatitis
type B hepatitis
0
$T1$ developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients.
hepatitis
HBsAg
0
$T1$ showed a highly statistically significant correlation with the infectivity of $T2$
HBeAg
HBsAg
0
$T1$ developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients.
hepatitis
HBeAg
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
venlafaxine
1
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
thrombocytopenia
1
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of $T2$
serotonin syndrome
venlafaxine
1
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
tranylcypromine
1
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
myoclonic jerks
1
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
muscle rigidity
1
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
myoclonic jerks
1
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
venlafaxine
1
$T1$.Within 2 h he became confused with jerking movements of his extremities, $T2$
venlafaxine
tremors
1
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
tremors
1
$T1$ in a 23-y-old male who was taking $T2$
serotonin syndrome
tranylcypromine
1
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
salivation
1
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
tranylcypromine
1
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
thrombocytopenia
1
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
salivation
1
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
muscle rigidity
1
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the $T2$
serotonin
serotonin syndrome
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
muscle rigidity
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
salivation
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
serotonin syndrome
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
serotonin syndrome
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
serotonin syndrome
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the $T2$
norepinephrine
serotonin syndrome
0
$T1$ in a 23-y-old male who was taking tranylcypromine for $T2$
serotonin syndrome
depression
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
tremors
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
myoclonic jerks
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
diazepam
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
hypoventilation
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
paralysis
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
thrombocytopenia
0
$T1$ in a 23-y-old male who was taking tranylcypromine for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
serotonin syndrome
rhabdomyolysis
0
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of $T2$
tranylcypromine
venlafaxine
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
venlafaxine
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
venlafaxine
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
venlafaxine
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of $T2$
depression
venlafaxine
0
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
diazepam
0
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
hypoventilation
0
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
paralysis
0
$T1$.Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.
venlafaxine
rhabdomyolysis
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking $T2$
serotonin
tranylcypromine
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
tranylcypromine
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking $T2$
norepinephrine
tranylcypromine
0
$T1$ for $T2$
tranylcypromine
depression
0
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
diazepam
0
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
hypoventilation
0
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
paralysis
0
$T1$ for depression.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
tranylcypromine
rhabdomyolysis
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
muscle rigidity
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
salivation
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
serotonin
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
serotonin
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
serotonin
0
$T1$ and $T2$
serotonin
norepinephrine
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for $T2$
serotonin
depression
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
tremors
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
myoclonic jerks
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
diazepam
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
hypoventilation
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
paralysis
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
thrombocytopenia
0
$T1$ and norepinephrine.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
serotonin
rhabdomyolysis
0
$T1$ and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
salivation
muscle rigidity
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
muscle rigidity
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
muscle rigidity
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
muscle rigidity
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
muscle rigidity
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
muscle rigidity
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.
tremors
muscle rigidity
0
$T1$, rigidity, salivation and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
myoclonic jerks
muscle rigidity
0
$T1$ i.v.he remained tremulous with muscle rigidity and clenched jaws.
diazepam
muscle rigidity
0
$T1$, and was paralyzed to control $T2$
hypoventilation
muscle rigidity
0
$T1$.His subsequent course was remarkable for non-immune thrombocytopenia which resolved.
muscle rigidity
paralysis
0
$T1$.His subsequent course was remarkable for non-immune $T2$
muscle rigidity
thrombocytopenia
0
$T1$.His subsequent course was remarkable for non-immune thrombocytopenia which resolved.
muscle rigidity
rhabdomyolysis
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
salivation
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
salivation
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
salivation
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
salivation
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
salivation
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, $T2$
tremors
salivation
0
$T1$, rigidity, $T2$
myoclonic jerks
salivation
0
$T1$ and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
salivation
diazepam
0
$T1$ and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
salivation
hypoventilation
0
$T1$ and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
salivation
paralysis
0
$T1$ and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
salivation
thrombocytopenia
0
$T1$ and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
salivation
rhabdomyolysis
0
$T1$, $T2$
confusion
agitation
0
$T1$, agitation and $T2$
confusion
hyperthermia
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
norepinephrine
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
depression
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
tremors
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
myoclonic jerks
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
diazepam
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
hypoventilation
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
paralysis
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
thrombocytopenia
0
$T1$, agitation and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
confusion
rhabdomyolysis
0
$T1$ and $T2$
agitation
hyperthermia
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
norepinephrine
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
depression
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
tremors
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
myoclonic jerks
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
diazepam
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
hypoventilation
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
paralysis
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
thrombocytopenia
0
$T1$ and hyperthermia.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
agitation
rhabdomyolysis
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
norepinephrine
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
depression
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
tremors
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
myoclonic jerks
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
diazepam
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
hypoventilation
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
paralysis
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
thrombocytopenia
0
$T1$.The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.
hyperthermia
rhabdomyolysis
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for $T2$
norepinephrine
depression
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
tremors
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
myoclonic jerks
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
diazepam
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
hypoventilation
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
paralysis
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
thrombocytopenia
0
$T1$.We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
norepinephrine
rhabdomyolysis
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
tremors
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
myoclonic jerks
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
diazepam
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
hypoventilation
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
paralysis
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
thrombocytopenia
0
$T1$.He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.
depression
rhabdomyolysis
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, $T2$
tremors
myoclonic jerks
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.
tremors
diazepam
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.
tremors
hypoventilation
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.
tremors
paralysis
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.
tremors
thrombocytopenia
0
$T1$ and rigidity.He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.
tremors
rhabdomyolysis
0
$T1$, rigidity, salivation and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
myoclonic jerks
diazepam
0
$T1$, rigidity, salivation and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
myoclonic jerks
hypoventilation
0
$T1$, rigidity, salivation and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
myoclonic jerks
paralysis
0
$T1$, rigidity, salivation and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
myoclonic jerks
thrombocytopenia
0
$T1$, rigidity, salivation and diaphoresis.His pupils were 7 mm and sluggishly reactive to light.
myoclonic jerks
rhabdomyolysis
0
$T1$ i.v.he remained tremulous with muscle rigidity and clenched jaws.
diazepam
hypoventilation
0
$T1$ i.v.he remained tremulous with muscle rigidity and clenched jaws.
diazepam
paralysis
0
$T1$ i.v.he remained tremulous with muscle rigidity and clenched jaws.
diazepam
thrombocytopenia
0
$T1$ i.v.he remained tremulous with muscle rigidity and clenched jaws.
diazepam
rhabdomyolysis
0
$T1$, and was paralyzed to control muscle rigidity.His subsequent course was remarkable for non-immune thrombocytopenia which resolved.
hypoventilation
paralysis
0
$T1$, and was paralyzed to control muscle rigidity.His subsequent course was remarkable for non-immune $T2$
hypoventilation
thrombocytopenia
0
$T1$, and was paralyzed to control muscle rigidity.His subsequent course was remarkable for non-immune thrombocytopenia which resolved.
hypoventilation
rhabdomyolysis
0
$T1$ which resolved.The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.
thrombocytopenia
paralysis
0
$T1$.His mental status normalized and he was transferred to a psychiatry ward.
rhabdomyolysis
paralysis
0
$T1$ which resolved.The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of $T2$
thrombocytopenia
rhabdomyolysis
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
dyskinesia
1
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
parkinsonian
1
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
dyskinesia
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
L-DOPA
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
L-DOPA
parkinsonian
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
L-DOPA
0
$T1$ were then tested in combination with $T2$
dopamine
L-DOPA
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including $T2$
L-DOPA
clonidine
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, $T2$
L-DOPA
physostigmine
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, $T2$
L-DOPA
methysergide
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, $T2$
L-DOPA
5-MDOT
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, $T2$
L-DOPA
propranolol
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and $T2$
L-DOPA
MK-801
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
yohimbine
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
meperidine
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
Baclofen
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
dystonic
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
Atropine
0
$T1$ to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
L-DOPA
chorea
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
dyskinesia
0
$T1$ symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
parkinsonian
dyskinesia
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
dyskinesia
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
clonidine
dyskinesia
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
physostigmine
dyskinesia
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
methysergide
dyskinesia
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
5-MDOT
dyskinesia
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
propranolol
dyskinesia
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
MK-801
dyskinesia
0
$T1$ and meperidine reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of $T2$
yohimbine
dyskinesia
0
$T1$ reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of $T2$
meperidine
dyskinesia
0
$T1$ was also useful in one monkey against a more dystonic form of $T2$
Baclofen
dyskinesia
0
$T1$.Atropine converted the $T2$
dyskinesia
dystonic
0
$T1$.$T2$
dyskinesia
Atropine
0
$T1$.Atropine converted the dystonic movements into $T2$
dyskinesia
chorea
0
$T1$.They were then treated chronically with $T2$
MPTP
L-DOPA/benserazide
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
dopamine
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
clonidine
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
physostigmine
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
methysergide
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
5-MDOT
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
propranolol
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
MK-801
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
yohimbine
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
meperidine
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
Baclofen
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
dystonic
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
Atropine
0
$T1$.They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.
MPTP
chorea
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
parkinsonian
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
dopamine
parkinsonian
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
clonidine
parkinsonian
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
physostigmine
parkinsonian
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
methysergide
parkinsonian
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
5-MDOT
parkinsonian
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
propranolol
parkinsonian
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of $T2$
MK-801
parkinsonian
0
$T1$ symptomatology.However, $T2$
parkinsonian
yohimbine
0
$T1$ symptomatology.However, yohimbine and $T2$
parkinsonian
meperidine
0
$T1$ symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
parkinsonian
Baclofen
0
$T1$ symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
parkinsonian
dystonic
0
$T1$ symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
parkinsonian
Atropine
0
$T1$ symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
parkinsonian
chorea
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
dopamine
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
clonidine
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
physostigmine
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
methysergide
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
5-MDOT
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
propranolol
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
MK-801
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
yohimbine
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
meperidine
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
Baclofen
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
dystonic
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
Atropine
0
$T1$ 50/12.5 mg/kg given orally daily for 2 months.This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.
L-DOPA/benserazide
chorea
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including $T2$
dopamine
clonidine
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, $T2$
dopamine
physostigmine
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, $T2$
dopamine
methysergide
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, $T2$
dopamine
5-MDOT
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, $T2$
dopamine
propranolol
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and $T2$
dopamine
MK-801
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
yohimbine
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
meperidine
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
Baclofen
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
dystonic
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
Atropine
0
$T1$ were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
dopamine
chorea
0
$T1$, $T2$
clonidine
physostigmine
0
$T1$, physostigmine, $T2$
clonidine
methysergide
0
$T1$, physostigmine, methysergide, $T2$
clonidine
5-MDOT
0
$T1$, physostigmine, methysergide, 5-MDOT, $T2$
clonidine
propranolol
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and $T2$
clonidine
MK-801
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, $T2$
clonidine
yohimbine
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and $T2$
clonidine
meperidine
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
clonidine
Baclofen
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
clonidine
dystonic
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
clonidine
Atropine
0
$T1$, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
clonidine
chorea
0
$T1$, $T2$
physostigmine
methysergide
0
$T1$, methysergide, $T2$
physostigmine
5-MDOT
0
$T1$, methysergide, 5-MDOT, $T2$
physostigmine
propranolol
0
$T1$, methysergide, 5-MDOT, propranolol, and $T2$
physostigmine
MK-801
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, $T2$
physostigmine
yohimbine
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and $T2$
physostigmine
meperidine
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
physostigmine
Baclofen
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
physostigmine
dystonic
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
physostigmine
Atropine
0
$T1$, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
physostigmine
chorea
0
$T1$, $T2$
methysergide
5-MDOT
0
$T1$, 5-MDOT, $T2$
methysergide
propranolol
0
$T1$, 5-MDOT, propranolol, and $T2$
methysergide
MK-801
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, $T2$
methysergide
yohimbine
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and $T2$
methysergide
meperidine
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
methysergide
Baclofen
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
methysergide
dystonic
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
methysergide
Atropine
0
$T1$, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
methysergide
chorea
0
$T1$, $T2$
5-MDOT
propranolol
0
$T1$, propranolol, and $T2$
5-MDOT
MK-801
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, $T2$
5-MDOT
yohimbine
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and $T2$
5-MDOT
meperidine
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
5-MDOT
Baclofen
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
5-MDOT
dystonic
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
5-MDOT
Atropine
0
$T1$, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
5-MDOT
chorea
0
$T1$, and $T2$
propranolol
MK-801
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, $T2$
propranolol
yohimbine
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and $T2$
propranolol
meperidine
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
propranolol
Baclofen
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
propranolol
dystonic
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
propranolol
Atropine
0
$T1$, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
propranolol
chorea
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, $T2$
MK-801
yohimbine
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and $T2$
MK-801
meperidine
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
MK-801
Baclofen
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
MK-801
dystonic
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
MK-801
Atropine
0
$T1$, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
MK-801
chorea
0
$T1$ and $T2$
yohimbine
meperidine
0
$T1$ and meperidine reduced predominantly the dyskinetic movements.$T2$
yohimbine
Baclofen
0
$T1$ and meperidine reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
yohimbine
dystonic
0
$T1$ and meperidine reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
yohimbine
Atropine
0
$T1$ and meperidine reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
yohimbine
chorea
0
$T1$ reduced predominantly the dyskinetic movements.$T2$
meperidine
Baclofen
0
$T1$ reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
meperidine
dystonic
0
$T1$ reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
meperidine
Atropine
0
$T1$ reduced predominantly the dyskinetic movements.Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
meperidine
chorea
0
$T1$ was also useful in one monkey against a more dystonic form of dyskinesia.Atropine converted the $T2$
Baclofen
dystonic
0
$T1$ was also useful in one monkey against a more dystonic form of dyskinesia.$T2$
Baclofen
Atropine
0
$T1$ was also useful in one monkey against a more dystonic form of dyskinesia.Atropine converted the dystonic movements into $T2$
Baclofen
chorea
0
$T1$ converted the $T2$
Atropine
dystonic
0
$T1$ movements into $T2$
dystonic
chorea
0
$T1$ converted the dystonic movements into $T2$
Atropine
chorea
0
$T1$ was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
Gastrointestinal toxicosis
CCNU
1
$T1$ was 1.2%.CONCLUSIONS: $T2$
hepatic failure
CCNU
1
$T1$.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
thrombocytopenia
CCNU
1
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
CCNU
1
$T1$ and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
anaemia
CCNU
1
$T1$, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
neutropenia
CCNU
1
$T1$ (24.3%).Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
vomiting
CCNU
1
$T1$-associated $T2$
CCNU
toxicity
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
CCNU
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
CCNU
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
epitheliotropic lymphoma
CCNU
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
mast cell tumour
CCNU
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
brain tumour
CCNU
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
histiocytic tumours
CCNU
0
$T1$ transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.The incidence of hepatic failure was 1.2%.
alanine
CCNU
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
toxicity
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
toxicity
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
toxicity
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
epitheliotropic lymphoma
toxicity
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
mast cell tumour
toxicity
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
brain tumour
toxicity
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
histiocytic tumours
toxicity
0
$T1$, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
neutropenia
toxicity
0
$T1$ and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
anaemia
toxicity
0
$T1$.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
thrombocytopenia
toxicity
0
$T1$ was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
Gastrointestinal toxicosis
toxicity
0
$T1$ (24.3%).Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
vomiting
toxicity
0
$T1$ transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.The incidence of hepatic failure was 1.2%.
alanine
toxicity
0
$T1$ was 1.2%.CONCLUSIONS: CCNU-associated $T2$
hepatic failure
toxicity
0
$T1$$T2$
haematological, renal, hepatic and gastrointestinal toxicities
haematological, renal, hepatic and gastrointestinal toxicities
0
$T1$$T2$
haematological, renal, hepatic and gastrointestinal toxicities
haematological, renal, hepatic and gastrointestinal toxicities
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
epitheliotropic lymphoma
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
mast cell tumour
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
brain tumour
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
histiocytic tumours
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
neutropenia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
anaemia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
thrombocytopenia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
Gastrointestinal toxicosis
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
vomiting
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
alanine
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
hepatic failure
0
$T1$$T2$
haematological, renal, hepatic and gastrointestinal toxicities
haematological, renal, hepatic and gastrointestinal toxicities
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
epitheliotropic lymphoma
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
mast cell tumour
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
brain tumour
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
histiocytic tumours
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
neutropenia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
anaemia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
thrombocytopenia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
Gastrointestinal toxicosis
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
vomiting
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
alanine
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
hepatic failure
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
epitheliotropic lymphoma
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
mast cell tumour
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
brain tumour
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
histiocytic tumours
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
neutropenia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
anaemia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
thrombocytopenia
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
Gastrointestinal toxicosis
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
vomiting
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
alanine
0
$T1$ in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.
haematological, renal, hepatic and gastrointestinal toxicities
hepatic failure
0
$T1$, brain tumour, histiocytic tumours and $T2$
mast cell tumour
epitheliotropic lymphoma
0
$T1$, histiocytic tumours and $T2$
brain tumour
epitheliotropic lymphoma
0
$T1$ and $T2$
histiocytic tumours
epitheliotropic lymphoma
0
$T1$.Throughout treatment, 56.9% of dogs experienced $T2$
epitheliotropic lymphoma
neutropenia
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced $T2$
epitheliotropic lymphoma
anaemia
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced $T2$
epitheliotropic lymphoma
thrombocytopenia
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
epitheliotropic lymphoma
Gastrointestinal toxicosis
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
epitheliotropic lymphoma
vomiting
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
epitheliotropic lymphoma
alanine
0
$T1$.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
epitheliotropic lymphoma
hepatic failure
0
$T1$, $T2$
mast cell tumour
brain tumour
0
$T1$, brain tumour, $T2$
mast cell tumour
histiocytic tumours
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced $T2$
mast cell tumour
neutropenia
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced $T2$
mast cell tumour
anaemia
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced $T2$
mast cell tumour
thrombocytopenia
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
mast cell tumour
Gastrointestinal toxicosis
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
mast cell tumour
vomiting
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
mast cell tumour
alanine
0
$T1$, brain tumour, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
mast cell tumour
hepatic failure
0
$T1$, $T2$
brain tumour
histiocytic tumours
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced $T2$
brain tumour
neutropenia
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced $T2$
brain tumour
anaemia
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced $T2$
brain tumour
thrombocytopenia
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
brain tumour
Gastrointestinal toxicosis
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
brain tumour
vomiting
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
brain tumour
alanine
0
$T1$, histiocytic tumours and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
brain tumour
hepatic failure
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced $T2$
histiocytic tumours
neutropenia
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced $T2$
histiocytic tumours
anaemia
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced $T2$
histiocytic tumours
thrombocytopenia
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
histiocytic tumours
Gastrointestinal toxicosis
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
histiocytic tumours
vomiting
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
histiocytic tumours
alanine
0
$T1$ and epitheliotropic lymphoma.Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.
histiocytic tumours
hepatic failure
0
$T1$, 34.2% experienced $T2$
neutropenia
anaemia
0
$T1$, 34.2% experienced anaemia and 14.2% experienced $T2$
neutropenia
thrombocytopenia
0
$T1$, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.$T2$
neutropenia
Gastrointestinal toxicosis
0
$T1$, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was $T2$
neutropenia
vomiting
0
$T1$, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
neutropenia
alanine
0
$T1$, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
neutropenia
hepatic failure
0
$T1$ and 14.2% experienced $T2$
anaemia
thrombocytopenia
0
$T1$ and 14.2% experienced thrombocytopenia.$T2$
anaemia
Gastrointestinal toxicosis
0
$T1$ and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was $T2$
anaemia
vomiting
0
$T1$ and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
anaemia
alanine
0
$T1$ and 14.2% experienced thrombocytopenia.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
anaemia
hepatic failure
0
$T1$.$T2$
thrombocytopenia
Gastrointestinal toxicosis
0
$T1$.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was $T2$
thrombocytopenia
vomiting
0
$T1$.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
thrombocytopenia
alanine
0
$T1$.Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).
thrombocytopenia
hepatic failure
0
$T1$ was detected in 37.8% of dogs, the most common sign of which was $T2$
Gastrointestinal toxicosis
vomiting
0
$T1$ was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).Potential renal toxicity and elevated $T2$
Gastrointestinal toxicosis
alanine
0
$T1$ was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
Gastrointestinal toxicosis
hepatic failure
0
$T1$ (24.3%).Potential renal toxicity and elevated $T2$
vomiting
alanine
0
$T1$ (24.3%).Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
vomiting
hepatic failure
0
$T1$ transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.The incidence of $T2$
alanine
hepatic failure
0
$T1$- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of $T2$
pilocarpine
status epilepticus
1
$T1$-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of $T2$
kainic acid
status epilepticus
1
$T1$- and kainic acid-induced $T2$
pilocarpine
seizures
1
$T1$-induced $T2$
kainic acid
seizures
1
$T1$ are highly effective in protecting against $T2$
steroids
pilocarpine
0
$T1$ are highly effective in protecting against pilocarpine- and $T2$
steroids
kainic acid
0
$T1$ are highly effective in protecting against pilocarpine- and kainic acid-induced $T2$
steroids
seizures
0
$T1$ are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of $T2$
steroids
status epilepticus
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
steroids
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
steroids
0
$T1$ seizures or lethality.We conclude that neuroactive $T2$
NMDA
steroids
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
benzodiazepine
steroids
0
$T1$, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
clonazepam
steroids
0
$T1$.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
toxicity
steroids
0
$T1$- and $T2$
pilocarpine
kainic acid
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
pilocarpine
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
pilocarpine
0
$T1$ seizures or lethality.We conclude that neuroactive steroids are highly effective in protecting against $T2$
NMDA
pilocarpine
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
benzodiazepine
pilocarpine
0
$T1$, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
clonazepam
pilocarpine
0
$T1$.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
toxicity
pilocarpine
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
kainic acid
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
kainic acid
0
$T1$ seizures or lethality.We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and $T2$
NMDA
kainic acid
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
benzodiazepine
kainic acid
0
$T1$, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
clonazepam
kainic acid
0
$T1$.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
toxicity
kainic acid
0
$T1$ and status epilepticus in mice, and may be of utility in the treatment of some forms of $T2$
seizures
status epilepticus
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
seizures
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
seizures
0
$T1$ seizures or lethality.We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced $T2$
NMDA
seizures
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
benzodiazepine
seizures
0
$T1$, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
clonazepam
seizures
0
$T1$.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
toxicity
seizures
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
status epilepticus
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
status epilepticus
0
$T1$ seizures or lethality.We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of $T2$
NMDA
status epilepticus
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
benzodiazepine
status epilepticus
0
$T1$, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
clonazepam
status epilepticus
0
$T1$.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
toxicity
status epilepticus
0
$T1$) and deoxycorticosterone ($T2$
3 alpha-hydroxy pregnane-20-ones
3 alpha-hydroxy pregnane-21-diol-20-ones
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
NMDA
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
benzodiazepine
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
clonazepam
0
$T1$) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-20-ones
toxicity
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
NMDA
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
benzodiazepine
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
clonazepam
0
$T1$) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
3 alpha-hydroxy pregnane-21-diol-20-ones
toxicity
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
benzodiazepine
NMDA
0
$T1$, indicating that some neuroactive steroids may have lower relative toxicity.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
clonazepam
NMDA
0
$T1$.Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
toxicity
NMDA
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than $T2$
benzodiazepine
clonazepam
0
$T1$ clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative $T2$
benzodiazepine
toxicity
0
$T1$, indicating that some neuroactive steroids may have lower relative $T2$
clonazepam
toxicity
0
$T1$ steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
SC-48334
flatulence
1
$T1$ groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.Diarrhea, flatulence, abdominal pain, and $T2$
zidovudine
weight loss
1
$T1$ groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.Diarrhea, $T2$
zidovudine
flatulence
1
$T1$ steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
SC-48334
abdominal pain
1
$T1$ steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
SC-48334
Diarrhea
1
$T1$ groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.Diarrhea, flatulence, $T2$
zidovudine
abdominal pain
1
$T1$ groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.$T2$
zidovudine
Diarrhea
1
$T1$ steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
SC-48334
weight loss
1
$T1$ steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
SC-48334
zidovudine
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
SC-48334
0
$T1$ steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human $T2$
SC-48334
immunodeficiency
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
zidovudine
0
$T1$ virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
immunodeficiency
zidovudine
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
immunodeficiency
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
Diarrhea
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
flatulence
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
abdominal pain
0
$T1$ and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.
HIV-1 infection
weight loss
0
$T1$ virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
immunodeficiency
Diarrhea
0
$T1$ virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
immunodeficiency
flatulence
0
$T1$ virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
immunodeficiency
abdominal pain
0
$T1$ virus (HIV).The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36).
immunodeficiency
weight loss
0
$T1$, $T2$
Diarrhea
flatulence
0
$T1$, flatulence, $T2$
Diarrhea
abdominal pain
0
$T1$, flatulence, abdominal pain, and $T2$
Diarrhea
weight loss
0
$T1$, $T2$
flatulence
abdominal pain
0
$T1$, abdominal pain, and $T2$
flatulence
weight loss
0
$T1$, and $T2$
abdominal pain
weight loss
0
$T1$ and malaise are again the most frequent side effects.Evidence of antitumor activity has been seen in 3 patients.
Hepatotoxicity
CB 3717
1
$T1$ in 10 patients.Hepatotoxicity and malaise are again the most frequent side effects.
renal toxicity
CB 3717
1
$T1$ are again the most frequent side effects.Evidence of antitumor activity has been seen in 3 patients.
malaise
CB 3717
1
$T1$ included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.
Toxicities
CB 3717
0
$T1$, ovarian cancer, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
breast cancer
CB 3717
0
$T1$, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
ovarian cancer
CB 3717
0
$T1$, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
hepatoma
CB 3717
0
$T1$.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
mesothelioma
CB 3717
0
$T1$, ovarian cancer, hepatoma, and mesothelioma.$T2$
breast cancer
Toxicities
0
$T1$, hepatoma, and mesothelioma.$T2$
ovarian cancer
Toxicities
0
$T1$, and mesothelioma.$T2$
hepatoma
Toxicities
0
$T1$.$T2$
mesothelioma
Toxicities
0
$T1$ included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.
Toxicities
Hepatotoxicity
0
$T1$ included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.
Toxicities
malaise
0
$T1$ included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.
Toxicities
renal toxicity
0
$T1$, $T2$
breast cancer
ovarian cancer
0
$T1$, ovarian cancer, $T2$
breast cancer
hepatoma
0
$T1$, ovarian cancer, hepatoma, and $T2$
breast cancer
mesothelioma
0
$T1$, ovarian cancer, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
breast cancer
Hepatotoxicity
0
$T1$, ovarian cancer, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
breast cancer
malaise
0
$T1$, ovarian cancer, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
breast cancer
renal toxicity
0
$T1$, $T2$
ovarian cancer
hepatoma
0
$T1$, hepatoma, and $T2$
ovarian cancer
mesothelioma
0
$T1$, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
ovarian cancer
Hepatotoxicity
0
$T1$, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
ovarian cancer
malaise
0
$T1$, hepatoma, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
ovarian cancer
renal toxicity
0
$T1$, and $T2$
hepatoma
mesothelioma
0
$T1$, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
hepatoma
Hepatotoxicity
0
$T1$, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
hepatoma
malaise
0
$T1$, and mesothelioma.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
hepatoma
renal toxicity
0
$T1$.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
mesothelioma
Hepatotoxicity
0
$T1$.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
mesothelioma
malaise
0
$T1$.Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.
mesothelioma
renal toxicity
0
$T1$ and $T2$
Hepatotoxicity
malaise
0
$T1$ in 10 patients.$T2$
renal toxicity
Hepatotoxicity
0
$T1$ in 10 patients.Hepatotoxicity and $T2$
renal toxicity
malaise
0
$T1$ and depression than ethopropazine treated patients.This suggests that $T2$
anxiety
benztropine
1
$T1$ than ethopropazine treated patients.This suggests that $T2$
depression
benztropine
1
$T1$ compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.This suggests that $T2$
tardive dyskinesia
benztropine
1
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
parkinsonian symptoms
1
$T1$ treated patients.This suggests that $T2$
ethopropazine
benztropine
0
$T1$ treated patients.This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced $T2$
ethopropazine
parkinsonian symptoms
0
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
ethopropazine
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
ethopropazine
0
$T1$ treatment, and significantly more anxiety and depression than $T2$
procyclindine
ethopropazine
0
$T1$ compared to their condition during procyclindine treatment, and significantly more anxiety and depression than $T2$
tardive dyskinesia
ethopropazine
0
$T1$ and depression than $T2$
anxiety
ethopropazine
0
$T1$ than $T2$
depression
ethopropazine
0
$T1$ is not the anticholinergic drug of choice in the treatment of neuroleptic-induced $T2$
benztropine
parkinsonian symptoms
0
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
benztropine
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
benztropine
0
$T1$ treatment, and significantly more anxiety and depression than ethopropazine treated patients.This suggests that $T2$
procyclindine
benztropine
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
parkinsonian symptoms
0
$T1$ treatment, and significantly more anxiety and depression than ethopropazine treated patients.This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced $T2$
procyclindine
parkinsonian symptoms
0
$T1$ compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced $T2$
tardive dyskinesia
parkinsonian symptoms
0
$T1$ and depression than ethopropazine treated patients.This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced $T2$
anxiety
parkinsonian symptoms
0
$T1$ than ethopropazine treated patients.This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced $T2$
depression
parkinsonian symptoms
0
$T1$ in 60 $T2$
fluphenazine enanthate
schizophrenic
0
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
procyclindine
0
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
tardive dyskinesia
0
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
anxiety
0
$T1$ in 60 schizophrenic outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
fluphenazine enanthate
depression
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
procyclindine
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
tardive dyskinesia
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
anxiety
0
$T1$ outpatients.Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
schizophrenic
depression
0
$T1$ compared to their condition during $T2$
tardive dyskinesia
procyclindine
0
$T1$ treatment, and significantly more $T2$
procyclindine
anxiety
0
$T1$ treatment, and significantly more anxiety and $T2$
procyclindine
depression
0
$T1$ compared to their condition during procyclindine treatment, and significantly more $T2$
tardive dyskinesia
anxiety
0
$T1$ compared to their condition during procyclindine treatment, and significantly more anxiety and $T2$
tardive dyskinesia
depression
0
$T1$ and $T2$
anxiety
depression
0
$T1$-induced $T2$
MA
neuronal damage
1
$T1$ as well as the alterations in the locomotor activity.The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.
hyperthermia
MA
1
$T1$ and $T2$
alpha-TC
DFO
0
$T1$ and DFO ameliorate the $T2$
alpha-TC
MA
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
alpha-TC
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
alpha-TC
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
alpha-TC
0
$T1$), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
DA
alpha-TC
0
$T1$ and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
serotonin
alpha-TC
0
$T1$ as well as the alterations in the locomotor activity.The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.
hyperthermia
alpha-TC
0
$T1$ concentration was lower in the MA-treated rats.These changes were significantly attenuated by alpha-TC and DFO.
glutathione
alpha-TC
0
$T1$ and DFO ameliorate the MA-induced $T2$
alpha-TC
neuronal damage
0
$T1$ ameliorate the $T2$
DFO
MA
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
DFO
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
DFO
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
DFO
0
$T1$), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
DA
DFO
0
$T1$ and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
serotonin
DFO
0
$T1$ as well as the alterations in the locomotor activity.The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.
hyperthermia
DFO
0
$T1$ concentration was lower in the MA-treated rats.These changes were significantly attenuated by alpha-TC and DFO.
glutathione
DFO
0
$T1$ ameliorate the MA-induced $T2$
DFO
neuronal damage
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
MA
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
MA
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
MA
0
$T1$), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
DA
MA
0
$T1$ and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
serotonin
MA
0
$T1$ concentration was lower in the MA-treated rats.These changes were significantly attenuated by alpha-TC and DFO.
glutathione
MA
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced $T2$
oxygen
neurotoxicity
0
$T1$ chelator, on the MA-induced $T2$
iron
neurotoxicity
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
DA
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
serotonin
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
hyperthermia
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
glutathione
0
$T1$.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
neurotoxicity
neuronal damage
0
$T1$ species, and deferoxamine (DFO), an $T2$
oxygen
iron
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
DA
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
serotonin
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
hyperthermia
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
glutathione
0
$T1$ species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
oxygen
neuronal damage
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
DA
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
serotonin
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
hyperthermia
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
glutathione
0
$T1$ chelator, on the MA-induced neurotoxicity.Male rats were treated with MA (10 mg/kg, every 2 h for four injections).
iron
neuronal damage
0
$T1$), $T2$
DA
serotonin
0
$T1$), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced $T2$
DA
hyperthermia
0
$T1$), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
DA
glutathione
0
$T1$), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
DA
neuronal damage
0
$T1$ and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced $T2$
serotonin
hyperthermia
0
$T1$ and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
serotonin
glutathione
0
$T1$ and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.
serotonin
neuronal damage
0
$T1$ as well as the alterations in the locomotor activity.The level of lipid peroxidation was higher and the reduced $T2$
hyperthermia
glutathione
0
$T1$ as well as the alterations in the locomotor activity.The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.
hyperthermia
neuronal damage
0
$T1$ concentration was lower in the MA-treated rats.These changes were significantly attenuated by alpha-TC and DFO.
glutathione
neuronal damage
0
$T1$-induced HC.However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent $T2$
IFS
HC
1
$T1$ was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.
Cystitis
IFS
1
$T1$ doses with $T2$
mesna
dexamethasone
0
$T1$-induced HC.However, the replacement of last two doses of mesna with saline or all of the mesna doses with $T2$
IFS
dexamethasone
0
$T1$ did not prevent $T2$
dexamethasone
HC
0
$T1$ was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.
Cystitis
dexamethasone
0
$T1$-induced HC.However, the replacement of last two doses of mesna with saline or all of the $T2$
IFS
mesna
0
$T1$ doses with dexamethasone did not prevent $T2$
mesna
HC
0
$T1$ was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.
Cystitis
mesna
0
$T1$ was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis.RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.
Cystitis
HC
0
$T1$ produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and $T2$
reserpine
tremor
1
$T1$ produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and $T2$
reserpine
tardive dsykinesia
1
$T1$ produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, $T2$
reserpine
catalepsy
1
$T1$ (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.These results show that $T2$
MK-801
reserpine
0
$T1$ (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.
MK-801
NMDA
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
MK-801
0
$T1$ (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as $T2$
MK-801
parkinsonian
0
$T1$ (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and $T2$
MK-801
tardive dsykinesia
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
MK-801
0
$T1$ (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.
MK-801
tremor
0
$T1$ (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.
MK-801
catalepsy
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
MK-801
0
$T1$ produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.The glutamatergic blockage produced by $T2$
reserpine
NMDA
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
reserpine
0
$T1$ produces different and abnormal movements, which are related to dose and schedule employed and can be considered as $T2$
reserpine
parkinsonian
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
reserpine
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
reserpine
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
NMDA
0
$T1$-like and tardive dsykinesia signs.The glutamatergic blockage produced by $T2$
parkinsonian
NMDA
0
$T1$ signs.The glutamatergic blockage produced by $T2$
tardive dsykinesia
NMDA
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
NMDA
0
$T1$ can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and $T2$
NMDA
tremor
0
$T1$ can restore these signs, such as vacuous chewing movements, tongue protrusions, $T2$
NMDA
catalepsy
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
NMDA
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
parkinsonian
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
tardive dsykinesia
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
oral dyskinesia
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
tremor
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
catalepsy
0
$T1$-related behaviors induced by reserpine treatments.This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.
dopamine
apomophine
0
$T1$-like and $T2$
parkinsonian
tardive dsykinesia
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
parkinsonian
0
$T1$-like and tardive dsykinesia signs.The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and $T2$
parkinsonian
tremor
0
$T1$-like and tardive dsykinesia signs.The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, $T2$
parkinsonian
catalepsy
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
parkinsonian
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
tardive dsykinesia
0
$T1$ signs.The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and $T2$
tardive dsykinesia
tremor
0
$T1$ signs.The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, $T2$
tardive dsykinesia
catalepsy
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
tardive dsykinesia
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
tremor
0
$T1$ in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
oral dyskinesia
catalepsy
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce $T2$
apomophine
oral dyskinesia
0
$T1$ and $T2$
catalepsy
tremor
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
tremor
0
$T1$ injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
apomophine
catalepsy
0
$T1$, it might be of relevance in the treatment of $T2$
morphine
sphincter of Oddi dyskinesia
1
$T1$ at the level of the sphincter of Oddi.Glyceryl trinitrate infusion completely normalized the $T2$
spasm
prostigmine
1
$T1$ at the level of the sphincter of Oddi.Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.
spasm
morphine
1
$T1$-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
prostigmine
sphincter of Oddi dyskinesia
1
$T1$ is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of $T2$
glyceryl trinitrate
sphincter of Oddi dyskinesia
0
$T1$-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
prostigmine
glyceryl trinitrate
0
$T1$ is able to overcome even the drastic effect of $T2$
glyceryl trinitrate
morphine
0
$T1$ at the level of the sphincter of Oddi.Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.
spasm
glyceryl trinitrate
0
$T1$ at the level of the sphincter of Oddi.Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.
spasm
sphincter of Oddi dyskinesia
0
$T1$-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.
prostigmine
morphine
0
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
T
1
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
M
1
$T1$-treated animals.We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb $T2$
T
atrophy
1
$T1$, whereas tetanic tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
M
atrophy
1
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
M
1
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
T
1
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
steroid
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
steroid
0
$T1$, whereas tetanic tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
M
steroid
0
$T1$-treated animals.We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither $T2$
T
steroid
0
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
steroid
0
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
steroid
0
$T1$ tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
tetanic
steroid
0
$T1$ caused muscle necrosis; (4) type IIb $T2$
steroid
atrophy
0
$T1$ caused muscle $T2$
steroid
necrosis
0
$T1$, resulting in the expected alterations in diaphragm contractile properties; (3) neither $T2$
atrophy
steroid
0
$T1$.The mechanism of this $T2$
corticosteroids
myopathy
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
M
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
T
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant $T2$
myopathy
reduction of food intake
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
loss in body weight
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
tetanic
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
atrophy
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
necrosis
0
$T1$ is poorly understood.Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
myopathy
atrophy
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
M
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
T
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
reduction of food intake
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
loss in body weight
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
tetanic
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
atrophy
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
necrosis
0
$T1$.The mechanism of this myopathy is poorly understood.
corticosteroids
atrophy
0
$T1$, whereas tetanic tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
M
T
0
$T1$, whereas $T2$
M
tetanic
0
$T1$, whereas tetanic tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
M
necrosis
0
$T1$, whereas tetanic tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
M
atrophy
0
$T1$ tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
tetanic
T
0
$T1$-treated animals.We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle $T2$
T
necrosis
0
$T1$-treated animals.We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb $T2$
T
atrophy
0
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar $T2$
reduction of food intake
loss in body weight
0
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
tetanic
0
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
atrophy
0
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
necrosis
0
$T1$ in the steroid-treated groups (-50 and -79% in M and T, respectively).This was associated with a similar loss in body weight.
reduction of food intake
atrophy
0
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
tetanic
0
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
atrophy
0
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
necrosis
0
$T1$.In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.
loss in body weight
atrophy
0
$T1$ tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
tetanic
atrophy
0
$T1$ tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
tetanic
necrosis
0
$T1$ tensions were similar.Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05).
tetanic
atrophy
0
$T1$; (4) type IIb $T2$
necrosis
atrophy
0
$T1$, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb $T2$
atrophy
atrophy
0
$T1$, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle $T2$
atrophy
necrosis
0
$T1$.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
metoprolol
hypotension
1
$T1$ with concomitant use of metoprolol.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
verapamil
heart block
1
$T1$ with concomitant use of metoprolol.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
verapamil
hypotension
1
$T1$.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
metoprolol
heart block
1
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
heart block
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
verapamil
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
metoprolol
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
hypotension
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
atropine
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
dopamine
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
dobutamine
0
$T1$ and complete heart block after verapamil SR and metoprolol treatment.A case report.
cardiogenic shock
calcium chloride
0
$T1$ and complete $T2$
hypotension
heart block
0
$T1$ as well as high doses of pressor agents such as dopamine and dobutamine.However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete $T2$
atropine
heart block
0
$T1$ and dobutamine.However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete $T2$
dopamine
heart block
0
$T1$.However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete $T2$
dobutamine
heart block
0
$T1$, the refractory hypotension and complete $T2$
calcium chloride
heart block
0
$T1$ with concomitant use of $T2$
verapamil
metoprolol
0
$T1$ with concomitant use of metoprolol.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous $T2$
verapamil
atropine
0
$T1$ with concomitant use of metoprolol.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as $T2$
verapamil
dopamine
0
$T1$ with concomitant use of metoprolol.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and $T2$
verapamil
dobutamine
0
$T1$ with concomitant use of metoprolol.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
verapamil
calcium chloride
0
$T1$.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous $T2$
metoprolol
atropine
0
$T1$.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as $T2$
metoprolol
dopamine
0
$T1$.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and $T2$
metoprolol
dobutamine
0
$T1$.The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
metoprolol
calcium chloride
0
$T1$ as well as high doses of pressor agents such as dopamine and dobutamine.However, shortly after the use of intravenous calcium chloride, the refractory $T2$
atropine
hypotension
0
$T1$ and dobutamine.However, shortly after the use of intravenous calcium chloride, the refractory $T2$
dopamine
hypotension
0
$T1$.However, shortly after the use of intravenous calcium chloride, the refractory $T2$
dobutamine
hypotension
0
$T1$, the refractory $T2$
calcium chloride
hypotension
0
$T1$ as well as high doses of pressor agents such as $T2$
atropine
dopamine
0
$T1$ as well as high doses of pressor agents such as dopamine and $T2$
atropine
dobutamine
0
$T1$ as well as high doses of pressor agents such as dopamine and dobutamine.However, shortly after the use of intravenous $T2$
atropine
calcium chloride
0
$T1$ and $T2$
dopamine
dobutamine
0
$T1$ and dobutamine.However, shortly after the use of intravenous $T2$
dopamine
calcium chloride
0
$T1$.However, shortly after the use of intravenous $T2$
dobutamine
calcium chloride
0
$T1$ were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
mucositis
lometrexol
1
$T1$ and mucositis were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
Thrombocytopenia
lometrexol
1
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
lometrexol
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
folic acid
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits $T2$
antipurine
glycinamide ribonucleotide
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo $T2$
antipurine
purine
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
cancer
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
methotrexate
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
toxicity
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
Thrombocytopenia
0
$T1$ antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.
antipurine
mucositis
0
$T1$ administration indicating that supplementation is unlikely to reduce toxicity by enhancing $T2$
folic acid
lometrexol
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
glycinamide ribonucleotide
lometrexol
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
purine
lometrexol
0
$T1$ plasma clearance.The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor.
lometrexol
cancer
0
$T1$.However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
methotrexate
lometrexol
0
$T1$ by enhancing $T2$
toxicity
lometrexol
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
glycinamide ribonucleotide
folic acid
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
purine
folic acid
0
$T1$ administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor.
folic acid
cancer
0
$T1$.However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
methotrexate
folic acid
0
$T1$ administration indicating that supplementation is unlikely to reduce $T2$
folic acid
toxicity
0
$T1$ and mucositis were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
Thrombocytopenia
folic acid
0
$T1$ were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
mucositis
folic acid
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo $T2$
glycinamide ribonucleotide
purine
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
glycinamide ribonucleotide
cancer
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably $T2$
glycinamide ribonucleotide
methotrexate
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
glycinamide ribonucleotide
toxicity
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
glycinamide ribonucleotide
Thrombocytopenia
0
$T1$ formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
glycinamide ribonucleotide
mucositis
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
purine
cancer
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably $T2$
purine
methotrexate
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
purine
toxicity
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
purine
Thrombocytopenia
0
$T1$ synthesis.Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
purine
mucositis
0
$T1$.However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
methotrexate
cancer
0
$T1$ by enhancing lometrexol plasma clearance.The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor.
toxicity
cancer
0
$T1$ and mucositis were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
Thrombocytopenia
cancer
0
$T1$ were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
mucositis
cancer
0
$T1$.However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
methotrexate
toxicity
0
$T1$.However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
methotrexate
Thrombocytopenia
0
$T1$.However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
methotrexate
mucositis
0
$T1$ and mucositis were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
Thrombocytopenia
toxicity
0
$T1$ were the major toxicities.There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
mucositis
toxicity
0
$T1$ and $T2$
Thrombocytopenia
mucositis
0
$T1$ induced by $T2$
hyperalgesia
8-bromo cyclic adenosine monophosphate
1
$T1$-induced hyperalgesia.The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.
prostaglandin E2
hyperalgesia
1
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.
analgesia
Morphine
0
$T1$.The intradermal injection of mu (morphine, $T2$
analgesia
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and $T2$
analgesia
morphiceptin
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa ($T2$
analgesia
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ($T2$
analgesia
[D-Pen2.5]-enkephalin
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and $T2$
analgesia
[D-Ser2]-[Leu]enkephalin-Thr
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.
analgesia
prostaglandin E2
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.
analgesia
hyperalgesia
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.
analgesia
naloxone
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.
analgesia
8-bromo cyclic adenosine monophosphate
0
$T1$.The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.
analgesia
cyclic adenosine monophosphate
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
Morphine
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
morphiceptin
Morphine
0
$T1$) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
Morphine
0
$T1$ and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Pen2.5]-enkephalin
Morphine
0
$T1$) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Ser2]-[Leu]enkephalin-Thr
Morphine
0
$T1$-induced hyperalgesia.The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.
prostaglandin E2
Morphine
0
$T1$ did not, however, alter the $T2$
Morphine
hyperalgesia
0
$T1$ and prevented by co-injection of pertussis toxin.$T2$
naloxone
Morphine
0
$T1$ did not, however, alter the hyperalgesia induced by $T2$
Morphine
8-bromo cyclic adenosine monophosphate
0
$T1$ did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the $T2$
Morphine
cyclic adenosine monophosphate
0
$T1$ and $T2$
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
morphiceptin
0
$T1$ and morphiceptin), kappa ($T2$
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ($T2$
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
[D-Pen2.5]-enkephalin
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and $T2$
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
[D-Ser2]-[Leu]enkephalin-Thr
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of $T2$
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
prostaglandin E2
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
hyperalgesia
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
naloxone
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
8-bromo cyclic adenosine monophosphate
0
$T1$ and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
Tyr-D-Ala-Gly-NMe-Phe-Gly-ol
cyclic adenosine monophosphate
0
$T1$), kappa ($T2$
morphiceptin
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ($T2$
morphiceptin
[D-Pen2.5]-enkephalin
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and $T2$
morphiceptin
[D-Ser2]-[Leu]enkephalin-Thr
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of $T2$
morphiceptin
prostaglandin E2
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
morphiceptin
hyperalgesia
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
morphiceptin
naloxone
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
morphiceptin
8-bromo cyclic adenosine monophosphate
0
$T1$), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
morphiceptin
cyclic adenosine monophosphate
0
$T1$) and delta ($T2$
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
[D-Pen2.5]-enkephalin
0
$T1$) and delta ([D-Pen2.5]-enkephalin and $T2$
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
[D-Ser2]-[Leu]enkephalin-Thr
0
$T1$) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of $T2$
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
prostaglandin E2
0
$T1$) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
hyperalgesia
0
$T1$) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
naloxone
0
$T1$) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
8-bromo cyclic adenosine monophosphate
0
$T1$) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide
cyclic adenosine monophosphate
0
$T1$ and $T2$
[D-Pen2.5]-enkephalin
[D-Ser2]-[Leu]enkephalin-Thr
0
$T1$ and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of $T2$
[D-Pen2.5]-enkephalin
prostaglandin E2
0
$T1$ and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Pen2.5]-enkephalin
hyperalgesia
0
$T1$ and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Pen2.5]-enkephalin
naloxone
0
$T1$ and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Pen2.5]-enkephalin
8-bromo cyclic adenosine monophosphate
0
$T1$ and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Pen2.5]-enkephalin
cyclic adenosine monophosphate
0
$T1$) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of $T2$
[D-Ser2]-[Leu]enkephalin-Thr
prostaglandin E2
0
$T1$) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Ser2]-[Leu]enkephalin-Thr
hyperalgesia
0
$T1$) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Ser2]-[Leu]enkephalin-Thr
naloxone
0
$T1$) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Ser2]-[Leu]enkephalin-Thr
8-bromo cyclic adenosine monophosphate
0
$T1$) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.
[D-Ser2]-[Leu]enkephalin-Thr
cyclic adenosine monophosphate
0
$T1$-induced hyperalgesia.The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by $T2$
prostaglandin E2
naloxone
0
$T1$-induced hyperalgesia.The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.
prostaglandin E2
8-bromo cyclic adenosine monophosphate
0
$T1$-induced hyperalgesia.The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.
prostaglandin E2
cyclic adenosine monophosphate
0
$T1$ and prevented by co-injection of pertussis toxin.Morphine did not, however, alter the $T2$
naloxone
hyperalgesia
0
$T1$ induced by 8-bromo cyclic adenosine monophosphate.We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the $T2$
hyperalgesia
cyclic adenosine monophosphate
0
$T1$ and prevented by co-injection of pertussis toxin.Morphine did not, however, alter the hyperalgesia induced by $T2$
naloxone
8-bromo cyclic adenosine monophosphate
0
$T1$ and prevented by co-injection of pertussis toxin.Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.
naloxone
cyclic adenosine monophosphate
0
$T1$.We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the $T2$
8-bromo cyclic adenosine monophosphate
cyclic adenosine monophosphate
0
$T1$ and ribavirin.Because of ribavirin-related $T2$
interferon
hemolytic anemia
1
$T1$, dose reduction is a common event in this therapy.In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.
hemolytic anemia
ribavirin
1
$T1$ during combination therapy.METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy.
hemolysis
ribavirin
0
$T1$ and ribavirin.Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.
interferon
ribavirin
0
$T1$.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.
chronic hepatitis C
ribavirin
0
$T1$-related severe side effects occurred (group B).We assessed the final efficacy and safety after reduction of ribavirin in groups A and B.
anemia
ribavirin
0
$T1$ and ribavirin.Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.
interferon
hemolysis
0
$T1$.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.
chronic hepatitis C
hemolysis
0
$T1$, dose reduction is a common event in this therapy.In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with $T2$
hemolytic anemia
hemolysis
0
$T1$ during combination therapy.METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy.
hemolysis
anemia
0
$T1$.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of $T2$
chronic hepatitis C
interferon
0
$T1$ and ribavirin.Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.
interferon
anemia
0
$T1$.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.
chronic hepatitis C
hemolytic anemia
0
$T1$.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.
chronic hepatitis C
anemia
0
$T1$, dose reduction is a common event in this therapy.In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.
hemolytic anemia
anemia
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
PAN
1
$T1$-induced $T2$
PAN
nephrotic syndrome
1
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
PAN
1
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
PAN
1
$T1$-induced nephrotic syndrome.The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote $T2$
PAN
sodium
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
PAN
0
$T1$(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
H
PAN
0
$T1$-induced nephrotic syndrome.The decreased abundance of NHE3, BSC-1, TSC, and Na-$T2$
PAN
K
0
$T1$(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
Cl
PAN
0
$T1$-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
thiazide
PAN
0
$T1$.The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote $T2$
nephrotic syndrome
sodium
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
nephrotic syndrome
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
nephrotic syndrome
0
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
nephrotic syndrome
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
nephrotic syndrome
0
$T1$(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
H
nephrotic syndrome
0
$T1$.The decreased abundance of NHE3, BSC-1, TSC, and Na-$T2$
nephrotic syndrome
K
0
$T1$(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
Cl
nephrotic syndrome
0
$T1$-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
thiazide
nephrotic syndrome
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
sodium
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
sodium
0
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
sodium
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
sodium
0
$T1$(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
H
sodium
0
$T1$-ATPase may play a compensatory role to promote $T2$
K
sodium
0
$T1$(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
Cl
sodium
0
$T1$-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
thiazide
sodium
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
proteinuria
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
hypoalbuminemia
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
ascites
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
H
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
K
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
Cl
0
$T1$.However, the molecular basis for the decreased renal sodium excretion remains undefined.
edema
thiazide
0
$T1$, $T2$
proteinuria
hypoalbuminemia
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive $T2$
proteinuria
ascites
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
H
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
K
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
Cl
0
$T1$, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
proteinuria
thiazide
0
$T1$, decreased urinary sodium excretion, and extensive $T2$
hypoalbuminemia
ascites
0
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
H
0
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
K
0
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
Cl
0
$T1$, decreased urinary sodium excretion, and extensive ascites.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
hypoalbuminemia
thiazide
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
H
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
K
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
Cl
0
$T1$.The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.
ascites
thiazide
0
$T1$(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
H
K
0
$T1$(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-$T2$
H
Cl
0
$T1$(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and $T2$
H
thiazide
0
$T1$(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
Cl
K
0
$T1$-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.
thiazide
K
0
$T1$-sensitive Na(+)-$T2$
thiazide
Cl
0
$T1$?A pilot study.
detrimental effect on memory and cognition
tamoxifen
1
$T1$?A pilot study.
detrimental effect on memory and cognition
anastrozole
1
$T1$?A pilot study.
detrimental effect on memory and cognition
breast cancer
0
$T1$, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.
anastrozole
breast cancer
0
$T1$ alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.
tamoxifen
breast cancer
0
$T1$.Verbal memory may be especially sensitive to changes in $T2$
breast cancer
oestrogen
0
$T1$?A pilot study.
detrimental effect on memory and cognition
oestrogen
0
$T1$, $T2$
anastrozole
tamoxifen
0
$T1$, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.
anastrozole
oestrogen
0
$T1$ alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.
tamoxifen
oestrogen
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
ADR
1
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
ADR
1
$T1$ group, numerous apoptotic cells were identified in the tubulointerstitial areas.Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.
nephropathy
NO
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
NO
0
$T1$ and apoptosis are important in the pathogenesis of the $T2$
NO
ADR
0
$T1$ levels and apoptosis to control levels.CONCLUSION: We suggest that interactions between $T2$
nitrite
NO
0
$T1$ prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.CONCLUSION: We suggest that interactions between $T2$
AG
NO
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
NO
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
NO
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
NO
0
$T1$ and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
phenylephrine
NO
0
$T1$ related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
acetylcholine
NO
0
$T1$ and apoptosis are important in the pathogenesis of the ADR-induced $T2$
NO
nephrosis
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
nephropathy
0
$T1$ group, numerous apoptotic cells were identified in the tubulointerstitial areas.Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.
nephropathy
ADR
0
$T1$ group, numerous apoptotic cells were identified in the tubulointerstitial areas.Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.
nephropathy
nitrite
0
$T1$ group, numerous apoptotic cells were identified in the tubulointerstitial areas.Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.
nephropathy
AG
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
nephropathy
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
nephropathy
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
nephropathy
0
$T1$ and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
phenylephrine
nephropathy
0
$T1$ related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
acetylcholine
nephropathy
0
$T1$ group, numerous apoptotic cells were identified in the tubulointerstitial areas.Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.
nephropathy
nephrosis
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
nitrite
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
AG
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
mesangial proliferation
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
tubulointerstitial inflammation
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
proteinuria
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
phenylephrine
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
acetylcholine
0
$T1$ induced by a single injection of adriamycin (ADR).METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system.
nephrotic syndrome
nephrosis
0
$T1$ levels and apoptosis to control levels.CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the $T2$
nitrite
ADR
0
$T1$ prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the $T2$
AG
ADR
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
ADR
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
ADR
0
$T1$ and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
phenylephrine
ADR
0
$T1$ related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
acetylcholine
ADR
0
$T1$-induced $T2$
ADR
nephrosis
0
$T1$ prevented the impairment of renal vascular bed responses and reduced both urine $T2$
AG
nitrite
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
nitrite
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
nitrite
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
nitrite
0
$T1$ and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
phenylephrine
nitrite
0
$T1$ related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
acetylcholine
nitrite
0
$T1$ levels and apoptosis to control levels.CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced $T2$
nitrite
nephrosis
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
AG
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
AG
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
AG
0
$T1$ and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
phenylephrine
AG
0
$T1$ related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
acetylcholine
AG
0
$T1$ prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels.CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced $T2$
AG
nephrosis
0
$T1$ and mild $T2$
mesangial proliferation
tubulointerstitial inflammation
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of $T2$
mesangial proliferation
proteinuria
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
phenylephrine
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
acetylcholine
0
$T1$ and mild tubulointerstitial inflammation.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
mesangial proliferation
nephrosis
0
$T1$.They also had significantly higher levels of $T2$
tubulointerstitial inflammation
proteinuria
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
phenylephrine
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
acetylcholine
0
$T1$.They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05).
tubulointerstitial inflammation
nephrosis
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
phenylephrine
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
acetylcholine
0
$T1$ compared with control and treatment groups (P < 0.05).Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
proteinuria
nephrosis
0
$T1$ and $T2$
phenylephrine
acetylcholine
0
$T1$ and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
phenylephrine
nephrosis
0
$T1$ related responses were significantly impaired in the ADR-nephropathy group.Apoptosis was not detected in controls.
acetylcholine
nephrosis
0
$T1$-induced $T2$
haloperidol
catalepsy
1
$T1$ improves haloperidol-induced $T2$
carteolol
catalepsy
0
$T1$ improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of $T2$
carteolol
akathisia
0
$T1$ improves $T2$
carteolol
haloperidol
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
carteolol
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
carteolol
0
$T1$ improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic $T2$
carteolol
dopamine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
carteolol
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.
apomorphine
carteolol
0
$T1$-induced head twitch in rats.Finally, carteolol did not inhibit physostigmine-induced lethality in rats.
5-hydroxytryptophan
carteolol
0
$T1$-induced lethality in rats.These results strongly suggest that $T2$
physostigmine
carteolol
0
$T1$ via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of $T2$
catalepsy
akathisia
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
catalepsy
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
catalepsy
0
$T1$ via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic $T2$
catalepsy
dopamine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
catalepsy
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.
apomorphine
catalepsy
0
$T1$-induced head twitch in rats.Finally, carteolol did not inhibit physostigmine-induced lethality in rats.
5-hydroxytryptophan
catalepsy
0
$T1$-induced lethality in rats.These results strongly suggest that carteolol improves haloperidol-induced $T2$
physostigmine
catalepsy
0
$T1$-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of $T2$
haloperidol
akathisia
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
akathisia
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
akathisia
0
$T1$ without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic $T2$
akathisia
dopamine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
akathisia
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.
apomorphine
akathisia
0
$T1$-induced head twitch in rats.Finally, carteolol did not inhibit physostigmine-induced lethality in rats.
5-hydroxytryptophan
akathisia
0
$T1$-induced lethality in rats.These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of $T2$
physostigmine
akathisia
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
haloperidol
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
haloperidol
0
$T1$-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic $T2$
haloperidol
dopamine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
haloperidol
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.
apomorphine
haloperidol
0
$T1$-induced head twitch in rats.Finally, carteolol did not inhibit physostigmine-induced lethality in rats.
5-hydroxytryptophan
haloperidol
0
$T1$-induced lethality in rats.These results strongly suggest that carteolol improves $T2$
physostigmine
haloperidol
0
$T1$, but was weaker than that of $T2$
propranolol
biperiden
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
dopamine
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and $T2$
propranolol
hyperlocomotion
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
apomorphine
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
5-hydroxytryptophan
0
$T1$, but was weaker than that of biperiden.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
propranolol
physostigmine
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
dopamine
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and $T2$
biperiden
hyperlocomotion
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
apomorphine
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
5-hydroxytryptophan
0
$T1$.Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
biperiden
physostigmine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
dopamine
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.
apomorphine
dopamine
0
$T1$-induced head twitch in rats.Finally, carteolol did not inhibit physostigmine-induced lethality in rats.
5-hydroxytryptophan
dopamine
0
$T1$-induced lethality in rats.These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic $T2$
physostigmine
dopamine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on $T2$
hyperlocomotion
apomorphine
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
5-hydroxytryptophan
0
$T1$ in rats.Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.
hyperlocomotion
physostigmine
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit $T2$
apomorphine
5-hydroxytryptophan
0
$T1$-induced stereotypy and locomotor activity in rats.In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.
apomorphine
physostigmine
0
$T1$-induced head twitch in rats.Finally, carteolol did not inhibit $T2$
5-hydroxytryptophan
physostigmine
0
$T1$ in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.The prompt discontinuation of $T2$
RPGN
D-penicillamine
1
$T1$ presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.
rheumatoid arthritis
D-penicillamine
0
$T1$ pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.A complete recovery of renal function was achieved in a few weeks.
steroid
D-penicillamine
0
$T1$ and antiplatelet agents.A complete recovery of renal function was achieved in a few weeks.
cyclophosphamide
D-penicillamine
0
$T1$.A complete recovery of renal function was achieved in a few weeks.
antiplatelet agents
D-penicillamine
0
$T1$ in these patients.The prompt discontinuation of $T2$
proteinuria
D-penicillamine
0
$T1$ presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.
rheumatoid arthritis
RPGN
0
$T1$ pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.A complete recovery of renal function was achieved in a few weeks.
steroid
RPGN
0
$T1$ and antiplatelet agents.A complete recovery of renal function was achieved in a few weeks.
cyclophosphamide
RPGN
0
$T1$.A complete recovery of renal function was achieved in a few weeks.
antiplatelet agents
RPGN
0
$T1$ in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and $T2$
RPGN
proteinuria
0
$T1$ presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.
rheumatoid arthritis
steroid
0
$T1$ presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.
rheumatoid arthritis
cyclophosphamide
0
$T1$ presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.
rheumatoid arthritis
antiplatelet agents
0
$T1$ presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.
rheumatoid arthritis
proteinuria
0
$T1$ pulse, plasmapheresis, $T2$
steroid
cyclophosphamide
0
$T1$ pulse, plasmapheresis, cyclophosphamide and $T2$
steroid
antiplatelet agents
0
$T1$ pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.A complete recovery of renal function was achieved in a few weeks.
steroid
proteinuria
0
$T1$ and $T2$
cyclophosphamide
antiplatelet agents
0
$T1$ and antiplatelet agents.A complete recovery of renal function was achieved in a few weeks.
cyclophosphamide
proteinuria
0
$T1$.A complete recovery of renal function was achieved in a few weeks.
antiplatelet agents
proteinuria
0
$T1$ 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day.
zidovudine
nausea
1
$T1$ 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day.
zidovudine
fatigue
1
$T1$ 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day.
zidovudine
headache
1
$T1$.Following a 3-week observation period, volunteers were treated with $T2$
HIV disease
zidovudine
0
$T1$ 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day.
zidovudine
megaloblastosis
0
$T1$.Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.
HIV disease
nausea
0
$T1$.Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.
HIV disease
fatigue
0
$T1$.Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.
HIV disease
headache
0
$T1$.Following a 3-week observation period, volunteers were treated with zidovudine 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals.
HIV disease
megaloblastosis
0
$T1$ (64%), $T2$
nausea
fatigue
0
$T1$ (64%), fatigue (55%) and $T2$
nausea
headache
0
$T1$ (64%), fatigue (55%) and headache (49%).These were generally self-limited, reappearing briefly at each dose increment.
nausea
megaloblastosis
0
$T1$ (55%) and $T2$
fatigue
headache
0
$T1$ (55%) and headache (49%).These were generally self-limited, reappearing briefly at each dose increment.
fatigue
megaloblastosis
0
$T1$ (49%).These were generally self-limited, reappearing briefly at each dose increment.
headache
megaloblastosis
0
$T1$ was found.Ethambutol was stopped and only small improvement of the visual acuity followed.
scotoma
isoniazid
1
$T1$ with an unusual central bitemporal hemianopic scotoma was found.Ethambutol was stopped and only small improvement of the visual acuity followed.
bilateral retrobulbar neuropathy
ethambutol
1
$T1$ with an unusual central bitemporal hemianopic scotoma was found.Ethambutol was stopped and only small improvement of the visual acuity followed.
bilateral retrobulbar neuropathy
isoniazid
1
$T1$ was found.Ethambutol was stopped and only small improvement of the visual acuity followed.
scotoma
ethambutol
1
$T1$ with an unusual central bitemporal hemianopic $T2$
bilateral retrobulbar neuropathy
scotoma
0
$T1$ with an unusual central bitemporal hemianopic scotoma was found.Ethambutol was stopped and only small improvement of the visual acuity followed.
bilateral retrobulbar neuropathy
toxicity
0
$T1$ and $T2$
ethambutol
isoniazid
0
$T1$ due to ethambutol are known.We emphasize the potential danger in the use of $T2$
toxicity
ethambutol
0
$T1$ due to ethambutol are known.We emphasize the potential danger in the use of ethambutol and $T2$
toxicity
isoniazid
0
$T1$ was found.Ethambutol was stopped and only small improvement of the visual acuity followed.
scotoma
toxicity
0
$T1$ profile, suggesting "hypercoagulability" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
blood coagulation
oral contraceptive
1
$T1$ 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.
retinopathy
oral contraceptive
1
$T1$ 14 days after initiation of contraceptive therapy.All four patients were of the A or AB blood group.
thrombophlebitis
oral contraceptive
1
$T1$ before receiving any medication, shortly after the base-line values were obtained.One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.
myocardial infarction
oral contraceptive
1
$T1$ profile, suggesting "hypercoagulability" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
blood coagulation
thromboembolic episodes
0
$T1$ profile, suggesting "$T2$
blood coagulation
hypercoagulability
0
$T1$ profile, suggesting "hypercoagulability" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
blood coagulation
myocardial infarction
0
$T1$ profile, suggesting "hypercoagulability" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
blood coagulation
retinopathy
0
$T1$ profile, suggesting "hypercoagulability" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
blood coagulation
thrombophlebitis
0
$T1$ in patients possessing the A antigen.It appears from these data that hematologic work-ups may be useful in women who are about to start long-term $T2$
thromboembolic episodes
oral contraceptive
0
$T1$" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
hypercoagulability
thromboembolic episodes
0
$T1$ before receiving any medication, shortly after the base-line values were obtained.One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.
myocardial infarction
thromboembolic episodes
0
$T1$ 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy.
retinopathy
thromboembolic episodes
0
$T1$ 14 days after initiation of contraceptive therapy.All four patients were of the A or AB blood group.
thrombophlebitis
thromboembolic episodes
0
$T1$" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
hypercoagulability
oral contraceptive
0
$T1$" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
hypercoagulability
myocardial infarction
0
$T1$" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
hypercoagulability
retinopathy
0
$T1$" before initiation of therapy.Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy.
hypercoagulability
thrombophlebitis
0
$T1$ before receiving any medication, shortly after the base-line values were obtained.One patient developed $T2$
myocardial infarction
retinopathy
0
$T1$ before receiving any medication, shortly after the base-line values were obtained.One patient developed retinopathy 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.
myocardial infarction
thrombophlebitis
0
$T1$ 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy.The fourth patient developed $T2$
retinopathy
thrombophlebitis
0
$T1$ requiring cardiac resuscitation.There are no previous reports of $T2$
hypotension
clonidine
1
$T1$ and hypotension requiring cardiac resuscitation.There are no previous reports of $T2$
bradycardia
clonidine
1
$T1$-associated $T2$
clonidine
cardiac arrest
1
$T1$ and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
cerebral palsy
cardiac arrest
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
cardiac arrest
0
$T1$, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
seizure disorder
cardiac arrest
0
$T1$, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
restlessness
cardiac arrest
0
$T1$ pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
baclofen
cardiac arrest
0
$T1$.During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation.
anxiety
cardiac arrest
0
$T1$ and hypotension requiring cardiac resuscitation.There are no previous reports of clonidine-associated $T2$
bradycardia
cardiac arrest
0
$T1$ requiring cardiac resuscitation.There are no previous reports of clonidine-associated $T2$
hypotension
cardiac arrest
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
cerebral palsy
0
$T1$ and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
cerebral palsy
clonidine
0
$T1$ and $T2$
cerebral palsy
seizure disorder
0
$T1$ and seizure disorder, receiving clonidine for $T2$
cerebral palsy
restlessness
0
$T1$ and seizure disorder, receiving clonidine for restlessness, who presented for placement of a $T2$
cerebral palsy
baclofen
0
$T1$ and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce $T2$
cerebral palsy
anxiety
0
$T1$ and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
cerebral palsy
bradycardia
0
$T1$ and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
cerebral palsy
hypotension
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
clonidine
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
seizure disorder
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
restlessness
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
baclofen
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
anxiety
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
bradycardia
0
$T1$ induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.
sevoflurane
hypotension
0
$T1$, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
seizure disorder
clonidine
0
$T1$, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
restlessness
clonidine
0
$T1$ pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
baclofen
clonidine
0
$T1$.During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation.
anxiety
clonidine
0
$T1$, receiving clonidine for $T2$
seizure disorder
restlessness
0
$T1$, receiving clonidine for restlessness, who presented for placement of a $T2$
seizure disorder
baclofen
0
$T1$, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce $T2$
seizure disorder
anxiety
0
$T1$, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
seizure disorder
bradycardia
0
$T1$, receiving clonidine for restlessness, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
seizure disorder
hypotension
0
$T1$, who presented for placement of a $T2$
restlessness
baclofen
0
$T1$, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce $T2$
restlessness
anxiety
0
$T1$, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
restlessness
bradycardia
0
$T1$, who presented for placement of a baclofen pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
restlessness
hypotension
0
$T1$ pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce $T2$
baclofen
anxiety
0
$T1$ pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
baclofen
bradycardia
0
$T1$ pump.Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
baclofen
hypotension
0
$T1$.During induction of anesthesia, the patient developed $T2$
anxiety
bradycardia
0
$T1$.During induction of anesthesia, the patient developed bradycardia and $T2$
anxiety
hypotension
0
$T1$ and $T2$
bradycardia
hypotension
0
$T1$ and locomotor activity, but not lethality.When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.
convulsions
cocaine
1
$T1$ produced no significant effects compared to control injections of saline, but $T2$
SM 21
UMB24
0
$T1$ had locomotor depressant actions.Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of $T2$
UMB24
cocaine
0
$T1$ and locomotor activity, but not lethality.When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but $T2$
convulsions
UMB24
0
$T1$ produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of $T2$
SM 21
cocaine
0
$T1$ and locomotor activity, but not lethality.When administered alone, (+/-)-$T2$
convulsions
SM 21
0
$T1$, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
hyperbilirubinemia
methimazole
1
$T1$.Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue $T2$
cholestatic jaundice
methimazole
1
$T1$, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
pruritus
methimazole
1
$T1$, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
icterus
methimazole
0
$T1$ therapy was resumed.Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.
propranolol
methimazole
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
methimazole
0
$T1$ was diagnosed, and propranolol therapy was resumed.Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.
cholestasis
methimazole
0
$T1$ levels were normal after 12 weeks without methimazole.In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.
bilirubin
methimazole
0
$T1$, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
icterus
cholestatic jaundice
0
$T1$, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
pruritus
cholestatic jaundice
0
$T1$ therapy was resumed.Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.
propranolol
cholestatic jaundice
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
cholestatic jaundice
0
$T1$, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
hyperbilirubinemia
cholestatic jaundice
0
$T1$ was diagnosed, and propranolol therapy was resumed.Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.
cholestasis
cholestatic jaundice
0
$T1$ levels were normal after 12 weeks without methimazole.In rare cases within the first few weeks of therapy, this drug can cause severe and reversible $T2$
bilirubin
cholestatic jaundice
0
$T1$, $T2$
icterus
pruritus
0
$T1$, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and $T2$
icterus
propranolol
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
icterus
0
$T1$, pruritus, and $T2$
icterus
hyperbilirubinemia
0
$T1$, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced $T2$
icterus
cholestasis
0
$T1$, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
icterus
bilirubin
0
$T1$, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and $T2$
pruritus
propranolol
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
pruritus
0
$T1$, and $T2$
pruritus
hyperbilirubinemia
0
$T1$, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced $T2$
pruritus
cholestasis
0
$T1$, and hyperbilirubinemia, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
pruritus
bilirubin
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
propranolol
0
$T1$, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and $T2$
hyperbilirubinemia
propranolol
0
$T1$ was diagnosed, and $T2$
cholestasis
propranolol
0
$T1$ therapy was resumed.Over the following 9 days, the symptoms improved and plasma $T2$
propranolol
bilirubin
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
hyperbilirubinemia
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
cholestasis
0
$T1$.The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications.
hyperthyroidism
bilirubin
0
$T1$, formed mainly of the conjugated fraction.Methimazole-induced $T2$
hyperbilirubinemia
cholestasis
0
$T1$, formed mainly of the conjugated fraction.Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.
hyperbilirubinemia
bilirubin
0
$T1$ was diagnosed, and propranolol therapy was resumed.Over the following 9 days, the symptoms improved and plasma $T2$
cholestasis
bilirubin
0
$T1$-induced interstitial nephritis and autoimmune hemolytic anemia.$T2$
ciprofloxacin
Hemolytic anemia
1
$T1$-induced interstitial nephritis and autoimmune hemolytic anemia.Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.
ciprofloxacin
end-stage renal disease
1
$T1$-induced interstitial nephritis and autoimmune hemolytic anemia.Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.
ciprofloxacin
interstitial nephritis
1
$T1$-induced interstitial nephritis and $T2$
ciprofloxacin
autoimmune hemolytic anemia
0
$T1$-induced interstitial nephritis and autoimmune hemolytic anemia.Hemolytic anemia improved after stopping the drug and initiation of $T2$
ciprofloxacin
steroid
0
$T1$.Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.
autoimmune hemolytic anemia
interstitial nephritis
0
$T1$ improved after stopping the drug and initiation of steroid therapy.Unfortunately, acute $T2$
Hemolytic anemia
interstitial nephritis
0
$T1$ therapy.Unfortunately, acute $T2$
steroid
interstitial nephritis
0
$T1$ was irreversible and the patient developed $T2$
interstitial nephritis
end-stage renal disease
0
$T1$.$T2$
autoimmune hemolytic anemia
Hemolytic anemia
0
$T1$.Hemolytic anemia improved after stopping the drug and initiation of $T2$
autoimmune hemolytic anemia
steroid
0
$T1$.Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.
autoimmune hemolytic anemia
end-stage renal disease
0
$T1$ improved after stopping the drug and initiation of $T2$
Hemolytic anemia
steroid
0
$T1$ improved after stopping the drug and initiation of steroid therapy.Unfortunately, acute interstitial nephritis was irreversible and the patient developed $T2$
Hemolytic anemia
end-stage renal disease
0
$T1$ therapy.Unfortunately, acute interstitial nephritis was irreversible and the patient developed $T2$
steroid
end-stage renal disease
0
$T1$ to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of $T2$
SIADH
VPA
1
$T1$ since he was 56 years old.After substituting VPA with zonisamide, the serum sodium level returned to normal.
tonic-clonic convulsions
VPA
0
$T1$, the serum sodium level returned to normal.We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of $T2$
zonisamide
VPA
0
$T1$ level returned to normal.We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of $T2$
sodium
VPA
0
$T1$ and the long-term administration of $T2$
weakness of the central nervous system
VPA
0
$T1$ since he was 56 years old.After substituting VPA with zonisamide, the serum sodium level returned to normal.
tonic-clonic convulsions
SIADH
0
$T1$, the serum sodium level returned to normal.We consider this episode of $T2$
zonisamide
SIADH
0
$T1$ level returned to normal.We consider this episode of $T2$
sodium
SIADH
0
$T1$ to be the result of a combination of factors including a $T2$
SIADH
weakness of the central nervous system
0
$T1$ since he was 56 years old.After substituting VPA with $T2$
tonic-clonic convulsions
zonisamide
0
$T1$ since he was 56 years old.After substituting VPA with zonisamide, the serum $T2$
tonic-clonic convulsions
sodium
0
$T1$ since he was 56 years old.After substituting VPA with zonisamide, the serum sodium level returned to normal.
tonic-clonic convulsions
weakness of the central nervous system
0
$T1$, the serum $T2$
zonisamide
sodium
0
$T1$, the serum sodium level returned to normal.We consider this episode of SIADH to be the result of a combination of factors including a $T2$
zonisamide
weakness of the central nervous system
0
$T1$ level returned to normal.We consider this episode of SIADH to be the result of a combination of factors including a $T2$
sodium
weakness of the central nervous system
0
$T1$ after treatment with milrinone, low doses of $T2$
hypotension
vasopressin
1
$T1$ after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of $T2$
hypotension
milrinone
1
$T1$ restored blood pressure without inhibiting the inotropic effect of $T2$
vasopressin
milrinone
0
$T1$ with hypotension after treatment with milrinone, low doses of $T2$
heart failure
vasopressin
0
$T1$ with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of $T2$
heart failure
milrinone
0
$T1$ with $T2$
heart failure
hypotension
0
$T1$ could produce a hypersensitivity condition similar to that of halothane $T2$
isoflurane
hepatitis
1
$T1$ and/or isoflurane could produce a hypersensitivity condition similar to that of halothane $T2$
enflurane
hepatitis
1
$T1$ either alone or subsequent to $T2$
hepatitis
halothane
1
$T1$ and/or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to $T2$
enflurane
halothane
0
$T1$ could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to $T2$
isoflurane
halothane
0
$T1$ adduct) has been detected on halothane hepatitis patients.This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
trifluoroacetyl
halothane
0
$T1$ condition similar to that of halothane hepatitis either alone or subsequent to $T2$
hypersensitivity
halothane
0
$T1$ and/or $T2$
enflurane
isoflurane
0
$T1$ adduct) has been detected on halothane hepatitis patients.This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
trifluoroacetyl
enflurane
0
$T1$ and/or isoflurane could produce a $T2$
enflurane
hypersensitivity
0
$T1$ adduct) has been detected on halothane hepatitis patients.This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
trifluoroacetyl
isoflurane
0
$T1$ could produce a $T2$
isoflurane
hypersensitivity
0
$T1$ adduct) has been detected on halothane hepatitis patients.This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
trifluoroacetyl
hepatitis
0
$T1$ condition similar to that of halothane $T2$
hypersensitivity
hepatitis
0
$T1$ adduct) has been detected on halothane hepatitis patients.This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
trifluoroacetyl
hypersensitivity
0
$T1$ of the bladder epithelium, which was not coincident with the presence of bladder calculi.A low yield of tumours at various other sites also arose following paracetamol feeding.
hyperplasia
paracetamol
1
$T1$ were only obtained from low dosage females and high dosage males.Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.
bladder tumours
paracetamol
1
$T1$-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known $T2$
paracetamol
hepatocarcinogens
1
$T1$ of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.
Papillomas
paracetamol
0
$T1$.A low yield of tumours at various other sites also arose following paracetamol feeding.
bladder calculi
paracetamol
0
$T1$ at various other sites also arose following paracetamol feeding.An electron microscope study of the livers of $T2$
tumours
paracetamol
0
$T1$ of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.However, significant yields of $T2$
Papillomas
bladder tumours
0
$T1$ were only obtained from low dosage females and high dosage males.Additionally, 20 to 25% of paracetamol-treated rats developed $T2$
bladder tumours
hyperplasia
0
$T1$ were only obtained from low dosage females and high dosage males.Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of $T2$
bladder tumours
bladder calculi
0
$T1$ were only obtained from low dosage females and high dosage males.Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.
bladder tumours
tumours
0
$T1$ were only obtained from low dosage females and high dosage males.Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.
bladder tumours
hepatocarcinogens
0
$T1$ of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.
Papillomas
hyperplasia
0
$T1$ of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.
Papillomas
bladder calculi
0
$T1$ of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.
Papillomas
tumours
0
$T1$ of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.
Papillomas
hepatocarcinogens
0
$T1$ of the bladder epithelium, which was not coincident with the presence of $T2$
hyperplasia
bladder calculi
0
$T1$ of the bladder epithelium, which was not coincident with the presence of bladder calculi.A low yield of $T2$
hyperplasia
tumours
0
$T1$ of the bladder epithelium, which was not coincident with the presence of bladder calculi.A low yield of tumours at various other sites also arose following paracetamol feeding.
hyperplasia
hepatocarcinogens
0
$T1$.A low yield of $T2$
bladder calculi
tumours
0
$T1$.A low yield of tumours at various other sites also arose following paracetamol feeding.
bladder calculi
hepatocarcinogens
0
$T1$ at various other sites also arose following paracetamol feeding.An electron microscope study of the livers of paracetamol-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known $T2$
tumours
hepatocarcinogens
0
$T1$, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and $T2$
muscle damage
lidocaine
1
$T1$, severe damage was also seen in harderian glands, especially after exposure to $T2$
muscle damage
mepivacaine
1
$T1$, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.Controls were injected with physiological saline.
bupivacaine hydrochloride
muscle damage
1
$T1$, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.Controls were injected with physiological saline.
bupivacaine hydrochloride
mepivacaine
0
$T1$, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.Controls were injected with physiological saline.
bupivacaine hydrochloride
lidocaine
0
$T1$, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.Controls were injected with physiological saline.
bupivacaine hydrochloride
epinephrine
0
$T1$, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.Controls were injected with physiological saline.
bupivacaine hydrochloride
diplopia
0
$T1$ and $T2$
mepivacaine
lidocaine
0
$T1$ and lidocaine plus $T2$
mepivacaine
epinephrine
0
$T1$ and lidocaine plus epinephrine.With these findings in rats, it is hypothesized that the temporary $T2$
mepivacaine
diplopia
0
$T1$ plus $T2$
lidocaine
epinephrine
0
$T1$ plus epinephrine.With these findings in rats, it is hypothesized that the temporary $T2$
lidocaine
diplopia
0
$T1$, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus $T2$
muscle damage
epinephrine
0
$T1$.With these findings in rats, it is hypothesized that the temporary $T2$
epinephrine
diplopia
0
$T1$, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.With these findings in rats, it is hypothesized that the temporary $T2$
muscle damage
diplopia
0
$T1$ induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
haloperidol
catalepsy
1
$T1$ analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
aryl-piperazine
catalepsy
0
$T1$ and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
buspirone
catalepsy
0
$T1$ were tested for their ability to reverse haloperidol induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
5-hydroxytryptaminergic agonists
catalepsy
0
$T1$ receptors neither inhibited nor potentiated reversal of $T2$
5-HT
catalepsy
0
$T1$ analogues of $T2$
aryl-piperazine
buspirone
0
$T1$ analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse $T2$
aryl-piperazine
haloperidol
0
$T1$ analogues of buspirone and other $T2$
aryl-piperazine
5-hydroxytryptaminergic agonists
0
$T1$ analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
aryl-piperazine
5-HT
0
$T1$ and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse $T2$
buspirone
haloperidol
0
$T1$ and other $T2$
buspirone
5-hydroxytryptaminergic agonists
0
$T1$ and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
buspirone
5-HT
0
$T1$ were tested for their ability to reverse $T2$
5-hydroxytryptaminergic agonists
haloperidol
0
$T1$ induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
haloperidol
5-HT
0
$T1$ were tested for their ability to reverse haloperidol induced catalepsy.Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
5-hydroxytryptaminergic agonists
5-HT
0
$T1$-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex $T2$
adrenaline
bradycardia
1
$T1$ acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex $T2$
diazepam
bradycardia
1
$T1$-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that $T2$
adrenaline
diazepam
0
$T1$ (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that $T2$
picrotoxin
diazepam
0
$T1$ acts through the benzodiazepine-GABA-$T2$
diazepam
chloride
0
$T1$ acts through the $T2$
diazepam
benzodiazepine
0
$T1$ acts through the benzodiazepine-$T2$
diazepam
GABA
0
$T1$ (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex $T2$
picrotoxin
bradycardia
0
$T1$ channel macromolecular complex within the central nervous system to facilitate reflex $T2$
chloride
bradycardia
0
$T1$-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex $T2$
benzodiazepine
bradycardia
0
$T1$-chloride channel macromolecular complex within the central nervous system to facilitate reflex $T2$
GABA
bradycardia
0
$T1$-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of $T2$
adrenaline
picrotoxin
0
$T1$-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the benzodiazepine-GABA-$T2$
adrenaline
chloride
0
$T1$-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the $T2$
adrenaline
benzodiazepine
0
$T1$-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the benzodiazepine-$T2$
adrenaline
GABA
0
$T1$ (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the benzodiazepine-GABA-$T2$
picrotoxin
chloride
0
$T1$ (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the $T2$
picrotoxin
benzodiazepine
0
$T1$ (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).The data indicate that diazepam acts through the benzodiazepine-$T2$
picrotoxin
GABA
0
$T1$-GABA-$T2$
benzodiazepine
chloride
0
$T1$-$T2$
GABA
chloride
0
$T1$-$T2$
benzodiazepine
GABA
0
$T1$- or cocaine-kindled seizures.The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled $T2$
lidocaine
seizures
1
$T1$.The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.
seizures
cocaine
1
$T1$.The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.
seizures
CBZ
0
$T1$ in preventing the development of toxic side effects in human $T2$
CBZ
cocaine
0
$T1$- or cocaine-kindled seizures.The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.
lidocaine
CBZ
0
$T1$- or cocaine-kindled seizures.The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.
lidocaine
cocaine
0
$T1$ in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.These data suggest that $T2$
nephrotic syndrome
D-penicillamine
1
$T1$ in 3 other patients; none developed renal insufficiency.These data suggest that $T2$
proteinuria
D-penicillamine
1
$T1$ may be effective in severe cases of $T2$
D-penicillamine
localized scleroderma
0
$T1$ also improved.The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.
contractures
D-penicillamine
0
$T1$.These data suggest that $T2$
renal insufficiency
D-penicillamine
0
$T1$ also improved.The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.
contractures
localized scleroderma
0
$T1$ in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.These data suggest that D-penicillamine may be effective in severe cases of $T2$
nephrotic syndrome
localized scleroderma
0
$T1$ in 3 other patients; none developed renal insufficiency.These data suggest that D-penicillamine may be effective in severe cases of $T2$
proteinuria
localized scleroderma
0
$T1$.These data suggest that D-penicillamine may be effective in severe cases of $T2$
renal insufficiency
localized scleroderma
0
$T1$ also improved.The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.
contractures
nephrotic syndrome
0
$T1$ also improved.The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.
contractures
proteinuria
0
$T1$ also improved.The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.
contractures
renal insufficiency
0
$T1$ in 1 patient and milder reversible $T2$
nephrotic syndrome
proteinuria
0
$T1$ in 1 patient and milder reversible proteinuria in 3 other patients; none developed $T2$
nephrotic syndrome
renal insufficiency
0
$T1$ in 3 other patients; none developed $T2$
proteinuria
renal insufficiency
0
$T1$-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.
fenoldopam
hypotension
1
$T1$ is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced $T2$
nitroprusside
hypotension
1
$T1$ general anaesthesia.Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).
halothane
hypotension
1
$T1$-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced $T2$
dopamine
hypotension
0
$T1$ nitroprusside-induced hypotension (P less than 0.01).Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.
sodium
hypotension
0
$T1$-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.
fenoldopam
dopamine
0
$T1$-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during $T2$
fenoldopam
sodium
0
$T1$-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).Sodium $T2$
fenoldopam
nitroprusside
0
$T1$ general anaesthesia.Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).
halothane
fenoldopam
0
$T1$ nitroprusside-induced hypotension (P less than 0.01).Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.
sodium
dopamine
0
$T1$ is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.Fenoldopam is a selective $T2$
nitroprusside
dopamine
0
$T1$ general anaesthesia.Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).
halothane
dopamine
0
$T1$ nitroprusside-induced hypotension (P less than 0.01).Sodium $T2$
sodium
nitroprusside
0
$T1$ general anaesthesia.Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).
halothane
sodium
0
$T1$ general anaesthesia.Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).
halothane
nitroprusside
0
$T1$-induced $T2$
adrenaline
arrhythmia
1
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
ouabain
arrhythmia
1
$T1$ were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-$T2$
arrhythmia
cibenzoline
0
$T1$- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-$T2$
digitalis
cibenzoline
0
$T1$ indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing $T2$
cibenzoline
Na
0
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
ouabain
cibenzoline
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
pentobarbital
cibenzoline
0
$T1$ indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on $T2$
cibenzoline
Ca
0
$T1$-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-$T2$
adrenaline
cibenzoline
0
$T1$-anesthetized dogs.Ten and 5 mg/kg i.v.
halothane
cibenzoline
0
$T1$- and adrenaline-induced $T2$
digitalis
arrhythmia
0
$T1$ were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing $T2$
arrhythmia
Na
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
pentobarbital
arrhythmia
0
$T1$ were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on $T2$
arrhythmia
Ca
0
$T1$-anesthetized dogs.Ten and 5 mg/kg i.v.
halothane
arrhythmia
0
$T1$- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing $T2$
digitalis
Na
0
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
ouabain
digitalis
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
pentobarbital
digitalis
0
$T1$- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on $T2$
digitalis
Ca
0
$T1$- and $T2$
digitalis
adrenaline
0
$T1$-anesthetized dogs.Ten and 5 mg/kg i.v.
halothane
digitalis
0
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
ouabain
Na
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
pentobarbital
Na
0
$T1$ channels, but effects of both drugs on $T2$
Na
Ca
0
$T1$-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing $T2$
adrenaline
Na
0
$T1$-anesthetized dogs.Ten and 5 mg/kg i.v.
halothane
Na
0
$T1$ in $T2$
ouabain
pentobarbital
0
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
ouabain
Ca
0
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
ouabain
adrenaline
0
$T1$ in pentobarbital-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in $T2$
ouabain
halothane
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
pentobarbital
Ca
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
pentobarbital
adrenaline
0
$T1$-anesthetized dogs.Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in $T2$
pentobarbital
halothane
0
$T1$-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on $T2$
adrenaline
Ca
0
$T1$-anesthetized dogs.Ten and 5 mg/kg i.v.
halothane
Ca
0
$T1$-anesthetized dogs.Ten and 5 mg/kg i.v.
halothane
adrenaline
0
$T1$-induced orofacial $T2$
reserpine
dyskinesia
1
$T1$ had a protective role against $T2$
Hibiscus rosa sinensis
reserpine
0
$T1$ had a protective role against reserpine-induced orofacial $T2$
Hibiscus rosa sinensis
dyskinesia
0
$T1$ dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.
superoxide
Hibiscus rosa sinensis
0
$T1$ reductase (GSH), an index of oxidative stress process.Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.
glutathione
Hibiscus rosa sinensis
0
$T1$ dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.
superoxide
reserpine
0
$T1$ reductase (GSH), an index of oxidative stress process.Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.
glutathione
reserpine
0
$T1$ dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.
superoxide
dyskinesia
0
$T1$ reductase (GSH), an index of oxidative stress process.Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.
glutathione
dyskinesia
0
$T1$ dismutase (SOD), catalase (CAT) and $T2$
superoxide
glutathione
0
$T1$ gellan decrease the mean 24-hour heart rate compared with placebo.This response was most pronounced during the active daytime period.
timolol
bradycardia
1
$T1$ gellan decrease the mean 24-hour heart rate compared with placebo.This response was most pronounced during the active daytime period.
timolol
glaucoma
0
$T1$ or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.
open-angle glaucoma
timolol
0
$T1$ with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.
ocular hypertension
timolol
0
$T1$ or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.
open-angle glaucoma
glaucoma
0
$T1$ with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.
ocular hypertension
glaucoma
0
$T1$ associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for $T2$
bradycardia
glaucoma
0
$T1$ or $T2$
open-angle glaucoma
ocular hypertension
0
$T1$ or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.
open-angle glaucoma
bradycardia
0
$T1$ with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).On the 13th day of each period, heart rate was recorded continuously during a typical, ambulant 24-hour period.
ocular hypertension
bradycardia
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
ABS
1
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with $T2$
chest pain
fluorouracil
1
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
fluorouracil
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
fluorouracil
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
fluorouracil
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
fluorouracil
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
cancer
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with $T2$
ischemic
fluorouracil
0
$T1$ for metastatic $T2$
fluorouracil
colorectal cancer
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
akinesis
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
cardiac complications
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
coronary vasospasm
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
thrombus
0
$T1$ for metastatic colorectal cancer.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
fluorouracil
catecholamines
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
ABS
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
ABS
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
ABS
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
ABS
0
$T1$ diagnosis as well as chemotherapy may have contributed the development of $T2$
cancer
ABS
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
ABS
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
ABS
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
ABS
0
$T1$.Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.
akinesis
ABS
0
$T1$ in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of $T2$
cardiac complications
ABS
0
$T1$, endothelial damage and consequent thrombus formation.In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of $T2$
coronary vasospasm
ABS
0
$T1$ formation.In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of $T2$
thrombus
ABS
0
$T1$ and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of $T2$
catecholamines
ABS
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with $T2$
acute cardiac syndrome
hyperkinesis
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive $T2$
acute cardiac syndrome
epicardial coronary disease
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.$T2$
acute cardiac syndrome
Cardiotoxicity
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
cancer
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
ischemic
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
chest pain
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
colorectal cancer
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
akinesis
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
cardiac complications
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
coronary vasospasm
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
thrombus
0
$T1$ characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
acute cardiac syndrome
catecholamines
0
$T1$ of the basal left ventricular (LV) segments without obstructive $T2$
hyperkinesis
epicardial coronary disease
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.$T2$
hyperkinesis
Cardiotoxicity
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
cancer
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
ischemic
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
chest pain
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
colorectal cancer
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
akinesis
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
cardiac complications
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
coronary vasospasm
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
thrombus
0
$T1$ of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
hyperkinesis
catecholamines
0
$T1$.$T2$
epicardial coronary disease
Cardiotoxicity
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
cancer
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
ischemic
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
chest pain
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
colorectal cancer
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
akinesis
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
cardiac complications
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
coronary vasospasm
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
thrombus
0
$T1$.Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.
epicardial coronary disease
catecholamines
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
cancer
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
ischemic
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
chest pain
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
colorectal cancer
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
akinesis
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
cardiac complications
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
coronary vasospasm
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
thrombus
0
$T1$ is not an uncommon adverse effect of chemotherapeutic agents.However, there are no reports of ABS secondary to chemotherapeutic agents.
Cardiotoxicity
catecholamines
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
cancer
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
cancer
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
cancer
0
$T1$.Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.
akinesis
cancer
0
$T1$ in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by $T2$
cardiac complications
cancer
0
$T1$, endothelial damage and consequent thrombus formation.In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by $T2$
coronary vasospasm
cancer
0
$T1$ formation.In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by $T2$
thrombus
cancer
0
$T1$ and stress related neuropeptides caused by $T2$
catecholamines
cancer
0
$T1$ $T2$
ischemic
chest pain
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic $T2$
ischemic
colorectal cancer
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
akinesis
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
cardiac complications
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
coronary vasospasm
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
thrombus
0
$T1$ chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
ischemic
catecholamines
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic $T2$
chest pain
colorectal cancer
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
akinesis
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
cardiac complications
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
coronary vasospasm
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
thrombus
0
$T1$, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
chest pain
catecholamines
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
akinesis
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
cardiac complications
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
coronary vasospasm
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
thrombus
0
$T1$.Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.
colorectal cancer
catecholamines
0
$T1$.Pathogenetic mechanisms of $T2$
akinesis
cardiac complications
0
$T1$.Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include $T2$
akinesis
coronary vasospasm
0
$T1$.Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent $T2$
akinesis
thrombus
0
$T1$.Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.
akinesis
catecholamines
0
$T1$ in cancer patients undergoing chemotherapy include $T2$
cardiac complications
coronary vasospasm
0
$T1$ in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent $T2$
cardiac complications
thrombus
0
$T1$ in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.In our patient, both supraphysiologic levels of plasma $T2$
cardiac complications
catecholamines
0
$T1$, endothelial damage and consequent $T2$
coronary vasospasm
thrombus
0
$T1$, endothelial damage and consequent thrombus formation.In our patient, both supraphysiologic levels of plasma $T2$
coronary vasospasm
catecholamines
0
$T1$ formation.In our patient, both supraphysiologic levels of plasma $T2$
thrombus
catecholamines
0
$T1$ infusion $T2$
propofol
pain
1
$T1$ was achieved without significant complications by prior administration of $T2$
pain
remifentanil
0
$T1$ infusion pain was achieved without significant complications by prior administration of $T2$
propofol
remifentanil
0
$T1$ as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).
fetal pulmonary hypertension
fluoxetine
1
$T1$ exposure in utero induces $T2$
fluoxetine
pulmonary hypertension
1
$T1$-induced contraction at both ages (P < 0.01).After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).
serotonin
fluoxetine
0
$T1$ saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).
oxygen
fluoxetine
0
$T1$ as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).
fetal pulmonary hypertension
serotonin
0
$T1$ as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).
fetal pulmonary hypertension
pulmonary hypertension
0
$T1$ as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).Postnatal mortality was increased among experimental animals, and arterial $T2$
fetal pulmonary hypertension
oxygen
0
$T1$-induced contraction at both ages (P < 0.01).After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal, but not adult, cells (P < 0.01).
serotonin
pulmonary hypertension
0
$T1$ saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced $T2$
oxygen
serotonin
0
$T1$ saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).
oxygen
pulmonary hypertension
0
$T1$ is associated with $T2$
Methadone
QT prolongation
1
$T1$ is associated with QT prolongation and higher reporting of $T2$
Methadone
syncope
1
$T1$ and higher reporting of $T2$
QT prolongation
syncope
0
$T1$ in a population of $T2$
syncope
heroin
0
$T1$ in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
TdP
syncope
0
$T1$ had QTc interval >0.440 s((1/2)).A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
buprenorphine
syncope
0
$T1$ and higher reporting of syncope in a population of $T2$
QT prolongation
heroin
0
$T1$ in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
TdP
QT prolongation
0
$T1$ had QTc interval >0.440 s((1/2)).A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
buprenorphine
QT prolongation
0
$T1$ is associated with QT prolongation and higher reporting of syncope in a population of $T2$
Methadone
heroin
0
$T1$ in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
TdP
Methadone
0
$T1$ had QTc interval >0.440 s((1/2)).A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
buprenorphine
Methadone
0
$T1$ in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
TdP
heroin
0
$T1$ had QTc interval >0.440 s((1/2)).A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
buprenorphine
heroin
0
$T1$ in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.
TdP
buprenorphine
0
$T1$ are still unclear, high-dose $T2$
peripheral neuropathy
cytosine arabinoside
1
$T1$.After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.
acute myeloid leukemia
peripheral neuropathy
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.
toxicity
peripheral neuropathy
0
$T1$ in his right foot.Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.
numbness
peripheral neuropathy
0
$T1$ was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.Although the mechanisms of $T2$
neuropathy
peripheral neuropathy
0
$T1$, and the symptoms subsequently responded to methylprednisolone.Although the mechanisms of $T2$
graft-versus-host disease
peripheral neuropathy
0
$T1$.Although the mechanisms of $T2$
methylprednisolone
peripheral neuropathy
0
$T1$.After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.
acute myeloid leukemia
cytosine arabinoside
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.
toxicity
cytosine arabinoside
0
$T1$ in his right foot.Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.
numbness
cytosine arabinoside
0
$T1$ was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.Although the mechanisms of peripheral neuropathy are still unclear, high-dose $T2$
neuropathy
cytosine arabinoside
0
$T1$, and the symptoms subsequently responded to methylprednisolone.Although the mechanisms of peripheral neuropathy are still unclear, high-dose $T2$
graft-versus-host disease
cytosine arabinoside
0
$T1$.Although the mechanisms of peripheral neuropathy are still unclear, high-dose $T2$
methylprednisolone
cytosine arabinoside
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with $T2$
toxicity
acute myeloid leukemia
0
$T1$.After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.
acute myeloid leukemia
numbness
0
$T1$.After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.
acute myeloid leukemia
neuropathy
0
$T1$.After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.
acute myeloid leukemia
graft-versus-host disease
0
$T1$.After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.
acute myeloid leukemia
methylprednisolone
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.
toxicity
numbness
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.
toxicity
neuropathy
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.
toxicity
graft-versus-host disease
0
$T1$ of cytosine arabinoside in the peripheral nervous system has been infrequently reported.A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.
toxicity
methylprednisolone
0
$T1$ in his right foot.Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.
numbness
neuropathy
0
$T1$ in his right foot.Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.
numbness
graft-versus-host disease
0
$T1$ in his right foot.Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.
numbness
methylprednisolone
0
$T1$ was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of $T2$
neuropathy
graft-versus-host disease
0
$T1$ was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to $T2$
neuropathy
methylprednisolone
0
$T1$, and the symptoms subsequently responded to $T2$
graft-versus-host disease
methylprednisolone
0
$T1$-induced $T2$
dexamethasone
hypertension
1
$T1$ prevented and reversed $T2$
atorvastatin
dexamethasone
0
$T1$ prevented and reversed dexamethasone-induced $T2$
atorvastatin
hypertension
0
$T1$ (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).
superoxide
atorvastatin
0
$T1$/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).Atorva affected neither plasma NOx nor thymus weight.
nitrate
atorvastatin
0
$T1$ (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).Atorva affected neither plasma NOx nor thymus weight.
nitrite
atorvastatin
0
$T1$ (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).
superoxide
dexamethasone
0
$T1$/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).Atorva affected neither plasma NOx nor thymus weight.
nitrate
dexamethasone
0
$T1$ (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).Atorva affected neither plasma NOx nor thymus weight.
nitrite
dexamethasone
0
$T1$ (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).
superoxide
hypertension
0
$T1$/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).Atorva affected neither plasma NOx nor thymus weight.
nitrate
hypertension
0
$T1$ (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).Atorva affected neither plasma NOx nor thymus weight.
nitrite
hypertension
0
$T1$ (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).Plasma $T2$
superoxide
nitrate
0
$T1$ (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).Plasma nitrate/$T2$
superoxide
nitrite
0
$T1$/$T2$
nitrate
nitrite
0
$T1$-induced thermal hyperalgesia, and capsaicin-induced $T2$
carrageenan
mechanical hyperalgesia
1
$T1$-induced $T2$
capsaicin
mechanical hyperalgesia
1
$T1$ receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.Their ester prodrugs 6 and 8 were orally active in three models of $T2$
KA
pain
0
$T1$ receptor antagonists, exhibited high GluR5 receptor affinity over other $T2$
KA
glutamate
0
$T1$ receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of $T2$
KA
formalin
0
$T1$ receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, $T2$
KA
carrageenan
0
$T1$ receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced $T2$
KA
mechanical hyperalgesia
0
$T1$ receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and $T2$
KA
capsaicin
0
$T1$ receptors.Their ester prodrugs 6 and 8 were orally active in three models of $T2$
glutamate
pain
0
$T1$: reversal of $T2$
pain
formalin
0
$T1$: reversal of formalin-induced paw licking, $T2$
pain
carrageenan
0
$T1$: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced $T2$
pain
mechanical hyperalgesia
0
$T1$: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and $T2$
pain
capsaicin
0
$T1$ receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of $T2$
glutamate
formalin
0
$T1$ receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, $T2$
glutamate
carrageenan
0
$T1$ receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced $T2$
glutamate
mechanical hyperalgesia
0
$T1$ receptors.Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and $T2$
glutamate
capsaicin
0
$T1$-induced paw licking, $T2$
formalin
carrageenan
0
$T1$-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced $T2$
formalin
mechanical hyperalgesia
0
$T1$-induced paw licking, carrageenan-induced thermal hyperalgesia, and $T2$
formalin
capsaicin
0
$T1$-induced thermal hyperalgesia, and $T2$
carrageenan
capsaicin
0
$T1$, have been available for almost 20 years.Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.
tacrolimus
nephrotoxicity
1
$T1$ and tacrolimus, have been available for almost 20 years.Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.
cyclosporine
nephrotoxicity
1
$T1$ and sirolimus ($T2$
mycophenolate mofetil
rapamycin
0
$T1$ and tacrolimus, have been available for almost 20 years.Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.
cyclosporine
rapamycin
0
$T1$, have been available for almost 20 years.Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.
tacrolimus
rapamycin
0
$T1$), have no $T2$
rapamycin
nephrotoxicity
0
$T1$ and tacrolimus, have been available for almost 20 years.Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.
cyclosporine
mycophenolate mofetil
0
$T1$, have been available for almost 20 years.Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.
tacrolimus
mycophenolate mofetil
0
$T1$ and sirolimus (rapamycin), have no $T2$
mycophenolate mofetil
nephrotoxicity
0
$T1$ and $T2$
cyclosporine
tacrolimus
0
$T1$ nor rHuEPO treatment influenced tumor growth rate per se.When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.)
carboplatin
anemia
1
$T1$ in tumors, whereas correction of $T2$
cyclophosphamide
anemia
0
$T1$ of cyclophosphamide in tumors, whereas correction of $T2$
cytotoxicity
anemia
0
$T1$ by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to $T2$
anemia
tumor
0
$T1$ of the rat) were implanted s.c. onto the hind food dorsum.Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
sarcoma
anemia
0
$T1$ by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved $T2$
anemia
oxygen
0
$T1$ of $T2$
cytotoxicity
cyclophosphamide
0
$T1$ in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to $T2$
cyclophosphamide
tumor
0
$T1$ nor rHuEPO treatment influenced tumor growth rate per se.When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.)
carboplatin
cyclophosphamide
0
$T1$ of the rat) were implanted s.c. onto the hind food dorsum.Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
sarcoma
cyclophosphamide
0
$T1$ in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved $T2$
cyclophosphamide
oxygen
0
$T1$ of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to $T2$
cytotoxicity
tumor
0
$T1$ nor rHuEPO treatment influenced tumor growth rate per se.When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.)
carboplatin
cytotoxicity
0
$T1$ of the rat) were implanted s.c. onto the hind food dorsum.Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
sarcoma
cytotoxicity
0
$T1$ of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved $T2$
cytotoxicity
oxygen
0
$T1$ nor rHuEPO treatment influenced tumor growth rate per se.When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.)
carboplatin
tumor
0
$T1$ of the rat) were implanted s.c. onto the hind food dorsum.Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
sarcoma
tumor
0
$T1$ supply to $T2$
oxygen
tumor
0
$T1$ of the rat) were implanted s.c. onto the hind food dorsum.Neither $T2$
sarcoma
carboplatin
0
$T1$ nor rHuEPO treatment influenced tumor growth rate per se.When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.)
carboplatin
oxygen
0
$T1$ of the rat) were implanted s.c. onto the hind food dorsum.Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
sarcoma
oxygen
0
$T1$-induced $T2$
lidocaine
convulsions
1
$T1$ (100 mg/kg, i.p.)and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
L-NAME
lidocaine
0
$T1$ is a proconvulsant mediator in $T2$
NO
lidocaine
0
$T1$ treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.
L-arginine
lidocaine
0
$T1$ (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.
diazepam
lidocaine
0
$T1$ (100 mg/kg, i.p.)and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
L-NAME
convulsions
0
$T1$ is a proconvulsant mediator in lidocaine-induced $T2$
NO
convulsions
0
$T1$ treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.
L-arginine
convulsions
0
$T1$ (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.
diazepam
convulsions
0
$T1$ (100 mg/kg, i.p.)and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
L-NAME
NO
0
$T1$ (100 mg/kg, i.p.)and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.
L-NAME
L-arginine
0
$T1$ (100 mg/kg, i.p.)and $T2$
L-NAME
diazepam
0
$T1$ treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.
L-arginine
NO
0
$T1$ (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.
diazepam
NO
0
$T1$ (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.In contrast, the $T2$
diazepam
L-arginine
0
$T1$ stress testing, metoprolol attenuates or eliminates evidence of $T2$
dobutamine
myocardial ischemia
1
$T1$ stress testing, $T2$
dobutamine
metoprolol
0
$T1$ attenuates or eliminates evidence of $T2$
metoprolol
myocardial ischemia
0
$T1$ single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.DESIGN: Randomized, double-blind, placebo-controlled trial.
technetium-99m sestamibi
metoprolol
0
$T1$ heart rate below 65 beats/minute or a total intravenous dose of 20 mg. MEASUREMENTS AND MAIN RESULTS: Metoprolol reduced maximum heart rate 31%, summed stress scores 29%, and summed difference scores 43% versus control.Metoprolol plus glucagon also reduced the maximum heart rate 29% versus control.
predobutamine
metoprolol
0
$T1$ single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.DESIGN: Randomized, double-blind, placebo-controlled trial.
technetium-99m sestamibi
dobutamine
0
$T1$ heart rate below 65 beats/minute or a total intravenous dose of 20 mg. MEASUREMENTS AND MAIN RESULTS: Metoprolol reduced maximum heart rate 31%, summed stress scores 29%, and summed difference scores 43% versus control.Metoprolol plus glucagon also reduced the maximum heart rate 29% versus control.
predobutamine
dobutamine
0
$T1$ single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.DESIGN: Randomized, double-blind, placebo-controlled trial.
technetium-99m sestamibi
myocardial ischemia
0
$T1$ heart rate below 65 beats/minute or a total intravenous dose of 20 mg. MEASUREMENTS AND MAIN RESULTS: Metoprolol reduced maximum heart rate 31%, summed stress scores 29%, and summed difference scores 43% versus control.Metoprolol plus glucagon also reduced the maximum heart rate 29% versus control.
predobutamine
myocardial ischemia
0
$T1$ single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.DESIGN: Randomized, double-blind, placebo-controlled trial.
technetium-99m sestamibi
predobutamine
0
$T1$ is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
muscle dysfunction
prednisolone
1
$T1$ is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear.
prednisolone
muscle atrophy
1
$T1$ than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
atrophy
prednisolone
0
$T1$ is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear.
prednisolone
acetylcholine
0
$T1$ tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.
tetanic
prednisolone
0
$T1$ did not correlate with muscle mass or AChR expression.Our results suggest that the neuromuscular dysfunction after $T2$
d-tubocurarine
prednisolone
0
$T1$ after $T2$
neuromuscular dysfunction
prednisolone
0
$T1$ is caused more by $T2$
muscle dysfunction
atrophy
0
$T1$ is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
muscle dysfunction
acetylcholine
0
$T1$ is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
muscle dysfunction
tetanic
0
$T1$ is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
muscle dysfunction
d-tubocurarine
0
$T1$ is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
muscle dysfunction
neuromuscular dysfunction
0
$T1$ is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
muscle dysfunction
muscle atrophy
0
$T1$ than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
atrophy
acetylcholine
0
$T1$ than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
atrophy
tetanic
0
$T1$ than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
atrophy
d-tubocurarine
0
$T1$ than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
atrophy
neuromuscular dysfunction
0
$T1$ than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.
atrophy
muscle atrophy
0
$T1$ tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.
tetanic
acetylcholine
0
$T1$ did not correlate with muscle mass or AChR expression.Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.
d-tubocurarine
acetylcholine
0
$T1$ after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear.
neuromuscular dysfunction
acetylcholine
0
$T1$ and derive less from changes in $T2$
muscle atrophy
acetylcholine
0
$T1$ tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.
tetanic
d-tubocurarine
0
$T1$ tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.
tetanic
neuromuscular dysfunction
0
$T1$ tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.
tetanic
muscle atrophy
0
$T1$ did not correlate with muscle mass or AChR expression.Our results suggest that the $T2$
d-tubocurarine
neuromuscular dysfunction
0
$T1$ did not correlate with muscle mass or AChR expression.Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.
d-tubocurarine
muscle atrophy
0
$T1$ after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear.
neuromuscular dysfunction
muscle atrophy
0
$T1$ may accompany the administration of intravenous $T2$
tetany
diltiazem
1
$T1$ and that $T2$
diltiazem
calcium chloride
0
$T1$ after the infusion of intravenous diltiazem.The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.
respiratory arrest
diltiazem
0
$T1$ may accompany the administration of intravenous diltiazem and that $T2$
tetany
calcium chloride
0
$T1$ after the infusion of intravenous diltiazem.The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.
respiratory arrest
tetany
0
$T1$ after the infusion of intravenous diltiazem.The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.
respiratory arrest
calcium chloride
0
$T1$.Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.
hematoma
ketoprofen
1
$T1$ results (P < .05).One patient in the ketoprofen group developed a postoperative intracranial hematoma.
platelet aggregation
ketoprofen
1
$T1$.If $T2$
SAH
ketoprofen
0
$T1$ impaired platelet function in patients with $T2$
acetaminophen
SAH
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
SAH
0
$T1$ results (P < .05).One patient in the ketoprofen group developed a postoperative intracranial hematoma.
platelet aggregation
SAH
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
SAH
0
$T1$.Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.
hematoma
SAH
0
$T1$.If ketoprofen is used before surgery on cerebral $T2$
SAH
artery aneurysms
0
$T1$.If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for $T2$
SAH
hemorrhage
0
$T1$ impaired platelet function in patients with SAH.If $T2$
acetaminophen
ketoprofen
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
ketoprofen
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
ketoprofen
0
$T1$ is used before surgery on cerebral $T2$
ketoprofen
artery aneurysms
0
$T1$ is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for $T2$
ketoprofen
hemorrhage
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
acetaminophen
0
$T1$ results (P < .05).One patient in the ketoprofen group developed a postoperative intracranial hematoma.
platelet aggregation
acetaminophen
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
acetaminophen
0
$T1$.Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.
hematoma
acetaminophen
0
$T1$ impaired platelet function in patients with SAH.If ketoprofen is used before surgery on cerebral $T2$
acetaminophen
artery aneurysms
0
$T1$ impaired platelet function in patients with SAH.If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for $T2$
acetaminophen
hemorrhage
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
platelet aggregation
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
adenosine diphosphate
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
hematoma
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
artery aneurysms
0
$T1$ SAH.Treatment was continued for 3 days postoperatively.
aneurysmal
hemorrhage
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
platelet aggregation
0
$T1$ results (P < .05).One patient in the ketoprofen group developed a postoperative intracranial $T2$
platelet aggregation
hematoma
0
$T1$ results (P < .05).One patient in the ketoprofen group developed a postoperative intracranial hematoma.
platelet aggregation
artery aneurysms
0
$T1$ results (P < .05).One patient in the ketoprofen group developed a postoperative intracranial hematoma.
platelet aggregation
hemorrhage
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
hematoma
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
artery aneurysms
0
$T1$ decreased after administration of ketoprofen.Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day.
adenosine diphosphate
hemorrhage
0
$T1$.Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.
hematoma
artery aneurysms
0
$T1$.Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.
hematoma
hemorrhage
0
$T1$, it may pose an additional risk factor for $T2$
artery aneurysms
hemorrhage
0
$T1$-myalgia syndrome.We conclude that 125 mg i.v.
arthralgia
iron dextran
1
$T1$-myalgia syndrome.We conclude that 125 mg i.v.
arthralgia
MP
0
$T1$ syndrome.We conclude that 125 mg i.v.
myalgia
MP
0
$T1$ should be given routinely before and after TDI of $T2$
MP
iron dextran
0
$T1$-$T2$
arthralgia
myalgia
0
$T1$ syndrome.We conclude that 125 mg i.v.
myalgia
iron dextran
0
$T1$.In 13 of these 27 patients symptoms were still present at the time of examination.
neuropathic symptoms
vincristine
1
$T1$ treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.The patients were interviewed with emphasis on neuropathic symptoms.
Non-Hodgkin's Lymphoma
vincristine
0
$T1$ $T2$
vincristine
neuropathy
0
$T1$ treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.The patients were interviewed with emphasis on neuropathic symptoms.
Non-Hodgkin's Lymphoma
neuropathic symptoms
0
$T1$ treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.The patients were interviewed with emphasis on neuropathic symptoms.
Non-Hodgkin's Lymphoma
neuropathy
0
$T1$.In 13 of these 27 patients symptoms were still present at the time of examination.
neuropathic symptoms
neuropathy
0
$T1$ therapy should be followed carefully for the development of autoimmune complications like $T2$
D-penicillamine
polymyositis
1
$T1$, who developed polymyositis while receiving D-penicillamine therapy.We described the special clinical course of the patient.
primary biliary cirrhosis
polymyositis
0
$T1$, toxicity limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
rheumatologic diseases
polymyositis
0
$T1$ limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
toxicity
polymyositis
0
$T1$/$T2$
polymyositis
dermatomyositis
0
$T1$, who developed polymyositis while receiving D-penicillamine therapy.We described the special clinical course of the patient.
primary biliary cirrhosis
D-penicillamine
0
$T1$, toxicity limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
rheumatologic diseases
primary biliary cirrhosis
0
$T1$ limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
toxicity
primary biliary cirrhosis
0
$T1$, who developed polymyositis while receiving D-penicillamine therapy.We described the special clinical course of the patient.
primary biliary cirrhosis
dermatomyositis
0
$T1$, toxicity limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
rheumatologic diseases
D-penicillamine
0
$T1$ limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
toxicity
D-penicillamine
0
$T1$ therapy should be followed carefully for the development of autoimmune complications like polymyositis/$T2$
D-penicillamine
dermatomyositis
0
$T1$, $T2$
rheumatologic diseases
toxicity
0
$T1$, toxicity limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
rheumatologic diseases
dermatomyositis
0
$T1$ limits its usefulness in many patients.Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
toxicity
dermatomyositis
0
$T1$), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.Neither patient complained of photosensitivity or flushing.
Adalat
telangiectasia
1
$T1$ 3 years later, with recurrence of telangiectasia.The photodistribution of the $T2$
amlodipine
telangiectasia
1
$T1$), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.Neither patient complained of photosensitivity or $T2$
Adalat
flushing
0
$T1$), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.Neither patient complained of photosensitivity or flushing.
Adalat
amlodipine
0
$T1$.Both patients reported a significant cosmetic improvement after discontinuing the drug.
flushing
telangiectasia
0
$T1$.Both patients reported a significant cosmetic improvement after discontinuing the drug.
flushing
amlodipine
0
$T1$ effects of $T2$
nephrotoxic
CsA
1
$T1$ effects of CsA and $T2$
nephrotoxic
FK506
1
$T1$ immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
macrolide
nephrotoxic
0
$T1$.These results suggest that the $T2$
rapamycin
nephrotoxic
0
$T1$ of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
hypertrophy
nephrotoxic
0
$T1$ were investigated.Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.
toxicity
nephrotoxic
0
$T1$ and $T2$
CsA
FK506
0
$T1$ immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
macrolide
CsA
0
$T1$.These results suggest that the nephrotoxic effects of $T2$
rapamycin
CsA
0
$T1$ of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
hypertrophy
CsA
0
$T1$ were investigated.Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.
toxicity
CsA
0
$T1$ immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
macrolide
FK506
0
$T1$.These results suggest that the nephrotoxic effects of CsA and $T2$
rapamycin
FK506
0
$T1$ of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
hypertrophy
FK506
0
$T1$ were investigated.Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.
toxicity
FK506
0
$T1$ immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
macrolide
rapamycin
0
$T1$ immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and $T2$
macrolide
hypertrophy
0
$T1$ immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 $T2$
macrolide
toxicity
0
$T1$ of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 toxicity were investigated.
hypertrophy
rapamycin
0
$T1$ were investigated.Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.
toxicity
rapamycin
0
$T1$ of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.The molecular mechanisms of CsA and FK506 $T2$
hypertrophy
toxicity
0
$T1$-induced fulminant hepatic failure, with signs and symptoms of $T2$
acetaminophen
cerebral edema
1
$T1$-induced $T2$
acetaminophen
fulminant hepatic failure
1
$T1$, with signs and symptoms of $T2$
fulminant hepatic failure
cerebral edema
0
$T1$: possible role of cranial decompression.Cerebral edema may complicate the course of fulminant hepatic failure.
overdose
cerebral edema
0
$T1$: possible role of cranial decompression.Cerebral edema may complicate the course of fulminant hepatic failure.
overdose
fulminant hepatic failure
0
$T1$: possible role of cranial decompression.Cerebral edema may complicate the course of fulminant hepatic failure.
overdose
acetaminophen
0
$T1$ after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.The serum gentamicin concentration had reached toxic levels when anuria developed.
acute renal failure
gentamicin
1
$T1$ in a neonate.The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.
nephropathy
gentamicin
0
$T1$ are presented.The serum gentamicin concentration had reached toxic levels when anuria developed.
penicillin
gentamicin
0
$T1$ developed.Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.
anuria
gentamicin
0
$T1$ Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.The pathological changes induced by $T2$
periodic acid
gentamicin
0
$T1$ in a neonate.The clinical and autopsy findings in a premature baby who died of $T2$
nephropathy
acute renal failure
0
$T1$ in a neonate.The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and $T2$
nephropathy
penicillin
0
$T1$ in a neonate.The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.
nephropathy
anuria
0
$T1$ in a neonate.The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.
nephropathy
periodic acid
0
$T1$ after therapy with gentamicin (5 mg/kg/day) and $T2$
acute renal failure
penicillin
0
$T1$ after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.The serum gentamicin concentration had reached toxic levels when $T2$
acute renal failure
anuria
0
$T1$ after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.The serum gentamicin concentration had reached toxic levels when anuria developed.
acute renal failure
periodic acid
0
$T1$ are presented.The serum gentamicin concentration had reached toxic levels when $T2$
penicillin
anuria
0
$T1$ are presented.The serum gentamicin concentration had reached toxic levels when anuria developed.
penicillin
periodic acid
0
$T1$ developed.Numerous $T2$
anuria
periodic acid
0
$T1$.This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the $T2$
DEN
precancerous lesions
1
$T1$ when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.
carcinogenesis
PB
0
$T1$ when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with $T2$
carcinogenesis
DEN
0
$T1$ when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the $T2$
carcinogenesis
precancerous lesions
0
$T1$ incidence decreased as compared with the results obtained by DEN alone.It is concluded that PB, which promotes $T2$
tumor
carcinogenesis
0
$T1$.This 'anti-carcinogen' effect acts on the initiation as well as on the promotion of the precancerous lesions.
DEN
PB
0
$T1$.Biochemical investigations are in progress to obtain more information about this 'paradoxical' $T2$
precancerous lesions
PB
0
$T1$ incidence decreased as compared with the results obtained by DEN alone.It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.
tumor
PB
0
$T1$ incidence decreased as compared with the results obtained by DEN alone.It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with $T2$
tumor
DEN
0
$T1$ incidence decreased as compared with the results obtained by DEN alone.It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.
tumor
precancerous lesions
0
$T1$ leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of $T2$
rigidity
fentanyl
1
$T1$ leading to $T2$
rigidity
respiratory failure
0
$T1$ leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.This was successfully reversed by $T2$
rigidity
naloxone
0
$T1$ is described in the post-operative period in an elderly patient who received a moderate dose of $T2$
respiratory failure
fentanyl
0
$T1$.This was successfully reversed by $T2$
fentanyl
naloxone
0
$T1$ is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.This was successfully reversed by $T2$
respiratory failure
naloxone
0
$T1$ may cause $T2$
bromocriptine
psychosis
1
$T1$ history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
psychiatric
psychosis
0
$T1$.Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
inhibition of lactation
psychosis
0
$T1$.These cases demonstrate that bromocriptine may cause $T2$
Parkinson's disease
psychosis
0
$T1$ history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
psychiatric
bromocriptine
0
$T1$.Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
inhibition of lactation
bromocriptine
0
$T1$.These cases demonstrate that $T2$
Parkinson's disease
bromocriptine
0
$T1$ history were seen with postpartum psychosis, having received bromocriptine for $T2$
psychiatric
inhibition of lactation
0
$T1$ history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for $T2$
psychiatric
Parkinson's disease
0
$T1$.Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for $T2$
inhibition of lactation
Parkinson's disease
0
$T1$ was predicted by a drop in EF determined during a cold pressor test.None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.
cardiac failure
MMC
1
$T1$ was predicted by a drop in EF determined during a cold pressor test.None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.
cardiac failure
doxorubicin
1
$T1$-related $T2$
MMC
cardiotoxicity
0
$T1$ is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with $T2$
cardiotoxicity
doxorubicin
0
$T1$ was predicted by a drop in EF determined during a cold pressor test.None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.
cardiac failure
cardiotoxicity
0
$T1$-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with $T2$
MMC
doxorubicin
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
DM
1
$T1$-$T2$
gentamicin
ARF
1
$T1$ (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
glycosuria
P
0
$T1$-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).These values were not different from those of Group III: maximal decrease in CCr 73% ($T2$
gentamicin
P
0
$T1$ (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
renal dysfunction
P
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
P
0
$T1$ + gentamicin).Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
DM
P
0
$T1$ (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).These values were not different from those of Group III: maximal decrease in CCr 73% ($T2$
ARF
P
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
P
0
$T1$ less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; $T2$
P
tubular necrosis
0
$T1$ (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent $T2$
glycosuria
gentamicin
0
$T1$ (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of $T2$
glycosuria
renal dysfunction
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
glycosuria
0
$T1$ + gentamicin).Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
DM
glycosuria
0
$T1$ (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent gentamicin-$T2$
glycosuria
ARF
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
glycosuria
0
$T1$ (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
glycosuria
tubular necrosis
0
$T1$ (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent $T2$
renal dysfunction
gentamicin
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
gentamicin
0
$T1$ + gentamicin).Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
DM
gentamicin
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
gentamicin
0
$T1$-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; $T2$
gentamicin
tubular necrosis
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
renal dysfunction
0
$T1$ + gentamicin).Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
DM
renal dysfunction
0
$T1$ (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent gentamicin-$T2$
renal dysfunction
ARF
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
renal dysfunction
0
$T1$ (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
renal dysfunction
tubular necrosis
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
ARF
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular $T2$
streptozotocin
glucose
0
$T1$-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
streptozotocin
tubular necrosis
0
$T1$ + gentamicin).Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
DM
ARF
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
DM
0
$T1$ + gentamicin).Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
DM
tubular necrosis
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
ARF
0
$T1$ (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; $T2$
ARF
tubular necrosis
0
$T1$ reabsorption with phlorizin (P).DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
glucose
tubular necrosis
0
$T1$-induced $T2$
levodopa
dyskinesias
1
$T1$ had no effect on levodopa-induced early morning of "off-period" segmental dystonia.These results fail to support the notion that $T2$
Tiapride
levodopa
0
$T1$ had no effect on levodopa-induced early morning of "off-period" segmental dystonia.These results fail to support the notion that levodopa-induced $T2$
Tiapride
dyskinesias
0
$T1$ derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
benzamide
Tiapride
0
$T1$, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
metoclopramide
Tiapride
0
$T1$ with aggravation of end-of-dose akinesia led to its cessation in 14 patients.$T2$
Parkinsonism
Tiapride
0
$T1$ had no effect on levodopa-induced early morning of "off-period" segmental $T2$
Tiapride
dystonia
0
$T1$ had no effect on levodopa-induced early morning of "off-period" segmental dystonia.These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of $T2$
Tiapride
dopamine
0
$T1$ derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
benzamide
levodopa
0
$T1$, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
metoclopramide
levodopa
0
$T1$ with aggravation of end-of-dose akinesia led to its cessation in 14 patients.Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia.
Parkinsonism
levodopa
0
$T1$.These results fail to support the notion that $T2$
dystonia
levodopa
0
$T1$-induced dyskinesias are caused by overstimulation of a separate group of $T2$
levodopa
dopamine
0
$T1$ derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
benzamide
dyskinesias
0
$T1$, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
metoclopramide
dyskinesias
0
$T1$ with aggravation of end-of-dose akinesia led to its cessation in 14 patients.Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia.
Parkinsonism
dyskinesias
0
$T1$.These results fail to support the notion that levodopa-induced $T2$
dystonia
dyskinesias
0
$T1$ are caused by overstimulation of a separate group of $T2$
dyskinesias
dopamine
0
$T1$ derivative closely related to $T2$
benzamide
metoclopramide
0
$T1$ derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from $T2$
benzamide
Parkinsonism
0
$T1$ derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
benzamide
dystonia
0
$T1$ derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
benzamide
dopamine
0
$T1$, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from $T2$
metoclopramide
Parkinsonism
0
$T1$, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
metoclopramide
dystonia
0
$T1$, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.
metoclopramide
dopamine
0
$T1$ with aggravation of end-of-dose akinesia led to its cessation in 14 patients.Tiapride had no effect on levodopa-induced early morning of "off-period" segmental $T2$
Parkinsonism
dystonia
0
$T1$ with aggravation of end-of-dose akinesia led to its cessation in 14 patients.Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia.
Parkinsonism
dopamine
0
$T1$.These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of $T2$
dystonia
dopamine
0
$T1$ injection, and at 10th minutes following each stimulus for analysis in terms of frequency, amplitude, and power spectrum.RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.
penicillin-G
epilepsy
1
$T1$-induced cortical epileptic activity independent from stimulus intensity.In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.
penicillin
epilepsy
0
$T1$ injection, and at 10th minutes following each stimulus for analysis in terms of frequency, amplitude, and power spectrum.RESULTS: High frequency hippocampal DBS suppressed the acute $T2$
penicillin-G
penicillin
0
$T1$ like psychopathology.Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.
psychosis
Ketamine
1
$T1$ infusion while differences in BOLD responses measured with fMRI were detected.During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).
S-ketamine
psychosis
0
$T1$ infusion while differences in BOLD responses measured with fMRI were detected.During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).
S-ketamine
NMDA
0
$T1$ infusion while differences in BOLD responses measured with fMRI were detected.During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).
S-ketamine
schizophrenia
0
$T1$ infusion while differences in BOLD responses measured with fMRI were detected.During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).
S-ketamine
Ketamine
0
$T1$.In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic $T2$
glutamatergic dysfunction
S-ketamine
0
$T1$ like psychopathology.Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.
psychosis
NMDA
0
$T1$ like psychopathology.Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.
psychosis
schizophrenia
0
$T1$.In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.
glutamatergic dysfunction
psychosis
0
$T1$ receptor dysfunction in the pathophysiology of $T2$
NMDA
schizophrenia
0
$T1$ induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.Our results provide further support for the hypothesis of an $T2$
Ketamine
NMDA
0
$T1$.In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.
glutamatergic dysfunction
NMDA
0
$T1$ induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of $T2$
Ketamine
schizophrenia
0
$T1$.In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.
glutamatergic dysfunction
schizophrenia
0
$T1$.In a counterbalanced, placebo-controlled, double-blind study design, healthy subjects were administered a continuous subanesthetic S-ketamine infusion while differences in BOLD responses measured with fMRI were detected.
glutamatergic dysfunction
Ketamine
0
$T1$-induced dopaminergic $T2$
METH
neurotoxicity
1
$T1$-induced dopaminergic neurotoxicity and suggest that mechanisms independent of $T2$
METH
DA
0
$T1$ and suggest that mechanisms independent of $T2$
neurotoxicity
DA
0
$T1$.However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
toxicity
DA
0
$T1$ to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
L-dihydroxyphenylalanine
DA
0
$T1$ on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
alpha-methyl-para-tyrosine
DA
0
$T1$ that are of comparable magnitude on both sides of the brain.Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of $T2$
dopaminergic deficits
DA
0
$T1$.However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
toxicity
METH
0
$T1$ to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
L-dihydroxyphenylalanine
METH
0
$T1$ on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
alpha-methyl-para-tyrosine
METH
0
$T1$ that are of comparable magnitude on both sides of the brain.Taken together, these findings demonstrate that DA is not essential for the development of $T2$
dopaminergic deficits
METH
0
$T1$.However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
toxicity
neurotoxicity
0
$T1$ to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
L-dihydroxyphenylalanine
neurotoxicity
0
$T1$ on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
alpha-methyl-para-tyrosine
neurotoxicity
0
$T1$ that are of comparable magnitude on both sides of the brain.Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic $T2$
dopaminergic deficits
neurotoxicity
0
$T1$.However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
toxicity
L-dihydroxyphenylalanine
0
$T1$.However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
toxicity
alpha-methyl-para-tyrosine
0
$T1$.However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data.
toxicity
dopaminergic deficits
0
$T1$ to reverse the protective effect of $T2$
L-dihydroxyphenylalanine
alpha-methyl-para-tyrosine
0
$T1$ to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
L-dihydroxyphenylalanine
dopaminergic deficits
0
$T1$ on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
alpha-methyl-para-tyrosine
dopaminergic deficits
0
$T1$.Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.
cocaine
multiple cranial-nerve involvement
1
$T1$.Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.
cocaine
brainstem dysgenesis
0
$T1$, born to a $T2$
brainstem dysgenesis
cocaine-addicted
0
$T1$.We report on an infant with multiple cranial-nerve involvement attributable to $T2$
fetal anomalies
brainstem dysgenesis
0
$T1$ attributable to $T2$
multiple cranial-nerve involvement
brainstem dysgenesis
0
$T1$.Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.
cocaine
cocaine-addicted
0
$T1$.Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.
cocaine
fetal anomalies
0
$T1$.We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a $T2$
fetal anomalies
cocaine-addicted
0
$T1$ attributable to brainstem dysgenesis, born to a $T2$
multiple cranial-nerve involvement
cocaine-addicted
0
$T1$.We report on an infant with $T2$
fetal anomalies
multiple cranial-nerve involvement
0
$T1$-induced renal damage.This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.
streptozotocin
diabetic nephropathy
1
$T1$, which is accompanied by the production of reactive oxygen species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
renal failure
streptozotocin
0
$T1$ species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
oxygen
streptozotocin
0
$T1$-induced renal damage.This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and $T2$
streptozotocin
renal injury
0
$T1$-induced renal damage.This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.
streptozotocin
glucose
0
$T1$, which is accompanied by the production of reactive oxygen species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
renal failure
diabetic nephropathy
0
$T1$ species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
oxygen
diabetic nephropathy
0
$T1$ compared with Nrf2(+/+) mice.Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.
renal injury
diabetic nephropathy
0
$T1$ induced ROS production and activated expression of Nrf2 and its downstream genes.Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.
glucose
diabetic nephropathy
0
$T1$, which is accompanied by the production of reactive $T2$
renal failure
oxygen
0
$T1$, which is accompanied by the production of reactive oxygen species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
renal failure
renal injury
0
$T1$, which is accompanied by the production of reactive oxygen species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
renal failure
glucose
0
$T1$ species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
oxygen
renal injury
0
$T1$ species (ROS).Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.
oxygen
glucose
0
$T1$ compared with Nrf2(+/+) mice.Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.
renal injury
glucose
0
$T1$ in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical $T2$
TXA
seizures
1
$T1$ in 3 patients.All patients with seizures did not have permanent neurological abnormalities.
ischemic brain injury
TXA
0
$T1$.All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
neurological abnormalities
TXA
0
$T1$, metabolic, or hyperthermia-induced causes for their seizures was apparent.CONCLUSION: Our results suggest that use of high-dose $T2$
brain ischemic
TXA
0
$T1$-induced causes for their seizures was apparent.CONCLUSION: Our results suggest that use of high-dose $T2$
hyperthermia
TXA
0
$T1$ in 3 patients.All patients with seizures did not have permanent neurological abnormalities.
ischemic brain injury
seizures
0
$T1$.All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
neurological abnormalities
seizures
0
$T1$, metabolic, or hyperthermia-induced causes for their seizures was apparent.CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical $T2$
brain ischemic
seizures
0
$T1$-induced causes for their seizures was apparent.CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical $T2$
hyperthermia
seizures
0
$T1$ in 3 patients.All patients with seizures did not have permanent $T2$
ischemic brain injury
neurological abnormalities
0
$T1$ in 3 patients.All patients with seizures did not have permanent neurological abnormalities.
ischemic brain injury
brain ischemic
0
$T1$ in 3 patients.All patients with seizures did not have permanent neurological abnormalities.
ischemic brain injury
hyperthermia
0
$T1$.All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
neurological abnormalities
brain ischemic
0
$T1$.All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
neurological abnormalities
hyperthermia
0
$T1$, metabolic, or $T2$
brain ischemic
hyperthermia
0
$T1$ disappeared completely after $T2$
Dysosmia
pyrazinamide
1
$T1$, hyperuricemia or digestive disorders.In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.
hepatic toxicity
Dysosmia
0
$T1$ or digestive disorders.In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.
hyperuricemia
Dysosmia
0
$T1$, hyperuricemia or digestive disorders.In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.
hepatic toxicity
pyrazinamide
0
$T1$ or digestive disorders.In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.
hyperuricemia
pyrazinamide
0
$T1$, $T2$
hepatic toxicity
hyperuricemia
0
$T1$ compared with the placebo group.The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).
hearing loss
sulindac
1
$T1$ plus $T2$
DFMO
sulindac
0
$T1$.A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
colorectal adenomas
DFMO
0
$T1$ after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.
adenomatous polyps
DFMO
0
$T1$ compared with the placebo group.The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).
hearing loss
DFMO
0
$T1$ of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.
toxicity
DFMO
0
$T1$ from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).There is a <2 dB difference in mean threshold for patients treated with $T2$
ototoxicity
DFMO
0
$T1$.A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
colorectal adenomas
sulindac
0
$T1$ after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.
adenomatous polyps
sulindac
0
$T1$ of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.
toxicity
sulindac
0
$T1$ from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).There is a <2 dB difference in mean threshold for patients treated with DFMO plus $T2$
ototoxicity
sulindac
0
$T1$.A phase III clinical trial assessed the recurrence of $T2$
colorectal adenomas
adenomatous polyps
0
$T1$.A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
colorectal adenomas
hearing loss
0
$T1$.A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
colorectal adenomas
toxicity
0
$T1$.A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
colorectal adenomas
ototoxicity
0
$T1$ after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.
adenomatous polyps
hearing loss
0
$T1$ after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.Temporary hearing loss is a known $T2$
adenomatous polyps
toxicity
0
$T1$ after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.
adenomatous polyps
ototoxicity
0
$T1$ of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.
toxicity
hearing loss
0
$T1$ compared with the placebo group.The estimated attributable risk of $T2$
hearing loss
ototoxicity
0
$T1$ of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.
toxicity
ototoxicity
0
$T1$ after $T2$
mental slowing
trihexyphenidyl
1
$T1$ and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.METHODS: This study comprised 24 cognitively intact, health elderly adults (12 APOE epsilon4 carriers) at an outpatient geriatric psychiatry research clinic.
confusion
mental slowing
0
$T1$ and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.METHODS: This study comprised 24 cognitively intact, health elderly adults (12 APOE epsilon4 carriers) at an outpatient geriatric psychiatry research clinic.
confusion
trihexyphenidyl
0
$T1$+PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit $T2$
T
aggressive behavior
1
$T1$ (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
steroid
5-HT
0
$T1$ (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
steroid
PCPA
0
$T1$ (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
steroid
T
0
$T1$ (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
steroid
aggressive behavior
0
$T1$ (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.
steroid
5-HIAA
0
$T1$ was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.Based on these data, it can be speculated that pubertal AAS users with low central $T2$
PCPA
5-HT
0
$T1$+PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.Based on these data, it can be speculated that pubertal AAS users with low central $T2$
T
5-HT
0
$T1$ may be especially prone to exhibit $T2$
5-HT
aggressive behavior
0
$T1$ in certain brain areas, but to a much lesser extent than PCPA.Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
5-HIAA
5-HT
0
$T1$+$T2$
T
PCPA
0
$T1$ was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.Based on these data, it can be speculated that pubertal AAS users with low central 5-HT may be especially prone to exhibit $T2$
PCPA
aggressive behavior
0
$T1$ in certain brain areas, but to a much lesser extent than PCPA.Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
5-HIAA
PCPA
0
$T1$ in certain brain areas, but to a much lesser extent than PCPA.Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
5-HIAA
T
0
$T1$ in certain brain areas, but to a much lesser extent than PCPA.Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
5-HIAA
aggressive behavior
0
$T1$.In the latter group, $T2$
paclitaxel
brain edema
1
$T1$ cubic phases in different dosages.Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg $T2$
carboplatin
paclitaxel
0
$T1$.In the latter group, brain edema was markedly reduced and dealt medically.
paclitaxel
glioblastoma
0
$T1$ have a poor prognosis in spite of surgery and radiation therapy.Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.
brain tumors
paclitaxel
0
$T1$ cubic phases in different dosages.Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.
carboplatin
glioblastoma
0
$T1$ have a poor prognosis in spite of surgery and radiation therapy.Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.
brain tumors
carboplatin
0
$T1$ cubic phases in different dosages.Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.
carboplatin
brain edema
0
$T1$ have a poor prognosis in spite of surgery and radiation therapy.Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.
brain tumors
glioblastoma
0
$T1$ was markedly reduced and dealt medically.Intracavitary chemotherapy in recurrent $T2$
brain edema
glioblastoma
0
$T1$ have a poor prognosis in spite of surgery and radiation therapy.Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.
brain tumors
brain edema
0
$T1$.It appears that $T2$
obsessive-compulsive disorder
methylphenidate
1
$T1$ and early Alzheimer's disease was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
treatment-resistant depression
methylphenidate
0
$T1$ was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
Alzheimer's disease
methylphenidate
0
$T1$.The patient had no prior psychiatric history, but he had a sister with obsessive-compulsive disorder.
fluvoxamine
methylphenidate
0
$T1$ history, but he had a sister with obsessive-compulsive disorder.It appears that $T2$
psychiatric
methylphenidate
0
$T1$ and early Alzheimer's disease was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
treatment-resistant depression
obsessive-compulsive disorder
0
$T1$ was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
Alzheimer's disease
obsessive-compulsive disorder
0
$T1$.The patient had no prior psychiatric history, but he had a sister with $T2$
fluvoxamine
obsessive-compulsive disorder
0
$T1$ history, but he had a sister with $T2$
psychiatric
obsessive-compulsive disorder
0
$T1$ and early $T2$
treatment-resistant depression
Alzheimer's disease
0
$T1$ and early Alzheimer's disease was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by $T2$
treatment-resistant depression
fluvoxamine
0
$T1$ and early Alzheimer's disease was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
treatment-resistant depression
psychiatric
0
$T1$ was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by $T2$
Alzheimer's disease
fluvoxamine
0
$T1$ was started on methylphenidate.Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
Alzheimer's disease
psychiatric
0
$T1$.The patient had no prior $T2$
fluvoxamine
psychiatric
0
$T1$ caused by $T2$
cardiac arrest
metoclopramide
1
$T1$ 0.5-1 mg and chest compressions, before sinus rhythm again took over.We interpret this as episodes of $T2$
atropine
cardiac arrest
0
$T1$ caused by metoclopramide.The rapid injection via the central venous route and the concomitant tapering of $T2$
cardiac arrest
dopamine
0
$T1$ 0.5-1 mg and chest compressions, before sinus rhythm again took over.We interpret this as episodes of cardiac arrest caused by $T2$
atropine
metoclopramide
0
$T1$.The rapid injection via the central venous route and the concomitant tapering of $T2$
metoclopramide
dopamine
0
$T1$ 0.5-1 mg and chest compressions, before sinus rhythm again took over.We interpret this as episodes of cardiac arrest caused by metoclopramide.
atropine
dopamine
0
$T1$ prophylactically for obstetric and gynecologic procedures.Eight of these cases of severe immune $T2$
cefotetan
hemolytic anemia
1
$T1$, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.
cephalosporins
hemolytic anemia
0
$T1$, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received $T2$
cephalosporins
cefotetan
0
$T1$ with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.
cauda equina syndrome
lignocaine
1
$T1$ with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.
cauda equina syndrome
neurotoxicity
0
$T1$ with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.
cauda equina syndrome
neurological deficits
0
$T1$ was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.All cases sustained permanent neurological deficits.
neurotoxicity
lignocaine
0
$T1$.We recommend that hyperbaric $T2$
neurological deficits
lignocaine
0
$T1$ was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.All cases sustained permanent $T2$
neurotoxicity
neurological deficits
0
$T1$-induced peak dose $T2$
L-dopa
dyskinesia
1
$T1$ patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like $T2$
parkinsonian
L-dopa
0
$T1$ patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose $T2$
parkinsonian
dyskinesia
0
$T1$ patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.These results are compatible with the hypothesis that an $T2$
parkinsonian
hyperkinetic
0
$T1$ abnormal involuntary movement, like $T2$
hyperkinetic
L-dopa
0
$T1$ abnormal involuntary movement, like L-dopa-induced peak dose $T2$
hyperkinetic
dyskinesia
0
$T1$ in approximately 30% of the $T2$
ocular hypertension
dexamethasone
1
$T1$-treated eyes.Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
dexamethasone
steroid glaucoma
0
$T1$-treated eyes.$T2$
dexamethasone
Steroid
0
$T1$-treated eyes.Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
dexamethasone
primary open angle glaucoma
0
$T1$ in approximately 30% of the dexamethasone-treated eyes.Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
ocular hypertension
steroid glaucoma
0
$T1$ in approximately 30% of the dexamethasone-treated eyes.$T2$
ocular hypertension
Steroid
0
$T1$ in approximately 30% of the dexamethasone-treated eyes.Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
ocular hypertension
primary open angle glaucoma
0
$T1$ treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.This system may provide an acute model in which to study the pathogenic mechanisms involved in $T2$
Steroid
steroid glaucoma
0
$T1$ and $T2$
steroid glaucoma
primary open angle glaucoma
0
$T1$ treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and $T2$
Steroid
primary open angle glaucoma
0
$T1$ resulting from prolonged use of $T2$
cognitive deterioration
DM
1
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
cognitive deterioration
0
$T1$, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
nausea
cognitive deterioration
0
$T1$, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
restlessness
cognitive deterioration
0
$T1$, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
insomnia
cognitive deterioration
0
$T1$, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
ataxia
cognitive deterioration
0
$T1$ to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
nystagmus
cognitive deterioration
0
$T1$ (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
aggressive behavior
cognitive deterioration
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
DM
0
$T1$, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
nausea
DM
0
$T1$, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
restlessness
DM
0
$T1$, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
insomnia
DM
0
$T1$, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
ataxia
DM
0
$T1$ to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
nystagmus
DM
0
$T1$ (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).There have also been two reported fatalities from DM overdoses (Fleming 1986).
aggressive behavior
DM
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
nausea
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
restlessness
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
insomnia
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
ataxia
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
nystagmus
0
$T1$, is the main ingredient in a number of widely available, over-the-counter antitussives.Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.
3-hydroxy-N-methylmorphinan
aggressive behavior
0
$T1$, $T2$
nausea
restlessness
0
$T1$, restlessness, $T2$
nausea
insomnia
0
$T1$, restlessness, insomnia, $T2$
nausea
ataxia
0
$T1$, restlessness, insomnia, ataxia, slurred speech and $T2$
nausea
nystagmus
0
$T1$, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and $T2$
nausea
aggressive behavior
0
$T1$, $T2$
restlessness
insomnia
0
$T1$, insomnia, $T2$
restlessness
ataxia
0
$T1$, insomnia, ataxia, slurred speech and $T2$
restlessness
nystagmus
0
$T1$, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and $T2$
restlessness
aggressive behavior
0
$T1$, $T2$
insomnia
ataxia
0
$T1$, ataxia, slurred speech and $T2$
insomnia
nystagmus
0
$T1$, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and $T2$
insomnia
aggressive behavior
0
$T1$, slurred speech and $T2$
ataxia
nystagmus
0
$T1$, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and $T2$
ataxia
aggressive behavior
0
$T1$ to mood changes, perceptual alterations, inattention, disorientation and $T2$
nystagmus
aggressive behavior
0
$T1$ values.Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients.
lithium
Polyuria
1
$T1$ clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.These findings have been compared with norms and with values of the same tests from screening prior to lithium, available for most of our patients.
Creatinine
lithium
0
$T1$ clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.These findings have been compared with norms and with values of the same tests from screening prior to lithium, available for most of our patients.
Creatinine
Polyuria
0
$T1$.The case illustrates that, despite the results of earlier studies, $T2$
heart block
trazodone
1
$T1$ may be responsible for fulminant $T2$
phenylethylbarbiturate
hepatitis
1
$T1$ itself or $T2$
Quinidine
phenylethylbarbiturate
0
$T1$ itself or phenylethylbarbiturate may be responsible for fulminant $T2$
Quinidine
hepatitis
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
suprofen
1
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
hay fever
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
asthma
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
alcohol
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
ibuprofen
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
renal disease
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
kidney stones
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
gout
0
$T1$ syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States.Through August 1986, a total of 163 cases of this syndrome were reported.
flank pain
uric acid
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from $T2$
suprofen
hay fever
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and $T2$
suprofen
asthma
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use $T2$
suprofen
alcohol
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
suprofen
ibuprofen
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
suprofen
renal disease
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
suprofen
kidney stones
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
suprofen
gout
0
$T1$-exposed control subjects who did not have the syndrome.Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
suprofen
uric acid
0
$T1$ and $T2$
hay fever
asthma
0
$T1$ and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use $T2$
hay fever
alcohol
0
$T1$ and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially $T2$
hay fever
ibuprofen
0
$T1$ and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting $T2$
hay fever
renal disease
0
$T1$ and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of $T2$
hay fever
kidney stones
0
$T1$ and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of $T2$
hay fever
gout
0
$T1$ and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
hay fever
uric acid
0
$T1$ (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use $T2$
asthma
alcohol
0
$T1$ (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially $T2$
asthma
ibuprofen
0
$T1$ (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting $T2$
asthma
renal disease
0
$T1$ (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of $T2$
asthma
kidney stones
0
$T1$ (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of $T2$
asthma
gout
0
$T1$ (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
asthma
uric acid
0
$T1$ (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially $T2$
alcohol
ibuprofen
0
$T1$ (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting $T2$
alcohol
renal disease
0
$T1$ (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of $T2$
alcohol
kidney stones
0
$T1$ (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of $T2$
alcohol
gout
0
$T1$ (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
alcohol
uric acid
0
$T1$), preexisting $T2$
ibuprofen
renal disease
0
$T1$), preexisting renal disease, a history of $T2$
ibuprofen
kidney stones
0
$T1$), preexisting renal disease, a history of kidney stones, a history of $T2$
ibuprofen
gout
0
$T1$), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.These were findings that were suggestive but did not reach conventional statistical significance.
ibuprofen
uric acid
0
$T1$, a history of $T2$
renal disease
kidney stones
0
$T1$, a history of kidney stones, a history of $T2$
renal disease
gout
0
$T1$, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.These were findings that were suggestive but did not reach conventional statistical significance.
renal disease
uric acid
0
$T1$, a history of $T2$
kidney stones
gout
0
$T1$, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.These were findings that were suggestive but did not reach conventional statistical significance.
kidney stones
uric acid
0
$T1$, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.These were findings that were suggestive but did not reach conventional statistical significance.
gout
uric acid
0
$T1$ probably occurs more often than is recognized.It is important to recognize this reaction when it occurs and to avoid further $T2$
hemolytic-uremic syndrome
quinine
1
$T1$, aspirin, and dipyridamole.The patients have all regained some degree of renal function.
prednisone
hemolytic-uremic syndrome
0
$T1$, and dipyridamole.The patients have all regained some degree of renal function.
aspirin
hemolytic-uremic syndrome
0
$T1$.The patients have all regained some degree of renal function.
dipyridamole
hemolytic-uremic syndrome
0
$T1$, aspirin, and dipyridamole.The patients have all regained some degree of renal function.
prednisone
quinine
0
$T1$, and dipyridamole.The patients have all regained some degree of renal function.
aspirin
quinine
0
$T1$.The patients have all regained some degree of renal function.
dipyridamole
quinine
0
$T1$, $T2$
prednisone
aspirin
0
$T1$, aspirin, and $T2$
prednisone
dipyridamole
0
$T1$, and $T2$
aspirin
dipyridamole
0
$T1$ therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.The rate of resolution of the radiographic findings may be helpful in distinguishing between true $T2$
heparin
pyeloureteritis cystica
1
$T1$ in this patient.The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.
infection
pyeloureteritis cystica
0
$T1$.A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.
inflammation
pyeloureteritis cystica
0
$T1$ and cleared rapidly subsequent to its discontinuation.The rate of resolution of the radiographic findings may be helpful in distinguishing between true $T2$
thrombophlebitis
pyeloureteritis cystica
0
$T1$ and $T2$
pyeloureteritis cystica
submucosal hemorrhage
0
$T1$.A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.
inflammation
infection
0
$T1$ in this patient.The disease occurred subsequent to the initiation of $T2$
infection
heparin
0
$T1$ in this patient.The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic $T2$
infection
thrombophlebitis
0
$T1$ in this patient.The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.
infection
submucosal hemorrhage
0
$T1$.A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.
inflammation
heparin
0
$T1$.A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.
inflammation
thrombophlebitis
0
$T1$.A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.
inflammation
submucosal hemorrhage
0
$T1$ therapy for suspected pelvic $T2$
heparin
thrombophlebitis
0
$T1$ therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and $T2$
heparin
submucosal hemorrhage
0
$T1$ and cleared rapidly subsequent to its discontinuation.The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and $T2$
thrombophlebitis
submucosal hemorrhage
0
$T1$ were examined histochemically and electron microscopically.Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
alpha-benzene hexachloride
hepatomas
1
$T1$ induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
liver lesions
hepatomas
0
$T1$ cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.At the 16th week of carcinogen feeding, hyperplastic nodules appeared and advanced to further stages.
tumor
hepatomas
0
$T1$ appeared to have been formed.No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by $T2$
hepatomas
ethyl-alpha-p-chlorophenoxyisobutyrate
0
$T1$ induced in mice by 500 ppm $T2$
liver lesions
alpha-benzene hexachloride
0
$T1$ were examined histochemically and electron microscopically.Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the $T2$
alpha-benzene hexachloride
tumor
0
$T1$ were examined histochemically and electron microscopically.Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
alpha-benzene hexachloride
ethyl-alpha-p-chlorophenoxyisobutyrate
0
$T1$ induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the $T2$
liver lesions
tumor
0
$T1$ induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
liver lesions
ethyl-alpha-p-chlorophenoxyisobutyrate
0
$T1$ cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.At the 16th week of carcinogen feeding, hyperplastic nodules appeared and advanced to further stages.
tumor
ethyl-alpha-p-chlorophenoxyisobutyrate
0
$T1$ hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.This report also suggests that, even after long-term administration, the $T2$
quinidine
hepatic toxicity
1
$T1$ dehydrogenase values.We concluded that this patient had $T2$
lactic acid
quinidine
0
$T1$ dehydrogenase values.We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.
lactic acid
hepatic toxicity
0
$T1$, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
CCl4
hepatotoxicity
1
$T1$, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
CHCl3
hepatotoxicity
1
$T1$ and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
acetaminophen
hepatotoxicity
1
$T1$ $T2$
galactosamine
hepatotoxicity
1
$T1$) effect of $T2$
cardiotoxic
adriamycin
1
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
acetaminophen
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
adriamycin
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
CCl4
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
CHCl3
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
galactosamine
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
CS
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
hepatotoxicity
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, $T2$
cholesteryl hemisuccinate
gamma-cholesteryloxybutyric acid
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced $T2$
cholesteryl hemisuccinate
toxicity
0
$T1$, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.
cholesteryl hemisuccinate
cardiotoxic
0
$T1$ and galactosamine and against the lethal (and presumably cardiotoxic) effect of $T2$
acetaminophen
adriamycin
0
$T1$, CHCl3, $T2$
CCl4
acetaminophen
0
$T1$, $T2$
CHCl3
acetaminophen
0
$T1$ and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
acetaminophen
galactosamine
0
$T1$ and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
acetaminophen
CS
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
acetaminophen
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
acetaminophen
0
$T1$ and galactosamine and against the lethal (and presumably $T2$
acetaminophen
cardiotoxic
0
$T1$, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of $T2$
CCl4
adriamycin
0
$T1$, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of $T2$
CHCl3
adriamycin
0
$T1$ administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
adriamycin
galactosamine
0
$T1$ administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
adriamycin
CS
0
$T1$ administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
adriamycin
hepatotoxicity
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
adriamycin
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
adriamycin
0
$T1$, $T2$
CCl4
CHCl3
0
$T1$, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
CCl4
galactosamine
0
$T1$, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
CCl4
CS
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
CCl4
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
CCl4
0
$T1$, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably $T2$
CCl4
cardiotoxic
0
$T1$, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
CHCl3
galactosamine
0
$T1$, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
CHCl3
CS
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
CHCl3
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
CHCl3
0
$T1$, acetaminophen and galactosamine and against the lethal (and presumably $T2$
CHCl3
cardiotoxic
0
$T1$ hepatotoxicity).However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.
galactosamine
CS
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
galactosamine
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
galactosamine
0
$T1$) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
cardiotoxic
galactosamine
0
$T1$).However, based on the data presented, we can not exclude the possibility that CS administration inhibits chemical bioactivation.
hepatotoxicity
CS
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
CS
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
CS
0
$T1$) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
cardiotoxic
CS
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
hepatotoxicity
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
hepatotoxicity
0
$T1$) effect of adriamycin administration.Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.
cardiotoxic
hepatotoxicity
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced $T2$
gamma-cholesteryloxybutyric acid
toxicity
0
$T1$, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
gamma-cholesteryloxybutyric acid
cardiotoxic
0
$T1$.The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.
toxicity
cardiotoxic
0
$T1$ as well as neuropathy.The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and $T2$
hematological and gastrointestinal toxicities
dexamethasone
1
$T1$ as well as neuropathy.The results suggest that bortezomib in combination with $T2$
hematological and gastrointestinal toxicities
cyclophosphamide
1
$T1$.The results suggest that $T2$
neuropathy
bortezomib
1
$T1$ as well as neuropathy.The results suggest that $T2$
hematological and gastrointestinal toxicities
bortezomib
1
$T1$.The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and $T2$
neuropathy
dexamethasone
1
$T1$.The results suggest that bortezomib in combination with $T2$
neuropathy
cyclophosphamide
1
$T1$ in combination with $T2$
bortezomib
cyclophosphamide
0
$T1$ at 900 mg/m(2) and $T2$
cyclophosphamide
dexamethasone
0
$T1$ at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed $T2$
cyclophosphamide
MM
0
$T1$ in combination with cyclophosphamide at 900 mg/m(2) and $T2$
bortezomib
dexamethasone
0
$T1$ in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed $T2$
bortezomib
MM
0
$T1$ is an effective induction treatment for patients with newly diagnosed $T2$
dexamethasone
MM
0
$T1$ as well as neuropathy.The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed $T2$
hematological and gastrointestinal toxicities
MM
0
$T1$.The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed $T2$
neuropathy
MM
0
$T1$ as well as $T2$
hematological and gastrointestinal toxicities
neuropathy
0
$T1$ 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
amlodipine
headache
1
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
telmisartan
dizziness
1
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
telmisartan
headache
1
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
telmisartan
diarrhea
1
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
telmisartan
edema
1
$T1$ 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
amlodipine
diarrhea
1
$T1$ 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
amlodipine
edema
1
$T1$ 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
amlodipine
cough
1
$T1$ 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
amlodipine
dizziness
1
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
telmisartan
cough
1
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with $T2$
telmisartan
amlodipine
0
$T1$ 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
telmisartan
hypertension
0
$T1$ 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.
amlodipine
hypertension
0
$T1$ was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of headache, dizziness, and diarrhea were similar between the 2 groups.
edema
hypertension
0
$T1$ was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of headache, dizziness, and diarrhea were similar between the 2 groups.
cough
hypertension
0
$T1$, dizziness, and diarrhea were similar between the 2 groups.CONCLUSIONS: Among these Indian patients with stage II $T2$
headache
hypertension
0
$T1$, and diarrhea were similar between the 2 groups.CONCLUSIONS: Among these Indian patients with stage II $T2$
dizziness
hypertension
0
$T1$ were similar between the 2 groups.CONCLUSIONS: Among these Indian patients with stage II $T2$
diarrhea
hypertension
0
$T1$ was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and $T2$
edema
cough
0
$T1$ was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of $T2$
edema
headache
0
$T1$ was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of headache, $T2$
edema
dizziness
0
$T1$ was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of headache, dizziness, and $T2$
edema
diarrhea
0
$T1$ was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of $T2$
cough
headache
0
$T1$ was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of headache, $T2$
cough
dizziness
0
$T1$ was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.The incidences of headache, dizziness, and $T2$
cough
diarrhea
0
$T1$, $T2$
headache
dizziness
0
$T1$, dizziness, and $T2$
headache
diarrhea
0
$T1$, and $T2$
dizziness
diarrhea
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
corticosteroids
1
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
Oxacillin
1
$T1$ should be included among the drugs that can cause $T2$
Oxacillin
leucocytoclastic vasculitis
1
$T1$ in severe cases can prevent complications.Oxacillin should be included among the drugs that can cause $T2$
corticosteroids
leucocytoclastic vasculitis
1
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
leucocytoclastic vasculitis
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
leucocytoclastic vasculitis
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
purpura
leucocytoclastic vasculitis
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
leucocytoclastic vasculitis
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.
rash
leucocytoclastic vasculitis
0
$T1$, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
abdominal pain
leucocytoclastic vasculitis
0
$T1$, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
arthralgia
leucocytoclastic vasculitis
0
$T1$.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
renal involvement
leucocytoclastic vasculitis
0
$T1$, medications, collagen vascular disease and neoplasia.However, in half of the cases no etiologic factor is identified.
infections
leucocytoclastic vasculitis
0
$T1$ and neoplasia.However, in half of the cases no etiologic factor is identified.
collagen vascular disease
leucocytoclastic vasculitis
0
$T1$.However, in half of the cases no etiologic factor is identified.
neoplasia
leucocytoclastic vasculitis
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
Oxacillin
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
purpura
Oxacillin
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
Oxacillin
0
$T1$ in severe cases can prevent complications.$T2$
corticosteroids
Oxacillin
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.
rash
Oxacillin
0
$T1$, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
abdominal pain
Oxacillin
0
$T1$, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
arthralgia
Oxacillin
0
$T1$.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
renal involvement
Oxacillin
0
$T1$, medications, collagen vascular disease and neoplasia.However, in half of the cases no etiologic factor is identified.
infections
Oxacillin
0
$T1$ and neoplasia.However, in half of the cases no etiologic factor is identified.
collagen vascular disease
Oxacillin
0
$T1$.However, in half of the cases no etiologic factor is identified.
neoplasia
Oxacillin
0
$T1$, developed $T2$
Staphylococcus aureus bacteremia
renal failure
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
purpura
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.$T2$
Staphylococcus aureus bacteremia
Necrotic blisters
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
corticosteroids
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
rash
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
abdominal pain
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
arthralgia
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
renal involvement
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
infections
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
collagen vascular disease
0
$T1$, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
Staphylococcus aureus bacteremia
neoplasia
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
purpura
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.$T2$
renal failure
Necrotic blisters
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
rash
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
abdominal pain
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
arthralgia
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
renal involvement
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
infections
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
collagen vascular disease
0
$T1$ and diffuse, symmetric, palpable purpuric lesions on his feet.Necrotic blisters were noted on his fingers.
renal failure
neoplasia
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
purpura
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
purpura
corticosteroids
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable $T2$
rash
purpura
0
$T1$ of the lower extremities often accompanied by $T2$
purpura
abdominal pain
0
$T1$ of the lower extremities often accompanied by abdominal pain, $T2$
purpura
arthralgia
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and $T2$
purpura
renal involvement
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.Etiologic factors or associated disorders include $T2$
purpura
infections
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, $T2$
purpura
collagen vascular disease
0
$T1$ of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and $T2$
purpura
neoplasia
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
corticosteroids
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
rash
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
abdominal pain
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
arthralgia
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
renal involvement
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
infections
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
collagen vascular disease
0
$T1$ were noted on his fingers.Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.
Necrotic blisters
neoplasia
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.
rash
corticosteroids
0
$T1$, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
abdominal pain
corticosteroids
0
$T1$, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
arthralgia
corticosteroids
0
$T1$.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.
renal involvement
corticosteroids
0
$T1$, medications, collagen vascular disease and neoplasia.However, in half of the cases no etiologic factor is identified.
infections
corticosteroids
0
$T1$ and neoplasia.However, in half of the cases no etiologic factor is identified.
collagen vascular disease
corticosteroids
0
$T1$.However, in half of the cases no etiologic factor is identified.
neoplasia
corticosteroids
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by $T2$
rash
abdominal pain
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, $T2$
rash
arthralgia
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and $T2$
rash
renal involvement
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.
rash
infections
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.
rash
collagen vascular disease
0
$T1$ disappeared after three weeks and renal function returned to normal.Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.
rash
neoplasia
0
$T1$, $T2$
abdominal pain
arthralgia
0
$T1$, arthralgia, and $T2$
abdominal pain
renal involvement
0
$T1$, arthralgia, and renal involvement.Etiologic factors or associated disorders include $T2$
abdominal pain
infections
0
$T1$, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, $T2$
abdominal pain
collagen vascular disease
0
$T1$, arthralgia, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and $T2$
abdominal pain
neoplasia
0
$T1$, and $T2$
arthralgia
renal involvement
0
$T1$, and renal involvement.Etiologic factors or associated disorders include $T2$
arthralgia
infections
0
$T1$, and renal involvement.Etiologic factors or associated disorders include infections, medications, $T2$
arthralgia
collagen vascular disease
0
$T1$, and renal involvement.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and $T2$
arthralgia
neoplasia
0
$T1$.Etiologic factors or associated disorders include $T2$
renal involvement
infections
0
$T1$.Etiologic factors or associated disorders include infections, medications, $T2$
renal involvement
collagen vascular disease
0
$T1$.Etiologic factors or associated disorders include infections, medications, collagen vascular disease and $T2$
renal involvement
neoplasia
0
$T1$, medications, $T2$
infections
collagen vascular disease
0
$T1$, medications, collagen vascular disease and $T2$
infections
neoplasia
0
$T1$ and $T2$
collagen vascular disease
neoplasia
0
$T1$ and respiratory depression, whereas morphine-induced bradycardia was less affected.Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to $T2$
hypotension
morphine
1
$T1$ at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
hypothermia
morphine
1
$T1$ and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
catalepsy
morphine
1
$T1$ was less affected.Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to $T2$
bradycardia
morphine
1
$T1$ significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to $T2$
naloxazone
morphine
0
$T1$, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, $T2$
analgesia
naloxazone
0
$T1$ and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, $T2$
catalepsy
naloxazone
0
$T1$ at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, $T2$
hypothermia
naloxazone
0
$T1$ significantly attenuated the morphine-induced $T2$
naloxazone
hypotension
0
$T1$ significantly attenuated the morphine-induced hypotension and $T2$
naloxazone
respiratory depression
0
$T1$ significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced $T2$
naloxazone
bradycardia
0
$T1$, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.
analgesia
morphine
0
$T1$, whereas morphine-induced bradycardia was less affected.Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to $T2$
respiratory depression
morphine
0
$T1$, $T2$
analgesia
catalepsy
0
$T1$, catalepsy and $T2$
analgesia
hypothermia
0
$T1$, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced $T2$
analgesia
hypotension
0
$T1$, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and $T2$
analgesia
respiratory depression
0
$T1$, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced $T2$
analgesia
bradycardia
0
$T1$ and $T2$
catalepsy
hypothermia
0
$T1$ and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced $T2$
catalepsy
hypotension
0
$T1$ and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and $T2$
catalepsy
respiratory depression
0
$T1$ and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced $T2$
catalepsy
bradycardia
0
$T1$ at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced $T2$
hypothermia
hypotension
0
$T1$ at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and $T2$
hypothermia
respiratory depression
0
$T1$ at a dose which completely eliminated high-affinity binding in brain membranes.Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced $T2$
hypothermia
bradycardia
0
$T1$ and $T2$
hypotension
respiratory depression
0
$T1$ and respiratory depression, whereas morphine-induced $T2$
hypotension
bradycardia
0
$T1$, whereas morphine-induced $T2$
respiratory depression
bradycardia
0
$T1$, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of $T2$
weight loss
daunorubicin
1
$T1$ clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
doxorubicin
hematologic toxicity
1
$T1$ is ongoing with the aim of improving efficacy without aggravating $T2$
etoposide
hematologic toxicity
1
$T1$ activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
daunorubicin
hematologic toxicity
1
$T1$, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
weight loss
etoposide
1
$T1$, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from $T2$
weight loss
doxorubicin
1
$T1$, weight loss, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
myelosuppression
dexrazoxane
0
$T1$ and high doses of $T2$
dexrazoxane
etoposide
0
$T1$ activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
daunorubicin
dexrazoxane
0
$T1$ clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
doxorubicin
dexrazoxane
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
dexrazoxane
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
dexrazoxane
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
dexrazoxane
0
$T1$ and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating $T2$
dexrazoxane
hematologic toxicity
0
$T1$, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
weight loss
dexrazoxane
0
$T1$ from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
cytotoxicity
dexrazoxane
0
$T1$ combining $T2$
metastases
dexrazoxane
0
$T1$, weight loss, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
myelosuppression
etoposide
0
$T1$, weight loss, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of $T2$
myelosuppression
daunorubicin
0
$T1$, weight loss, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from $T2$
myelosuppression
doxorubicin
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
myelosuppression
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
myelosuppression
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
myelosuppression
0
$T1$, weight loss, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
myelosuppression
hematologic toxicity
0
$T1$, $T2$
myelosuppression
weight loss
0
$T1$, weight loss, nor the in vitro $T2$
myelosuppression
cytotoxicity
0
$T1$, weight loss, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
myelosuppression
metastases
0
$T1$ activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
daunorubicin
etoposide
0
$T1$ clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
doxorubicin
etoposide
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
etoposide
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
etoposide
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
etoposide
0
$T1$ from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
cytotoxicity
etoposide
0
$T1$ combining dexrazoxane and high doses of $T2$
metastases
etoposide
0
$T1$ clinically, the potent antagonism of $T2$
doxorubicin
daunorubicin
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
daunorubicin
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
daunorubicin
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
daunorubicin
0
$T1$ from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of $T2$
cytotoxicity
daunorubicin
0
$T1$ activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
daunorubicin
metastases
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
doxorubicin
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
doxorubicin
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
doxorubicin
0
$T1$ from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from $T2$
cytotoxicity
doxorubicin
0
$T1$ clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.
doxorubicin
metastases
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against $T2$
epipodophyllotoxin
anthracycline
0
$T1$-induced $T2$
anthracycline
cardiotoxicity
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
hematologic toxicity
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
weight loss
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
cytotoxicity
0
$T1$-induced cardiotoxicity.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
anthracycline
metastases
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced $T2$
epipodophyllotoxin
cardiotoxicity
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
hematologic toxicity
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
weight loss
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
cytotoxicity
0
$T1$ etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.
epipodophyllotoxin
metastases
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
hematologic toxicity
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
weight loss
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
cytotoxicity
0
$T1$.EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
cardiotoxicity
metastases
0
$T1$, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
weight loss
hematologic toxicity
0
$T1$ from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
cytotoxicity
hematologic toxicity
0
$T1$ combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating $T2$
metastases
hematologic toxicity
0
$T1$, nor the in vitro $T2$
weight loss
cytotoxicity
0
$T1$, nor the in vitro cytotoxicity from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
weight loss
metastases
0
$T1$ from doxorubicin.CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.
cytotoxicity
metastases
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against $T2$
scopolamine
amnesia
1
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
impaired learning and memory
aniracetam
0
$T1$ were seen at oral aniracetam doses of 10-100 mg/kg.Generally, the dose-response curves were bell-shaped.
impaired cognitive functions
aniracetam
0
$T1$ applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
hypercapnia
aniracetam
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
scopolamine
aniracetam
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
amnesia
aniracetam
0
$T1$ or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
chloramphenicol
aniracetam
0
$T1$ injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
cycloheximide
aniracetam
0
$T1$, another pyrrolidinone derivative was used for comparison.It was active only in six of nine tests and had about one-tenth the potency of aniracetam.
Piracetam
aniracetam
0
$T1$ derivative was used for comparison.It was active only in six of nine tests and had about one-tenth the potency of aniracetam.
pyrrolidinone
aniracetam
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
impaired learning and memory
impaired cognitive functions
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or $T2$
impaired learning and memory
hypercapnia
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the $T2$
impaired learning and memory
scopolamine
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against $T2$
impaired learning and memory
amnesia
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by $T2$
impaired learning and memory
chloramphenicol
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by $T2$
impaired learning and memory
cycloheximide
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
impaired learning and memory
Piracetam
0
$T1$ in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).
impaired learning and memory
pyrrolidinone
0
$T1$ applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of $T2$
hypercapnia
impaired cognitive functions
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of $T2$
scopolamine
impaired cognitive functions
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of $T2$
amnesia
impaired cognitive functions
0
$T1$ or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of $T2$
chloramphenicol
impaired cognitive functions
0
$T1$ injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of $T2$
cycloheximide
impaired cognitive functions
0
$T1$ were seen at oral aniracetam doses of 10-100 mg/kg.Generally, the dose-response curves were bell-shaped.
impaired cognitive functions
Piracetam
0
$T1$ were seen at oral aniracetam doses of 10-100 mg/kg.Generally, the dose-response curves were bell-shaped.
impaired cognitive functions
pyrrolidinone
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or $T2$
scopolamine
hypercapnia
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or $T2$
amnesia
hypercapnia
0
$T1$ or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or $T2$
chloramphenicol
hypercapnia
0
$T1$ injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or $T2$
cycloheximide
hypercapnia
0
$T1$ applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
hypercapnia
Piracetam
0
$T1$ applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
hypercapnia
pyrrolidinone
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by $T2$
scopolamine
chloramphenicol
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by $T2$
scopolamine
cycloheximide
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
scopolamine
Piracetam
0
$T1$-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
scopolamine
pyrrolidinone
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by $T2$
amnesia
chloramphenicol
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by $T2$
amnesia
cycloheximide
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
amnesia
Piracetam
0
$T1$ for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
amnesia
pyrrolidinone
0
$T1$ or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by $T2$
chloramphenicol
cycloheximide
0
$T1$ or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
chloramphenicol
Piracetam
0
$T1$ or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
chloramphenicol
pyrrolidinone
0
$T1$ injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
cycloheximide
Piracetam
0
$T1$ injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
cycloheximide
pyrrolidinone
0
$T1$, another $T2$
Piracetam
pyrrolidinone
0
$T1$ can be elicited by opioid and cholinergic receptors, and the potentiation of $T2$
catalepsy
morphine
1
$T1$ can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by $T2$
catalepsy
nicotine
1
$T1$ induced by $T2$
morphine
nicotine
0
$T1$, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by $T2$
atropine
nicotine
0
$T1$ also decreased catalepsy induced by morphine plus nicotine.Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.
naloxone
nicotine
0
$T1$, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
mecamylamine
nicotine
0
$T1$, decreased the effect of a single dose of morphine.It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by $T2$
hexamethonium
nicotine
0
$T1$, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of $T2$
atropine
morphine
0
$T1$ also decreased catalepsy induced by morphine plus nicotine.Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.
naloxone
morphine
0
$T1$, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
mecamylamine
morphine
0
$T1$, decreased the effect of a single dose of morphine.It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of $T2$
hexamethonium
morphine
0
$T1$, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.It was concluded that morphine $T2$
atropine
catalepsy
0
$T1$ also decreased catalepsy induced by morphine plus nicotine.Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.
naloxone
catalepsy
0
$T1$, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
mecamylamine
catalepsy
0
$T1$, decreased the effect of a single dose of morphine.It was concluded that morphine $T2$
hexamethonium
catalepsy
0
$T1$ also decreased catalepsy induced by morphine plus nicotine.Intraperitoneal administration of $T2$
naloxone
atropine
0
$T1$, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
mecamylamine
atropine
0
$T1$, but not intraperitoneal or intracerebroventricular injection of $T2$
atropine
hexamethonium
0
$T1$, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.Intracerebroventricular injection of atropine, hexamethonium, and $T2$
mecamylamine
naloxone
0
$T1$ also decreased catalepsy induced by morphine plus nicotine.Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of $T2$
naloxone
hexamethonium
0
$T1$, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
mecamylamine
hexamethonium
0
$T1$ and provides comparable antitumor efficacy, when used in combination with $T2$
neutropenia
cyclophosphamide
1
$T1$ by significantly reducing cardiotoxicity and grade 4 $T2$
doxorubicin
neutropenia
1
$T1$) of AC patients developed cardiotoxicity (P =.0002).Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).
CHF
cyclophosphamide
1
$T1$) of AC patients developed cardiotoxicity (P =.0002).Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).
CHF
doxorubicin
1
$T1$ by significantly reducing $T2$
doxorubicin
cardiotoxicity
0
$T1$ and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with $T2$
cardiotoxicity
cyclophosphamide
0
$T1$ and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for $T2$
cardiotoxicity
MBC
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
cardiotoxicity
0
$T1$) of AC patients developed cardiotoxicity (P =.0002).Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).
CHF
cardiotoxicity
0
$T1$ response rates (World Health Organization criteria), time to progression, and survival.RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).
tumor
cardiotoxicity
0
$T1$ and grade 4 $T2$
cardiotoxicity
neutropenia
0
$T1$ by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with $T2$
doxorubicin
cyclophosphamide
0
$T1$ by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for $T2$
doxorubicin
MBC
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
doxorubicin
0
$T1$ response rates (World Health Organization criteria), time to progression, and survival.RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).
tumor
doxorubicin
0
$T1$ as first-line therapy for $T2$
cyclophosphamide
MBC
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
cyclophosphamide
0
$T1$ response rates (World Health Organization criteria), time to progression, and survival.RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).
tumor
cyclophosphamide
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
MBC
0
$T1$) of AC patients developed cardiotoxicity (P =.0002).Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).
CHF
MBC
0
$T1$ response rates (World Health Organization criteria), time to progression, and survival.RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).
tumor
MBC
0
$T1$ and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for $T2$
neutropenia
MBC
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
CHF
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
tumor
0
$T1$.Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).
toxicity
neutropenia
0
$T1$ response rates (World Health Organization criteria), time to progression, and survival.RESULTS: Six percent of MC patients versus 21% (including five cases of $T2$
tumor
CHF
0
$T1$) of AC patients developed cardiotoxicity (P =.0002).Median cumulative doxorubicin dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =.0001, hazard ratio, 5.04).
CHF
neutropenia
0
$T1$ response rates (World Health Organization criteria), time to progression, and survival.RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).
tumor
neutropenia
0
$T1$ was observed, whereas the dose of 10 mg/kg was ineffective.A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.
decrease of MBP and HR
bupivacaine
1
$T1$, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.Thus, consistent with its direct effect on heart, PAF appears to be implicated in $T2$
BN 52021
bupivacaine
0
$T1$, a specific antagonist of PAF, against bupivacaine-induced $T2$
BN 52021
cardiovascular toxicity
0
$T1$ was observed, whereas the dose of 10 mg/kg was ineffective.A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.
decrease of MBP and HR
BN 52021
0
$T1$, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced $T2$
BN 52021
cardiovascular alterations
0
$T1$.Thus, consistent with its direct effect on heart, PAF appears to be implicated in $T2$
cardiovascular toxicity
bupivacaine
0
$T1$-induced $T2$
bupivacaine
cardiovascular alterations
0
$T1$ was observed, whereas the dose of 10 mg/kg was ineffective.A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.
decrease of MBP and HR
cardiovascular toxicity
0
$T1$.Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced $T2$
cardiovascular toxicity
cardiovascular alterations
0
$T1$ was observed, whereas the dose of 10 mg/kg was ineffective.A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.
decrease of MBP and HR
cardiovascular alterations
0
$T1$.In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of $T2$
marrow toxicity
AZT
1
$T1$ and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
anemia
AZT
1
$T1$ (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
leukopenia
AZT
1
$T1$ possesses minimal anti-HIV activity and has no effect on the ability of $T2$
BAU
AZT
0
$T1$.In vitro, at a concentration of 100 mumol/L, $T2$
marrow toxicity
BAU
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
BAU
0
$T1$-related toxicity.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
Urd
BAU
0
$T1$.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
toxicity
BAU
0
$T1$ and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
anemia
BAU
0
$T1$ (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
leukopenia
BAU
0
$T1$.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
megaloblastosis
BAU
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
AZT
0
$T1$-related toxicity.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
Urd
AZT
0
$T1$.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
toxicity
AZT
0
$T1$.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.
megaloblastosis
AZT
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
marrow toxicity
0
$T1$-related toxicity.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
Urd
marrow toxicity
0
$T1$.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
toxicity
marrow toxicity
0
$T1$ and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced $T2$
anemia
marrow toxicity
0
$T1$ (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced $T2$
leukopenia
marrow toxicity
0
$T1$.When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced $T2$
megaloblastosis
marrow toxicity
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
Urd
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
toxicity
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
anemia
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
leukopenia
0
$T1$ virus (HIV) activity.Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.
immunodeficiency
megaloblastosis
0
$T1$-related $T2$
Urd
toxicity
0
$T1$-related toxicity.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced $T2$
Urd
anemia
0
$T1$-related toxicity.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and $T2$
Urd
leukopenia
0
$T1$-related toxicity.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved $T2$
Urd
megaloblastosis
0
$T1$.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced $T2$
toxicity
anemia
0
$T1$.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and $T2$
toxicity
leukopenia
0
$T1$.In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved $T2$
toxicity
megaloblastosis
0
$T1$ and $T2$
anemia
leukopenia
0
$T1$ and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved $T2$
anemia
megaloblastosis
0
$T1$ (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved $T2$
leukopenia
megaloblastosis
0
$T1$-induced $T2$
CP
cystitis
1
$T1$-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these $T2$
CP
painful syndromes
1
$T1$ 5 mg./kg.i.v.
acrolein
painful syndromes
1
$T1$-induced cystitis may be an interesting new behavioral model of inflammatory $T2$
CP
visceral pain
0
$T1$ 5 mg./kg.i.v.
acrolein
CP
0
$T1$, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.In female rats, CP 200 mg./kg.
morphine
CP
0
$T1$.At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
naloxone
CP
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
CP
0
$T1$, were observed.In female rats, CP 200 mg./kg.
edema
CP
0
$T1$ may be an interesting new behavioral model of inflammatory $T2$
cystitis
visceral pain
0
$T1$ 5 mg./kg.i.v.
acrolein
cystitis
0
$T1$, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.In female rats, CP 200 mg./kg.
morphine
cystitis
0
$T1$.At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
naloxone
cystitis
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
cystitis
0
$T1$, were observed.In female rats, CP 200 mg./kg.
edema
cystitis
0
$T1$ may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these $T2$
cystitis
painful syndromes
0
$T1$ 5 mg./kg.i.v.
acrolein
visceral pain
0
$T1$, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.In female rats, CP 200 mg./kg.
morphine
visceral pain
0
$T1$.At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
naloxone
visceral pain
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
visceral pain
0
$T1$, were observed.In female rats, CP 200 mg./kg.
edema
visceral pain
0
$T1$, allowing a better understanding of these $T2$
visceral pain
painful syndromes
0
$T1$, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.In female rats, CP 200 mg./kg.
morphine
acrolein
0
$T1$.At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
naloxone
acrolein
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
acrolein
0
$T1$, were observed.In female rats, CP 200 mg./kg.
edema
acrolein
0
$T1$.At the time of administration of $T2$
naloxone
morphine
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
morphine
0
$T1$, histological modifications of the bladder wall, such as chorionic and muscle layer $T2$
morphine
edema
0
$T1$, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.In female rats, CP 200 mg./kg.
morphine
painful syndromes
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
naloxone
0
$T1$.At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer $T2$
naloxone
edema
0
$T1$.At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
naloxone
painful syndromes
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
edema
0
$T1$.A dose of 0.5 mg./kg.
behavioral disorders
painful syndromes
0
$T1$, were observed.In female rats, CP 200 mg./kg.
edema
painful syndromes
0
$T1$/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that $T2$
hyperalgesia
morphine
1
$T1$ which in 2 cases were accompanied by myoclonus.In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.
hyperesthesia
morphine
1
$T1$ increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that $T2$
neuralgia
morphine
1
$T1$ and high doses of morphine are available, experimental support from animal studies indicates that $T2$
myoclonus
morphine
1
$T1$/$T2$
hyperalgesia
myoclonus
0
$T1$ patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.All cases were retrospectively sampled from three different hospitals in Copenhagen.
cancer
hyperalgesia
0
$T1$ which in 2 cases were accompanied by myoclonus.In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.
hyperesthesia
hyperalgesia
0
$T1$ increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.Although only few clinical descriptions of the relationship between $T2$
neuralgia
hyperalgesia
0
$T1$ patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.All cases were retrospectively sampled from three different hospitals in Copenhagen.
cancer
myoclonus
0
$T1$ which in 2 cases were accompanied by myoclonus.In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.
hyperesthesia
myoclonus
0
$T1$ increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.Although only few clinical descriptions of the relationship between hyperalgesia/$T2$
neuralgia
myoclonus
0
$T1$ patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.All cases were retrospectively sampled from three different hospitals in Copenhagen.
cancer
morphine
0
$T1$ patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.All cases were retrospectively sampled from three different hospitals in Copenhagen.
cancer
hyperesthesia
0
$T1$ patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.All cases were retrospectively sampled from three different hospitals in Copenhagen.
cancer
neuralgia
0
$T1$ which in 2 cases were accompanied by myoclonus.In 3 patients a pre-existing $T2$
hyperesthesia
neuralgia
0
$T1$ occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.We conclude that $T2$
Thrombophlebitis
vancomycin
1
$T1$ (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
rash
vancomycin
1
$T1$ (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
proteinuria
vancomycin
1
$T1$ were confined to patients receiving an aminoglycoside plus vancomycin.We conclude that $T2$
ototoxicity
vancomycin
1
$T1$, administered appropriately, constitutes safe, effective therapy for $T2$
vancomycin
infections
0
$T1$ and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.We conclude that $T2$
nephrotoxicity
vancomycin
0
$T1$ plus vancomycin.We conclude that $T2$
aminoglycoside
vancomycin
0
$T1$ occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for $T2$
Thrombophlebitis
infections
0
$T1$ (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
rash
infections
0
$T1$ and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for $T2$
nephrotoxicity
infections
0
$T1$ (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
proteinuria
infections
0
$T1$ were confined to patients receiving an aminoglycoside plus vancomycin.We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for $T2$
ototoxicity
infections
0
$T1$ plus vancomycin.We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for $T2$
aminoglycoside
infections
0
$T1$ (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).$T2$
rash
Thrombophlebitis
0
$T1$ occurred only with infusion through peripheral cannulae; $T2$
Thrombophlebitis
nephrotoxicity
0
$T1$ (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).$T2$
proteinuria
Thrombophlebitis
0
$T1$ occurred only with infusion through peripheral cannulae; nephrotoxicity and $T2$
Thrombophlebitis
ototoxicity
0
$T1$ occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an $T2$
Thrombophlebitis
aminoglycoside
0
$T1$ (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; $T2$
rash
nephrotoxicity
0
$T1$ (4 of 54), nephrotoxicity (4 of 50), $T2$
rash
proteinuria
0
$T1$ (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and $T2$
rash
ototoxicity
0
$T1$ (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an $T2$
rash
aminoglycoside
0
$T1$ (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; $T2$
proteinuria
nephrotoxicity
0
$T1$ and $T2$
nephrotoxicity
ototoxicity
0
$T1$ and ototoxicity were confined to patients receiving an $T2$
nephrotoxicity
aminoglycoside
0
$T1$ (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and $T2$
proteinuria
ototoxicity
0
$T1$ (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an $T2$
proteinuria
aminoglycoside
0
$T1$ were confined to patients receiving an $T2$
ototoxicity
aminoglycoside
0
$T1$, SCH 23390 or sulpiride.4.
fluphenazine
catalepsy
1
$T1$.4.
sulpiride
catalepsy
1
$T1$ or sulpiride.4.
SCH 23390
catalepsy
1
$T1$ antagonists.5.
dopamine
catalepsy
0
$T1$, SCH 23390 or sulpiride.4.
fluphenazine
dopamine
0
$T1$ or sulpiride.4.
SCH 23390
dopamine
0
$T1$.4.
sulpiride
dopamine
0
$T1$ with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by $T2$
SKF 38393
dopamine
0
$T1$ did not cause potentiated inhibitory effect on catalepsy induced by $T2$
quinpirole
dopamine
0
$T1$ with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.5.
SKF 38393
catalepsy
0
$T1$ did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.5.
quinpirole
catalepsy
0
$T1$, $T2$
fluphenazine
SCH 23390
0
$T1$, SCH 23390 or $T2$
fluphenazine
sulpiride
0
$T1$, SCH 23390 or sulpiride.4.
fluphenazine
SKF 38393
0
$T1$, SCH 23390 or sulpiride.4.
fluphenazine
quinpirole
0
$T1$ or $T2$
SCH 23390
sulpiride
0
$T1$ or sulpiride.4.
SCH 23390
SKF 38393
0
$T1$ or sulpiride.4.
SCH 23390
quinpirole
0
$T1$.4.
sulpiride
SKF 38393
0
$T1$.4.
sulpiride
quinpirole
0
$T1$ with $T2$
SKF 38393
quinpirole
0
$T1$-induced rat paw $T2$
carrageenan
edema
1
$T1$ model (mice) and $T2$
writhing
carrageenan
1
$T1$ of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
dextran
etodolac
0
$T1$), was condensed with the polysaccharide polymer $T2$
EAI
dextran
0
$T1$ of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
dextran
acetic acid
0
$T1$ of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
dextran
writhing
0
$T1$ of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
dextran
carrageenan
0
$T1$ of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
dextran
edema
0
$T1$), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
EAI
etodolac
0
$T1$ induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).
acetic acid
etodolac
0
$T1$ model (mice) and carrageenan-induced rat paw edema model, respectively.In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).
writhing
etodolac
0
$T1$-induced rat paw edema model, respectively.In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).
carrageenan
etodolac
0
$T1$ model, respectively.In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).
edema
etodolac
0
$T1$), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
EAI
acetic acid
0
$T1$), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
EAI
writhing
0
$T1$), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
EAI
carrageenan
0
$T1$), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).IR spectral data confirmed formation of ester bonding in the conjugates.
EAI
edema
0
$T1$ induced $T2$
acetic acid
writhing
0
$T1$ induced writhing model (mice) and $T2$
acetic acid
carrageenan
0
$T1$ induced writhing model (mice) and carrageenan-induced rat paw $T2$
acetic acid
edema
0
$T1$ model (mice) and carrageenan-induced rat paw $T2$
writhing
edema
0
$T1$ infusion therapy.$T2$
dobutamine
Eosinophilic myocarditis
1
$T1$ (eosinophilic) myocarditis was related to $T2$
hypersensitivity
dobutamine
1
$T1$ was related to $T2$
myocarditis
dobutamine
1
$T1$ (eosinophilic) $T2$
hypersensitivity
myocarditis
0
$T1$ and myocarditis with abundant eosinophils.Myocarditis is rare and eosinophilic myocarditis is rarer.
hypertrophic cardiomyopathy
hypersensitivity
0
$T1$ (eosinophilic) myocarditis was related to dobutamine infusion therapy.$T2$
hypersensitivity
Eosinophilic myocarditis
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.
biventricular failure
hypersensitivity
0
$T1$ with regional variability and moderate mitral regurgitation.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
left ventricular dysfunction
hypersensitivity
0
$T1$.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
mitral regurgitation
hypersensitivity
0
$T1$ and myocarditis with abundant eosinophils.Myocarditis is rare and eosinophilic myocarditis is rarer.
hypertrophic cardiomyopathy
myocarditis
0
$T1$ was related to dobutamine infusion therapy.$T2$
myocarditis
Eosinophilic myocarditis
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.
biventricular failure
myocarditis
0
$T1$ with regional variability and moderate mitral regurgitation.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
left ventricular dysfunction
myocarditis
0
$T1$.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
mitral regurgitation
myocarditis
0
$T1$ and myocarditis with abundant eosinophils.Myocarditis is rare and eosinophilic myocarditis is rarer.
hypertrophic cardiomyopathy
Eosinophilic myocarditis
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.
biventricular failure
hypertrophic cardiomyopathy
0
$T1$ and myocarditis with abundant eosinophils.Myocarditis is rare and eosinophilic myocarditis is rarer.
hypertrophic cardiomyopathy
dobutamine
0
$T1$ with regional variability and moderate mitral regurgitation.The recipient's heart showed the features of apical $T2$
left ventricular dysfunction
hypertrophic cardiomyopathy
0
$T1$.The recipient's heart showed the features of apical $T2$
mitral regurgitation
hypertrophic cardiomyopathy
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.
biventricular failure
Eosinophilic myocarditis
0
$T1$ with regional variability and moderate mitral regurgitation.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
left ventricular dysfunction
Eosinophilic myocarditis
0
$T1$.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
mitral regurgitation
Eosinophilic myocarditis
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.
biventricular failure
dobutamine
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate $T2$
biventricular failure
left ventricular dysfunction
0
$T1$ and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate $T2$
biventricular failure
mitral regurgitation
0
$T1$ with regional variability and moderate mitral regurgitation.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
left ventricular dysfunction
dobutamine
0
$T1$.The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.
mitral regurgitation
dobutamine
0
$T1$ with regional variability and moderate $T2$
left ventricular dysfunction
mitral regurgitation
0
$T1$-induced $T2$
ATRA
erythema nodosum
1
$T1$ subsided rapidly and the skin lesions regressed completely.All patients achieved complete remission without withdrawal of ATRA.
Fever
ATRA
1
$T1$ who developed erythema nodosum during ATRA therapy.Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
APL
ATRA
0
$T1$ erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.The skin biopsy taken from each patient was consistent with erythema nodosum.
painful
ATRA
0
$T1$ is very effective in $T2$
steroid
ATRA
0
$T1$ who developed erythema nodosum during ATRA therapy.Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
APL
erythema nodosum
0
$T1$ subsided rapidly and the skin lesions regressed completely.All patients achieved complete remission without withdrawal of ATRA.
Fever
erythema nodosum
0
$T1$ erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.The skin biopsy taken from each patient was consistent with erythema nodosum.
painful
erythema nodosum
0
$T1$ is very effective in ATRA-induced $T2$
steroid
erythema nodosum
0
$T1$ who developed erythema nodosum during ATRA therapy.Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
APL
Fever
0
$T1$ who developed erythema nodosum during ATRA therapy.Fever and subsequent multiple $T2$
APL
painful
0
$T1$ who developed erythema nodosum during ATRA therapy.Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
APL
steroid
0
$T1$ erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.The skin biopsy taken from each patient was consistent with erythema nodosum.
painful
Fever
0
$T1$ subsided rapidly and the skin lesions regressed completely.All patients achieved complete remission without withdrawal of ATRA.
Fever
steroid
0
$T1$ erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.The skin biopsy taken from each patient was consistent with erythema nodosum.
painful
steroid
0
$T1$ whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not $T2$
thrombocytopenia
heparin
1
$T1$.Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.
arterial or venous thromboemboli
heparin
1
$T1$) or arterial (4 patients) or both.Platelet counts were mildly decreased in all but 2 patients on second presentation.
pulmonary emboli
heparin
1
$T1$; therapy with alternative anticoagulants, not $T2$
thromboembolism
heparin
0
$T1$ (11 patients).Three patients died.
warfarin
heparin
0
$T1$.Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.
arterial or venous thromboemboli
thrombocytopenia
0
$T1$ whenever a recently hospitalized patient returns with $T2$
thrombocytopenia
thromboembolism
0
$T1$) or arterial (4 patients) or both.Platelet counts were mildly decreased in all but 2 patients on second presentation.
pulmonary emboli
thrombocytopenia
0
$T1$ (11 patients).Three patients died.
warfarin
thrombocytopenia
0
$T1$.Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.
arterial or venous thromboemboli
thromboembolism
0
$T1$.Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.
arterial or venous thromboemboli
pulmonary emboli
0
$T1$.Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.
arterial or venous thromboemboli
warfarin
0
$T1$) or arterial (4 patients) or both.Platelet counts were mildly decreased in all but 2 patients on second presentation.
pulmonary emboli
thromboembolism
0
$T1$ (11 patients).Three patients died.
warfarin
thromboembolism
0
$T1$) or arterial (4 patients) or both.Platelet counts were mildly decreased in all but 2 patients on second presentation.
pulmonary emboli
warfarin
0
$T1$ was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.
edema
valsartan
1
$T1$ was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).CONCLUSIONS: The data show that valsartan is at least as effective as $T2$
edema
amlodipine
1
$T1$ antagonist, valsartan, with a reference therapy, amlodipine.METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
angiotensin II
valsartan
0
$T1$.The results also show $T2$
hypertension
valsartan
0
$T1$ in the treatment of mild to moderate hypertension.The results also show $T2$
amlodipine
valsartan
0
$T1$ to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, $T2$
valsartan
dihydropyridine
0
$T1$ to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine $T2$
valsartan
calcium
0
$T1$ antagonist, valsartan, with a reference therapy, amlodipine.METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
angiotensin II
hypertension
0
$T1$ antagonist, valsartan, with a reference therapy, amlodipine.METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
angiotensin II
amlodipine
0
$T1$ antagonist, valsartan, with a reference therapy, amlodipine.METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
angiotensin II
edema
0
$T1$ antagonist, valsartan, with a reference therapy, amlodipine.METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
angiotensin II
dihydropyridine
0
$T1$ antagonist, valsartan, with a reference therapy, amlodipine.METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
angiotensin II
calcium
0
$T1$ in the treatment of mild to moderate $T2$
amlodipine
hypertension
0
$T1$ was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate $T2$
edema
hypertension
0
$T1$.The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, $T2$
hypertension
dihydropyridine
0
$T1$.The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine $T2$
hypertension
calcium
0
$T1$ in the treatment of mild to moderate hypertension.The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, $T2$
amlodipine
dihydropyridine
0
$T1$ in the treatment of mild to moderate hypertension.The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine $T2$
amlodipine
calcium
0
$T1$ was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.
edema
dihydropyridine
0
$T1$ was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.
edema
calcium
0
$T1$ $T2$
dihydropyridine
calcium
0
$T1$ induced by haloperidol (1 mg/kg i.p.)and by $T2$
catalepsy
reserpine
1
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the $T2$
CGS 21680
catalepsy
1
$T1$ induced by $T2$
catalepsy
haloperidol
1
$T1$ A2A receptor antagonists.Furthermore, $T2$
adenosine
KF17837
0
$T1$ induced by haloperidol (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
catalepsy
KF17837
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.)
CGS 21680
KF17837
0
$T1$ (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
haloperidol
KF17837
0
$T1$ (5 mg/kg i.p.).These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.
reserpine
KF17837
0
$T1$; 25 mg/kg i.p.)plus benserazide (6.25 mg/kg i.p.).
L-DOPA
KF17837
0
$T1$ (6.25 mg/kg i.p.).These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.
benserazide
KF17837
0
$T1$ may be a useful drug in the treatment of $T2$
KF17837
parkinsonism
0
$T1$ induced by haloperidol (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
catalepsy
adenosine
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.)
CGS 21680
adenosine
0
$T1$ (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
haloperidol
adenosine
0
$T1$ (5 mg/kg i.p.).These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.
reserpine
adenosine
0
$T1$; 25 mg/kg i.p.)plus benserazide (6.25 mg/kg i.p.).
L-DOPA
adenosine
0
$T1$ (6.25 mg/kg i.p.).These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by $T2$
benserazide
adenosine
0
$T1$ A2A receptor antagonists.Furthermore, KF17837 may be a useful drug in the treatment of $T2$
adenosine
parkinsonism
0
$T1$ induced by haloperidol (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
catalepsy
L-DOPA
0
$T1$ induced by haloperidol (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
catalepsy
benserazide
0
$T1$ induced by haloperidol (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
catalepsy
parkinsonism
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by $T2$
CGS 21680
haloperidol
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.)
CGS 21680
reserpine
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.)
CGS 21680
L-DOPA
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.)
CGS 21680
benserazide
0
$T1$ (10 micrograms), in a dose-dependent manner.KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.)
CGS 21680
parkinsonism
0
$T1$ (1 mg/kg i.p.)and by $T2$
haloperidol
reserpine
0
$T1$ (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
haloperidol
L-DOPA
0
$T1$ (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
haloperidol
benserazide
0
$T1$ (1 mg/kg i.p.)and by reserpine (5 mg/kg i.p.).
haloperidol
parkinsonism
0
$T1$ (5 mg/kg i.p.).These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.
reserpine
L-DOPA
0
$T1$ (5 mg/kg i.p.).These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.
reserpine
benserazide
0
$T1$ (5 mg/kg i.p.).These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.
reserpine
parkinsonism
0
$T1$; 25 mg/kg i.p.)plus $T2$
L-DOPA
benserazide
0
$T1$; 25 mg/kg i.p.)plus benserazide (6.25 mg/kg i.p.).
L-DOPA
parkinsonism
0
$T1$ (6.25 mg/kg i.p.).These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.
benserazide
parkinsonism
0
$T1$ induced by nomifensine in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.
hyperactivity
fluvoxamine
1
$T1$ induced by nomifensine in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered $T2$
hyperactivity
methoxamine
1
$T1$ induced by $T2$
hyperactivity
nomifensine
1
$T1$-induced hyperactivity.The $T2$
amphetamine
hyperactivity
1
$T1$ given repeatedly acts differently than citalopram, another selective $T2$
fluvoxamine
serotonin
0
$T1$ was not affected by repeated treatment with fluvoxamine.Given three times fluvoxamine had no effect on the immobilization time in the "behavioral despair" test in rats.
methoxamine
fluvoxamine
0
$T1$-induced hyperactivity.The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
amphetamine
fluvoxamine
0
$T1$ in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.
nomifensine
fluvoxamine
0
$T1$ given repeatedly acts differently than $T2$
fluvoxamine
citalopram
0
$T1$ was not affected by repeated treatment with fluvoxamine.Given three times fluvoxamine had no effect on the immobilization time in the "behavioral despair" test in rats.
methoxamine
serotonin
0
$T1$-induced hyperactivity.The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
amphetamine
serotonin
0
$T1$ induced by nomifensine in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.
hyperactivity
serotonin
0
$T1$ in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.
nomifensine
serotonin
0
$T1$, another selective $T2$
citalopram
serotonin
0
$T1$-induced hyperactivity.The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
amphetamine
methoxamine
0
$T1$ in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered $T2$
nomifensine
methoxamine
0
$T1$ was not affected by repeated treatment with fluvoxamine.Given three times fluvoxamine had no effect on the immobilization time in the "behavioral despair" test in rats.
methoxamine
citalopram
0
$T1$-induced hyperactivity.The hyperactivity induced by $T2$
amphetamine
nomifensine
0
$T1$-induced hyperactivity.The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
amphetamine
citalopram
0
$T1$ induced by nomifensine in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.
hyperactivity
citalopram
0
$T1$ in mice remained unaffected by fluvoxamine.The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.
nomifensine
citalopram
0
$T1$ among CHF patients.The myriad clinical presentation of $T2$
amiodarone
myxedema coma
1
$T1$, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.This case report carries an important clinical application given the frequent usage of $T2$
hypothyroidism
amiodarone
1
$T1$ among CHF patients.The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among $T2$
amiodarone
CHF
0
$T1$ and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among $T2$
myxedema coma
CHF
0
$T1$, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.
hypothyroidism
CHF
0
$T1$) or intravenous tri-iodo-thyronine (T3).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T4
CHF
0
$T1$).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T3
CHF
0
$T1$ patients presenting with $T2$
CHF
hypotension
0
$T1$ patients presenting with hypotension, $T2$
CHF
weakness
0
$T1$) or intravenous tri-iodo-thyronine (T3).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T4
amiodarone
0
$T1$).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T3
amiodarone
0
$T1$ among CHF patients.The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with $T2$
amiodarone
hypotension
0
$T1$ among CHF patients.The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, $T2$
amiodarone
weakness
0
$T1$, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.
hypothyroidism
myxedema coma
0
$T1$) or intravenous tri-iodo-thyronine (T3).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T4
myxedema coma
0
$T1$).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T3
myxedema coma
0
$T1$ and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with $T2$
myxedema coma
hypotension
0
$T1$ and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, $T2$
myxedema coma
weakness
0
$T1$) or intravenous tri-iodo-thyronine (T3).Patients with CHF on amiodarone may suffer serious morbidity and mortality from $T2$
T4
hypothyroidism
0
$T1$).Patients with CHF on amiodarone may suffer serious morbidity and mortality from $T2$
T3
hypothyroidism
0
$T1$, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.
hypothyroidism
hypotension
0
$T1$, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.
hypothyroidism
weakness
0
$T1$) or intravenous tri-iodo-thyronine ($T2$
T4
T3
0
$T1$) or intravenous tri-iodo-thyronine (T3).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T4
hypotension
0
$T1$) or intravenous tri-iodo-thyronine (T3).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T4
weakness
0
$T1$).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T3
hypotension
0
$T1$).Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
T3
weakness
0
$T1$, $T2$
hypotension
weakness
0
$T1$ suppressed baseline $T2$
PTZ
startle
1
$T1$ increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline $T2$
yohimbine
startle
1
$T1$ suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline $T2$
mCPP
startle
1
$T1$, because of the non-specific cue and the long-term effect.In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.
anxiety
startle
0
$T1$(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
5-HT
startle
0
$T1$(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
GABA
startle
0
$T1$, because of the non-specific cue and the long-term effect.In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.
anxiety
yohimbine
0
$T1$, because of the non-specific cue and the long-term effect.In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.
anxiety
5-HT
0
$T1$, because of the non-specific cue and the long-term effect.In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.
anxiety
mCPP
0
$T1$, because of the non-specific cue and the long-term effect.In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.
anxiety
GABA
0
$T1$, because of the non-specific cue and the long-term effect.In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.
anxiety
PTZ
0
$T1$(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
5-HT
yohimbine
0
$T1$ increased baseline startle amplitude in the LES, while $T2$
yohimbine
mCPP
0
$T1$(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
GABA
yohimbine
0
$T1$ increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and $T2$
yohimbine
PTZ
0
$T1$(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
5-HT
mCPP
0
$T1$(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the $T2$
5-HT
GABA
0
$T1$(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
5-HT
PTZ
0
$T1$(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
GABA
mCPP
0
$T1$ suppressed baseline startle in both the LES and FPS and $T2$
mCPP
PTZ
0
$T1$(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.
GABA
PTZ
0
$T1$, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
fever
sulphasalazine
1
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
sulphasalazine
1
$T1$ disappeared, and PR3-ANCA titer normalized 3 months later.This case suggests that $T2$
pleural effusion
sulphasalazine
1
$T1$ can induce PR3-ANCA-positive necrotizing $T2$
sulphasalazine
glomerulonephritis
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
glomerulonephritis
0
$T1$, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
red eyes
glomerulonephritis
0
$T1$ disappeared, and PR3-ANCA titer normalized 3 months later.This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing $T2$
pleural effusion
glomerulonephritis
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
glomerulonephritis
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
glomerulonephritis
0
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
glomerulonephritis
0
$T1$, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
fever
glomerulonephritis
0
$T1$, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
chest pain
glomerulonephritis
0
$T1$ therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing $T2$
steroid
glomerulonephritis
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
sulphasalazine
0
$T1$, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
red eyes
sulphasalazine
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
sulphasalazine
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
sulphasalazine
0
$T1$, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
chest pain
sulphasalazine
0
$T1$ therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.This case suggests that $T2$
steroid
sulphasalazine
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
red eyes
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
pleural effusion
0
$T1$ developed red eyes, pleural effusion, $T2$
ulcerative colitis
eosinophilia
0
$T1$ developed red eyes, pleural effusion, eosinophilia and $T2$
ulcerative colitis
urinary abnormalities
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed $T2$
ulcerative colitis
segmental necrotizing glomerulonephritis
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
fever
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
chest pain
0
$T1$ developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
ulcerative colitis
steroid
0
$T1$, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the $T2$
red eyes
pleural effusion
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
red eyes
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
red eyes
0
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
red eyes
0
$T1$, $T2$
fever
red eyes
0
$T1$, $T2$
red eyes
chest pain
0
$T1$, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after $T2$
red eyes
steroid
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
pleural effusion
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
pleural effusion
0
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
pleural effusion
0
$T1$, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the $T2$
fever
pleural effusion
0
$T1$, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after steroid therapy, the $T2$
chest pain
pleural effusion
0
$T1$ therapy, the $T2$
steroid
pleural effusion
0
$T1$ and $T2$
eosinophilia
urinary abnormalities
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed $T2$
eosinophilia
segmental necrotizing glomerulonephritis
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
fever
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
chest pain
0
$T1$ and urinary abnormalities after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
eosinophilia
steroid
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed $T2$
urinary abnormalities
segmental necrotizing glomerulonephritis
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
fever
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
chest pain
0
$T1$ after restarting of sulphasalazine treatment.Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.
urinary abnormalities
steroid
0
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
fever
0
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
chest pain
0
$T1$ without deposition of immunoglobulin or complement.Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.
segmental necrotizing glomerulonephritis
steroid
0
$T1$, red eyes, $T2$
fever
chest pain
0
$T1$, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after $T2$
fever
steroid
0
$T1$, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.One month after $T2$
chest pain
steroid
0
$T1$, refractory to atropine and adrenaline.The cardiac depressant actions of phenytoin and hypothermia can be additive.
bradycardia
phenytoin
1
$T1$ may lead to an adverse cardiac event in children.As $T2$
hypothermia
phenytoin
0
$T1$ and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.During anaesthesia and surgery, he inadvertently became moderately hypothermic.
Chiari malformation
phenytoin
0
$T1$ prophylaxis.Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.
seizure
phenytoin
0
$T1$ and adrenaline.The cardiac depressant actions of phenytoin and hypothermia can be additive.
atropine
phenytoin
0
$T1$.The cardiac depressant actions of phenytoin and hypothermia can be additive.
adrenaline
phenytoin
0
$T1$ and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.During anaesthesia and surgery, he inadvertently became moderately hypothermic.
Chiari malformation
hypothermia
0
$T1$ prophylaxis.Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.
seizure
hypothermia
0
$T1$, refractory to atropine and adrenaline.The cardiac depressant actions of phenytoin and hypothermia can be additive.
bradycardia
hypothermia
0
$T1$ and adrenaline.The cardiac depressant actions of phenytoin and hypothermia can be additive.
atropine
hypothermia
0
$T1$.The cardiac depressant actions of phenytoin and hypothermia can be additive.
adrenaline
hypothermia
0
$T1$ and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.During anaesthesia and surgery, he inadvertently became moderately hypothermic.
Chiari malformation
seizure
0
$T1$ and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.During anaesthesia and surgery, he inadvertently became moderately hypothermic.
Chiari malformation
bradycardia
0
$T1$ and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.During anaesthesia and surgery, he inadvertently became moderately hypothermic.
Chiari malformation
atropine
0
$T1$ and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.During anaesthesia and surgery, he inadvertently became moderately hypothermic.
Chiari malformation
adrenaline
0
$T1$ prophylaxis.Following phenytoin administration, the patient developed acute severe $T2$
seizure
bradycardia
0
$T1$ prophylaxis.Following phenytoin administration, the patient developed acute severe bradycardia, refractory to $T2$
seizure
atropine
0
$T1$ prophylaxis.Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and $T2$
seizure
adrenaline
0
$T1$, refractory to $T2$
bradycardia
atropine
0
$T1$, refractory to atropine and $T2$
bradycardia
adrenaline
0
$T1$ and $T2$
atropine
adrenaline
0
$T1$ might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or $T2$
tic-like symptoms
amisulpride
1
$T1$ who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
schizophrenic
amisulpride
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
amisulpride
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
amisulpride
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
amisulpride
0
$T1$, clozapine, or $T2$
quetiapine
amisulpride
0
$T1$, or $T2$
clozapine
amisulpride
0
$T1$ after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
involuntary eye-blinking movements
amisulpride
0
$T1$ recurred after the dose reduction.We then placed her on an additional 100 mg per day of quetiapine.
psychosis
amisulpride
0
$T1$ who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
schizophrenic
tic-like symptoms
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
tic-like symptoms
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
tic-like symptoms
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
tic-like symptoms
0
$T1$ might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as $T2$
tic-like symptoms
quetiapine
0
$T1$ might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, $T2$
tic-like symptoms
clozapine
0
$T1$ after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
involuntary eye-blinking movements
tic-like symptoms
0
$T1$ recurred after the dose reduction.We then placed her on an additional 100 mg per day of quetiapine.
psychosis
tic-like symptoms
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
schizophrenic
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
schizophrenic
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
schizophrenic
0
$T1$ who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
schizophrenic
quetiapine
0
$T1$ who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
schizophrenic
clozapine
0
$T1$ who developed frequent $T2$
schizophrenic
involuntary eye-blinking movements
0
$T1$ who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
schizophrenic
psychosis
0
$T1$, $T2$
risperidone
olanzapine
0
$T1$, olanzapine and $T2$
risperidone
ziprasidone
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
quetiapine
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
clozapine
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
involuntary eye-blinking movements
0
$T1$, olanzapine and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
risperidone
psychosis
0
$T1$ and $T2$
olanzapine
ziprasidone
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
quetiapine
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
clozapine
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
involuntary eye-blinking movements
0
$T1$ and ziprasidone.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
olanzapine
psychosis
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
quetiapine
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
clozapine
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
involuntary eye-blinking movements
0
$T1$.However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
ziprasidone
psychosis
0
$T1$, $T2$
quetiapine
clozapine
0
$T1$ after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
involuntary eye-blinking movements
quetiapine
0
$T1$ recurred after the dose reduction.We then placed her on an additional 100 mg per day of quetiapine.
psychosis
quetiapine
0
$T1$ after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
involuntary eye-blinking movements
clozapine
0
$T1$ recurred after the dose reduction.We then placed her on an additional 100 mg per day of quetiapine.
psychosis
clozapine
0
$T1$ after 5 months of amisulpride treatment (1000 mg per day).The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
involuntary eye-blinking movements
psychosis
0
$T1$ and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.
DH
ASA
1
$T1$ that normally occur at low incidence, as reported from previous single dose studies, could also be induced with $T2$
malformations
ASA
1
$T1$ in the SD rats and hydrocephalus in the Wistar rats.Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).
VSD
ASA
1
$T1$ confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.
gastrointestinal toxicity
ASA
0
$T1$ were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.
MD
ASA
0
$T1$ in the Wistar rats.Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).
hydrocephalus
ASA
0
$T1$ confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.
gastrointestinal toxicity
malformations
0
$T1$ in the SD rats and hydrocephalus in the Wistar rats.Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).
VSD
malformations
0
$T1$ were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.
MD
malformations
0
$T1$ and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.
DH
malformations
0
$T1$ in the Wistar rats.Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).
hydrocephalus
malformations
0
$T1$ confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.
gastrointestinal toxicity
VSD
0
$T1$ confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.
gastrointestinal toxicity
MD
0
$T1$ confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.
gastrointestinal toxicity
DH
0
$T1$ confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.
gastrointestinal toxicity
hydrocephalus
0
$T1$ were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of $T2$
MD
VSD
0
$T1$ and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of $T2$
DH
VSD
0
$T1$ in the SD rats and $T2$
VSD
hydrocephalus
0
$T1$ and $T2$
DH
MD
0
$T1$ were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and $T2$
MD
hydrocephalus
0
$T1$ and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and $T2$
DH
hydrocephalus
0
$T1$ should be used cautiously in patients with a risk of $T2$
Metoclopramide
torsade de pointes
1
$T1$ were given simultaneously.These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.
erythromycin
torsade de pointes
1
$T1$ and erythromycin were given simultaneously.These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.
cisapride
torsade de pointes
1
$T1$ who developed torsade de pointes after intravenous and oral administration of metoclopramide.This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.
left bundle branch block
torsade de pointes
0
$T1$ and torsade de pointes.However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.
long QT syndrome
torsade de pointes
0
$T1$.We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.
procainamide
torsade de pointes
0
$T1$ who developed torsade de pointes after intravenous and oral administration of metoclopramide.This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.
left bundle branch block
Metoclopramide
0
$T1$ and torsade de pointes.However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.
long QT syndrome
Metoclopramide
0
$T1$.We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.
procainamide
Metoclopramide
0
$T1$ and erythromycin were given simultaneously.These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.
cisapride
Metoclopramide
0
$T1$ were given simultaneously.These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.
erythromycin
Metoclopramide
0
$T1$ and torsade de pointes.However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.
long QT syndrome
left bundle branch block
0
$T1$.We report on a 92-year-old woman with preexisting complete $T2$
procainamide
left bundle branch block
0
$T1$ who developed torsade de pointes after intravenous and oral administration of metoclopramide.This patient also developed torsade de pointes when $T2$
left bundle branch block
cisapride
0
$T1$ who developed torsade de pointes after intravenous and oral administration of metoclopramide.This patient also developed torsade de pointes when cisapride and $T2$
left bundle branch block
erythromycin
0
$T1$ and torsade de pointes.However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to $T2$
long QT syndrome
procainamide
0
$T1$ and torsade de pointes.However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.
long QT syndrome
cisapride
0
$T1$ and torsade de pointes.However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.
long QT syndrome
erythromycin
0
$T1$.We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.
procainamide
cisapride
0
$T1$.We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.
procainamide
erythromycin
0
$T1$ and $T2$
cisapride
erythromycin
0
$T1$-induced $T2$
levodopa
dyskinesias
1
$T1$ treatment in fluctuating $T2$
apomorphine
Parkinson's disease
0
$T1$-induced dyskinesias.The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
levodopa
apomorphine
0
$T1$ agonists or COMT inhibitors.Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.
dopamine
apomorphine
0
$T1$.The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
dyskinesias
apomorphine
0
$T1$ complications play a lesser role.Given the marked degree of efficacy of subcutaneous $T2$
psychiatric
apomorphine
0
$T1$-induced dyskinesias.The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
levodopa
Parkinson's disease
0
$T1$ agonists or COMT inhibitors.Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.
dopamine
Parkinson's disease
0
$T1$.The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
dyskinesias
Parkinson's disease
0
$T1$ complications play a lesser role.Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating $T2$
psychiatric
Parkinson's disease
0
$T1$ agonists or COMT inhibitors.Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.
dopamine
levodopa
0
$T1$-induced dyskinesias.The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and $T2$
levodopa
psychiatric
0
$T1$ agonists or COMT inhibitors.Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.
dopamine
dyskinesias
0
$T1$ agonists or COMT inhibitors.Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy.
dopamine
psychiatric
0
$T1$.The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and $T2$
dyskinesias
psychiatric
0
$T1$ use, may precipitate agitation, delirium, aberrant thermoregulation, $T2$
cocaine
rhabdomyolysis
1
$T1$ use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and $T2$
cocaine
sudden death
1
$T1$ use, may precipitate agitation, $T2$
cocaine
delirium
1
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
delirium
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
delirium
0
$T1$, and to have died in summer months.EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
hyperthermia
delirium
0
$T1$ in autopsy blood that were similar to those for controls.The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, $T2$
benzoylecgonine
delirium
0
$T1$, $T2$
agitation
delirium
0
$T1$, aberrant thermoregulation, $T2$
delirium
rhabdomyolysis
0
$T1$, aberrant thermoregulation, rhabdomyolysis, and $T2$
delirium
sudden death
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
cocaine
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
cocaine
0
$T1$, and to have died in summer months.EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
hyperthermia
cocaine
0
$T1$ in autopsy blood that were similar to those for controls.The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent $T2$
benzoylecgonine
cocaine
0
$T1$ use, may precipitate $T2$
cocaine
agitation
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
overdose
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
hyperthermia
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
benzoylecgonine
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
agitation
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
rhabdomyolysis
0
$T1$.We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
toxicity
sudden death
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
hyperthermia
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
benzoylecgonine
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
agitation
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
rhabdomyolysis
0
$T1$ without excited delirium.Compared with controls, EDDs were more frequently black, male, and younger.
overdose
sudden death
0
$T1$, and to have died in summer months.EDDs had concentrations of cocaine and $T2$
hyperthermia
benzoylecgonine
0
$T1$, and to have died in summer months.EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
hyperthermia
agitation
0
$T1$, and to have died in summer months.EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
hyperthermia
rhabdomyolysis
0
$T1$, and to have died in summer months.EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
hyperthermia
sudden death
0
$T1$ in autopsy blood that were similar to those for controls.The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate $T2$
benzoylecgonine
agitation
0
$T1$ in autopsy blood that were similar to those for controls.The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, $T2$
benzoylecgonine
rhabdomyolysis
0
$T1$ in autopsy blood that were similar to those for controls.The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and $T2$
benzoylecgonine
sudden death
0
$T1$, delirium, aberrant thermoregulation, $T2$
agitation
rhabdomyolysis
0
$T1$, delirium, aberrant thermoregulation, rhabdomyolysis, and $T2$
agitation
sudden death
0
$T1$, and $T2$
rhabdomyolysis
sudden death
0
$T1$ events in patients receiving heparin.Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.
thromboembolic
heparin
1
$T1$ are reported.Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.
thrombocytopenia
heparin
1
$T1$, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.Specific risk factors have not been identified; therefore, all patients receiving heparin should be monitored.
hemorrhagic and thromboembolic complications
heparin
1
$T1$, and hemorrhage.Sixty-two patients with a heparin-induced thrombocytopenia are reported.
thrombosis
heparin
0
$T1$ testing, using the patient's plasma, is indicated.Management consists of cessation of $T2$
platelet aggregation
heparin
0
$T1$, and hemorrhage.Sixty-two patients with a heparin-induced $T2$
thrombosis
thrombocytopenia
0
$T1$ are reported.Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.
thrombocytopenia
hemorrhagic and thromboembolic complications
0
$T1$ are reported.Clinical manifestations of this disorder include hemorrhage or, more frequently, $T2$
thrombocytopenia
thromboembolic
0
$T1$ are reported.Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.
thrombocytopenia
platelet aggregation
0
$T1$, and hemorrhage.Sixty-two patients with a heparin-induced thrombocytopenia are reported.
thrombosis
hemorrhagic and thromboembolic complications
0
$T1$, and hemorrhage.Sixty-two patients with a heparin-induced thrombocytopenia are reported.
thrombosis
thromboembolic
0
$T1$, and hemorrhage.Sixty-two patients with a heparin-induced thrombocytopenia are reported.
thrombosis
platelet aggregation
0
$T1$ events in patients receiving heparin.Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.
thromboembolic
hemorrhagic and thromboembolic complications
0
$T1$, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.Specific risk factors have not been identified; therefore, all patients receiving heparin should be monitored.
hemorrhagic and thromboembolic complications
platelet aggregation
0
$T1$ events in patients receiving heparin.Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.
thromboembolic
platelet aggregation
0
$T1$ promptly resolved with nifedipine.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of $T2$
chest pain
5-FU
1
$T1$, and chest pain promptly resolved with nifedipine.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of $T2$
Prinzmetal's angina
5-FU
1
$T1$ $T2$
5-FU
cardiotoxicity
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
cardiotoxicity
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
colon carcinoma
cardiotoxicity
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
metastasis
cardiotoxicity
0
$T1$ promptly resolved with nifedipine.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU $T2$
chest pain
cardiotoxicity
0
$T1$, and chest pain promptly resolved with nifedipine.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU $T2$
Prinzmetal's angina
cardiotoxicity
0
$T1$.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU $T2$
nifedipine
cardiotoxicity
0
$T1$ may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU $T2$
coronary spasm
cardiotoxicity
0
$T1$ antagonists may probably be used in the prevention or treatment of 5-FU $T2$
calcium
cardiotoxicity
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
5-FU
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
colon carcinoma
5-FU
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
metastasis
5-FU
0
$T1$.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of $T2$
nifedipine
5-FU
0
$T1$ may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of $T2$
coronary spasm
5-FU
0
$T1$ antagonists may probably be used in the prevention or treatment of $T2$
calcium
5-FU
0
$T1$.We report a case of a patient with $T2$
angina
colon carcinoma
0
$T1$.We report a case of a patient with colon carcinoma and liver $T2$
angina
metastasis
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
chest pain
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
Prinzmetal's angina
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
nifedipine
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
coronary spasm
0
$T1$.We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
angina
calcium
0
$T1$ and liver $T2$
colon carcinoma
metastasis
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and $T2$
colon carcinoma
chest pain
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in $T2$
colon carcinoma
Prinzmetal's angina
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with $T2$
colon carcinoma
nifedipine
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
colon carcinoma
coronary spasm
0
$T1$ and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
colon carcinoma
calcium
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and $T2$
metastasis
chest pain
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in $T2$
metastasis
Prinzmetal's angina
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with $T2$
metastasis
nifedipine
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
metastasis
coronary spasm
0
$T1$ who presented chest pain after 5-fluorouracil (5-FU) administration.Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
metastasis
calcium
0
$T1$, and $T2$
Prinzmetal's angina
chest pain
0
$T1$ promptly resolved with $T2$
chest pain
nifedipine
0
$T1$ promptly resolved with nifedipine.These data suggest that $T2$
chest pain
coronary spasm
0
$T1$ promptly resolved with nifedipine.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that $T2$
chest pain
calcium
0
$T1$, and chest pain promptly resolved with $T2$
Prinzmetal's angina
nifedipine
0
$T1$, and chest pain promptly resolved with nifedipine.These data suggest that $T2$
Prinzmetal's angina
coronary spasm
0
$T1$, and chest pain promptly resolved with nifedipine.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that $T2$
Prinzmetal's angina
calcium
0
$T1$.These data suggest that $T2$
nifedipine
coronary spasm
0
$T1$.These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that $T2$
nifedipine
calcium
0
$T1$ may be the cause of cardiotoxicity due to 5-FU, and that $T2$
coronary spasm
calcium
0
$T1$ due to $T2$
dermatitis
gold
1
$T1$ related $T2$
Tiopronin
nephritis
1
$T1$ due to gold thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the $T2$
dermatitis
Tiopronin
1
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
toxicity
RA
0
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
toxicity
nephritis
0
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between $T2$
toxicity
dermatitis
0
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
toxicity
Tiopronin
0
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a $T2$
toxicity
D-Penicillamine
0
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to $T2$
toxicity
gold
0
$T1$ were studied for possible associations with class I and II HLA antigens.A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold $T2$
toxicity
thiosulphate
0
$T1$ except for the Tiopronin related $T2$
RA
nephritis
0
$T1$ due to gold thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with $T2$
dermatitis
RA
0
$T1$ except for the $T2$
RA
Tiopronin
0
$T1$ like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with $T2$
D-Penicillamine
RA
0
$T1$ thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with $T2$
gold
RA
0
$T1$ and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with $T2$
thiosulphate
RA
0
$T1$ due to gold thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related $T2$
dermatitis
nephritis
0
$T1$ like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related $T2$
D-Penicillamine
nephritis
0
$T1$ thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related $T2$
gold
nephritis
0
$T1$ and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related $T2$
thiosulphate
nephritis
0
$T1$ like compound) and class I antigens B35-Cw4, and between $T2$
D-Penicillamine
dermatitis
0
$T1$ due to gold $T2$
dermatitis
thiosulphate
0
$T1$ like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the $T2$
D-Penicillamine
Tiopronin
0
$T1$ thiosulphate and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the $T2$
gold
Tiopronin
0
$T1$ and B35.Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the $T2$
thiosulphate
Tiopronin
0
$T1$ like compound) and class I antigens B35-Cw4, and between dermatitis due to $T2$
D-Penicillamine
gold
0
$T1$ like compound) and class I antigens B35-Cw4, and between dermatitis due to gold $T2$
D-Penicillamine
thiosulphate
0
$T1$ $T2$
gold
thiosulphate
0
$T1$.Both had brain surgery before DPH treatment.
overdose
DPH
1
$T1$.Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.
cerebellar dysfunction
DPH
1
$T1$ due to DPH overdose.Both had brain surgery before DPH treatment.
hemiparesis
DPH
1
$T1$ due to DPH overdose.Both had brain surgery before DPH treatment.
hemiparesis
toxicity
0
$T1$ due to DPH $T2$
hemiparesis
overdose
0
$T1$.Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.
cerebellar dysfunction
hemiparesis
0
$T1$ due to DPH overdose.Both had brain surgery before DPH treatment.
hemiparesis
cerebral damage
0
$T1$ $T2$
DPH
toxicity
0
$T1$ are liable to manifest $T2$
cerebral damage
DPH
0
$T1$.Both had brain surgery before DPH treatment.
overdose
toxicity
0
$T1$.Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.
cerebellar dysfunction
toxicity
0
$T1$ are liable to manifest DPH $T2$
cerebral damage
toxicity
0
$T1$.Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.
cerebellar dysfunction
overdose
0
$T1$.Both had brain surgery before DPH treatment.
overdose
cerebral damage
0
$T1$.Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.
cerebellar dysfunction
cerebral damage
0
$T1$ and PGI2 did not correlate with urodynamic parameters in patients with OAB.CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.
PGF2alpha
OAB
1
$T1$ positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.
PGE2
OAB
1
$T1$ have important roles in the development of OAB symptoms in female patients.Urinary levels of these factors may be used as markers to evaluate $T2$
PGs
OAB
0
$T1$ positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.
PGE2
PGs
0
$T1$ and PGI2 did not correlate with urodynamic parameters in patients with OAB.CONCLUSIONS: NGF and $T2$
PGF2alpha
PGs
0
$T1$ did not correlate with urodynamic parameters in patients with OAB.CONCLUSIONS: NGF and $T2$
PGI2
PGs
0
$T1$ did not correlate with urodynamic parameters in patients with OAB.CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.
PGI2
OAB
0
$T1$ positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).Urinary NGF, $T2$
PGE2
PGF2alpha
0
$T1$ positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).Urinary NGF, PGF2alpha and $T2$
PGE2
PGI2
0
$T1$ and $T2$
PGF2alpha
PGI2
0
$T1$ a few minutes after initiation of intravenous $T2$
low back pain
amiodarone
1
$T1$, who experienced an acute devastating $T2$
atrial fibrillation
low back pain
0
$T1$, who experienced an acute devastating low back pain a few minutes after initiation of intravenous $T2$
atrial fibrillation
amiodarone
0
$T1$ after $T2$
postoperative myalgia
succinylcholine
1
$T1$.IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.
myalgia
succinylcholine
1
$T1$.IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.
myalgia
postoperative myalgia
0
$T1$.Pretreatment with dexamethasone is not justified to prevent $T2$
inflammation
postoperative myalgia
0
$T1$ is not justified to prevent $T2$
dexamethasone
postoperative myalgia
0
$T1$.Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after $T2$
inflammation
succinylcholine
0
$T1$ is not justified to prevent postoperative myalgia after $T2$
dexamethasone
succinylcholine
0
$T1$.IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.
myalgia
inflammation
0
$T1$.IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine-induced postoperative myalgia.
myalgia
dexamethasone
0
$T1$.Pretreatment with $T2$
inflammation
dexamethasone
0
$T1$ are rare in patients with progressive supranuclear palsy (PSP).In this report we describe an unusual case of reversible $T2$
dystonias
levodopa
1
$T1$-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of $T2$
levodopa
PSP
0
$T1$ have been reported in Parkinson's disease and multiple system atrophy.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
dyskinesias
levodopa
0
$T1$ and multiple system atrophy.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
Parkinson's disease
levodopa
0
$T1$.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
multiple system atrophy
levodopa
0
$T1$-induced Oromandibular dystonia ($T2$
levodopa
OMD
0
$T1$ are rare in patients with progressive supranuclear palsy (PSP).In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of $T2$
dystonias
PSP
0
$T1$ have been reported in Parkinson's disease and multiple system atrophy.Cranial $T2$
dyskinesias
dystonias
0
$T1$ and multiple system atrophy.Cranial $T2$
Parkinson's disease
dystonias
0
$T1$.Cranial $T2$
multiple system atrophy
dystonias
0
$T1$ are rare in patients with progressive supranuclear palsy (PSP).In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia ($T2$
dystonias
OMD
0
$T1$ have been reported in Parkinson's disease and multiple system atrophy.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
dyskinesias
PSP
0
$T1$ and multiple system atrophy.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
Parkinson's disease
PSP
0
$T1$.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
multiple system atrophy
PSP
0
$T1$) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of $T2$
OMD
PSP
0
$T1$ have been reported in $T2$
dyskinesias
Parkinson's disease
0
$T1$ have been reported in Parkinson's disease and $T2$
dyskinesias
multiple system atrophy
0
$T1$ have been reported in Parkinson's disease and multiple system atrophy.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
dyskinesias
OMD
0
$T1$ and $T2$
Parkinson's disease
multiple system atrophy
0
$T1$ and multiple system atrophy.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
Parkinson's disease
OMD
0
$T1$.Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).
multiple system atrophy
OMD
0
$T1$-induced $T2$
streptomycin
vestibulotoxicity
1
$T1$ suppresses $T2$
edaravone
streptomycin
0
$T1$ suppresses streptomycin-induced $T2$
edaravone
vestibulotoxicity
0
$T1$.Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.
cerebral infarction
edaravone
0
$T1$.Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.
cerebral infarction
streptomycin
0
$T1$.Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.
cerebral infarction
vestibulotoxicity
0
$T1$ as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative $T2$
ketamine
hallucinations
1
$T1$ only.After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.
oxygen
ketamine
0
$T1$, unless contraindicated or risky, remains the only necessary complementary drug to $T2$
Diazepam
ketamine
0
$T1$ as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.
ketamine
glycopyrrolate
0
$T1$ as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.Local anaesthetic blocks were useful in decreasing the requirement for postoperative $T2$
ketamine
analgesia
0
$T1$ only.After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.
oxygen
Diazepam
0
$T1$ only.After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.
oxygen
glycopyrrolate
0
$T1$ only.After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.
oxygen
hallucinations
0
$T1$ only.After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.
oxygen
analgesia
0
$T1$, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.
Diazepam
glycopyrrolate
0
$T1$, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative $T2$
Diazepam
hallucinations
0
$T1$, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.Local anaesthetic blocks were useful in decreasing the requirement for postoperative $T2$
Diazepam
analgesia
0
$T1$.Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.
hallucinations
glycopyrrolate
0
$T1$.An antisialogue was usually unnecessary in operations lasting up to 2 h, $T2$
analgesia
glycopyrrolate
0
$T1$.Local anaesthetic blocks were useful in decreasing the requirement for postoperative $T2$
hallucinations
analgesia
0
$T1$-induced $T2$
scopolamine
amnesia
1
$T1$.These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive $T2$
amnesia
steroids
0
$T1$ to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive $T2$
PREGS
steroids
0
$T1$ receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.
NMDA
steroids
0
$T1$(A)Rs and NMDARs).The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
GABA
steroids
0
$T1$ and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.
11-ketopregnenolone sulphate
steroids
0
$T1$-induced amnesia.These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive $T2$
scopolamine
steroids
0
$T1$ to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced $T2$
PREGS
amnesia
0
$T1$ receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced $T2$
NMDA
amnesia
0
$T1$(A)Rs and NMDARs).The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
GABA
amnesia
0
$T1$ and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced $T2$
11-ketopregnenolone sulphate
amnesia
0
$T1$ receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural $T2$
NMDA
PREGS
0
$T1$(A)Rs and NMDARs).The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
GABA
PREGS
0
$T1$ and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural $T2$
11-ketopregnenolone sulphate
PREGS
0
$T1$ to be an order of magnitude more effective than its synthetic enantiomer in reversing $T2$
PREGS
scopolamine
0
$T1$(A)Rs and NMDARs).The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
GABA
NMDA
0
$T1$ and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of $T2$
11-ketopregnenolone sulphate
NMDA
0
$T1$ receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing $T2$
NMDA
scopolamine
0
$T1$(A)Rs and NMDARs).The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
GABA
11-ketopregnenolone sulphate
0
$T1$(A)Rs and NMDARs).The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.
GABA
scopolamine
0
$T1$ and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing $T2$
11-ketopregnenolone sulphate
scopolamine
0
$T1$ from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral $T2$
allodynia
capsaicin
1
$T1$ in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
acute and chronic pain
adenosine
0
$T1$, presumed to reflect central sensitization in humans after peripheral capsaicin injection.The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of $T2$
hypersensitivity
adenosine
0
$T1$ injection.The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of $T2$
capsaicin
adenosine
0
$T1$ report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.
pain
adenosine
0
$T1$ from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.
allodynia
adenosine
0
$T1$ and is not due to prolonged residence of $T2$
neuropathic pain
adenosine
0
$T1$ in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
acute and chronic pain
hypersensitivity
0
$T1$ in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
acute and chronic pain
capsaicin
0
$T1$ in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
acute and chronic pain
pain
0
$T1$ in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
acute and chronic pain
allodynia
0
$T1$ in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
acute and chronic pain
neuropathic pain
0
$T1$, presumed to reflect central sensitization in humans after peripheral $T2$
hypersensitivity
capsaicin
0
$T1$ report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of $T2$
pain
hypersensitivity
0
$T1$ from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of $T2$
allodynia
hypersensitivity
0
$T1$, presumed to reflect central sensitization in humans after peripheral capsaicin injection.The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic $T2$
hypersensitivity
neuropathic pain
0
$T1$ report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral $T2$
pain
capsaicin
0
$T1$ injection.The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic $T2$
capsaicin
neuropathic pain
0
$T1$ report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and $T2$
pain
allodynia
0
$T1$ report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.
pain
neuropathic pain
0
$T1$ from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.
allodynia
neuropathic pain
0
$T1$ and hypercalcemia during $T2$
hypothyroidism
lithium
1
$T1$ is a risk factor for hypothyroidism and hypercalcemia during $T2$
thyroid illness
lithium
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.
bipolar disorder
lithium
0
$T1$ or endocrinological diagnoses from the hospital's out-patient clinics.OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.
psychiatric
lithium
0
$T1$ levels associated with aging.CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during $T2$
calcium
lithium
0
$T1$ levels in patients on lithium treatment were unchanged from baseline levels.After lithium treatment, calcium levels were higher than either baseline levels or control levels.
Magnesium
lithium
0
$T1$ during $T2$
hypercalcemia
lithium
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.
bipolar disorder
thyroid illness
0
$T1$ or endocrinological diagnoses from the hospital's out-patient clinics.OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.
psychiatric
thyroid illness
0
$T1$ levels associated with aging.CONCLUSIONS: Familial $T2$
calcium
thyroid illness
0
$T1$ levels in patients on lithium treatment were unchanged from baseline levels.After lithium treatment, calcium levels were higher than either baseline levels or control levels.
Magnesium
thyroid illness
0
$T1$ is a risk factor for $T2$
thyroid illness
hypothyroidism
0
$T1$ is a risk factor for hypothyroidism and $T2$
thyroid illness
hypercalcemia
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no $T2$
bipolar disorder
psychiatric
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.
bipolar disorder
calcium
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.
bipolar disorder
Magnesium
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.
bipolar disorder
hypothyroidism
0
$T1$ receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.
bipolar disorder
hypercalcemia
0
$T1$ or endocrinological diagnoses from the hospital's out-patient clinics.OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.
psychiatric
calcium
0
$T1$ or endocrinological diagnoses from the hospital's out-patient clinics.OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.
psychiatric
Magnesium
0
$T1$ or endocrinological diagnoses from the hospital's out-patient clinics.OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.
psychiatric
hypothyroidism
0
$T1$ or endocrinological diagnoses from the hospital's out-patient clinics.OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.
psychiatric
hypercalcemia
0
$T1$ levels in patients on lithium treatment were unchanged from baseline levels.After lithium treatment, calcium levels were higher than either baseline levels or control levels.
Magnesium
calcium
0
$T1$ levels associated with aging.CONCLUSIONS: Familial thyroid illness is a risk factor for $T2$
calcium
hypothyroidism
0
$T1$ levels associated with aging.CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and $T2$
calcium
hypercalcemia
0
$T1$ levels in patients on lithium treatment were unchanged from baseline levels.After lithium treatment, calcium levels were higher than either baseline levels or control levels.
Magnesium
hypothyroidism
0
$T1$ levels in patients on lithium treatment were unchanged from baseline levels.After lithium treatment, calcium levels were higher than either baseline levels or control levels.
Magnesium
hypercalcemia
0
$T1$ and $T2$
hypothyroidism
hypercalcemia
0
$T1$ include fever, anemia, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
sirolimus
capillary leak
1
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
sirolimus
0
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
psoriasis
0
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
capillary leak
0
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
dexamethasone
0
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
fever
0
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
anemia
0
$T1$ following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.
toxicity
inflammatory diseases
0
$T1$ include fever, anemia, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
sirolimus
psoriasis
0
$T1$-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.CONCLUSIONS: Severe adverse effects of $T2$
dexamethasone
sirolimus
0
$T1$ include $T2$
sirolimus
fever
0
$T1$ include fever, $T2$
sirolimus
anemia
0
$T1$ include fever, anemia, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
sirolimus
inflammatory diseases
0
$T1$ may develop $T2$
psoriasis
capillary leak
0
$T1$-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.
dexamethasone
psoriasis
0
$T1$, anemia, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
fever
psoriasis
0
$T1$, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
anemia
psoriasis
0
$T1$ may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with $T2$
psoriasis
inflammatory diseases
0
$T1$-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.
dexamethasone
capillary leak
0
$T1$, anemia, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
fever
capillary leak
0
$T1$, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
anemia
capillary leak
0
$T1$ from various systemic therapies, clinical monitoring is advisable for patients with $T2$
capillary leak
inflammatory diseases
0
$T1$-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.CONCLUSIONS: Severe adverse effects of sirolimus include $T2$
dexamethasone
fever
0
$T1$-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.CONCLUSIONS: Severe adverse effects of sirolimus include fever, $T2$
dexamethasone
anemia
0
$T1$-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.
dexamethasone
inflammatory diseases
0
$T1$, $T2$
fever
anemia
0
$T1$, anemia, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
fever
inflammatory diseases
0
$T1$, and capillary leak syndrome.These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.
anemia
inflammatory diseases
0
$T1$ (MMG) and the enhanced electromyographic activity (EMG).5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with $T2$
muscle rigidity
haloperidol
1
$T1$ site of $T2$
glycine
NMDA
0
$T1$ (MMG) and the enhanced electromyographic activity (EMG).5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.
muscle rigidity
glycine
0
$T1$ had no effect on the muscle tone.The present results suggest that blockade of the $T2$
haloperidol
glycine
0
$T1$ injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.The present results suggest that blockade of the $T2$
5,7-DCKA
glycine
0
$T1$ (MMG) and the enhanced electromyographic activity (EMG).5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.
muscle rigidity
NMDA
0
$T1$ had no effect on the muscle tone.The present results suggest that blockade of the glycine site of $T2$
haloperidol
NMDA
0
$T1$ injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.The present results suggest that blockade of the glycine site of $T2$
5,7-DCKA
NMDA
0
$T1$ (MMG) and the enhanced electromyographic activity (EMG).$T2$
muscle rigidity
5,7-DCKA
0
$T1$ injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with $T2$
5,7-DCKA
haloperidol
0
$T1$, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.
Myopathy
Lovastatin
1
$T1$ is highly effective and generally well tolerated as therapy for primary $T2$
Lovastatin
hypercholesterolemia
0
$T1$ levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.
cholesterol
Lovastatin
0
$T1$ (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).
triglycerides
Lovastatin
0
$T1$ kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.
creatine
Lovastatin
0
$T1$ levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.
cholesterol
hypercholesterolemia
0
$T1$ (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).
triglycerides
hypercholesterolemia
0
$T1$, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.
Myopathy
hypercholesterolemia
0
$T1$ kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.
creatine
hypercholesterolemia
0
$T1$ (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL $T2$
triglycerides
cholesterol
0
$T1$ levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.
cholesterol
Myopathy
0
$T1$ levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose.
cholesterol
creatine
0
$T1$ (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).
triglycerides
Myopathy
0
$T1$ (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL).
triglycerides
creatine
0
$T1$, defined as muscle symptoms with $T2$
Myopathy
creatine
0
$T1$-induced $T2$
quipazine
head twitches
1
$T1$-induced $T2$
apomorphine
aggressiveness
1
$T1$-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of $T2$
apomorphine
REMD
0
$T1$, and reduced (immediately after completing of REMD) or increased (96 hr after completing of $T2$
aggressiveness
REMD
0
$T1$) $T2$
REMD
quipazine
0
$T1$) quipazine-induced $T2$
REMD
head twitches
0
$T1$-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) $T2$
apomorphine
quipazine
0
$T1$-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced $T2$
apomorphine
head twitches
0
$T1$, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) $T2$
aggressiveness
quipazine
0
$T1$, and reduced (immediately after completing of REMD) or increased (96 hr after completing of REMD) quipazine-induced $T2$
aggressiveness
head twitches
0
$T1$ developed.Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.
parkinsonism
haloperidol
1
$T1$ was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.The present study points to patient characteristics that may be of significance in the development of EPS due to $T2$
Akathisia
haloperidol
0
$T1$ lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.The present study points to patient characteristics that may be of significance in the development of EPS due to $T2$
benzodiazepine
haloperidol
0
$T1$ in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.The present study points to patient characteristics that may be of significance in the development of EPS due to $T2$
lorazepam
haloperidol
0
$T1$ developed.$T2$
parkinsonism
Akathisia
0
$T1$ developed.Akathisia was controlled by the $T2$
parkinsonism
benzodiazepine
0
$T1$ developed.Akathisia was controlled by the benzodiazepine $T2$
parkinsonism
lorazepam
0
$T1$ was controlled by the $T2$
Akathisia
benzodiazepine
0
$T1$ was controlled by the benzodiazepine $T2$
Akathisia
lorazepam
0
$T1$ $T2$
benzodiazepine
lorazepam
0
$T1$ over time, and may be the first case of veno-occlusive related solely to $T2$
hepatic veno-occlusive disease
6-thioguanine
1
$T1$ after 10 months of maintenance therapy with 6-thioguanine.Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement.
acute lymphocytic leukemia
hepatic veno-occlusive disease
0
$T1$ about the terminal hepatic veins persisted.This case presented a unique opportunity to observe the histologic features of clinically reversible $T2$
fibrosis
hepatic veno-occlusive disease
0
$T1$ after 10 months of maintenance therapy with 6-thioguanine.Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement.
acute lymphocytic leukemia
6-thioguanine
0
$T1$ about the terminal hepatic veins persisted.This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to $T2$
fibrosis
6-thioguanine
0
$T1$ after 10 months of maintenance therapy with 6-thioguanine.Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement.
acute lymphocytic leukemia
fibrosis
0
$T1$ (cystitis and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
bladder irritation
IF
1
$T1$, simplifies the treatment and provides optimum protection for the urinary epithelium.Protection with oral $T2$
IF
MESNA
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
IF
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
IF
0
$T1$ and/or symptoms of bladder irritation (cystitis and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
haematuria
IF
0
$T1$ and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
cystitis
IF
0
$T1$).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
pollakisuria
IF
0
$T1$ of the cytostatic treatment.Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include $T2$
toxicity
IF
0
$T1$ (cystitis and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
bladder irritation
MESNA
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
bladder irritation
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
bladder irritation
0
$T1$ and/or symptoms of $T2$
haematuria
bladder irritation
0
$T1$ ($T2$
bladder irritation
cystitis
0
$T1$ (cystitis and $T2$
bladder irritation
pollakisuria
0
$T1$ (cystitis and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic $T2$
bladder irritation
toxicity
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
MESNA
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
MESNA
0
$T1$ and/or symptoms of bladder irritation (cystitis and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
haematuria
MESNA
0
$T1$ and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
cystitis
MESNA
0
$T1$).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
pollakisuria
MESNA
0
$T1$ of the cytostatic treatment.Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.
toxicity
MESNA
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable $T2$
thiol
lung cancer
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
haematuria
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
cystitis
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
pollakisuria
0
$T1$ under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
lung cancer
toxicity
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
haematuria
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
cystitis
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
pollakisuria
0
$T1$ compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.
thiol
toxicity
0
$T1$ and/or symptoms of bladder irritation ($T2$
haematuria
cystitis
0
$T1$ and/or symptoms of bladder irritation (cystitis and $T2$
haematuria
pollakisuria
0
$T1$ and/or symptoms of bladder irritation (cystitis and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic $T2$
haematuria
toxicity
0
$T1$ and $T2$
cystitis
pollakisuria
0
$T1$ and pollakisuria).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic $T2$
cystitis
toxicity
0
$T1$).There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic $T2$
pollakisuria
toxicity
0
$T1$.The subjects were ten patients found to have normal left ventricles and coronary arteries.
hypaque 76
hypotension
1
$T1$.The subjects were ten patients found to have normal left ventricles and coronary arteries.
hypaque 76
QTC prolongation
1
$T1$ occurred in 30 seconds to one minute in association with marked $T2$
QTC prolongation
hypotension
0
$T1$ acted as a tumor enhancement agent, with primary emphasis on the development of $T2$
TP
prostate cancer
1
$T1$ (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.The incubation periods averaged 10.6 months.
N-nitroso-N-methylurea
prostate cancer
1
$T1$.More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.
testosterone
prostate cancer
0
$T1$ enhancement agent, with primary emphasis on the development of $T2$
tumor
prostate cancer
0
$T1$.More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with $T2$
testosterone
N-nitroso-N-methylurea
0
$T1$ (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.The incubation periods averaged 10.6 months.
N-nitroso-N-methylurea
TP
0
$T1$ (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.The incubation periods averaged 10.6 months.
N-nitroso-N-methylurea
tumor
0
$T1$.More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.
testosterone
TP
0
$T1$.More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.
testosterone
tumor
0
$T1$ acted as a $T2$
TP
tumor
0
$T1$/ACTH) stimulation of the rat locus ceruleus.The movement disorder investigated in these studies has some features in common with human idiopathic $T2$
MSH
dystonia
1
$T1$, and information obtained in these studies may be of potential clinical benefit.The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.
dystonia
ACTH
1
$T1$, and information obtained in these studies may be of potential clinical benefit.The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.
dystonia
movement disorder
0
$T1$, and information obtained in these studies may be of potential clinical benefit.The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.
dystonia
depression
0
$T1$/ACTH) stimulation of the rat locus ceruleus.The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.
MSH
ACTH
0
$T1$/ACTH) stimulation of the rat locus ceruleus.The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.
MSH
movement disorder
0
$T1$/ACTH) stimulation of the rat locus ceruleus.The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.
MSH
depression
0
$T1$ N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the $T2$
ACTH
movement disorder
0
$T1$ N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term $T2$
ACTH
depression
0
$T1$ at Purkinje cell synapses (previously described by others) that resulted in the long duration of the $T2$
depression
movement disorder
0
$T1$-induced $T2$
alfentanil
muscle rigidity
1
$T1$ in a dose-dependent fashion.The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.
muscle rigidity
D-MED
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
D-MED
0
$T1$-induced muscle rigidity in a dose-dependent fashion.The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.
alfentanil
D-MED
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
medetomidine
D-MED
0
$T1$ [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
idazoxan
D-MED
0
$T1$ [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
DG-5128
D-MED
0
$T1$ animals were flaccid, $T2$
D-MED
akinetic
0
$T1$ animals were flaccid, akinetic, and lacked a $T2$
D-MED
startle
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
muscle rigidity
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
medetomidine
muscle rigidity
0
$T1$ [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
idazoxan
muscle rigidity
0
$T1$ [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
DG-5128
muscle rigidity
0
$T1$ in a dose-dependent fashion.The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.
muscle rigidity
akinetic
0
$T1$ in a dose-dependent fashion.The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.
muscle rigidity
startle
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
alfentanil
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
medetomidine
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
idazoxan
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
DG-5128
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
akinetic
0
$T1$ and anesthesia in rats and dogs.Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.
muscle flaccidity
startle
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
medetomidine
alfentanil
0
$T1$ [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
idazoxan
alfentanil
0
$T1$ [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
DG-5128
alfentanil
0
$T1$-induced muscle rigidity in a dose-dependent fashion.The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.
alfentanil
akinetic
0
$T1$-induced muscle rigidity in a dose-dependent fashion.The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.
alfentanil
startle
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, $T2$
medetomidine
idazoxan
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist $T2$
medetomidine
DG-5128
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
medetomidine
akinetic
0
$T1$), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
medetomidine
startle
0
$T1$ [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist $T2$
idazoxan
DG-5128
0
$T1$ [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
idazoxan
akinetic
0
$T1$ [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
idazoxan
startle
0
$T1$ [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
DG-5128
akinetic
0
$T1$ [10 mg/kg], or; 6) saline.Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment.
DG-5128
startle
0
$T1$, and lacked a $T2$
akinetic
startle
0
$T1$.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
imipenem/cilastatin
seizure
1
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
imipenem
seizure
0
$T1$) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
CVA
seizure
0
$T1$ and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
head trauma
seizure
0
$T1$ developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
renal disease
seizure
0
$T1$.Both patients had received maximum doses of other beta-lactam antibiotics without evidence of $T2$
phenytoin
seizure
0
$T1$ antibiotics without evidence of $T2$
beta-lactam
seizure
0
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident ($T2$
imipenem
CVA
0
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or $T2$
imipenem
head trauma
0
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of $T2$
imipenem
renal disease
0
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of $T2$
imipenem
imipenem/cilastatin
0
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
imipenem
phenytoin
0
$T1$ therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
imipenem
beta-lactam
0
$T1$) or $T2$
CVA
head trauma
0
$T1$) or head trauma and no evidence of $T2$
CVA
renal disease
0
$T1$) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of $T2$
CVA
imipenem/cilastatin
0
$T1$) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
CVA
phenytoin
0
$T1$) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
CVA
beta-lactam
0
$T1$ and no evidence of $T2$
head trauma
renal disease
0
$T1$ and no evidence of renal disease developed seizures while receiving maximum doses of $T2$
head trauma
imipenem/cilastatin
0
$T1$ and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
head trauma
phenytoin
0
$T1$ and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
head trauma
beta-lactam
0
$T1$ developed seizures while receiving maximum doses of $T2$
renal disease
imipenem/cilastatin
0
$T1$ developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
renal disease
phenytoin
0
$T1$ developed seizures while receiving maximum doses of imipenem/cilastatin.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
renal disease
beta-lactam
0
$T1$.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
imipenem/cilastatin
phenytoin
0
$T1$.Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.
imipenem/cilastatin
beta-lactam
0
$T1$.Both patients had received maximum doses of other $T2$
phenytoin
beta-lactam
0
$T1$-induced $T2$
streptozotocin
diabetes
1
$T1$, and bethanechol.6.
ATP
streptozotocin
0
$T1$.6.
bethanechol
streptozotocin
0
$T1$, and bethanechol.6.
ATP
diabetes
0
$T1$.6.
bethanechol
diabetes
0
$T1$, and $T2$
ATP
bethanechol
0
$T1$-induced $T2$
phenylephrine
hypertension
1
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
hypertension
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
hypertension
0
$T1$ instituted 2 h after $T2$
hypertension
MCAO
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
hypertension
0
$T1$ instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the $T2$
hypertension
ischemic
0
$T1$ instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical $T2$
hypertension
neuronal dysfunction
0
$T1$ staining.In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
2,3,5-triphenyltetrazolium
hypertension
0
$T1$ instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves $T2$
hypertension
edema
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on $T2$
cerebral ischemia
brain edema
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
MCAO
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
isoflurane
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
ischemic
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
neuronal dysfunction
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
2,3,5-triphenyltetrazolium
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
edema
0
$T1$: effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.
cerebral ischemia
phenylephrine
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
MCAO
0
$T1$ formation and histochemical injury was studied.Under $T2$
brain edema
isoflurane
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
ischemic
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
neuronal dysfunction
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
2,3,5-triphenyltetrazolium
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
edema
0
$T1$ formation and histochemical injury was studied.Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
brain edema
phenylephrine
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
MCAO
0
$T1$ does not aggravate edema in the ischemic core, that it improves edema in the periphery of the $T2$
MCAO
ischemic
0
$T1$ does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical $T2$
MCAO
neuronal dysfunction
0
$T1$ staining.In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
2,3,5-triphenyltetrazolium
MCAO
0
$T1$ does not aggravate edema in the ischemic core, that it improves $T2$
MCAO
edema
0
$T1$-induced hypertension instituted 2 h after $T2$
phenylephrine
MCAO
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
ischemic
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
neuronal dysfunction
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
2,3,5-triphenyltetrazolium
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
edema
0
$T1$ anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.
isoflurane
phenylephrine
0
$T1$ territory, and that it reduces the area of histochemical $T2$
ischemic
neuronal dysfunction
0
$T1$ staining.In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
2,3,5-triphenyltetrazolium
ischemic
0
$T1$ in the periphery of the $T2$
edema
ischemic
0
$T1$-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the $T2$
phenylephrine
ischemic
0
$T1$ staining.In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
2,3,5-triphenyltetrazolium
neuronal dysfunction
0
$T1$ in the periphery of the ischemic territory, and that it reduces the area of histochemical $T2$
edema
neuronal dysfunction
0
$T1$-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical $T2$
phenylephrine
neuronal dysfunction
0
$T1$ staining.In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
2,3,5-triphenyltetrazolium
edema
0
$T1$ staining.In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.
2,3,5-triphenyltetrazolium
phenylephrine
0
$T1$-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves $T2$
phenylephrine
edema
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
pneumonitis
amiodarone
1
$T1$.The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.
hypersensitivity pneumonitis
amiodarone
1
$T1$ are characteristic but nonspecific.The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.
pulmonary toxicity
amiodarone
0
$T1$, infection, and malignancy.While withdrawal of $T2$
heart failure
amiodarone
0
$T1$, and malignancy.While withdrawal of $T2$
infection
amiodarone
0
$T1$.While withdrawal of $T2$
malignancy
amiodarone
0
$T1$ leads to clinical improvement in majority of cases, this is not always possible or advisable.Dose reduction or concomitant $T2$
amiodarone
steroid
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
pneumonitis
pulmonary toxicity
0
$T1$.The clinical and radiographic features of amiodarone-induced $T2$
hypersensitivity pneumonitis
pulmonary toxicity
0
$T1$ are characteristic but nonspecific.The diagnosis depends on exclusion of other entities, such as $T2$
pulmonary toxicity
heart failure
0
$T1$ are characteristic but nonspecific.The diagnosis depends on exclusion of other entities, such as heart failure, $T2$
pulmonary toxicity
infection
0
$T1$ are characteristic but nonspecific.The diagnosis depends on exclusion of other entities, such as heart failure, infection, and $T2$
pulmonary toxicity
malignancy
0
$T1$ are characteristic but nonspecific.The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.
pulmonary toxicity
steroid
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated $T2$
pneumonitis
hypersensitivity pneumonitis
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
pneumonitis
heart failure
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
pneumonitis
infection
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
pneumonitis
malignancy
0
$T1$.The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
pneumonitis
steroid
0
$T1$.The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.
hypersensitivity pneumonitis
heart failure
0
$T1$.The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.
hypersensitivity pneumonitis
infection
0
$T1$.The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.
hypersensitivity pneumonitis
malignancy
0
$T1$.The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific.
hypersensitivity pneumonitis
steroid
0
$T1$, $T2$
heart failure
infection
0
$T1$, infection, and $T2$
heart failure
malignancy
0
$T1$, infection, and malignancy.While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable.
heart failure
steroid
0
$T1$, and $T2$
infection
malignancy
0
$T1$, and malignancy.While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable.
infection
steroid
0
$T1$.While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable.
malignancy
steroid
0
$T1$ was found in 9 of 17 tuberculosis patients treated with rifampin.Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.
proteinuria
rifampin
1
$T1$ was found in 9 of 17 tuberculosis patients treated with rifampin.Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.
proteinuria
tuberculous
0
$T1$ patients.This last finding may be related to time of testing and/or endogenous serum binding of $T2$
tuberculous
rifampin
0
$T1$ under prior oral diuretic treatment.$T2$
hypokalaemia
Chlorthalidone
1
$T1$ under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypokalaemia
potassium
0
$T1$ (50 mg daily) was given for 14 days.Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.
Chlorthalidone
potassium
0
$T1$ who had shown hypokalaemia under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypertension
potassium
0
$T1$ delivery to the distal renal tubules remains sufficiently high to allow increased $T2$
sodium
potassium
0
$T1$ system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased $T2$
aldosterone
potassium
0
$T1$-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased $T2$
angiotensin
potassium
0
$T1$ who had shown $T2$
hypertension
hypokalaemia
0
$T1$ under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypokalaemia
sodium
0
$T1$ under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypokalaemia
aldosterone
0
$T1$ under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypokalaemia
angiotensin
0
$T1$ who had shown hypokalaemia under prior oral diuretic treatment.$T2$
hypertension
Chlorthalidone
0
$T1$ (50 mg daily) was given for 14 days.Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.
Chlorthalidone
sodium
0
$T1$ (50 mg daily) was given for 14 days.Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.
Chlorthalidone
aldosterone
0
$T1$ (50 mg daily) was given for 14 days.Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.
Chlorthalidone
angiotensin
0
$T1$ who had shown hypokalaemia under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypertension
sodium
0
$T1$ who had shown hypokalaemia under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypertension
aldosterone
0
$T1$ who had shown hypokalaemia under prior oral diuretic treatment.Chlorthalidone (50 mg daily) was given for 14 days.
hypertension
angiotensin
0
$T1$ system, while $T2$
aldosterone
sodium
0
$T1$-aldosterone system, while $T2$
angiotensin
sodium
0
$T1$-$T2$
angiotensin
aldosterone
0
$T1$ induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.
acute renal failure
gentamicin
1
$T1$ induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.
acute renal failure
vitamin C
0
$T1$ induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.
acute renal failure
urea
0
$T1$ induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.
acute renal failure
creatinine
0
$T1$ induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.
acute renal failure
potassium
0
$T1$-treated animals and beneficial effects of $T2$
gentamicin
vitamin C
0
$T1$ and creatinine and higher level of potassium.The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).
urea
gentamicin
0
$T1$ and higher level of potassium.The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).
creatinine
gentamicin
0
$T1$.The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).
potassium
gentamicin
0
$T1$ and creatinine and higher level of potassium.The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).
urea
vitamin C
0
$T1$ and higher level of potassium.The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).
creatinine
vitamin C
0
$T1$.The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).
potassium
vitamin C
0
$T1$ and $T2$
urea
creatinine
0
$T1$ and creatinine and higher level of $T2$
urea
potassium
0
$T1$ and higher level of $T2$
creatinine
potassium
0
$T1$ was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.Pulse power analysis may be helpful in determining the etiology of and treating $T2$
oxytocin
hypotension
1
$T1$ was associated with a decrease in systemic vascular resistance and a compensatory increase in $T2$
oxytocin
stroke
0
$T1$.Pulse power analysis (also called "pulse contour analysis") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.
blood loss
oxytocin
0
$T1$ volume, heart rate and cardiac output.Pulse power analysis may be helpful in determining the etiology of and treating $T2$
stroke
hypotension
0
$T1$.Pulse power analysis (also called "pulse contour analysis") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.
blood loss
hypotension
0
$T1$.Pulse power analysis (also called "pulse contour analysis") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.
blood loss
stroke
0
$T1$ (150 mg/kg; i.p.; 48 h).
cystitis
CYP
1
$T1$.This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with $T2$
CYP
bladder inflammation
0
$T1$ (150 mg/kg; i.p.; 48 h).
cystitis
bladder inflammation
0
$T1$ (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg $T2$
elevated intraocular pressure
FA
1
$T1$ treated with the fluocinolone acetonide (FA) intravitreal implant.DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg $T2$
uveitis
FA
0
$T1$ (IOP) in patients with $T2$
elevated intraocular pressure
uveitis
0
$T1$ treated with the fluocinolone acetonide (FA) intravitreal implant.DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.
uveitis
hypotony
0
$T1$ intravitreal implant or standard therapy were analyzed.RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively.
FA
hypotony
0
$T1$ (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed.
elevated intraocular pressure
hypotony
0
$T1$-induced $T2$
levodopa
dyskinesias
1
$T1$, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced $T2$
PD
dyskinesias
0
$T1$, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.Pallidal stimulation improves bradykinesia and $T2$
PD
rigidity
0
$T1$, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.Pallidal stimulation improves $T2$
PD
bradykinesia
0
$T1$, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving $T2$
PD
levodopa
0
$T1$, such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.
PD
hyper- or dyskinetic
0
$T1$ to a minor extent; however, its strength seems to be in improving levodopa-induced $T2$
rigidity
dyskinesias
0
$T1$ and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced $T2$
bradykinesia
dyskinesias
0
$T1$.Stimulation often produces an improvement in the $T2$
dyskinesias
hyper- or dyskinetic
0
$T1$ and $T2$
bradykinesia
rigidity
0
$T1$ to a minor extent; however, its strength seems to be in improving $T2$
rigidity
levodopa
0
$T1$ to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.Stimulation often produces an improvement in the $T2$
rigidity
hyper- or dyskinetic
0
$T1$ and rigidity to a minor extent; however, its strength seems to be in improving $T2$
bradykinesia
levodopa
0
$T1$ and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.Stimulation often produces an improvement in the $T2$
bradykinesia
hyper- or dyskinetic
0
$T1$-induced dyskinesias.Stimulation often produces an improvement in the $T2$
levodopa
hyper- or dyskinetic
0
$T1$.Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.
myocardial infarction
PPA
1
$T1$ used in over-the-counter cold remedies and weight-control preparations worldwide.Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.
amine
PPA
0
$T1$ episodes and hemorrhagic strokes in younger women.Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
hypertensive
PPA
0
$T1$ in younger women.Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
hemorrhagic strokes
PPA
0
$T1$ that have been reported so far.Physicians and patients should be alert to the potential cardiac risk associated with the use of $T2$
myocardial injury
PPA
0
$T1$ is involved.We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.
overdose
PPA
0
$T1$.Phenylpropanolamine (PPA) is a sympathetic $T2$
myocardial infarction
amine
0
$T1$.Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.
myocardial infarction
hypertensive
0
$T1$.Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.
myocardial infarction
hemorrhagic strokes
0
$T1$.Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.
myocardial infarction
myocardial injury
0
$T1$.Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.
myocardial infarction
overdose
0
$T1$ used in over-the-counter cold remedies and weight-control preparations worldwide.Its use has been associated with $T2$
amine
hypertensive
0
$T1$ used in over-the-counter cold remedies and weight-control preparations worldwide.Its use has been associated with hypertensive episodes and $T2$
amine
hemorrhagic strokes
0
$T1$ used in over-the-counter cold remedies and weight-control preparations worldwide.Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.
amine
myocardial injury
0
$T1$ used in over-the-counter cold remedies and weight-control preparations worldwide.Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.
amine
overdose
0
$T1$ episodes and $T2$
hypertensive
hemorrhagic strokes
0
$T1$ episodes and hemorrhagic strokes in younger women.Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
hypertensive
myocardial injury
0
$T1$ episodes and hemorrhagic strokes in younger women.Several reports have linked the abuse of PPA with myocardial injury, especially when $T2$
hypertensive
overdose
0
$T1$ in younger women.Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
hemorrhagic strokes
myocardial injury
0
$T1$ in younger women.Several reports have linked the abuse of PPA with myocardial injury, especially when $T2$
hemorrhagic strokes
overdose
0
$T1$ is involved.We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.
overdose
myocardial injury
0
$T1$.This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of $T2$
visual disturbances
risperidone
1
$T1$ patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
schizophrenic
risperidone
0
$T1$ consumption.Risperidone administration was continued and the visual disturbances gradually wore off.
LSD
risperidone
0
$T1$ with classic antipsychotics, were successfully treated with risperidone.They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
EPS
risperidone
0
$T1$ patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
schizophrenic
visual disturbances
0
$T1$ consumption.Risperidone administration was continued and the visual disturbances gradually wore off.
LSD
visual disturbances
0
$T1$ with classic antipsychotics, were successfully treated with risperidone.They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
EPS
visual disturbances
0
$T1$ patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
schizophrenic
LSD
0
$T1$ patients, who had a prior history of LSD abuse and who had previously developed $T2$
schizophrenic
EPS
0
$T1$ with classic antipsychotics, were successfully treated with risperidone.They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
EPS
LSD
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
DOX
1
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
DOX
0
$T1$.Activation of the nuclear enzyme $T2$
heart failure
poly(ADP-ribose)
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
cardiotoxicity
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor $T2$
poly(ADP-ribose)
anthracycline
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
PJ34
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
cardiac dysfunction
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
lactate
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
creatine
0
$T1$ polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
poly(ADP-ribose)
cardiac complications
0
$T1$ of DOX.PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the $T2$
cardiotoxicity
DOX
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
DOX
0
$T1$ significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the cardiotoxicity of DOX.
PJ34
DOX
0
$T1$ and increased the survival of the animals.In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.
cardiac dysfunction
DOX
0
$T1$ dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the cardiotoxicity of DOX.
lactate
DOX
0
$T1$ kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the cardiotoxicity of DOX.
creatine
DOX
0
$T1$ associated with the $T2$
cardiac complications
DOX
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
cardiotoxicity
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
anthracycline
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
PJ34
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
cardiac dysfunction
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
lactate
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
creatine
0
$T1$.Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.
heart failure
cardiac complications
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
cardiotoxicity
0
$T1$ significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the $T2$
PJ34
cardiotoxicity
0
$T1$ and increased the survival of the animals.In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.
cardiac dysfunction
cardiotoxicity
0
$T1$ dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the $T2$
lactate
cardiotoxicity
0
$T1$ kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the $T2$
creatine
cardiotoxicity
0
$T1$ of DOX.PARP inhibitors may exert protective effects against the development of severe $T2$
cardiotoxicity
cardiac complications
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
PJ34
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
cardiac dysfunction
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
lactate
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
creatine
0
$T1$ antibiotic.Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.
anthracycline
cardiac complications
0
$T1$ and increased the survival of the animals.In addition $T2$
cardiac dysfunction
PJ34
0
$T1$ significantly reduced the DOX-induced increase in the serum $T2$
PJ34
lactate
0
$T1$ significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and $T2$
PJ34
creatine
0
$T1$ significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the cardiotoxicity of DOX.
PJ34
cardiac complications
0
$T1$ and increased the survival of the animals.In addition PJ34 significantly reduced the DOX-induced increase in the serum $T2$
cardiac dysfunction
lactate
0
$T1$ and increased the survival of the animals.In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and $T2$
cardiac dysfunction
creatine
0
$T1$ and increased the survival of the animals.In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.
cardiac dysfunction
cardiac complications
0
$T1$ dehydrogenase and $T2$
lactate
creatine
0
$T1$ dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the cardiotoxicity of DOX.
lactate
cardiac complications
0
$T1$ kinase activities but not metalloproteinase activation in the heart.Thus, PARP activation contributes to the cardiotoxicity of DOX.
creatine
cardiac complications
0
$T1$.Serial electrocardiographic monitoring may be considered when $T2$
TDP
fluconazole
1
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
fluconazole
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
fluconazole
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
fluconazole
0
$T1$ followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.
premature ventricular contractions
fluconazole
0
$T1$ and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.
NSVT
fluconazole
0
$T1$ of rapidly activating delayed rectifier potassium currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
depression
fluconazole
0
$T1$ currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
potassium
fluconazole
0
$T1$, leading to TDP.Serial electrocardiographic monitoring may be considered when $T2$
prolongation of the QT interval
fluconazole
0
$T1$ is administered in patients who are at risk for $T2$
fluconazole
ventricular arrhythmias
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
TDP
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
TDP
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
TDP
0
$T1$ followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to $T2$
premature ventricular contractions
TDP
0
$T1$ and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to $T2$
NSVT
TDP
0
$T1$ of rapidly activating delayed rectifier potassium currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
depression
TDP
0
$T1$ currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
potassium
TDP
0
$T1$, leading to $T2$
prolongation of the QT interval
TDP
0
$T1$.Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for $T2$
TDP
ventricular arrhythmias
0
$T1$, $T2$
coronary artery disease
cardiomyopathy
0
$T1$, cardiomyopathy, $T2$
coronary artery disease
congestive heart failure
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
premature ventricular contractions
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
NSVT
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
depression
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
potassium
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
prolongation of the QT interval
0
$T1$, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
coronary artery disease
ventricular arrhythmias
0
$T1$, $T2$
cardiomyopathy
congestive heart failure
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
premature ventricular contractions
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
NSVT
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
depression
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
potassium
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
prolongation of the QT interval
0
$T1$, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
cardiomyopathy
ventricular arrhythmias
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
premature ventricular contractions
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
NSVT
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
depression
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
potassium
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
prolongation of the QT interval
0
$T1$, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
congestive heart failure
ventricular arrhythmias
0
$T1$ and $T2$
NSVT
premature ventricular contractions
0
$T1$ of rapidly activating delayed rectifier potassium currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and $T2$
depression
premature ventricular contractions
0
$T1$ currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and $T2$
potassium
premature ventricular contractions
0
$T1$ followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause $T2$
premature ventricular contractions
prolongation of the QT interval
0
$T1$ followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.
premature ventricular contractions
ventricular arrhythmias
0
$T1$ of rapidly activating delayed rectifier potassium currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of $T2$
depression
NSVT
0
$T1$ currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of $T2$
potassium
NSVT
0
$T1$ and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause $T2$
NSVT
prolongation of the QT interval
0
$T1$ and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.
NSVT
ventricular arrhythmias
0
$T1$ of rapidly activating delayed rectifier $T2$
depression
potassium
0
$T1$ of rapidly activating delayed rectifier potassium currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
depression
prolongation of the QT interval
0
$T1$ of rapidly activating delayed rectifier potassium currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
depression
ventricular arrhythmias
0
$T1$ currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
potassium
prolongation of the QT interval
0
$T1$ currents.In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
potassium
ventricular arrhythmias
0
$T1$, leading to TDP.Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for $T2$
prolongation of the QT interval
ventricular arrhythmias
0
$T1$ recommended by NASCIS may cause acute corticosteroid $T2$
methylprednisolone
myopathy
1
$T1$.To our knowledge, this is the first discussion considering the possibility that the $T2$
spinal cord injury
methylprednisolone
0
$T1$ recommended by NASCIS may cause acute $T2$
methylprednisolone
corticosteroid
0
$T1$ myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.To our knowledge, this is the first discussion considering the possibility that the $T2$
steroid
methylprednisolone
0
$T1$.To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute $T2$
spinal cord injury
corticosteroid
0
$T1$.To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid $T2$
spinal cord injury
myopathy
0
$T1$ myopathy, instead of any protection that methylprednisolone offers to the $T2$
steroid
spinal cord injury
0
$T1$ $T2$
corticosteroid
myopathy
0
$T1$ myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute $T2$
steroid
corticosteroid
0
$T1$ myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid $T2$
steroid
myopathy
0
$T1$-induced $T2$
scopolamine
impairment in word recall
1
$T1$, yet correlations between central and peripheral responses have not been properly studied.This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.
Alzheimer's disease
tropicamide
0
$T1$, yet correlations between central and peripheral responses have not been properly studied.This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.
Alzheimer's disease
pilocarpine
0
$T1$, yet correlations between central and peripheral responses have not been properly studied.This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.
Alzheimer's disease
scopolamine
0
$T1$, yet correlations between central and peripheral responses have not been properly studied.This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.
Alzheimer's disease
impairment in word recall
0
$T1$.Thus, $T2$
tropicamide
pilocarpine
0
$T1$-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with $T2$
scopolamine
tropicamide
0
$T1$ 60, 90 and 120 minutes after administration (p < 0.05).CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with $T2$
impairment in word recall
tropicamide
0
$T1$-induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.
scopolamine
pilocarpine
0
$T1$ 60, 90 and 120 minutes after administration (p < 0.05).CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.
impairment in word recall
pilocarpine
0
$T1$-induced $T2$
acetazolamide
Gerstmann syndrome
1
$T1$ induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.We report a case of $T2$
confusion
acetazolamide
0
$T1$.We report a case of $T2$
renal impairment
acetazolamide
0
$T1$ induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.We report a case of acetazolamide-induced $T2$
confusion
Gerstmann syndrome
0
$T1$.We report a case of acetazolamide-induced $T2$
renal impairment
Gerstmann syndrome
0
$T1$ induced by acetazolamide is a well known adverse drug reaction in patients with $T2$
confusion
renal impairment
0
$T1$ shortly after the introduction of $T2$
hypomania
olanzapine
1
$T1$ (DSM-IV) who developed $T2$
psychotic disorder
hypomania
0
$T1$ (DSM-IV) who developed hypomania shortly after the introduction of $T2$
psychotic disorder
olanzapine
0
$T1$ due to $T2$
ALF
paracetamol
1
$T1$ and $T2$
Superoxide
hydrogen peroxide
0
$T1$ and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
Superoxide
ALF
0
$T1$ in patients with acute liver failure (ALF).In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
bacterial infections
Superoxide
0
$T1$ radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.
oxygen
Superoxide
0
$T1$ and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
Superoxide
paracetamol
0
$T1$ and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
Superoxide
overdose
0
$T1$ and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine ($T2$
Superoxide
fMLP
0
$T1$ production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
hydrogen peroxide
ALF
0
$T1$ in patients with acute liver failure (ALF).In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
bacterial infections
hydrogen peroxide
0
$T1$ radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.
oxygen
hydrogen peroxide
0
$T1$ production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
hydrogen peroxide
paracetamol
0
$T1$ production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
hydrogen peroxide
overdose
0
$T1$ production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine ($T2$
hydrogen peroxide
fMLP
0
$T1$ in patients with acute liver failure (ALF).In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
bacterial infections
ALF
0
$T1$ radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.
oxygen
ALF
0
$T1$ due to paracetamol $T2$
ALF
overdose
0
$T1$) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
fMLP
ALF
0
$T1$ in patients with acute liver failure (ALF).In the present study, $T2$
bacterial infections
oxygen
0
$T1$ in patients with acute liver failure (ALF).In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
bacterial infections
paracetamol
0
$T1$ in patients with acute liver failure (ALF).In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
bacterial infections
overdose
0
$T1$ in patients with acute liver failure (ALF).In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
bacterial infections
fMLP
0
$T1$ radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.
oxygen
paracetamol
0
$T1$ radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.
oxygen
overdose
0
$T1$ radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.
oxygen
fMLP
0
$T1$ $T2$
paracetamol
overdose
0
$T1$) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
fMLP
paracetamol
0
$T1$) from a further 18 ALF patients was unaffected compared with control neutrophils.Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).
fMLP
overdose
0
$T1$ produced a clear profile of $T2$
Haloperidol
cognitive impairment
1
$T1$ that was not worsened by concomitant $T2$
cognitive impairment
sertraline
0
$T1$ produced a clear profile of cognitive impairment that was not worsened by concomitant $T2$
Haloperidol
sertraline
0
$T1$-induced $T2$
ciprofloxacin
acute renal failure
1
$T1$ associated with ciprofloxacin is uncommon.Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
Nephrotoxicity
ciprofloxacin
0
$T1$ who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.
cancer
ciprofloxacin
0
$T1$ levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.Allergic interstitial nephritis is believed to be the underlying pathological-process.
creatinine
ciprofloxacin
0
$T1$ is believed to be the underlying pathological-process.Definitive diagnosis requires performance of renal biopsy, although this is not always feasible.
interstitial nephritis
ciprofloxacin
0
$T1$ associated with ciprofloxacin is uncommon.Five patients with $T2$
Nephrotoxicity
cancer
0
$T1$ associated with ciprofloxacin is uncommon.Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
Nephrotoxicity
acute renal failure
0
$T1$ associated with ciprofloxacin is uncommon.Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
Nephrotoxicity
creatinine
0
$T1$ associated with ciprofloxacin is uncommon.Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
Nephrotoxicity
interstitial nephritis
0
$T1$ who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.
cancer
acute renal failure
0
$T1$ who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.Other than elevation of serum $T2$
cancer
creatinine
0
$T1$ who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.
cancer
interstitial nephritis
0
$T1$ levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.Allergic interstitial nephritis is believed to be the underlying pathological-process.
creatinine
acute renal failure
0
$T1$ is believed to be the underlying pathological-process.Definitive diagnosis requires performance of renal biopsy, although this is not always feasible.
interstitial nephritis
acute renal failure
0
$T1$ levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.Allergic $T2$
creatinine
interstitial nephritis
0
$T1$ can be treated when recognized early, possibly without discontinuation of $T2$
Torsade de pointes
pentamidine
1
$T1$, including torsade de pointes.This article reports two cases of this complication and reviews all reported cases to date.
ventricular tachyarrhythmias
pentamidine
0
$T1$.When QTc interval prolongation is observed, early $T2$
pentamidine
magnesium
0
$T1$ may synergistically induce torsade.Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.
hypomagnesemia
pentamidine
0
$T1$.When $T2$
pentamidine
QTc interval prolongation
0
$T1$, including torsade de pointes.This article reports two cases of this complication and reviews all reported cases to date.
ventricular tachyarrhythmias
Torsade de pointes
0
$T1$, including torsade de pointes.This article reports two cases of this complication and reviews all reported cases to date.
ventricular tachyarrhythmias
magnesium
0
$T1$, including torsade de pointes.This article reports two cases of this complication and reviews all reported cases to date.
ventricular tachyarrhythmias
hypomagnesemia
0
$T1$, including torsade de pointes.This article reports two cases of this complication and reviews all reported cases to date.
ventricular tachyarrhythmias
QTc interval prolongation
0
$T1$ can be treated when recognized early, possibly without discontinuation of pentamidine.When QTc interval prolongation is observed, early $T2$
Torsade de pointes
magnesium
0
$T1$ may synergistically induce torsade.Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.
hypomagnesemia
Torsade de pointes
0
$T1$ can be treated when recognized early, possibly without discontinuation of pentamidine.When $T2$
Torsade de pointes
QTc interval prolongation
0
$T1$ may synergistically induce torsade.Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.
hypomagnesemia
magnesium
0
$T1$ is observed, early $T2$
QTc interval prolongation
magnesium
0
$T1$ may synergistically induce torsade.Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.
hypomagnesemia
QTc interval prolongation
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
malondialdehyde
1
$T1$, $T2$
malondialdehyde
oxypurines
0
$T1$, oxypurines, and $T2$
malondialdehyde
nucleosides
0
$T1$, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during $T2$
malondialdehyde
ischemic
0
$T1$ intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w.of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
acetylsalicylate
malondialdehyde
0
$T1$ drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of $T2$
hypotensive
malondialdehyde
0
$T1$ at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of $T2$
nitroprusside
malondialdehyde
0
$T1$, and $T2$
oxypurines
nucleosides
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
oxypurines
0
$T1$, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during $T2$
oxypurines
ischemic
0
$T1$ intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w.of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
acetylsalicylate
oxypurines
0
$T1$ drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of malondialdehyde, $T2$
hypotensive
oxypurines
0
$T1$ at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of malondialdehyde, $T2$
nitroprusside
oxypurines
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
nucleosides
0
$T1$ in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during $T2$
nucleosides
ischemic
0
$T1$ intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w.of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
acetylsalicylate
nucleosides
0
$T1$ drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of malondialdehyde, oxypurines, and $T2$
hypotensive
nucleosides
0
$T1$ at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of malondialdehyde, oxypurines, and $T2$
nitroprusside
nucleosides
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
ischemic
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
acetylsalicylate
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
hypotensive
0
$T1$ (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.Peripheral venous blood samples were withdrawn from the femoral vein four times (once every 5 min) before ischemia (0 time) and 5, 15, and 30 min after ischemia.
cerebral ischemia
nitroprusside
0
$T1$ intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w.of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
acetylsalicylate
ischemic
0
$T1$ drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during $T2$
hypotensive
ischemic
0
$T1$ at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during $T2$
nitroprusside
ischemic
0
$T1$ intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w.of the $T2$
acetylsalicylate
hypotensive
0
$T1$ intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w.of the hypotensive drug $T2$
acetylsalicylate
nitroprusside
0
$T1$ drug $T2$
hypotensive
nitroprusside
0
$T1$ ophthalmic drops, presented with profound $T2$
echothiophate iodide
muscle weakness
1
$T1$ resulting from ocular instillation of echothiophate iodide eye drops.A patient developed a severe cholinergic syndrome from the use of $T2$
toxicity
echothiophate iodide
0
$T1$ resulting from ocular instillation of echothiophate iodide eye drops.A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound $T2$
toxicity
muscle weakness
0
$T1$ resulting from ocular instillation of echothiophate iodide eye drops.A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of $T2$
toxicity
myasthenia gravis
0
$T1$ ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of $T2$
echothiophate iodide
myasthenia gravis
0
$T1$ and was initially given the diagnosis of $T2$
muscle weakness
myasthenia gravis
0
$T1$ for metastatic parameningeal embryonal rhabdomyosarcoma.$T2$
carboplatin
Acute renal failure
1
$T1$.$T2$
embryonal rhabdomyosarcoma
Acute renal failure
0
$T1$ for metastatic parameningeal $T2$
carboplatin
embryonal rhabdomyosarcoma
0
$T1$ for ovarian failure after cancer therapy may also have increased risk of $T2$
estrogens
endometrial carcinoma
1
$T1$, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of $T2$
Hodgkin disease
endometrial carcinoma
0
$T1$ after cancer therapy may also have increased risk of $T2$
ovarian failure
endometrial carcinoma
0
$T1$ therapy may also have increased risk of $T2$
cancer
endometrial carcinoma
0
$T1$, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.Young women on replacement estrogens for $T2$
Hodgkin disease
ovarian failure
0
$T1$, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.Young women on replacement $T2$
Hodgkin disease
estrogens
0
$T1$, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.Young women on replacement estrogens for ovarian failure after $T2$
Hodgkin disease
cancer
0
$T1$ for $T2$
estrogens
ovarian failure
0
$T1$ after $T2$
ovarian failure
cancer
0
$T1$ for ovarian failure after $T2$
estrogens
cancer
0
$T1$ must be considered a possible side effect of $T2$
obstructive sleep apnea syndrome
androgen
1
$T1$.Our report provides direct evidence for this role.
sleep apnea
obstructive sleep apnea syndrome
0
$T1$.Our report provides direct evidence for this role.
sleep apnea
androgen
0
$T1$ invoked by $T2$
proteinuria
puromycin aminonucleoside
1
$T1$ in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.
puromycin aminonucleoside
captopril
0
$T1$ invoked by puromycin aminonucleoside in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.
proteinuria
captopril
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
captopril
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
captopril
0
$T1$ and potassium, endogenous creatinine clearance, body weight, and food and water consumption.However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of $T2$
sodium
captopril
0
$T1$, endogenous creatinine clearance, body weight, and food and water consumption.However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of $T2$
potassium
captopril
0
$T1$ clearance, body weight, and food and water consumption.However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of $T2$
creatinine
captopril
0
$T1$ bodies were consistently present in urine and several lethalities occurred during multiple dosing of $T2$
ketone
captopril
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
puromycin aminonucleoside
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
puromycin aminonucleoside
0
$T1$ in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, $T2$
puromycin aminonucleoside
sodium
0
$T1$ in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and $T2$
puromycin aminonucleoside
potassium
0
$T1$ in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous $T2$
puromycin aminonucleoside
creatinine
0
$T1$ in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.
puromycin aminonucleoside
ketone
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
proteinuria
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
proteinuria
0
$T1$ invoked by puromycin aminonucleoside in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, $T2$
proteinuria
sodium
0
$T1$ invoked by puromycin aminonucleoside in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and $T2$
proteinuria
potassium
0
$T1$ invoked by puromycin aminonucleoside in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous $T2$
proteinuria
creatinine
0
$T1$ invoked by puromycin aminonucleoside in SHR.Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.
proteinuria
ketone
0
$T1$ patients.The possibility of reproducing the same $T2$
hypertensive
renal abnormality
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
sodium
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
potassium
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
creatinine
0
$T1$ patients.The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
hypertensive
ketone
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
sodium
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
potassium
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
creatinine
0
$T1$ with captopril was examined in SHR.Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
renal abnormality
ketone
0
$T1$ and $T2$
sodium
potassium
0
$T1$ and potassium, endogenous $T2$
sodium
creatinine
0
$T1$ and potassium, endogenous creatinine clearance, body weight, and food and water consumption.However, $T2$
sodium
ketone
0
$T1$, endogenous $T2$
potassium
creatinine
0
$T1$, endogenous creatinine clearance, body weight, and food and water consumption.However, $T2$
potassium
ketone
0
$T1$ clearance, body weight, and food and water consumption.However, $T2$
creatinine
ketone
0
$T1$-free.Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG.
seizure
enflurane
1
$T1$ may prove to be a safe fast acting activator of $T2$
enflurane
epileptic
0
$T1$-free.Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG.
seizure
epileptic
0
$T1$ is an experimental chemotherapeutic agent currently undergoing clinical evaluation.We report our results with magnetic resonance (MR) in demonstrating reversible $T2$
Tiazofurin
cerebral abnormalities
1
$T1$-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.The patient's subjective assessment of mood rating, an objective test of performance, a test for amnesia, and vital signs were recorded for up to 300 min after administration of the trial drug.
diazepam
amnesia
1
$T1$-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.The patient's subjective assessment of mood rating, an objective test of performance, a test for amnesia, and vital signs were recorded for up to 300 min after administration of the trial drug.
diazepam
Ro15-1788
0
$T1$, or vital signs.The $T2$
amnesia
Ro15-1788
0
$T1$ rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.
hypertensive
epinephrine
1
$T1$ content of the kidney on a molar basis was unchanged.Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.
catecholamine
epinephrine
0
$T1$ and epinephrine in proportions similar to those found in the kidney.This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.
norepinephrine
epinephrine
0
$T1$ had no effect on stimulus-induced overflow in either group.Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.
Propranolol
epinephrine
0
$T1$ alone do not suggest alpha-adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after $T2$
phentolamine
epinephrine
0
$T1$ rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.
hypertensive
catecholamine
0
$T1$ rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.
hypertensive
norepinephrine
0
$T1$ rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.
hypertensive
Propranolol
0
$T1$ rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.
hypertensive
phentolamine
0
$T1$ content of the kidney on a molar basis was unchanged.Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both $T2$
catecholamine
norepinephrine
0
$T1$ content of the kidney on a molar basis was unchanged.Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.
catecholamine
Propranolol
0
$T1$ content of the kidney on a molar basis was unchanged.Stimulus-induced fractional overflow of neurotransmitter from the epinephrine-treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney.
catecholamine
phentolamine
0
$T1$ and epinephrine in proportions similar to those found in the kidney.This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.
norepinephrine
Propranolol
0
$T1$ and epinephrine in proportions similar to those found in the kidney.This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.
norepinephrine
phentolamine
0
$T1$ had no effect on stimulus-induced overflow in either group.Phentolamine increased stimulus-induced overflow in both groups although the increment in overflow was greater in the epinephrine-treated group.
Propranolol
phentolamine
0
$T1$ in 173 of 210 cases and found only one case of $T2$
hydroxychloroquine
chorioretinopathy
1
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
Iridocyclitis
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
arthritis
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
uveitis
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
ocular pain
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
decreased visual acuity
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
photophobia
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
corticosteroids
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
cataracts
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
band keratopathy
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
chloroquine
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
hydroxychloroquine
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
chorioretinopathy
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
keratoconjunctivitis
0
$T1$ closely for eleven years.Thirty-six of the 210 patients (17.2%) developed iridocyclitis.
juvenile rheumatoid arthritis
glaucoma
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the $T2$
Iridocyclitis
arthritis
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
uveitis
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
ocular pain
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
decreased visual acuity
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
photophobia
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
corticosteroids
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
cataracts
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
band keratopathy
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
chloroquine
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
hydroxychloroquine
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
chorioretinopathy
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
keratoconjunctivitis
0
$T1$ was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.However, 30% of the patients developed uveitis after 16 years of age.
Iridocyclitis
glaucoma
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
uveitis
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
ocular pain
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
decreased visual acuity
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
photophobia
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
corticosteroids
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
cataracts
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
band keratopathy
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
chloroquine
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
hydroxychloroquine
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
chorioretinopathy
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
keratoconjunctivitis
0
$T1$.However, 30% of the patients developed uveitis after 16 years of age.
arthritis
glaucoma
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
uveitis
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
uveitis
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
uveitis
0
$T1$ were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.Typical keratoconjunctivitis sicca developed in three of the uveitis cases.
corticosteroids
uveitis
0
$T1$ and JRA was not noted previously.Surgical treatment of $T2$
uveitis
cataracts
0
$T1$ and JRA was not noted previously.Surgical treatment of cataracts, $T2$
uveitis
band keratopathy
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chloroquine
uveitis
0
$T1$ in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
hydroxychloroquine
uveitis
0
$T1$ attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chorioretinopathy
uveitis
0
$T1$ sicca developed in three of the uveitis cases.This association with $T2$
keratoconjunctivitis
uveitis
0
$T1$ and JRA was not noted previously.Surgical treatment of cataracts, band keratopathy, and $T2$
uveitis
glaucoma
0
$T1$, $T2$
ocular pain
decreased visual acuity
0
$T1$, decreased visual acuity, or $T2$
ocular pain
photophobia
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
corticosteroids
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
cataracts
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
band keratopathy
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
chloroquine
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
hydroxychloroquine
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
chorioretinopathy
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
keratoconjunctivitis
0
$T1$, decreased visual acuity, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
ocular pain
glaucoma
0
$T1$, or $T2$
decreased visual acuity
photophobia
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
corticosteroids
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
cataracts
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
band keratopathy
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
chloroquine
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
hydroxychloroquine
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
chorioretinopathy
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
keratoconjunctivitis
0
$T1$, or photophobia, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
decreased visual acuity
glaucoma
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
corticosteroids
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
cataracts
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
band keratopathy
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
chloroquine
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
hydroxychloroquine
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
chorioretinopathy
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
keratoconjunctivitis
0
$T1$, in order of decreasing frequency.Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
photophobia
glaucoma
0
$T1$ were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.Typical keratoconjunctivitis sicca developed in three of the uveitis cases.
corticosteroids
cataracts
0
$T1$ were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.Typical keratoconjunctivitis sicca developed in three of the uveitis cases.
corticosteroids
band keratopathy
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered $T2$
chloroquine
corticosteroids
0
$T1$ in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered $T2$
hydroxychloroquine
corticosteroids
0
$T1$ attributable to these drugs.Systemically administered $T2$
chorioretinopathy
corticosteroids
0
$T1$ were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.Typical $T2$
corticosteroids
keratoconjunctivitis
0
$T1$ were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.Typical keratoconjunctivitis sicca developed in three of the uveitis cases.
corticosteroids
glaucoma
0
$T1$, $T2$
cataracts
band keratopathy
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chloroquine
cataracts
0
$T1$ in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
hydroxychloroquine
cataracts
0
$T1$ attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chorioretinopathy
cataracts
0
$T1$ sicca developed in three of the uveitis cases.This association with uveitis and JRA was not noted previously.
keratoconjunctivitis
cataracts
0
$T1$, band keratopathy, and $T2$
cataracts
glaucoma
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chloroquine
band keratopathy
0
$T1$ in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
hydroxychloroquine
band keratopathy
0
$T1$ attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chorioretinopathy
band keratopathy
0
$T1$ sicca developed in three of the uveitis cases.This association with uveitis and JRA was not noted previously.
keratoconjunctivitis
band keratopathy
0
$T1$, and $T2$
band keratopathy
glaucoma
0
$T1$ or $T2$
chloroquine
hydroxychloroquine
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of $T2$
chloroquine
chorioretinopathy
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chloroquine
keratoconjunctivitis
0
$T1$ or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chloroquine
glaucoma
0
$T1$ in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
hydroxychloroquine
keratoconjunctivitis
0
$T1$ in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
hydroxychloroquine
glaucoma
0
$T1$ attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chorioretinopathy
keratoconjunctivitis
0
$T1$ attributable to these drugs.Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
chorioretinopathy
glaucoma
0
$T1$ sicca developed in three of the uveitis cases.This association with uveitis and JRA was not noted previously.
keratoconjunctivitis
glaucoma
0
$T1$ and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.
water intoxication
oxytocin
1
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of $T2$
abortions
water intoxication
0
$T1$ and instructed to watch the diuresis and report such early signs of the syndrome as $T2$
water intoxication
asthenia
0
$T1$ and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular $T2$
water intoxication
irritability
0
$T1$ and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or $T2$
water intoxication
headaches
0
$T1$ and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers $T2$
water intoxication
lactate
0
$T1$ and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent $T2$
water intoxication
dextrose
0
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.
abortions
oxytocin
0
$T1$, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.
asthenia
oxytocin
0
$T1$, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.
irritability
oxytocin
0
$T1$.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.
headaches
oxytocin
0
$T1$ and a 5 per cent dextrose and water solutions.The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.
lactate
oxytocin
0
$T1$ and water solutions.The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases.
dextrose
oxytocin
0
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as $T2$
abortions
asthenia
0
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular $T2$
abortions
irritability
0
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or $T2$
abortions
headaches
0
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers $T2$
abortions
lactate
0
$T1$ is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent $T2$
abortions
dextrose
0
$T1$, muscular $T2$
asthenia
irritability
0
$T1$, muscular irritability, or $T2$
asthenia
headaches
0
$T1$, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers $T2$
asthenia
lactate
0
$T1$, muscular irritability, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent $T2$
asthenia
dextrose
0
$T1$, or $T2$
irritability
headaches
0
$T1$, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers $T2$
irritability
lactate
0
$T1$, or headaches.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent $T2$
irritability
dextrose
0
$T1$.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers $T2$
headaches
lactate
0
$T1$.The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent $T2$
headaches
dextrose
0
$T1$ and a 5 per cent $T2$
lactate
dextrose
0
